FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Heher, EC Rennke, HG Laubach, JP Richardson, PG AF Heher, Eliot C. Rennke, Helmut G. Laubach, Jacob P. Richardson, Paul G. TI Kidney Disease and Multiple Myeloma SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Review ID STEM-CELL TRANSPLANTATION; LIGHT-CHAIN DEPOSITION; ACUTE-RENAL-FAILURE; PRIMARY SYSTEMIC AMYLOIDOSIS; SINGLE-AGENT CARFILZOMIB; HIGH-DOSE DEXAMETHASONE; BENCE-JONES PROTEINS; MONOCLONAL GAMMOPATHY; UNDETERMINED SIGNIFICANCE; PROTEASOME INHIBITION AB Kidney injury is a common complication of multiple myeloma and other plasma cell dyscrasias, and it is associated with increased mortality. Multiple pathogenic mechanisms can contribute to kidney injury in the patient with myeloma, some of which are the result of nephrotoxic monoclonal Ig and some of which are independent of paraprotein deposition. The pathogenic mechanisms that underlie paraprotein-related kidney disease are increasingly well understood. A novel assay allowing the quantification of free light chains in the serum has aided the diagnosis of new onset disease and allowed for the earlier detection of relapse. Novel myeloma agents have shown considerable promise in reversing renal failure in some patients and improving outcomes. Stem cell transplantation remains a mainstay of management for younger patients with myeloma who are suitable candidates for intensive therapy, whereas the role of new drugs, plasma exchange, and kidney transplantation continues to evolve. C1 [Heher, Eliot C.] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. [Heher, Eliot C.] Massachusetts Gen Hosp, Transplantat Ctr, Boston, MA 02114 USA. [Rennke, Helmut G.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Laubach, Jacob P.; Richardson, Paul G.] Dana Farber Canc Inst, Div Hematol Malignancy, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. RP Heher, EC (reprint author), Massachusetts Gen Hosp, Div Nephrol, 165 Cambridge St, Boston, MA 02114 USA. EM eheher@partners.org FU Rick Corman Multiple Myeloma Research Fund FX This work was, in part, supported by the Rick Corman Multiple Myeloma Research Fund. NR 100 TC 22 Z9 24 U1 0 U2 6 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV 7 PY 2013 VL 8 IS 11 BP 2007 EP 2017 DI 10.2215/CJN.12231212 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 250FR UT WOS:000326836400023 PM 23868898 ER PT J AU Kraut, JA Nagami, GT AF Kraut, Jeffrey A. Nagami, Glenn T. TI The Serum Anion Gap in the Evaluation of Acid-Base Disorders: What Are Its Limitations and Can Its Effectiveness Be Improved? SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Review ID CRITICALLY-ILL PATIENTS; METABOLIC-ACIDOSIS; LABORATORY EVALUATION; CLINICAL-DIAGNOSIS; HYPERLACTATEMIA; HYPOALBUMINEMIA; MORTALITY; LACTATE; SCREEN AB The serum anion gap has been utilized to identify errors in the measurement of electrolytes, to detect paraproteins, and, most relevant to the nephrologist, to evaluate patients with suspected acid-base disorders. In regard to the latter purpose, traditionally an increased anion gap is identified when it exceeds the upper limit of normal for a particular clinical laboratory measurement. However, because there is a wide range of normal values (often 8-10 mEq/L), an increase in anion concentration can be present in the absence of an increased anion gap. In addition, the type of retained anion can affect the magnitude of the increase in anion gap relative to change in serum [HCO3-] being greater with lactic acidosis compared with ketoacidosis. This review examines the methods of calculation of the serum anion gap in textbooks and published literature, the effect of perturbations other than changes in acid-base balance, and its effectiveness in identifying mild and more severe disturbances in acid-base balance. Limitations of the present methods of determining the normal anion gap and change in the anion gap are highlighted. The possibility of identifying the baseline value for individuals to optimize the use of the calculation in the detection of metabolic acidosis is suggested. C1 [Kraut, Jeffrey A.; Nagami, Glenn T.] Vet Affairs Greater Los Angeles Healthcare Syst, Med & Res Serv, Los Angeles, CA 90073 USA. [Kraut, Jeffrey A.] Univ Calif Los Angeles, Membrane Biol Lab, Los Angeles, CA USA. [Kraut, Jeffrey A.; Nagami, Glenn T.] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Div Nephrol, Los Angeles, CA 90095 USA. RP Kraut, JA (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Div Nephrol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jkraut@ucla.edu FU US Department of Veterans Affairs; UCLA Academic Senate FX This review was supported by funds from the US Department of Veterans Affairs and from the UCLA Academic Senate. NR 39 TC 12 Z9 13 U1 2 U2 7 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV 7 PY 2013 VL 8 IS 11 BP 2018 EP 2024 DI 10.2215/CJN.04040413 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 250FR UT WOS:000326836400024 PM 23833313 ER PT J AU Groarke, JD Cheng, S Moslehi, J AF Groarke, John D. Cheng, Susan Moslehi, Javid TI Cancer-Drug Discovery and Cardiovascular Surveillance SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material AB The story of impressive evolution in treatment for chronic myeloid leukemia has taken an unexpected turn, as serious adverse cardiovascular events have occurred in patients treated with the tyrosine kinase inhibitors ponatinib and nilotinib. Targeted BCR-ABL protein kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia (CML) and have established tyrosine kinase inhibition as a model for cancer-drug discovery and therapy in general. In 2001, imatinib became the first such tyrosine kinase inhibitor therapy to be approved by the Food and Drug Administration (FDA). Initially developed as part of a series of compounds that inhibit the platelet-derived growth factor receptor, imatinib was also shown to have potency against ABL and KIT kinases. Despite imatinib's breakthrough success, more than 20% of patients are resistant to the drug. Therefore, second- and third-generation inhibitors dasatinib, ... C1 [Groarke, John D.; Moslehi, Javid] Dana Farber Canc Inst, Cardiooncol Program, Boston, MA 02115 USA. [Groarke, John D.; Cheng, Susan; Moslehi, Javid] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02115 USA. [Groarke, John D.; Cheng, Susan; Moslehi, Javid] Harvard Univ, Sch Med, Boston, MA USA. RP Groarke, JD (reprint author), Dana Farber Canc Inst, Cardiooncol Program, Boston, MA 02115 USA. NR 4 TC 25 Z9 25 U1 0 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 7 PY 2013 VL 369 IS 19 BP 1779 EP 1781 DI 10.1056/NEJMp1313140 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 247HF UT WOS:000326607800005 PM 24180496 ER PT J AU Cortes, JE Kim, DW Pinilla-Ibarz, J le Coutre, P Paquette, R Chuah, C Nicolini, FE Apperley, JF Khoury, HJ Talpaz, M DiPersio, J DeAngelo, DJ Abruzzese, E Rea, D Baccarani, M Muller, MC Gambacorti-Passerini, C Wong, S Lustgarten, S Rivera, VM Clackson, T Turner, CD Haluska, FG Guilhot, F Deininger, MW Hochhaus, A Hughes, T Goldman, JM Shah, NP Kantarjian, H AF Cortes, J. E. Kim, D. -W. Pinilla-Ibarz, J. le Coutre, P. Paquette, R. Chuah, C. Nicolini, F. E. Apperley, J. F. Khoury, H. J. Talpaz, M. DiPersio, J. DeAngelo, D. J. Abruzzese, E. Rea, D. Baccarani, M. Mueller, M. C. Gambacorti-Passerini, C. Wong, S. Lustgarten, S. Rivera, V. M. Clackson, T. Turner, C. D. Haluska, F. G. Guilhot, F. Deininger, M. W. Hochhaus, A. Hughes, T. Goldman, J. M. Shah, N. P. Kantarjian, H. CA PACE Investigators TI A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID CHRONIC MYELOID-LEUKEMIA; ABL KINASE DOMAIN; CHRONIC MYELOGENOUS LEUKEMIA; DIAGNOSED CHRONIC-PHASE; INHIBITOR THERAPY; FOLLOW-UP; IMATINIB RESISTANCE; OCCLUSIVE DISEASE; MUTATIONS; NILOTINIB AB BackgroundPonatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to-isoleucine mutation at position 315 (T315I). We conducted a phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL). MethodsWe enrolled 449 heavily pretreated patients who had CML or Ph-positive ALL with resistance to or unacceptable side effects from dasatinib or nilotinib or who had the BCR-ABL T315I mutation. Ponatinib was administered at an initial dose of 45 mg once daily. The median follow-up was 15 months. ResultsAmong 267 patients with chronic-phase CML, 56% had a major cytogenetic response (51% of patients with resistance to or unacceptable side effects from dasatinib or nilotinib and 70% of patients with the T315I mutation), 46% had a complete cytogenetic response (40% and 66% in the two subgroups, respectively), and 34% had a major molecular response (27% and 56% in the two subgroups, respectively). Responses were observed regardless of the baseline BCR-ABL kinase domain mutation status and were durable; the estimated rate of a sustained major cytogenetic response of at least 12 months was 91%. No single BCR-ABL mutation conferring resistance to ponatinib was detected. Among 83 patients with accelerated-phase CML, 55% had a major hematologic response and 39% had a major cytogenetic response. Among 62 patients with blast-phase CML, 31% had a major hematologic response and 23% had a major cytogenetic response. Among 32 patients with Ph-positive ALL, 41% had a major hematologic response and 47% had a major cytogenetic response. Common adverse events were thrombocytopenia (in 37% of patients), rash (in 34%), dry skin (in 32%), and abdominal pain (in 22%). Serious arterial thrombotic events were observed in 9% of patients; these events were considered to be treatment-related in 3%. A total of 12% of patients discontinued treatment because of an adverse event. ConclusionsPonatinib had significant antileukemic activity across categories of disease stage and mutation status. (Funded by Ariad Pharmaceuticals and others; PACE ClinicalTrials.gov number, NCT01207440.) C1 [Cortes, J. E.; Kantarjian, H.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Kim, D. -W.] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea. [Pinilla-Ibarz, J.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [le Coutre, P.] Charite, D-13353 Berlin, Germany. [Mueller, M. C.] Univ Med Mannheim, Med Klin 3, Mannheim, Germany. [Hochhaus, A.] Univ Klinikum Jena, Abt Hamatol & Onkol, Jena, Germany. [Paquette, R.] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA. [Chuah, C.] Singapore Gen Hosp, Duke Natl Univ Singapore Grad Med Sch, Singapore, Singapore. [Nicolini, F. E.] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France. [Rea, D.] Hop St Louis, Serv Malad Sang, Paris, France. [Rea, D.] Hop St Louis, CIC, Paris, France. [Guilhot, F.] Ctr Hosp Univ Poitiers, INSERM CIC, Poitiers, France. [Apperley, J. F.; Goldman, J. M.] Univ London Imperial Coll Sci Technol & Med, Ctr Haematol, London, England. [Khoury, H. J.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Talpaz, M.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [DiPersio, J.] Washington Univ, Sch Med, St Louis, MO USA. [DeAngelo, D. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Abruzzese, E.] Univ Roma Tor Vergata, S Eugenio Hosp, Rome, Italy. [Baccarani, M.] S Orsola Malpighi Univ Hosp, Dept Hematol & Oncol L&A Seragnoli, Bologna, Italy. [Gambacorti-Passerini, C.] Univ Milano Bicocca, Azienda Osped San Gerardo, Unita Ric Clin Ematol, Monza, Italy. [Wong, S.] MolecularMD, Portland, OR USA. [Lustgarten, S.; Rivera, V. M.; Clackson, T.; Turner, C. D.; Haluska, F. G.] Ariad Pharmaceut, Cambridge, MA USA. [Deininger, M. W.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Hughes, T.] Inst Med & Vet Sci, Adelaide, SA 5000, Australia. [Shah, N. P.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Cortes, JE (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. EM jcortes@mdanderson.org RI von Bubnoff, Nikolas/F-2351-2017; Ottmann, Oliver/D-5007-2016; OI GAMBACORTI PASSERINI, CARLO/0000-0001-6058-515X; Ottmann, Oliver/0000-0001-9559-1330; holyoake, tessa/0000-0002-0608-6066; Hochhaus, Andreas/0000-0003-0626-0834 FU Ariad Pharmaceuticals FX Funded by Ariad Pharmaceuticals and others; PACE ClinicalTrials.gov number, NCT01207440.) NR 42 TC 250 Z9 257 U1 7 U2 36 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 7 PY 2013 VL 369 IS 19 BP 1783 EP 1796 DI 10.1056/NEJMoa1306494 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA 247HF UT WOS:000326607800007 PM 24180494 ER PT J AU Specks, U Ikle, D Stone, JH AF Specks, Ulrich Ikle, David Stone, John H. TI Induction Regimens for ANCA-Associated Vasculitis REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID THERAPY C1 [Specks, Ulrich] Mayo Clin, Rochester, MN 55905 USA. [Ikle, David] Rho, Chapel Hill, NC USA. [Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Specks, U (reprint author), Mayo Clin, Rochester, MN 55905 USA. FU NCI NIH HHS [P01 CA043904]; NIAID NIH HHS [U01 AI067075, U01 AI088635, R34 AI095135] NR 4 TC 3 Z9 4 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 7 PY 2013 VL 369 IS 19 BP 1865 EP 1866 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 247HF UT WOS:000326607800031 PM 24195565 ER PT J AU Bhatt, AS Marty, FM Meyerson, M AF Bhatt, Ami S. Marty, Francisco M. Meyerson, Matthew TI Bradyrhizobium enterica in Cord Colitis Syndrome Reply SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Bhatt, Ami S.; Meyerson, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA. [Marty, Francisco M.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Bhatt, AS (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. EM matthew_meyerson@dfci.harvard.edu NR 2 TC 0 Z9 0 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 7 PY 2013 VL 369 IS 19 BP 1867 EP 1867 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 247HF UT WOS:000326607800034 PM 24195568 ER PT J AU Cho, JM Ibbott, G Gillin, M Gonzalez-Lepera, C Titt, U Paganetti, H Kerr, M Mawlawi, O AF Cho, Jongmin Ibbott, Geoffrey Gillin, Michael Gonzalez-Lepera, Carlos Titt, Uwe Paganetti, Harald Kerr, Matthew Mawlawi, Osama TI Feasibility of proton-activated implantable markers for proton range verification using PET SO PHYSICS IN MEDICINE AND BIOLOGY LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; MONTE-CARLO SIMULATIONS; RADIATION-THERAPY; IN-ROOM; DOSE PERTURBATIONS; CT NUMBERS; BEAM; DISTRIBUTIONS; RADIOTHERAPY; TISSUE AB Proton beam range verification using positron emission tomography (PET) currently relies on proton activation of tissue, the products of which decay with a short half-life and necessitate an on-site PET scanner. Tissue activation is, however, negligible near the distal dose fall-off region of the proton beam range due to their high interaction energy thresholds. Therefore Monte Carlo simulation is often supplemented for comparison with measurement; however, this also may be associated with systematic and statistical uncertainties. Therefore, we sought to test the feasibility of using long-lived proton-activated external materials that are inserted or infused into the target volume for more accurate proton beam range verification that could be performed at an off-site PET scanner. We irradiated samples of >= 98% O-18-enriched water, natural Cu foils, and >97% Zn-68-enriched foils as candidate materials, along with samples of tissue-equivalent materials including O-16 water, heptane (C7H16), and polycarbonate (C16H14O3)(n), at four depths (ranging from 100% to 3% of center of modulation (COM) dose) along the distal fall-off of a modulated 160 MeV proton beam. Samples were irradiated either directly or after being embedded in Plastic Water (R) or balsa wood. We then measured the activity of the samples using PET imaging for 20 or 30 min after various delay times. Measured activities of candidate materials were up to 100 times greater than those of the tissue-equivalent materials at the four distal dose fall-off depths. The C1 [Cho, Jongmin] Univ Texas Houston, Grad Sch Biomed Sci Houston, Houston, TX 77030 USA. [Cho, Jongmin; Ibbott, Geoffrey; Gillin, Michael; Titt, Uwe; Kerr, Matthew] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA. [Gonzalez-Lepera, Carlos] Univ Texas MD Anderson Canc Ctr, Dept Nucl Med, Houston, TX 77030 USA. [Paganetti, Harald] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Paganetti, Harald] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Mawlawi, Osama] Univ Texas MD Anderson Canc Ctr, Dept Imaging Phys, Houston, TX 77030 USA. RP Cho, JM (reprint author), Univ Texas Houston, Grad Sch Biomed Sci Houston, Houston, TX 77030 USA. EM jcho2@mdanderson.org FU National Institutes of Health through MD Anderson's Cancer Center [CA016672] FX The authors thank Reinhard Schulte at Loma Linda University Medical Center; Pablo Yepes at Rice University; Wen Hsi at ProCure Treatment Centers; Moiz Ahmad at Stanford University; Francesco Stingo in the Department of Biostatistics; Lawrence Bronk, Bryan Stewart, Kevin Casey, and Kevin Vredevoogd in the Department of Radiation Physics; Ryan Bosca in the Department of Imaging Physics and the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center. This research was supported in part by the National Institutes of Health through MD Anderson's Cancer Center Support Grant (CA016672). NR 35 TC 3 Z9 3 U1 0 U2 4 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 0031-9155 EI 1361-6560 J9 PHYS MED BIOL JI Phys. Med. Biol. PD NOV 7 PY 2013 VL 58 IS 21 BP 7497 EP 7512 DI 10.1088/0031-9155/58/21/7497 PG 16 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA 244HA UT WOS:000326377100005 PM 24099853 ER PT J AU Nansel, TR Haynie, DL Lipsky, LM Wang, J Mehta, SN Laffel, LMB AF Nansel, Tonja R. Haynie, Denise L. Lipsky, Leah M. Wang, Jing Mehta, Sanjeev N. Laffel, Lori M. B. TI Relationships among parent and youth healthful eating attitudes and youth dietary intake in a cross-sectional study of youth with type 1 diabetes SO INTERNATIONAL JOURNAL OF BEHAVIORAL NUTRITION AND PHYSICAL ACTIVITY LA English DT Article DE Dietary intake; Social cognitive theory; Type 1 diabetes; Children; Adolescents ID SOCIAL COGNITIVE THEORY; CARDIOVASCULAR RISK-FACTORS; VEGETABLE CONSUMPTION; SELF-EFFICACY; ENVIRONMENTAL-INFLUENCES; PHYSICAL-ACTIVITY; GLYCEMIC CONTROL; CHILDREN; FRUIT; ADOLESCENTS AB Background: Constructs based on Social Cognitive Theory have shown utility in understanding dietary behavior; however, little research has examined these relations in youth and parents concurrently. Unique demands of dietary management among families of youth with type 1 diabetes (T1D) suggest the importance of investigation in this population. The purpose of this study was to develop and evaluate youth and parent measures of self-efficacy, outcome expectations, and barriers for healthful eating, and parent modeling of healthful eating, in a sample of youth with type 1 diabetes and their parents. Methods: Youth (n= 252) ages 8-18 years with diabetes duration = 1 year and parents completed self-report measures of healthful eating attitudes including self-efficacy, perceived barriers, positive and negative outcome expectations; youth reported parent modeling of healthful eating. Youth dietary intake from 3-day diet records was used to calculate the Healthy Eating Index 2005 and the Nutrient Rich Foods 9.3 index, measures of overall diet quality. The relations among parent and youth healthful eating attitudes, parent modeling, and youth diet quality were examined using structural equation modeling. Results: Internal consistency and test-retest reliability of the measures were acceptable. The structural equation model demonstrated acceptable fit (CFI/TLI= 0.94/0.94; RMSEA= 0.03), and items loaded the hypothesized factors. Parent modeling (beta) over cap = : 27; p = 02) and attitudes toward healthful eating (latent variable comprised of self-efficacy, barriers, outcome expectations) ((beta) over cap = : 16; p = 04) had direct effects on youth diet quality. Parent modeling had a direct effect on youth attitudes ((beta) over cap = : 49; p < : 001) ; parent attitudes had an indirect effect on youth attitudes through parent modeling (<(beta)over cap> =: 12; p;< : 001). Youth attitudes were not associated with youth diet quality. Overall, the model accounted for 20% of the variance in child diet quality. Conclusions: Parent diet-related behaviors demonstrated an impact on youth attitudes and diet quality, suggesting the importance of family-based clinical and public health efforts to improve diet. C1 [Nansel, Tonja R.; Haynie, Denise L.; Lipsky, Leah M.; Wang, Jing] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Hlth Behav Branch, Div Intramural Populat Hlth Res, NIH,DHHS, Bethesda, MD 20892 USA. [Mehta, Sanjeev N.; Laffel, Lori M. B.] Joslin Diabet Ctr, Pediat Adolescent & Young Adult Sect, Genet & Epidemiol Sect, Boston, MA 02215 USA. RP Nansel, TR (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Hlth Behav Branch, Div Intramural Populat Hlth Res, NIH,DHHS, 6100 Execut Blvd,Rm 7B13,MSC 7510, Bethesda, MD 20892 USA. EM nanselt@mail.nih.gov OI Nansel, Tonja/0000-0002-8298-7595; Haynie, Denise/0000-0002-8270-6079 FU intramural research program of the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development [HHSN267200703434C] FX This research was supported by the intramural research program of the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, contract number HHSN267200703434C. NR 66 TC 4 Z9 4 U1 3 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1479-5868 J9 INT J BEHAV NUTR PHY JI Int. J. Behav. Nutr. Phys. Act. PD NOV 6 PY 2013 VL 10 AR 125 DI 10.1186/1479-5868-10-125 PG 10 WC Nutrition & Dietetics; Physiology SC Nutrition & Dietetics; Physiology GA 290VX UT WOS:000329787700001 PM 24195642 ER PT J AU Zhang, XQ Xin, X Dong, YL Zhang, YY Yu, BW Mao, JR Xie, ZC AF Zhang, Xiaoqin Xin, Xin Dong, Yuanlin Zhang, Yiying Yu, Buwei Mao, Jianren Xie, Zhongcong TI Surgical Incision-Induced Nociception Causes Cognitive Impairment and Reduction in Synaptic NMDA Receptor 2B in Mice SO JOURNAL OF NEUROSCIENCE LA English DT Article ID LONG-TERM-POTENTIATION; STIMULATED ADENYLYL CYCLASES; NR2B SUBTYPE RECEPTOR; FEAR MEMORY; NEUROPATHIC PAIN; BEHAVIORAL SENSITIZATION; GENETIC ENHANCEMENT; RETROGRADE-AMNESIA; POSTOPERATIVE PAIN; CONTEXTUAL FEAR AB Postoperative cognitive dysfunction (POCD) is associated with impairments in daily functioning, and increased morbidity and mortality. However, the causes and neuropathogenesis of POCD remain largely unknown. Uncontrolled pain often occurs postoperatively. We therefore set out to determine the effects of surgical incision-induced nociception on the cognitive function and its underlying mechanisms in 3- and 9-month-old mice. The mice had surgical incision in the hindpaw and then were tested for nociceptive threshold, learning, and memory. Brain levels of NMDA receptor and cyclin-dependent kinase 5 (CDK5) were also assessed. We found that surgical incision-induced nociception in mice led to a decreased freezing time in the tone test (which assesses the hippocampus-independent learning and memory function), but not the context test, of Fear Conditioning System at 3 and 7 d, but not 30 d post incision in 9-month-old, but not 3-month-old mice. Consistently, the surgical incision selectively decreased synaptic NMDA receptor 2B levels in the medial prefrontal cortex, and increased levels of tumor necrosis factor-alpha and CDK5 in the cortex, but not hippocampus, of the mice. Finally, eutectic mixture of local anesthetics and CDK5 inhibitor, roscovitine, attenuated the surgical incision-induced reduction in the synaptic NMDA receptor 2B levels and learning impairment. These results suggested that surgical incision-induced nociception reduced the synaptic NMDA receptor 2B level in the medial prefrontal cortex of mice, which might lead to hippocampus-independent learning impairment, contributing to POCD. These findings call for further investigation to determine the role of surgical incision-induced nociception in POCD. C1 [Zhang, Xiaoqin; Xin, Xin; Dong, Yuanlin; Zhang, Yiying; Xie, Zhongcong] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Geriatr Anesthesia Res Unit, Charlestown, MA 02129 USA. [Zhang, Xiaoqin; Xin, Xin; Dong, Yuanlin; Zhang, Yiying; Xie, Zhongcong] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Zhang, Xiaoqin; Yu, Buwei] Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Dept Anesthesia, Shanghai 200025, Peoples R China. [Xin, Xin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Anesthesia, Beijing 100730, Peoples R China. [Xin, Xin] Peking Union Med Coll, Beijing 100730, Peoples R China. [Mao, Jianren] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Translat Pain Res,Dept Anesthesia Crit Care &, Charlestown, MA 02129 USA. RP Xie, ZC (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Geriatr Anesthesia Res Unit, 149 13th St,Room 4310, Charlestown, MA 02129 USA. EM zxie@partners.org FU National Institutes of Health, Bethesda, Maryland [R21AG038994, R01 GM088801, R01 AG041274]; Alzheimer's Association, Chicago, Illinois; Cure Alzheimer's Fund, Wellesley, Massachusetts FX This research was supported by R21AG038994, R01 GM088801, and R01 AG041274 from the National Institutes of Health, Bethesda, Maryland; Investigator-initiated Research grant from Alzheimer's Association, Chicago, Illinois; and Cure Alzheimer's Fund, Wellesley, Massachusetts to Z.X. NR 66 TC 16 Z9 18 U1 1 U2 11 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 6 PY 2013 VL 33 IS 45 BP 17737 EP 17748 DI 10.1523/JNEUROSCI.2049-13.2013 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 252PI UT WOS:000327019100022 PM 24198365 ER PT J AU Zhang, XL Tian, YL Li, Z Tian, XY Sun, HB Liu, H Moore, A Ran, CZ AF Zhang, Xueli Tian, Yanli Li, Zeng Tian, Xiaoyu Sun, Hongbin Liu, Hong Moore, Anna Ran, Chongzhao TI Design and Synthesis of Curcumin Analogues for in Vivo Fluorescence Imaging and Inhibiting Copper-Induced Cross-Linking of Amyloid Beta Species in Alzheimer's Disease SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; PITTSBURGH COMPOUND-B; A-BETA; MOUSE MODEL; TRANSGENIC MICE; PEPTIDE AGGREGATION; PROTEIN OLIGOMERS; PRECURSOR PROTEIN; MEMORY DEFICITS; ALPHA-HELICES AB In this article, we first designed and synthesized curcumin-based near-infrared (NIR) fluorescence imaging probes for detecting both soluble and insoluble amyloid beta (A beta) species and then an inhibitor that could attenuate cross-linking of A beta induced by copper. According to our previous results and the possible structural stereohindrance compatibility of the A beta peptide and the hydrophobic/hydrophilic property of the A beta 13-20 (HHQKLVFF) fragment, NIR imaging probe CRANAD-58 was designed and synthesized. As expected CRANAD-58 showed significant fluorescence property changes upon mixing with both soluble and insoluble A beta species in vitro. In vivo NIR imaging revealed that CRANAD-58 was capable of differentiating transgenic and wild-type mice as young as 4 months old, the age that lacks apparently visible A beta plaques and A beta is likely in its soluble forms. According to our limited studies on the interaction mechanism between CRANAD-58 and A beta, we also designed CRANAD-17 to attenuate the cross-linking of A beta 42 induced by copper. It is well-known that the coordination of copper with imidazoles on Histidine-13 and 14 (H13, H14) of A beta peptides could initialize covalent cross-linking of A beta. In CRANAD-17, a curcumin scaffold was used as an anchoring moiety to usher the designed compound to the vicinity of H13 and H14 of A beta, and imidazole rings were incorporated to compete with H13/H14 for copper binding. The results of SDS-PAGE gel and Western blot indicated that CRANAD-17 was capable of inhibiting A beta 42 cross-linking induced by copper. This raises a potential for CRANAD-17 to be considered for AD therapy. C1 [Zhang, Xueli; Tian, Yanli; Moore, Anna; Ran, Chongzhao] Harvard Univ, Sch Med,Mol Imaging Lab, Massachusetts Gen Hosp,Dept Radiol,, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA 02129 USA. [Zhang, Xueli; Sun, Hongbin] China Pharmaceut Univ, Coll Pharm, Ctr Drug Discovery, Nanjing 210009, Jiangsu, Peoples R China. [Zhang, Xueli; Sun, Hongbin] China Pharmaceut Univ, Coll Pharm, State Key Lab Nat Med, Nanjing 210009, Jiangsu, Peoples R China. [Tian, Yanli] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Parasitol, Guangzhou 510275, Guangdong, Peoples R China. [Li, Zeng; Liu, Hong] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China. [Tian, Xiaoyu] Northeastern Univ, Ctr Drug Discovery, Boston, MA 02115 USA. RP Moore, A (reprint author), Harvard Univ, Sch Med,Mol Imaging Lab, Massachusetts Gen Hosp,Dept Radiol,, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Bldg 75, Charlestown, MA 02129 USA. EM amoore@helix.mgh.harvard.edu; cran@nmr.mgh.haryard.edu FU [K25AG036760] FX This work was supported by K25AG036760 award to C.R. The authors would also like to thank Alana Ross and Pamela Pantazopoulos, B.S. for proofreading this manuscript. NR 105 TC 58 Z9 59 U1 25 U2 188 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0002-7863 EI 1520-5126 J9 J AM CHEM SOC JI J. Am. Chem. Soc. PD NOV 6 PY 2013 VL 135 IS 44 BP 16397 EP 16409 DI 10.1021/ja405239v PG 13 WC Chemistry, Multidisciplinary SC Chemistry GA 249JU UT WOS:000326774300038 PM 24116384 ER PT J AU Trombetta-eSilva, J Eadie, EP Zhang, YH Norris, RA Borg, TK Bradshaw, AD AF Trombetta-eSilva, Jessica Eadie, Erik P. Zhang, Yuhua Norris, Russell A. Borg, Thomas K. Bradshaw, Amy D. TI The Effects of Age and the Expression of SPARC on Extracellular Matrix Production by Cardiac Fibroblasts in 3-D Cultures SO PLOS ONE LA English DT Article ID FIBRILLAR COLLAGEN CONTENT; DIASTOLIC FUNCTION ROLE; CONNECTIVE-TISSUE; IN-VITRO; NETWORK; HEART; BIOLOGY; MUSCLE; TENDON AB Fibrillar collagen is the primary component of the cardiac interstitial extracellular matrix. This extracellular matrix undergoes dramatic changes from birth to adulthood and then into advanced age. As evidence, fibrillar collagen content was compared in sections from neonates, adult, and old hearts and was found to increase at each respective age. Cardiac fibroblasts are the principle cell type that produce and control fibrillar collagen content. To determine whether fibroblast production, processing, and deposition of collagen differed with age, primary cardiac fibroblasts from neonate, adult, and old mice were isolated and cultured in 3-dimensional (3D) fibrin gels. Fibroblasts from each age aligned in fibrin gels along points of tension and deposited extracellular matrix. By confocal microscopy, wild-type neonate fibroblasts appeared to deposit less collagen into fibrillar structures than fibroblasts from adults. However, by immunoblot analysis, differences in procollagen production and processing of collagen I were not detected in neonate versus adult fibroblasts. In contrast, fibroblasts from old mice demonstrated increased efficiency of procollagen processing coupled with decreased production of total collagen. SPARC is a collagen-binding protein previously shown to affect cardiac collagen deposition. Accordingly, in the absence of SPARC, less collagen appeared to be associated with fibroblasts of each age grown in fibrin gels. In addition, the increased efficiency of procollagen alpha 1(I) processing in old wild-type fibroblasts was not detected in old SPARC-null fibroblasts. Increased levels of fibronectin were detected in wild-type neonate fibroblasts over that of adult and old fibroblasts but not in SPARC-null neonate fibroblasts versus older ages. Immunostaining of SPARC overlapped with that of collagen I but not to that of fibronectin in 3D cultures. Hence, whereas increases in procollagen processing, influenced by SPARC expression, plausibly contribute to increased collagen deposition in old hearts, other cellular mechanisms likely affect differential collagen deposition by neonate fibroblasts. C1 [Trombetta-eSilva, Jessica; Bradshaw, Amy D.] Med Univ S Carolina, Dept Craniofacial Biol, Charleston, SC 29425 USA. [Eadie, Erik P.; Norris, Russell A.; Borg, Thomas K.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. [Zhang, Yuhua; Bradshaw, Amy D.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Bradshaw, Amy D.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. RP Bradshaw, AD (reprint author), Med Univ S Carolina, Dept Craniofacial Biol, Charleston, SC 29425 USA. EM bradshad@musc.edu FU Research Service of the Department of Veterans Affairs [1I01BX001385-01A1]; National Heart, Lung, and Blood Institute [HL085847]; National Institute of Dental and Craniofacial Research [DE023009-02] FX This study was supported by the Research Service of the Department of Veterans Affairs (Dr. Bradshaw: 1I01BX001385-01A1) and grants from the National Heart, Lung, and Blood Institute (Dr. Borg: HL085847) and the National Institute of Dental and Craniofacial Research (Ms Trombetta-eSilva: DE023009-02). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 22 TC 6 Z9 6 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 6 PY 2013 VL 8 IS 11 AR e79715 DI 10.1371/journal.pone.0079715 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 247XD UT WOS:000326656200078 PM 24223185 ER PT J AU Okubo, Y Mera, T Wang, LM Faustman, DL AF Okubo, Yoshiaki Mera, Toshiyuki Wang, Limei Faustman, Denise L. TI Homogeneous Expansion of Human T-Regulatory Cells Via Tumor Necrosis Factor Receptor 2 SO SCIENTIFIC REPORTS LA English DT Article ID IN-VITRO EXPANSION; PERIPHERAL-BLOOD; INCREASED POPULATIONS; AUTOIMMUNE-DISEASES; PROMOTES EXPANSION; RAPAMYCIN; VIVO; TNF; STRATEGIES; INHIBITOR AB T-regulatory cells (T-regs) are a rare lymphocyte subtype that shows promise for treating infectious disease, allergy, graft-versus-host disease, autoimmunity, and asthma. Clinical applications of T-regs have not been fully realized because standard methods of expansion ex vivo produce heterogeneous progeny consisting of mixed populations of CD4 + T cells. Heterogeneous progeny are risky for human clinical trials and face significant regulatory hurdles. With the goal of producing homogeneous T-regs, we developed a novel expansion protocol targeting tumor necrosis factor receptors (TNFR) on T-regs. In in vitro studies, a TNFR2 agonist was found superior to standard methods in proliferating human T-regs into a phenotypically homogeneous population consisting of 14 cell surface markers. The TNFR2 agonist-expanded T-regs also were functionally superior in suppressing a key T-reg target cell, cytotoxic T-lymphocytes. Targeting the TNFR2 receptor during ex vivo expansion is a new means for producing homogeneous and potent human T-regs for clinical opportunities. C1 [Faustman, Denise L.] Massachusetts Gen Hosp, Immunobiol Lab, Boston, MA 02129 USA. Harvard Univ, Sch Med, Boston, MA 02129 USA. RP Faustman, DL (reprint author), Massachusetts Gen Hosp, Immunobiol Lab, Rm 3602,MGH East,Bldg 149,13th St, Boston, MA 02129 USA. EM faustman@helix.mgh.harvard.edu FU Iacocca Foundation FX We thank the Iacocca Foundation for the support of this program. We thank M. Davis for her editorial comments and critique of the paper. NR 49 TC 24 Z9 25 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD NOV 6 PY 2013 VL 3 AR 3153 DI 10.1038/srep03153 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 246YQ UT WOS:000326578200009 PM 24193319 ER PT J AU Saver, JL Fonarow, GC Schwamm, LH AF Saver, Jeffrey L. Fonarow, Gregg C. Schwamm, Lee H. TI Acute Ischemic Stroke and Timing of Treatment Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Saver, Jeffrey L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90095 USA. [Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Saver, JL (reprint author), Univ Calif Los Angeles, Comprehens Stroke Ctr, 710 Westwood Plaza, Los Angeles, CA 90095 USA. EM jsaver@mednet.ucla.edu OI Saver, Jeffrey/0000-0001-9141-2251; Schwamm, Lee/0000-0003-0592-9145 NR 3 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 6 PY 2013 VL 310 IS 17 BP 1856 EP 1857 DI 10.1001/jama.2013.278898 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 246PH UT WOS:000326550900022 PM 24193086 ER PT J AU Ayers, DC Franklin, PD Ring, DC AF Ayers, David C. Franklin, Patricia D. Ring, David C. TI The Role of Emotional Health in Functional Outcomes After Orthopaedic Surgery: Extending the Biopsychosocial Model to Orthopaedics SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article C1 [Ayers, David C.] UMass Mem Med Ctr, Dept Orthopaed & Phys Rehabil, Arthrit & Joint Replacement Ctr, 119 Belmont St, Worcester, MA 01605 USA. [Franklin, Patricia D.] Univ Massachusetts, Sch Med, Dept Orthoped & Phys Rehabil, Worcester, MA 01655 USA. [Ring, David C.] Massachusetts Gen Hosp, Dept Orthopaed Surg, MGH Orthopaed Hand & Upper Extrem Serv, Yawkey Ctr 2100, Boston, MA 02114 USA. RP Ayers, DC (reprint author), UMass Mem Med Ctr, Dept Orthopaed & Phys Rehabil, Arthrit & Joint Replacement Ctr, 119 Belmont St, Worcester, MA 01605 USA. EM dring@partners.org NR 69 TC 16 Z9 16 U1 0 U2 0 PU JOURNAL BONE JOINT SURGERY PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02492 USA SN 0021-9355 EI 1535-1386 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD NOV 6 PY 2013 VL 95 IS 21 AR e165 DI 10.2106/JBJS.L.00799 PG 7 WC Orthopedics; Surgery SC Orthopedics; Surgery GA V47AM UT WOS:000209924700008 ER PT J AU Gurol, ME Greenberg, SM AF Gurol, M. Edip Greenberg, Steven M. TI A physiologic biomarker for cerebral amyloid angiopathy SO NEUROLOGY LA English DT Editorial Material ID WHITE-MATTER LESIONS; REACTIVITY; FLOW C1 [Gurol, M. Edip; Greenberg, Steven M.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Gurol, ME (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. EM edip@mail.harvard.edu RI Gurol, Edip/J-2279-2014 OI Gurol, Edip/0000-0002-2169-4457 FU NIA NIH HHS [R01 AG026484, R01AG026484, R01AG021084]; NINDS NIH HHS [K24NS056207, 5R01NS070834-01/02, T32NS048005, R01 NS070834, R01NS070834, U54NS057405, T32 NS048005, R01 NS070834-02] NR 10 TC 4 Z9 4 U1 2 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD NOV 5 PY 2013 VL 81 IS 19 BP 1650 EP 1651 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA AA0FE UT WOS:000330770100005 PM 24097811 ER PT J AU Taylor, JW Flanagan, EP O'Neill, BP Siegal, T Omuro, A DeAngelis, L Baehring, J Nishikawa, R Pinto, F Chamberlain, M Hoang-Xuan, K Gonzalez-Aguilar, A Batchelor, T Blay, JY Korfel, A Betensky, RA Lopes, MBS Schiff, D AF Taylor, Jennie W. Flanagan, Eoin P. O'Neill, Brian P. Siegal, Tali Omuro, Antonio DeAngelis, Lisa Baehring, Joachim Nishikawa, Ryo Pinto, Fernando Chamberlain, Marc Hoang-Xuan, Khe Gonzalez-Aguilar, Alberto Batchelor, Tracy Blay, Jean-Yves Korfel, Agnieszka Betensky, Rebecca A. Lopes, Maria-Beatriz S. Schiff, David TI Primary leptomeningeal lymphoma International Primary CNS Lymphoma Collaborative Group report SO NEUROLOGY LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; MENINGEAL DISSEMINATION; FLOW-CYTOMETRY; INVOLVEMENT; CHEMOTHERAPY; EXPERIENCE; DIAGNOSIS; SURVIVAL AB Objective: To evaluate clinical presentation, optimal diagnostic evaluation and treatment, and outcome in primary leptomeningeal lymphoma, a rare form of primary CNS lymphoma without parenchymal or systemic involvement. Methods: The International Primary CNS Lymphoma Collaborative Group, a multidisciplinary group of physicians with a particular interest in primary CNS lymphoma, retrospectively identified cases of lymphoma isolated to the leptomeninges as diagnosed by CSF cytology, flow cytometry, or biopsy, without systemic or parenchymal brain/spinal cord lymphoma or immunodeficiency. Results: Forty-eight patients were identified, with median age at diagnosis of 51 years and median Eastern Cooperative Oncology Group performance status of 2. Presenting symptoms were multifocal in 68%. Leptomeningeal enhancement was seen in 74% and CSF profile was abnormal in all cases. CSF cytology detected malignant lymphocytes in 67%. Flow cytometry identified monoclonal population in 80%, as did receptor gene rearrangement studies in 71%. Sixty-two percent had B-cell lymphoma, 19% T-cell, and 19% unclassified. Treatment varied and included fractionated radiotherapy (36%), systemic chemotherapy (78%), and intra-CSF chemotherapy (66%), with 66% receiving >= 2 modalities. Seventy-one percent had a favorable clinical response; ultimately, 44% received salvage treatment. Median overall survival was 24 months, with 11 patients still alive at 50 months follow-up. Conclusion: Primary leptomeningeal lymphoma is a rare form of primary CNS lymphoma. Patients usually present with multifocal symptoms, with evidence of leptomeningeal enhancement and diagnostic CSF analysis. Although treatment is highly variable, patients have a better prognosis than previously reported and a subset may be cured. C1 [Taylor, Jennie W.; Batchelor, Tracy; Betensky, Rebecca A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Flanagan, Eoin P.; O'Neill, Brian P.] Mayo Clin, Rochester, MN USA. [Siegal, Tali] Hadassah Hebrew Univ Med Ctr, Jerusalem, Israel. [Omuro, Antonio; DeAngelis, Lisa] Mem Sloan Kettering, New York, NY USA. [Baehring, Joachim] Yale Univ, New Haven, CT USA. [Nishikawa, Ryo] Saitama Med Univ, Kawagoe, Saitama, Japan. [Pinto, Fernando] Kings Coll Hosp London, London, England. [Chamberlain, Marc] Univ Washington, Seattle, WA 98195 USA. [Hoang-Xuan, Khe; Gonzalez-Aguilar, Alberto] UPMC, APHP, LOC Natl Expert Ctr, Paris, France. [Blay, Jean-Yves] Ctr Leon Berard, F-69373 Lyon, France. [Korfel, Agnieszka] Charite Univ Med Berlin, Berlin, Germany. [Betensky, Rebecca A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Lopes, Maria-Beatriz S.; Schiff, David] Univ Virginia, Charlottesville, VA 22903 USA. RP Schiff, D (reprint author), Univ Virginia, Charlottesville, VA 22903 USA. EM davidschiff@virginia.edu RI Blay, Jean-Yves/N-3966-2016; OI Blay, Jean-Yves/0000-0001-7190-120X; Omuro, Antonio/0000-0003-4299-3664 FU NIH [3P30CA008748-47S2, 1U01CA137443-01, R01CA075971, R03CA165070, UL1RR025758, P50NS051343, P30CA006516, P50AG005134, P01AG036694, R01NS070834, R01AG026484, R33 DK074099, R01CA057683]; MSKCC Department of Neurology Research and Development Fund; NIH KL2; [T32NS 07494-8]; [P50CA 108961-7]; [P30CA 15083-38] FX J. Taylor and E. Flanagan report no disclosures. B. O'Neill serves on the scientific advisory boards of the V Foundation, Sontag Foundation, and Advance Brain Cancer Cure (ABC2). He serves as a member of the editorial advisory board of Neuro-Oncology and the Journal of NeuroOncology. He receives honoraria for his textbook Principles of NeuroOncology. He receives research support as principal investigator/director of T32NS 07494-8, P50CA 108961-7, and P30CA 15083-38; site principal investigator for 28XS094-1 (The Cancer Genome Atlas Program); and principal investigator of ABC2-1 (Advance Brain Cancer Cure). T. Siegal has received funding for travel, honoraria and research support from Roche, Schering-Plough, and Merck Serono pharmaceutical companies, and served on the advisory board and as a consultant for Roche and Schering-Plough. A. Omuro served on the scientific advisory board for Roche and Novocure. He has received funding by NIH grants 3P30CA008748-47S2 and 1U01CA137443-01. He has received institutional support through the MSKCC Department of Neurology Research and Development Fund to conduct clinical research and research support for conduction of clinical trials from the B*Cured Foundation, CERN Foundation, Roche/Genentech, Sanofi, Plexxikon, Tactics Therapeutics, and Merck. L. DeAngelis serves on the scientific advisory board for NFLPA. She serves on the editorial boards for Neurology, Neuro-Oncology, Journal of Neuro-Oncology, CNS Oncology, and British Medical Journal. She has received royalties from Oxford University Press for Neurologic Complications of Cancer. She has received research support from NIH KL2 award for Babak Navi (mentor). J. Baehring serves on the advisory board of Genentech. He has received honoraria from SigmaTau for lectures and round table discussions. R. Nishikawa serves on the advisory board of Hoffmann-La Roche Ltd. He has received honoraria for lectures and writings from MSD K. K., Chugai Pharmaceutical Co. Ltd., and Nobelpharma Co. Ltd. F. Pinto, M. Chamberlain, K. Hoang-Xuan, and A. Gonzalez-Aguilar report no disclosures. T. Batchelor serves as a consultant or advisor for Merck & Co., Inc., Roche, Kirin Pharmaceuticals, Spectrum, Champions Biotechnology, Advance Medical, and Novartis. He has received honoraria from UpToDate, Inc., Robert Michael Educational Institute LLC, Educational Concepts Group, Research to Practice, Imedex, Oakstone Medical Publishing, and American Society of Hematology. He has received research funding from Pfizer, AstraZeneca, Millennium, and NIH. J. Blay reports no disclosures. A. Korfel serves on the advisory board for Mundipharma and Riemser. She has received funding for travel from Mundipharma, Pfizer, Roche, and Riemser. She has received commercial research support from Mundipharma, Pfizer, Roche, and Riemser. R. Betensky has served on NIH Study Sections. She has received NIH funding for research (R01CA075971, R03CA165070, UL1RR025758, P50NS051343, P30CA006516, P50AG005134, P01AG036694, R01NS070834, R01AG026484, R33 DK074099, R01CA057683). She has received funding for travel to meetings for 2 Institute of Medicine Committees, for scientific conferences, and for seminars sponsored by consulting networks. She has served as associate editor for Biostatistics.; She has consulted for Columbia University, ME Medical Center, Edison Pharmaceuticals, Novartis Pharmaceuticals, Cowen Group, GLG Consulting, Guidepoint Global Consulting, Bank of America/Merrill Lynch, ISI Research, Invus Group, SimulConsult, DeMatteo Monness Consulting, Medpanel Consulting, Summer Street Research Partners, and Masimo. M. Lopes reports no disclosures. D. Schiff has served on advisory boards for Genentech. He serves on DSMBs for Celldex and Vascular Biogenics. He is a consultant without personal compensation for Tau Therapeutics and has received travel funding from Merck. He receives royalties from UpToDate. Go to Neurology.org for full disclosures. NR 34 TC 16 Z9 17 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD NOV 5 PY 2013 VL 81 IS 19 BP 1690 EP 1696 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA AA0FE UT WOS:000330770100012 PM 24107866 ER PT J AU Wrann, CD White, JP Salogiannnis, J Laznik-Bogoslavski, D Wu, J Ma, D Lin, JD Greenberg, ME Spiegelman, BM AF Wrann, Christiane D. White, James P. Salogiannnis, John Laznik-Bogoslavski, Dina Wu, Jun Ma, Di Lin, Jiandie D. Greenberg, Michael E. Spiegelman, Bruce M. TI Exercise Induces Hippocampal BDNF through a PGC-1 alpha/FNDC5 Pathway SO CELL METABOLISM LA English DT Article ID MITOCHONDRIAL BIOGENESIS; PHYSICAL-ACTIVITY; RECEPTOR-ALPHA; GROWTH-FACTOR; ERR-ALPHA; HEPATIC GLUCONEOGENESIS; SYNAPTIC PLASTICITY; COGNITIVE FUNCTION; ENERGY-METABOLISM; COACTIVATOR PGC-1 AB Exercise can improve cognitive function and has been linked to the increased expression of brain-derived neurotrophic factor (BDNF). However, the underlying molecular mechanisms driving the elevation of this neurotrophin remain unknown. Here we show that FNDC5, a previously identified muscle protein that is induced in exercise and is cleaved and secreted as irisin, is also elevated by endurance exercise in the hippocampus of mice. Neuronal Fndc5 gene expression is regulated by PGC-1 alpha, and Pgc1a(-/-) mice show reduced Fndc5 expression in the brain. Forced expression of FNDC5 in primary cortical neurons increases Bdnf expression, whereas RNAi-mediated knockdown of FNDC5 reduces Bdnf. Importantly, peripheral delivery of FNDC5 to the liver via adenoviral vectors, resulting in elevated blood irisin, induces expression of Bdnf and other neuroprotective genes in the hippocampus. Taken together, our findings link endurance exercise and the important metabolic mediators, PGC-1 alpha and FNDC5, with BDNF expression in the brain. C1 [Wrann, Christiane D.; White, James P.; Laznik-Bogoslavski, Dina; Wu, Jun; Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Wrann, Christiane D.; White, James P.; Laznik-Bogoslavski, Dina; Wu, Jun; Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA. [Salogiannnis, John; Greenberg, Michael E.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA. [Ma, Di; Lin, Jiandie D.] Univ Michigan, Med Ctr, Inst Life Sci, Ann Arbor, MI 48109 USA. [Ma, Di; Lin, Jiandie D.] Univ Michigan, Med Ctr, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA. RP Greenberg, ME (reprint author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA. EM michael_greenberg@hms.harvard.edu; bruce_spiegelman@dfci.harvard.edu FU German Research Foundation (DFG) [WR 157/3-1]; JPB Foundation; NIH [DK31405, DK90861] FX We are grateful to Alfredo Cassina-Gimenez (Dana-Farber Cancer Institute) and Alan R. Mardinly (Harvard Medical School) for helpful experimental advice and useful discussions. We thank Pere Puigserver for the plasmids for the lentiviral hairpins against Ppargc1a. C.D.W. was supported by a fellowship from the German Research Foundation (DFG, WR 157/3-1). This work is funded by the JPB Foundation and by NIH grants (DK31405 and DK90861) (to B.M.S.). B.M.S. is a shareholder and consultant to Ember Therapeutics. NR 65 TC 117 Z9 127 U1 8 U2 65 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1550-4131 EI 1932-7420 J9 CELL METAB JI Cell Metab. PD NOV 5 PY 2013 VL 18 IS 5 BP 649 EP 659 DI 10.1016/j.cmet.2013.09.008 PG 11 WC Cell Biology; Endocrinology & Metabolism SC Cell Biology; Endocrinology & Metabolism GA 255PW UT WOS:000327253300007 PM 24120943 ER PT J AU Cholerton, B Baker, LD Craft, S AF Cholerton, Brenna Baker, Laura D. Craft, Suzanne TI Insulin, cognition, and dementia SO EUROPEAN JOURNAL OF PHARMACOLOGY LA English DT Review DE Alzheimer's disease; Insulin; Cognition; Diabetes; Aging ID CENTRAL-NERVOUS-SYSTEM; ACTIVATED-RECEPTOR-GAMMA; MODERATE ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E GENOTYPE; CORONARY-ARTERY-DISEASE; TRANSGENIC MOUSE MODEL; MIDLIFE BLOOD-PRESSURE; IMPAIRED OLDER-ADULTS; VASCULAR RISK-FACTORS AB Cognitive disorders of aging represent a serious threat to the social and economic welfare of current society, It is now widely recognized that pathology related to such conditions, particularly Alzheimer's disease, likely begins years or decades prior to the onset of clinical dementia symptoms. This revelation has led researchers to consider candidate mechanisms precipitating the cascade of neuropathological events that eventually lead to clinical Alzheimer's disease. Insulin, a hormone with potent effects in the brain, has recently received a great deal of attention for its potential beneficial and protective role in cognitive function. Insulin resistance, which refers to the reduced sensitivity of target tissues to the favorable effects of insulin, is related to multiple chronic conditions known to impact cognition and increase dementia risk. With insulin resistance-associated conditions reaching epidemic proportions, the prevalence of Alzheimer's disease and other cognitive disorders will continue to rise exponentially. Fortunately, these chronic insulin-related conditions are amenable to pharmacological intervention. As a result, novel therapeutic strategies that focus on increasing insulin sensitivity in the brain may be an important target for protecting or treating cognitive decline. The following review will highlight our current understanding of the role of insulin in brain, potential mechanisms underlying the link between insulin resistance and dementia, and current experimental therapeutic strategies aimed at improving cognitive function via modifying the brain's insulin sensitivity. (C) 2013 Elsevier B.V. All rights reserved. C1 [Cholerton, Brenna] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Cholerton, Brenna] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Baker, Laura D.; Craft, Suzanne] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA. RP Craft, S (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA. EM suzcraft@wakehealth.edu FU NIA NIH HHS [R01 AG010880, P50 AG005136] NR 143 TC 48 Z9 48 U1 6 U2 23 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-2999 EI 1879-0712 J9 EUR J PHARMACOL JI Eur. J. Pharmacol. PD NOV 5 PY 2013 VL 719 IS 1-3 BP 170 EP 179 DI 10.1016/j.ejphar.2013.08.008 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 258VQ UT WOS:000327487200020 PM 24070815 ER PT J AU Lim, S Meigs, JB AF Lim, Soo Meigs, James B. TI Ectopic fat and cardiometabolic and vascular risk SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Review DE Ectopic fat; Cardiometabolic risk; Systemically acting fat; Locally acting fat ID EPICARDIAL ADIPOSE-TISSUE; TYPE-2 DIABETIC-PATIENTS; CORONARY-HEART-DISEASE; RENAL SINUS FAT; INSULIN-RESISTANCE ATHEROSCLEROSIS; CARDIOVASCULAR MAGNETIC-RESONANCE; VISCERAL ABDOMINAL FAT; CHRONIC KIDNEY-DISEASE; HUMAN SKELETAL-MUSCLE; TOTAL-BODY FAT AB Given that the variation in how regional adipose tissue handles and stores excess dietary energy has substantial cardiometabolic implications, ectopic fat distribution might be an important predictor of cardiometabolic and vascular risk, in addition to overall obesity itself. Conceptually, ectopic fat depots may be divided into systemically acting fat depots and locally acting fat depots. Systemically acting fat depots include visceral fat, fat in the liver, muscle, or neck, and subcutaneous fat. Accumulation in the abdominal visceral area, compared with overall obesity, has an equally or more important role in the development of cardiometabolic risk. Fat depots in liver/muscle tissue cause adverse cardiometabolic effects by affecting energy metabolism. Fat depots in lower-body subcutaneous areas may be protective regarding cardiometabolic risk, by trapping remnant energy. Fat accumulation in the neck is a unique type of fat depot that may increase cardiovascular risk by increasing insulin resistance. Locally acting fat depots include pericardial fat, perivascular fat, and renal sinus fat. These fat depots have effects primarily on adjacent anatomic organs, directly via lipotoxicity and indirectly via cytokine secretion. Pericardial fat is associated with coronary atherosclerosis. Perivascular fat may play an independent role in adverse vascular biology, including arterial stiffness. Renal sinus fat is a unique fat depot that may confer additional cardiometabolic risk. Thus, ectopic fat depots may contribute to the understanding of the link between body composition and cardiometabolic risk. In this review, we focus on the role and clinical implications of ectopic fat depots in cardiometabolic and vascular risk. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Lim, Soo; Meigs, James B.] Massachusetts Gen Hosp, Dept Med, Div Gen Med, Boston, MA 02114 USA. [Lim, Soo; Meigs, James B.] Harvard Univ, Sch Med, Boston, MA USA. [Lim, Soo] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Internal Med, Songnam 463707, South Korea. RP Lim, S (reprint author), Seoul Natl Univ, Coll Med, Bundang Hosp, Div Endocrinol & Metab,Dept Internal Med, 166 Gumi Ro, Songnam 463707, South Korea. EM limsoo@snu.ac.kr FU [2K24 DK080140] FX The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology. James B. Meigs is supported by 2K24 DK080140. NR 171 TC 47 Z9 47 U1 1 U2 21 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD NOV 5 PY 2013 VL 169 IS 3 BP 166 EP 176 DI 10.1016/j.ijcard.2013.08.077 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 254CH UT WOS:000327139800010 PM 24063931 ER PT J AU Bovenberg, MSS Degeling, MH Hejazi, S Amante, RJ van Keulen, M Jeuken, JWM Akbaripanahi, S Vleggeert-Lankamp, CLA Tannous, M Wesseling, P Wurdinger, T Tannous, BA AF Bovenberg, M. Sarah S. Degeling, M. Hannah Hejazi, Seyedali Amante, Romain J. van Keulen, Marte Jeuken, Judith W. M. Akbaripanahi, Sepideh Vleggeert-Lankamp, Carmen L. A. Tannous, Marie Wesseling, Pieter Wurdinger, Thomas Tannous, Bakhos A. TI Multiplex Blood Reporters for Simultaneous Monitoring of Cellular Processes SO ANALYTICAL CHEMISTRY LA English DT Article ID IN-VIVO; VARGULA-HILGENDORFII; GENE-EXPRESSION; PLASMID DNA; LUCIFERASE; GLIOBLASTOMA; THERAPY; CANCER; VITRO; MICE AB Reporters secreted into the conditioned medium of cells in culture or into blood in vivo have shown to be useful tools for simple and noninvasive monitoring of biological processes in real-time. Here, we characterize the naturally secreted Vargula luciferase as a secreted blood reporter and show that this reporter can be multiplexed with the secreted Gaussia luciferase and alkaline phosphatase for simultaneous monitoring of three different cellular processes in the same biological system. We applied this system to monitor the response of three different subsets of glioma cells to a clinically relevant chemotherapeutic agent in the same well in culture or animal in vivo. This system could be extended to any field to detect multiple processes in the same biological system and is amenable for high-throughput screening to find drugs that affect multiple cellular populations/phenomena simultaneously. C1 [Bovenberg, M. Sarah S.; Degeling, M. Hannah; Hejazi, Seyedali; Amante, Romain J.; van Keulen, Marte; Akbaripanahi, Sepideh; Wurdinger, Thomas; Tannous, Bakhos A.] Massachusetts Gen Hosp, Ctr Neurosci, Dept Neurol, Expt Therapeut & Mol Imaging Lab, Boston, MA 02129 USA. [Bovenberg, M. Sarah S.; Degeling, M. Hannah; Hejazi, Seyedali; Amante, Romain J.; van Keulen, Marte; Akbaripanahi, Sepideh; Wurdinger, Thomas; Tannous, Bakhos A.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA. [Bovenberg, M. Sarah S.; Degeling, M. Hannah; Vleggeert-Lankamp, Carmen L. A.] Leiden Univ, Med Ctr, Dept Neurosurg, NL-2333 ZA Leiden, Netherlands. [van Keulen, Marte; Wurdinger, Thomas] Vrije Univ Amsterdam Med Ctr, Ctr Canc, Dept Neurosurg, Neurooncol Res Grp, NL-1081 HZ Amsterdam, Netherlands. [Jeuken, Judith W. M.] PAMM, Dept Pathol, NL-5623 EJ Eindhoven, Netherlands. [Tannous, Marie] Notre Dame Univ Louaize, Fac Nat & Appl Sci, Zouk Mosbeh, Lebanon. [Wesseling, Pieter] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 GA Nijmegen, Netherlands. [Wesseling, Pieter] Vrije Univ Amsterdam Med Ctr, Dept Pathol, NL-1081 HZ Amsterdam, Netherlands. RP Tannous, BA (reprint author), Massachusetts Gen Hosp, Ctr Neurosci, Bldg 149,13th St, Charlestown, MA 02129 USA. EM btannous@hms.harvard.edu FU NIH/NINDS [P30NS045776, 1R01NS064983]; NIH/NCI [1R01CA166077]; Fulbright scholarship; Huygens Scholarship Program; VSB Foundation; Saal van Zwanenberg Foundation; Dr. Hendrik Muller Vaderlandsch fonds; Dutch Cancer Society (ICWF Kankerbestrijding); Hersenstichting/Dutch Brain Foundation; Jo Keur Foundation (Leiden University Medical Center, the Netherlands) FX This work was supported by grants from NIH/NINDS P30NS045776, 1R01NS064983, and NIH/NCI 1R01CA166077 (BAT). M.S.B. was supported by a Fulbright scholarship, the Huygens Scholarship Program, the VSB Foundation, and the Saal van Zwanenberg Foundation. M.H.D. was supported by a Fulbright scholarship, the Saal van Zwanenberg Foundation, the VSB Foundation, the Dr. Hendrik Muller Vaderlandsch fonds, the Dutch Cancer Society (ICWF Kankerbestrijding), the Hersenstichting/Dutch Brain Foundation, and the Jo Keur Foundation (Leiden University Medical Center, the Netherlands). NR 19 TC 2 Z9 3 U1 0 U2 9 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 EI 1520-6882 J9 ANAL CHEM JI Anal. Chem. PD NOV 5 PY 2013 VL 85 IS 21 BP 10205 EP 10210 DI 10.1021/ac401798v PG 6 WC Chemistry, Analytical SC Chemistry GA 248OQ UT WOS:000326711400035 PM 24131224 ER PT J AU Miquel, M Spampinato, U Latxague, C Aviles-Olmos, I Bader, B Bertram, K Bhatia, K Burbaud, P Burghaus, L Cho, JW Cuny, E Danek, A Foltynie, T Ruiz, PJG Gimenez-Roldan, S Guehl, D Guridi, J Hariz, M Jarman, P Kefalopoulou, ZM Limousin, P Lipsman, N Lozano, AM Moro, E Ngy, D Rodriguez-Oroz, MC Shang, HF Shin, H Walker, RH Yokochi, F Zrinzo, L Tison, F AF Miquel, Marie Spampinato, Umberto Latxague, Chrystelle Aviles-Olmos, Iciar Bader, Benedikt Bertram, Kelly Bhatia, Kailash Burbaud, Pierre Burghaus, Lothar Cho, Jin Whan Cuny, Emmanuel Danek, Adrian Foltynie, Thomas Garcia Ruiz, Pedro J. Gimenez-Roldan, Santiago Guehl, Dominique Guridi, Jorge Hariz, Marwan Jarman, Paul Kefalopoulou, Zinovia Maria Limousin, Patricia Lipsman, Nir Lozano, Andres M. Moro, Elena Ngy, Dhita Cruz Rodriguez-Oroz, Maria Shang, Huifang Shin, Hyeeun Walker, Ruth H. Yokochi, Fusako Zrinzo, Ludvic Tison, Francois TI Short and Long Term Outcome of Bilateral Pallidal Stimulation in Chorea-Acanthocytosis SO PLOS ONE LA English DT Article ID DEEP-BRAIN-STIMULATION; PRIMARY GENERALIZED DYSTONIA; PARKINSONS-DISEASE; GLOBUS-PALLIDUS; FOLLOW-UP; HUNTINGTONS-DISEASE; RATING-SCALE; NEUROACANTHOCYTOSIS; DISORDERS; NEURODEGENERATION AB Background: Chorea-acanthocytosis (ChAc) is a neuroacanthocytosis syndrome presenting with severe movement disorders poorly responsive to drug therapy. Case reports suggest that bilateral deep brain stimulation (DBS) of the ventro-postero-lateral internal globus pallidus (GPi) may benefit these patients. To explore this issue, the present multicentre (n=12) retrospective study collected the short and long term outcome of 15 patients who underwent DBS. Methods: Data were collected in a standardized way 2-6 months preoperatively, 1-5 months (early) and 6 months or more (late) after surgery at the last follow-up visit (mean follow-up: 29.5 months). Results: Motor severity, assessed by the Unified Huntington's Disease Rating Scale-Motor Score, UHDRS-MS), was significantly reduced at both early and late post-surgery time points (mean improvement 54.3% and 44.1%, respectively). Functional capacity (UHDRS-Functional Capacity Score) was also significantly improved at both post-surgery time points (mean 75.5% and 73.3%, respectively), whereas incapacity (UHDRS-Independence Score) improvement reached significance at early post-surgery only (mean 37.3%). Long term significant improvement of motor symptom severity (>= 20 % from baseline) was observed in 61.5 % of the patients. Chorea and dystonia improved, whereas effects on dysarthria and swallowing were variable. Parkinsonism did not improve. Linear regression analysis showed that preoperative motor severity predicted motor improvement at both post-surgery time points. The most serious adverse event was device infection and cerebral abscess, and one patient died suddenly of unclear cause, 4 years after surgery. Conclusion: This study shows that bilateral DBS of the GPi effectively reduces the severity of drug-resistant hyperkinetic movement disorders such as present in ChAc. C1 [Miquel, Marie; Spampinato, Umberto; Latxague, Chrystelle; Tison, Francois] CHU Bordeaux, Serv Neurol, Bordeaux, France. [Miquel, Marie] CH Francois Mitterrand, Serv Neurol, Pau, France. [Spampinato, Umberto] Univ Bordeaux, INSERM, U862, Neuroctr Magendie, Bordeaux, France. [Spampinato, Umberto; Aviles-Olmos, Iciar; Foltynie, Thomas; Hariz, Marwan; Kefalopoulou, Zinovia Maria; Limousin, Patricia; Zrinzo, Ludvic] UCL, Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, Unit Funct Neurosurg, London, England. [Bader, Benedikt; Danek, Adrian] Univ Munich, Neurol Klin & Poliklin, Munich, Germany. [Bertram, Kelly] Alfred Hosp, Melbourne, Vic, Australia. [Bertram, Kelly] Monash Univ, Van Cleef Roet Ctr Nervous Dis, Melbourne, Vic 3004, Australia. [Bhatia, Kailash] UCL, Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London, England. [Burbaud, Pierre; Guehl, Dominique] CHU Bordeaux, Serv Neurophysiol Clin, Bordeaux, France. [Burghaus, Lothar] Univ Hosp Cologne, Dept Neurol, Cologne, Germany. [Cho, Jin Whan; Shin, Hyeeun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurol, Seoul, South Korea. [Cuny, Emmanuel] CHU Bordeaux, Serv Neurochirurg, Bordeaux, France. [Garcia Ruiz, Pedro J.] Fdn Jimenez Diaz, Dept Neurol, E-28040 Madrid, Spain. [Gimenez-Roldan, Santiago] Univ Gregorio Maranon, Gen Hosp, Serv Neurol, Madrid, Spain. [Guridi, Jorge] Univ Navarra Clin, Dept Neurol & Neurosurg, Pamplona, Spain. [Jarman, Paul] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England. [Lipsman, Nir; Lozano, Andres M.] Univ Toronto, Toronto Western Hosp, Univ Hlth Network, Div Neurosurg, Toronto, ON M5T 2S8, Canada. [Moro, Elena] Univ Toronto, Toronto Western Hosp, Univ Hlth Network, Morton & Gloria Shulman Movement Disorders Ctr, Toronto, ON M5T 2S8, Canada. [Moro, Elena] Univ Hosp Ctr Grenoble, Dept Psychiat & Neurol, Movement Disorders Ctr, Grenoble, France. [Ngy, Dhita; Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. [Ngy, Dhita] Avicenna Med Ctr, New York, NY USA. [Cruz Rodriguez-Oroz, Maria] Univ Hosp Donostia, BioDonostia Res Inst, Dept Neurol, Neurosci Unit, San Sebastian, Spain. [Shang, Huifang] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu 610064, Sichuan, Peoples R China. [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. [Yokochi, Fusako] Tokyo Metropolitan Neurol Hosp, Dept Neurol, Fuchu, Tokyo, Japan. [Tison, Francois] Univ Bordeaux, Inst Malad Neurodegenerat, UMR 5293, Bordeaux, France. [Tison, Francois] CNRS, Inst Malad Neurodegenerat, UMR 5293, Bordeaux, France. RP Spampinato, U (reprint author), CHU Bordeaux, Serv Neurol, Bordeaux, France. EM umberto.spampinato@inserm.fr OI Bhatia, Kailash/0000-0001-8185-286X FU ERA-net E-Rare consortium European Multidisciplinary Initiative on Neuroacanthocytosis (EMINA); Neuroacanthocytosis Advocacy; EMINA consortium [BMBF 01GM1003] FX This study was supported by the ERA-net E-Rare consortium European Multidisciplinary Initiative on Neuroacanthocytosis (EMINA); www.e-rare.eu/node/474. Western blot analysis for chorein was performed with the financial support of the Neuroacanthocytosis Advocacy and the EMINA consortium (BMBF 01GM1003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 40 TC 12 Z9 13 U1 0 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 5 PY 2013 VL 8 IS 11 AR e79241 DI 10.1371/journal.pone.0079241 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 247EE UT WOS:000326597400054 PM 24223913 ER PT J AU Yamada, T Azuma, K Muta, E Kim, J Sugawara, S Zhang, GL Matsueda, S Kasama-Kawaguchi, Y Yamashita, Y Yamashita, T Nishio, K Itoh, K Hoshino, T Sasada, T AF Yamada, Teppei Azuma, Koichi Muta, Emi Kim, Jintaek Sugawara, Shunichi Zhang, Guang Lan Matsueda, Satoko Kasama-Kawaguchi, Yuri Yamashita, Yuichi Yamashita, Takuto Nishio, Kazuto Itoh, Kyogo Hoshino, Tomoaki Sasada, Tetsuro TI EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation SO PLOS ONE LA English DT Article ID GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; THERAPEUTIC CANCER VACCINES; LUNG-CANCER; ACQUIRED-RESISTANCE; CLINICAL-RESPONSE; PEPTIDE COMPLEX; POINT MUTATION; HIGH-AFFINITY; GEFITINIB AB Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, has achieved high clinical response rates in patients with non-small cell lung cancers (NSCLCs). However, over time, most tumors develop acquired resistance to EGFR-TKIs, which is associated with the secondary EGFR T790M resistance mutation in about half the cases. Currently there are no effective treatment options for patients with this resistance mutation. Here we identified two novel HLA-A*0201 (A2)-restricted T cell epitopes containing the mutated methionine residue of the EGFR T790M mutation, T790M-5 (MQLMPFGCLL) and T790M-7 (LIMQLMPFGCL), as potential targets for EGFR-TKI-resistant patients. When peripheral blood cells were repeatedly stimulated in vitro with these two peptides and assessed by antigen-specific IFN-gamma secretion, T cell lines responsive to T790M-5 and T790M-7 were established in 5 of 6 (83%) and 3 of 6 (50%) healthy donors, respectively. Additionally, the T790M-5- and T790M-7-specific T cell lines displayed an MHC class I-restricted reactivity against NSCLC cell lines expressing both HLA-A2 and the T790M mutation. Interestingly, the NSCLC patients with antigen-specific T cell responses to these epitopes showed a significantly less frequency of EGFR-T790M mutation than those without them [1 of 7 (14%) vs 9 of 15 (60%); chi-squared test, p = 0.0449], indicating the negative correlation between the immune responses to the EGFR-T790M-derived epitopes and the presence of EGFR-T790M mutation in NSCLC patients. This finding could possibly be explained by the hypothesis that immune responses to the mutated neo-antigens derived from T790M might prevent the emergence of tumor cell variants with the T790M resistance mutation in NSCLC patients during EGFR-TKI treatment. Together, our results suggest that the identified T cell epitopes might provide a novel immunotherapeutic approach for prevention and/or treatment of EGFR-TKI resistance with the secondary EGFR T790M resistance mutation in NSCLC patients. C1 [Yamada, Teppei; Muta, Emi; Kim, Jintaek; Matsueda, Satoko; Kasama-Kawaguchi, Yuri; Itoh, Kyogo; Sasada, Tetsuro] Kurume Univ, Sch Med, Dept Immunol & Immunotherapy, Kurume, Fukuoka 830, Japan. [Yamada, Teppei; Yamashita, Yuichi] Fukuoka Univ, Sch Med, Dept Surg, Fukuoka 81401, Japan. [Azuma, Koichi; Hoshino, Tomoaki] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Kurume, Fukuoka 830, Japan. [Sugawara, Shunichi] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Miyagi, Japan. [Zhang, Guang Lan] Boston Univ, Metropolitan Coll, Boston, MA 02215 USA. [Zhang, Guang Lan] Harvard Univ, Sch Med, Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. [Yamashita, Takuto] Kurume Univ, Grad Sch Med, Ctr Biostat, Kurume, Fukuoka 830, Japan. [Nishio, Kazuto] Kinki Univ, Sch Med, Dept Genome Biol, Osaka 589, Japan. RP Sasada, T (reprint author), Kurume Univ, Sch Med, Dept Immunol & Immunotherapy, Kurume, Fukuoka 830, Japan. EM tsasada@med.kurume-u.ac.jp FU JSPS [23591913]; Mitsubishi Foundation FX This study was supported by the JSPS Grant-in-Aid for Scientific Research (C) 23591913 and the Mitsubishi Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 49 TC 7 Z9 8 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 5 PY 2013 VL 8 IS 11 AR e78389 DI 10.1371/journal.pone.0078389 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 247EE UT WOS:000326597400023 PM 24223798 ER PT J AU Desbordes, G Negi, LT AF Desbordes, Gaelle Negi, Lobsang T. TI A new era for mind studies: training investigators in both scientific and contemplative methods of inquiry SO FRONTIERS IN HUMAN NEUROSCIENCE LA English DT Editorial Material DE contemplative science; subjective experience; neurophenomenology; consciousness; meditation ID COMPASSION MEDITATION; SUBJECTIVE EXPERIENCE; BRAIN DYNAMICS; PERSPECTIVES; SYNCHRONY; RESPONSES; BUDDHIST C1 [Desbordes, Gaelle] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Desbordes, Gaelle] Boston Univ, Ctr Computat Neurosci & Neural Technol, Boston, MA 02215 USA. [Negi, Lobsang T.] Emory Univ, Dept Relig, Atlanta, GA 30322 USA. RP Desbordes, G (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. EM desbordes@gmail.com RI Desbordes, Gaelle/B-5924-2008 OI Desbordes, Gaelle/0000-0002-6117-2880 NR 45 TC 8 Z9 8 U1 7 U2 19 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1662-5161 J9 FRONT HUM NEUROSCI JI Front. Hum. Neurosci. PD NOV 5 PY 2013 VL 7 AR 741 DI 10.3389/fnhum.2013.00741 PG 4 WC Neurosciences; Psychology SC Neurosciences & Neurology; Psychology GA 245WP UT WOS:000326494900001 PM 24204340 ER PT J AU Alam, SM Dennison, SM Aussedat, B Vohra, Y Park, PK Fernandez-Tejada, A Stewart, S Jaeger, FH Anasti, K Blinn, JH Kepler, TB Bonsignori, M Liao, HX Sodroski, JG Danishefsky, SJ Haynes, BF AF Alam, S. Munir Dennison, S. Moses Aussedat, Baptiste Vohra, Yusuf Park, Peter K. Fernandez-Tejada, Alberto Stewart, Shelley Jaeger, Frederick H. Anasti, Kara Blinn, Julie H. Kepler, Thomas B. Bonsignori, Mattia Liao, Hua-Xin Sodroski, Joseph G. Danishefsky, Samuel J. Haynes, Barton F. TI Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID HUMAN MONOCLONAL-ANTIBODIES; ENVELOPE; PROTEIN; DESIGN; PG9; PEPTIDES; EPITOPES; BINDING; RV144; IDENTIFICATION AB Current HIV-1 vaccines elicit strain-specific neutralizing antibodies. Broadly neutralizing antibodies (BnAbs) are not induced by current vaccines, but are found in plasma in similar to 20% of HIV-1-infected individuals after several years of infection. One strategy for induction of unfavored antibody responses is to produce homogeneous immunogens that selectively express BnAb epitopes but minimally express dominant strain-specific epitopes. Here we report that synthetic, homogeneously glycosylated peptides that bind avidly to variable loop 1/2 (V1V2) BnAbs PG9 and CH01 bind minimally to strain-specific neutralizing V2 antibodies that are targeted to the same envelope polypeptide site. Both oligomannose derivatization and conformational stabilization by disulfide-linked dimer formation of synthetic V1V2 peptides were required for strong binding of V1V2 BnAbs. An HIV-1 vaccine should target BnAb unmutated common ancestor (UCA) B-cell receptors of naive B cells, but to date no HIV-1 envelope constructs have been found that bind to the UCA of V1V2 BnAb PG9. We demonstrate herein that V1V2 glycopeptide dimers bearing Man(5)GlcNAc(2) glycan units bind with apparent nanomolar affinities to UCAs of V1V2 BnAbs PG9 and CH01 and with micromolar affinity to the UCA of a V2 strain-specific antibody. The higher-affinity binding of these V1V2 glycopeptides to BnAbs and their UCAs renders these glycopeptide constructs particularly attractive immunogens for targeting subdominant HIV-1 envelope V1V2-neutralizing antibody-producing B cells. C1 [Alam, S. Munir; Dennison, S. Moses; Stewart, Shelley; Jaeger, Frederick H.; Anasti, Kara; Blinn, Julie H.; Bonsignori, Mattia; Liao, Hua-Xin; Haynes, Barton F.] Duke Univ, Med Ctr, Duke Human Vaccine Inst, Durham, NC 27710 USA. [Alam, S. Munir; Bonsignori, Mattia; Liao, Hua-Xin; Haynes, Barton F.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Alam, S. Munir] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA. [Haynes, Barton F.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA. [Aussedat, Baptiste; Vohra, Yusuf; Park, Peter K.; Fernandez-Tejada, Alberto; Danishefsky, Samuel J.] Sloan Kettering Inst Canc Res, Bioorgan Chem Lab, New York, NY 10065 USA. [Kepler, Thomas B.] Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA. [Sodroski, Joseph G.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Sodroski, Joseph G.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02215 USA. [Sodroski, Joseph G.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. [Sodroski, Joseph G.] MIT, Massachusetts Gen Hosp, Ragon Inst, Cambridge, MA 02139 USA. [Sodroski, Joseph G.] Harvard Univ, Cambridge, MA 02139 USA. [Danishefsky, Samuel J.] Columbia Univ, Dept Chem, New York, NY 10027 USA. RP Danishefsky, SJ (reprint author), Sloan Kettering Inst Canc Res, Bioorgan Chem Lab, New York, NY 10065 USA. EM s-danishefsky@ski.mskcc.org; barton.haynes@duke.edu RI Fernandez-Tejada, Alberto/M-2439-2015; OI Fernandez-Tejada, Alberto/0000-0002-1680-0059; Vohra, Yusuf/0000-0003-0385-2965 FU Center for HIV/AIDS Vaccine Immunology (CHAVI) [Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)] [AI0678501]; Duke Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (CHAVI-ID) (DAIDS, NIAID, NIH) [UM1-AI100645]; Collaboration for AIDS Vaccine Discovery Grant from The Bill and Melinda Gates Foundation [OPP1033098]; American Cancer Society [PF-11-014-01-CDD]; European Commission FX We acknowledge the technical assistance of Hieu Nguyen (Duke Human Vaccine Institute) for SDS/PAGE analysis of V1V2 peptides, and Kim McClammy for secretarial assistance. This work was funded by Center for HIV/AIDS Vaccine Immunology (CHAVI) [Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)] Grant AI0678501; Duke Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery (CHAVI-ID) (DAIDS, NIAID, NIH) Grant UM1-AI100645; and a Collaboration for AIDS Vaccine Discovery Grant (OPP1033098; to B. F. H.) from The Bill and Melinda Gates Foundation. P. K. P. was supported by a postdoctoral fellowship (PF-11-014-01-CDD) from the American Cancer Society. A.F.-T. thanks the European Commission (Marie Curie International Outgoing Fellowship) for financial support. NR 42 TC 36 Z9 36 U1 1 U2 26 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 5 PY 2013 VL 110 IS 45 BP 18214 EP 18219 DI 10.1073/pnas.1317855110 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 246PG UT WOS:000326550800051 PM 24145434 ER PT J AU Yuan, P Ito, K Perez-Lorenzo, R Del Guzzo, C Lee, JH Shen, CH Bosenberg, MW McMahon, M Cantley, LC Zheng, B AF Yuan, Ping Ito, Koichi Perez-Lorenzo, Rolando Del Guzzo, Christina Lee, Jung Hyun Shen, Che-Hung Bosenberg, Marcus W. McMahon, Martin Cantley, Lewis C. Zheng, Bin TI Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE LKB1; Vemurafenib ID METASTATIC MELANOMA; LKB1-AMPK PATHWAY; BRAF INHIBITORS; METFORMIN; METABOLISM; GROWTH; CANCER; RESISTANCE; MUTATIONS; TUMORIGENESIS AB Biguanides, such as the diabetes therapeutics metformin and phenformin, have demonstrated antitumor activity both in vitro and in vivo. The energy-sensing AMP-activated protein kinase (AMPK) is known to be a major cellular target of biguanides. Based on our discovery of cross-talk between the AMPK and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) signaling pathways, we investigated the antitumor effects of combining phenformin with a BRAF inhibitor PLX4720 on the proliferation of BRAF-mutated melanoma cells in vitro and on BRAF-driven tumor growth in vivo. Cotreatment of BRAF-mutated melanoma cell lines with phenformin and PLX4720 resulted in synergistic inhibition of cell viability, compared with the effects of the single agent alone. Moreover, treatment with phenformin significantly delayed the development of resistance to PLX4720 in cultured melanoma cells. Biochemical analyses showed that phenformin and PLX4720 exerted cooperative effects on inhibiting mTOR signaling and inducing apoptosis. Noticeably, phenformin selectively targeted subpopulations of cells expressing JARID1B, a marker for slow cycling melanoma cells, whereas PLX4720 selectively targeted JARID1B-negative cells. Finally, in contrast to their use as single agents, the combination of phenformin and PLX4720 induced tumor regression in both nude mice bearing melanoma xenografts and in a genetically engineered BRAF(V600E)/PTENnull-driven mouse model of melanoma. These results strongly suggest that significant therapeutic advantage may be achieved by combining AMPK activators such as phenformin with BRAF inhbitors for the treatment of melanoma. C1 [Yuan, Ping; Lee, Jung Hyun; Shen, Che-Hung; Zheng, Bin] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA. [Yuan, Ping; Lee, Jung Hyun; Shen, Che-Hung; Zheng, Bin] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Ito, Koichi; Perez-Lorenzo, Rolando; Del Guzzo, Christina] Columbia Univ, Med Ctr, Inst Canc Genet, New York, NY 10032 USA. [Ito, Koichi; Perez-Lorenzo, Rolando; Del Guzzo, Christina] Columbia Univ, Med Ctr, Dept Dermatol, New York, NY 10032 USA. [Ito, Koichi; Perez-Lorenzo, Rolando; Del Guzzo, Christina] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY 10032 USA. [Bosenberg, Marcus W.] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA. [McMahon, Martin] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA. [McMahon, Martin] Univ Calif San Francisco, Dept Cell & Mol Pharmacol, San Francisco, CA 94158 USA. [Cantley, Lewis C.] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA. RP Cantley, LC (reprint author), Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA. EM lcantley@hms.harvard.edu; bin.zheng@cbrc2.mgh.harvard.edu RI Cantley, Lewis/D-1800-2014 OI Cantley, Lewis/0000-0002-1298-7653 FU National Institutes of Health [R00-CA133245, R01-CA166717, R01-GM56302, P01-CA120964]; Elizabeth and Oliver Stanton Young Investigator Award from the Melanoma Research Alliance; V Foundation Scholar award; Irma T. Hirschl Career Scientist Award FX We thank Jaewoo Choi, Lee Hedden, Sheila Shaigany, Allison Wang, and Yaqing Zhang for technical assistance; members of the B.Z. laboratory for helpful discussions; and Ken Swanson for critical comments on the manuscript. This work is supported by National Institutes of Health Grants R00-CA133245 (to B.Z.), R01-CA166717 (to B.Z.), R01-GM56302 (to L. C. C.), and P01-CA120964 (to L. C. C.); the Elizabeth and Oliver Stanton Young Investigator Award from the Melanoma Research Alliance; a V Foundation Scholar award; and an Irma T. Hirschl Career Scientist Award (to B.Z.). NR 30 TC 57 Z9 57 U1 2 U2 13 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 5 PY 2013 VL 110 IS 45 BP 18226 EP 18231 DI 10.1073/pnas.1317577110 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 246PG UT WOS:000326550800053 PM 24145418 ER PT J AU Mao, YD Castillo-Menendez, LR Sodroski, JG AF Mao, Youdong Castillo-Menendez, Luis R. Sodroski, Joseph G. TI Reply to Subramaniam, van Heel, and Henderson: Validity of the cryo- electron microscopy structures of the HIV-1 envelope glycoprotein complex SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Letter ID SINGLE-PARTICLE; MOLECULAR ARCHITECTURE; EM STRUCTURE; CRYOMICROSCOPY; VALIDATION; IMAGES; TRIMER C1 [Mao, Youdong; Castillo-Menendez, Luis R.; Sodroski, Joseph G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS,Dept Microbiol & Immunob, Boston, MA 02115 USA. [Sodroski, Joseph G.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. [Sodroski, Joseph G.] MIT, Ragon Inst MGH, Cambridge, MA 02139 USA. [Sodroski, Joseph G.] Harvard Univ, Cambridge, MA 02139 USA. RP Sodroski, JG (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS,Dept Microbiol & Immunob, 44 Binney St, Boston, MA 02115 USA. EM joseph_sodroski@dfci.harvard.edu FU NIAID NIH HHS [R01 AI093256, R37 AI024755, UM1 AI100645] NR 19 TC 9 Z9 9 U1 0 U2 14 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 5 PY 2013 VL 110 IS 45 BP E4178 EP E4182 DI 10.1073/pnas.1316666110 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 246PG UT WOS:000326550800005 PM 24350339 ER PT J AU Huang, G Schaff, HV Sundt, TM Rahimtoola, SH AF Huang, Grace Schaff, Hartzell V. Sundt, Thoralf M. Rahimtoola, Shahbudin H. TI Treatment of Obstructive Thrombosed Prosthetic Heart Valve SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Review DE obstructive valve thrombosis; prosthetic heart valve thrombosis; valve thrombosis ID THROMBOLYTIC THERAPY; SURGICAL-TREATMENT; SINGLE-CENTER; 1ST LINE; MANAGEMENT; EXPERIENCE; DISEASE; TERM; THROMBOEMBOLISM; FIBRINOLYSIS AB Obstructive thrombosed prosthetic heart valve (OTPHV) is a serious complication of heart valve replacement. There are no generally accepted criteria for management of these patients. Therefore, in September 2012, a literature survey of studies published after 1995 was performed to analyze the data regarding clinical outcomes of patients with OTPHV treated with thrombolytic agents and with surgery since 1996. The search yielded appropriate and relevant studies, which included 17 studies comprising 756 patients who had received thrombolytic therapy and 13 studies comprising 662 patients who had received surgery. The data on these 2 groups was analyzed in detail relating to frequency of use of the diagnostic studies, baseline patient data, and on the rate of complete success, outcomes, and complications of the therapy they had received, and the limitations of the studies. We have then developed a strategy for therapy of OTPHV. (C) 2013 by the American College of Cardiology Foundation C1 [Huang, Grace; Rahimtoola, Shahbudin H.] Univ So Calif, LAC USC Med Ctr, Keck Sch Med,Griffith Ctr, Div Cardiovasc Med,Dept Med, Los Angeles, CA 90033 USA. [Schaff, Hartzell V.] Mayo Clin, Div Cardiovasc Surg, Rochester, MN USA. [Sundt, Thoralf M.] Massachusetts Gen Hosp, Div Cardiac Surg, Boston, MA 02114 USA. RP Rahimtoola, SH (reprint author), Univ So Calif, LAC USC Med Ctr, 1200 North State St Old Gen Hosp Room 3221, Los Angeles, CA 90033 USA. EM rahimtoo@usc.edu OI Schaff, Hartzell/0000-0003-0994-027X NR 33 TC 15 Z9 16 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 5 PY 2013 VL 62 IS 19 BP 1731 EP 1736 DI 10.1016/j.jacc.2013.07.075 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 242KI UT WOS:000326239100002 PM 23994405 ER PT J AU Jia, HB Abtahian, F Aguirre, AD Lee, S Chia, S Lowe, H Kato, KJ Yonetsu, T Vergallo, R Hu, SN Tian, JW Lee, H Park, SJ Jang, YS Raffel, OC Mizuno, K Uemura, S Itoh, T Kakuta, T Choi, SY Dauerman, HL Prasad, A Toma, C McNulty, I Zhang, S Yu, B Fuster, V Narula, J Virmani, R Jang, IK AF Jia, Haibo Abtahian, Farhad Aguirre, Aaron D. Lee, Stephen Chia, Stanley Lowe, Harry Kato, Koji Yonetsu, Taishi Vergallo, Rocco Hu, Sining Tian, Jinwei Lee, Hang Park, Seung-Jung Jang, Yang-Soo Raffel, Owen C. Mizuno, Kyoichi Uemura, Shiro Itoh, Tomonori Kakuta, Tsunekazu Choi, So-Yeon Dauerman, Harold L. Prasad, Abhiram Toma, Catalin McNulty, Iris Zhang, Shaosong Yu, Bo Fuster, Valentine Narula, Jagat Virmani, Renu Jang, Ik-Kyung TI In Vivo Diagnosis of Plaque Erosion and Calcified Nodule in Patients With Acute Coronary Syndrome by Intravascular Optical Coherence Tomography SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE acute coronary syndrome; calcified nodule; optical coherence tomography; plaque erosion; plaque rupture ID ATHEROSCLEROTIC PLAQUES; MYOCARDIAL-INFARCTION; VULNERABLE PLAQUE; CULPRIT LESION; DEATH; MORPHOLOGY; ULTRASOUND; RUPTURE; THROMBOSIS AB Objectives The aim of this study was to characterize the morphological features of plaque erosion and calcified nodule in patients with acute coronary syndrome (ACS) by optical coherence tomography (OCT). Background Plaque erosion and calcified nodule have not been systematically investigated in vivo. Methods A total of 126 patients with ACS who had undergone pre-intervention OCT imaging were included. The culprit lesions were classified as plaque rupture (PR), erosion (OCT-erosion), calcified nodule (OCT-CN), or with a new set of diagnostic criteria for OCT. Results The incidences of PR, OCT-erosion, and OCT-CN were 43.7%, 31.0%, and 7.9%, respectively. Patients with OCTerosion were the youngest, compared with those with PR and OCT-CN (53.8 +/- 13.1 years vs. 60.6 +/- 11.5 years, 65.1 +/- 5.0 years, p = 0.005). Compared with patients with PR, presentation with non-ST-segment elevation ACS was more common in patients with OCT-erosion (61.5% vs. 29.1%, p = 0.008) and OCT-CN (100% vs. 29.1%, p < 0.001). The OCT-erosion had a lower frequency of lipid plaque (43.6% vs. 100%, p < 0.001), thicker fibrous cap (169.3 +/- 99.1 mu m vs. 60.4 +/- 16.6 mu m, p < 0.001), and smaller lipid arc (202.8 +/- 73.6 degrees vs. 275.8 +/- 60.4 degrees, p < 0.001) than PR. The diameter stenosis was least severe in OCT-erosion, followed by OCT-CN and PR (55.4 +/- 14.7% vs. 66.1 +/- 13.5% vs. 68.8 +/- 12.9%, p < 0.001). Conclusions Optical coherence tomography is a promising modality for identifying OCT-erosion and OCT-CN in vivo. The OCTerosion is a frequent finding in patients with ACS, especially in those with non-ST-segment elevation ACS and younger patients. The OCT-CN is the least common etiology for ACS and is more common in older patients. (The Massachusetts General Hospital Optical Coherence Tomography Registry; NCT01110538) (C) 2013 by the American College of Cardiology Foundation C1 [Jia, Haibo; Hu, Sining; Tian, Jinwei; Yu, Bo] Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Key Lab Myocardial Ischemia,Chinese Minist Educ, Harbin 150086, Peoples R China. [Jia, Haibo; Abtahian, Farhad; Kato, Koji; Yonetsu, Taishi; Vergallo, Rocco; Hu, Sining; Tian, Jinwei; McNulty, Iris; Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA. [Aguirre, Aaron D.; Jang, Yang-Soo] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. [Lee, Stephen] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China. [Chia, Stanley] Natl Heart Ctr Singapore, Singapore, Singapore. [Lowe, Harry] Concord Repatriat Gen Hosp, Sydney, NSW, Australia. [Lee, Hang] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA. [Park, Seung-Jung] Asan Med Ctr, Seoul, South Korea. [Aguirre, Aaron D.; Jang, Yang-Soo] Yonsei Univ, Severance Cardiovasc Hosp, Seoul 120749, South Korea. [Raffel, Owen C.] Prince Charles Hosp, Brisbane, Qld 4032, Australia. [Mizuno, Kyoichi] Nippon Med Sch, Dept Cardiovasc Med, Tokyo 113, Japan. [Uemura, Shiro] Nara Med Univ, Nara, Japan. [Itoh, Tomonori] Iwate Med Sch, Mem Heart Ctr, Div Cardiol, Morioka, Iwate, Japan. [Kakuta, Tsunekazu] Tsuchiura Kyodo Gen Hosp, Tsuchiura, Ibaraki, Japan. [Choi, So-Yeon] Ajou Univ Hosp, Suwon, South Korea. [Dauerman, Harold L.] Univ Vermont, Coll Med, Fletcher Allen Healthcare, Div Cardiol, Burlington, VT USA. [Prasad, Abhiram] Mayo Clin, Dept Internal Med, Div Cardiovasc Med, Rochester, MN USA. [Toma, Catalin] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Zhang, Shaosong] LightLab Imaging Inc, St Jude Med, Westford, MA USA. [Fuster, Valentine; Narula, Jagat] Mt Sinai Hosp, New York, NY 10029 USA. [Virmani, Renu] Cardiovasc Pathol Inst, Gaithersburg, MD USA. RP Yu, B (reprint author), Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Key Lab Myocardial Ischemia,Chinese Minist Educ, Harbin 150086, Peoples R China. EM yubodr@163.com; ijang@partners.org RI Fuster, Valentin/H-4319-2015 OI Fuster, Valentin/0000-0002-9043-9986 FU St. Jude Medical; Cardiology Division of Massachusetts General Hospital; National Natural Science Foundation of China [81200076, 30871064/C140401]; Open Foundation of Key Laboratory of Myocardial Ischemia (Harbin Medical University); Chinese Ministry of Education [KF201205]; National Institute of Health [T32HL094301]; Enrico ed Enrica Sovena Foundation, Italy; Abbott Vascular and Medtronic; Abbott Vascular; BioSensors International; Biotronik; Boston Scientific; Medtronic; MicroPort Medical; OrbusNeich Medical; SINO Medical Technology; Terumo Corporation; LightLab Imaging/St. Jude Medical FX This study was supported by research grants from St. Jude Medical, the Cardiology Division of Massachusetts General Hospital. Dr. Jia has received a grant from the National Natural Science Foundation of China (grant contract number: 81200076) and Open Foundation of Key Laboratory of Myocardial Ischemia (Harbin Medical University), Chinese Ministry of Education (KF201205). Dr. Aguirre is funded by National Institute of Health T32HL094301. Dr. Vergallo has received a grant from the Enrico ed Enrica Sovena Foundation, Italy. Dr. Dauerman has served as consultant to Medtronic and The Medicines Company; and has received research grants from Abbott Vascular and Medtronic. Dr. Zhang is an employee of St. Jude Medical. Dr. Yu has received a grant from the National Natural Science Foundation of China (grant contract number: 30871064/C140401). Dr. Virmani has received research support from Abbott Vascular, BioSensors International, Biotronik, Boston Scientific, Medtronic, MicroPort Medical, OrbusNeich Medical, SINO Medical Technology, and Terumo Corporation; honoraria from Abbott Vascular, Boston Scientific, Terumo Corporation, and Lutonix; served as consultant to Abbott Vascular, 480 Biomedical, and WL Gore; and served on the speakers' bureau for Merck. Dr. Jang has received research grants and consulting fees from LightLab Imaging/St. Jude Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Stephen Nicholls, MBBS, PhD, served as Guest Editor for this article. NR 18 TC 117 Z9 120 U1 2 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 5 PY 2013 VL 62 IS 19 BP 1748 EP 1758 DI 10.1016/j.jacc.2013.05.071 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 242KI UT WOS:000326239100005 PM 23810884 ER PT J AU Ackerman, SL Gonzales, R Stahl, MS Metlay, JP AF Ackerman, Sara L. Gonzales, Ralph Stahl, Melissa S. Metlay, Joshua P. TI One size does not fit all: evaluating an intervention to reduce antibiotic prescribing for acute bronchitis SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Antibiotics; Clinician practice patterns; Patient education; Quality improvement ID RESPIRATORY-TRACT INFECTIONS; RANDOMIZED CONTROLLED-TRIAL; UNCOMPLICATED ACUTE BRONCHITIS; PRIMARY-CARE; CLUSTER; ADULTS; PRINCIPLES; MANAGEMENT; PROGRAM; COUGH AB Background: Overuse of antibiotics for upper respiratory tract infections (URIs) and acute bronchitis is a persistent and vexing problem. In the U.S., more than half of all patients with upper respiratory tract infections and acute bronchitis are treated with antibiotics annually, despite the fact that most cases are viral in etiology and are not responsive to antibiotics. Interventions aiming to reduce unnecessary antibiotic prescribing have had mixed results, and successes have been modest. The objective of this evaluation is to use mixed methods to understand why a multi-level intervention to reduce antibiotic prescribing for acute bronchitis among primary care providers resulted in measurable improvement in only one third of participating clinicians. Methods: Clinician perspectives on print-based and electronic intervention strategies, and antibiotic prescribing more generally, were elicited through structured telephone surveys at high and low performing sites after the first year of intervention at the Geisinger Health System in Pennsylvania (n = 29). Results: Compared with a survey on antibiotic use conducted 10 years earlier, clinicians demonstrated greater awareness of antibiotic resistance and how it is impacted by individual prescribing decisions-including their own. However, persistent perceived barriers to reducing prescribing included patient expectations, time pressure, and diagnostic uncertainty, and these factors were reported as differentially undermining specific intervention components' effectiveness. An exam room poster depicting a diagnostic algorithm was the most popular strategy. Conclusions: Future efforts to reduce antibiotic prescribing should address multi-level barriers identified by clinicians and tailor strategies to differences at individual clinician and group practice levels, focusing in particular on changing how patients and providers make decisions together about antibiotic use. C1 [Ackerman, Sara L.] Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94143 USA. [Gonzales, Ralph] Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA. [Stahl, Melissa S.] Ctr Hlth Res, Geisinger Hlth Syst, Danville, PA USA. [Metlay, Joshua P.] Massachusetts Gen Hosp, Gen Med Div, Boston, MA 02114 USA. RP Ackerman, SL (reprint author), Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94143 USA. EM sara.ackerman@ucsf.edu FU Centers for Disease Control and Prevention [R01-CI000611]; National Institutes of Health [K24-AI073957] FX The study on which this report is based was supported by grant R01-CI000611 from the Centers for Disease Control and Prevention and K24-AI073957 (JPM) from the National Institutes of Health. The authors are grateful for the contributions from the many participants at the Geisinger Health System, including clinicians at all study sites and the programmers and assistants who helped extract data and complete telephone interviews. We also extend thanks to Judy Maselli, MPH, for her valuable assistance with data analysis, and to two reviewers who provided us with invaluable suggestions for improvement. NR 41 TC 6 Z9 7 U1 1 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD NOV 4 PY 2013 VL 13 AR 462 DI 10.1186/1472-6963-13-462 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 285CG UT WOS:000329370200001 PM 24188573 ER PT J AU Cho, H Guo, YY Sosnovik, DE Josephson, L AF Cho, Hoonsung Guo, Yanyan Sosnovik, David E. Josephson, Lee TI Imaging DNA with Fluorochrome Bearing Metals SO INORGANIC CHEMISTRY LA English DT Article ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; RECOMBINANT HUMAN DNASE; CYSTIC-FIBROSIS SPUTUM; NUCLEIC-ACIDS; MAGNETIC NANOPARTICLES; FLUORESCENCE DETECTION; ETHIDIUM HOMODIMER; EXTRACELLULAR DNA; PLASMA DNA; CLEARANCE AB Molecules that fluoresce upon binding DNA are widely used in assaying and visualizing DNA in cells and tissues. However, using light to visualize DNA in animals is limited by the attenuation of light transmission by biological tissues. Moreover, it is now clear that DNA is an important mediator of dead cell clearance, coagulation reactions, and an immunogen in autoimmune lupus. Attaching metals (e.g., superparamagnetic nanoparticles, gadolinium ions, radioactive metal ions) to DNA-binding fluorochromes provides a way of imaging DNA in whole animals, and potentially humans, without light. Imaging metal-bearing, DNA-binding fluorochromes and their target DNA by magnetic resonance imaging may shed light on the many key roles of DNA in health and disease beyond the storage of genetic information. C1 [Cho, Hoonsung; Guo, Yanyan; Josephson, Lee] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Translat Nucl Med & Mol Imaging, Boston, MA 02114 USA. [Sosnovik, David E.; Josephson, Lee] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Sosnovik, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr,Cardiol Div, Boston, MA 02114 USA. RP Josephson, L (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Translat Nucl Med & Mol Imaging, Boston, MA 02114 USA. EM ljosephson@mgh.harvard.edu FU NIBIB NIH HHS [R01 EB011996] NR 51 TC 0 Z9 0 U1 1 U2 9 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0020-1669 EI 1520-510X J9 INORG CHEM JI Inorg. Chem. PD NOV 4 PY 2013 VL 52 IS 21 BP 12216 EP 12222 DI 10.1021/ic400404g PG 7 WC Chemistry, Inorganic & Nuclear SC Chemistry GA 248BR UT WOS:000326669200005 PM 23646914 ER PT J AU Barlesi, F Besse, B Chu, Q Gandhi, L Griesinger, F Felip, E Kang, JH Kim, SW Rosell, R Sequist, LV Soo, R Wallmark, J Avsar, E Ofosu-Appiah, W Pain, S Akimov, M Garon, EB AF Barlesi, Fabrice Besse, Benjamin Chu, Quincy Gandhi, Leena Griesinger, Frank Felip, Enriqueta Kang, Jin Hyoung Kim, Sang-We Rosell, Rafael Sequist, Lecia V. Soo, Ross Wallmark, John Avsar, Emin Ofosu-Appiah, William Pain, Scott Akimov, Mikhail Garon, Edward B. TI PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH EGFR-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE ADVANCED NSCLC; AUY922; EGFR-mutant; HSP90 C1 [Barlesi, Fabrice] Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France. [Besse, Benjamin] Inst Gustave Roussy, Villejuif, France. [Gandhi, Leena] Dana Farber Canc Inst, Boston, MA USA. [Griesinger, Frank] Carl von Ossietzky Univ Oldenburg, Pius Hosp Oldenburg, D-26111 Oldenburg, Germany. [Felip, Enriqueta] Vall Dhebron Univ Hosp, Barcelona, Spain. [Kang, Jin Hyoung] Catholic Univ Korea, Seoul, South Korea. [Kim, Sang-We] Asan Med Ctr, Seoul, South Korea. [Rosell, Rafael] Hosp Univ Germans, Barcelona, Spain. [Sequist, Lecia V.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Soo, Ross] Natl Univ Singapore, Inst Canc, Singapore 117548, Singapore. [Avsar, Emin; Ofosu-Appiah, William] Novartis Pharmaceut, E Hanover, NJ USA. [Pain, Scott; Akimov, Mikhail] Novartis Pharma Ag, Basel, Switzerland. [Garon, Edward B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P1.11-037 BP S611 EP S612 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624903018 ER PT J AU Brahmer, JR Horn, L Antonia, SJ Spigel, D Gandhi, L Sequist, LV Sankar, V Ahlers, CM Wigginton, JM Kollia, G Gupta, A Gettinger, SN AF Brahmer, Julie R. Horn, Leora Antonia, Scott J. Spigel, David Gandhi, Leena Sequist, Lecia V. Sankar, Vindira Ahlers, Christoph M. Wigginton, Jon M. Kollia, Georgia Gupta, Ashok Gettinger, Scott N. TI NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC): OVERALL SURVIVAL AND LONG-TERM SAFETY IN A PHASE 1 TRIAL SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE programmed death-1 receptor; nivolumab; NSCLC; survival C1 [Brahmer, Julie R.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Horn, Leora] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Antonia, Scott J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Spigel, David] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA. [Gandhi, Leena] Dana Farber Canc Inst, Boston, MA USA. [Sequist, Lecia V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sankar, Vindira; Ahlers, Christoph M.; Wigginton, Jon M.; Kollia, Georgia; Gupta, Ashok] Bristol Myers Squibb, New York, NY USA. [Gettinger, Scott N.] Yale Canc Ctr, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO18.03 BP S365 EP S366 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901245 ER PT J AU Camidge, DR Janne, PA Sequist, LV Chand, V Dowling, E Gu, Y Schnell, D Oxnard, GR AF Camidge, D. Ross Jaenne, Pasi A. Sequist, Lecia V. Chand, Vikram Dowling, Elizabeth Gu, Yu Schnell, David Oxnard, Geoffrey R. TI A PHASE IB STUDY OF HIGH-DOSE INTERMITTENT (HDI) AFATINIB IN EGFR T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO REVERSIBLE EGFR TKIS SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE T790M; EGFR; afatinib; NSCLC C1 [Camidge, D. Ross] Univ Colorado, Boulder, CO 80309 USA. [Jaenne, Pasi A.; Oxnard, Geoffrey R.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA. [Sequist, Lecia V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Chand, Vikram] Boehringer Ingelheim Pharmaceut Inc, Clin Dev Oncol, Ridgefield, CT USA. [Dowling, Elizabeth] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA. [Gu, Yu] Boehringer Ingelheim Pharmaceut Inc, Biometr & Data Management, Ridgefield, CT USA. [Schnell, David] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P2.11-011 BP S893 EP S893 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624904166 ER PT J AU Camidge, DR Bazhenova, L Salgia, R Weiss, GJ Langer, CJ Shaw, AT Narasimhan, NI Dorer, DJ Rivera, VM Zhang, J Clackson, T Haluska, FG Gettinger, SN AF Camidge, D. Ross Bazhenova, Lyudmila Salgia, Ravi Weiss, Glen J. Langer, Corey J. Shaw, Alice T. Narasimhan, Narayana I. Dorer, David J. Rivera, Victor M. Zhang, Joshua Clackson, Tim Haluska, Frank G. Gettinger, Scott N. TI UPDATED RESULTS OF A FIRST-IN-HUMAN DOSE-FINDING STUDY OF THE ALK/EGFR INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE NSCLC; ALK; EGFR; AP26113 C1 [Camidge, D. Ross] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA. [Bazhenova, Lyudmila] Uscd, Moores Canc Ctr, La Jolla, CA USA. [Salgia, Ravi] Univ Chicago, Chicago, IL 60637 USA. [Weiss, Glen J.] Scottsdale Healthcare, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA. [Langer, Corey J.] Univ Penn, Philadelphia, PA 19104 USA. [Shaw, Alice T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Narasimhan, Narayana I.; Dorer, David J.; Rivera, Victor M.; Zhang, Joshua; Clackson, Tim; Haluska, Frank G.] ARIAD Pharmaceut Inc, Cambridge, MA USA. [Gettinger, Scott N.] Yale Univ, New Haven, CT 06520 USA. NR 0 TC 3 Z9 3 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO07.06 BP S296 EP S297 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901138 ER PT J AU Chaft, JE Hellmann, MD Dunphy, M Jappe, W Sima, CS Downey, RJ Travis, WD Azzoli, CG Kris, MG AF Chaft, Jamie E. Hellmann, Matthew D. Dunphy, Mark Jappe, Whitney Sima, Camelia S. Downey, Robert J. Travis, William D. Azzoli, Christopher G. Kris, Mark G. TI A PHASE II STUDY OF 18F-FDG PET GUIDED OPTIMIZATION OF NEOADJUVANT CHEMOTHERAPY FOR RESECTABLE NON-SMALL CELL LUNG CANCER SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE neoadjuvant chemotherapy; PET scan; non-small cell lung cancer C1 [Chaft, Jamie E.; Hellmann, Matthew D.; Dunphy, Mark; Jappe, Whitney; Sima, Camelia S.; Downey, Robert J.; Travis, William D.; Kris, Mark G.] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Azzoli, Christopher G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO25.09 BP S412 EP S413 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624902018 ER PT J AU Chaft, JE Arcila, M Patel, P Apelian, DM Mattson, A Coeshott, C Kris, MG Azzoli, CG AF Chaft, Jamie E. Arcila, Maria Patel, Payal Apelian, David M. Mattson, Alicia Coeshott, Claire Kris, Mark G. Azzoli, Christopher G. TI PHASE 2 STUDY OF THE GI-4000 KRAS VACCINE FOLLOWING CURATIVE THERAPY IN PATIENTS WITH STAGE I-III LUNG ADENOCARCINOMA HARBORING A KRAS G12C, G12D, G12V OR G12R MUTATION SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE early stage; KRAS-mutant NSCLC; vaccine C1 [Chaft, Jamie E.; Patel, Payal; Kris, Mark G.] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Arcila, Maria] Mem Sloan Kettering Canc Ctr, Dept Mol Pathol, New York, NY USA. [Apelian, David M.; Mattson, Alicia; Coeshott, Claire] Globeimmune, Louisville, CO USA. [Azzoli, Christopher G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO08.04 BP S302 EP S302 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901148 ER PT J AU Chong, C Wirth, L Chen, A Sholl, L Janne, P Johnson, B AF Chong, Curtis Wirth, Lori Chen, Aileen Sholl, Lynette Janne, Pasi Johnson, Bruce TI MEDICAL MANAGEMENT OF PULMONARY CARCINOID TUMORS SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE Atypical Carcinoid; Neuroendocrine lung cancer; Pulmonary Carcinoid; typical carcinoid C1 [Chong, Curtis; Chen, Aileen; Sholl, Lynette; Janne, Pasi; Johnson, Bruce] Dana Farber Canc Inst, Boston, MA USA. [Wirth, Lori] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P2.16-004 BP S948 EP S948 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624904260 ER PT J AU Costa, DB Yasuda, H Park, E Yun, CH Huberman, MS Oxnard, GR Sequist, LV Riely, G Soo, R Eck, MJ Kobayashi, SS AF Costa, Daniel B. Yasuda, Hiroyuki Park, Eunyoung Yun, Cai-Hong Huberman, Mark S. Oxnard, Geoffrey R. Sequist, Lecia V. Riely, Gregory Soo, Ross Eck, Michael J. Kobayashi, Susumu S. TI CLINICAL, STRUCTURAL AND BIOCHEMICAL CHARACTERIZATION OF EGFR EXON 20 INSERTION MUTATIONS IN LUNG CANCER SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE EGFR; exon 20 insertions; non-small-cell lung cancer; gefitinib/erlotinib C1 [Costa, Daniel B.; Yasuda, Hiroyuki; Huberman, Mark S.; Kobayashi, Susumu S.] Beth Israel Deaconess Med Ctr, Boston, MA USA. [Park, Eunyoung; Yun, Cai-Hong; Oxnard, Geoffrey R.; Eck, Michael J.] Dana Farber Canc Inst, Boston, MA USA. [Sequist, Lecia V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Riely, Gregory] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Soo, Ross] Natl Univ Singapore, Singapore 117548, Singapore. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO16.06 BP S355 EP S355 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901229 ER PT J AU Costa, DB Shaw, AT Ou, SHI Solomon, BJ Riely, GJ Ahn, MJ Zhou, CC Shreeve, SM Wiltshire, R Selaru, P Polli, A Schnell, P Camidge, DR Crino, L AF Costa, Daniel B. Shaw, Alice T. Ou, Sai-Hong I. Solomon, Benjamin J. Riely, Gregory J. Ahn, Myung-Ju Zhou, Caicun Shreeve, S. Martin Wiltshire, Robin Selaru, Paulina Polli, Anna Schnell, Patrick Camidge, D. Ross Crino, Lucio TI CLINICAL EXPERIENCE WITH CRIZOTINIB IN PATIENTS WITH ADVANCED ALK-REARRANGED NON-SMALL CELL LUNG CANCER AND BRAIN METASTASES IN PROFILE 1005 AND PROFILE 1007 SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE intracranial disease control rate; systemic response; Crizotinib; brain metastases C1 [Costa, Daniel B.] Beth Israel Deaconess Med Ctr, Boston, MA USA. [Shaw, Alice T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. [Ou, Sai-Hong I.] Univ Calif Irvine, Irvine, CA 92717 USA. [Solomon, Benjamin J.] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia. [Riely, Gregory J.] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Ahn, Myung-Ju] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea. [Zhou, Caicun] Shanghai Pulm Hosp, Shanghai, Peoples R China. [Shreeve, S. Martin; Selaru, Paulina; Schnell, Patrick] Pfizer Oncol, New York, NY USA. [Wiltshire, Robin] Pfizer Oncol, Surrey, England. [Polli, Anna] Pfizer Oncol, Milan, Italy. [Camidge, D. Ross] Univ Colorado, Boulder, CO 80309 USA. [Crino, Lucio] Univ Hosp Perugia, Perugia, Italy. NR 0 TC 3 Z9 3 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO07.02 BP S294 EP S295 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901135 ER PT J AU Currow, D Temel, J AF Currow, David Temel, Jennifer TI ANAMORELIN HCL FOR THE TREATMENT OF ANOREXIA-CACHEXIA IN NSCLC: BASELINE CHARACTERISTICS OF PATIENTS IN THE PHASE III CLINICAL TRIAL ROMANA 2 (HT-ANAM-302) SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE cancer cachexia; anamorelin HCl; ghrelin receptor agonist; anorexia-cachexia C1 [Currow, David] Flinders Univ S Australia, Bedford Pk, SA, Australia. [Temel, Jennifer] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P3.24-031 BP S1314 EP S1314 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624906190 ER PT J AU Doherty, JP Reckamp, KL Connell, JO Letrent, S Ramalingam, SS Boyer, M Janne, PA Park, K Kim, DW Gadgeel, S Bottomley, A AF Doherty, Jim P. Reckamp, Karen L. Connell, Joseph O. Letrent, Stephen Ramalingam, Suresh S. Boyer, Michael Jaenne, Pasi A. Park, Keunchil Kim, Dong-Wan Gadgeel, Shirish Bottomley, Andrew TI PATIENT REPORT OF DACOMITINIB (PF-00299804)-ASSOCIATED SYMPTOM AND HRQOL BENEFIT IN PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE patient-reported outcomes; erlotinib; dacomitinib; non-small cell lung cancer C1 [Doherty, Jim P.; Connell, Joseph O.; Letrent, Stephen] Pfizer Oncol, New York, NY USA. [Reckamp, Karen L.] City Hope Natl Med Ctr, Duarte, CA USA. [Ramalingam, Suresh S.] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA. [Boyer, Michael] Sydney Canc Ctr, Sydney, NSW, Australia. [Jaenne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA. [Park, Keunchil] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea. [Kim, Dong-Wan] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea. [Gadgeel, Shirish] Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48202 USA. [Bottomley, Andrew] EORTC, Qual Life Dept, Brussels, Belgium. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P2.11-032 BP S906 EP S906 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624904187 ER PT J AU Dolly, SO Krug, LM Wagner, AJ Schwartz, LH Bendell, JC Lauchle, JO Seiwert, TY Rihawi, K Tunariu, N Zauderer, MG Delasos, L Kwiatkowski, D Marcoux, JP Rabin, MS Apt, D Fredrickson, J Lackner, M Koeppen, H Ware, JA Burris, HA De Bono, JS Kindler, H AF Dolly, Saoirse O. Krug, Lee M. Wagner, Andrew J. Schwartz, Lawrence H. Bendell, Johanna C. Lauchle, Jennifer O. Seiwert, Tanguy Y. Rihawi, Karim Tunariu, Nina Zauderer, Marjorie G. Delasos, Lukas Kwiatkowski, David Marcoux, J. P. Rabin, Michael S. Apt, Doris Fredrickson, Jill Lackner, Mark Koeppen, Hartmut Ware, Joseph A. Burris, Howard A. De Bono, Johann S. Kindler, Hedy TI EVALUATION OF TOLERABILITY AND ANTI-TUMOR ACTIVITY OF GDC-0980, AN ORAL PI3K/MTOR INHIBITOR, ADMINISTERED TO PATIENTS WITH ADVANCED MALIGNANT PLEURAL MESOTHELIOMA (MPM) SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE PI3K; GDC-0980; MPM; mTOR C1 [Dolly, Saoirse O.; Rihawi, Karim; Tunariu, Nina; De Bono, Johann S.] Royal Marsden Hosp, Drug Dev Unit, London, England. [Dolly, Saoirse O.; Rihawi, Karim; Tunariu, Nina; De Bono, Johann S.] Royal Marsden Hosp, London, England. [Dolly, Saoirse O.; Rihawi, Karim; Tunariu, Nina; De Bono, Johann S.] Inst Canc Res, London, England. [Krug, Lee M.; Zauderer, Marjorie G.; Delasos, Lukas] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, Dept Med, New York, NY USA. [Wagner, Andrew J.; Kwiatkowski, David; Marcoux, J. P.; Rabin, Michael S.] Dana Farber Canc Inst, Boston, MA USA. [Schwartz, Lawrence H.] Columbia Univ, Med Ctr, Dept Radiol, New York, NY 10027 USA. [Bendell, Johanna C.; Burris, Howard A.] Sarah Cannon Res Inst, Nashville, TN USA. [Lauchle, Jennifer O.; Apt, Doris; Fredrickson, Jill] Genentech Inc, Exploratory Clin Dev, San Francisco, CA USA. [Seiwert, Tanguy Y.; Kindler, Hedy] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Lackner, Mark; Koeppen, Hartmut] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA USA. [Ware, Joseph A.] Genentech Inc, Small Mol Clin Pharmacol, San Francisco, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO09.01 BP S307 EP S308 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901155 ER PT J AU Dy, GK Vansteenkiste, J Thomas, M De Pas, T Grossi, F De Greve, J Felip, E Canon, JL Gray, J De Braud, F Reck, M Thongprasert, S Planchard, D Gridelli, C Roussou, P Gurnani, M Atalla, G Sternberg, DW Engelman, JA AF Dy, Grace K. Vansteenkiste, Johan Thomas, Michael De Pas, Tommaso Grossi, Francesco De Greve, Jacques Felip, Enriqueta Canon, Jean-Luc Gray, Jhanelle De Braud, Filippo Reck, Martin Thongprasert, Sumitra Planchard, David Gridelli, Cesare Roussou, Pantelia Gurnani, Maya Atalla, Gena Sternberg, David W. Engelman, Jeffrey A. TI EPIDEMIOLOGY OF PI3K PATHWAY ALTERATIONS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): FINDINGS FROM THE INTERNATIONAL BASALT-1 STUDY SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE biomarker; buparlisib; PI3K/Akt/mTOR pathway; non-small cell lung cancer C1 [Dy, Grace K.] Roswell Pk Canc Inst, Buffalo, NY USA. [Vansteenkiste, Johan] Univ Hosp KU Leuven, Leuven, Belgium. [Thomas, Michael] Univ Klinikum Heidelberg, Thoraxklin, Heidelberg, Germany. [De Pas, Tommaso] European Inst Oncol, Milan, Italy. [Grossi, Francesco] Natl Inst Canc Res, Genoa, Italy. [De Greve, Jacques] Vrije Univ Brussel, Uz Brussel, Brussels, Belgium. [Felip, Enriqueta] Hosp Univ Vall Dhebron, Barcelona, Spain. [Canon, Jean-Luc] Grand Hop Charleroi, Charleroi, Belgium. [Gray, Jhanelle] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [De Braud, Filippo] Fdn IRCCS Ist Nazl Tumori, Milan, Italy. [Reck, Martin] Lung Clin Grosshansdorf, Hamburg, Germany. [Thongprasert, Sumitra] Chiang Mai Univ, Chiang Mai, Thailand. [Planchard, David] Inst Gustave Roussy, Villejuif, France. [Gridelli, Cesare] SG Moscati Hosp, Avellino, Italy. [Roussou, Pantelia] Novartis Pharma Ag, Basel, Switzerland. [Gurnani, Maya; Atalla, Gena; Sternberg, David W.] Novartis Pharmaceut, E Hanover, NJ USA. [Engelman, Jeffrey A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. RI De Greve, Jacques/J-4939-2012; Gridelli, Cesare/K-7909-2016 OI De Greve, Jacques/0000-0002-2389-0742; NR 0 TC 0 Z9 0 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA O04.05 BP S145 EP S146 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624900173 ER PT J AU Franklin, WA Haney, J Merrick, DT Jones, KL Gowan, K Van Bokoven, A Bunn, P Miller, Y Aisner, D AF Franklin, Wilbur A. Haney, Jerry Merrick, Daniel T. Jones, Kenneth L. Gowan, Katherine Van Bokoven, Adrie Bunn, Paul Miller, York Aisner, Dara TI TRANSITIONING TO NEXT GEN TESTING OF LUNG CARCINOMA SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE Sequencing; Next Generation; mutations; predictive C1 [Franklin, Wilbur A.; Haney, Jerry; Jones, Kenneth L.; Gowan, Katherine; Van Bokoven, Adrie; Aisner, Dara] Univ Colorado Anschutz Med Campus, Aurora, CO USA. [Merrick, Daniel T.; Miller, York] Univ Colorado, Denver Vet Affairs Med Ctr, Boulder, CO 80309 USA. [Bunn, Paul] Univ Colorado Denver AMS, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO01.03 BP S254 EP S255 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901077 ER PT J AU Gadgeel, S Ou, SH Chiappori, AA Riely, G Lee, RM Garcia, L Sato, J Yokoyama, S Tanaka, T Gandhi, L AF Gadgeel, Shirish Ou, Sai-Hong Chiappori, Alberto A. Riely, Gregory Lee, Ruey-Min Garcia, Linta Sato, Jotaro Yokoyama, Shumpei Tanaka, Tomohiro Gandhi, Leena TI A PHASE 1 DOSE ESCALATION STUDY OF A NEW ALK INHIBITOR, CH5424802/RO5424802, IN ALK+ NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WHO HAVE FAILED CRIZOTINIB (AF-002JG/NP28761, NCT01588028) SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE ALK-inhibitor; Crizotinib-failure; Phase I; CH5424802 C1 [Gadgeel, Shirish] Karmonos Canc Inst, Detroit, MI USA. [Ou, Sai-Hong] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA 92717 USA. [Chiappori, Alberto A.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Riely, Gregory] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Lee, Ruey-Min] Hoffmann La Roche Inc, Nutley, NJ USA. [Garcia, Linta] Chugai Pharmaceut Co Ltd, Berkeley Hts, NJ USA. [Sato, Jotaro; Yokoyama, Shumpei; Tanaka, Tomohiro] Chugai Pharmaceut Co Ltd, Tokyo, Japan. [Gandhi, Leena] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 7 Z9 8 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA O16.06 BP S199 EP S199 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624900247 ER PT J AU Garon, EB Balmanoukian, A Hamid, O Hui, RN Gandhi, L Leighl, N Gubens, MA Goldman, J Lubiniecki, GM Lunceford, J Gergich, K Rizvi, N AF Garon, Edward B. Balmanoukian, Ani Hamid, Omid Hui, Rina Gandhi, Leena Leighl, Natasha Gubens, Matthew A. Goldman, Jonathan Lubiniecki, Gregory M. Lunceford, Jared Gergich, Kevin Rizvi, Naiyer TI PRELIMINARY CLINICAL SAFETY AND ACTIVITY OF MK-3475 MONOTHERAPY FOR THE TREATMENT OF PREVIOUSLY TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE lambrolizumab; PD-1; PD-L1 C1 [Garon, Edward B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Balmanoukian, Ani; Hamid, Omid] Angeles Clin & Res Inst, Los Angeles, CA USA. [Hui, Rina] Westmead Hosp, Dept Med Oncol, Westmead, NSW, Australia. [Hui, Rina] Blacktown Hosp, Blacktown, NSW, Australia. [Gandhi, Leena] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA. [Leighl, Natasha] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Gubens, Matthew A.] UCSF, Div Hematol & Oncol, San Francisco, CA USA. [Goldman, Jonathan] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Lubiniecki, Gregory M.] Merck Res Labs, Boston, MA USA. [Lunceford, Jared; Gergich, Kevin] Merck & Co Inc, Whitehouse Stn, NJ USA. [Rizvi, Naiyer] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO18.02 BP S364 EP S365 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901244 ER PT J AU Gettinger, S Horn, L Antonia, SJ Spigel, DR Gandhi, L Sequist, LV Sankar, V Ahlers, CM Wigginton, JM Kollia, G Gupta, A Brahmer, JR AF Gettinger, Scott Horn, Leora Antonia, Scott J. Spigel, David R. Gandhi, Leena Sequist, Lecia V. Sankar, Vindira Ahlers, Christoph M. Wigginton, Jon M. Kollia, Georgia Gupta, Ashok Brahmer, Julie R. TI EFFICACY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): SUBPOPULATION RESPONSE ANALYSIS IN A PHASE 1 TRIAL SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE programmed death-1 receptor; nivolumab; NSCLC; subpopulations C1 [Gettinger, Scott] Yale Canc Ctr, New Haven, CT USA. [Horn, Leora] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Antonia, Scott J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Spigel, David R.] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA. [Gandhi, Leena] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sequist, Lecia V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sankar, Vindira; Ahlers, Christoph M.; Wigginton, Jon M.; Kollia, Georgia; Gupta, Ashok] Bristol Myers Squibb Co, New York, NY 10154 USA. [Brahmer, Julie R.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P2.11-038 BP S909 EP S909 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624904193 ER PT J AU Gettinger, SN Kowanetz, M Soria, JC Gandhi, L Horn, L Gordon, MS Spigel, D Cruz, C Conkling, P Antonia, S Koeppen, H Xiao, YY Mokatrin, A Shen, XD Fine, G Herbst, RS AF Gettinger, Scott N. Kowanetz, Marcin Soria, Jean-Charles Gandhi, Leena Horn, Leora Gordon, Michael S. Spigel, David Cruz, Cristina Conkling, Paul Antonia, Scott Koeppen, Hartmut Xiao, Yuanyuan Mokatrin, Ahmad Shen, Xiaodong Fine, Gregg Herbst, Roy S. TI MOLECULAR CORRELATES OF PD-L1 STATUS AND PREDICTIVE BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH THE ANTI-PDL1 ANTIBODY MPDL3280A SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE PD-1; immunotherapy; predictive biomarker; PD-L1 C1 [Gettinger, Scott N.; Herbst, Roy S.] Yale Univ, Sch Med, New Haven, CT 06520 USA. [Kowanetz, Marcin; Koeppen, Hartmut; Xiao, Yuanyuan; Mokatrin, Ahmad; Shen, Xiaodong; Fine, Gregg] Genentech Inc, San Francisco, CA USA. [Soria, Jean-Charles] Inst Gustave Roussy, Villejuif, France. [Gandhi, Leena] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA. [Horn, Leora] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Gordon, Michael S.] Pinnacle Oncol Hematol, Scottsdale, AZ USA. [Cruz, Cristina] Vall Dhebron Univ Hosp, Barcelona, Spain. [Conkling, Paul] Virginia Oncol Associates, Newport News, VA USA. [Antonia, Scott] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. NR 0 TC 2 Z9 2 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO19.09 BP S376 EP S377 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901259 ER PT J AU Giaccone, G Camidge, DR Janne, PA Solomon, B James, LP Tang, YY Martini, JF Goldberg, Z Shreeve, SM Shaw, AT AF Giaccone, Giuseppe Camidge, David Ross Jaenne, Pasi A. Solomon, Ben James, Leonard P. Tang, Yiyun Martini, Jean-Francois Goldberg, Zelanna Shreeve, S. Martin Shaw, Alice T. TI COMBINED PAN-ERBB AND ALK/ROS1/MET INHIBITION WITH DACOMITINIB AND CRIZOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): UPDATE OF A PHASE I TRIAL SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE dacomitinib; NSCLC; resistance; Crizotinib C1 [Giaccone, Giuseppe] Georgetown Univ, Washington, DC 20057 USA. [Camidge, David Ross] Univ Colorado, Boulder, CO 80309 USA. [Jaenne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA. [Solomon, Ben] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia. [James, Leonard P.; Tang, Yiyun; Martini, Jean-Francois; Goldberg, Zelanna; Shreeve, S. Martin] Pfizer Oncol, New York, NY USA. [Shaw, Alice T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO07.07 BP S297 EP S297 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901139 ER PT J AU Gill, RR Richards, W Yeap, BY Bueno, R Sugarbaker, DJ AF Gill, Ritu R. Richards, William Yeap, Beow Y. Bueno, Raphael Sugarbaker, David J. TI NOVEL CLINICAL ASSESSMENT OF MALIGNANT PLEURAL MESOTHELIOMA SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE Clinical T status; malignant pleural mesothelioma; TNM staging; T2 critereon C1 [Gill, Ritu R.; Richards, William; Bueno, Raphael; Sugarbaker, David J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Yeap, Beow Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 BP S939 EP S939 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624904242 ER PT J AU Gill, RR Richards, W Yeap, BY Bueno, R Sugarbaker, DJ AF Gill, Ritu R. Richards, William Yeap, Beow Y. Bueno, Raphael Sugarbaker, David J. TI QUANTITATIVE CLINICAL T CLASSIFICATION CRITERIA FOR MALIGNANT PLEURAL MESOTHELIOMA. SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE T status; mesothelioma; tumor volume; EPP C1 [Gill, Ritu R.; Richards, William; Bueno, Raphael; Sugarbaker, David J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Yeap, Beow Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO09.11 BP S313 EP S313 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901163 ER PT J AU Hammerman, P AF Hammerman, Peter TI NOVEL TARGETS IN SQUAMOUS CANCER SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE squamous cell carcinoma; cancer genomics; fibroblast growth factor receptors C1 [Hammerman, Peter] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MS03.2 BP S43 EP S43 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624900051 ER PT J AU Horn, L Herbst, RS Spigel, D Gettinger, SN Gordon, MS Hollebecque, A Gandhi, L Felip, E Heist, R Mokatrin, A Kowanetz, M Waterkamp, D Fine, G Soria, JC AF Horn, Leora Herbst, Roy S. Spigel, David Gettinger, Scott N. Gordon, Michael S. Hollebecque, Antoine Gandhi, Leena Felip, Enriqueta Heist, Rebecca Mokatrin, Ahmad Kowanetz, Marcin Waterkamp, Daniel Fine, Gregg Soria, Jean-Charles TI AN ANALYSIS OF THE RELATIONSHIP OF CLINICAL ACTIVITY TO BASELINE EGFR STATUS, PDL1 EXPRESSION AND PRIOR TREATMENT HISTORY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) FOLLOWING PD-L1 BLOCKADE WITH MPDL3280A (ANTI-PDL1) SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE PD-L1; metastatic; PD-1; immunotherapy C1 [Horn, Leora] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Herbst, Roy S.; Gettinger, Scott N.] Yale Univ, Sch Med, New Haven, CT 06520 USA. [Spigel, David] Tennessee Oncol Pllc, Sarah Cannon Res Inst, Franklin, TN USA. [Gordon, Michael S.] Pinnacle Oncol Hematol, Scottsdale, AZ USA. [Hollebecque, Antoine; Soria, Jean-Charles] Inst Gustave Roussy, Villejuif, France. [Gandhi, Leena] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA. [Felip, Enriqueta] Vall Dhebron Univ Hosp, Barcelona, Spain. [Heist, Rebecca] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mokatrin, Ahmad; Kowanetz, Marcin; Waterkamp, Daniel; Fine, Gregg] Genentech Inc, San Francisco, CA USA. NR 0 TC 6 Z9 6 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO18.01 BP S364 EP S364 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901243 ER PT J AU Imielinski, M Greulich, H Kaplan, B Araujo, L Amann, J Horn, L Villalona-Calero, M Meyerson, M Carbone, DP AF Imielinski, Marcin Greulich, Heidi Kaplan, Bethany Araujo, Luiz Amann, Joseph Horn, Leora Villalona-Calero, Miguel Meyerson, Matthew Carbone, David P. TI ONCOGENIC ARAF MUTATION IN LUNG ADENOCARCINOMA SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE Sorafenib; Sequencing; Raf; lung adenocarcinoma C1 [Imielinski, Marcin; Greulich, Heidi; Kaplan, Bethany; Meyerson, Matthew] Dana Farber Canc Inst, Boston, MA USA. [Araujo, Luiz; Amann, Joseph; Villalona-Calero, Miguel; Carbone, David P.] Ohio State Wexner Med Ctr, James Thorac Ctr, Columbus, OH USA. [Horn, Leora] Vanderbilt Univ, Div Hematol Oncol, Dept Med, Nashville, TN USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO15.05 BP S349 EP S350 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901219 ER PT J AU Janne, PA Mann, H Smith, I AF Jaenne, Pasi A. Mann, Helen Smith, Ian TI THE SELECT-1 STUDY DESIGN: SELUMETINIB IN COMBINATION WITH DOCETAXEL FOR SECOND-LINE TREATMENT OF KRAS MUTATION-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE selumetinib; NSCLC; metastatic; KRAS C1 [Jaenne, Pasi A.] Dana Farber Canc Inst, Boston, MA USA. [Mann, Helen; Smith, Ian] Astrazeneca, Cambridge, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P3.11-029 BP S1201 EP S1201 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624905358 ER PT J AU Janne, PA Lorusso, P Clemett, D Lovick, S Tchinou, C Smith, I AF Jaenne, Pasi A. Lorusso, Patricia Clemett, Delyth Lovick, Susan Tchinou, Catherine Smith, Ian TI EXPLORATION OF THE RELATIONSHIP BETWEEN NEUTROPHIL COUNT AND CLINICAL CONSEQUENCES IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING SELUMETINIB PLUS DOCETAXEL: PREDICTED EFFECT OF PRIMARY PROPHYLACTIC GCSF SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE selumetinib; NSCLC; metastatic; KRAS C1 [Jaenne, Pasi A.] Dana Farber Canc Inst, Boston, MA USA. [Lorusso, Patricia] Hudson Webber Canc Res Ctr, Detroit, MI USA. [Clemett, Delyth; Lovick, Susan; Tchinou, Catherine; Smith, Ian] Astra Zeneca, Cambridge, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P3.11-028 BP S1200 EP S1201 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624905357 ER PT J AU Janne, PA Clemett, D Mann, H Smith, I AF Jaenne, Pasi A. Clemett, Delyth Mann, Helen Smith, Ian TI EFFICACY OF STANDARD CARE FOR SECOND-LINE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) BY KRAS MUTATION STATUS: OBSERVATIONS ON MEK INHIBITOR ENHANCEMENT OF CHEMOTHERAPY SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE NSCLC; KRAS; MEK C1 [Jaenne, Pasi A.] Dana Farber Canc Inst, Boston, MA USA. [Clemett, Delyth; Mann, Helen; Smith, Ian] Astrazeneca, London, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA O16.02 BP S196 EP S197 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624900244 ER PT J AU Keith, R Wagh, A Friedman, M Merrick, DT Choo, K Hickey, G Hudish, T Johnson, M Tennis, M Dwyer-Nield, L AF Keith, Robert Wagh, Ajay Friedman, Micah Merrick, Daniel T. Choo, Kevin Hickey, Greg Hudish, Tyler Johnson, Micah Tennis, Meredith Dwyer-Nield, Lori TI CHANGES IN PULMONARY IMMUNE CELL RECRUITMENT AND FUNCTION DURING CIGARETTE SMOKE-INDUCED LUNG CARCINOGENESIS IN MICE SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE Lung cancer; chemoprevention; inflammation; smoking C1 [Keith, Robert; Johnson, Micah] Univ Colorado Denver, Denver VAMC, Denver, CO USA. [Wagh, Ajay; Merrick, Daniel T.; Hickey, Greg] Univ Colorado, Denver VAMC, Boulder, CO 80309 USA. [Friedman, Micah; Choo, Kevin; Hudish, Tyler] Denver VAMC, Denver, CO USA. [Tennis, Meredith] Univ Colorado Anschutz Med Campus, Aurora, CO USA. [Dwyer-Nield, Lori] Univ Colorado Denver, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P2.03-007 BP S764 EP S764 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624903283 ER PT J AU Kris, MG Camidge, DR Giaccone, G Hida, T O'Connell, J Taylor, I Zhang, H Gold-Berg, Z Janne, PA AF Kris, Mark G. Camidge, David Ross Giaccone, Giuseppe Hida, Toyoaki O'Connell, Joseph Taylor, Ian Zhang, Hui Gold-Berg, Zelanna Jaenne, Pasi A. TI RESULTS WITH DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR, IN A PHASE II COHORT OF PATIENTS WITH HER2-MUTANT OR AMPLIFIED LUNG CANCERS SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE dacomitinib; tyrosine kinase inhibitor; Lung cancer; phase II C1 [Kris, Mark G.] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Camidge, David Ross] Univ Colorado, Boulder, CO 80309 USA. [Giaccone, Giuseppe] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA. [Hida, Toyoaki] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan. [Jaenne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA. NR 0 TC 1 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P1.11-032 BP S609 EP S610 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624903014 ER PT J AU Kris, MG Johnson, B Berry, L Kwiatkowski, D Iafrate, AJ Wistuba, I Varella-Garcia, M Franklin, W Aronson, S Su, PF Shyr, Y Camidge, DR Sequist, LV Glisson, B Khuri, FR Garon, EB Pao, W Rudin, CM Schiller, J Haura, EB Socinski, MA Shirai, K Giaccone, G Ladanyi, M Kugler, K Minna, JD Bunn, P AF Kris, Mark G. Johnson, Bruce Berry, Lynne Kwiatkowski, David Iafrate, A. J. Wistuba, Ignacio Varella-Garcia, Marileila Franklin, Wilbur Aronson, Sandy Su, Pei-Fang Shyr, Yu Camidge, D. Ross Sequist, Lecia V. Glisson, Bonnie Khuri, Fadlo R. Garon, Edward B. Pao, William Rudin, Charles M. Schiller, Joan Haura, Eric B. Socinski, Mark A. Shirai, Keisuke Giaccone, Giuseppe Ladanyi, Marc Kugler, Kelly Minna, John D. Bunn, Paul TI TREATMENT WITH THERAPIES MATCHED TO ONCOGENIC DRIVERS IMPROVES SURVIVAL IN PATIENTS WITH LUNG CANCERS: RESULTS FROM THE LUNG CANCER MUTATION CONSORTIUM (LCMC) SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE targeted therapies; Adenocarcinoma; oncogenes; genotyping C1 [Kris, Mark G.; Ladanyi, Marc] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Johnson, Bruce] Dana Farber Canc Inst, Boston, MA USA. [Berry, Lynne; Su, Pei-Fang; Shyr, Yu] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Kwiatkowski, David] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Iafrate, A. J.; Sequist, Lecia V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wistuba, Ignacio; Glisson, Bonnie] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Varella-Garcia, Marileila; Franklin, Wilbur; Kugler, Kelly] Univ Colorado, Sch Med, Boulder, CO 80309 USA. [Camidge, D. Ross] Univ Colorado, Canc Ctr, Boulder, CO 80309 USA. [Khuri, Fadlo R.] Emory Univ, Atlanta, GA 30322 USA. [Garon, Edward B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Pao, William] Vanderbilt Univ, Div Hematol Oncol, Dept Med, Nashville, TN USA. [Rudin, Charles M.] Johns Hopkins, Baltimore, MD USA. [Schiller, Joan] UT Southwestern Med Ctr, Harold C Simmons Canc Ctr, Dallas, TX USA. [Haura, Eric B.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Socinski, Mark A.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Shirai, Keisuke] Med Univ S Carolina, Charleston, SC USA. [Giaccone, Giuseppe] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA. [Minna, John D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA. [Minna, John D.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX USA. [Bunn, Paul] Univ Colorado Denver AMS, Denver, CO USA. NR 0 TC 3 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 BP S3 EP S4 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624900005 ER PT J AU Liptrot, T Mann, H Smith, I Mcwalter, G Dougherty, B Walker, J Orr, MC Hodgson, D Shaw, AT Pereira, JR Jeannin, G Vansteenkiste, J Barrios, CHE Franke, FA Crino, L Janne, PA Smith, P AF Liptrot, Tom Mann, Helen Smith, Ian Mcwalter, Gael Dougherty, Brian Walker, Jill Orr, Maria C. Hodgson, Darren Shaw, Alice T. Pereira, Jose Rodrigues Jeannin, Gaelle Vansteenkiste, Johan Barrios, Carlos H. E. Franke, Fabio A. Crino, Lucio Jaenne, Pasi A. Smith, Paul TI IMPACT OF KRAS CODON SUB-TYPES IN A PHASE II SECOND-LINE TRIAL IN KRAS-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) OF SELUMETINIB PLUS DOCETAXEL VERSUS DOCETAXEL ALONE SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE selumetinib; NSCLC; metastatic; KRAS C1 [Liptrot, Tom; Mann, Helen; Smith, Ian; Mcwalter, Gael; Walker, Jill; Orr, Maria C.; Hodgson, Darren; Smith, Paul] Astrazeneca, Luton, Beds, England. [Dougherty, Brian] Astrazeneca, Wilmington, DE USA. [Shaw, Alice T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Pereira, Jose Rodrigues] Inst Brasileiro Cancerol Toracica, Sao Paulo, Brazil. [Jeannin, Gaelle] Hop Gabriel Montpied, Serv Pneumol, Clermont Ferrand, France. [Vansteenkiste, Johan] Univ Hosp KU Leuven, Resp Oncol Unit Pneumol, Leuven, Belgium. [Franke, Fabio A.] Hosp Caridade Ijui, Cacon, Ijui, RS, Brazil. [Crino, Lucio] Hosp S Maria Misericordia, Med Oncol Div, Udine, Italy. [Jaenne, Pasi A.] Dana Farber Canc Inst, Boston, MA USA. RI Barrios, Carlos/G-8525-2015 NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO18.12 BP S372 EP S372 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901252 ER PT J AU Merrick, DT Edwards, MG Franklin, W Sugita, M Miller, Y Friedman, M Dwyer-Nield, L Tennis, M Choo, K Hickey, G Kennedy, T Van Bokhoven, A Heasley, L Hirsch, FR Bunn, PA Geraci, M Keith, RL Nemenoff, R AF Merrick, Daniel T. Edwards, Michael G. Franklin, Wilbur Sugita, Michio Miller, York Friedman, Micah Dwyer-Nield, Lori Tennis, Meredith Choo, Kevin Hickey, Greg Kennedy, Tim Van Bokhoven, Adrie Heasley, Lynn Hirsch, Fred R. Bunn, Paul A. Geraci, Mark Keith, Robert L. Nemenoff, Raphael TI PATHWAY ANALYSIS OF GENE EXPRESSION PROFILES THAT DISTINGUISH PERSISTENT FROM REGRESSIVE BRONCHIAL DYSPLASIA INDICATE SYNERGISTIC ROLE FOR POLO-LIKE KINASE 1 (PLK1) AND EPOXIDE HYDROLASE 3 (EPHX3) IN MALIGNANT PROGRESSION SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE bronchial dysplasia; Malignant progression; Epoxide hydrolase 3; Polo-like kinase 1 C1 [Merrick, Daniel T.; Miller, York; Friedman, Micah; Choo, Kevin; Keith, Robert L.] Denver VAMC, Denver, CO USA. [Edwards, Michael G.; Franklin, Wilbur; Sugita, Michio; Dwyer-Nield, Lori; Tennis, Meredith; Hickey, Greg; Van Bokhoven, Adrie; Heasley, Lynn; Hirsch, Fred R.; Bunn, Paul A.; Geraci, Mark; Nemenoff, Raphael] Univ Colorado, Boulder, CO 80309 USA. [Kennedy, Tim] Presbyterian St Lukes Hosp, Denver, CO 80218 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA O12.02 BP S179 EP S180 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624900220 ER PT J AU Nelson, A Meyer, M Neumann, T Hayenga, J Katdare, R Presley, C Hawthorne, B Steinhauer, D Bell, T Spring, S Tourovskaia, A Patten, F Pawlick, G Colgan, T Wilbur, D Johnson, D Peled, N Aye, RW Zarogoulidis, P Chien, J AF Nelson, Alan Meyer, Michael Neumann, Thomas Hayenga, Jon Katdare, Rahul Presley, Chris Hawthorne, Ben Steinhauer, David Bell, Timothy Spring, Scarlett Tourovskaia, Anna Patten, Florence Pawlick, Gene Colgan, Terrance Wilbur, David Johnson, Douglas Peled, Nir Aye, Ralph W. Zarogoulidis, Paul Chien, Jason TI NON-INVASIVE DETECTION OF LUNG CANCER FROM CELLS IN SPUTUM USING CELL-CT (TM) SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE Cell-CT; sputum; cancer; 3D C1 [Nelson, Alan; Meyer, Michael; Neumann, Thomas; Hayenga, Jon; Katdare, Rahul; Presley, Chris; Hawthorne, Ben; Steinhauer, David; Bell, Timothy; Spring, Scarlett; Tourovskaia, Anna; Patten, Florence] Visiongate, Phoenix, AZ USA. [Pawlick, Gene] Kaiser Permanente, Oakland, CA USA. [Colgan, Terrance] Mt Sinai Hosp, Toronto, ON, Canada. [Wilbur, David] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Johnson, Douglas] Baptist Canc Inst, Pensacola, FL USA. [Peled, Nir] Chaim Sheba Med Ctr, Tel Hashomer, Israel. [Aye, Ralph W.] Swedish Med Ctr, Dept Thorac & Foregut Surg, Englewood, CO 80110 USA. [Zarogoulidis, Paul] Aristotle Univ Thessaloniki, G Papanikolaou Gen Hosp, Dept Pulm, Oncol Unit, Thessaloniki, Greece. [Chien, Jason] Gilead Sci Inc, Foster City, CA 94404 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P1.20-006 BP S686 EP S686 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624903141 ER PT J AU Novello, S Scagliotti, G Ramlau, R Favaretto, A Barlesi, F Akerley, W Von Pawel, J Orlov, S Spigel, DR Santoro, A Shepherd, F Hirsh, V Sequist, LV Shuster, D Zahir, H Wang, Q Schwartz, B Von Roemeling, R Sandler, AB AF Novello, Silvia Scagliotti, Giorgio Ramlau, Rodryg Favaretto, Adolfo Barlesi, Fabrice Akerley, Wallace Von Pawel, Joachim Orlov, Sergey Spigel, David R. Santoro, Armando Shepherd, Frances Hirsh, Vera Sequist, Lecia V. Shuster, Dale Zahir, Hamim Wang, Qiang Schwartz, Brian Von Roemeling, Reinhard Sandler, Allan B. TI EFFICACY ANALYSIS FOR MOLECULAR SUBGROUPS IN MARQUEE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF TIVANTINIB (ARQ 197) PLUS ERLOTINIB VERSUS PLACEBO PLUS ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC) SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE tivantinib; erlotinib C1 [Novello, Silvia; Scagliotti, Giorgio] Univ Turin, Dept Oncol, I-10124 Turin, Italy. [Ramlau, Rodryg] Poznan Univ Med Sci, Dept Oncol, Poznan, Poland. [Favaretto, Adolfo] Ist Oncol Veneto, Padua, Italy. [Barlesi, Fabrice] Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France. [Akerley, Wallace] Univ Utah, Sch Med, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Von Pawel, Joachim] Asklepios Fachkliniken Munchen Gauting, Munich, Germany. [Orlov, Sergey] St Petersburg State Med Univ, St Petersburg, Russia. [Spigel, David R.] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA. [Santoro, Armando] Ist Clin Humanitas, Dept Med Oncol, Rozzano, Italy. [Shepherd, Frances] Univ Toronto, Dept Med Oncol, Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON M5S 1A1, Canada. [Hirsh, Vera] McGill Univ, Ctr Hlth, Montreal, PQ H3A 2T5, Canada. [Sequist, Lecia V.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Shuster, Dale; Zahir, Hamim; Wang, Qiang; Von Roemeling, Reinhard] Daiichi Sankyo Inc, Parsippany, NJ USA. [Schwartz, Brian] Arqule Inc, Woburn, MA USA. [Sandler, Allan B.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P2.11-024 BP S901 EP S902 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624904179 ER PT J AU Ostroff, R Mehan, MR Williams, S Franklin, W Feser, W Baron, A Geraci, M Merrick, DT Keith, R Miller, Y AF Ostroff, Rachel Mehan, Michael R. Williams, Stephen Franklin, Wilbur Feser, William Baron, Anna Geraci, Mark Merrick, Daniel T. Keith, Robert Miller, York TI DISCOVERY OF CIRCULATING PROTEIN BIOMARKERS OF LUNG DYSPLASIA SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE dysplasia; Proteomic analysis; Biomarkers C1 [Ostroff, Rachel; Mehan, Michael R.; Williams, Stephen] Somalogic, Boulder, CO USA. [Franklin, Wilbur; Feser, William; Baron, Anna; Geraci, Mark] Univ Colorado, Canc Ctr, Boulder, CO 80309 USA. [Merrick, Daniel T.; Keith, Robert; Miller, York] Univ Colorado, Denver Vet Affairs Med Ctr, Boulder, CO 80309 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P2.02-014 BP S756 EP S756 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624903269 ER PT J AU Ostroff, R Mehan, MR Williams, S Niculescu-Mizil, A Franklin, W Merrick, DT Van Bokhoven, A Wolf, H Feser, W Baron, A Miller, Y AF Ostroff, Rachel Mehan, Michael R. Williams, Stephen Niculescu-Mizil, Alexandru Franklin, Wilbur Merrick, Daniel T. Van Bokhoven, Adrie Wolf, Holly Feser, William Baron, Anna Miller, York TI PROTEOMIC INSIGHTS WITH LUNG CANCER TUMORS BASED ON HISTOPATHOLOGIC SUBTYPES AND GENOTYPES SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE Tumor markers; Proteomic analysis; Driver mutation; Histology markers C1 [Ostroff, Rachel; Mehan, Michael R.; Williams, Stephen] Somalogic, Boulder, CO USA. [Niculescu-Mizil, Alexandru] Nec Labs Amer, Princeton, NJ USA. [Franklin, Wilbur; Van Bokhoven, Adrie; Wolf, Holly; Feser, William; Baron, Anna] Univ Colorado, Canc Ctr, Boulder, CO 80309 USA. [Merrick, Daniel T.; Miller, York] Univ Colorado, Denver Vet Affairs Med Ctr, Boulder, CO 80309 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P2.02-015 BP S757 EP S757 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624903270 ER PT J AU Ou, SHI Riely, GJ Tang, YY Kim, DW Otterson, GA Crino, L Bartlett, CH Cohen, DP Clark, JW Janne, PA AF Ou, Sai-Hong I. Riely, Gregory J. Tang, Yiyun Kim, Dong-Wan Otterson, Gregory A. Crino, Lucio Bartlett, Cynthia H. Cohen, Darrel P. Clark, Jeffrey W. Jaenne, Pasi A. TI CLINICAL BENEFIT OF CONTINUING CRIZOTINIB BEYOND INITIAL DISEASE PROGRESSION IN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL-CELL LUNG CANCER SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE treatment beyond disease progression; Crizotinib; TKI; oncogene addiction C1 [Ou, Sai-Hong I.] Univ Calif Irvine, Irvine, CA 92717 USA. [Riely, Gregory J.] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Tang, Yiyun; Bartlett, Cynthia H.; Clark, Jeffrey W.] Pfizer Oncol, New York, NY USA. [Kim, Dong-Wan] Seoul Natl Univ Hosp, Seoul, South Korea. [Otterson, Gregory A.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Crino, Lucio] Univ Hosp Perugia, Perugia, Italy. [Clark, Jeffrey W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Jaenne, Pasi A.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO07.01 BP S294 EP S294 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901134 ER PT J AU Ou, SHI Kim, DW Camidge, DR Riely, G Salgia, R Shapiro, G Solomon, B Engelman, JA Kwak, EL Clark, JW Tye, L Wilner, K Usari, T Varella-Garcia, M Bergethon, K Iafrate, AJ Shaw, AT AF Ou, Sai-Hong I. Kim, Dong-Wan Camidge, D. Ross Riely, Gregory Salgia, Ravi Shapiro, Geoffrey Solomon, Ben Engelman, Jeffrey A. Kwak, Eunice L. Clark, Jeffrey W. Tye, Lesley Wilner, Keith Usari, Tiziana Varella-Garcia, Marileila Bergethon, Kristin Iafrate, A. J. Shaw, Alice T. TI CRIZOTINIB THERAPY FOR PATIENTS WITH ADVANCED ROS1-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC) SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE Crizotinib; ROS1; NSCLC; ALK C1 [Ou, Sai-Hong I.] Univ Calif Irvine, Irvine, CA 92717 USA. [Kim, Dong-Wan] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea. [Camidge, D. Ross; Varella-Garcia, Marileila] Univ Colorado, Boulder, CO 80309 USA. [Riely, Gregory] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Salgia, Ravi] Univ Chicago, Chicago, IL 60637 USA. [Shapiro, Geoffrey] Dana Farber Canc Inst, Boston, MA USA. [Solomon, Ben] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia. [Engelman, Jeffrey A.; Kwak, Eunice L.; Clark, Jeffrey W.; Iafrate, A. J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA. [Tye, Lesley; Wilner, Keith] Pfizer Oncol, New York, NY USA. [Usari, Tiziana] Pfizer Oncol, Milan, Italy. [Bergethon, Kristin] Duke Univ, Sch Med, Durham, NC 27706 USA. [Shaw, Alice T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO07.03 BP S295 EP S295 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901136 ER PT J AU Ou, SHI Gadgeel, S Chiappori, AA Gandhi, L Azada, M Garcia, L Takaya, I Yokoyama, S Kamei, T Tanaka, T Lee, RM Riely, G AF Ou, Sai-Hong I. Gadgeel, Shirish Chiappori, Alberto A. Gandhi, Leena Azada, Michele Garcia, Linta Takaya, Itsumi Yokoyama, Shumpei Kamei, Tomonori Tanaka, Tomohiro Lee, Ruey-Min Riely, Gregory TI CONSISTENT THERAPEUTIC EFFICACY OF CH5424802/RO5424802 IN BRAIN METASTASES AMONG CRIZOTINIB-REFRACTORY ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN AN ONGOING PHASE I/II STUDY (AF-002JG/NP28761, NCT01588028). SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE ALK-inhibitor; CH5424802/RO5424802; CNS metastasis; Efficacy C1 [Ou, Sai-Hong I.; Azada, Michele] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA 92717 USA. [Gadgeel, Shirish] Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48202 USA. [Chiappori, Alberto A.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Gandhi, Leena] Dana Farber Canc Inst, Boston, MA USA. [Garcia, Linta] Chugai Pharmaceut Co Ltd, Berkeley, CA USA. [Takaya, Itsumi; Yokoyama, Shumpei; Kamei, Tomonori; Tanaka, Tomohiro] Chugai Pharmaceut Co Ltd, Tokyo, Japan. [Lee, Ruey-Min] Hoffmann La Roche Inc, Nutley, NJ USA. [Riely, Gregory] Mem Sloan Kettering Canc Ctr, New York, NY USA. NR 0 TC 2 Z9 2 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA O16.07 BP S200 EP S200 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624900248 ER PT J AU Oxnard, GR Paweletz, CP Kuang, YN Messineo, MM Connell, AO Mach, SL Butaney, M Lo, PC Jackman, DM Janne, PA AF Oxnard, Geoffrey R. Paweletz, Cloud P. Kuang, Yanan Messineo, Melissa M. Connell, Allison O. Mach, Stacy L. Butaney, Mohit Lo, Peter C. Jackman, David M. Jaenne, Pasi A. TI DEVELOPMENT OF A CLINICAL-GRADE QUANTITATIVE ASSAY FOR NON-INVASIVE MEASUREMENT OF TUMOR GENOTYPE IN CELL-FREE PLASMA DNA (CFDNA) USING NEXT-GENERATION QUANTITATIVE GENOTYPING SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE digital droplet PCR; NSCLC; EGFR; plasma DNA C1 [Oxnard, Geoffrey R.; Paweletz, Cloud P.; Kuang, Yanan; Messineo, Melissa M.; Connell, Allison O.; Mach, Stacy L.; Butaney, Mohit; Lo, Peter C.; Jackman, David M.; Jaenne, Pasi A.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P3.06-054 BP S1099 EP S1099 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624905181 ER PT J AU Oxnard, GR Heng, JC Rainville, IR Sable-Hunt, AL Root, EJ Wiesner, GL Carbone, DP Janne, PA Garber, JE AF Oxnard, Geoffrey R. Heng, Jennifer C. Rainville, Irene R. Sable-Hunt, Alicia L. Root, Elizabeth J. Wiesner, Georgia L. Carbone, David P. Jaenne, Pasi A. Garber, Judy E. TI A PROSPECTIVE INTERNET-BASED STUDY OF PATIENTS WITH LUNG CANCER HARBORING BASELINE EGFR T790M TO IDENTIFY GERMLINE CARRIERS AND CHARACTERIZE FAMILIAL RISK SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE EGFR; T790M mutation; germline genetics; familial lung cancer C1 [Oxnard, Geoffrey R.; Heng, Jennifer C.; Rainville, Irene R.; Root, Elizabeth J.; Jaenne, Pasi A.; Garber, Judy E.] Dana Farber Canc Inst, Boston, MA USA. [Wiesner, Georgia L.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Carbone, David P.] Ohio State Wexner Med Ctr, Columbus, OH USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO15.06 BP S350 EP S350 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901220 ER PT J AU Padda, SK Rosenberg-Hasson, Y Neal, JW Gettinger, SN Engelman, JA Janne, PA West, HL Subramaniam, D Leach, JW Lara, PN Wax, MB Wakelee, HA Clary, DO Zhou, LS AF Padda, Sukhmani K. Rosenberg-Hasson, Yael Neal, Joel W. Gettinger, Scott N. Engelman, Jeffrey A. Jaenne, Pasi A. West, Howard L. Subramaniam, Deepa Leach, Joseph W. Lara, Primo N. Wax, Michael B. Wakelee, Heather A. Clary, Douglas O. Zhou, Lisa TI CORRELATIVE ANALYSIS OF CIRCULATING BIOMARKERS FROM A PHASE 1B/2 TRIAL OF CABOZANTINIB (C) WITH OR WITHOUT ERLOTINIB (E) IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE cabozantinib; biomarker; erlotinib C1 [Padda, Sukhmani K.; Neal, Joel W.; Wakelee, Heather A.; Zhou, Lisa] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA. [Rosenberg-Hasson, Yael] Stanford Univ, Sch Med, Inst Immun Transplantat & Infect, Stanford, CA 94305 USA. [Gettinger, Scott N.] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA. [Engelman, Jeffrey A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. [Jaenne, Pasi A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA. [West, Howard L.] Swedish Canc Inst, Seattle, WA USA. [Subramaniam, Deepa] Georgetown Univ, Lombardi Canc Ctr, Washington, DC 20057 USA. [Leach, Joseph W.] Virginia Piper Canc Inst, Minneapolis, MN USA. [Lara, Primo N.] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA. [Wax, Michael B.] Summit Med Grp, Berkeley Hts, NJ USA. [Clary, Douglas O.] Exelixis Inc, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P3.06-003 BP S1072 EP S1073 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624905131 ER PT J AU Poghosyan, H Joseph, JG Bell, J Cooley, ME AF Poghosyan, Hermine Joseph, Jill G. Bell, Janice Cooley, Mary E. TI THE ASSOCIATION BETWEEN HAVING A FIRST-DEGREE FAMILY HISTORY OF CANCER AND SMOKING STATUS SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE health promotion; smoking-cessation; family cancer history C1 [Poghosyan, Hermine] Univ Massachusetts Boston, Coll Nursing & Hlth Sci, Boston, MA USA. [Joseph, Jill G.; Bell, Janice] Univ Calif Davis, Betty Irene Moore Sch Nursing, Davis, CA USA. [Cooley, Mary E.] Dana Farber Canc Inst, Phyllis Cantor Ctr Res Nursing & Patient Care Ser, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA O06.04 BP S154 EP S155 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624900185 ER PT J AU Ramalingam, SS Shapiro, G Hirsh, V Zaric, B Ceric, T Poddubskaya, E Goldman, J Ciuleanu, T Khuri, FR Spicer, J Skrylnik, O Felip, E Manegold, C Andric, Z Rosell, R Badovinac, S Pieters, T Modiano, MR Vukovic, VM Yalcin, I Teofilovici, F El-Hariry, I Guo, W Bahcall, SR Goss, G Fennell, D AF Ramalingam, Suresh S. Shapiro, Geoffrey Hirsh, Vera Zaric, Bojan Ceric, Timur Poddubskaya, Elena Goldman, Jonathan Ciuleanu, Tudor Khuri, Fadlo R. Spicer, James Skrylnik, Olga Felip, Enriqueta Manegold, Christian Andric, Zoran Rosell, Rafael Badovinac, Sonja Pieters, Thierry Modiano, Manuel R. Vukovic, Vojislav M. Yalcin, Ilker Teofilovici, Florentina El-Hariry, Iman Guo, Wei Bahcall, Safi R. Goss, Glenwood Fennell, Dean TI GALAXY-1: RANDOMIZED PHASE II STUDY OF DOCETAXEL WITH OR WITHOUT GANETESPIB IN ADVANCED LUNG ADENOCARCINOMA: RESULTS IN BIOMARKER SUB-GROUPS AND ALL ADENOCARCINOMA PATIENTS. SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE heat shock protein; ganetespib; NSCLC; docetaxel C1 [Ramalingam, Suresh S.; Khuri, Fadlo R.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA. [Shapiro, Geoffrey] Dana Farber Canc Inst, Boston, MA USA. [Hirsh, Vera] McGill Univ, Hlth Ctr, Montreal, PQ H3A 2T5, Canada. [Zaric, Bojan] Inst Pulm Dis Vojvodina, Vojvodina, Serbia. [Ceric, Timur] Univ Sarajevo, Ctr 5Clin, Sarajevo 71000, Bosnia & Herceg. [Poddubskaya, Elena] Blokhin Russian Oncol Res Ctr, Unit Russian Acad Med, Moscow, Russia. [Goldman, Jonathan] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Ciuleanu, Tudor] Prof Dr Ion Chiricuta Inst Oncol, Cluj Napoca, Romania. [Spicer, James] Kings Coll London, London, England. [Skrylnik, Olga] Municipal Inst Dnipropetrovsk City Multispecialty, Dnepropetrovsk, Ukraine. [Felip, Enriqueta] Hosp Gen Valle Hebron, Barcelona, Spain. [Manegold, Christian] Klinikum Mannheim GmbH, Mannheim, Germany. [Andric, Zoran] Clin Hosp Ctr Bezanijska Kosa, Belgrade, Serbia. [Rosell, Rafael] Catalan Inst Oncol, Barcelona, Spain. [Badovinac, Sonja] Clin Hosp Ctr Zagreb, Zagreb, Croatia. [Pieters, Thierry] Clin Univ St Luc, Woluwe St Lambert, Belgium. [Modiano, Manuel R.] Acrc, Los Angeles, CA USA. [Vukovic, Vojislav M.; Yalcin, Ilker; Teofilovici, Florentina; El-Hariry, Iman; Guo, Wei; Bahcall, Safi R.] Synta Pharmaceut, Lexington, MA USA. [Goss, Glenwood] Ottawa Hosp Ctr, Ottawa, ON, Canada. [Fennell, Dean] Univ Leicester, Leicester LE1 7RH, Leics, England. NR 0 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA O03.01 BP S139 EP S139 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624900164 ER PT J AU Ranson, M Pao, W Kim, DW Kim, SW Ohe, Y Felip, E Planchard, D Ghiorghiu, S Cantarini, M Cross, D Janne, PA AF Ranson, Malcolm Pao, William Kim, Dong-Wan Kim, Sang-We Ohe, Yuichiro Felip, Enriqueta Planchard, David Ghiorghiu, Serban Cantarini, Mireille Cross, Darren Jaenne, Pasi A. TI AZD9291: AN IRREVERSIBLE, POTENT AND SELECTIVE TYROSINE KINASE INHIBITOR (TKI) OF ACTIVATING (EGFRM plus ) AND RESISTANCE (T790M) MUTATIONS IN ADVANCED NSCLC SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE AZD9291; Phase I; EGFR mutations; T790M mutation C1 [Ranson, Malcolm] Christie Hosp NHS Trust, Manchester, Lancs, England. [Pao, William] Vanderbilt Univ, Dept Med, Div Hematol Oncol, Nashville, TN USA. [Kim, Dong-Wan] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea. [Kim, Sang-We] Asan Med Ctr, Dept Oncol, Seoul, South Korea. [Ohe, Yuichiro] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba, Japan. [Felip, Enriqueta] Hosp Univ Vall Dhebron, Barcelona, Spain. [Planchard, David] Inst Gustave Roussy, Villejuif, France. [Ghiorghiu, Serban; Cantarini, Mireille; Cross, Darren] Astrazeneca, London, England. [Jaenne, Pasi A.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 8 Z9 9 U1 0 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO21.12 BP S389 EP S389 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901280 ER PT J AU Richards, W Gill, RR Yeap, BY Bueno, R Sugarbaker, DJ AF Richards, William Gill, Ritu R. Yeap, Beow Y. Bueno, Raphael Sugarbaker, David J. TI VALIDATION OF A STAGE-INDEPENDENT PRE-OPERATIVE RISK ASSESSMENT ALGORITHM FOR PATIENTS CONSIDERING SURGERY FOR MALIGNANT PLEURAL MESOTHELIOMA. SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE mesothelioma; Prognosis; surgery C1 [Richards, William; Gill, Ritu R.; Bueno, Raphael; Sugarbaker, David J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Yeap, Beow Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO14.08 BP S344 EP S345 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901211 ER PT J AU Rigotti, NA AF Rigotti, Nancy A. TI SMOKING CESSATION SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract C1 [Rigotti, Nancy A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MTE08.1 BP S95 EP S95 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624900113 ER PT J AU Schuler, M Yang, JC Sequist, LV Hirsh, V O'Byrne, K Yamamoto, N Massey, D Shahidi, M Zazulina, V Mok, T AF Schuler, Martin Yang, James C. Sequist, Lecia V. Hirsh, Vera O'Byrne, Kenneth Yamamoto, Nobuyuki Massey, Daniel Shahidi, Mehdi Zazulina, Victoria Mok, Tony TI EFFICACY OF AFATINIB VS. CHEMOTHERAPY IN TREATMENT-NAIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) HARBOURING ACTIVATING EGFR MUTATIONS WITH OR WITHOUT METASTATIC BRAIN DISEASE SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE afatinib; brain metastases; EGFR C1 [Schuler, Martin] Univ Duisburg Essen, West German Canc Ctr, Essen, Germany. [Yang, James C.] Natl Taiwan Univ Hosp, Taipei, Taiwan. [Sequist, Lecia V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hirsh, Vera] McGill Univ, Montreal, PQ H3A 2T5, Canada. [O'Byrne, Kenneth] Princess Alexandra Hosp, Woolloongabba, Qld, Australia. [Yamamoto, Nobuyuki] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan. [Massey, Daniel; Shahidi, Mehdi; Zazulina, Victoria] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany. [Mok, Tony] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. NR 0 TC 4 Z9 4 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO07.13 BP S299 EP S300 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901144 ER PT J AU Sequist, LV Yang, JC Yamamoto, N O'Byrne, K Schuler, M Mok, T Geater, SL Massey, D Wind, S O'Brien, D Lorence, R Wu, YL AF Sequist, Lecia V. Yang, James C. Yamamoto, Nobuyuki O'Byrne, Kenneth Schuler, Martin Mok, Tony Geater, Sarayut Lucien Massey, Daniel Wind, Sven O'Brien, Dennis Lorence, Robert Wu, Yi-Long TI COMPARATIVE SAFETY PROFILE OF AFATINIB IN ASIAN AND NON-ASIAN PATIENTS WITH EGFR MUTATION-POSITIVE (EGFR M plus ) NON-SMALL CELL LUNG CANCER (NSCLC) SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE safety; EGFR; afatinib C1 [Sequist, Lecia V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Yang, James C.; Yamamoto, Nobuyuki] Natl Taiwan Univ Hosp, Taipei, Taiwan. [O'Byrne, Kenneth] Princess Alexandra Hosp, Woolloongabba, Qld, Australia. [Schuler, Martin] Univ Duisburg Essen, West German Canc Ctr, Essen, Germany. [Mok, Tony] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. [Geater, Sarayut Lucien] Prince Songkla Univ, Hat Yai, Thailand. [Massey, Daniel] Boehringer Ingelheim GmbH & Co KG, Bracknell, West Berkshire, England. [Wind, Sven] Boehringer Ingelheim Pharma GmbH & Co KG, Rheinland Pfalz, Germany. [O'Brien, Dennis; Lorence, Robert] Boehringer Ingelheim Pharmaceut, Ridgefield, CT USA. [Wu, Yi-Long] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P3.11-023 BP S1197 EP S1197 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624905352 ER PT J AU Shaw, AT Solomon, BJ Mok, T Kim, DW Wilner, KD Selaru, P Polli, A AF Shaw, Alice T. Solomon, Benjamin J. Mok, Tony Kim, Dong-Wan Wilner, Keith D. Selaru, Paulina Polli, Anna TI EFFECT OF TREATMENT DURATION ON INCIDENCE OF ADVERSE EVENTS (AES) IN A PHASE III STUDY OF CRIZOTINIB VERSUS CHEMOTHERAPY IN ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE Crizotinib; treatment duration; adverse events; safety C1 [Shaw, Alice T.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Solomon, Benjamin J.] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia. [Mok, Tony] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. [Wilner, Keith D.; Selaru, Paulina] Pfizer Oncol, New York, NY USA. [Polli, Anna] Pfizer Oncol, Milan, Italy. NR 0 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P2.11-041 BP S911 EP S912 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624904196 ER PT J AU Soria, JC Sequist, LV Gadgeel, S Goldman, J Wakelee, H Varga, A Fidias, P Wozniak, AJ Neal, JW Doebele, RC Garon, EB Jaw-Tsai, S Caunt, L Kaur, P Rolfe, L Camidge, DR Allen, A AF Soria, Jean-Charles Sequist, Lecia V. Gadgeel, Shirish Goldman, Jonathan Wakelee, Heather Varga, Andrea Fidias, Panagiotis Wozniak, Antoinette J. Neal, Joel W. Doebele, Robert C. Garon, Edward B. Jaw-Tsai, Sarah Caunt, Lisa Kaur, Paramjit Rolfe, Lindsey Camidge, D. Ross Allen, Andrew TI FIRST-IN-HUMAN EVALUATION OF CO-1686, AN IRREVERSIBLE, HIGHLY, SELECTIVE TYROSINE KINASE INHIBITOR OF MUTATIONS OF EGFR (ACTIVATING AND T790M) SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE T790M; EGFR TKI; NSCLC; CO-1686 C1 [Soria, Jean-Charles; Varga, Andrea] Inst Gustave Roussy, Villejuif, France. [Sequist, Lecia V.; Fidias, Panagiotis] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Gadgeel, Shirish; Wozniak, Antoinette J.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48202 USA. [Goldman, Jonathan; Garon, Edward B.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Wakelee, Heather; Neal, Joel W.] Stanford Univ, Stanford, CA 94305 USA. [Doebele, Robert C.; Camidge, D. Ross] Univ Colorado, Boulder, CO 80309 USA. NR 0 TC 8 Z9 8 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA O03.06 BP S141 EP S142 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624900168 ER PT J AU Varon, J Mak, RH Cardarella, SH Janne, PA Oxnard, GR AF Varon, Jack Mak, Raymond H. Cardarella, Stephanie H. Jaenne, Pasi A. Oxnard, Geoffrey R. TI A PRACTICE-BASED ANALYSIS TO GAUGE THE FEASIBILITY OF GENOTYPE-DIRECTED INDUCTION THERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC) SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE Locally advanced disease; Practice-based analysis; Targeted therapy; non-small cell lung cancer C1 [Varon, Jack] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Mak, Raymond H.; Cardarella, Stephanie H.; Jaenne, Pasi A.; Oxnard, Geoffrey R.] Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P3.12-004 BP S1215 EP S1216 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624906024 ER PT J AU Wakelee, HA Karlovich, CA Wen, W Sun, JM Chien, S Mann, E Donnell, PO Angenendt, P Dziadziusko, R Horn, L Spigel, D Sequist, LV Solomon, B Soria, JC Camidge, DR Goldman, J Gadgeel, S Raponi, M Wu, L Park, K AF Wakelee, Heather A. Karlovich, Chris A. Wen, Wei Sun, Jong-Mu Chien, Sean Mann, Elaina Donnell, Patrick O. Angenendt, Philipp Dziadziusko, Rafal Horn, Leora Spigel, David Sequist, Lecia V. Solomon, Benjamin Soria, Jean-Charles Camidge, D. Ross Goldman, Jonathan Gadgeel, Shirish Raponi, Mitch Wu, Lin Park, Keunchil TI SERIAL MONITORING OF PLASMA EGFR T790M LEVELS AND EVALUATION OF EGFR MUTATIONAL STATUS IN MATCHED TISSUE AND PLASMA FROM NSCLC PATIENTS TREATED WITH CO-1686 SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE EGFR plasma concordance cobas C1 [Wakelee, Heather A.] Stanford Univ, Div Oncol, Stanford, CA 94305 USA. [Karlovich, Chris A.; Raponi, Mitch] Clovis Oncol, Mol Diagnost, Boulder, CO USA. [Wen, Wei; Chien, Sean; Donnell, Patrick O.; Wu, Lin] Roche Mol Syst, Pleasanton, CA USA. [Sun, Jong-Mu; Park, Keunchil] Sungkyunkwan Univ, Div Hematol Oncol, Samsung Med Ctr, Sch Med, Seoul, South Korea. [Mann, Elaina] Clovis Oncol, Boulder, CO USA. [Angenendt, Philipp] Inostics, Hamburg, Germany. [Dziadziusko, Rafal] Med Univ Gdansk, Gdansk, Poland. [Horn, Leora] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Spigel, David] Sarah Cannon Res Inst, Nashville, TN USA. [Sequist, Lecia V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Solomon, Benjamin] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia. [Soria, Jean-Charles] Inst Gustave Roussy, Villejuif, France. [Camidge, D. Ross] Univ Colorado, Boulder, CO 80309 USA. [Goldman, Jonathan] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Gadgeel, Shirish] Karmonos Canc Inst, Detroit, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO21.10 BP S388 EP S389 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901279 ER PT J AU Yang, JC Sequist, LV Geater, SL Tsai, CM Mok, TSK Schuler, M Yamamoto, N Massey, D Zazulina, V Wu, YL AF Yang, James C. Sequist, Lecia V. Geater, Sarayut Lucien Tsai, Chun-Ming Mok, Tony Shu Kam Schuler, Martin Yamamoto, Nobuyuki Massey, Daniel Zazulina, Victoria Wu, Yi-Long TI ACTIVITY OF AFATINIB IN UNCOMMON EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS: FINDINGS FROM THREE TRIALS OF AFATINIB IN EGFR MUTATION-POSITIVE LUNG CANCER SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE Uncommon EGFR mutations; afatinib; NSCLC; T790M C1 [Yang, James C.] Natl Taiwan Univ, Grad Inst Oncol, Taipei, Taiwan. [Sequist, Lecia V.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Geater, Sarayut Lucien] Prince Songkla Univ, Fac Med, Hat Yai, Thailand. [Tsai, Chun-Ming] Taipei Vet Gen Hosp, Taipei, Taiwan. [Mok, Tony Shu Kam] Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China. [Schuler, Martin] Univ Hosp Essen, Dept Med Oncol, West German Canc Ctr, Essen, Germany. [Yamamoto, Nobuyuki] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan. [Massey, Daniel] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany. [Zazulina, Victoria] Boehringer Ingelheim GmbH & Co KG, Clin Dev & Med Affairs, Ingelheim, Germany. [Wu, Yi-Long] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China. NR 0 TC 9 Z9 9 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA O03.05 BP S141 EP S141 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624900167 ER PT J AU Min, L Ibrahim, N AF Min, Le Ibrahim, Nageatte TI Ipilimumab-induced autoimmune adrenalitis SO LANCET DIABETES & ENDOCRINOLOGY LA English DT Editorial Material C1 [Min, Le] Brigham & Womens Hosp, Boston, MA 02115 USA. [Ibrahim, Nageatte] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Min, L (reprint author), Brigham & Womens Hosp, Div Endocrinol, 221 Longwood Ave, Boston, MA 02115 USA. EM lmin1@partners.org FU NICHD NIH HHS [K08 HD070957]; NIDDK NIH HHS [T32 DK007529] NR 0 TC 10 Z9 10 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2213-8587 J9 LANCET DIABETES ENDO JI Lancet Diabetes Endocrinol. PD NOV PY 2013 VL 1 IS 3 BP E15 EP E15 DI 10.1016/S2213-8587(13)70031-7 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AP1AU UT WOS:000341799600028 PM 24622375 ER PT J AU Lippincott, MF True, C Seminara, SB AF Lippincott, Margaret F. True, Cadence Seminara, Stephanie B. TI Use of genetic models of idiopathic hypogonadotrophic hypogonadism in mice and men to understand the mechanisms of disease SO EXPERIMENTAL PHYSIOLOGY LA English DT Article ID MONKEY MACACA-MULATTA; GNRH PULSE-GENERATOR; NEUROKININ-B; ARCUATE NUCLEUS; FEMALE RAT; DEVELOPMENTAL-CHANGES; KISSPEPTIN NEURONS; REPRODUCTIVE AXIS; HORMONE SECRETION; TACR3 MUTATIONS AB Mutations in the genes encoding the neuropeptides kisspeptin and neurokinin B, as well as their receptors, are associated with gonadotrophin-releasing hormone(GnRH) deficiency and a failure to initiate and/or progress through puberty. Although the total number of patients studied to date is small, mutations in the kisspeptin pathway appear to result in lifelong GnRH deficiency. Mice with mutations in kisspeptin and the kisspeptin receptor, Kiss1(-/-) and Kiss1r(-/-), respectively, appear to be phenocopies of the human with abnormal sexual maturation and infertility. In contrast, mutations in the neurokinin B pathway lead to a more variable adult reproductive phenotype, with a subset of hypogonadotrophic individuals demonstrating paradoxical recovery of reproductive function later in life. While 'reversal' remains poorly understood, the ability to recover reproductive function indicates that neurokinin B may play different roles in the initiation of sexual maturation compared with the maintenance of adult reproductive function. Mice with mutations in the gene encoding the neurokinin B receptor, Tacr3, have abnormal oestrous cycles and subfertility but, similar to their human counterparts, appear less severely affected than mice with kisspeptin deficiency. Further investigations into the interaction between the kisspeptin and neurokinin B pathways will reveal key insights into how GnRH neuronal modulation occurs at puberty and throughout reproductive life. C1 [Seminara, Stephanie B.] Massachusetts Gen Hosp, Harvard Reprod Sci Ctr, Boston, MA 02114 USA. [Seminara, Stephanie B.] Massachusetts Gen Hosp, Dept Med, Reprod Endocrine Unit, Boston, MA 02114 USA. RP Seminara, SB (reprint author), Massachusetts Gen Hosp, Harvard Reprod Sci Ctr, 55 Fruit St, Boston, MA 02114 USA. EM sseminara@partners.org OI Lippincott, Margaret/0000-0002-3533-1999 FU National Institutes of Health [U54 HD028138, ROI HD043341, K24 HD067388] FX This work was supported by National Institutes of Health grants U54 HD028138, ROI HD043341 and K24 HD067388. NR 44 TC 6 Z9 6 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0958-0670 EI 1469-445X J9 EXP PHYSIOL JI Exp. Physiol. PD NOV PY 2013 VL 98 IS 11 BP 1522 EP 1527 DI 10.1113/expphysiol.2013.071910 PG 6 WC Physiology SC Physiology GA AN9OM UT WOS:000340936400001 PM 23955308 ER PT J AU Gray, DA Borba, CPC Harris, BL Dominguez, S Boxill, R Wang, EKS Henderson, DC AF Gray, D. A. Borba, C. P. C. Harris, B. L. Dominguez, S. Boxill, R. Wang, E. K. S. Henderson, D. C. TI Understanding cohort differences in appraisals of reconstruction priorities of mental health systems in post-conflict Liberia SO AFRICAN JOURNAL OF PSYCHIATRY LA English DT Article DE Mental Health; Liberia; Treatment Settings; Elders; Needs Assessment ID WAR; REFUGEES; VIOLENCE; TRAUMA; POLICY; CARE AB Objective: This study analyzes the relationship between informants' age and their assessment of mental health needs in post-conflict society and examines if mental health needs assessment priorities differ depending upon whether or not the informant was exposed to the Liberian civil war. Method: A cross-sectional survey was conducted in March 2009 to obtain data on mental health needs of Liberian children, adolescents and young adults. A total of 171 individuals were interviewed. The data were analyzed using a two-way ANOVA. Results: Elder respondents expressed a preference for young adults to receive services in a church/mosque (F = 4.020, p < .05); for adolescents in volunteer programs (F = 3.987, p < .05) and for children in sports programs (F = 4.396, p < .05). Experiencing conflict did exert some influence on treatment setting preferences. Those who resided outside Liberia during the conflict cited a preference for traditional healers and medical clinics. However, this preference was for the children and young adult age categories. Those who experienced the civil war reported significantly higher preferences for adolescent services to be located in medical clinics, with traditional healers, and in churches/mosques. Conclusion: This study provides additional support for the premise that the utilization of psychiatric services needs to be viewed from the perspective of Liberians and that there are differences in preferences across groups. Our results suggest that service providers and policy makers take into account the age of the patient when deciding where to locate treatment settings for the population. C1 [Gray, D. A.; Dominguez, S.; Boxill, R.; Wang, E. K. S.; Henderson, D. C.] Massachusetts Gen Hosp, MD Div Global Psychiat, Boston, MA 02114 USA. [Borba, C. P. C.; Wang, E. K. S.; Henderson, D. C.] Harvard Univ, Sch Med, Boston, MA USA. [Harris, B. L.] Univ Liberia, AM Dogliotti Coll Med, Monrovia, CA, Liberia. RP Gray, DA (reprint author), 25 Staniford St,2nd Floor, Boston, MA 02114 USA. EM deborahagray@comcast.net FU McCall MacBain Foundation FX This research was supported by the McCall MacBain Foundation. We appreciate the efforts of the Liberia Minister of Health and Social Welfare, Dr. Walter T Gwenigale and we are endlessly grateful to all the local research assistants who carried out these interviews: Amos Cassell, Michael Badeior Wilson, Augustus W. Nelson Sr., Kollie F. Gbelema - M, S. Swen Kun, Jr., Fatu Nelson, Sametta T. Thomas, Lena T. Cummings, Sr. Patience Payne, Habakkuk Garpehn, S. Benedict Dossen, Alphonso C. Williams, Zuorkuan Patience Flomo, Beatrice M. K. Newland, Augustus Yarkerseh Voahn, Messie B. B. Allen, David Sheik Konneh, Emmanuel W. Wonkpah, Thomas Nimineh, Roye Bloh, and Philiminah M'Bakellah. Additionally, a number of talented and dedicated collaborators made this work possible. The authors would like to thank the following individuals for their tireless efforts and technical support: Dr. Mardia Harris Stone, Yale University-Clinton Foundation Senior Fellow in International Healthcare Management; Dr. Hilary Dennis (WHO); Massachusetts General Hospital/Harvard Medical School Liberian Mental Health Working Group, Dr. Richard F. Mollica, James Lavelle LICSW, and Nicole Colucci BA; Ghislaine Grasser (Coordinator, McCall MacBain Foundation Liberia Project); Sr. Barbara Brilliant and Dr. Judith Baessler (Mother Patern College of Health Sciences); Samuel Gibson (LUADA); Christien Veldnik (Medecin du Monde); ACF, Center for Victims of Torture, and Cap Anamur. We also appreciate the inputs and efforts of the following staff from the Ministry of Health and Social Welfare: Clle Vivian Cherue, Deputy Minister for Administration; S. Tornorlah Varpilah, Deputy Minister for Planning, Research and Vital Statistics; Nmah Bropleh, Assistant Minister for Planning and Chairperson of the Mental Health Policy Committee; Jessie Ebba-Duncan, Assistant Minister for Preventive Services; David Franklin, National Mental Health Coordinator, Mental Health Unit; Lydia Mai Sherman, Senior Coordinator, Social Welfare Department; Habakkuk Garpehn, Assistant, Social Welfare Department; Patrick Sawyer, Mental Health Unit. We would also like to thank Elizabeth Dugan PhD (University of Massachusetts Boston Gerontology Program) for her comments on an earlier version of this manuscript. NR 37 TC 1 Z9 1 U1 2 U2 5 PU IN HOUSE PUBLICATIONS PI JOHANNESBURG PA PO BOX 412748, CRAIGHALL 2024, JOHANNESBURG, 00000, SOUTH AFRICA SN 1994-8220 J9 AFR J PSYCHIATRY JI Afr. J. Psychiatry PD NOV PY 2013 VL 16 IS 6 BP 437 EP 444 DI 10.4314/ajpsy.v16i6.56 PG 8 WC Psychiatry SC Psychiatry GA AM2DS UT WOS:000339659900008 ER PT J AU Finley, EP Pugh, JA Lanham, HJ Leykum, LK Cornell, J Veerapaneni, P Parchman, ML AF Finley, Erin P. Pugh, Jacqueline A. Lanham, Holly Jordan Leykum, Luci K. Cornell, John Veerapaneni, Poornachand Parchman, Michael L. TI Relationship Quality and Patient-Assessed Quality of Care in VA Primary Care Clinics: Development and Validation of the Work Relationships Scale SO ANNALS OF FAMILY MEDICINE LA English DT Article DE relationships; primary care; quality of care; patient satisfaction; Veteran's Administration ID RELATIONSHIP-CENTERED CARE; HEALTH-CARE; VETERANS; TRANSFORMATION AB PURPOSE Efforts to better understand the impact of clinic member relationships on care quality in primary care clinics have been limited by the absence of a validated instrument to assess these relationships. The purpose of this study was to develop and validate a scale assessing relationships within primary care clinics. METHODS The Work Relationships Scale (WRS) was developed and administered as part of a survey of learning and relationships among 17 Department of Veterans Affairs (VA) primary care clinics. A Rasch partial-credit model and principal components analysis were used to evaluate item performance, select the final items for inclusion, and establish unidimensionality for the WRS. The WRS was then validated against semistructured clinic member interviews and VA Survey of Healthcare Experiences of Patients (SHEP) data. RESULTS Four hundred fifty-seven clinicians and staff completed the clinic survey, and 247 participated in semistructured interviews. WRS scores were significantly associated with clinic-level reporting for 2 SHEP variables: overall rating of personal doctor/nurse (r(2) = 0.43, P <. 01) and overall rating of health care (r(2) = 0.25, P <. 05). Interview data describing relationship characteristics were consistent with variability in WRS scores across low-scoring and high-scoring clinics. CONCLUSIONS The WRS shows promising validity as a measure assessing the quality of relationships in primary care settings; moreover, primary care clinics with lower WRS scores received poorer patient quality ratings for both individual clinicians and overall health care. Relationships play an important role in shaping care delivery and should be assessed as part of efforts to improve patient care within primary care settings. C1 [Finley, Erin P.; Pugh, Jacqueline A.; Lanham, Holly Jordan; Leykum, Luci K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Finley, Erin P.; Pugh, Jacqueline A.; Lanham, Holly Jordan; Leykum, Luci K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Lanham, Holly Jordan] Univ Texas Austin, McCombs Sch Business, Austin, TX 78712 USA. [Lanham, Holly Jordan; Veerapaneni, Poornachand] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [Cornell, John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat & Epidemiol, San Antonio, TX 78229 USA. [Parchman, Michael L.] Grp Hlth Cooperat Puget Sound, MacColl Ctr Hlth Care Innovat, Grp Hlth Res Inst, Seattle, WA USA. RP Finley, EP (reprint author), VERDICT Res Unit 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM finleye@uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X; Parchman, Michael/0000-0001-7129-2889; Finley, Erin/0000-0003-4497-7721 FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (HSRD) [IIR 06-063]; National Institute of Mental Health [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI) FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (HSR&D) project no. IIR 06-063. Dr. Finley is an investigator with the Implementation Research Institute, George Warren Brown School of Social Work, Washington University, St. Louis; through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI). NR 24 TC 11 Z9 11 U1 0 U2 12 PU ANNALS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672 USA SN 1544-1709 EI 1544-1717 J9 ANN FAM MED JI Ann. Fam. Med. PD NOV-DEC PY 2013 VL 11 IS 6 BP 543 EP 549 DI 10.1370/afm.1554 PG 7 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA AI3XU UT WOS:000336799800007 PM 24218378 ER PT J AU Castelino, FV Varga, J AF Castelino, Flavia V. Varga, John TI Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development SO EXPERT REVIEW OF CLINICAL IMMUNOLOGY LA English DT Review DE autoantibodies; biomarker; classification criteria; gene expression; scleroderma ID INTERSTITIAL LUNG-DISEASE; PULMONARY ARTERIAL-HYPERTENSION; SURFACTANT PROTEIN-D; RNA-POLYMERASE-III; GROWTH-DIFFERENTIATION FACTOR-15; VON-WILLEBRAND-FACTOR; C-REACTIVE PROTEIN; RAYNAUDS-PHENOMENON; THERAPEUTIC TARGET; SEROLOGIC FEATURES AB Systemic sclerosis (SSc) is a clinically heterogeneous orphan disease of unknown etiology and no effective therapy. It is characterized by protean manifestations, an unpredictable disease course and variable outcomes. Clinical manifestations reflect underlying autoimmunity, small vessel vasculopathy and progressive multi-organ fibrosis. Predicting disease progression, pattern and severity of complications and response to therapy in SSc remain major challenges both for the management of patients and for the development of effective disease-modifying therapies. This review summarizes contemporary understanding of novel and emerging biomarkers for SSc. We focus on the development of new classification criteria, the utility of SSc-specific autoantibodies as diagnostic and prognostic markers, and on biomarkers for skin and lung involvement. Finally, we review genome-wide expression analysis as a tool to predict therapeutic responses. We anticipate that the development, validation and application of these biomarkers, singly or more likely in combination, will have a transformative impact in SSc, informing early diagnosis, classification and management, as well as the design, execution and interpretation of clinical trials of novel therapeutic agents. C1 [Castelino, Flavia V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol, Boston, MA 02114 USA. [Varga, John] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA. RP Castelino, FV (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol, Yawkey 2C-2100,55 Fruit St, Boston, MA 02114 USA. EM fcastelino@partners.org FU NIAMS [K08 AR062592, R01 AR42309]; Scleroderma Foundation FX FV Castelino was supported by grant K08 AR062592 from NIAMS and by the Scleroderma Foundation. J Varga was supported by R01 AR42309 from NIAMS. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 116 TC 15 Z9 15 U1 0 U2 11 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1744-666X EI 1744-8409 J9 EXPERT REV CLIN IMMU JI Expert Rev. Clin. Immunol. PD NOV PY 2013 VL 9 IS 11 BP 1077 EP 1090 DI 10.1586/1744666X.2013.848792 PG 14 WC Immunology SC Immunology GA AI8QX UT WOS:000337188500014 PM 24168414 ER PT J AU Schalock, PC Thyssen, JP AF Schalock, Peter C. Thyssen, Jacob P. TI Metal Hypersensitivity Reactions to Implants: Opinions and Practices of Patch Testing Dermatologists SO DERMATITIS LA English DT Article ID IN-STENT RESTENOSIS; ORTHOPEDIC IMPLANTS; CONTACT-DERMATITIS; BONE-CEMENT; ALLERGY; NICKEL; ASSOCIATION; SURGERY; DEVICES AB Background Cutaneous metal hypersensitivity reactions (MHR) are common but rare with implanted devices. Objectives This study aimed to characterize the opinions of dermatologists who are actively evaluating/advising patients with MHR. Methods A questionnaire was distributed to all individuals who attended the European Society of Contact Dermatitis (ESCD) 2012 and the American Contact Dermatitis Society 2013 meetings. Results A total of 119 individuals responded with a participation rates of 10% (ESCD) and 32% (American Contact Dermatitis Society). Ninety-six percent of the respondents evaluate MHR and 91% were attending physicians. Orthopedic and dental devices were common problems compared with cardiovascular devices. Patch testing is the top choice for evaluating MHR. Lymphocyte transformation and intradermal tests are rarely used. Eighty-two percent of the respondents evaluate plastic/glue components in symptomatic patients postimplant. Most dermatologists use a tray specifically for joint allergy or a history-based custom array of allergens. Those patients with a strong clinical history of metal allergy should be evaluated before metal implantation (54%), whereas others forgo evaluation and recommend a titanium implant based on history alone (38%). Diagnostic criteria for postimplant reactions were evaluated. Eight percent of the respondents felt that no evaluation was necessary, with ESCD respondents being significantly more likely to not recommend evaluation (P = 0.001). Conclusions Metal hypersensitivity reactions consultation requests are common for preimplant and postimplant issues. Patch testing is currently the best test for MHR. C1 [Schalock, Peter C.] Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Thyssen, Jacob P.] Univ Copenhagen, Gentofte Hosp, Dept Dermatoallergol, Natl Allergy Res Ctr, Copenhagen, Denmark. RP Schalock, PC (reprint author), Massachusetts Gen Hosp, Dept Dermatol, BAR622,55 Fruit St, Boston, MA 02114 USA. EM schalock.prof@gmail.com OI Schalock, Peter/0000-0001-8953-4639 NR 27 TC 11 Z9 11 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1710-3568 EI 2162-5220 J9 DERMATITIS JI Dermatitis PD NOV-DEC PY 2013 VL 24 IS 6 BP 313 EP 320 DI 10.1097/DER.0b013e3182a67d90 PG 8 WC Dermatology SC Dermatology GA AG6DE UT WOS:000335507900006 PM 24201465 ER PT J AU Berry, DL Halpenny, B Chang, P Hayes, JH Noel, J Vedachalam, S Fox, E Sorrentino, E AF Berry, Donna Lynn Halpenny, Barbara Chang, Peter Hayes, Julia H. Noel, Jon Vedachalam, Srik Fox, Erica Sorrentino, Erica TI Health literacy screening prior to education for patients with cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 155 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500152 ER PT J AU Bestvina, CM Zullig, LL Rushing, C Chino, FL Samsa, G Altomare, I Tulsky, JA Ubel, PA Schrag, D Nicolla, J Abernethy, AP Peppercorn, JM Zafar, Y AF Bestvina, Christine M. Zullig, Leah L. Rushing, Christel Chino, Fumiko Ladd Samsa, Greg Altomare, Ivy Tulsky, James A. Ubel, Peter A. Schrag, Deborah Nicolla, Jonathan Abernethy, Amy Pickar Peppercorn, Jeffrey M. Zafar, Yousuf TI Patient-oncologist cost communication, financial distress, and medication adherence SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Duke Univ, Med Ctr, Durham, NC USA. Durham VA Med Ctr, Hlth Serv Res & Dev, Durham, NC USA. Duke Univ, Sch Med, Durham, NC USA. Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA. Duke Univ, Med Ctr, Ctr Palliat Care, Durham, NC USA. Duke Univ, Fuqua Sch Business, Durham, NC 27706 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Duke Canc Inst, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 2 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500003 ER PT J AU Blouin, GC Chio, C Kim, EB Ryan, DP AF Blouin, Gayle C. Chio, Christine Kim, E. Bridget Ryan, David P. TI Evaluating adherence to off-label policy at an academic outpatient cancer center and assessing reimbursement of high-cost drugs SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Massachusetts Gen Hosp, Dept Pharm, Boston, MA 02114 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc, Div Hematol & Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 61 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500062 ER PT J AU Bryar, JM Dalby, CK Anastas, S Brady, L Hassett, MJ Shulman, LN Jacobson, JO AF Bryar, Julie M. Dalby, Carole Kathleen Anastas, Susan Brady, Lauren Hassett, Michael J. Shulman, Lawrence N. Jacobson, Joseph O. TI Implementation of chemotherapy treatment plans (CTP) in a large comprehensive cancer center (CCC): The key roles of infrastructure and data sharing SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 [Bryar, Julie M.; Dalby, Carole Kathleen; Anastas, Susan; Brady, Lauren; Hassett, Michael J.; Shulman, Lawrence N.; Jacobson, Joseph O.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 20 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500021 ER PT J AU Chiang, AC McNiff, K Kadlubek, P Neuss, MN Joseph, J AF Chiang, Anne C. McNiff, Kristen Kadlubek, Pamela Neuss, Michael N. Joseph, Jacobson TI Assessment of quality improvement efforts by ASCO's Quality Oncology Practice Initiative (QOPI) participants SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Yale Canc Ctr, New Haven, CT USA. Amer Soc Clin Oncol, Alexandria, VA USA. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 55 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500056 ER PT J AU Dalby, CK Nesbitt, M Kennerley, K Lacoursiere, L Frechette, C Flaherty, S Catalano, PJ Fuller, F Thiele, J Gilchrist, H Kostka, J Buswell, LA AF Dalby, Carole Kathleen Nesbitt, Marylou Kennerley, Kathleen Lacoursiere, Lisa Frechette, Carol Flaherty, Stephen Catalano, Paul J. Fuller, Frances Thiele, Jodi Gilchrist, Heather Kostka, Judith Buswell, Lori A. TI Standardizing chemotherapy education for quality improvement. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Milford Reg Med Ctr, Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Milford, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 136 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500133 ER PT J AU Dalby, CK Catalano, PJ Donohue, CC Bryar, JM Norden, AD Kostka, J Jacobson, JO AF Dalby, Carole Kathleen Catalano, Paul J. Donohue, Caitlin C. Bryar, Julie M. Norden, Andrew David Kostka, Judith Jacobson, Joseph O. TI Limitations of QOPI end-of-life (EOL) data use for purposes of accountability: Comparison of sample versus full cohort analysis. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 [Dalby, Carole Kathleen; Catalano, Paul J.; Donohue, Caitlin C.; Bryar, Julie M.; Norden, Andrew David; Kostka, Judith; Jacobson, Joseph O.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 87 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500087 ER PT J AU Donohue, CC Kaymakcalan, M Elfiky, A Dalby, CK Bryar, JM Jacobson, JO AF Donohue, Caitlin C. Kaymakcalan, Marina Elfiky, Aymen Dalby, Carole Kathleen Bryar, Julie M. Jacobson, Joseph O. TI Improving quality and safety of oncology patient care: Standardization of the post-clinic message triage process SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 163 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500160 ER PT J AU Dougherty, DW Kadlubek, P Pham, T Earle, C Malin, J Breathwaite, L Jacobson, JO AF Dougherty, David W. Kadlubek, Pamela Trang Pham Earle, Craig Malin, Jennifer Breathwaite, Larry Jacobson, Joseph O. TI Opportunities for improved end-of-life (EOL) care for adult patients with advanced cancer: Results of a longitudinal assessment of care provided by Quality Oncology Practice Initiative (QOPI) participants. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Univ Rochester, Med Ctr, Rochester, NY 14642 USA. Amer Soc Clin Oncol, Alexandria, VA USA. Inst Clin Evaluat Sci, Toronto, ON, Canada. WellPoint Inc, Indianapolis, IN USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 132 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500129 ER PT J AU Elfiky, A Kaymakcalan, M Stuver, S Sweeney, C Jacobson, JO Weingart, S AF Elfiky, Aymen Kaymakcalan, Marina Stuver, Sherri Sweeney, Christopher Jacobson, Joseph O. Weingart, Saul TI Developing and promoting evidence-based use of granulocyte colony stimulating factors (GCSF) in the palliative chemotherapy setting SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 172 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500169 ER PT J AU Gross, A Mann, S Weingart, S Kalfin, M Norden, AD Buswell, LA Constantine, M Fuller, F Briccetti, F Thiele, J Freter, R Kostka, J Sherwood, GK O'Connor, J Bunnell, CA AF Gross, Anne Mann, Susan Weingart, Saul Kalfin, Michael Norden, Andrew David Buswell, Lori A. Constantine, Michael Fuller, Frances Briccetti, Frederick Thiele, Jodi Freter, Rolf Kostka, Judith Sherwood, Geoffrey K. O'Connor, Janet Bunnell, Craig A. TI Disseminating team training across an academic cancer center and community-based satellites SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Milford Reg Med Ctr, Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Milford, MA USA. Dana Farber Canc Inst, New Hampshire Oncol Hematol, Londonderry, NH USA. South Shore Hosp, Brigham & Womens Canc Ctr, Dana Farber Canc Inst, S Weymouth, MA USA. Faulkner Hosp, Dana Farber Canc Inst, Boston, MA USA. Faulkner Hosp, Dana Farber Canc Inst, Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 188 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500185 ER PT J AU Kansagra, AJ Brooks, G Gao, JH Jamali, L Kundi, M Saini, N Stankiewicz, R Rao, SR Linden, EA Jacobson, JO AF Kansagra, Ankit J. Brooks, Gabriel Gao, Jenny Hong Jamali, Layli Kundi, Meenakshi Saini, Neeraj Stankiewicz, Rosemary Rao, Sowmya R. Linden, Erica Ann Jacobson, Joseph O. TI Risk factors for the development of chemotherapy-related hospitalization (CRH) in patients treated with palliative intent: Results of a 9-year nested case control study SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Tufts Univ, Baystate Med Ctr, Springfield, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. North Shore Med Ctr, Salem, MA USA. Massachusetts Gen Hosp, North Shore Canc Ctr, Boston, MA 02114 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 3 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500004 ER PT J AU Lennes, IT Bohlen, N Rosato, E Fitzgerald, E Cashavelly, BJ Lafleur, K Ahmed, S Burke, D Ryan, DP AF Lennes, Inga Tolin Bohlen, Nie Rosato, Erika Fitzgerald, Ellen Cashavelly, Barbara J. Lafleur, Katie Ahmed, Sami Burke, Debra Ryan, David P. TI Chemotherapy order review, activation, preparation, and administration redesign at a large academic cancer center. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Div Hematol & Oncol, Ctr Canc, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 221 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500215 ER PT J AU Losk, K Kadish, S Golshan, M Lin, N Hirshfield-Bartek, J Cutone, L Bunnell, CA Weingart, S AF Losk, Katya Kadish, Sarah Golshan, Mehra Lin, Nancy Hirshfield-Bartek, Judith Cutone, Linda Bunnell, Craig A. Weingart, Saul TI Reducing breast cancer chemotherapy treatment delays by improving the transition from surgical to medical oncology SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 51 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500052 ER PT J AU Ozanne, E Drohan, B Hughes, KS AF Ozanne, Elissa Drohan, Brian Hughes, Kevin S. TI Breast cancer risk assessment: How risk models can "overdiagnose" risk SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 184 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500181 ER PT J AU Parikh, AR Kim, B Pantoja, P Tisnado, DM Ahluwalia, SC Walling, AM Asch, SM Lorenz, K AF Parikh, Aparna Raj Kim, Benjamin Pantoja, Philip Tisnado, Diana M. Ahluwalia, Sangeeta C. Walling, Anne M. Asch, Steven M. Lorenz, Karl TI How is KRAS testing associated with treatment and supportive care for patients with metastatic colorectal cancer? VA national assist project SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Univ Calif San Francisco, Div Hematol & Oncol, San Francisco, CA 94143 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 64 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500065 ER PT J AU Shelton, JB Ochotorena, L Bennett, CJ Shekelle, P Goldzweig, C AF Shelton, Jeremy B. Ochotorena, Lee Bennett, Carol J. Shekelle, Paul Goldzweig, Caroline TI Reducing inappropriate PSA-based prostate cancer screening in men age 75 or older with a highly specific computerized clinical decision support tool. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 233 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500227 ER PT J AU Spring, L Li, SL Soiffer, R Alyea, E Glotzbecker, B AF Spring, Laura Li, Shuli Soiffer, Robert Alyea, Edwin Glotzbecker, Brett TI Readmissions following allogeneic hematopoietic stem cell transplantation. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Brigham & Womens Hosp, Boston, MA 02115 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 265 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500258 ER PT J AU Temel, JS Bondarde, SA Jain, MM Yan, Y Duus, EM Allen, S Mann, W AF Temel, Jennifer S. Bondarde, Shailesh Arjun Jain, Minish Mahendra Yan, Ying Duus, Elizabeth Manning Allen, Suzan Mann, William TI Evaluation of quality of life from a phase II study of anamorelin HCl in NSCLC patients. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. Shatabdi Super Specialty Hosp, Nasik, India. Ruby Hall Clin, Pune, Maharashtra, India. Helsinn Therapeut US Inc, Bridgewater, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 42 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500043 ER PT J AU Warner, J Hughes, KS Krauss, JC Maddux, S Yu, PP Ambinder, EP AF Warner, Jeremy Hughes, Kevin S. Krauss, John C. Maddux, Suzanne Yu, Peter Paul Ambinder, Edward P. TI An interoperable HL7 document standard to improve the quality of cancer care across multiple locations SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Vanderbilt Univ, Div Hematol Oncol, Nashville, TN 37235 USA. Vanderbilt Univ, Dept Biomed Informat, Nashville, TN 37235 USA. Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. Univ Michigan, Ctr Canc, Div Hematol Oncol, Ann Arbor, MI 48109 USA. Amer Soc Clin Oncol, Alexandria, VA USA. Palo Alto Med Fdn, Mountain View, CA USA. Mt Sinai, Tisch Canc Inst, Icahn Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 12 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500013 ER PT J AU Levitan, EB Lewis, CE Tinker, LF Eaton, CB Ahmed, A Manson, JE Snetselaar, LG Martin, LW Trevisan, M Howard, BV Shikany, JM AF Levitan, Emily B. Lewis, Cora E. Tinker, Lesley F. Eaton, Charles B. Ahmed, Ali Manson, JoAnn E. Snetselaar, Linda G. Martin, Lisa W. Trevisan, Maurizio Howard, Barbara V. Shikany, James M. TI Mediterranean and DASH Diet Scores and Mortality in Women With Heart Failure SO CIRCULATION-HEART FAILURE LA English DT Article DE diet; heart failure; mortality; nutrition ID STOP HYPERTENSION; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; LIFE-STYLE; RISK; ADHERENCE; PREVENTION; QUALITY; ASSOCIATIONS; PROTEIN AB Background Current dietary recommendations for patients with heart failure (HF) are largely based on data from non-HF populations; evidence on associations of dietary patterns with outcomes in HF is limited. We therefore evaluated associations of Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diet scores with mortality among postmenopausal women with HF. Methods and Results Women's Health Initiative participants were followed up from the date of HF hospitalization through the date of death or last participant contact before August 2009. Mediterranean and DASH diet scores were calculated from food-frequency questionnaires. Cox proportional hazards models adjusted for demographics, health behaviors, and health status were used to calculate hazard ratios and 95% confidence intervals (CI). For a median of 4.6 years of follow-up, 1385 of 3215 (43.1%) participants who experienced a HF hospitalization died. Multivariable-adjusted hazard ratios were 1 (reference), 1.05 (95% CI, 0.89-1.24), 0.97 (95% CI, 0.81-1.17), and 0.85 (95% CI, 0.70-1.02) across quartiles of the Mediterranean diet score (P trend=0.08) and 1 (reference), 1.04 (95% CI, 0.89-1.21), 0.83 (95% CI, 0.70-0.98), and 0.84 (95% CI, 0.70-1.00) across quartiles of the DASH diet score (P trend=0.01). Diet score components, vegetables, nuts, and whole grain intake, were inversely associated with mortality. Conclusions Higher DASH diet scores were associated with modestly lower mortality in women with HF, and there was a nonsignificant trend toward an inverse association with Mediterranean diet scores. These data provide support for the concept that dietary recommendations developed for other cardiovascular conditions or general populations may also be appropriate in patients with HF. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000611. C1 [Levitan, Emily B.; Lewis, Cora E.; Ahmed, Ali; Shikany, James M.] Univ Alabama Birmingham, Birmingham, AL 35924 USA. [Ahmed, Ali] Birmingham VA Med Ctr, Birmingham, AL USA. [Tinker, Lesley F.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Eaton, Charles B.] Brown Univ, Providence, RI 02912 USA. [Manson, JoAnn E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Snetselaar, Linda G.] Univ Iowa, Iowa City, IA USA. [Martin, Lisa W.] George Washington Univ, Washington, DC USA. [Trevisan, Maurizio] CUNY City Coll, New York, NY 10031 USA. [Howard, Barbara V.] MedStar Hlth Res Inst, Hyattsville, MD USA. [Howard, Barbara V.] Georgetown Howard Univ Ctr Clin & Translat Sci, Washington, DC USA. RP Levitan, EB (reprint author), Univ Alabama Birmingham, Dept Epidemiol, 1530 3rd Ave S,RPHB 230K, Birmingham, AL 35924 USA. EM elevitan@uab.edu FU National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C] FX The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. NR 35 TC 23 Z9 23 U1 1 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD NOV PY 2013 VL 6 IS 6 BP 1116 EP 1123 DI 10.1161/CIRCHEARTFAILURE.113.000495 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AD4AY UT WOS:000333189500004 PM 24107587 ER PT J AU Gaggin, HK Motiwala, S Bhardwaj, A Parks, KA Januzzi, JL AF Gaggin, Hanna K. Motiwala, Shweta Bhardwaj, Anju Parks, Kimberly A. Januzzi, James L., Jr. TI Soluble Concentrations of the Interleukin Receptor Family Member ST2 and ss-Blocker Therapy in Chronic Heart Failure SO CIRCULATION-HEART FAILURE LA English DT Article DE -adrenergic blockers; biological markers; heart failure; prognosis ID NATRIURETIC PEPTIDE; MYOCARDIAL-INFARCTION; CARDIAC STRUCTURE; SERUM; CARVEDILOL; DYSFUNCTION; METOPROLOL; MORTALITY; TRIAL AB Background Concentrations of soluble (s)ST2 predict prognosis in heart failure. We recently found changing doses of -blocker (BB) may affect sST2 concentrations. It remains unclear whether sST2 concentrations identify benefit of BB therapy, however. Methods and Results A total of 151 subjects with heart failure attributable to left ventricular systolic dysfunction were examined in this post hoc analysis; >96% were taking BB at enrollment. Medication regimen and sST2 values were obtained during 10 months. Cardiovascular events were examined as a function of baseline sST2 status (low 35 versus high >35 ng/mL) and final achieved BB dose (high 50 versus low <50 mg daily equivalent dose of metoprolol succinate). Patients with low sST2 titrated to high-dose BB had the lowest cardiovascular event rate at 0.53 events (P=0.001), and lowest cumulative hazard (P=0.003). Those with low sST2/low-dose BB, or high sST2/high-dose BB had intermediate outcomes (0.92 and 1.19 events). Patients with high sST2 treated with low-dose BB had the highest cardiovascular event rate (2.08 events) and the highest cumulative hazard. Compared with low sST2/high-dose BB, those with high sST2 treated with low-dose BB had an odds ratio of 6.77 (P<0.001) for a cardiovascular event. Patients with low sST2/low-dose BB or high sST2/high-dose BB had intermediate odds ratios for cardiovascular events (P=0.18 and 0.02). Similar results were found for heart failure hospitalization and cardiovascular death. Conclusions Although BB therapy exerted dose-related benefits across all study participants, sST2 measurement identifies patients with chronic heart failure who may particularly benefit from higher BB doses. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00351390. C1 [Gaggin, Hanna K.; Motiwala, Shweta; Bhardwaj, Anju; Parks, Kimberly A.; Januzzi, James L., Jr.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. RP Januzzi, JL (reprint author), Massachusetts Gen Hosp, Div Cardiol, Yawkey 5984,55 Fruit St, Boston, MA 02114 USA. EM jjanuzzi@partners.org FU Roche Diagnostics Corporation (Indianapolis, IN); Critical Diagnostics; Dennis and Marilyn Barry Cardiology Fellowship; Ruth and James Clark Fund for Cardiac Research Innovation; Roman W. DeSanctis Clinical Scholar Endowment FX The ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study was funded in part by Roche Diagnostics Corporation (Indianapolis, IN). The sponsor had no role in design, data collection, analysis, article preparation, interpretation, or decision to submit the article for publication. This substudy was funded by an unrestricted grant from Critical Diagnostics who had no role in study design, data analysis, article preparation, or decision to submit the manuscript for publication. Drs Bhardwaj and Motiwala were supported by the Dennis and Marilyn Barry Cardiology Fellowship. Dr Gaggin is supported in part by the Ruth and James Clark Fund for Cardiac Research Innovation, and Dr Januzzi is supported in part by the Roman W. DeSanctis Clinical Scholar Endowment. NR 24 TC 26 Z9 30 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD NOV PY 2013 VL 6 IS 6 BP 1206 EP 1213 DI 10.1161/CIRCHEARTFAILURE.113.000457 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AD4AY UT WOS:000333189500015 PM 24114865 ER PT J AU Hickman, S El Khoury, J AF Hickman, S. El Khoury, J. TI The microglial sensome SO JOURNAL OF MOLECULAR NEUROSCIENCE LA English DT Meeting Abstract CT 21st Annual Meeting of the Israel-Society-for-Neuroscience / 1st Binational Australian-Israeli Meeting on Neuroscience CY DEC 15-15, 2012 CL Eilat, ISRAEL SP Israel Soc Neuroscience C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0895-8696 EI 1559-1166 J9 J MOL NEUROSCI JI J. Mol. Neurosci. PD NOV PY 2013 VL 51 SU 1 BP S34 EP S34 PG 1 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA AC9DF UT WOS:000332833800082 ER PT J AU Paucar, M Xiang, FQ Moore, R Walker, R Winnberg, E Svenningsson, P AF Paucar, Martin Xiang, Fengqing Moore, Richard Walker, Ruth Winnberg, Elisabeth Svenningsson, Per TI Genotype-phenotype analysis in inherited prion disease with eight octapeptide repeat insertional mutation SO PRION LA English DT Article DE PRNP polymorphic codon 129; octapeptide repeat insertions (OPRI); Huntington disease-like 1; inherited prion disease (IPD); base pair insertions (BPI); Huntington's disease; PRNP ID CREUTZFELDT-JAKOB-DISEASE; PRP KNOCKOUT MICE; PROTEIN GENE; ONSET; SUSCEPTIBILITY; HETEROGENEITY; DEMENTIA; FEATURES; SCRAPIE; FAMILY AB A minority of inherited prion diseases (IPD) are caused by four to 12 extra octapeptide repeat insertions (OPRI) in the prion protein gene (PRNP). Only four families affected by IPD with 8-OPRI have been reported, one of them was a three-generation Swedish kindred in which four of seven affected subjects had chorea which was initially attributed to Huntington's disease (HD). Following the exclusion of HD, this phenotype was labeled Huntington disease-like 1 (HDL1). Here, we provide an update on the Swedish 8-OPRI family, describe the clinical features of one of its affected members with video-recordings, compare the four 8-OPRI families and study the effect of PRNP polymorphic codon 129 and gender on phenotype. Surprisingly, the Swedish kindred displayed the longest survival of all of the 8-OPRI families with a mean of 15.1 years from onset of symptoms. Subjects with PRNP polymorphic codon 129M in the mutated allele had significantly earlier age of onset, longer survival and earlier age of death than 129V subjects. Homozygous 129MM had earlier age of onset than 129VV. Females had a significantly earlier age of onset and earlier age of death than males. Up to 50% of variability in age of onset was conferred by the combined effect of PRNP polymorphic codon 129 and gender. An inverse correlation between early age of onset and long survival was found for this mutation. C1 [Paucar, Martin; Svenningsson, Per] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden. [Paucar, Martin; Svenningsson, Per] Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden. [Xiang, Fengqing] Karolinska Inst, Ctr Mol Med, Dept Womans & Childrens Hlth, Stockholm, Sweden. [Walker, Ruth] James Peters Vet Med Affair Ctr, Bronx, NY USA. [Walker, Ruth] Mt Sinai Sch Med, New York, NY USA. [Winnberg, Elisabeth] Ersta Skondal Univ Coll, Dept Caring Sci, Stockholm, Sweden. RP Paucar, M (reprint author), Karolinska Inst, Ctr Mol Med, Stockholm, Sweden. EM martin.paucar-arce@karolinska.se OI Xiang, Fengqing/0000-0003-0892-1536; Paucar, Martin/0000-0003-3735-1480 NR 37 TC 1 Z9 1 U1 0 U2 5 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1933-6896 EI 1933-690X J9 PRION JI Prion PD NOV-DEC PY 2013 VL 7 IS 6 BP 501 EP 510 DI 10.4161/pri.27260 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AC0QP UT WOS:000332200100006 PM 24275071 ER PT J AU Margolis, A Young, H Lis, J Schuna, A AF Margolis, Amanda Young, Henry Lis, Jennifer Schuna, Arthur TI A telepharmacy intervention to improve inhaler adherence in veterans with chronic obstructive pulmonary disease SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Letter ID CARE C1 [Margolis, Amanda] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA. [Margolis, Amanda; Lis, Jennifer; Schuna, Arthur] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Young, Henry] Univ Georgia, Coll Pharm, Clin & Adm Pharm, Athens, GA 30602 USA. RP Margolis, A (reprint author), Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA. EM arpitterle@wisc.edu FU NCATS NIH HHS [9U54TR000021, UL1 TR000427]; NCRR NIH HHS [1UL1RR025011, UL1 RR025011] NR 8 TC 1 Z9 2 U1 0 U2 0 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 EI 1535-2900 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD NOV 1 PY 2013 VL 70 IS 21 BP 1875 EP 1876 DI 10.2146/ajhp120241 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AB4SS UT WOS:000331780800006 PM 24128957 ER PT J AU Cerda, R Lee, PT AF Cerda, Rodrigo Lee, Patrick T. TI Modern Cholera in the Americas: An Opportunistic Societal Infection SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material AB In the Americas, the only two cholera epidemics of the past century have occurred in the past 25 years. Lessons from the 1991 Peruvian cholera epidemic can help to focus and refine the response to the current Haitian epidemic. After three years of acute epidemic response, we have an opportunity to refocus on the chronic conditions that make societies vulnerable to cholera. More importantly, even as international attention wanes in the aftermath of the earthquake and acute epidemic, we are faced with a need for continued and coordinated investment in improving Haiti's structural defenses againstcholera, in particular access to improved water and sanitation. C1 [Cerda, Rodrigo] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Cerda, Rodrigo; Lee, Patrick T.] Harvard Univ, Sch Med, Boston, MA USA. [Lee, Patrick T.] Cambridge Hlth Alliance, Primary Care Ctr, Cambridge, MA USA. RP Cerda, R (reprint author), Massachusetts Gen Hosp, Dept Med, 55 Fruit St,Bigelow 740, Boston, MA 02114 USA. EM rcerda@partners.org NR 21 TC 0 Z9 0 U1 4 U2 11 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD NOV PY 2013 VL 103 IS 11 BP 1934 EP 1937 DI 10.2105/AJPH.2013.301567 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4BG UT WOS:000331038500029 PM 24028256 ER PT J AU Sorensen, G Pednekar, MS Sinha, DN Stoddard, AM Nagler, E Aghi, MB Lando, HA Viswanath, K Pawar, P Gupta, PC AF Sorensen, Glorian Pednekar, Mangesh S. Sinha, Dhirendra N. Stoddard, Anne M. Nagler, Eve Aghi, Mira B. Lando, Harry A. Viswanath, Kasisomayajula Pawar, Pratibha Gupta, Prakash C. TI Effects of a Tobacco Control Intervention for Teachers in India: Results of the Bihar School Teachers Study SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID ORAL-CANCER; PRIMARY PREVENTION; 2 REGIONS; CESSATION; SMOKING; PROGRAM; PROJECT; HEALTH; TRIAL AB Objectives. We assessed a school-based intervention designed to promote tobacco control among teachers in the Indian state of Bihar. Methods. We used a cluster-randomized design to test the intervention, which comprised educational efforts, tobacco control policies, and cessation support and was tailored to the local social context. In 2009 to 2011, we randomly selected 72 schools from participating school districts and randomly assigned them in blocks (rural or urban) to intervention or delayed-intervention control conditions. Results. Immediately after the intervention, the 30-day quit rate was 50% in the intervention and 15% in the control group (P = .001). At the 9-month post-intervention survey, the adjusted 6-month quit rate was 19% in the intervention and 7% in the control group (P = .06). Among teachers employed for the entire academic year of the intervention, the adjusted 6-month abstinence rates were 20% and 5%, respectively, for the intervention and control groups (P = .04). Conclusions. These findings demonstrate the potent impact of an intervention that took advantage of social resources among teachers, who can serve as role models for tobacco control in their communities. C1 [Sorensen, Glorian; Nagler, Eve; Viswanath, Kasisomayajula] Dana Farber Canc Inst, Boston, MA 02215 USA. [Sorensen, Glorian; Nagler, Eve; Viswanath, Kasisomayajula] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Pednekar, Mangesh S.; Pawar, Pratibha; Gupta, Prakash C.] Healis Sekhsaria Inst Publ Hlth, Navi Mumbai, India. [Sinha, Dhirendra N.] Sch Prevent Oncol, Patna, Bihar, India. [Stoddard, Anne M.] New England Res Inst, Watertown, MA 02172 USA. [Lando, Harry A.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. RP Sorensen, G (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM glorian_sorensen@dfci.harvard.edu RI Mashamba-Thompson, Tivani /B-6087-2014 FU National Cancer Institute [5R01 CA120958, 5 K05 CA108663]; Education Department of the Bihar State Government FX This work was supported by the National Cancer Institute (grants 5R01 CA120958, and 5 K05 CA108663).; The authors thank the numerous investigators and staff members in India and the United States who contributed to this study, including Quayyim Ansari, Lauren Becker, Linnea Benson-Whelan, Ellen Connorton, Caitlin Eicher Caspi, Joshua Gagne, Adam Gerberick, Christopher Kenwood, Neha Mathur, Amruta Miland, Shree Mukesh, Claudia R. Pischke, Divya Ramamurthi, David Rothfarb, Laura Shulman, Melanie Silverman, Gupteshwar Singh, Manibala Singh, and Lorraine Wallace. In addition, this work could not have been completed without the participation of the 72 government schools in Bihar and the Health Educators and staff at the School of Preventive Oncology in Patna, Bihar. Lastly, the authors also thank the Education Department of the Bihar State Government for its support of this study. NR 37 TC 7 Z9 7 U1 0 U2 4 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD NOV PY 2013 VL 103 IS 11 BP 2035 EP 2040 DI 10.2105/AJPH.2013.301303 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4BG UT WOS:000331038500044 PM 24028234 ER PT J AU Ahveninen, J Huang, S Belliveau, JW Chang, WT Hamalainen, M AF Ahveninen, Jyrki Huang, Samantha Belliveau, John W. Chang, Wei-Tang Haemaelaeinen, Matti TI Dynamic Oscillatory Processes Governing Cued Orienting and Allocation of Auditory Attention SO JOURNAL OF COGNITIVE NEUROSCIENCE LA English DT Article ID GAMMA-BAND ACTIVITY; SCALE NEURAL-NETWORK; SPATIAL ATTENTION; SELECTIVE ATTENTION; VISUAL-ATTENTION; ALPHA-BAND; WORKING-MEMORY; CORTICAL ACTIVITY; PARIETAL CORTEX; TOP-DOWN AB In everyday listening situations, we need to constantly switch between alternative sound sources and engage attention according to cues that match our goals and expectations. The exact neuronal bases of these processes are poorly understood. We investigated oscillatory brain networks controlling auditory attention using cortically constrained fMRI-weighted magneto-encephalography/EEG source estimates. During consecutive trials, participants were instructed to shift attention based on a cue, presented in the ear where a target was likely to follow. To promote audiospatial attention effects, the targets were embedded in streams of dichotically presented standard tones. Occasionally, an unexpected novel sound occurred opposite to the cued ear to trigger involuntary orienting. According to our cortical power correlation analyses, increased frontoparietal/temporal 30-100 Hz gamma activity at 200-1400 msec after cued orienting predicted fast and accurate discrimination of subsequent targets. This sustained correlation effect, possibly reflecting voluntary engagement of attention after the initial cue-driven orienting, spread from the TPJ, anterior insula, and inferior frontal cortices to the right FEFs. Engagement of attention to one ear resulted in a significantly stronger increase of 7.5-15 Hz alpha in the ipsilateral than contralateral parieto-occipital cortices 200-600 msec after the cue onset, possibly reflecting cross-modal modulation of the dorsal visual pathway during audiospatial attention. Comparisons of cortical power patterns also revealed significant increases of sustained right medial frontal cortex theta power, right dorsolateral pFC and anterior insula/inferior frontal cortex beta power, and medial parietal cortex and posterior cingulate cortex gamma activity after cued versus novelty-triggered orienting (600-1400 msec). Our results reveal sustained oscillatory patterns associated with voluntary engagement of auditory spatial attention, with the frontoparietal and temporal gamma increases being best predictors of subsequent behavioral performance. C1 [Ahveninen, Jyrki; Huang, Samantha; Belliveau, John W.; Chang, Wei-Tang; Haemaelaeinen, Matti] Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol,Massachusetts Gen Hosp, Charlestown, MA USA. [Belliveau, John W.; Haemaelaeinen, Matti] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA USA. RP Ahveninen, J (reprint author), MGH MIT HMS Martinos Ctr, Bldg 149 13th St, Charlestown, MA 02129 USA. EM jyrki@nmr.mgh.harvard.edu RI Hamalainen, Matti/C-8507-2013 FU National Institutes of Health [R01MH083744, R21DC010060, R01HD040712, R01NS037462, 5R01EB009048, P41RR14075]; National Center for Research Resources Shared Instrumentation [S10RR014978, S10RR021110, S10RR019307, S10RR014798, S10RR023401] FX We thank An-Yi Hung, Natsuko Mori, Stephanie Rossi, Chinmayi Tengshe, and Nao Suzuki for their help. This work was supported by National Institutes of Health Awards R01MH083744, R21DC010060, R01HD040712, R01NS037462, 5R01EB009048, and P41RR14075. The research environment was supported by National Center for Research Resources Shared Instrumentation Grants S10RR014978, S10RR021110, S10RR019307, S10RR014798, and S10RR023401. NR 128 TC 16 Z9 18 U1 2 U2 15 PU MIT PRESS PI CAMBRIDGE PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA SN 0898-929X EI 1530-8898 J9 J COGNITIVE NEUROSCI JI J. Cogn. Neurosci. PD NOV PY 2013 VL 25 IS 11 BP 1926 EP 1943 DI 10.1162/jocn_a_00452 PG 18 WC Neurosciences; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 301GG UT WOS:000330520200011 PM 23915050 ER PT J AU Wintermark, M Sanelli, PC Albers, GW Bello, J Derdeyn, C Hetts, SW Johnson, MH Kidwell, C Lev, MH Liebeskind, DS Rowley, H Schaefer, PW Sunshine, JL Zaharchuk, G Meltzer, CC AF Wintermark, M. Sanelli, P. C. Albers, G. W. Bello, J. Derdeyn, C. Hetts, S. W. Johnson, M. H. Kidwell, C. Lev, M. H. Liebeskind, D. S. Rowley, H. Schaefer, P. W. Sunshine, J. L. Zaharchuk, G. Meltzer, C. C. TI Imaging Recommendations for Acute Stroke and Transient Ischemic Attack Patients: A Joint Statement by the American Society of Neuroradiology, the American College of Radiology, and the Society of NeuroInterventional Surgery SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID PERFUSION COMPUTED-TOMOGRAPHY; ACUTE HEMISPHERIC STROKE; DIFFUSION-WEIGHTED MR; TISSUE-PLASMINOGEN ACTIVATOR; HEALTH-CARE PROFESSIONALS; ANGIOGRAPHY SOURCE IMAGES; CEREBRAL-BLOOD-FLOW; DIGITAL-SUBTRACTION-ANGIOGRAPHY; EVALUATION TRIAL EPITHET; CAROTID-ARTERY STENOSIS AB Stroke is a leading cause of death and disability worldwide. Imaging plays a critical role in evaluating patients suspected of acute stroke and transient ischemic attack, especially before initiating treatment. Over the past few decades, major advances have occurred in stroke imaging and treatment, including Food and Drug Administration approval of recanalization therapies for the treatment of acute ischemic stroke. A wide variety of imaging techniques has become available to assess vascular lesions and brain tissue status in acute stroke patients. However, the practical challenge for physicians is to understand the multiple facets of these imaging techniques, including which imaging techniques to implement and how to optimally use them, given available resources at their local institution. Important considerations include constraints of time, cost, access to imaging modalities, preferences of treating physicians, availability of expertise, and availability of endovascular therapy. The choice of which imaging techniques to employ is impacted by both the time urgency for evaluation of patients and the complexity of the literature on acute stroke imaging. Ideally, imaging algorithms should incorporate techniques that provide optimal benefit for improved patient outcomes without delaying treatment. C1 [Wintermark, M.] Univ Virginia, Dept Radiol, Charlottesville, VA 22098 USA. [Wintermark, M.] Univ Virginia, Dept Neurol, Charlottesville, VA 22098 USA. [Wintermark, M.] Univ Virginia, Dept Neurosurg, Charlottesville, VA 22098 USA. [Wintermark, M.] Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22098 USA. [Sanelli, P. C.] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Radiol, New York, NY USA. [Albers, G. W.] Stanford Univ, Stanford Stroke Ctr, Stanford, CA 94305 USA. [Bello, J.] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Radiol & Neurosurg, Bronx, NY 10467 USA. [Derdeyn, C.] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO USA. [Derdeyn, C.] Washington Univ, Sch Med, Stroke & Cerebrovasc Ctr, St Louis, MO USA. [Hetts, S. W.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Radiol, San Francisco, CA 94143 USA. [Hetts, S. W.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Biomed Imaging, San Francisco, CA 94143 USA. [Hetts, S. W.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Johnson, M. H.] Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06510 USA. [Johnson, M. H.] Yale Univ, Sch Med, Dept Neurosurg & Intervent Neuroradiol, New Haven, CT 06510 USA. [Kidwell, C.] Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA. [Kidwell, C.] Georgetown Univ, Med Ctr, Georgetown Univ Stroke Ctr, Washington, DC 20007 USA. [Lev, M. H.; Schaefer, P. W.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. [Liebeskind, D. S.] Univ Calif Los Angeles, Dept Neurol, Stroke Ctr, Los Angeles, CA 90024 USA. [Rowley, H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, Madison, WI USA. [Rowley, H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurol, Madison, WI USA. [Rowley, H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Neurosurg, Madison, WI USA. [Sunshine, J. L.] Case Western Reserve Univ, Dept Radiol, Cleveland, OH USA. [Sunshine, J. L.] Case Western Reserve Univ, Dept Neurol, Cleveland, OH USA. [Sunshine, J. L.] Case Western Reserve Univ, Dept Neurosurg, Cleveland, OH USA. [Zaharchuk, G.] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA. [Zaharchuk, G.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Meltzer, C. C.] Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA. [Meltzer, C. C.] Emory Univ, Sch Med, Dept Imaging Sci, Atlanta, GA USA. [Meltzer, C. C.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA USA. [Meltzer, C. C.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA. RP Wintermark, M (reprint author), Univ Virginia, Neuroradiol Div, Dept Radiol, Box 800170, Charlottesville, VA 22098 USA. EM Max.Wintermark@gmail.com OI Hetts, Steven/0000-0001-5885-7259; Wintermark, Max/0000-0002-6726-3951; Derdeyn, Colin/0000-0002-5932-2683 FU NINDS NIH HHS [R01 NS066506, K24 NS072272] NR 146 TC 24 Z9 25 U1 1 U2 5 PU AMER SOC NEURORADIOLOGY PI DENVILLE PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA SN 0195-6108 EI 1936-959X J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD NOV PY 2013 VL 34 IS 11 BP E117 EP E127 DI 10.3174/ajnr.A3690 PG 11 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 297DD UT WOS:000330234700001 PM 23907247 ER PT J AU Baker, K Barsamian, J Leone, D Donovan, BC Williams, D Carnevale, K Lansing, R Banzett, R AF Baker, Kathy Barsamian, Jennifer Leone, Danielle Donovan, Barbara C. Williams, Donna Carnevale, Kerry Lansing, Robert Banzett, Robert TI Routine Dyspnea Assessment on Unit Admission SO AMERICAN JOURNAL OF NURSING LA English DT Article DE dyspnea; dyspnea assessment; initial patient assessment; nurse education ID PALLIATIVE CARE; CANCER-PATIENTS; PAIN; MANAGEMENT; MECHANISMS; STATEMENT; SYMPTOMS; SCALES AB OVERVIEW: Dyspnea assessment is valuable in diagnosis, prognosis, symptom management, and targeted intervention, and in the allotment and management of patient care resources. The assessment of dyspnea, like that of pain, depends on patient self-report. Expert consensus panels have called for dyspnea to be measured quantitatively and documented on a routine basis, as is the practice with pain. But little information is available on how to measure and record dyspnea ratings systematically. Consequently, the prevalence of dyspnea in hospital settings may be greater than is generally recognized, and dyspnea may be insufficiently managed. This article describes a pilot study that sought to test the feasibility of measuring dyspnea as part of the initial patient assessment performed by nurses within several inpatient units of a large urban hospital. C1 [Baker, Kathy; Barsamian, Jennifer; Leone, Danielle; Donovan, Barbara C.; Williams, Donna; Carnevale, Kerry] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Lansing, Robert] Univ Arizona, Tucson, AZ USA. [Banzett, Robert] Harvard Univ, Sch Med, Div Pulm & Crit Care Med, Cambridge, MA 02138 USA. [Banzett, Robert] BIDMC, Boston, MA USA. RP Baker, K (reprint author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. EM kbaker2@bidmc.harvard.edu FU National Institute of Health [NR10006, NR12009] FX Kathy Baker and Barbara C. Donovan are clinical nurse specialists in medicine, Jennifer Barsamian and Kerry Carnevale are clinical nurse specialists in surgery, Danielle Leone is a clinical nurse II, and Donna Williams is a clinical nurse specialist in cardiology, all at Beth Israel Deaconess Medical Center (BIDMC) in Boston. Robert Lansing is a visiting scientist in the Division of Pulmonary, Critical Care, and Sleep Medicine at BIDMC and a professor emeritus at the University of Arizona, Tucson. Robert Banzett is an associate professor in the Division of Pulmonary and Critical Care Medicine at Harvard Medical School and BIDMC. Both Lansing and Banzett are supported by unrestricted educational National Institute of Health grants NR10006 and NR12009 to investigate the affective component of dyspnea and a novel dyspnea treatment. Robert Banzett is principal investigator in this endeavor. Contact author: Kathy Baker, kbaker2@bidmc.harvard.edu. The authors and planners have disclosed no potential conflicts of interest, financial or otherwise. NR 25 TC 6 Z9 6 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-936X EI 1538-7488 J9 AM J NURS JI Am. J. Nurs. PD NOV PY 2013 VL 113 IS 11 BP 42 EP 49 PG 8 WC Nursing SC Nursing GA 299CE UT WOS:000330371800015 PM 24113531 ER PT J AU Hyder, O Yaster, M Bateman, BT Firth, PG AF Hyder, Omar Yaster, Myron Bateman, Brian T. Firth, Paul G. TI Surgical Procedures and Outcomes Among Children with Sickle Cell Disease SO ANESTHESIA AND ANALGESIA LA English DT Article ID ACUTE CHEST SYNDROME; PREOPERATIVE BLOOD-TRANSFUSION; PERIOPERATIVE MANAGEMENT; SURGERY; ANESTHESIA; ANEMIA AB BACKGROUND: Although children with sickle cell disease often undergo surgery, there are limited current epidemiological data for this pediatric population. We performed a database analysis to estimate population characteristics, surgical procedures, and perioperative outcomes in this population. METHODS: We queried the Nationwide Inpatient Sample Database from 2000 to 2010 for discharges pertaining to patients <18 years of age having a diagnosis of sickle cell disease who underwent 1 or more surgical procedures during that admission. We abstracted surgical procedures using the Clinical Classifications Software procedure codes and the ICD-9-CM procedure codes. We described characteristics of patients undergoing the 6 most common procedures. RESULTS: During 2000 to 2010, 3.6 % (SE 0.12) of individual hospital discharges were of children with sickle cell disease who had undergone surgical procedures. The most frequent surgical procedures were cholecystectomy (1.47% [0.08]), tonsillectomy/adenoidectomy (0.81% [0.06]), splenectomy (0.62% [0.06]), repair of umbilical hernia (0.19% [0.02]), and appendectomy (0.17% [0.02]). Acute chest syndrome was recorded among 3.08% (0.60) of patients undergoing elective surgery. The incidence of stroke was 0.20% (0.11); death was reported in <11 patients (<0.20%). CONCLUSION: Surgical procedures such as cholecystectomy, tonsillectomy, splenectomy, hernia repair, and appendectomy account for a small but significant proportion of hospital admissions in children with sickle cell disease. Acute chest syndrome is among the most common complications of elective surgery, while stroke and death are rare. C1 [Hyder, Omar] Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA. [Yaster, Myron] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA. [Bateman, Brian T.; Firth, Paul G.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Bateman, Brian T.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA. RP Firth, PG (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02144 USA. EM pfirth@partners.org FU Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA FX Administrative funding, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA. NR 20 TC 5 Z9 5 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-2999 EI 1526-7598 J9 ANESTH ANALG JI Anesth. Analg. PD NOV PY 2013 VL 117 IS 5 BP 1192 EP 1196 DI 10.1213/ANE.0b013e3182a44d74 PG 5 WC Anesthesiology SC Anesthesiology GA 300AB UT WOS:000330435700023 PM 24108258 ER PT J AU Haridas, RP Mifflin, JA AF Haridas, Rajesh P. Mifflin, Jeffrey A. TI Researches Regarding the Morton Ether Inhaler at Massachusetts General Hospital, Boston SO ANESTHESIA AND ANALGESIA LA English DT Article AB The Morton ether inhaler in the possession of Massachusetts General Hospital, Boston, MA, was traced back to 1906 when the earliest known photograph of it was published. The authors believe that the inhaler was given by William T. G. Morton, MD, to J. Mason Warren, MD, in January 1847. The inhaler was acquired by the Warren Anatomical Museum at an unknown date, loaned to Massachusetts General Hospital in October 1946, and placed on permanent loan to Massachusetts General Hospital in April 1948. Many documents relating to the inhaler have disappeared, and it was only identified in 2009 as the inhaler that probably belonged to J. Mason Warren, MD. The inhaler is not believed to be the one that Morton used on October 16, 1846, at Massachusetts General Hospital. It is the only known example of a Morton ether inhaler with valves (excluding replicas or reproduction inhalers) and is probably of similar design to the inhaler that Morton used on October 16, 1846. C1 [Haridas, Rajesh P.; Mifflin, Jeffrey A.] Massachusetts Gen Hosp, Arch & Special Collect Program, Boston, MA 02114 USA. RP Haridas, RP (reprint author), 234 13th St, Mildura, Vic 3500, Australia. EM rajesh.haridas@bigpond.com NR 15 TC 3 Z9 3 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-2999 EI 1526-7598 J9 ANESTH ANALG JI Anesth. Analg. PD NOV PY 2013 VL 117 IS 5 BP 1230 EP 1235 DI 10.1213/ANE.0b013e31829cc6d2 PG 6 WC Anesthesiology SC Anesthesiology GA 300AB UT WOS:000330435700029 PM 24036621 ER PT J AU Hazani, R Ford, RS Rao, AJ Wilhelmi, BJ AF Hazani, Ron Ford, Rachel S. Rao, Arun J. Wilhelmi, Bradon J. TI Caudal Resection of the Upper Lateral Cartilages and Its Measured Effect on Tip Rotation SO ANNALS OF PLASTIC SURGERY LA English DT Article; Proceedings Paper CT 16th Annual Meeting of the Rhinoplasty-Society CY MAY 06, 2011 CL Boston, MA SP Rhinoplasty Soc DE open rhinoplasty; tip elevation; upper lateral cartilages; nasolabial angle ID RHINOPLASTY; GRAFT; FLAP AB Background: Commonly used maneuvers for upward tip rotation include cephalic trim of the lateral alar cartilages, caudal resection of the septum, and shortening of the upper lateral cartilages (ULCs). Few techniques for surgical manipulation of the ULCs are found in the literature, and none accurately describe the measured effect of the caudal resection on tip rotation. The purpose of this study is to predict the change in upward rotation of the nasal tip for a measured incremental resection of the ULCs. Methods: Ten fresh cadaveric noses were dissected with the aid of loupe magnification via an open rhinoplasty approach. The ULCs were sectioned in 20% increments, and measurements of the nasolabial angle (NLA) were recorded with the use of a goniometer. True lateral photographs were obtained for the photographic analysis of the specimens. Results: The average length of the ULC was 16.8 +/- 1.6 mm. Serial reduction of the ULC length by 4 sequential 20% increments resulted in a mean NLA change of 3.6, 2.7, 2.1, and 1.9 degrees, respectively. The average incremental change in NLA for the 4 resections was 2.6 degrees. Conclusions: Caudal resection of the ULC has a measurable effect on the upward rotation of the nasal tip. A 20% resection correlates with an average change in the NLA of 2.6 degrees. Because caudal resection of the ULC is a powerful tool in the armamentarium of the rhinoplasty surgeon that can cause narrowing of the internal nasal valve and hallowing of the lower nasal sidewalls, it should be used with caution in a selected group of patients when attempting to elevate the "droopy" tip. C1 [Hazani, Ron] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Ford, Rachel S.] Loma Linda Univ, Loma Linda, CA 92350 USA. [Rao, Arun J.] Univ Louisville, Louisville, KY 40292 USA. [Wilhelmi, Bradon J.] Univ Louisville, Div Plast Surg, Louisville, KY 40292 USA. RP Wilhelmi, BJ (reprint author), Univ Louisville, Sch Med, Div Plast Surg, 550 S Jackson St,ACB 2nd Floor, Louisville, KY 40292 USA. EM bjwilh01@louisville.edu NR 15 TC 2 Z9 2 U1 3 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-7043 EI 1536-3708 J9 ANN PLAS SURG JI Ann. Plast. Surg. PD NOV PY 2013 VL 71 IS 5 BP 450 EP 452 DI 10.1097/SAP.0b013e3182503af4 PG 3 WC Surgery SC Surgery GA 300IJ UT WOS:000330457300004 PM 23542831 ER PT J AU Lillemoe, KD AF Lillemoe, Keith D. TI Annals of Surgery and the European Surgical Association SO ANNALS OF SURGERY LA English DT Editorial Material C1 Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Lillemoe, KD (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St,White Bldg,Floor 5,Room 506, Boston, MA 02114 USA. EM klillemoe@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD NOV PY 2013 VL 258 IS 5 BP 677 EP 677 DI 10.1097/SLA.0b013e3182a6ffab PG 1 WC Surgery SC Surgery GA 300LS UT WOS:000330466000006 PM 24045447 ER PT J AU Smolderen, KG Whooley, MA AF Smolderen, Kim G. Whooley, Mary A. TI Psychological Distress and Medication Adherence Creating Order Out of Chaos? SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Editorial Material DE Editorials; hypertension; medication adherence; myocardial infarction ID CORONARY-HEART-DISEASE; SOUL C1 [Smolderen, Kim G.] Tilburg Univ, Ctr Res Psychol Somat Dis, NL-5000 LE Tilburg, Netherlands. [Smolderen, Kim G.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA. [Whooley, Mary A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. RP Smolderen, KG (reprint author), Tilburg Univ, Dept Med Psychol, POB 90153,Room T505, NL-5000 LE Tilburg, Netherlands. EM k.g.e.smolderen@gmail.com RI Smolderen, Kim/B-8078-2015 NR 10 TC 1 Z9 1 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2013 VL 6 IS 6 BP 615 EP 616 DI 10.1161/CIRCOUTCOMES.113.000633 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 298ZA UT WOS:000330362400006 PM 24221835 ER PT J AU Clarke, CL Grunwald, GK Allen, LA Baron, AE Peterson, PN Brand, DW Magid, DJ Masoudi, FA AF Clarke, Christina L. Grunwald, Gary K. Allen, Larry A. Baron, Anna E. Peterson, Pamela N. Brand, David W. Magid, David J. Masoudi, Frederick A. TI Natural History of Left Ventricular Ejection Fraction in Patients With Heart Failure SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE heart failure; outcomes assessment; prognosis; ventricular ejection fraction ID ASSOCIATION TASK-FORCE; AMERICAN-COLLEGE; MULTISTATE MODEL; PANEL-DATA; CARVEDILOL; SURVIVAL; DYSFUNCTION; GUIDELINES; METOPROLOL; MORTALITY AB Background-Patients with heart failure (HF) are typically designated as having reduced or preserved ejection fraction (HFREF, HFPEF) because of the importance of left ventricular ejection fraction (LVEF) on therapeutic decisions and prognosis. Such designations are not necessarily static, yet few data exist to describe the natural history of LVEF over time. Methods and Results-We identified 2413 patients from Kaiser Permanente Colorado with a primary discharge diagnosis of HF between January 1, 2001, and December 31, 2008, who had >= 2 LVEF measurements separated by >= 30 days. We used multi-state Markov modeling to examine transitions among HFREF, HFPEF, and death. We observed a total of 8183 transitions. Women were more likely than men to transition from HFREF to HFPEF (hazard ratio, 1.85; 95% confidence interval, 1.38-2.47). Patients who were adherent to beta-blockers were more likely to transition from HFREF to HFPEF (hazard ratio, 1.53; 95% confidence interval, 1.10-2.13) compared with patients who were nonadherent to beta-blockers, whereas angiotensin-converting enzyme or angiotensin II receptor blocker adherence was not associated with LVEF transitions. Patients who had a previous myocardial infarction were more likely to transition from HFPEF to HFREF (hazard ratio, 1.75; 95% confidence interval, 1.26-2.42). Conclusions-In this cohort of patients with HF, LVEF is a dynamic factor related to sex, coexisting conditions, and drug therapy. These findings have implications for left ventricular systolic function ascertainment in patients with HF and support evidence-based therapy use, especially beta-blockers. C1 [Clarke, Christina L.; Allen, Larry A.; Peterson, Pamela N.; Brand, David W.; Magid, David J.; Masoudi, Frederick A.] Kaiser Permanente Colorado Inst Hlth Res, Denver, CO 80231 USA. [Grunwald, Gary K.; Baron, Anna E.] Denver VA Med Ctr, Denver, CO USA. [Peterson, Pamela N.] Denver Hlth Med Ctr, Denver, CO USA. [Grunwald, Gary K.; Allen, Larry A.; Baron, Anna E.; Peterson, Pamela N.; Magid, David J.; Masoudi, Frederick A.] Univ Colorado Anschutz Med Campus, Denver, CO USA. RP Clarke, CL (reprint author), Kaiser Permanente Colorado Inst Hlth Res, 10065 E Harvard Ave,Suite 300, Denver, CO 80231 USA. EM Christina.L.Clarke@kp.org FU National Heart, Lung, and Blood Institute (Bethesda, MD) [K23 HL105896]; Agency for Healthcare Research and Quality [K08 HS019814-01]; National Heart, Lung, and Blood Institute [1RC1HL099395] FX Dr Allen is supported by grant K23 HL105896 from the National Heart, Lung, and Blood Institute (Bethesda, MD) and reports that he has provided consulting services for Amgen, Inc and Johnson & Johnson. Dr Peterson is supported by grant K08 HS019814-01 from the Agency for Healthcare Research and Quality. Dr Magid was supported by grant 1RC1HL099395 from the National Heart, Lung, and Blood Institute during the conduct of this research and creation of the article. The other authors report no conflicts. NR 26 TC 8 Z9 8 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2013 VL 6 IS 6 BP 680 EP + DI 10.1161/CIRCOUTCOMES.111.000045 PG 15 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 298ZA UT WOS:000330362400016 PM 24129973 ER PT J AU Heidenreich, PA Lin, ST Knowles, JW Perez, M Maddox, TM Ho, MP Rumsfeld, JS Sahay, A Massie, BM Tsai, TT Witteles, RM AF Heidenreich, Paul A. Lin, Shoutzu Knowles, Joshua W. Perez, Marco Maddox, Thomas M. Ho, Michael P. Rumsfeld, John S. Sahay, Anju Massie, Barry M. Tsai, Thomas T. Witteles, Ronald M. TI Variation in Use of Left Ventriculography in the Veterans Affairs Health Care System SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE cardiac catheterization; cardiac imaging techniques; small-area analysis ID CARDIOVASCULAR-COMPUTED-TOMOGRAPHY; ACUTE MYOCARDIAL-INFARCTION; AMERICAN-HEART-ASSOCIATION; CRITERIA WORKING GROUP; NUCLEAR-CARDIOLOGY; EJECTION FRACTION; APPROPRIATENESS CRITERIA; CORONARY INTERVENTION; MAGNETIC-RESONANCE; TASK-FORCE AB Background-Contrast left ventriculography is a method of measuring left ventricular function usually performed at the discretion of the invasive cardiologist during cardiac catheterization. We sought to determine variation in the use of left ventriculography in the Veterans Affairs (VA) Health Care System. Methods and Results-We identified adult patients who underwent cardiac catheterization including coronary angiography between 2000 and 2009 in the VA Health Care System. We determined patient and hospital predictors of the use of left ventriculography as well as the variation in use across VA facilities. Results were validated using data from the VA's Clinical Assessment, Reporting, and Tracking (CART) program. Of 457 170 cardiac catheterization procedures among 336 853 patients, left ventriculography was performed on 263 695 (58%) patients. Use of left ventriculography decreased over time (64% in 2000 to 50% in 2009) and varied markedly across facilities (< 1-> 95% of cardiac catheterizations). Patient factors explained little of the large variation in use between facilities. When the cohort was restricted to those with an echocardiogram in the prior 30 days and no intervening event, left ventriculography was still performed in 50% of cases. Conclusions-There is large variation in the use of left ventriculography across VA facilities that is not explained by patient characteristics. C1 [Heidenreich, Paul A.; Lin, Shoutzu; Sahay, Anju] VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA. [Heidenreich, Paul A.; Knowles, Joshua W.; Perez, Marco; Witteles, Ronald M.] Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA. [Maddox, Thomas M.; Ho, Michael P.; Rumsfeld, John S.; Tsai, Thomas T.] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Heidenreich, PA (reprint author), VA Palo Alto Hlth Care Syst, 111C,3801 Miranda Ave, Palo Alto, CA 94304 USA. EM paul.heidenreich@va.gov OI Heidenreich, Paul/0000-0001-7730-8490 FU Veteran Administration's Quality Enhancement and Research Initiative [04, 326]; American Heart Association [10FTF3360005]; VA Health Services Research and Development Career Development Award [09-415] FX Dr Heidenreich is supported by a grant from the Veteran Administration's Quality Enhancement and Research Initiative 04 to 326. Dr Knowles is supported by an American Heart Association National Fellow-to-Faculty transition award 10FTF3360005. Dr Maddox is supported by a grant from the VA Health Services Research and Development Career Development Award (09-415). NR 22 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2013 VL 6 IS 6 BP 687 EP 693 DI 10.1161/CIRCOUTCOMES.113.000199 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 298ZA UT WOS:000330362400017 PM 24192569 ER PT J AU Anderson, ML Peterson, ED Peng, SA Wang, TY Ohman, EM Bhatt, DL Saucedo, JF Roe, MT AF Anderson, Monique L. Peterson, Eric D. Peng, S. Andrew Wang, Tracy Y. Ohman, E. Magnus Bhatt, Deepak L. Saucedo, Jorge F. Roe, Matthew T. TI Differences in the Profile, Treatment, and Prognosis of Patients With Cardiogenic Shock by Myocardial Infarction Classification A Report From NCDR SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE myocardial infarction; outcome assessment; shock, cardiogenic ID ST-SEGMENT ELEVATION; ACUTE CORONARY SYNDROMES; REVASCULARIZE OCCLUDED CORONARIES; QUALITY IMPROVEMENT; ELDERLY-PATIENTS; TEMPORAL TRENDS; MANAGEMENT STRATEGIES; SURVIVAL BENEFIT; OUTCOMES; REGISTRY AB Background-Cardiogenic shock is a deadly complication of an acute myocardial infarction (MI). We sought to characterize differences in patient features, treatments, and outcomes of cardiogenic shock by MI classification: ST-segment-elevation MI (STEMI) versus non-ST-segment elevation MI (NSTEMI). Methods and Results-We compared differences in care by the shock status of 235 541 patients with STEMI and NSTEMI treated at 392 US hospitals from 2007 to 2011. Cardiogenic shock occurred in 12.2% of patients with STEMI versus 4.3% of patients with NSTEMI. Compared with STEMI shock, NSTEMI shock was more likely in patients who were older and predominantly women; had diabetes mellitus, hypertension, previous heart failure, MI, or peripheral arterial disease; and who received coronary artery bypass grafting (11.6% versus 21.2%; P<0.0001) but less likely to have received percutaneous coronary intervention (84.2% versus 35.3%; P<0.0001). Compared with patients with STEMI presenting with shock at admission, patients with NSTEMI presenting with shock had longer delays to percutaneous coronary intervention (1.2 versus 3.2 hours) and coronary artery bypass grafting (7.9 versus 55.9 hours). Cardiogenic shock in patients with STEMI was associated with a lower mortality risk (33.1% shock versus 2.0% no shock; adjusted odds ratio, 14.1; 95% confidence interval, 13.0-15.4; interaction P value <0.0001) compared with patients with NSTEMI (40.8% shock versus 2.3% no shock, odds ratio, 19.0; 95% confidence interval, 17.1-21.2). Conclusions-Cardiogenic shock is associated with high mortality in patients with STEMI and NSTEMI. However, urgent revascularization is more commonly pursued in patients with STEMI presenting with shock than in patients with NSTEMI. More research is needed to improve the outcomes for patients with MI presenting with shock, particularly those presenting with NSTEMI. C1 [Anderson, Monique L.; Peterson, Eric D.; Peng, S. Andrew; Wang, Tracy Y.; Ohman, E. Magnus; Roe, Matthew T.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Bhatt, Deepak L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA. [Saucedo, Jorge F.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA. RP Anderson, ML (reprint author), 7022 North Pavil DUMC,POB 17969, Durham, NC 27715 USA. EM monique.anderson@duke.edu FU American College of Cardiology Foundation's NCDR FX This research was supported by the American College of Cardiology Foundation's NCDR. The views expressed in this article represent those of the author(s) and do not necessarily represent the official views of the NCDR or its associated professional societies identified at www.ncdr.com. NR 31 TC 18 Z9 19 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2013 VL 6 IS 6 BP 708 EP 715 DI 10.1161/CIRCOUTCOMES.113.000262 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 298ZA UT WOS:000330362400020 PM 24221834 ER PT J AU Porhomayon, J Leissner, KB El-Solh, AA Nader, ND AF Porhomayon, Jahan Leissner, Kay B. El-Solh, Ali A. Nader, Nader D. TI Strategies in Postoperative Analgesia in the Obese Obstructive Sleep Apnea Patient SO CLINICAL JOURNAL OF PAIN LA English DT Review DE obstructive sleep apnea; pain; screening; surgery; monitoring; respiratory ID LAPAROSCOPIC BARIATRIC SURGERY; RANDOMIZED CONTROLLED-TRIAL; POSITIVE AIRWAY PRESSURE; CHRONIC OPIOID USE; ACUTE PAIN; PERIOPERATIVE COMPLICATIONS; DEXMEDETOMIDINE INFUSION; AMBULATORY SURGERY; RESPIRATORY EVENTS; MORBID-OBESITY AB Objective: Obstructive sleep apnea (OSA) has become an epidemic worldwide, and OSA patients frequently present for surgery. Comorbidities such as cardiovascular disease, diabetes, hypertension, stroke, gastrointestinal disorder, metabolic syndrome, chronic pain, delirium, and pulmonary disorder increase the peri-operative risk for OSA patients. Methods: This is a narrative review of the impact of sedative and analgesic therapy on the intraoperative and postoperative course of an obese OSA patient. Results: An understanding of postoperative complications related to OSA and drug interactions in the context of opioid and non-opioid selection may benefit pain practitioner and patients equally. Conclusions: Management of acute postoperative pain in OSA patient remains complex. A comprehensive strategy is needed to reduce the complications and adverse events related to administration of analgesics and anesthetics. C1 [Porhomayon, Jahan] SUNY Buffalo, Dept Anesthesiol, Div Crit Care Med, VA Western New York Healthcare Syst,Buffalo Sch M, Buffalo, NY 14260 USA. [El-Solh, Ali A.] SUNY Buffalo, Dept Med, Div Pulm Crit Care & Sleep, VA Western New York Healthcare Syst,Buffalo Sch M, Buffalo, NY 14260 USA. [Nader, Nader D.] SUNY Buffalo, Dept Anesthesiol, Div Cardiothorac Anesthesia & Pain Med, VA Western New York Healthcare Syst,Buffalo Sch M, Buffalo, NY 14260 USA. [Leissner, Kay B.] Boston Univ, Sch Med, VA Boston Healthcare Syst, Div Anesthesia & Crit Care Med, West Roxbury, MA USA. [Leissner, Kay B.] Harvard Univ, Sch Med, Dept Anesthesia, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Porhomayon, J (reprint author), VA Med Ctr, Rm 203C,3495 Bailey Ave, Buffalo, NY 14215 USA. EM jahanpor@buffalo.edu OI Nader, Nader/0000-0002-5744-7319 NR 118 TC 9 Z9 9 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0749-8047 EI 1536-5409 J9 CLIN J PAIN JI Clin. J. Pain PD NOV PY 2013 VL 29 IS 11 BP 998 EP 1005 PG 8 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA 298ZQ UT WOS:000330364100017 PM 23370080 ER PT J AU Dick, RW Berning, JR Dawson, W Ginsburg, RD Miller, C Shybut, GT AF Dick, Randall W. Berning, Jacqueline R. Dawson, William Ginsburg, Richard D. Miller, Clay Shybut, George T. TI Athletes and the Arts - The Role of Sports Medicine in the Performing Arts SO CURRENT SPORTS MEDICINE REPORTS LA English DT Review ID SYMPHONY ORCHESTRAS; INJURY INCIDENCE; HEALTH-PROBLEMS; HEARING-LOSS; MUSCULOSKELETAL; INSTRUMENTALISTS; MUSICIANS; EXPOSURE; BALLET; DANCE AB Performing artists are athletes. Like athletes, performing artists practice and/or perform most days with little off season, play through pain, "compete" in challenging environments, and risk career-threatening injury. Athletes and the Arts is a multiorganizational initiative linking the sport athlete and musician/performing artist communities. Performing artists of all ages and genre are an underserved population related to medical coverage, care, injury prevention, performance enhancement, and wellness. Sports medicine professionals are a valuable resource for filling this gap by applying existing knowledge of treating sport athletes (nutrition, injury prevention) while gaining a better understanding of performers' unique needs (hearing loss, focal dystonia) and environment. These applications can occur in the clinical setting and through developing organizational policies. By better understanding the needs of the performing arts population and applying existing concepts and knowledge, sports medicine professionals can expand their impact to a new patient base that desperately needs support. C1 [Dick, Randall W.] Hlth & Safety Sports Consultants LLC, Carmel, IN 46033 USA. [Berning, Jacqueline R.] Univ Colorado, Colorado Springs, CO 80907 USA. [Dawson, William] Northwestern Univ, Feinberg Sch Med, Glenview, IL USA. [Ginsburg, Richard D.] Harvard Univ, Sch Med, Dept Psychiat, MGH Sport Psychol Program,Massachusetts Gen Hosp, Boston, MA 02115 USA. [Miller, Clay] Sports Med North, Peabody, MA USA. [Shybut, George T.] Wellington Orthopaed & Sports Med, Cincinnati, OH USA. RP Dick, RW (reprint author), Hlth & Safety Sports Consultants LLC, 4969 Huntington Dr, Carmel, IN 46033 USA. EM 4969rwd@gmail.com NR 59 TC 3 Z9 3 U1 7 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1537-890X EI 1537-8918 J9 CURR SPORT MED REP JI Curr. Sport. Med. Rep. PD NOV-DEC PY 2013 VL 12 IS 6 BP 397 EP 403 PG 7 WC Sport Sciences SC Sport Sciences GA 298YN UT WOS:000330360800009 PM 24225525 ER PT J AU Thurler, AH Kuo, B AF Thurler, Andrea H. Kuo, Braden TI From Heave to Leave Understanding Cyclic Vomiting Syndrome SO GASTROENTEROLOGY NURSING LA English DT Article ID ADULTS AB Cyclic vomiting syndrome (CVS) is an idiopathic functional gastrointestinal disorder that has been underrecognized in the adult population. Nausea, vomiting, and abdominal pain are common presentations to gastrointestinal nursing. There are multiple differential diagnoses the clinician must consider prior to a diagnosis of CVS to recognize the disorder. CVS occurs in 4 phases: (a) interepisodic, (b) prodromal, (c) vomiting, and (d) recovery. Each phase has specific treatment guidelines. There is no specific "cure" for CVS; proper management is key. Increasing awareness of CVS is paramount to its detection. CVS has been examined in the pediatric population and has often been considered a pediatric disorder. More recently, it has come to be recognized in the adult population. Proper care and management of these patients allow for better support for patients and their families who are often on the primary caregivers. Nurses are often on the front lines of care and knowledge of CVS from the beginning should lead to shortened hospital stays and optimal patient care. C1 [Thurler, Andrea H.; Kuo, Braden] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Thurler, AH (reprint author), Massachusetts Gen Hosp Gastroenterol, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. EM athurler@partners.org NR 20 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1042-895X EI 1538-9766 J9 GASTROENTEROL NURS JI Gastroenterol. Nurs. PD NOV-DEC PY 2013 VL 36 IS 6 BP 407 EP 413 DI 10.1097/SGA.0000000000000013 PG 7 WC Gastroenterology & Hepatology; Nursing SC Gastroenterology & Hepatology; Nursing GA 298ZP UT WOS:000330364000002 PM 24304524 ER PT J AU Stein, SM Tiersten, A Hochster, HS Blank, SV Pothuri, B Curtin, J Shapira, I Levinson, B Ivy, P Joseph, B Guddati, AK Muggia, F AF Stein, Stacey M. Tiersten, Amy Hochster, Howard S. Blank, Stephanie V. Pothuri, Bhavana Curtin, John Shapira, Ilan Levinson, Benjamin Ivy, Percy Joseph, Benson Guddati, Achuta Kumar Muggia, Franco TI A Phase 2 Study of Oxaliplatin Combined With Continuous Infusion Topotecan for Patients With Previously Treated Ovarian Cancer SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Article DE Phase 2; Oxalipatin; Topotecan; Continuous infusion; Ovarian cancer ID PEGYLATED LIPOSOMAL DOXORUBICIN; RECURRENT EPITHELIAL OVARIAN; PLATINUM-BASED CHEMOTHERAPY; TRIAL; GEMCITABINE; CARBOPLATIN; COMBINATION; STATISTICS; PACLITAXEL; RESISTANT AB Background: Phase 2 trials suggest that prolonged intravenous (IV) infusion of the topoisomerase 1 inhibitor topotecan may be less toxic than when given by standard IV bolus 5-day administration. Oxaliplatin exhibits efficacy in platinum-pretreated disease and shows preclinical synergy with topoisomerase 1 inhibitors. We sought to determine the efficacy and safety of oxaliplatin plus infusion topotecan in recurrent platinum-pretreated ovarian cancer. Methods: Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers previously treated with 1 to 2 prior regimens including platinum and taxane received oxaliplatin (85 mg/m(2) day 1 and day 15) and topotecan (0.4 mg/m(2) per day) by continuous IV infusion over 14 days every 4 weeks. The primary objective of the trial was to estimate the objective response rate in platinum-resistant disease (stratum 1) and in platinum-sensitive disease (stratum 2). Toxicities were assessed in all patients. Results: Thirty-eight patients received 144 cycles of therapy (median, 4; range, 1-6). The most common grade 3 and grade 4 toxicities included thrombocytopenia (grade 3, 37%; and grade 4, 19%), neutropenia (grade 3, 37%; grade 4, 11%), and anemia (grade 3, 15%). Response occurred in 4 of 19 patients in stratum I (21%; 95% confidence intervals, 6%-46%) and 9 of 19 patients in stratum 2 (47%; 95% CI, 24%-71%). Three in each stratum had lengthy complete responses. Conclusions: Biweekly oxaliplatin plus a 14-day continuous IV infusion of topotecan, given monthly, is an active regimen in platinum-pretreated ovarian cancer and merits additional evaluation. C1 [Stein, Stacey M.; Hochster, Howard S.] Yale Univ, Sch Med, Dept Med, Div Med Oncol, New Haven, CT 06510 USA. [Tiersten, Amy; Joseph, Benson; Muggia, Franco] NYU, Sch Med, Dept Med, Div Med Oncol, New York, NY USA. [Blank, Stephanie V.; Pothuri, Bhavana; Curtin, John] NYU, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, New York, NY USA. [Shapira, Ilan] Albert Einstein Coll Med, Beth Israel Canc Ctr, Bronx, NY USA. NYU, Sch Med, New York, NY USA. [Levinson, Benjamin] NYU, Sch Med, Dept Populat Hlth, Div Biostat, New York, NY USA. [Ivy, Percy] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. [Guddati, Achuta Kumar] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Internal Med, Boston, MA 02115 USA. RP Guddati, AK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Internal Med, Boston, MA 02115 USA. EM drgakumar@yahoo.com OI Curtin, John/0000-0002-9370-5119; Muggia, Franco/0000-0003-0703-9146 FU Department of Health and Human Services, National Cancer Institute [N01-CM-62204] FX Supported by the Department of Health and Human Services, National Cancer Institute contract number N01-CM-62204, New York Cancer Consortium (PI: Joseph A. Sparano, MD) NR 27 TC 7 Z9 7 U1 2 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1048-891X EI 1525-1438 J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PD NOV PY 2013 VL 23 IS 9 BP 1577 EP 1582 DI 10.1097/IGC.0b013e3182a809e0 PG 6 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 299DC UT WOS:000330374300007 PM 24172094 ER PT J AU Etemad, B Gonzalez, OA McDonough, S Pena-Cruz, V Sagar, M AF Etemad, Behzad Gonzalez, Oscar A. McDonough, Sean Pena-Cruz, Victor Sagar, Manish TI Early Infection HIV-1 Envelope V1-V2 Genotypes Do Not Enhance Binding or Replication in Cells Expressing High Levels of alpha 4 beta 7 Integrin SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE gut homing integrin alpha 4 beta 7; mucosal transmission; HIV-1 envelope; selection at transmission; gut-associated lymphoid tissue ID IMMUNODEFICIENCY-VIRUS TYPE-1; HETEROSEXUAL TRANSMISSION; VACCINE EFFICACY; VARIANTS; SELECTION; ANTIBODY; ALPHA(4)BETA(7); SENSITIVITY; RECEPTOR; FUSION AB It has been postulated that HIV-1 envelope properties, such as shorter and less-glycosylated V1-V2 loops commonly observed among non-subtype B early-transmitted viruses, promote utilization of the gut homing integrin alpha 4 beta 7. This property potentially confers an advantage to some HIV-1 variants early after acquisition. We found that replication-competent recombinant viruses incorporating HIV-1 subtype A compact and less-glycosylated early versus chronic phase V1-V2 loops demonstrated no significant difference in binding to alpha 4 beta 7 high CD8(+) T cells or replication in alpha 4 beta 7 high CD4(+) T cells. Integrin alpha 4 beta 7 usage does not select for shorter less-glycosylated envelopes during transmission. C1 [Etemad, Behzad; Gonzalez, Oscar A.; Pena-Cruz, Victor; Sagar, Manish] Boston Univ, Sch Med, Dept Med, Div Infect Dis, Boston, MA 02118 USA. [McDonough, Sean] Dana Farber Canc Res Ctr, Boston, MA USA. RP Sagar, M (reprint author), Boston Univ, Sch Med, Evans Biomed Res Ctr, 650 Albany St,EBRC-647, Boston, MA 02118 USA. EM msagar@bu.edu FU National Institute of Health [AI1077473] FX Supported by National Institute of Health Grant AI1077473 (M.S.). NR 26 TC 7 Z9 7 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2013 VL 64 IS 3 BP 249 EP 253 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 300GY UT WOS:000330453600004 PM 23797693 ER PT J AU Eberhart, MG Yehia, BR Hillier, A Voytek, CD Blank, MB Frank, I Metzger, DS Brady, KA AF Eberhart, Michael G. Yehia, Baligh R. Hillier, Amy Voytek, Chelsea D. Blank, Michael B. Frank, Ian Metzger, David S. Brady, Kathleen A. TI Behind the Cascade: Analyzing Spatial Patterns Along the HIV Care Continuum SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE GIS; spatial patterns; care linkage; retention; viral suppression ID ANTIRETROVIRAL THERAPY; DELAYED ENTRY; MEDICAL-CARE; 2ND-ORDER ANALYSIS; VIRAL SUPPRESSION; RISK-FACTORS; HEALTH-CARE; PREVENTION; RETENTION; DIAGNOSIS AB Background: Successful HIV treatment as prevention requires individuals to be tested, aware of their status, linked to and retained in care, and virally suppressed. Spatial analysis may be useful for monitoring HIV care by identifying geographic areas with poor outcomes. Methods: Retrospective cohort of 1704 people newly diagnosed with HIV identified from Philadelphia's Enhanced HIV/AIDS Reporting System in 2008-2009, with follow-up to 2011. Outcomes of interest were not linked to care, not linked to care within 90 days, not retained in care, and not virally suppressed. Spatial patterns were analyzed using K-functions to identify "hot spots" for targeted intervention. Geographic components were included in regression analyses along with demographic factors to determine their impact on each outcome. Results: Overall, 1404 persons (82%) linked to care; 75% (1059/1404) linked within 90 days; 37% (526/1059) were retained in care; and 72% (379/526) achieved viral suppression. Fifty-nine census tracts were in hot spots, with no overlap between outcomes. Persons residing in geographic areas identified by the local K-function analyses were more likely to not link to care [adjusted odds ratio 1.76 (95% confidence interval: 1.30 to 2.40)], not link to care within 90 days (1.49, 1.12-1.99), not be retained in care (1.84, 1.39-2.43), and not be virally suppressed (3.23, 1.87-5.59) than persons not residing in the identified areas. Conclusions: This study is the first to identify spatial patterns as a strong independent predictor of linkage to care, retention in care, and viral suppression. Spatial analyses are a valuable tool for characterizing the HIV epidemic and treatment cascade. C1 [Eberhart, Michael G.; Brady, Kathleen A.] Philadelphia Dept Publ Hlth, AIDS Activ Coordinating Off, Philadelphia, PA 19107 USA. [Yehia, Baligh R.; Brady, Kathleen A.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Yehia, Baligh R.] Philadelphia Vet Affairs Ctr Hlth Equ Res & Promo, Philadelphia, PA USA. [Hillier, Amy] Univ Penn, Sch Design, Philadelphia, PA 19104 USA. [Voytek, Chelsea D.; Blank, Michael B.; Metzger, David S.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Frank, Ian] Univ Penn, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Metzger, David S.] Treatment Res Inst, Philadelphia, PA USA. RP Eberhart, MG (reprint author), Philadelphia Dept Publ Hlth, AIDS Activ Coordinating Off, 1101 Market St,8th Floor, Philadelphia, PA 19107 USA. EM michael.eberhart@phila.gov RI Metzger, David/D-9499-2012 FU Centers for Disease Control and Prevention [PS13-130202, U62/003959]; DC Developmental Center for AIDS Research [5P30AI087714]; [P30-AI45008]; [K23-MH097647] FX Supported in part by a cooperative agreement with the Centers for Disease Control and Prevention (PS13-130202, # U62/003959). Preparation of this manuscript was supported in part by supplemental funds to the grant 5P30AI087714 (DC Developmental Center for AIDS Research) for the Enhanced Comprehensive HIV Prevention Planning Initiative (CFAR ECHPP Initiative), as well as the following grants: P30-AI45008, K23-MH097647. The sponsors had no involvement in the research or resulting publication. NR 47 TC 20 Z9 20 U1 2 U2 15 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2013 VL 64 SU 1 BP S42 EP S51 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 300JW UT WOS:000330461200007 PM 24126447 ER PT J AU Baxter, LE Campbell, A DeShields, M Levounis, P Martin, JA McNicholas, L Payte, JT Salsitz, EA Taylor, T Wilford, BB AF Baxter, Louis E., Sr. Campbell, Anthony DeShields, Michael Levounis, Petros Martin, Judith A. McNicholas, Laura Payte, J. Thomas Salsitz, Edwin A. Taylor, Trusandra Wilford, Bonnie B. TI Safe Methadone Induction and Stabilization Report of an Expert Panel SO JOURNAL OF ADDICTION MEDICINE LA English DT Review DE methadone; methadone dosing; methadone induction; methadone mortality; methadone overdose; opioid agonist treatment ID MAINTENANCE TREATMENT; OVERDOSE DEATHS; OPIOID DEPENDENCE; UNITED-STATES; INTERINDIVIDUAL VARIABILITY; HEROIN-ADDICTION; TOXICITY; MORTALITY; EPIDEMIC; PLASMA AB Objectives: Methadone is a well-studied, safe, and effective medication when dispensed and consumed properly. However, a number of studies have identified elevated rates of overdose and death in patients being treated with methadone for either addiction or chronic pain. Among patients being treated with methadone in federally certified opioid treatment programs, deaths most often occur during the induction and stabilization phases of treatment. To address this issue, the federal Substance Abuse and Mental Health Services Administration invited the American Society of Addiction Medicine to convene an expert panel to develop a consensus statement on methadone induction and stabilization, with recommendations to reduce the risk of patient overdose or death related to methadone maintenance treatment of addiction. Methods: A comprehensive literature search of English-language publications (1979-2011) was conducted via MEDLINE and EM-BASE. Methadone Action Group members evaluated the resulting information and collaborated in formulating the consensus statement presented here, which subsequently was reviewed by more than 100 experts in the field. Results: Published data indicate that deaths during methadone induction occur because the initial dose is too high, the dose is increased too rapidly, or the prescribed methadone interacts with another drug. Therefore, the Methadone Action Group has developed recommendations to help methadone providers avoid or minimize these risks. Conclusions: Careful management of methadone induction and stabilization, coupled with patient education and increased clinical vigilance, can save lives in this vulnerable patient population. C1 [Baxter, Louis E., Sr.] Amer Soc Addict Med, Methadone Act Grp, Chevy Chase, MD USA. [Baxter, Louis E., Sr.] Profess Assistance Program New Jersey, Princeton, NJ USA. [Baxter, Louis E., Sr.] Univ Med & Dent New Jersey, Princeton, NJ USA. [Campbell, Anthony] Substance Abuse & Mental Hlth Serv Adm, US Publ Hlth Serv, Ctr Substance Abuse Treatment, Rockville, MD USA. [Campbell, Anthony] Substance Abuse & Mental Hlth Serv Adm, Div Pharmacol Therapies, Ctr Substance Abuse Treatment, Rockville, MD USA. [DeShields, Michael] Camden Cty Hlth Serv Ctr, Blackwood, NJ USA. [Levounis, Petros] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07103 USA. [Martin, Judith A.] City & Cty San Francisco, Dept Publ Hlth, Community Behav Hlth Serv, San Francisco, CA USA. [Martin, Judith A.] City & Cty San Francisco, Dept Publ Hlth, Substance Abuse Serv, San Francisco, CA USA. [McNicholas, Laura] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [McNicholas, Laura] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Payte, J. Thomas] Colonial Management Grp LP, Wimberly, TX USA. [Salsitz, Edwin A.] Albert Einstein Med Ctr, New York, NY USA. [Salsitz, Edwin A.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA. [Taylor, Trusandra] JEVS Human Serv, Philadelphia, PA USA. [Wilford, Bonnie B.] JBS Int Inc, Ctr Hlth Serv & Outcomes Res, Easton, MD 21601 USA. RP Wilford, BB (reprint author), JBS Int Inc, Ctr Hlth Serv & Outcomes Res, 210 Marlboro Ave,Ste 31,PMB 187, Easton, MD 21601 USA. EM bbwilford@aol.com FU Substance Abuse and Mental Health Services Administration of the US Department of Health and Human Services FX Supported by the Substance Abuse and Mental Health Services Administration of the US Department of Health and Human Services. No funding was accepted from commercial sources. SAMHSA had no role in the data collection, analysis, or manuscript preparation. NR 89 TC 13 Z9 13 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD NOV-DEC PY 2013 VL 7 IS 6 BP 377 EP 386 DI 10.1097/01.ADM.0000435321.39251.d7 PG 10 WC Substance Abuse SC Substance Abuse GA 300KV UT WOS:000330463700001 PM 24189172 ER PT J AU Bhatnagar, R Phelps, L Rietz, K Juergens, T Russell, D Miller, N Ahearn, E AF Bhatnagar, Ritu Phelps, Lori Rietz, Kristi Juergens, Timothy Russell, Douglas Miller, Nathan Ahearn, Eileen TI The Effects of Mindfulness Training on Post-Traumatic Stress Disorder Symptoms and Heart Rate Variability in Combat Veterans SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Article C1 [Bhatnagar, Ritu; Miller, Nathan; Ahearn, Eileen] Univ Wisconsin Hosp & Clin, Madison, WI 53705 USA. [Bhatnagar, Ritu; Phelps, Lori; Rietz, Kristi; Juergens, Timothy; Russell, Douglas; Ahearn, Eileen] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Bhatnagar, R (reprint author), Univ Wisconsin Hosp & Clin, 600 Highland Ave, Madison, WI 53705 USA. EM ritusb@yahoo.com NR 10 TC 11 Z9 11 U1 3 U2 15 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1075-5535 EI 1557-7708 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD NOV PY 2013 VL 19 IS 11 BP 860 EP 861 DI 10.1089/acm.2012.0602 PG 2 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 300JL UT WOS:000330460100002 PM 23738678 ER PT J AU Liu, WJ Li, XL Zhao, YS Meng, XM Wan, C Yang, BX Lan, HY Lin, HY Xia, Y AF Liu, Wenjing Li, Xiaoling Zhao, Yueshui Meng, Xiao-Ming Wan, Chao Yang, Baoxue Lan, Hui-Yao Lin, Herbert Y. Xia, Yin TI Dragon (Repulsive Guidance Molecule RGMb) Inhibits E-cadherin Expression and Induces Apoptosis in Renal Tubular Epithelial Cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID MORPHOGENETIC PROTEIN CORECEPTOR; REGULATES HEPCIDIN EXPRESSION; FIBROSIS; KIDNEY; NEOGENIN; INJURY; RECEPTORS; INFLAMMATION; TRANSITION; MECHANISMS AB Dragon is one of the three members of the repulsive guidance molecule (RGM) family, i.e. RGMa, RGMb (Dragon), and RGMc (hemojuvelin). We previously identified the RGM members as bone morphogenetic protein (BMP) co-receptors that enhance BMP signaling. Our previous studies found that Dragon is highly expressed in the tubular epithelial cells of mouse kidneys. However, the roles of Dragon in renal epithelial cells are yet to be defined. We now show that overexpression of Dragon increased cell death induced by hypoxia in association with increased cleaved poly(ADP-ribose) polymerase and cleaved caspase-3 levels in mouse inner medullary collecting duct (IMCD3) cells. Dragon also inhibited E-cadherin expression but did not affect epithelial-to-mesenchymal transition induced by TGF-beta in IMCD3 cells. Previous studies suggest that the three RGM members can function as ligands for the receptor neogenin. Interestingly, our present study demonstrates that the Dragon actions on apoptosis and E-cadherin expression in IMCD3 cells were mediated by the neogenin receptor but not through the BMP pathway. Dragon expression in the kidney was up-regulated by unilateral ureteral obstruction in mice. Compared with wild-type mice, heterozygous Dragon knock-out mice exhibited 45-66% reduction in Dragon mRNA expression, decreased epithelial apoptosis, and increased tubular E-cadherin expression and had attenuated tubular injury after unilateral ureteral obstruction. Our results suggest that Dragon may impair tubular epithelial integrity and induce epithelial apoptosis both in vitro and in vivo. C1 [Liu, Wenjing; Li, Xiaoling; Zhao, Yueshui; Wan, Chao; Xia, Yin] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Key Lab Regenerat Med,Minist Educ, Hong Kong, Hong Kong, Peoples R China. [Wan, Chao; Xia, Yin] Chinese Univ Hong Kong, Shenzhen Res Inst, Sch Biomed Sci Core Lab, Shenzhen 518057, Peoples R China. [Lin, Herbert Y.] Harvard Univ, Ctr Syst Biol,Med Sch, Massachusetts Gen Hosp,Program Membrane Biol, Program Anemia Signaling Res,Div Nephrol,Dept Med, Boston, MA 02114 USA. [Meng, Xiao-Ming; Lan, Hui-Yao] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China. [Meng, Xiao-Ming; Lan, Hui-Yao] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China. [Yang, Baoxue] Peking Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing 100191, Peoples R China. [Yang, Baoxue] Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing 100191, Peoples R China. RP Lin, HY (reprint author), Richard B Simches Res Ctr, Program Membrane Biol, 185 Cambridge St,CPZN-8216, Boston, MA 02114 USA. EM Lin.Herbert@mgh.harvard.edu; Xia.Yin@cuhk.edu.hk RI Lan, hui/C-9734-2015 OI Lan, hui/0000-0003-4283-9755 FU Hong Kong Research Grant Council (RGC) [N_CUHK432/12, 81261160507]; National Natural Science Foundation of China (NSFC) [N_CUHK432/12, 81261160507]; Chinese University of Hong Kong; RGC/General Research Fund (GRF) [CUHK477311]; CUHK [2041603, 2041747]; Shenzhen Science and Technology Research and Development Funding [SZRI-C.02.12.006]; National Institute of Health [RO1 DK-069533, RO1 DK-071837]; Chinese University of Hong Kong postgraduate scholarships FX This work was supported by the Hong Kong Research Grant Council (RGC) and National Natural Science Foundation of China (NSFC) joint grants N_CUHK432/12 and 81261160507 (to Y. X. and B. Y.), the startup fund offered by The Chinese University of Hong Kong (to Y. X.), RGC/General Research Fund (GRF) grant CUHK477311 (to Y. X.), CUHK direct grants 2041603 and 2041747 (to Y. X.), Shenzhen Science and Technology Research and Development Funding SZRI-C.02.12.006 (to Y. X.), and National Institute of Health Grants RO1 DK-069533 and RO1 DK-071837 (to H. Y. L.).; Supported by Chinese University of Hong Kong postgraduate scholarships. NR 38 TC 8 Z9 8 U1 1 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 1 PY 2013 VL 288 IS 44 BP 31528 EP 31539 DI 10.1074/jbc.M113.517573 PG 12 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 302HX UT WOS:000330596200012 PM 24052264 ER PT J AU Kim, M Song, LK Moon, J Sun, ZYJ Bershteyn, A Hanson, M Cain, D Goka, S Kelsoe, G Wagner, G Irvine, D Reinherz, EL AF Kim, Mikyung Song, Likai Moon, James Sun, Zhen-Yu J. Bershteyn, Anna Hanson, Melissa Cain, Derek Goka, Selasie Kelsoe, Garnett Wagner, Gerhard Irvine, Darrell Reinherz, Ellis L. TI Immunogenicity of Membrane-bound HIV-1 gp41 Membrane-proximal External Region (MPER) Segments Is Dominated by Residue Accessibility and Modulated by Stereochemistry SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID B-CELL RESPONSES; IMMUNE-RESPONSE; NEUTRALIZING ANTIBODIES; PEPTIDE EPITOPE; VIRUS; PROTEIN; AFFINITY; ANTIGEN; MATURATION; BROAD AB Structural characterization of epitope-paratope pairs has contributed to the understanding of antigenicity. By contrast, few structural studies relate to immunogenicity, the process of antigen-induced immune responses in vivo. Using a lipid-arrayed membrane-proximal external region (MPER) of HIV-1 glycoprotein 41 as a model antigen, we investigated the influence of physicochemical properties on immunogenicity in relation to structural modifications of MPER/liposome vaccines. Anchoring the MPER to the membrane via an alkyl tail or transmembrane domain retained the MPER on liposomes in vivo, while preserving MPER secondary structure. However, structural modifications that affected MPER membrane orientation and antigenic residue accessibility strongly impacted induced antibody responses. The solvent-exposed MPER tryptophan residue (Trp-680) was immunodominant, focusing immune responses, despite sequence variability elsewhere. Nonetheless, immunogenicity could be readily manipulated using site-directed mutagenesis or structural constraints to modulate amino acid surface display. These studies provide fundamental insights for immunogen design aimed at targeting B cell antibody responses. C1 [Kim, Mikyung; Goka, Selasie; Reinherz, Ellis L.] Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA. [Kim, Mikyung; Goka, Selasie; Reinherz, Ellis L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Kim, Mikyung] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA. [Song, Likai] Natl High Magnet Field Lab, Tallahassee, FL 32310 USA. [Moon, James; Bershteyn, Anna; Hanson, Melissa; Irvine, Darrell] MIT, Dept Mat Sci & Engn & Biol Engn, Cambridge, MA 02139 USA. [Sun, Zhen-Yu J.; Wagner, Gerhard] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Cain, Derek; Kelsoe, Garnett] Duke Univ, Dept Immunol, Sch Med, Durham, NC 27710 USA. RP Kim, M (reprint author), Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA. EM mikyung_kim@dfci.harvard.edu; ellis_reinherz@dfci.harvard.edu OI Hanson, Melissa/0000-0003-3270-8460 FU National Institutes of Health [AI 84785, AI 91693, AI 81579]; NIAID [HHSN272201000053C]; Bill and Melinda Gates Foundation; National High Magnetic Field Laboratory User Collaboration Grants Program [5080] FX This work was supported by National Institutes of Health Grants AI 84785 (to E. L. R. and G. W.), AI 91693 (to E. L. R., G. W., G. H. K., and D. I.), AI 81579 and HHSN272201000053C from NIAID and a Collaboration for AIDS Vaccine Discovery grant from the Bill and Melinda Gates Foundation (to E. L. R., G. W. and D. I.) and a Global Health grant from the Bill and Melinda Gates Foundation (to G. H. K.).; Supported by National High Magnetic Field Laboratory User Collaboration Grants Program Grant 5080. NR 55 TC 19 Z9 19 U1 1 U2 15 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 1 PY 2013 VL 288 IS 44 BP 31888 EP 31901 DI 10.1074/jbc.M113.494609 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 302HX UT WOS:000330596200038 PM 24047898 ER PT J AU Zhu, L Zhong, MH Zhao, JY Rhee, H Caesar, I Knight, EM Volpicelli-Daley, L Bustos, V Netzer, W Liu, LJ Lucast, L Ehrlich, ME Robakis, NK Gandy, SE Cai, DM AF Zhu, Li Zhong, Minghao Zhao, Jiaying Rhee, Hannah Caesar, Ina Knight, Elysse M. Volpicelli-Daley, Laura Bustos, Victor Netzer, William Liu, Lijuan Lucast, Louise Ehrlich, Michelle E. Robakis, Nikolaos K. Gandy, Samuel E. Cai, Dongming TI Reduction of Synaptojanin 1 Accelerates A beta Clearance and Attenuates Cognitive Deterioration in an Alzheimer Mouse Model SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID AMYLOID-PRECURSOR-PROTEIN; GAMMA-SECRETASE; IN-VIVO; PRESENILIN-MUTATIONS; EARLY ENDOSOMES; DOWN-SYNDROME; DISEASE; METABOLISM; MICE; PHOSPHORYLATION AB Recent studies link synaptojanin 1 (synj1), the main phosphoinositol (4,5)-biphosphate phosphatase (PI(4,5)P-2-degrading enzyme) in the brain and synapses, to Alzheimer disease. Here we report a novel mechanism by which synj1 reversely regulates cellular clearance of amyloid-beta (A beta). Genetic down-regulation of synj1 reduces both extracellular and intracellular A beta levels in N2a cells stably expressing the Swedish mutant of amyloid precursor protein (APP). Moreover, synj1 haploinsufficiency in an Alzheimer disease transgenic mouse model expressing the Swedish mutant APP and the presenilin-1 mutant Delta E9 reduces amyloid plaque load, as well as A beta(40) and A beta(42) levels in hippocampus of 9-month-old animals. Reduced expression of synj1 attenuates cognitive deficits in these transgenic mice. However, reduction of synj1 does not affect levels of full-length APP and the C-terminal fragment, suggesting that A beta generation by beta- and gamma-secretase cleavage is not affected. Instead, synj1 knockdown increases A beta uptake and cellular degradation through accelerated delivery to lysosomes. These effects are partially dependent upon elevated PI(4,5)P-2 with synj1 down-regulation. In summary, our data suggest a novel mechanism by which reduction of a PI(4,5)P-2-degrading enzyme, synj1, improves amyloid-induced neuropathology and behavior deficits through accelerating cellular A beta clearance. C1 [Zhu, Li; Zhao, Jiaying; Rhee, Hannah; Caesar, Ina; Knight, Elysse M.; Ehrlich, Michelle E.; Gandy, Samuel E.; Cai, Dongming] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Zhu, Li; Zhao, Jiaying; Rhee, Hannah; Caesar, Ina; Knight, Elysse M.; Ehrlich, Michelle E.; Gandy, Samuel E.; Cai, Dongming] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Robakis, Nikolaos K.] Icahn Sch Med Mt Sinai, Dept Psychiat Neurosci & Expt Therapeut, New York, NY 10029 USA. [Zhu, Li; Zhao, Jiaying; Rhee, Hannah; Caesar, Ina; Knight, Elysse M.; Ehrlich, Michelle E.; Gandy, Samuel E.; Cai, Dongming] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Zhong, Minghao] New York Med Coll, Dept Pathol, Vahalla, NY 10595 USA. [Volpicelli-Daley, Laura; Liu, Lijuan; Lucast, Louise] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06519 USA. [Volpicelli-Daley, Laura; Liu, Lijuan; Lucast, Louise] Yale Univ, Sch Med, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT 06519 USA. [Bustos, Victor; Netzer, William] Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10065 USA. RP Cai, DM (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. EM dongming.cai@mssm.edu OI knight, Elysse/0000-0001-8372-1214 FU National Institutes of Health [NS047229]; Department of Neurology and Friedman Brain Institute of Icahn Mount Sinai School of Medicine; Ellison Foundation; National Institutes of Health-National Cancer Institute Shared Resources Grant [5R24CA095823-04]; National Science Foundation Major Research Instrumentation Grant [DBI-9724504]; National Institutes of Health Shared Instrumentation Grant [1S10RR09145-01] FX This work was supported, in whole or in part, by National Institutes of Health Grant NS047229 (to N.R.). This work was also supported by a seed fund provided to Dongming Cai by the Department of Neurology and Friedman Brain Institute of Icahn Mount Sinai School of Medicine, funds from the Ellison Foundation (to P.D.), National Institutes of Health-National Cancer Institute Shared Resources Grant 5R24CA095823-04, National Science Foundation Major Research Instrumentation Grant DBI-9724504, and National Institutes of Health Shared Instrumentation Grant 1S10RR09145-01. NR 48 TC 14 Z9 15 U1 1 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 1 PY 2013 VL 288 IS 44 BP 32050 EP 32063 DI 10.1074/jbc.M113.504365 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 302HX UT WOS:000330596200056 PM 24052255 ER PT J AU Aizer, AA Chen, MH McCarthy, EP Mendu, ML Koo, S Wilhite, TJ Graham, PL Choueiri, TK Hoffman, KE Martin, NE Hu, JC Nguyen, PL AF Aizer, Ayal A. Chen, Ming-Hui McCarthy, Ellen P. Mendu, Mallika L. Koo, Sophia Wilhite, Tyler J. Graham, Powell L. Choueiri, Toni K. Hoffman, Karen E. Martin, Neil E. Hu, Jim C. Nguyen, Paul L. TI Marital Status and Survival in Patients With Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID METASTATIC BREAST-CANCER; DIURNAL CORTISOL RHYTHM; CELL LUNG-CANCER; QUALITY-OF-LIFE; PROSTATE-CANCER; SOCIAL SUPPORT; PSYCHOLOGICAL DISTRESS; ALCOHOL-CONSUMPTION; CLINICAL-OUTCOMES; HEART-FAILURE AB Purpose To examine the impact of marital status on stage at diagnosis, use of definitive therapy, and cancer-specific mortality among each of the 10 leading causes of cancer-related death in the United States. Methods We used the Surveillance, Epidemiology and End Results program to identify 1,260,898 patients diagnosed in 2004 through 2008 with lung, colorectal, breast, pancreatic, prostate, liver/intrahepatic bile duct, non-Hodgkin lymphoma, head/neck, ovarian, or esophageal cancer. We used multivariable logistic and Cox regression to analyze the 734,889 patients who had clinical and follow-up information available. Results Married patients were less likely to present with metastatic disease (adjusted odds ratio [ OR], 0.83; 95% CI, 0.82 to 0.84; P < .001), more likely to receive definitive therapy (adjusted OR, 1.53; 95% CI, 1.51 to 1.56; P < .001), and less likely to die as a result of their cancer after adjusting for demographics, stage, and treatment (adjusted hazard ratio, 0.80; 95% CI, 0.79 to 0.81; P < .001) than unmarried patients. These associations remained significant when each individual cancer was analyzed (P < .05 for all end points for each malignancy). The benefit associated with marriage was greater in males than females for all outcome measures analyzed (P < .001 in all cases). For prostate, breast, colorectal, esophageal, and head/neck cancers, the survival benefit associated with marriage was larger than the published survival benefit of chemotherapy. Conclusion Even after adjusting for known confounders, unmarried patients are at significantly higher risk of presentation with metastatic cancer, undertreatment, and death resulting from their cancer. This study highlights the potentially significant impact that social support can have on cancer detection, treatment, and survival. (C) 2013 by American Society of Clinical Oncology C1 [Aizer, Ayal A.] Harvard Radiat Oncol Program, Boston, MA USA. [McCarthy, Ellen P.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Mendu, Mallika L.; Koo, Sophia; Graham, Powell L.; Martin, Neil E.; Nguyen, Paul L.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Wilhite, Tyler J.] Harvard Univ, Sch Med, Boston, MA USA. [Chen, Ming-Hui] Univ Connecticut, Storrs, CT USA. [Hoffman, Karen E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Hu, Jim C.] Univ Calif Los Angeles, Los Angeles, CA USA. RP Nguyen, PL (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. EM pnguyen@LROC.harvard.edu RI Martin, Neil/E-2193-2014; OI Martin, Neil/0000-0002-8164-8516; Koo, Sophia/0000-0002-4973-7439 FU Heritage Medical Research Institute/Prostate Cancer Foundation Young Investigator Award; JCRT Foundation Grant FX Supported by a Heritage Medical Research Institute/Prostate Cancer Foundation Young Investigator Award, JCRT Foundation Grant, Fitz's Cancer Warriors, David and Cynthia Chapin, and a grant from an anonymous family foundation. NR 62 TC 131 Z9 131 U1 7 U2 29 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 BP 3869 EP 3876 DI 10.1200/JCO.2013.49.6489 PG 8 WC Oncology SC Oncology GA 301OD UT WOS:000330540700007 PM 24062405 ER PT J AU Johnson, BE Kabbinavar, F Fehrenbacher, L Hainsworth, J Kasubhai, S Kressel, B Lin, CY Marsland, T Patel, T Polikoff, J Rubin, M White, L Yang, JCH Bowden, C Miller, V AF Johnson, Bruce E. Kabbinavar, Fairooz Fehrenbacher, Louis Hainsworth, John Kasubhai, Saifuddin Kressel, Bruce Lin, Chin-Yu Marsland, Thomas Patel, Taral Polikoff, Jonathan Rubin, Mark White, Leonard Yang, James Chih-Hsin Bowden, Chris Miller, Vincent TI ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID MAINTENANCE THERAPY; OPEN-LABEL; PLUS; MULTICENTER; GEMCITABINE; CISPLATIN; EGFR; COMBINATION; CARBOPLATIN; RECURRENT AB Purpose This phase III trial was performed to assess the potential benefit of adding maintenance erlotinib to bevacizumab after a first-line chemotherapy regimen with bevacizumab for advanced non-small- cell lung cancer (NSCLC). Patients and Methods One thousand one hundred forty-five patients with histologically or cytologically confirmed NSCLC (stage IIIB with malignant pleural effusion, stage IV, or recurrent) received four cycles of chemotherapy plus bevacizumab. Seven hundred forty-three patients without disease progression or significant toxicity were then randomly assigned (1: 1) to bevacizumab (15 mg/kg, day 1, 21-day cycle) plus either placebo or erlotinib (150 mg per day). The primary end point was progression-free survival (PFS). Results Median PFS from time of random assignment was 3.7 months with bevacizumab/placebo and 4.8 months with bevacizumab/erlotinib (hazard ratio [HR], 0.71; 95% CI, 0.58 to 0.86; P < .001). Median overall survival (OS) times from random assignment were 13.3 and 14.4 months with bevacizumab/placebo and bevacizumab/erlotinib, respectively (HR, 0.92; 95% CI, 0.70 to 1.21; P = .5341). During the postchemotherapy phase, there were more adverse events (AEs) overall, more grade 3 and 4 AEs (mainly rash and diarrhea), more serious AEs, and more AEs leading to erlotinib/placebo discontinuation in the bevacizumab/erlotinib arm versus the bevacizumab/placebo arm. The incidence of AEs leading to bevacizumab discontinuation was similar in both treatment arms. Conclusion The addition of erlotinib to bevacizumab significantly improved PFS but not OS. Although generally well tolerated, the modest impact on survival and increased toxicity associated with the addition of erlotinib to bevacizumab maintenance mean that this two-drug maintenance regimen will not lead to a new postchemotherapy standard of care. (C) 2013 by American Society of Clinical Oncology C1 [Johnson, Bruce E.] Dana Farber Canc Inst, Boston, MA 02215 USA. [Kabbinavar, Fairooz] Univ Calif Los Angeles, Translat Oncol Res Int, Los Angeles, CA USA. [Fehrenbacher, Louis] Kaiser Permanente No Calif, Vallejo, CA USA. [Lin, Chin-Yu; Bowden, Chris] Genentech Inc, San Francisco, CA 94080 USA. [Polikoff, Jonathan] So Calif Permanente Med Grp, San Diego, CA 92120 USA. [Hainsworth, John] Sarah Cannon Res Inst, Nashville, TN USA. [Kasubhai, Saifuddin] Northwest Med Specialties, Tacoma, WA USA. [Kressel, Bruce] Sibley Mem Hosp, Washington, DC USA. [Marsland, Thomas] Integrated Community Oncol Network, Orange Pk, FL USA. [Rubin, Mark] Florida Canc Specialists, Ft Myers, FL USA. [Patel, Taral] Mark H Zangmeister Ctr, Columbus, OH USA. [White, Leonard] Ctr Canc Care & Res, Arch Med Serv, St Louis, MO USA. [Miller, Vincent] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, New York, NY 10021 USA. [Miller, Vincent] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, New York, NY 10021 USA. [Yang, James Chih-Hsin] Natl Taiwan Univ, Taipei 10764, Taiwan. RP Johnson, BE (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Dana 1234, Boston, MA 02215 USA. EM BEJohnson@Partners.org OI Yang, James Chih-Hsin/0000-0002-5586-5138 FU Genentech, South San Francisco, CA FX Supported by Genentech, South San Francisco, CA. NR 19 TC 63 Z9 64 U1 0 U2 7 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 BP 3926 EP + DI 10.1200/JCO.2012.47.3983 PG 10 WC Oncology SC Oncology GA 301OD UT WOS:000330540700015 PM 24101054 ER PT J AU Gainor, JF Shaw, AT AF Gainor, Justin F. Shaw, Alice T. TI Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID GROWTH-FACTOR-RECEPTOR; CHRONIC MYELOID-LEUKEMIA; GASTROINTESTINAL STROMAL TUMORS; CHROMOSOME-POSITIVE LEUKEMIAS; CHRONIC MYELOGENOUS LEUKEMIA; EML4-ALK FUSION GENE; ACQUIRED-RESISTANCE; NONSMALL CELL; MESENCHYMAL TRANSITION; MUTANT EGFR AB The success of tyrosine kinase inhibitors (TKIs) in select patients with non-small-cell lung cancer (NSCLC) has transformed management of the disease, placing new emphasis on understanding the molecular characteristics of tumor specimens. It is now recognized that genetic alterations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) define two unique subtypes of NSCLC that are highly responsive to genotype-directed TKIs. Despite this initial sensitivity, however, the long-term effectiveness of such therapies is universally limited by the development of resistance. Identifying the mechanisms underlying this resistance is an area of intense, ongoing investigation. In this review, we provide an overview of recent experience in the field, focusing on results from preclinical resistance models and studies of patient-derived, TKI-resistant tumor specimens. Although diverse TKI resistance mechanisms have been identified within EGFR-mutant and ALK-positive patients, we highlight common principles of resistance shared between these groups. These include the development of secondary mutations in the kinase target, gene amplification of the primary oncogene, and upregulation of bypass signaling tracts. In EGFR-mutant and ALK-positive patients alike, acquired resistance may also be a dynamic and multifactorial process that may necessitate the use of treatment combinations. We believe that insights into the mechanisms of TKI resistance in patients with EGFR mutations or ALK rearrangements may inform the development of novel treatment strategies in NSCLC, which may also be generalizable to other kinase-driven malignancies. (C) 2013 by American Society of Clinical Oncology C1 [Gainor, Justin F.; Shaw, Alice T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. RP Shaw, AT (reprint author), Massachusetts Gen Hosp, Dept Med, 55 Fruit St, Boston, MA 02114 USA. EM ashaw1@partners.org FU National Institutes of Health [5R01CA164273-02]; V Foundation Translational Research; Evan Spirito Memorial Foundation FX Supported by National Institutes of Health Grant No. 5R01CA164273-02, by a V Foundation Translational Research grant, and by the Evan Spirito Memorial Foundation for support of lung cancer research. A. T. S. is the Charles W. and Jennifer C. Johnson MIT Koch Institute Clinical Investigator. NR 143 TC 97 Z9 103 U1 2 U2 19 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 BP 3987 EP 3996 DI 10.1200/JCO.2012.45.2029 PG 10 WC Oncology SC Oncology GA 301OD UT WOS:000330540700023 PM 24101047 ER PT J AU Desai, GS Orrego, JMF Kambadakone, AR Sahani, DV AF Desai, Gaurav S. Orrego, Jorge M. Fuentes Kambadakone, Avinash R. Sahani, Dushyant V. TI Performance of Iterative Reconstruction and Automated Tube Voltage Selection on the Image Quality and Radiation Dose in Abdominal CT Scans SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY LA English DT Article DE abdomen; radiation dose; iterative reconstruction; image quality ID FILTERED BACK-PROJECTION; HEPATIC ARTERIAL PHASE; COMPUTED-TOMOGRAPHY; MULTIDETECTOR CT; REDUCTION; ALGORITHM; LIVER; MDCT; EXPOSURE; IMPACT AB Objective: To study the impact of sinogram-affirmed iterative reconstruction (SAFIRE) and concurrent application of automated tube voltage selection (ATVS) on image quality (IQ) and radiation dose. Methods: A phantom was scanned using various computed tomography (CT) parameters (kV, 80-120; mAs, 50-200). Abdomen contrast-enhanced CT (CECTs) in 170 adults were performed using dose-modified protocols: in 145 patients (group I), ATVS was applied (mAs, 111-649); in 25 (group II), the kV was fixed at 120 (reference mAs, 150). In 95 patients, standard-dose (SD) scan was available. Two readers evaluated the IQ of filtered back projection (FBP) and SAFIRE (levels 1, 3, and 5) images. Results: In phantom, nonlinear drop in noise with increasing strengths of IR (levels S1-S5) was noted. The dose-modified IR scan was rated diagnostic in all 170 patients, with IQ score comparable to that of SD-FBP (P = 0.3). Lower kV (100/80) was prescribed by ATVS in 70% examinations in group I. In comparison with SD-FBP, the mean dose in CT dose index in group I (IR, 3.2 mGy; SD-FBP, 13.02 mGy; P < 0.0001) and in group II (IR, 4.8 mGy; SD-FBP, 11.8 mGy; P < 0.001) was 75.4% and 59.3% lower. Conclusions: Use of SAFIRE and ATVS provides diagnostic quality images at 59.3% to 75.4% reduced dose compared with SD-FBP scan. C1 [Desai, Gaurav S.; Orrego, Jorge M. Fuentes; Kambadakone, Avinash R.; Sahani, Dushyant V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Abdominal Imaging & Intervent,Dept Radiol, Boston, MA 02114 USA. RP Sahani, DV (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Abdominal Imaging & Intervent,Dept Radiol, Boston, MA 02114 USA. EM dsahani@partners.org OI Fuentes-Orrego, Jorge/0000-0002-9254-0746 NR 41 TC 17 Z9 17 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0363-8715 EI 1532-3145 J9 J COMPUT ASSIST TOMO JI J. Comput. Assist. Tomogr. PD NOV-DEC PY 2013 VL 37 IS 6 BP 897 EP 903 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 298UC UT WOS:000330349000009 PM 24270111 ER PT J AU Brownell, H Lundgren, K Cayer-Meade, C Milione, J Katz, DI Kearns, K AF Brownell, Hiram Lundgren, Kristine Cayer-Meade, Carol Milione, Janet Katz, Douglas I. Kearns, Kevin TI Treatment of Metaphor Interpretation Deficits Subsequent to Traumatic Brain Injury SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE language and communication impairment; metaphor; treatment ID APHASIA; REHABILITATION; DISORDERS; MEMORY; ADULTS AB Objective: To improve oral interpretation of metaphors by patients with traumatic brain injury (TBI). Design: Both single subject experimental design and group analysis. Setting: Patients' homes. Participants: Eight adult patients with moderate to severe traumatic brain injury sustained 3 to 20 years before testing. Intervention: The Metaphor Training Program consisted typically of 10 baseline sessions, 3 to 9 1-hour sessions of structured intervention, and 10 posttraining baseline sessions. Training used extensive practice with simple graphic displays to illustrate semantic associations. Main Outcome Measures: Quality of orally produced metaphor interpretation and accuracy of line orientation judgments served as dependent measures obtained during baseline, training, posttraining, and at a 3- to 4-month follow-up. Untrained line orientation judgments provided a control measure. Results: Group data showed significant improvement in metaphor interpretation but not in line orientation. Six of 8 patients individually demonstrated significant improvement in metaphor interpretation. Gains persisted for 3 of the 6 patients at the 3- to 4-month follow-up. Conclusion: The Metaphor Training Program can improve cognitive-communication performance for individuals with moderate to severe traumatic brain injury. Results support the potential for treating patients' residual cognitive-linguistic deficits. C1 [Brownell, Hiram] Boston Coll, Chestnut Hill, MA 02467 USA. [Brownell, Hiram; Lundgren, Kristine; Cayer-Meade, Carol; Milione, Janet; Katz, Douglas I.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Brownell, Hiram; Lundgren, Kristine; Cayer-Meade, Carol; Milione, Janet] VA Boston Healthcare Syst, West Roxbury, MA USA. [Lundgren, Kristine] Univ N Carolina, Greensboro, NC 27412 USA. [Katz, Douglas I.] Braintree Rehabil Hosp, Braintree, MA USA. [Kearns, Kevin] SUNY Coll Fredonia, Fredonia, NY 14063 USA. RP Brownell, H (reprint author), Boston Coll, Dept Psychol, Chestnut Hill, MA 02467 USA. EM hiram.brownell@bc.edu FU National Institute of Deafness and Other Communication Disorders [R21 DC007165, P30 DC05432, RO1DC0520702]; Research Service of the Boston VA Healthcare System FX The study was supported by the National Institute of Deafness and Other Communication Disorders grants R21 DC007165, P30 DC05432, and RO1DC0520702 as well as the Research Service of the Boston VA Healthcare System. NR 32 TC 2 Z9 2 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 EI 1550-509X J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD NOV-DEC PY 2013 VL 28 IS 6 BP 446 EP 452 DI 10.1097/HTR.0b013e31825b5e85 PG 7 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 299AA UT WOS:000330365200009 PM 22832370 ER PT J AU Raposo, RAS Abdel-Mohsen, M Holditch, SJ Kuebler, PJ Cheng, RG Eriksson, EM Liao, W Pillai, SK Nixon, DF AF Raposo, Rui Andre Saraiva Abdel-Mohsen, Mohamed Holditch, Sara J. Kuebler, Peter J. Cheng, Rex G. Eriksson, Emily M. Liao, Wilson Pillai, Satish K. Nixon, Douglas F. TI Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE restriction factors; HIV-1; HLA class I ID HIV-1 INFECTION; IN-VITRO; SAMHD1 RESTRICTS; T-LYMPHOCYTES; CCR5; REPLICATION; PROGRESSION; ALLELE; CELLS; VIVO AB The genetic background of HIV-1-infected subjects, particularly the HLA class I haplotype, appears to be critical in determining disease progression rates, thought to be a result of the role of HIV-1-specific CD8(+) T cell responses. The HLA-B*57 allele is strongly associated with viremic suppression and slower disease progression. However, there is considerable heterogeneity in HIV-1 disease progression rates among HLAB* 57-positive subjects, suggesting that additional factors may help to contain viral replication. In this report, we investigated the association between host restriction factors, other established immunological parameters, and HLA type in HIV-1-seronegative individuals. Our results demonstrate that healthy, uninfected HLA-B*57-positive individuals exhibit significantly higher gene-expression levels of host restriction factors, such as APOBEC3A, APOBEC3B, BST-2/tetherin, and ISG15. Interestingly, HLA-B*57 individuals have significantly lower CD4(+) T cell frequencies but harbor slightly more activated CD4(+) T cells compared with their HLA-B*35 counterparts. We detected significant correlations between CD4(+) T cell activation and expression of several APOBEC3 family members, BST-2/tetherin, SAMHD1, and TRIM5 alpha in HLA-B*57-positive individuals. To our knowledge, this is the first report showing distinct associations between host restriction factors and HLA class I genotype. Our results provide insights into natural protection mechanisms and immunity against HIV-1 that fall outside of classical HLA-mediated effects. C1 [Raposo, Rui Andre Saraiva; Holditch, Sara J.; Kuebler, Peter J.; Cheng, Rex G.; Eriksson, Emily M.; Nixon, Douglas F.] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94110 USA. [Abdel-Mohsen, Mohamed; Pillai, Satish K.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA. [Liao, Wilson] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94110 USA. [Pillai, Satish K.] Blood Syst Res Inst, San Francisco, CA USA. [Pillai, Satish K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Nixon, DF (reprint author), Univ Calif San Francisco, Div Expt Med, 1001 Potrero Ave,Bldg 3,Room 603,Box 1234, San Francisco, CA 94110 USA. EM douglas.nixon@ucsf.edu OI Nixon, Douglas/0000-0002-2801-1786; Raposo, R. Andre/0000-0001-5435-0290 FU U.S. National Institutes of Health (NIH) [AI093179, 1K01DA024654, K08AR057763]; Peter and Shelagh Godsoe Family Foundation thorough the AIDS Research Institute at UCSF; UCSF-Gladstone Institute of Virology & Immunology Center for AIDS Research [P30-AI027763]; Academic Senate under UCSF Resource Allocation Program; Howard Hughes Medical Institute; American-Scandinavian Foundation; Creative and Novel Ideas in HIV Research Program [P30 AI027767-24]; National Institute of Allergies and Infectious Diseases; U.S. NIH; International AIDS Society; Office of AIDS Research FX This work was supported by grants from the U.S. National Institutes of Health (NIH)(AI093179 to D.F.N.; 1K01DA024654 to S. K. P.; and K08AR057763 to W. L.), the Peter and Shelagh Godsoe Family Foundation thorough the AIDS Research Institute at UCSF (to P.J.K. and D.F.N.), the UCSF-Gladstone Institute of Virology & Immunology Center for AIDS Research (P30-AI027763 to R. A. S. R.), and, in part, from a grant provided by the Academic Senate under UCSF Resource Allocation Program awards (to D.F.N.). Fellowship funding was provided from the Howard Hughes Medical Institute to R. G. C. and from the American-Scandinavian Foundation to E. M. E. Further funding was from the Creative and Novel Ideas in HIV Research Program through a supplement to the University of Alabama at Birmingham Center for AIDS Research funding (P30 AI027767-24 to W. L.), made possible by collaborative efforts of the Office of AIDS Research; National Institute of Allergies and Infectious Diseases, U.S. NIH; and International AIDS Society. NR 44 TC 8 Z9 8 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 EI 1938-3673 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD NOV PY 2013 VL 94 IS 5 BP 1051 EP 1059 DI 10.1189/jlb.0313150 PG 9 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 301MZ UT WOS:000330537700021 PM 23929683 ER PT J AU Pedrelli, P Nyer, M Holt, D Bakow, BR Fava, M Baer, L Cassiello, C Mulligan, M Cusin, C Farabaugh, A AF Pedrelli, Paola Nyer, Maren Holt, Daphne Bakow, Brianna R. Fava, Maurizio Baer, Lee Cassiello, Clair Mulligan, Maura Cusin, Cristina Farabaugh, Amy TI Correlates of Irritability in College Students With Depressive Symptoms SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE Depression; irritability; young adults; risky behavior ID ALCOHOL-USE DISORDERS; IDENTIFICATION TEST AUDIT; SEQUENCED TREATMENT ALTERNATIVES; GENDER-DIFFERENCES; ANXIETY DISORDERS; RELIEVE DEPRESSION; SUICIDE IDEATION; SUBSTANCE-ABUSE; ANGER ATTACKS; QUESTIONNAIRE AB Depression is a prevalent psychiatric disorder associated with significant personal and societal burden. There is accumulating evidence for the presence of a subtype of depression characterized by the presence of irritability that is associated with increased morbidity, risk for suicidal ideation, and functional impairments in adults. Little is known about the features of depressive symptoms with and without irritability among young adults in college. The primary aim of this study was to characterize the presentation of college students with depressive symptoms and irritability. Two-hundred eighty-seven undergraduate college students with depressive symptoms with and without irritability were compared across several psychiatric and functional outcome variables. Independent samples t-tests or logistic regressions were conducted for each outcome variable using the irritability item of the Beck Depression Inventory as a dichotomous grouping variable. Analyses were conducted separately for the men and the women. Both male and female students with depressive symptoms and severe irritability reported a greater severity of depressive symptoms compared with their peers with no or mild irritability. In the women, the presence of irritability was associated with greater symptoms of anxiety, whereas in the men, it was associated with increased likelihood of engaging in risky behaviors, including compulsive use of alcohol, illicit drugs, and prescription drugs. The male and female college students with depressive symptoms with and without irritability did not differ on severity of suicidal ideation, hopelessness, or cognitive functioning. The findings from this study suggest that depressive symptoms and irritability may characterize a subtype of college students who have a greater symptom burden and with the potential need for more aggressive and prompt treatment. C1 [Pedrelli, Paola; Nyer, Maren; Holt, Daphne; Bakow, Brianna R.; Fava, Maurizio; Baer, Lee; Cassiello, Clair; Cusin, Cristina; Farabaugh, Amy] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. [Mulligan, Maura] Wentworth Inst Technol, Boston, MA USA. RP Pedrelli, P (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, One Bowdoin Sq,6th Floor, Boston, MA 02114 USA. EM ppadrelli@partners.org FU JED foundation FX This project was supported by a grant from the JED foundation. NR 47 TC 5 Z9 5 U1 2 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 EI 1539-736X J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD NOV PY 2013 VL 201 IS 11 BP 953 EP 958 DI 10.1097/NMD.0000000000000038 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 299DU UT WOS:000330376300006 PM 24177482 ER PT J AU Haggerty, G Kahoud, D Walsh, E Ahmed, Z Blais, MA AF Haggerty, Greg Kahoud, Dustin Walsh, Eric Ahmed, Zain Blais, Mark A. TI A Brief Inpatient Measure of Global Psychiatric Symptom Severity Initial Validation of the Brief Symptom Measure-25 for an Adolescent Inpatient Sample SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE Inpatient; adolescent; global symptom severity; outcome; assessment ID CHILD-BEHAVIOR CHECKLIST; SCHWARTZ OUTCOME SCALE-10; QUALITY-OF-LIFE; MENTAL-HEALTH; VALIDITY; VALIDATION; ATTACHMENT; DISTRESS; VERSION AB Adolescent psychiatry is experiencing a growing need for brief yet psychometrically robust outcome measures for inpatient settings. Outcome measures currently available present limitations to clinicians and patients alike in terms of their excessive length, time of completion, difficulty to score, and focus on specific clusters of symptoms. The present study sought to validate the Brief Symptom Measure-25 (BSM-25) as a brief and easily administered measure of global psychiatric symptom severity in adolescent inpatient samples. This study evaluated the results from 154 adolescent inpatients who completed several self-report measures at admission. The findings demonstrate that the instrument has good construct validity when compared with validated measures of psychological health and well-being, behavioral problems, and interpersonal distress. We also showed the sensitivity to change of the BSM-25 from admission to discharge, and we showed that this healthy change was paralleled in several measures (self-reports and clinician ratings), using data from 75 adolescent psychiatric inpatients who were assessed at admission and also at discharge. Although this is only the first step in the validation of this measure for an adolescent inpatient setting, the BSM-25 shows promise as a brief outcome measure of global psychiatric symptom severity while maintaining validity and instrument sensitivity. C1 [Haggerty, Greg; Walsh, Eric; Ahmed, Zain] Nassau Univ Med Ctr, Von Tauber Inst Global Psychiat, E Meadow, NY USA. [Kahoud, Dustin] Long Isl Univ, Brookville, NY USA. [Blais, Mark A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Haggerty, G (reprint author), 320 First Ave, Massapequa Pk, NY 11762 USA. EM Ghag541@aol.com FU American Psychoanalytic Association FX This study was supported in part by a research grant awarded to the first author from the American Psychoanalytic Association. NR 30 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 EI 1539-736X J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD NOV PY 2013 VL 201 IS 11 BP 971 EP 976 DI 10.1097/NMD.0000000000000040 PG 6 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 299DU UT WOS:000330376300009 PM 24177485 ER PT J AU Hower, H Case, BG Hoeppner, B Yen, S Goldstein, T Goldstein, B Birmaher, B Weinstock, L Topor, D Hunt, J Strober, M Ryan, N Axelson, D Gill, MK Keller, MB AF Hower, Heather Case, Brady G. Hoeppner, Bettina Yen, Shirley Goldstein, Tina Goldstein, Benjamin Birmaher, Boris Weinstock, Lauren Topor, David Hunt, Jeffrey Strober, Michael Ryan, Neal Axelson, David Gill, Mary Kay Keller, Martin B. TI Use of Mental Health Services in Transition Age Youth with Bipolar Disorder SO JOURNAL OF PSYCHIATRIC PRACTICE LA English DT Article DE bipolar disorder; longitudinal studies; treatment use; transition-age youth; children; adolescents ID FAMILY-FOCUSED TREATMENT; COMORBIDITY SURVEY REPLICATION; RANDOMIZED CONTROLLED-TRIAL; FOLLOW-UP EVALUATION; SUPPLEMENT NCS-A; SPECTRUM DISORDERS; EARLY INTERVENTION; EARLY PSYCHOSIS; ADOLESCENTS; CHILDREN AB Objectives. There is concern that treatment of serious mental illness in the United States declines precipitously following legal emancipation at age 18 years and transition from specialty youth clinical settings. We examined age transition effects on treatment utilization in a sample of youth with bipolar disorder. Methods. Youth with bipolar disorder (N = 413) 7-18 years of age were assessed approximately twice per year (mean interval 8.2 months) for at least 4 years. Annual use of any individual, group, and family therapy, psychopharmacology visits, and hospitalization at each year of age, and monthly use from ages 17 through 19 years, were examined. The effect of age transition to 18 years on monthly visit probability was tested in the subsample with observed transitions (n = 204). Putative sociodemographic moderators and the influence of clinical course were assessed. Results. Visit probabilities for the most common modalities-psychopharmacology, individual psychotherapy, and home-based care-generally fell from childhood to young adulthood. For example, the annual probability of at least one psychopharmacology visit was 97% at age 8, 75% at age 17, 60% at age 19, and 46% by age 22. Treatment probabilities fell in transition-age youth from age 17 through 19, but a specific transition effect at age 18 was not found. Declines did not vary based on sociodemographic characteristics and were not explained by changing severity of the bipolar illness or functioning. Conclusions. Mental health treatment declined with age in this sample of youth with bipolar disorder, but reductions were not concentrated during or after the transition to age 18 years. Declines were unrelated to symptom severity or impairment. C1 [Hower, Heather; Weinstock, Lauren] Brown Univ, Providence, RI 02912 USA. [Hower, Heather; Weinstock, Lauren; Keller, Martin B.] Butler Hosp, Providence, RI 02906 USA. [Case, Brady G.; Hunt, Jeffrey] Brown Univ, East Providence, RI USA. [Case, Brady G.; Hunt, Jeffrey] Emma Pendleton Bradley Hosp, East Providence, RI USA. [Hoeppner, Bettina] Massachusetts Gen Hosp, Cambridge, MA USA. [Hoeppner, Bettina; Topor, David] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Goldstein, Tina; Birmaher, Boris; Ryan, Neal; Gill, Mary Kay] Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Goldstein, Tina; Birmaher, Boris; Ryan, Neal; Gill, Mary Kay] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Goldstein, Benjamin] Univ Toronto, Sunnybrook Hlth Sci Ctr, Ctr Youth Bipolar Disorder, Toronto, ON M5S 1A1, Canada. [Topor, David] VA Boston Healthcare Syst, Boston, MA USA. [Strober, Michael] Univ Calif Los Angeles, Los Angeles, CA USA. [Axelson, David] Nationwide Childrens Hosp, Columbus, OH USA. RP Hower, H (reprint author), Brown Univ, Dept Psychiat & Human Behav, Box G BH, Providence, RI 02912 USA. RI Case, Brady/M-1879-2015; OI Case, Brady/0000-0001-9512-0416; Weinstock, Lauren/0000-0001-9970-235X FU NIDA [K12 DA000357-11]; American Academy of Child and Adolescent Psychiatry Eli Lilly Pilot Research Award; American Psychiatric Association AstraZeneca Young Minds in Psychiatry Award; NIH [K01 DA027097]; Brown University; NIMH; NIDA; NICHD; Pittsburgh Foundation; Ryan Licht Sang Bipolar Foundation,; Maine Center for Disease Control and Prevention, Youth Suicide Prevention Program; Pfizer; Pittsburgh Fine Foundation; National Institute of Mental Health (NIMH) [MH59691, MH59929, MH59977] FX Dr. Case's work on this project was supported in part by NIDA K12 DA000357-11 (trainee Dr. Case); he has received research grant support from the American Academy of Child and Adolescent Psychiatry Eli Lilly Pilot Research Award and the American Psychiatric Association AstraZeneca Young Minds in Psychiatry Award, and is a consultant for Optum Behavioral Health and Blue Cross Blue Shield of Rhode Island. Dr. Hoeppner has received research grant support from NIH K01 DA027097, has served as consultant, received fees for statistical analyses, and payment for lectures from Brown University, and is employed by Massachusetts General Hospital as a research faculty member. Dr. Yen has received research grant support from NIMH. Dr. T Goldstein has received research grant support from NIMH, NIDA, NICHD, The Pittsburgh Foundation, and The Ryan Licht Sang Bipolar Foundation, payment for lectures at the Mental Health America of Franklin County, Columbus, OH, and the Maine Center for Disease Control and Prevention, Youth Suicide Prevention Program, royalties from Guilford Press, and is employed at the University of Pittsburgh Medical Center. Dr. B Goldstein has received research grant support from Pfizer, honorarium from Purdue Pharma, and is a consultant for BMS. Dr. Birmaher has received research grant support from NIMH and The Pittsburgh Fine Foundation, royalties from Random House, Lippincott Williams & Wilkins, and UpToDate, and is employed at the University of Pittsburgh Medical Center. Dr. Hunt has received research grant support from NIMH, and is the Senior Editor for The Brown University Child and Adolescent Psychopharmacology Update (published by John Wiley and Sons). Dr. Strober received payment for reviewing the manuscript. Dr. Ryan has received research grant support from NIMH, is on the scientific advisory board for the Child Mind Institute, and is employed at the University of Pittsburgh Medical Center. Dr. Axelson has received research grant support from NIMH; he was previously employed at the University of Pittsburgh Medical Center (he transitioned to Nationwide Children's Hospital in July 2013). Dr. Keller has received research grant support from Pfizer and NIMH, honoraria from CENEREX, Medtronic, and Sierra Neuropharma ceuticals, and is on the advisory board for CENEREX. The remaining authors have no disclosures.; The project described in this article was supported by National Institute of Mental Health (NIMH) Grants MH59691 (to Drs. Keller/Yen), MH59929 (to Dr. Birmaher), and MH59977 (to Dr. Strober). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIMH or the National Institutes of Health. NR 58 TC 3 Z9 3 U1 3 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1527-4160 EI 1538-1145 J9 J PSYCHIATR PRACT JI J. Psychiatr. Pract. PD NOV PY 2013 VL 19 IS 6 BP 464 EP 476 DI 10.1097/01.pra.0000438185.81983.8b PG 13 WC Psychiatry SC Psychiatry GA 300CD UT WOS:000330441100004 PM 24241500 ER PT J AU Muhammed, M Anagnostou, T Desalermos, A Kourkoumpetis, TK Carneiro, HA Glavis-Bloom, J Coleman, JJ Mylonakis, E AF Muhammed, Maged Anagnostou, Theodora Desalermos, Athanasios Kourkoumpetis, Themistoklis K. Carneiro, Herman A. Glavis-Bloom, Justin Coleman, Jeffrey J. Mylonakis, Eleftherios TI Fusarium Infection Report of 26 Cases and Review of 97 Cases From the Literature SO MEDICINE LA English DT Review ID ACUTE LYMPHOBLASTIC-LEUKEMIA; OF-THE-LITERATURE; LIPOSOMAL AMPHOTERICIN-B; STEM-CELL TRANSPLANTATION; INVASIVE FUNGAL DISEASE; ACUTE MYELOID-LEUKEMIA; CUTANEOUS INFECTION; OXYSPORUM INFECTION; IMMUNOCOMPROMISED PATIENT; PERITONEAL-DIALYSIS AB Fusarium species is a ubiquitous fungus that causes opportunistic infections. We present 26 cases of invasive fusariosis categorized according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria of fungal infections. All cases (20 proven and 6 probable) were treated from January 2000 until January 2010. We also review 97 cases reported since 2000. The most important risk factors for invasive fusariosis in our patients were compromised immune system, specifically lung transplantation (n = 6) and hematologic malignancies (n = 5), and burns (n = 7 patients with skin fusariosis), while the most commonly infected site was the skin in 11 of 26 patients. The mortality rates among our patients with disseminated, skin, and pulmonary fusariosis were 50%, 40%, and 37.5%, respectively. Fusarium solani was the most frequent species, isolated from 49% of literature cases. Blood cultures were positive in 82% of both current study and literature patients with disseminated fusariosis, while the remaining 16% had 2 noncontiguous sites of infection but negative blood cultures. Surgical removal of focal lesions was effective in both current study and literature cases. Skin lesions in immunocompromised patients should raise the suspicion for skin or disseminated fusariosis. The combination of medical monotherapy with voriconazole or amphotericin B and surgery in such cases is highly suggested. C1 [Muhammed, Maged; Anagnostou, Theodora; Desalermos, Athanasios; Kourkoumpetis, Themistoklis K.; Carneiro, Herman A.; Glavis-Bloom, Justin; Coleman, Jeffrey J.; Mylonakis, Eleftherios] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA USA. [Anagnostou, Theodora; Coleman, Jeffrey J.; Mylonakis, Eleftherios] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Infect Dis, Providence, RI 02903 USA. RP Mylonakis, E (reprint author), Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, 593 Eddy St, Providence, RI 02903 USA. EM emylonakis@lifespan.org RI Coleman, Jeffrey/E-2981-2015; OI Coleman, Jeffrey/0000-0001-8579-1996; Glavis-Bloom, Justin/0000-0002-4879-1572 FU National Institutes of Health [P01 AI 083214, AI075286, AI079569, T32 AI007061] FX This research was supported by a National Institutes of Health grant P01 AI 083214, a R01 award AI075286 and a R21 award AI079569 to EM, and a T32 AI007061 to JJC. The authors have no conflicts of interest to disclose. NR 140 TC 32 Z9 32 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD NOV PY 2013 VL 92 IS 6 BP 305 EP 316 DI 10.1097/MD.0000000000000008 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 300KM UT WOS:000330462800002 PM 24145697 ER PT J AU Tracy, EE Zephyrin, LC Rosman, DA Berkowitz, LR AF Tracy, Erin E. Zephyrin, Laurie C. Rosman, David A. Berkowitz, Lori R. TI Credentialing Based on Surgical Volume, Physician Workforce Challenges, and Patient Access SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID LAPAROSCOPIC HYSTERECTOMY; UNITED-STATES; VAGINAL HYSTERECTOMY; SURGEON VOLUME; COLON-CANCER; OUTCOMES; CARE AB Advances within the medical profession have resulted in an increase in available medical therapeutic options and minimally invasive surgical techniques for common gynecologic conditions. In many circumstances, this has led to a reduction in surgical volume for many common conditions in benign gynecology. There is also some evidence that a threshold number of cases may exist, below which surgical competence may be affected. Although the practice of medicine continues to evolve, there is broad recognition of a projected workforce shortage of physicians. If credentialing or privileging bodies establish criteria based solely on the number of procedures performed by an individual physician, patient access may be greatly affected. From a public health perspective, these issues cannot be considered in isolation. Thoughtful analysis of existing data and recognition of patient access issues should be carefully weighed before any dramatic changes in hospital privileging or hiring practices. Consideration for ongoing maintenance of credentialing should be carefully balanced and strategies for ongoing assurance of competency may require creative alternatives to simple numerical documentation. Differential approaches to regions with different densities of physicians may also be necessary. C1 [Tracy, Erin E.] Massachusetts Gen Hosp, Boston, MA 02180 USA. Veteran Hlth Adm, Off Patient Care Serv, Womens Hlth Serv, Washington, DC USA. RP Tracy, EE (reprint author), Massachusetts Gen Hosp, 406 Fruit St, Boston, MA 02180 USA. EM EETracy@partners.org NR 29 TC 5 Z9 5 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD NOV PY 2013 VL 122 IS 5 BP 947 EP 951 DI 10.1097/AOG.0b013e3182a5fde5 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 300EZ UT WOS:000330448500004 PM 24104770 ER PT J AU Hung, KJ Tsai, AC Johnson, TRB Walensky, RP Bangsberg, DR Kerry, VB AF Hung, Kristin J. Tsai, Alexander C. Johnson, Timothy R. B. Walensky, Rochelle P. Bangsberg, David R. Kerry, Vanessa B. TI Scope of Global Health Training in US Obstetrics and Gynecology Residency Programs SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID SETTING PRIORITIES; RESEARCH INVESTMENTS; DEVELOPING-COUNTRIES; SYSTEMATIC ANALYSIS; SURGICAL DISEASE; PUBLIC-HEALTH; SURGERY; OPPORTUNITIES; CAPACITY; AFRICA AB OBJECTIVE: To enumerate global health training activities in U. S. obstetrics and gynecology residency programs and to examine the worldwide distribution of programmatic activity relative to the maternal and perinatal disease burden. METHODS: Using a systematic, web-based protocol, we searched for global health training opportunities at all U. S. obstetrics and gynecology residency programs. Country-level data on disability-adjusted life-years resulting from maternal and perinatal conditions were obtained from the Global Burden of Disease study. We calculated Spearman's rank correlation coefficients to estimate the cross-country association between programmatic activity and disease burden. RESULTS: Of the 243 accredited U. S. obstetrics and gynecology residency programs, we identified 41 (17%) with one of several possible predefined categories of programmatic activity. Thirty-three residency programs offered their residents opportunities to participate in one or more elective-based rotations, eight offered extended field-based training, and 18 offered research activities. A total of 128 programmatic activities were dispersed across 64 different countries. At the country level, the number of programmatic activities had a statistically significant association with the total disease burden resulting from maternal (Spearman's rho=0.37, 95% confidence interval [CI] 0.14-0.57) and perinatal conditions (rho=0.34, 95% CI 0.10-0.54) but not gynecologic cancers (rho=-0.24, 95% CI -0.46 to 0.01). CONCLUSIONS: There are few global health training opportunities for U. S. obstetrics and gynecology residents. These activities are disproportionately distributed among countries with greater burdens of disease. C1 [Hung, Kristin J.] Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Boston, MA 02215 USA. Harvard Univ, Massachusetts Gen Hosp, Ctr Global Hlth, Dept Psychiat,MD Div Global Psychiat, Cambridge, MA 02138 USA. Harvard Univ, Massachusetts Gen Hosp, Dept Med, Div Pulm & Crit Care, Cambridge, MA 02138 USA. Harvard Univ, Massachusetts Gen Hosp, Dept Med, Div Gen Med, Cambridge, MA 02138 USA. Harvard Univ, Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Cambridge, MA 02138 USA. Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Infect Dis, Cambridge, MA 02138 USA. Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA. Univ Michigan Hlth Syst, Dept Obstet & Gynecol, Ann Arbor, MI USA. Mbarara Univ Sci & Technol, Mbarara, Uganda. RP Hung, KJ (reprint author), Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, 330 Brookline Ave,East Campus,Kirstein 317, Boston, MA 02215 USA. EM khung@bidmc.harvard.edu RI yan, liu/A-1822-2015; OI yan, liu/0000-0001-8517-1084; Walensky, Rochelle P./0000-0002-8795-379X; Tsai, Alexander/0000-0001-6397-7917 FU Mark and Lisa Schwartz Foundation; Klingenstein Family Foundation; Harvard University Center for AIDS Research, through U.S. National Institutes of Health (NIH) [P30AI060354]; NIH [K23MH096620, R01AI058736, K24MH087227] FX Supported by the Mark and Lisa Schwartz Foundation; the Klingenstein Family Foundation; and the Harvard University Center for AIDS Research, through U.S. National Institutes of Health (NIH) P30AI060354. The authors also acknowledge salary support from NIH K23MH096620 (A. C. T.), NIH R01AI058736 (R. P. W.), and NIH K24MH087227 (D.R.B.). NR 38 TC 10 Z9 10 U1 3 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 EI 1873-233X J9 OBSTET GYNECOL JI Obstet. Gynecol. PD NOV PY 2013 VL 122 IS 5 BP 1101 EP 1109 DI 10.1097/AOG.0b013e3182a9c1c8 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 300EZ UT WOS:000330448500024 PM 24104785 ER PT J AU Burkhardt, UE Wu, CJ AF Burkhardt, Ute E. Wu, Catherine J. TI Boosting leukemia-specific T cell responses in patients following stem cell transplantation SO ONCOIMMUNOLOGY LA English DT Editorial Material DE cancer vaccines; CLL; immune reconstitution; multiepitope vaccines; neoantigens; stem cell transplantation; whole tumor-cell vaccination ID CHRONIC LYMPHOCYTIC-LEUKEMIA; VACCINES; IMMUNITY AB Whole tumor cell-based vaccines administered within the first 2 to 3 months after allogeneic stem cell transplantation stand out as a promising approach to enhance graft-vs.-leukemia responses. herein, the implications of this finding for the development of strategies to improve the outcome of patients subjected to allogeneic stem cell transplantation are discussed. C1 [Burkhardt, Ute E.; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Dept Med Oncol, Boston, MA 02115 USA. [Wu, Catherine J.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA USA. RP Wu, CJ (reprint author), Dana Farber Canc Inst, Canc Vaccine Ctr, Dept Med Oncol, Boston, MA 02115 USA. EM cwu@partners.org FU NCI NIH HHS [R01 CA155010] NR 10 TC 1 Z9 1 U1 0 U2 0 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 2162-4011 EI 2162-402X J9 ONCOIMMUNOLOGY JI OncoImmunology PD NOV PY 2013 VL 2 IS 11 AR e26587 DI 10.4161/onci.26587 PG 3 WC Oncology; Immunology SC Oncology; Immunology GA 299VU UT WOS:000330424600032 PM 24482749 ER PT J AU Schietinger, A Arina, A Liu, RB Wells, S Huang, JH Engels, B Bindokas, V Bartkowiak, T Lee, D Herrmann, A Piston, DW Pittet, MJ Lin, PC Zal, T Schreiber, H AF Schietinger, Andrea Arina, Ainhoa Liu, Rebecca B. Wells, Sam Huang, Jianhua Engels, Boris Bindokas, Vytas Bartkowiak, Todd Lee, David Herrmann, Andreas Piston, David W. Pittet, Mikael J. Lin, P. Charles Zal, Tomasz Schreiber, Hans TI Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer SO ONCOIMMUNOLOGY LA English DT Article DE imaging; cancer; tumor microenvironment; tumor immunology; CD8 T cell; stroma ID ANTIGENIC CANCER-CELLS; SUPPRESSOR-CELLS; STROMAL FIBROBLASTS; ESTABLISHED TUMORS; IMMUNE SUPPRESSION; CROSS-PRESENTATION; INTERFERON-GAMMA; LOSS VARIANTS; EXPRESSION; ERADICATION AB A fluorescence-based, high-resolution imaging approach was used to visualize longitudinally the cellular events unfolding during T cell-mediated tumor destruction. The dynamic interplay of T cells, cancer cells, cancer antigen loss variants, and stromal cells-all color-coded in vivo-was analyzed in established, solid tumors that had developed behind windows implanted on the backs of mice. Events could be followed repeatedly within precisely the same tumor region-before, during and after adoptive T cell therapy-thereby enabling for the first time a longitudinal in vivo evaluation of protracted events, an analysis not possible with terminal imaging of surgically exposed tumors. T cell infiltration, stromal interactions, and vessel destruction, as well as the functional consequences thereof, including the elimination of cancer cells and cancer cell variants were studied. Minimal perivascular T cell infiltrates initiated vascular destruction inside the tumor mass eventually leading to macroscopic central tumor necrosis. Prolonged engagement of T cells with tumor antigen-crosspresenting stromal cells correlated with high IFN gamma cytokine release and bystander elimination of antigen-negative cancer cells. The high-resolution, longitudinal, in vivo imaging approach described here will help to further a better mechanistic understanding of tumor eradication by T cells and other anti-cancer therapies. C1 [Schietinger, Andrea; Arina, Ainhoa; Liu, Rebecca B.; Engels, Boris; Schreiber, Hans] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA. [Wells, Sam; Piston, David W.] Vanderbilt Univ, Sch Med, Dept Physiol & Biophys, Nashville, TN 37212 USA. [Huang, Jianhua; Lin, P. Charles] Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37212 USA. [Huang, Jianhua; Lin, P. Charles] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA. [Bindokas, Vytas] Univ Chicago, Chicago, IL USA. [Bartkowiak, Todd; Zal, Tomasz] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA. [Lee, David] Univ Chicago, Sch Med, Chicago, IL 60637 USA. [Herrmann, Andreas] Dept Canc Immunotherapeut, Duarte, CA USA. [Herrmann, Andreas] Dept Tumor Immunol, Duarte, CA USA. [Pittet, Mikael J.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Pittet, Mikael J.] Harvard Univ, Sch Med, Boston, MA USA. [Lin, P. Charles] NCI, Ctr Canc Res, NIH, Frederick, MD 21701 USA. RP Schreiber, H (reprint author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA. EM hszz@uchicago.edu FU National Institute of Health; NCI; [R01-CA22677]; [R01-CA37516]; [P01-CA97296]; [R01-CA137059] FX We thank Ann Schue for excellent help in arranging the mouse transfers from University of Chicago to Vanderbilt University; Laura DeBusk, Kimberly Boelte, and CarolAnn Bonner for help and technical assistance, Anita Chong, Alexander Chervonsky, Maki Motobu, Karin Schreiber, Heather Booras, David Binder, and Christian Idel for technical advice and helpful discussions, and at the University of Texas MD Anderson Cancer Center, Anna Zal and Felix Nwajei for help with the contextual analysis of cell motility. We thank Mary Philip for critical reading of the manuscript and valuable suggestions. We thank the University of Chicago Cancer Research Center Core facilities, especially R Duggan, D Leclerc and M Olson for expert assistance with cell sorting and flow cytometric analysis, the Vanderbilt Cell Imaging Shared Resource, and Christine Labno, University of Chicago Light Microscopy Core, for technical assistance. This work was supported by National Institute of Health, Activities to Promote Research Collaborations (APRC) program from the NCI, and grants, R01-CA22677, R01-CA37516 and P01-CA97296 to H.S, as well as R01-CA137059 to T.Z. NR 64 TC 20 Z9 20 U1 1 U2 8 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 2162-4011 EI 2162-402X J9 ONCOIMMUNOLOGY JI OncoImmunology PD NOV PY 2013 VL 2 IS 11 AR e26677 DI 10.4161/onci.26677 PG 14 WC Oncology; Immunology SC Oncology; Immunology GA 299VU UT WOS:000330424600003 PM 24482750 ER PT J AU Kamani, D Darr, EA Randolph, GW AF Kamani, Dipti Darr, E. Ashlie Randolph, Gregory W. TI Electrophysiologic Monitoring Characteristics of the Recurrent Laryngeal Nerve Preoperatively Paralyzed or Invaded with Malignancy SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE recurrent laryngeal nerve monitoring; IONM; thyroid malignancy; invasive malignancy; vocal cord paralysis; electrophysiologic parameters; surgery for thyroid cancer; EMG ID THYROID-SURGERY; IDENTIFICATION; MANAGEMENT; DISEASE; VOICE; NECK AB Objective. To elucidate electrophysiologic responses of the recurrent laryngeal nerves that were preoperatively paralyzed or invaded by malignancy and to use this information as an added functional parameter for intraoperative management of recurrent laryngeal nerves with malignant invasion. Study Design. Case series with chart review. Settings. Academic, tertiary care center. Subjects and Methods. All consecutive neck surgeries with nerve monitoring performed by senior author (GWR) between December 1995 and January 2007 were reviewed after obtaining Institutional Review Board approval from Massachusetts Eye and Ear Infirmary Human Subjects Committee and the Partners Human Research Committee. Electrophysiologic parameters in all cases with preoperative vocal cord paralysis/paresis, and the recurrent laryngeal nerve invasion by cancer, were studied. Results. Of the 1138 surgeries performed, 25 patients (2.1%) had preoperative vocal cord dysfunction. In patients with preoperative vocal cord dysfunction, recognizable recurrent laryngeal nerve electrophysiologic activity was preserved in over 50% of cases. Malignant invasion of the recurrent laryngeal nerve was found in 22 patients (1.9%). Neural invasion of the recurrent laryngeal nerve was associated with preoperative vocal cord paralysis in only 50% of these patients. In nerves invaded by malignancy, 60% maintained recognizable electrophysiologic activity, which was more commonly present and robust when vocal cord function was preserved. Conclusion. Knowledge of electrophysiologic intraoperative neural monitoring provides additional functional information and, along with preoperative vocal cord function information, aids in constructing decision algorithms regarding intraoperative management of the recurrent laryngeal nerve, in prognosticating postoperative outcomes, and in patient counseling regarding postoperative expectations. C1 [Kamani, Dipti; Darr, E. Ashlie; Randolph, Gregory W.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Div Thyroid & Parathyroid Surg, Boston, MA USA. [Randolph, Gregory W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Surg Oncol Endocrine Surg Serv, Boston, MA USA. RP Randolph, GW (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Thyroid & Parathyroid Surg, 243 Charles St, Boston, MA 02114 USA. EM Gregory_Randolph@meei.harvard.edu NR 21 TC 7 Z9 7 U1 0 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD NOV PY 2013 VL 149 IS 5 BP 682 EP 688 DI 10.1177/0194599813504735 PG 7 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 301EH UT WOS:000330515100007 PM 24046274 ER PT J AU Cauley, CE Pittman, M Zhou, J Valsangkar, N Liss, A Fernandez-del Castillo, C Warshaw, AL Lillemoe, KD Thayer, SP AF Cauley, C. E. Pittman, M. Zhou, J. Valsangkar, N. Liss, A. Fernandez-del Castillo, C. Warshaw, A. L. Lillemoe, K. D. Thayer, S. P. TI Prognostic Value of Circulating Tumor Cells in Patients With Pancreatic Adenocarcinoma SO PANCREAS LA English DT Meeting Abstract C1 [Cauley, C. E.; Zhou, J.; Valsangkar, N.; Liss, A.; Fernandez-del Castillo, C.; Warshaw, A. L.; Lillemoe, K. D.; Thayer, S. P.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Cauley, C. E.; Zhou, J.; Valsangkar, N.; Liss, A.; Fernandez-del Castillo, C.; Warshaw, A. L.; Lillemoe, K. D.; Thayer, S. P.] Massachusetts Gen Hosp, Warshaw Inst, Boston, MA 02114 USA. [Pittman, M.] Massachusetts Gen Hosp, Dept Cytopathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2013 VL 42 IS 8 BP 1342 EP 1342 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 300MQ UT WOS:000330468400050 ER PT J AU Holland, CT Odinokova, IV Lugea, A Shalbueva, N Mareninova, OA Gukovsky, I Gukovskaya, AS AF Holland, C. T. Odinokova, I. V. Lugea, A. Shalbueva, N. Mareninova, O. A. Gukovsky, I. Gukovskaya, A. S. TI Mitochondria Regulate Trypsinogen Activation in Pancreatitis SO PANCREAS LA English DT Meeting Abstract C1 VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2013 VL 42 IS 8 BP 1354 EP 1354 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 300MQ UT WOS:000330468400099 ER PT J AU Li, L Waldron, RT Lugea, A Pandol, SJ AF Li, L. Waldron, R. T. Lugea, A. Pandol, S. J. TI Hyperglycemia and Hyperinsulinemia Promote Pancreatic Stellate Cells Activation and Galectin-3 Expression: Potential Role in Pancreatic Cancer Development SO PANCREAS LA English DT Meeting Abstract C1 [Li, L.; Waldron, R. T.; Lugea, A.; Pandol, S. J.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Waldron, R. T.; Lugea, A.; Pandol, S. J.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Li, L.] Southeast Univ, Zhongda Hosp, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China. NR 0 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2013 VL 42 IS 8 BP 1362 EP 1363 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 300MQ UT WOS:000330468400132 ER PT J AU Marchegiani, G Kenudson, MM Morales-Oyarvide, V Thayer, S Ferrone, C Warshaw, AL Lillemoe, K Fernandez-del Castillo, C AF Marchegiani, G. Kenudson, M. Mino Morales-Oyarvide, V. Thayer, S. Ferrone, C. Warshaw, A. L. Lillemoe, K. Fernandez-del Castillo, C. TI IPMN Involving the Main Pancreatic Duct: Biology, Epidemiology, and Long-Term Outcomes Following Resection SO PANCREAS LA English DT Meeting Abstract C1 [Marchegiani, G.; Thayer, S.; Ferrone, C.; Warshaw, A. L.; Lillemoe, K.; Fernandez-del Castillo, C.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Kenudson, M. Mino; Morales-Oyarvide, V.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2013 VL 42 IS 8 BP 1365 EP 1365 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 300MQ UT WOS:000330468400143 ER PT J AU Perkins, J Pitman, M Fernandez-del Castillo, C Warshaw, AL Lillemoe, K Liss, AS Thayer, SP AF Perkins, J. Pitman, M. Fernandez-del Castillo, C. Warshaw, A. L. Lillemoe, K. Liss, A. S. Thayer, S. P. TI Can Circulating Tumor Cells be Used to Diagnose Pancreatic Ductal Adenocarcinoma in Surgical Candidates? SO PANCREAS LA English DT Meeting Abstract C1 [Perkins, J.; Fernandez-del Castillo, C.; Warshaw, A. L.; Lillemoe, K.; Liss, A. S.; Thayer, S. P.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. [Perkins, J.; Fernandez-del Castillo, C.; Warshaw, A. L.; Lillemoe, K.; Liss, A. S.; Thayer, S. P.] Harvard Univ, Sch Med, Warshaw Inst, Boston, MA USA. [Fernandez-del Castillo, C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2013 VL 42 IS 8 BP 1376 EP 1376 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 300MQ UT WOS:000330468400185 ER PT J AU Yamaguchi, J Mino-Kenudson, M Liss, AS Lillemoe, KD Fernandez-del Castillo, C Warshaw, AL Thayer, SP AF Yamaguchi, J. Mino-Kenudson, M. Liss, A. S. Lillemoe, K. D. Fernandez-del Castillo, C. Warshaw, A. L. Thayer, S. P. TI Loss of TFF2 in Pancreatic Duct Glands (PDG) Results in the Formation of IPMN Suggesting TFF2 May Function as a Tumor Suppressor SO PANCREAS LA English DT Meeting Abstract C1 [Yamaguchi, J.; Liss, A. S.; Lillemoe, K. D.; Fernandez-del Castillo, C.; Warshaw, A. L.; Thayer, S. P.] Massachusetts Gen Hosp, Warshaw Inst, Boston, MA 02114 USA. [Yamaguchi, J.; Liss, A. S.; Lillemoe, K. D.; Fernandez-del Castillo, C.; Warshaw, A. L.; Thayer, S. P.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Mino-Kenudson, M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Mino-Kenudson, M.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2013 VL 42 IS 8 BP 1389 EP 1390 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 300MQ UT WOS:000330468400240 ER PT J AU Yuan, J Liu, Y Tan, T Li, L Pandol, SJ AF Yuan, J. Liu, Y. Tan, T. Li, L. Pandol, S. J. TI Alcohol-induced Experimental Pancreatitis: Role of Protein Kinase D SO PANCREAS LA English DT Meeting Abstract C1 Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2013 VL 42 IS 8 BP 1390 EP 1391 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 300MQ UT WOS:000330468400244 ER PT J AU Walker, JA Gouzi, JY Long, JB Huang, SD Maher, RC Xia, HJ Khalil, K Ray, A Van Vactor, D Bernards, R Bernards, A AF Walker, James A. Gouzi, Jean Y. Long, Jennifer B. Huang, Sidong Maher, Robert C. Xia, Hongjing Khalil, Kheyal Ray, Arjun Van Vactor, David Bernards, Rene Bernards, Andre TI Genetic and Functional Studies Implicate Synaptic Overgrowth and Ring Gland cAMP/PKA Signaling Defects in the Drosophila melanogaster Neurofibromatosis-1 Growth Deficiency SO PLOS GENETICS LA English DT Article ID RECEPTOR TYROSINE KINASE; ANAPLASTIC LYMPHOMA KINASE; GTPASE-ACTIVATING PROTEIN; ANGIOGENIC FACTOR MIDKINE; INSULIN-LIKE PEPTIDES; ADENYLYL-CYCLASE; LIFE-SPAN; FAT-BODY; TUMOR-SUPPRESSOR; EYE DEVELOPMENT AB Neurofibromatosis type 1 (NF1), a genetic disease that affects 1 in 3,000, is caused by loss of a large evolutionary conserved protein that serves as a GTPase Activating Protein (GAP) for Ras. Among Drosophila melanogaster Nf1 (dNf1) null mutant phenotypes, learning/memory deficits and reduced overall growth resemble human NF1 symptoms. These and other dNf1 defects are relatively insensitive to manipulations that reduce Ras signaling strength but are suppressed by increasing signaling through the 3'-5' cyclic adenosine monophosphate (cAMP) dependent Protein Kinase A (PKA) pathway, or phenocopied by inhibiting this pathway. However, whether dNf1 affects cAMP/PKA signaling directly or indirectly remains controversial. To shed light on this issue we screened 486 1st and 2nd chromosome deficiencies that uncover >80% of annotated genes for dominant modifiers of the dNf1 pupal size defect, identifying responsible genes in crosses with mutant alleles or by tissue-specific RNA interference (RNAi) knockdown. Validating the screen, identified suppressors include the previously implicated dAlk tyrosine kinase, its activating ligand jelly belly (jeb), two other genes involved in Ras/ERK signal transduction and several involved in cAMP/PKA signaling. Novel modifiers that implicate synaptic defects in the dNf1 growth deficiency include the intersectin-related synaptic scaffold protein Dap160 and the cholecystokinin receptor-related CCKLR-17D1 drosulfakinin receptor. Providing mechanistic clues, we show that dAlk, jeb and CCKLR-17D1 are among mutants that also suppress a recently identified dNf1 neuromuscular junction (NMJ) overgrowth phenotype and that manipulations that increase cAMP/PKA signaling in adipokinetic hormone (AKH)-producing cells at the base of the neuroendocrine ring gland restore the dNf1 growth deficiency. Finally, supporting our previous contention that ALK might be a therapeutic target in NF1, we report that human ALK is expressed in cells that give rise to NF1 tumors and that NF1 regulated ALK/RAS/ERK signaling appears conserved in man. C1 [Walker, James A.; Gouzi, Jean Y.; Maher, Robert C.; Xia, Hongjing; Khalil, Kheyal; Ray, Arjun; Bernards, Andre] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA. [Walker, James A.; Gouzi, Jean Y.; Maher, Robert C.; Xia, Hongjing; Khalil, Kheyal; Ray, Arjun; Bernards, Andre] Harvard Univ, Sch Med, Charlestown, MA USA. [Walker, James A.; Bernards, Andre] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Long, Jennifer B.; Van Vactor, David] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA. [Huang, Sidong; Bernards, Rene] Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands. RP Walker, JA (reprint author), Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA. EM abernards@helix.mgh.harvard.edu OI Bernards, Rene/0000-0001-8677-3423 FU NIH/NGMS [1-R01 GM084220]; Children's Tumor Foundation; Dutch cancer society [NKI 2009-4496] FX JAW, RCM, HX, KK, AR and AB were supported by NIH/NGMS grant 1-R01 GM084220. AB also received support from an anonymous donor. JYG was supported by Young Investigator Award from the Children's Tumor Foundation. SH and RB were supported by Dutch cancer society grant NKI 2009-4496. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 104 TC 8 Z9 9 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7404 J9 PLOS GENET JI PLoS Genet. PD NOV PY 2013 VL 9 IS 11 AR e1003958 DI 10.1371/journal.pgen.1003958 PG 22 WC Genetics & Heredity SC Genetics & Heredity GA 299BG UT WOS:000330369000040 PM 24278035 ER PT J AU Zhou, GL Beloiartsev, A Yu, BL Baron, DM Zhou, WH Niedra, R Lu, NF Tainsh, LT Zapol, WM Seed, B Bloch, KD AF Zhou, Guo Ling Beloiartsev, Arkadi Yu, Binglan Baron, David M. Zhou, Weihua Niedra, Rasma Lu, Naifang Tainsh, Laurel T. Zapol, Warren M. Seed, Brian Bloch, Kenneth D. TI Deletion of the Murine Cytochrome P450 Cyp2j Locus by Fused BAC-Mediated Recombination Identifies a Role for Cyp2j in the Pulmonary Vascular Response to Hypoxia SO PLOS GENETICS LA English DT Article ID EPOXYGENASE-DERIVED EICOSANOIDS; ARACHIDONIC-ACID METABOLITES; EMBRYONIC STEM-CELLS; EPOXYEICOSATRIENOIC ACIDS; P-450 METABOLITES; VASOCONSTRICTION; MICE; GENE; HYPERTENSION; INJURY AB Epoxyeicosatrienoic acids (EETs) confer vasoactive and cardioprotective functions. Genetic analysis of the contributions of these short-lived mediators to pathophysiology has been confounded to date by the allelic expansion in rodents of the portion of the genome syntenic to human CYP2J2, a gene encoding one of the principle cytochrome P450 epoxygenases responsible for the formation of EETs in humans. Mice have eight potentially functional genes that could direct the synthesis of epoxygenases with properties similar to those of CYP2J2. As an initial step towards understanding the role of the murine Cyp2j locus, we have created mice bearing a 626-kb deletion spanning the entire region syntenic to CYP2J2, using a combination of homologous and site-directed recombination strategies. A mouse strain in which the locus deletion was complemented by transgenic delivery of BAC sequences encoding human CYP2J2 was also created. Systemic and pulmonary hemodynamic measurements did not differ in wild-type, null, and complemented mice at baseline. However, hypoxic pulmonary vasoconstriction (HPV) during left mainstem bronchus occlusion was impaired and associated with reduced systemic oxygenation in null mice, but not in null mice bearing the human transgene. Administration of an epoxygenase inhibitor to wild-type mice also impaired HPV. These findings demonstrate that Cyp2j gene products regulate the pulmonary vascular response to hypoxia. C1 [Zhou, Guo Ling; Zhou, Weihua; Niedra, Rasma; Lu, Naifang; Seed, Brian] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. [Beloiartsev, Arkadi; Yu, Binglan; Baron, David M.; Tainsh, Laurel T.; Zapol, Warren M.; Bloch, Kenneth D.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Bloch, Kenneth D.] Massachusetts Gen Hosp, Cardiol Res Ctr, Boston, MA 02114 USA. RP Zhou, GL (reprint author), Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. EM bseed@ccib.mgh.harvard.edu; kdbloch@partners.org FU Massachusetts General Hospital, NIH [HL074352]; Fondation LeDucq FX This work was supported by private funding in Massachusetts General Hospital, NIH (HL074352), and the Fondation LeDucq. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 5 Z9 5 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7404 J9 PLOS GENET JI PLoS Genet. PD NOV PY 2013 VL 9 IS 11 AR e1003950 DI 10.1371/journal.pgen.1003950 PG 13 WC Genetics & Heredity SC Genetics & Heredity GA 299BG UT WOS:000330369000035 PM 24278032 ER PT J AU Tsai, AC Bangsberg, DR Weiser, SD AF Tsai, Alexander C. Bangsberg, David R. Weiser, Sheri D. TI Harnessing Poverty Alleviation to Reduce the Stigma of HIV in Sub-Saharan Africa SO PLOS MEDICINE LA English DT Editorial Material ID AIDS-RELATED STIGMA; ANTIRETROVIRAL THERAPY; RURAL UGANDA; SOUTH-AFRICA; FOOD INSECURITY; MENTAL-HEALTH; QUALITATIVE-ANALYSIS; ECONOMIC-IMPACT; HIV/AIDS; PEOPLE C1 [Tsai, Alexander C.] Massachusetts Gen Hosp, Chester M Pierce MD Div Global Psychiat, Boston, MA 02114 USA. [Tsai, Alexander C.; Bangsberg, David R.] Harvard Univ, Sch Med, Boston, MA USA. [Tsai, Alexander C.; Bangsberg, David R.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA. [Bangsberg, David R.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA. [Bangsberg, David R.] Mbarara Univ Sci & Technol, Mbarara, Uganda. [Weiser, Sheri D.] Univ Calif San Francisco, San Francisco Gen Hosp, Div HIV AIDS, San Francisco, CA USA. RP Tsai, AC (reprint author), Massachusetts Gen Hosp, Chester M Pierce MD Div Global Psychiat, Boston, MA 02114 USA. EM actsai@partners.org OI Tsai, Alexander/0000-0001-6397-7917 FU NIMH NIH HHS [K23MH079713, K23 MH096620, K23MH096620, K24MH087227] NR 73 TC 33 Z9 33 U1 1 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD NOV PY 2013 VL 10 IS 11 AR e1001557 DI 10.1371/journal.pmed.1001557 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 299CD UT WOS:000330371600014 PM 24319400 ER PT J AU Gupta, S Gach, JS Becerra, JC Phan, TB Pudney, J Moldoveanu, Z Joseph, SB Landucci, G Supnet, MJ Ping, LH Corti, D Moldt, B Hel, Z Lanzavecchia, A Ruprecht, RM Burton, DR Mestecky, J Anderson, DJ Forthal, DN AF Gupta, Sandeep Gach, Johannes S. Becerra, Juan C. Phan, Tran B. Pudney, Jeffrey Moldoveanu, Zina Joseph, Sarah B. Landucci, Gary Supnet, Medalyn Jude Ping, Li-Hua Corti, Davide Moldt, Brian Hel, Zdenek Lanzavecchia, Antonio Ruprecht, Ruth M. Burton, Dennis R. Mestecky, Jiri Anderson, Deborah J. Forthal, Donald N. TI The Neonatal Fc Receptor (FcRn) Enhances Human Immunodeficiency Virus Type 1 (HIV-1) Transcytosis across Epithelial Cells SO PLOS PATHOGENS LA English DT Article ID ANTIBODY-DEPENDENT ENHANCEMENT; FEMALE GENITAL-TRACT; MONOCLONAL-ANTIBODIES; DENDRITIC CELLS; HIV-1-INFECTED INDIVIDUALS; 1-INFECTED INDIVIDUALS; MEDIATED PRESENTATION; CERVICAL ECTOPY; HUMAN PLACENTA; VAGINAL PH AB The mechanisms by which human immunodeficiency virus type 1 (HIV-1) crosses mucosal surfaces to establish infection are unknown. Acidic genital secretions of HIV-1-infected women contain HIV-1 likely coated by antibody. We found that the combination of acidic pH and Env-specific IgG, including that from cervicovaginal and seminal fluids of HIV-1-infected individuals, augmented transcytosis across epithelial cells as much as 20-fold compared with Env-specific IgG at neutral pH or non-specific IgG at either pH. Enhanced transcytosis was observed with clinical HIV-1 isolates, including transmitted/founder strains, and was eliminated in Fc neonatal receptor (FcRn)-knockdown epithelial cells. Non-neutralizing antibodies allowed similar or less transcytosis than neutralizing antibodies. However, the ratio of total: infectious virus was higher for neutralizing antibodies, indicating that they allowed transcytosis while blocking infectivity of transcytosed virus. Immunocytochemistry revealed abundant FcRn expression in columnar epithelia lining the human endocervix and penile urethra. Acidity and Env-specific IgG enhance transcytosis of virus across epithelial cells via FcRn and could facilitate translocation of virus to susceptible target cells following sexual exposure. C1 [Gupta, Sandeep; Gach, Johannes S.; Becerra, Juan C.; Phan, Tran B.; Landucci, Gary; Supnet, Medalyn Jude; Forthal, Donald N.] Univ Calif Irvine, Dept Med, Irvine Sch Med, Div Infect Dis, Irvine, CA 92717 USA. [Pudney, Jeffrey; Anderson, Deborah J.] Boston Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA. [Moldoveanu, Zina; Mestecky, Jiri] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Joseph, Sarah B.; Ping, Li-Hua] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Joseph, Sarah B.; Ping, Li-Hua] Univ N Carolina, Ctr AIDS Res, Chapel Hill, NC USA. [Corti, Davide; Lanzavecchia, Antonio] Inst Res Biomed, Bellinzona, Switzerland. [Corti, Davide] Humabs BioMed SA, Bellinzona, Switzerland. [Moldt, Brian; Burton, Dennis R.] Scripps Res Inst, Int AIDS Vaccine Initiat Neutralizing Antibody Ct, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA. [Moldt, Brian; Burton, Dennis R.] Scripps Res Inst, Ctr HIV AIDS Vaccine Immunol & Immunogen Discover, La Jolla, CA 92037 USA. [Hel, Zdenek] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Lanzavecchia, Antonio] ETH, Inst Microbiol, CH-8092 Zurich, Switzerland. [Ruprecht, Ruth M.] Texas Biomed Res Inst, San Antonio, TX USA. [Burton, Dennis R.] Massachusetts Gen Hosp, MIT, Ragon Inst, Boston, MA USA. [Burton, Dennis R.] Harvard Univ, Boston, MA 02115 USA. [Mestecky, Jiri] Charles Univ Prague, Sch Med 1, Inst Microbiol & Immunol, Prague, Czech Republic. RP Gupta, S (reprint author), Univ Calif Irvine, Dept Med, Irvine Sch Med, Div Infect Dis, Irvine, CA 92717 USA. EM dnfortha@uci.edu OI Hel, Zdenek/0000-0002-4923-4794; Gach, Johannes/0000-0002-5043-5710 FU National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI102715, U19 AI096398] FX Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Numbers R01AI102715 (DNF) and U19 AI096398 (DJA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 75 TC 40 Z9 41 U1 1 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD NOV PY 2013 VL 9 IS 11 AR e1003776 DI 10.1371/journal.ppat.1003776 PG 13 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 299HN UT WOS:000330386900035 PM 24278022 ER PT J AU Sok, D Laserson, U Laserson, J Liu, Y Vigneault, F Julien, JP Briney, B Ramos, A Saye, KF Le, K Mahan, A Wang, S Kardar, M Yaari, G Walker, LM Simen, BB John, EPS Chan-Hui, PY Swiderek, K Kleinstein, SH Alter, G Seaman, MS Chakraborty, AK Koller, D Wilson, IA Church, GM Burton, DR Poignard, P AF Sok, Devin Laserson, Uri Laserson, Jonathan Liu, Yi Vigneault, Francois Julien, Jean-Philippe Briney, Bryan Ramos, Alejandra Saye, Karen F. Le, Khoa Mahan, Alison Wang, Shenshen Kardar, Mehran Yaari, Gur Walker, Laura M. Simen, Birgitte B. John, Elizabeth P. St. Chan-Hui, Po-Ying Swiderek, Kristine Kleinstein, Stephen H. Alter, Galit Seaman, Michael S. Chakraborty, Arup K. Koller, Daphne Wilson, Ian A. Church, George M. Burton, Dennis R. Poignard, Pascal TI The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV Antibodies SO PLOS PATHOGENS LA English DT Article ID MEMORY B-CELLS; HIV-1-NEUTRALIZING ANTIBODIES; MONOCLONAL-ANTIBODIES; POTENT; VIRUS; GP120; INFECTION; INDIVIDUALS; RECOGNITION; GENERATION AB Broadly neutralizing HIV antibodies (bnAbs) are typically highly somatically mutated, raising doubts as to whether they can be elicited by vaccination. We used 454 sequencing and designed a novel phylogenetic method to model lineage evolution of the bnAbs PGT121-134 and found a positive correlation between the level of somatic hypermutation (SHM) and the development of neutralization breadth and potency. Strikingly, putative intermediates were characterized that show approximately half the mutation level of PGT121-134 but were still capable of neutralizing roughly 40-80% of PGT121-134 sensitive viruses in a 74-virus panel at median titers between 15- and 3-fold higher than PGT121-134. Such antibodies with lower levels of SHM may be more amenable to elicitation through vaccination while still providing noteworthy coverage. Binding characterization indicated a preference of inferred intermediates for native Env binding over monomeric gp120, suggesting that the PGT121-134 lineage may have been selected for binding to native Env at some point during maturation. Analysis of glycan-dependent neutralization for inferred intermediates identified additional adjacent glycans that comprise the epitope and suggests changes in glycan dependency or recognition over the course of affinity maturation for this lineage. Finally, patterns of neutralization of inferred bnAb intermediates suggest hypotheses as to how SHM may lead to potent and broad HIV neutralization and provide important clues for immunogen design. C1 [Sok, Devin; Briney, Bryan; Ramos, Alejandra; Saye, Karen F.; Le, Khoa; Walker, Laura M.; Burton, Dennis R.; Poignard, Pascal] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA. [Sok, Devin; Julien, Jean-Philippe; Briney, Bryan; Ramos, Alejandra; Saye, Karen F.; Le, Khoa; Wilson, Ian A.; Burton, Dennis R.; Poignard, Pascal] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA. [Sok, Devin; Julien, Jean-Philippe; Briney, Bryan; Ramos, Alejandra; Saye, Karen F.; Le, Khoa; Burton, Dennis R.] Scripps Res Inst, Scripps Ctr HIV AIDS Vaccine Immunol & Immunogen, La Jolla, CA 92037 USA. [Laserson, Uri] MIT, Dept Math, Cambridge, MA 02139 USA. [Laserson, Uri; Church, George M.] Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Laserson, Uri; Vigneault, Francois; Church, George M.] Harvard Univ, Sch Med, Dept Genet, Cambridge, MA 02138 USA. [Laserson, Jonathan; Liu, Yi; Koller, Daphne] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA. [Liu, Yi] Stanford Univ, Sch Med, Biomed Informat Training Program, Stanford, CA 94305 USA. [Vigneault, Francois] AbVitro Inc, Boston, MA USA. [Julien, Jean-Philippe; Wilson, Ian A.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA. [Ramos, Alejandra; Poignard, Pascal] Int AIDS Vaccine Initiat, New York, NY USA. [Mahan, Alison; Alter, Galit; Chakraborty, Arup K.; Burton, Dennis R.] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA USA. [Mahan, Alison; Alter, Galit; Chakraborty, Arup K.; Burton, Dennis R.] Harvard Univ, Boston, MA 02115 USA. [Wang, Shenshen; Chakraborty, Arup K.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA. [Wang, Shenshen; Kardar, Mehran; Chakraborty, Arup K.] MIT, Dept Phys, Cambridge, MA 02139 USA. [Yaari, Gur; Kleinstein, Stephen H.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA. [Simen, Birgitte B.; John, Elizabeth P. St.] Roche Co, Life Sci 454, Branford, CT USA. [Chan-Hui, Po-Ying; Swiderek, Kristine] Theraclone Sci Inc, Seattle, WA USA. [Seaman, Michael S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Chakraborty, Arup K.] MIT, Inst Med Engn & Sci, Dept Chem, Cambridge, MA 02139 USA. RP Sok, D (reprint author), Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA. EM burton@scripps.edu RI poignard, pascal/N-6678-2013 OI Mahan, Alison/0000-0003-4284-8467; FU International AIDS Vaccine Initiative through the Neutralizing Antibody Consortium [SFP1849]; NIH [R01 AI033292, AI84817, 1U19AI090970]; Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery [UM1AI100663]; NIH Interdisciplinary Training Program in Immunology [5T32AI007606-10]; Canadian Institutes of Health Research fellowship; NIH Bioinformatics and Integrative Genomics Fellowship; Center for Excellence in Genomic Science; Bill and Melinda Gates foundation [38619]; DOE, Basic Energy Sciences, Office of Science [DE-AC02-06CH11357]; NCI [Y1-CO-1020]; NIGMS [Y1-GM-1104] FX This work was supported by the International AIDS Vaccine Initiative through the Neutralizing Antibody Consortium SFP1849 (DRB, PP), NIH R01 AI033292 (DRB), AI84817 (IAW) and 1U19AI090970 (PP), Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery Grant UM1AI100663 (DRB); NIH Interdisciplinary Training Program in Immunology 5T32AI007606-10 (DS), Canadian Institutes of Health Research fellowship (JPJ), NIH Bioinformatics and Integrative Genomics Fellowship (UL), Center for Excellence in Genomic Science (GMC). A portion of the neutralization experiments were done by Michael Seaman's group (Beth Israel Deaconess Medical Center, Harvard Medical School) and this work was funded through the Bill and Melinda Gates foundation (grant no. 38619). Use of the Advanced Photon Source was supported by the DOE, Basic Energy Sciences, Office of Science, under contract no. DE-AC02-06CH11357. GM/CA CAT has been funded in whole or in part with federal funds from NCI (grant Y1-CO-1020) and NIGMS (grant Y1-GM-1104). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 55 TC 73 Z9 73 U1 3 U2 19 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD NOV PY 2013 VL 9 IS 11 AR e1003754 DI 10.1371/journal.ppat.1003754 PG 20 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 299HN UT WOS:000330386900025 PM 24278016 ER PT J AU Toups, MSP Myers, AK Wisniewski, SR Kurian, B Morris, DW Rush, AJ Fava, M Trivedi, MH AF Toups, Marisa S. P. Myers, Alyson K. Wisniewski, Stephen R. Kurian, Benji Morris, David W. Rush, Augustus John Fava, Maurizio Trivedi, Madhukar H. TI Relationship Between Obesity and Depression: Characteristics and Treatment Outcomes With Antidepressant Medication SO PSYCHOSOMATIC MEDICINE LA English DT Article DE depression; obesity; treatment resistance ID BODY-MASS INDEX; STAR-ASTERISK-D; TREATMENT-RESISTANT DEPRESSION; SUBSTANCE USE; US ADULTS; DISORDER; ASSOCIATION; CITALOPRAM; EPIDEMIOLOGY; COMORBIDITY AB Objective: Obesity and major depressive disorder often co-occur. However, differences between obese and normal-weight depressed patients and the moderating effect of obesity on antidepressant treatment outcome are not well studied. Methods: Adults (n = 662) with major depressive disorder in the Combining Medications to Enhance Depression Outcomes study were randomized to treatment with escitalopram plus placebo, bupropion plus escitalopram, or venlafaxine plus mirtazapine for a 12-week primary treatment phase and 16-week follow-up. Body mass index (BMI) was calculated at baseline and categorized according to World health Organization criteria: normal or low weight (NW), overweight, Obese I and Obese II+. A repeated-effects model, unadjusted and adjusted for baseline variables, assessed outcomes. Results: Obesity was common (46.2%), only 25.5% were NW. Higher BMI was associated with greater medical illness (p < .001), social phobia (p = .003), and bulimia (p = .026). Lower BMI was associated with more frequent post-traumatic stress disorder (p = .002) and drug abuse (p < .001). Treatment outcomes did not differ including Week 12 remission rates (NW 36%, overweight 40%, Obese I 43%, Obese II+ 37%; p = .69). Lower BMI was associated with more frequent (p = .024 [unadjusted] and .053 [adjusted]) and more severe (p = .008 [unadjusted] and .053 [adjusted]) adverse effects. Conclusions: BMI was related to clinical presentation and prevalence of comorbidities, hut not antidepressant outcomes. Lower BMI classes had more psychiatric comorbidities, potentially obscuring the relationship between BMI and antidepressant effects. C1 [Toups, Marisa S. P.; Myers, Alyson K.; Kurian, Benji; Morris, David W.; Trivedi, Madhukar H.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Myers, Alyson K.] Univ Texas SW Med Ctr Dallas, Dept Endocrinol, Dallas, TX 75390 USA. [Wisniewski, Stephen R.] Univ Pittsburgh, Epidemiol Data Ctr, Pittsburgh, PA USA. [Rush, Augustus John] Duke Natl Univ Singapore, Off Clin Sci, Singapore, Singapore. [Fava, Maurizio] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Trivedi, MH (reprint author), Univ Texas SW Med Ctr Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM madhukar.trivedi@utsouthwestern.edu OI Wisniewski, Stephen/0000-0002-3877-9860; Rush, Augustus/0000-0003-2004-2382 FU National Institute of Mental Health [N01MH-90003]; National Institute of Mental Health Bristol-Myers Squibb; CeNekv BioPharma; Cephalon, Inc.; CNS Response, Inc.; Compel/is Pharmaceuticals; ypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon Sumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; i3 Innovus/Ingenis; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson,John son Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp FX COMED conducted with funds from a contract front the National Institute of Mental Health (No. N01MH-90003). Marisa S.P Toups has nothing to disclose. Alyson K. Myers has nothing to disclose. Dr. Wisniewski has received honoraria from Cyberonic Inc., ImaRx Therapeutics, Inc., Bristol-Myers Squibb Company, Organon, Case-Western University, Singapore Clinical Research Institute, Dey Pharmaceuticals, and Venebio; he has received research support from Eli Lilly Benji Kurian has nothing to disclose. David W Morris has nothing to disclose. Dr Rush has received consulting fees from Otsuka Pharmaceutical Co, Ltd, University of Michigan, and Brain Resource Ltd; speaketifees from Singapore College of Family Physicians; loyalties from Guilford Publications and the University of Texas Southwestern Medical Center; travel grant from Cl/VP and research slipport from the National Institute of Mental Health Bristol-Myers Squibb; CeNekv BioPharma; Cephalon, Inc.; CNS Response, Inc.; Compel/is Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon Sumitomo Pharma Co. Inc.;.Dov Pharmaceuticals, Inc.; Ed,gemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; En Vivo Pharmaceuticals, Inc.; ePharmaSolutions; EPIX Pharmaceuticals. Inc.; Euthymies Bioscience, Inc.; Mime -Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; GenOmind, LW; GlaxoSmithKiine; Grunenthal GmbH; i3 Innovus/Ingenis; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson,John son Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante, Inc.; Merck di Co., Inc.; MSI Methylation Sciences, Inc.; Naurex. Inc.; Neuralstem, Inc.; Neuronetics, Inc.; Next-gime Pharmaceuticals; Novartis AG; Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Otsuka Pharmaceuticals; Pamlab,.LIC; Pfizer Inc.; PharmaStar; Pharmaviteg LI,C;.Pharmokx Therapeutics;.PreciSkin Human Biolaboratory; Prexa Pharmaceuticals, Inc.; Puretech V.Inures; PsychoGenics; Psylin Neurosciences, Inc.; Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Scumfi-Aventis US LLC; Sepmcor Inc.; Seryier Laboratories; Schering-Plough Corporation; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals,.Inc.; Somerset Pharmaceuticals., Inc.; Sunovion Pharmaceuticals,. Supernus Pharmaceuticals. Inc.; Synthelabo; Takeda Pharmaceutical Company Limited; Tal Medical., Inc.; Ten.agenex Pharmaceuticals, Inc.; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, inc', and Vivid(Pharmaceuticals, Inc.; been on the speaker's bureau :16r Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstmZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CUE Institutc/Physicians Postgraduate Press, Inc.; Eli Lilly and C0171Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/Primedia; MGH.Psychiatry Academy/Reed Elsei)ier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.;.PharmaStilly United BioSource,Corp.; and Wyeth-Ayerst Laboratories; has equity holdings in Compel/is; has received royalty income from Sequential Parallel Comparison Design (SPCD), which are licensed by MGH to RCT Logic. LLC, and patent application :for a combination of azapirones and hupropion in;Major Depressive Disorder (MDD). Dr. Tivedi has received honoraria from or is on the speaker's' bureau fir Abbott Lahoratorie,s, Ahdi Ibrahim, Alco (Organon Pharmaceuticals Inc.; ), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb Company, Cephalon, Inc., Concert Pharmaceuticals, Inc, Eli Lilly & Company Evotec, Fibre Kramer Pharmaceuticals. NR 29 TC 11 Z9 11 U1 1 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0033-3174 EI 1534-7796 J9 PSYCHOSOM MED JI Psychosom. Med. PD NOV-DEC PY 2013 VL 75 IS 9 BP 863 EP 872 DI 10.1097/PSY.0000000000000000 PG 10 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 300NB UT WOS:000330469500009 PM 24163386 ER PT J AU Peccora, CD Ross, EL Hanna, GM AF Peccora, Christian D. Ross, Edgar L. Hanna, George M. TI Aberrant Intrathecal Pump Refill Ultrasound-guided Aspiration of a Substantial Quantity of Subcutaneous Hydromorphone SO REGIONAL ANESTHESIA AND PAIN MEDICINE LA English DT Article ID LOCALIZATION; INJECTION; ACCESS; PORT AB Intrathecal drug delivery systems are an effective and increasingly common pain treatment modality for certain patient populations. Pumps are surgically inserted in a subcutaneous abdominal pocket and refilled with highly concentrated medication at regular intervals. Inadvertent injection of medication outside the pump is a known complication of the refill procedure. We describe the injection of hydromorphone into the pump's surrounding subcutaneous pocket, subsequent opioid overdose, and the novel application of ultrasound to visualize and aspirate the subcutaneous drug. Ultrasonography can be used as an effective modality for rapid diagnosis and treatment of an accidental pocket fill. C1 [Peccora, Christian D.; Ross, Edgar L.; Hanna, George M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02114 USA. [Hanna, George M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. RP Hanna, GM (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. EM ghanna2@partners.org NR 9 TC 4 Z9 4 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1098-7339 EI 1532-8651 J9 REGION ANESTH PAIN M JI Region. Anesth. Pain Med. PD NOV-DEC PY 2013 VL 38 IS 6 BP 544 EP 546 DI 10.1097/AAP.0000000000000008 PG 3 WC Anesthesiology SC Anesthesiology GA 300PL UT WOS:000330475800012 PM 24121607 ER PT J AU Bressler, SB Almukhtar, T Aiello, LP Bressler, NM Ferris, FL Glassman, AR Greven, CM AF Bressler, Susan B. Almukhtar, Talat Aiello, Lloyd P. Bressler, Neil M. Ferris, Frederick L., III Glassman, Adam R. Greven, Craig M. CA Diabet Retinopathy Clinical Res Ne TI GREEN OR YELLOW LASER TREATMENT FOR DIABETIC MACULAR EDEMA Exploratory Assessment Within the Diabetic Retinopathy Clinical Research Network SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES LA English DT Article DE diabetic macular edema; laser photocoagulation; laser wavelength ID ARGON BLUE-GREEN; WAVELENGTH SELECTION; PHOTOCOAGULATION; RANIBIZUMAB; KRYPTON AB Purpose: Explore differences in green compared with yellow focal/grid laser treatment on functional and anatomical endpoints in eyes with diabetic macular edema. Methods: Data from two randomized clinical trials were evaluated for differences in visual acuity and optical coherence tomography parameters for eyes assigned to sham injection + prompt laser, ranibizumab + prompt laser, or prompt laser only: among subgroups of eyes treated exclusively and electively with either green or yellow laser. Results: In the sham injection + prompt laser group, the mean visual acuity letter score change for eyes receiving green and yellow laser treatment, respectively, was + 2.4 +/- 14 and + 5.1 +/- 13 at the 52-week visit (P = 0.06) and + 2.4 +/- 15 and + 6.0 +/- 13 at the 104-week visit (P = 0.13), with no corresponding evidence of differences in optical coherence tomography thickness. When comparing wavelength groups in the ranibizumab + prompt laser and prompt laser-only groups, meaningful differences in visual acuity and optical coherence tomography thickness were not detected at 1 year or 2 years. Conclusion: A trend toward improved vision outcome with yellow laser observed in one trial was not corroborated by anatomical outcomes or by the other trial. In this study, without random assignment to different wavelengths controlling for bias and confounding, it is not possible to determine whether one wavelength is better than the other. C1 [Bressler, Susan B.; Bressler, Neil M.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD 21205 USA. [Almukhtar, Talat; Glassman, Adam R.] Jaeb Ctr Hlth Res, Tampa, FL 33647 USA. [Aiello, Lloyd P.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Dept Ophthalmol,Beetham Eye Inst, Boston, MA 02115 USA. [Ferris, Frederick L., III] NEI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA. [Ferris, Frederick L., III] NIH, Bethesda, MD 20892 USA. [Greven, Craig M.] Wake Forest Univ, Ctr Eye, Dept Ophthalmol, Winston Salem, NC 27109 USA. RP Almukhtar, T (reprint author), Jaeb Ctr Hlth Res, 15310 Amberly Dr,Suite 350, Tampa, FL 33647 USA. EM drcrstat6@jaeb.org FU National Eye Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health; Department of Health and Human Services [EY14231, EY14229, EY18817]; Office of Research Administration; Abbott Medical Optics; Allergan; Bausch Lomb; Bristol-Meyer-Squibb; Carl Zeiss Meditec; EMMES Corporation; ForSight Labs; LLC Genentech; Genzyme Corporation; Lumenis; Notal Vision; Novartis; Regeneron FX Supported by the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services EY14231, EY14229, EY18817 through cooperative agreements. The funding organization (National Institutes of Health) participated in oversight of the conduct of the study and review of the article but not directly in the design or conduct of the study or in the collection, management, analysis, or interpretation of the data or in the preparation of the article. Genentech provided ranibizumab for the study. In addition, Genentech provided funds to DRCR. net to defray the study's clinical site costs. As described in the Diabetic Retinopathy Clinical Research Network (DRCR.net) Industry Collaboration Guidelines (available at: www.drcr.net), the DRCR.net had complete control over the design of the protocol, ownership of the data, and all editorial content of presentations and publications related to the protocol. A complete list of all DRCR. net investigator financial disclosures can be found at www. drcr. net. Writing committee financial disclosures: N. M. Bressler: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution (such as the School of Medicine) that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored projects are not directly compensated by the sponsor but may receive salary or other support from the institution to support their effort on the projects. Dr. N. M. Bressler is the Principal Investigator of grants at The Johns Hopkins University sponsored by the following entities (not including the National Institutes of Health): Abbott Medical Optics, Allergan, Bausch & Lomb, Bristol-Meyer-Squibb, Carl Zeiss Meditec, EMMES Corporation, ForSight Labs, LLC Genentech, Genzyme Corporation, Lumenis, Notal Vision, Novartis, and Regeneron. A complete list of all DRCR.net investigator financial disclosures can be found at www.drcr.net. NR 23 TC 2 Z9 3 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0275-004X EI 1539-2864 J9 RETINA-J RET VIT DIS JI Retin.-J. Retin. Vitr. Dis. PD NOV-DEC PY 2013 VL 33 IS 10 BP 2080 EP 2088 PG 9 WC Ophthalmology SC Ophthalmology GA 297EI UT WOS:000330237900012 PM 23792486 ER PT J AU Sarber, KM Dion, GR Weitzel, EK McMains, KC AF Sarber, Kathleen M. Dion, Gregory Robert Weitzel, Erik K. McMains, Kevin C. TI Approaching Chronic Sinusitis SO SOUTHERN MEDICAL JOURNAL LA English DT Review DE chronic rhinosinusitis; chronic sinusitis; nasal airway obstruction; nasal irrigation; rhinosinusitis ID COMMON VARIABLE IMMUNODEFICIENCY; FUROATE NASAL SPRAY; REFRACTORY CHRONIC RHINOSINUSITIS; RANDOMIZED CONTROLLED-TRIAL; ALLERGIC FUNGAL SINUSITIS; CYSTIC-FIBROSIS; DOUBLE-BLIND; LONG-TERM; ANTIBODY DEFICIENCY; COMPUTED-TOMOGRAPHY AB Chronic sinusitis is a common disease that encompasses a number of syndromes that are characterized by sinonasal mucosal inflammation. Chronic sinusitis can be defined as two or more of the following symptoms lasting for more than 12 consecutive weeks: discolored rhinorrhea, postnasal drip, nasal obstruction, facial pressure or pain, or decreased sense of smell. Chronic sinusitis is further classified as chronic sinusitis with polyposis, chronic sinusitis without polyposis, or allergic fungal sinusitis using physical examination, and histologic and radiographic findings. Treatment methods for chronic sinusitis are based upon categorization of the disease and include oral and inhaled corticosteroids, nasal saline irrigations, and antibiotics in selected patients. Understanding the various forms of chronic sinusitis and managing and ruling out comorbidities are key to successful management of this common disorder. C1 San Antonio Mil Med Ctr, Ft Sam Houston, TX USA. Wilford Hall Ambulatory Surg Ctr, San Antonio, TX USA. Audie L Murphy Vet Hosp, San Antonio, TX USA. RP Dion, GR (reprint author), Dept Otolaryngol, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. EM greg.r.dion.mil@mail.mil NR 77 TC 2 Z9 2 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 EI 1541-8243 J9 SOUTH MED J JI South.Med.J. PD NOV PY 2013 VL 106 IS 11 BP 642 EP 648 DI 10.1097/SMJ.0000000000000018 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 298VB UT WOS:000330351500011 PM 24192597 ER PT J AU Simpson, AK Osler, P Wood, KB AF Simpson, Andrew K. Osler, Polina Wood, Kirkham B. TI Utility of Postoperative Radiographs After Anterior Lumbar Interbody Fusion With or Without Posterior Instrumentation SO SPINE LA English DT Article DE lumbar spine; fusion; radiograph; imaging; utility ID RADIATION-EXPOSURE; SCANS AB Study Design. Retrospective clinical and radiographical review. Objective. To evaluate the utility of plain radiographical surveillance after anterior lumbar interbody fusion and determine to what extent radiographical findings affect postoperative decision making. Summary of Background Data. Postoperative radiographical surveillance is a ubiquitous practice among spine surgeons, which lacks evidence and has received growing attention in an environment of increasing health care cost and receding resources. Lumbar interbody fusions are being performed with increasing frequency from numerous approaches; nonetheless, there are no evidence-based guidelines for postoperative radiographical evaluation of patients after these procedures. Methods. One hundred forty-six consecutive patients who underwent anterior lumbar interbody fusion with or without short segment posterior fusion from 2008 to 2011 were reviewed. Exclusion criteria were less than 6 months of follow-up, prior surgery, hybrid constructs with disc arthroplasty, and concurrent posterior fusion of greater than 3 levels. Three hundred fifty-nine radiographical series and 330 clinic notes of the included 67 patients were reviewed. Radiographs were evaluated for abnormalities and clinic notes reviewed for any changes in clinical management by multiple reviewers. Interobserver reliability, sensitivity, specificity, and positive and negative predictive values were calculated. Results. There was no single instance of a change in treatment course based on radiographical findings alone in any of the 330 clinic visits of the 67 included patients during an average 15.8-month postoperative follow-up period. Thirty-four of the 67 patients (51%) had some change in their management on the basis of their clinical symptoms and/or examination. Interobserver agreement for change in management was 0.96 (kappa = 0.918). Sensitivity (6%), specificity (97%), positive predictive value (67%), and negative predictive value (50%) were calculated. Conclusion. Routine postoperative radiographical surveillance has minimal value for asymptomatic patients after anterior lumbar interbody fusion with or without posterior fusion. Obtaining a limited number of postoperative films of these patients in the absence of clinical symptoms or risk factors could significantly reduce health care costs and unnecessary radiation exposure. C1 [Simpson, Andrew K.] Emory Univ, Dept Orthopaed, Emory Spine Ctr, Atlanta, GA 30322 USA. [Osler, Polina; Wood, Kirkham B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg, Boston, MA USA. RP Simpson, AK (reprint author), Emory Univ, Dept Orthopaed, Emory Spine Ctr, Atlanta, GA 30322 USA. EM andrew.k.simpson@emory.edu OI Osler, Polina/0000-0003-4883-2925 NR 8 TC 2 Z9 2 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0362-2436 EI 1528-1159 J9 SPINE JI SPINE PD NOV 1 PY 2013 VL 38 IS 23 BP 2038 EP 2042 DI 10.1097/BRS.0b013e3182a81f67 PG 5 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 299DZ UT WOS:000330376800020 PM 23963014 ER PT J AU Behbod, B Sordillo, JE Hoffman, EB Datta, S Muilenberg, ML Scott, JA Chew, GL Platts-Mills, TAE Schwartz, J Burge, H Gold, DR AF Behbod, B. Sordillo, J. E. Hoffman, E. B. Datta, S. Muilenberg, M. L. Scott, J. A. Chew, G. L. Platts-Mills, T. A. E. Schwartz, J. Burge, H. Gold, D. R. TI Wheeze in infancy: protection associated with yeasts in house dust contrasts with increased risk associated with yeasts in indoor air and other fungal taxa SO ALLERGY LA English DT Article DE asthma; fungi; housing; wheeze; yeast ID 1ST YEAR; AIRBORNE FUNGI; CHILDHOOD ASTHMA; LIFE; EXPOSURE; COHORT; GLUCAN; SENSITIZATION; ENVIRONMENTS; RESPONSES AB BackgroundWhile fungal exposures are assumed to provoke wheeze through irritant or allergenic mechanisms, little is known about the differential effects of indoor and outdoor fungi on early-life wheeze. MethodsIn a Boston prospective birth cohort of 499 at-risk infants, culturable fungi in bedroom air and dust and outdoor air were measured at the age of 2-3months. Wheeze was determined using bimonthly telephone questionnaires. Odds ratios were estimated for an interquartile increase in fungal natural log-transformed concentrations, adjusting for predictors of wheeze and potential confounders. ResultsIncreased odds of any wheeze' (1 vs 0 episodes) by age one were positively associated with indoor dust Alternaria [odds ratio (OR)=1.83; 95% confidence interval (CI), 1.07-3.14], Penicillium [OR=1.18; (0.98-1.43)], and Cladosporium [OR=1.47; (1.16-1.85)]; indoor air Penicillium [OR=1.26; (0.92-1.74)]; and outdoor air Cladosporium [OR=1.68; (1.04-2.72)]. In contrast, indoor dust yeasts were protective [OR=0.78; (0.66-0.93)]. Frequent wheeze' (2 vs <2 episodes) by age one was borderline associated with dust yeasts [OR=0.86; (0.70-1.04)] and indoor air yeasts [OR=1.53; (0.93-2.53)]. Alternaria concentration was associated with any wheeze for children with maternal mold sensitization [OR=9.16; (1.37-61.22)], but not for those without maternal mold sensitization [OR=1.32; (0.79-2.20)]. ConclusionsWhile wheeze rates were higher with exposures to fungal taxa considered to be irritant or allergenic in sensitive subjects, yeasts in the home had a strong protective association with wheeze in infancy. Molecular microbiologic studies may elucidate specific components of innate microbiologic stimulants that lead to contrasting effects on wheeze development. C1 [Behbod, B.; Hoffman, E. B.; Schwartz, J.; Burge, H.; Gold, D. R.] Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA. [Sordillo, J. E.; Datta, S.; Gold, D. R.] Harvard Univ, Sch Med, Channing Lab, Boston, MA 02215 USA. [Hoffman, E. B.] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA. [Hoffman, E. B.] Harvard Univ, Sch Med, Boston, MA 02215 USA. [Muilenberg, M. L.] Univ Massachusetts, Amherst, MA 01003 USA. [Scott, J. A.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. [Chew, G. L.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. [Platts-Mills, T. A. E.] Univ Virginia, Charlottesville, VA USA. RP Behbod, B (reprint author), Harvard Univ, Sch Publ Hlth, 401 Pk Dr West, Boston, MA 02215 USA. EM bbehbod@post.harvard.edu RI Scott, James/A-8598-2011 OI Scott, James/0000-0002-5073-0832 FU Harvard-Cyprus Endowment Scholarship; [R01 AI035786]; [EPA RD-83241601]; [AI-20565]; [K99 HL109162 02] FX This manuscript has been supported by the following grants: R01 AI035786, EPA RD-83241601, AI-20565, and K99 HL109162 02. Dr Behbod's doctorate has been supported by Harvard-Cyprus Endowment Scholarship. NR 35 TC 13 Z9 13 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0105-4538 EI 1398-9995 J9 ALLERGY JI Allergy PD NOV PY 2013 VL 68 IS 11 BP 1410 EP 1418 DI 10.1111/all.12254 PG 9 WC Allergy; Immunology SC Allergy; Immunology GA 294IP UT WOS:000330039100009 PM 24118031 ER PT J AU Piette, JD Aikens, JE Trivedi, R Parrish, D Standiford, C Marinec, NS Striplin, D Bernstein, SJ AF Piette, John D. Aikens, James E. Trivedi, Ranak Parrish, Diana Standiford, Connie Marinec, Nicolle S. Striplin, Dana Bernstein, Steven J. TI Depression Self-Management Assistance Using Automated Telephonic Assessments and Social Support SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; INTERACTIVE VOICE RESPONSE; QUALITY-OF-LIFE; PRIMARY-CARE; CHRONIC ILLNESS; MOBILE ASSESSMENT; MENTAL-DISORDERS; HEALTH; TIME; INTERVENTIONS AB Objective: To understand patient participation in interactive voice response (IVR) depression monitoring and Self-management support calls and estimate the workload from clinical alerts based on patients' IVR reports. Study Design: Observational study from program implementation in 13 community- and university-based primary care practices. Methods: Patients with depression were identified using electronic records and enrolled by telephone. Patients were asked to complete IVR assessments weekly; those with significantly improved symptoms had the option of completing assessments monthly. Patients could enroll with an informal caregiver who received automated feedback based on patients' IVR reports. Clinicians received alerts regarding significant changes in the scores on the Patient Health Questionnaire 9-item depression measure, antidepressant adherence problems, or suicidal ideation. Results: A total of 387 patients were followed for 12,042 weeks. More than half (59%) opted to participate with a caregiver. Patients completed 68% of 7912 attempted IVR assessments. Assessment completion was unrelated to patients' depressive symptoms and was higher among those who participated with a caregiver, were married, had more comorbidities, or reported missing a prior appointment. Assessment completion was lower when patients received monthly versus weekly assessment attempts. Clinical alerts were generated during 4.9% of follow-up weeks; most represented medication adherence problems (2.8%). Alerts indicating suicidal ideation were rare (0.2% of patient-weeks). Conclusions: IVR support calls represent a viable strategy for increasing access to depression monitoring and self-management assistance in primary care. These programs generate a manageable number of alerts, most of which can be triaged with limited physician involvement. C1 [Piette, John D.; Marinec, Nicolle S.; Striplin, Dana; Bernstein, Steven J.] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI 48113 USA. [Piette, John D.; Parrish, Diana; Marinec, Nicolle S.; Striplin, Dana; Bernstein, Steven J.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. [Aikens, James E.] Univ Michigan, Sch Med, Dept Family Med, Ann Arbor, MI USA. [Trivedi, Ranak] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence Outcomes Older Adults, Seattle, WA USA. [Trivedi, Ranak] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. RP Piette, JD (reprint author), VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, HSR&D Ctr Excellence, POB 130170, Ann Arbor, MI 48113 USA. EM jpiette@umich.edu FU University of Michigan Health System Faculty Group Practice; Blue Cross and Blue Shield of Michigan; National Institute of Mental Health [R01 MH096699-01]; National Institute of Diabetes and Sigestive Kidney Diseases [P30DK092926] FX Funding was provided by the University of Michigan Health System Faculty Group Practice, Blue Cross and Blue Shield of Michigan, and grant R01 MH096699-01 from the National Institute of Mental Health. Funding for Dr Piette and Dr Trivedi was from their VA Career Scientist and Career Development awards. Other financial support came from grant number P30DK092926 from the National Institute of Diabetes and Sigestive Kidney Diseases. NR 51 TC 12 Z9 13 U1 3 U2 11 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD NOV PY 2013 VL 19 IS 11 BP 892 EP 900 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 297PM UT WOS:000330267400003 PM 24511987 ER PT J AU Ly, DP Glied, SA AF Ly, Dan P. Glied, Sherry A. TI Variations in the Service Quality of Medical Practices SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID HEALTH-CARE; REGIONAL-VARIATIONS; PHYSICIAN; SATISFACTION; PATIENT; STATES AB Objectives: To examine regional variation in the service quality of physician practices and to assess the association of this variation with the supply and organization of physicians. Study Design: Secondary analyses of the Community Tracking Study (CTS) household and physician surveys. Methods: A total of 40,339 individuals who had seen a primary care physician because of an illness or injury and 17,345 generalist physicians across 4 survey time periods in 60 CTS sites were included. Service quality measures used were lag between making an appointment and seeing a physician, and wait time at the physician's office. Our supply measure was the physician-to-population ratio. Our organizational measure was the percentage of physicians in group practices. Multivariate regressions were performed to examine the relationship between service quality and the supply and organization of physicians. Results: There was substantial variation in the service quality of physician visits across the country. For example, in 2003, the average wait time to see a doctor was 16 minutes in Milwaukee but more than 41 minutes in Miami; the average appointment lag for a sick visit in 2003 was 1.2 days in west-central Alabama but almost 6 days in Northwestern Washington. Service quality was not associated with the primary care physician-to-population ratio and had varying associations with the organization of practices. Conclusions: Cross-site variation in service quality of care in primary care has been large, persistent, and associated with the organization of practices. Areas with higher primary care physician-to-population ratios had longer, not shorter, appointment lags. C1 [Ly, Dan P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Glied, Sherry A.] Columbia Univ, Dept Hlth Policy & Management, Mailman Sch Publ Hlth, New York, NY USA. RP Ly, DP (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM dply@partners.org NR 32 TC 0 Z9 0 U1 1 U2 5 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD NOV PY 2013 VL 19 IS 11 BP E378 EP E385 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 297PM UT WOS:000330267400007 PM 24511996 ER PT J AU Prentice, JC Davies, ML Pizer, SD AF Prentice, Julia C. Davies, Michael L. Pizer, Steven D. TI Using Health Outcomes to Validate Access Quality Measures SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID ACCOUNTABLE CARE; PERFORMANCE; MORTALITY AB Background: Medicare payment reforms will reimburse accountable care organizations (ACOs) for providing high-quality healthcare. Quality measures that reliably predict health outcomes are required. Objectives: To compare the ability of alternative wait time measures to predict glycated hemoglobin (A1C) levels among diabetes patients. Study Design: This retrospective observational study relied on Veterans Health Administration utilization data and Medicare claims data from 2005 to 2010. Methods: Outcomes included an average A1C level and uncontrolled A1C. Heckman selection models simultaneously predicted the presence of an A1C value and its level. Models were risk-adjusted for prior individual health status. The main explanatory variables of interest were facility-level primary care wait times measured in days. Several measures were tested, including capacity measures and retrospective and prospective time stamp measures. The time stamp measures used either the date the appointment was created in the scheduling system (create date) or the date the patient or provider desired the appointment (desired date) as the start date for wait time computation. All measures were calculated separately for new and returning patients. Results: New patient capacity and create date measures significantly predicted outcomes, but desired date measures did not. The returning patient retrospective create date and desired date wait time measures significantly predicted higher and uncontrolled A1C, but capacity and prospective create date measures did not. Conclusions: Different administrative wait times predict A1C for new and returning patients. To properly measure quality. ACOs should use wait time measures that demonstrate relationships with outcomes for subpopulations of patients. C1 [Prentice, Julia C.; Pizer, Steven D.] US Dept Vet Affairs, Boston, MA USA. [Prentice, Julia C.; Pizer, Steven D.] Boston Univ, Sch Med & Publ Hlth, Boston, MA 02215 USA. [Davies, Michael L.] US Dept Vet Affairs, Washington, DC USA. RP Prentice, JC (reprint author), VA Boston Hlth Care Syst, 150 South Huntington Ave,Mail Stop 152H, Boston, MA 02130 USA. EM jprentic@bu.edu FU Systems Redesign Office in the Department of Veterans Affairs FX Funding for this research was provided by the Systems Redesign Office in the Department of Veterans Affairs. NR 33 TC 2 Z9 2 U1 1 U2 3 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD NOV PY 2013 VL 19 IS 11 BP E367 EP E377 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 297PM UT WOS:000330267400006 PM 24511995 ER PT J AU Nishino, M Dahlberg, SE Cardarella, S Jackman, DM Rabin, MS Ramaiya, NH Hatabu, H Janne, PA Johnson, BE AF Nishino, Mizuki Dahlberg, Suzanne E. Cardarella, Stephanie Jackman, David M. Rabin, Michael S. Ramaiya, Nikhil H. Hatabu, Hiroto Jaenne, Pasi A. Johnson, Bruce E. TI Volumetric Tumor Growth in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutations During EGFR-Tyrosine Kinase Inhibitor Therapy Developing Criteria to Continue Therapy Beyond RECIST Progression SO CANCER LA English DT Article DE lung cancer; computed tomography; tumor volume; tumor growth rate; epidermal growth factor receptor tyrosine kinase inhibitors ID DIFFERENT TREATMENT MODALITIES; GUIDELINE VERSION 1.1; FACTOR RECEPTOR; ACQUIRED-RESISTANCE; RESPONSE CRITERIA; SOLID TUMORS; 1ST-LINE TREATMENT; PROGNOSTIC-FACTOR; OPEN-LABEL; GEFITINIB AB BACKGROUNDThe objective of this study was to define the volumetric tumor growth rate in patients who had advanced nonsmall cell lung cancer (NSCLC) with sensitizing epidermal growth factor receptor (EGFR) mutations and had initially received treatment with EGFR-tyrosine kinase inhibitor (TKI) therapy beyond progression. METHODSThe study included 58 patients with advanced NSCLC who had sensitizing EGFR mutations treated with first-line gefitinib or erlotinib, had baseline computed tomography (CT) scans available that revealed a measurable lung lesion, had at least 2 follow-up CT scans during TKI therapy, and had experienced volumetric tumor growth. The tumor volume (in mm(3)) of the dominant lung lesion was measured on baseline and follow-up CT scans during therapy. In total, 405 volume measurements were analyzed in a linear mixed-effects model, fitting time as a random effect, to define the growth rate of the logarithm of tumor volume (log(e)V). RESULTSA linear mixed-effects model was fitted to predict the growth of log(e)V, adjusting for time in months from baseline. Log(e)V was estimated as a function of time in months among patients whose tumors started growing after the nadir: log(e)V=0.12*time+7.68. In this formula, the regression coefficient for time, 0.12/month, represents the growth rate of log(e)V (standard error, 0.015/month; P<.001). When adjusted for baseline volume, log(e)V(0), the growth rate was also 0.12/month (standard error, 0.015/month; P<.001; log(e)V=0.12*months+0.72 log(e)V(0)+0.61). CONCLUSIONSTumor volume models defined volumetric tumor growth after the nadir in patients with EGFR-mutant, advanced NSCLC who were receiving TKI, providing a reference value for the tumor growth rate in patients who progress after the nadir on TKI therapy. The results can be studied further in additional cohorts to develop practical criteria to help identify patients who are slowly progressing and can safely remain on EGFR-TKIs. Cancer 2013;119:3761-3768. (c) 2013 American Cancer Society. C1 [Nishino, Mizuki; Ramaiya, Nikhil H.; Hatabu, Hiroto] Dana Farber Canc Inst, Dept Radiol, Boston, MA 02215 USA. [Nishino, Mizuki; Cardarella, Stephanie; Jackman, David M.; Rabin, Michael S.; Ramaiya, Nikhil H.; Hatabu, Hiroto; Jaenne, Pasi A.; Johnson, Bruce E.] Brigham & Womens Hosp, Boston, MA 02215 USA. [Dahlberg, Suzanne E.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA. [Cardarella, Stephanie; Jackman, David M.; Rabin, Michael S.; Jaenne, Pasi A.; Johnson, Bruce E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Cardarella, Stephanie; Jackman, David M.; Rabin, Michael S.; Jaenne, Pasi A.; Johnson, Bruce E.] Dana Farber Canc Inst, Dept Med, Boston, MA 02215 USA. RP Nishino, M (reprint author), Dana Farber Canc Inst, Dept Radiol, 450 Brookline Ave, Boston, MA 02215 USA. EM mizuki_nishino@dfci.harvard.edu FU National Cancer Institute (NCI) [1K23CA157631]; National Institutes of Health (NIH) [1RO1CA114465-07, 5R21 CA11627-02]; NCI Specialized Program of Research Excellence (SPORE) in Lung Cancer [2P50CA090578-10]; Genentech Inc.; Doris and William Krupp Research Fund in Thoracic Oncology; American Society of Clinical Oncology Translational Research Professorship FX The investigators were supported by grant 1K23CA157631 from the National Cancer Institute (NCI) (M.N.), by grants 1RO1CA114465-07 (B.E.J./P.A.J.) and 5R21 CA11627-02 (H. H.) from the National Institutes of Health (NIH), by grant 2P50CA090578-10 (B.E.J./P.A.J.) from the NCI Specialized Program of Research Excellence (SPORE) in Lung Cancer, by a grant from Genentech Inc., by a grant from the Doris and William Krupp Research Fund in Thoracic Oncology, and by an American Society of Clinical Oncology Translational Research Professorship. NR 53 TC 9 Z9 9 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD NOV 1 PY 2013 VL 119 IS 21 BP 3761 EP 3768 DI 10.1002/cncr.28290 PG 8 WC Oncology SC Oncology GA 295BN UT WOS:000330091700008 PM 23922022 ER PT J AU Wright, AA Howitt, BE Myers, AP Dahlberg, SE Palescandolo, E Van Hummelen, P MacConaill, LE Shoni, M Wagle, N Jones, RT Quick, CM Laury, A Katz, IT Hahn, WC Matulonis, UA Hirsch, MS AF Wright, Alexi A. Howitt, Brooke E. Myers, Andrea P. Dahlberg, Suzanne E. Palescandolo, Emanuele Van Hummelen, Paul MacConaill, Laura E. Shoni, Melina Wagle, Nikhil Jones, Robert T. Quick, Charles M. Laury, Anna Katz, Ingrid T. Hahn, William C. Matulonis, Ursula A. Hirsch, Michelle S. TI Oncogenic Mutations in Cervical Cancer Genomic Differences Between Adenocarcinomas and Squamous Cell Carcinomas of the Cervix SO CANCER LA English DT Article DE cervical cancer; adenocarcinoma; squamous cell carcinoma; somatic mutations; PIK3CA; EGFR; KRAS; DNA mutational analysis; human papillomavirus; mutation ID HUMAN-PAPILLOMAVIRUS GENOTYPE; METASTATIC COLORECTAL-CANCER; THERAPEUTIC TARGET; PIK3CA MUTATION; KRAS MUTATIONS; BRAF MUTATIONS; UNITED-STATES; LUNG-CANCER; PATHWAY; EXPRESSION AB BACKGROUNDCervical cancer is the second leading cause of cancer deaths among women worldwide. The objective of this study was to describe the most common oncogenic mutations in cervical cancers and to explore genomic differences between the 2 most common histologic subtypes: adenocarcinoma and squamous cell carcinoma. METHODSA high-throughput genotyping platform, termed Oncomap, was used to interrogate 80 cervical tumors for 1250 known mutations in 139 cancer genes. Samples were analyzed using a mass spectrometry-based genotyping platform and were validated using orthogonal chemistry. Epidermal growth factor receptor (EGFR) mutations were further validated by massive parallel sequencing. Human papilloma virus (HPV) genotyping also was performed. RESULTSValidated mutations were detected in 48 of 80 tumors (60%) examined. The highest mutation rates were in the genes phosphatidylinositol 3-kinase, catalytic subunit (PIK3CA) (31.3%); Kirsten rat sarcoma viral oncogene homolog (KRAS) (8.8%); and EGFR (3.8%). PIK3CA mutation rates did not differ significantly between adenocarcinomas and squamous cell carcinomas (25% vs 37.5%, respectively; P=.33). In contrast, KRAS mutations were identified only in adenocarcinomas (17.5% vs 0%; P=.01), and a novel EGFR mutation was detected only in squamous cell carcinomas (0% vs 7.5%; P=.24). There were no associations between HPV-16 or HPV-18 and somatic mutations or overall survival. In adjusted analyses, PIK3CA mutations were associated with shorter survival (67.1 months vs 90.3 months; hazard ratio, 9.1; 95% confidence interval, 2.8-29.5 months; P<.001). CONCLUSIONSCervical cancers harbor high rates of potentially targetable oncogenic mutations. In addition, cervical squamous cell carcinoma and adenocarcinoma have distinct molecular profiles, suggesting that clinical outcomes may be improved with the use of more tailored treatment strategies, including PI3K and MEK inhibitors. Cancer 2013;119:3776-3783. (c) 2013 American Cancer Society. C1 [Wright, Alexi A.; Myers, Andrea P.; Palescandolo, Emanuele; Van Hummelen, Paul; MacConaill, Laura E.; Wagle, Nikhil; Hahn, William C.; Matulonis, Ursula A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Wright, Alexi A.; Howitt, Brooke E.; Myers, Andrea P.; Palescandolo, Emanuele; Van Hummelen, Paul; MacConaill, Laura E.; Shoni, Melina; Wagle, Nikhil; Quick, Charles M.; Laury, Anna; Katz, Ingrid T.; Hahn, William C.; Matulonis, Ursula A.; Hirsch, Michelle S.] Harvard Univ, Sch Med, Boston, MA USA. [Wright, Alexi A.] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02215 USA. [Wright, Alexi A.] Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA 02215 USA. [Howitt, Brooke E.; Quick, Charles M.; Laury, Anna; Hirsch, Michelle S.] Brigham & Womens Hosp, Dept Pathol, Div Womens & Perinatal Pathol, Boston, MA 02115 USA. [Dahlberg, Suzanne E.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA. [Dahlberg, Suzanne E.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Palescandolo, Emanuele; Van Hummelen, Paul; MacConaill, Laura E.; Jones, Robert T.; Hahn, William C.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02215 USA. [Van Hummelen, Paul; MacConaill, Laura E.; Wagle, Nikhil; Hahn, William C.] Harvard & Massachusetts Inst Technol, Broad Inst, Cambridge, MA USA. [Katz, Ingrid T.] Brigham & Womens Hosp, Dept Med, Div Womens Hlth, Boston, MA 02115 USA. [Katz, Ingrid T.] Brigham & Womens Hosp, Dept Med, Div Infect Dis, Boston, MA 02115 USA. RP Wright, AA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM alexi_wright@dfci.harvard.edu FU American Cancer Society [MRSG-13-013-01]; Conquer Cancer Foundation of the American Society for Clinical Oncology Career Development Award; Team Maureen Cervical Cancer Fund; Friends of the Dana-Farber Cancer Institute FX This research was supported in part by grant MRSG-13-013-01 from the American Cancer Society, by a Conquer Cancer Foundation of the American Society for Clinical Oncology Career Development Award (to Dr. Wright), and by philanthropic funds from the Team Maureen Cervical Cancer Fund and the Friends of the Dana-Farber Cancer Institute. NR 41 TC 61 Z9 65 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD NOV 1 PY 2013 VL 119 IS 21 BP 3776 EP 3783 DI 10.1002/cncr.28288 PG 8 WC Oncology SC Oncology GA 295BN UT WOS:000330091700010 PM 24037752 ER PT J AU Elkin, EB Atoria, CL Leoce, N Bach, PB Schrag, D AF Elkin, Elena B. Atoria, Coral L. Leoce, Nicole Bach, Peter B. Schrag, Deborah TI Changes in the Availability of Screening Mammography, 2000-2010 SO CANCER LA English DT Article DE breast cancer; screening; mammography; access; disparities ID SERVICES TASK-FORCE; BREAST-CANCER SURVIVORS; UNITED-STATES; ACCESS; POPULATION; CAPACITY; TIMES; CARE AB BACKGROUNDRates of screening mammography have plateaued, and the number of mammography facilities has declined in the past decade. The objective of this study was to assess changes over time and geographic disparities in the availability of mammography services. METHODSUsing information from the US Food and Drug Administration and the US Census, county-level mammography capacity was defined as the number of mammography machines per 10,000 women aged40 years. Cross-sectional variation and longitudinal changes in capacity were examined in relation to county characteristics. RESULTSBetween 2000 and 2010, the number of mammography facilities declined 10% from 9434 to 8469, the number of mammography machines declined 10% from 13,100 to 11,762, and the median county mammography capacity decreased nearly 20% from 1.77 to 1.42 machines per 10,000 women aged40 years. In cross-sectional analysis, counties with greater percentages of uninsured residents, less educated residents, greater population density, and higher managed care penetration had lower mammography capacity. Conversely, counties with more hospital beds per 100,000 population had higher capacity. High initial mammography capacity, growth in both the percentage of the population aged65 years and the percentage living in poverty, and increased managed care penetration were all associated with a decrease in mammography capacity between 2000 and 2010. Only the percentage of rural residents was associated with an increase in capacity. CONCLUSIONSGeographic variation in mammography capacity and declines in capacity over time are associated with demographic, socioeconomic, and health care market characteristics. Maldistribution of mammography resources may explain geographic disparities in breast cancer screening rates. Cancer 2013;119:3847-3853. (c) 2013 American Cancer Society. C1 [Elkin, Elena B.; Atoria, Coral L.; Bach, Peter B.] Mem Sloan Kettering Canc Ctr, Ctr Hlth Policy & Outcomes, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Leoce, Nicole] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA. [Schrag, Deborah] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Dept Med Oncol, Boston, MA 02115 USA. RP Elkin, EB (reprint author), Mem Sloan Kettering Canc Ctr, Ctr Hlth Policy & Outcomes, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA. EM elkine@mskcc.org FU Susan G. Komen Breast Cancer Foundation [POP107806]; American Cancer Society [MRSG-06-127-01-CPHPS]; National Cancer Institute [K07-CA118189] FX Funded by grants from the Susan G. Komen Breast Cancer Foundation (POP107806; Principal Investigator: Elena B. Elkin), the American Cancer Society (MRSG-06-127-01-CPHPS; Principal Investigator: Elena B. Elkin), and the National Cancer Institute (K07-CA118189; Principal Investigator: Elena B. Elkin). NR 32 TC 4 Z9 4 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD NOV 1 PY 2013 VL 119 IS 21 BP 3847 EP 3853 DI 10.1002/cncr.28305 PG 7 WC Oncology SC Oncology GA 295BN UT WOS:000330091700018 PM 23943323 ER PT J AU Mifflin, J AF Mifflin, Jeffrey TI Illusions in motion: media archaeology of the moving panorama and related spectacles SO EARLY POPULAR VISUAL CULTURE LA English DT Book Review C1 [Mifflin, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Mifflin, J (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1746-0654 EI 1746-0662 J9 EARLY POPUL VIS CULT JI Early Popul. Vis. Cult. PD NOV 1 PY 2013 VL 11 IS 4 BP 438 EP 440 DI 10.1080/17460654.2013.837591 PG 3 WC Humanities, Multidisciplinary SC Arts & Humanities - Other Topics GA 295IN UT WOS:000330109900007 ER PT J AU Sadik, CD Sezin, T Kim, ND AF Sadik, Christian D. Sezin, Tanya Kim, Nancy D. TI Leukotrienes orchestrating allergic skin inflammation SO EXPERIMENTAL DERMATOLOGY LA English DT Article DE atopic dermatitis; inflammation; leukotrienes; lipid mediators; neutrophils ID INFL AMMATORY ARTHRITIS; T-CELL RECRUITMENT; B-4 RECEPTORS BLT1; ATOPIC-DERMATITIS; ARACHIDONIC-ACID; NEUTROPHIL RECRUITMENT; BLISTER FLUIDS; MURINE MODEL; MAST-CELLS; EXPRESSION AB Leukotrienes constitute a group of lipid mediators, which may be subdivided into two groups, with leukotriene B-4 on the one hand and cysteinyl leukotrienes on the other. Although leukotrienes are abundantly expressed in skin affected by diverse chronic inflammatory diseases, including atopic dermatitis, psoriasis, pemphigus vulgaris and bullous pemphigoid, their pathological roles in these diseases have remained elusive. Recent data now reveal that both leukotriene B-4 and cysteinyl leukotrienes are indispensable in the pathogenesis of atopic dermatitis, with leukotriene B-4 initiating the recruitment of inflammatory cells, particularly neutrophils and T(H)2 cells into the skin, and cysteinyl leukotrienes later inducing characteristic structural alterations of chronically affected skin, specifically skin fibrosis and keratinocyte proliferation. Thus, these results reveal a sequential cooperation of LTB4 and cysteinyl leukotrienes to initiate and perpetuate allergic skin inflammation. These new insights highlight leukotrienes as promising therapeutic targets in allergic skin inflammation and should encourage more research into the role of leukotrienes in other inflammatory skin diseases. C1 [Sadik, Christian D.; Sezin, Tanya] Univ Lubeck, Dept Dermatol Allergy & Venereol, D-23538 Lubeck, Germany. [Kim, Nancy D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis,Div Rheumatol Alle, Boston, MA USA. RP Sadik, CD (reprint author), Univ Lubeck, Dept Dermatol Allergy & Venereol, Ratzeburger Allee 160, D-23538 Lubeck, Germany. EM Christian.Sadik@uksh.de NR 64 TC 9 Z9 9 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0906-6705 EI 1600-0625 J9 EXP DERMATOL JI Exp. Dermatol. PD NOV PY 2013 VL 22 IS 11 BP 705 EP 709 DI 10.1111/exd.12239 PG 5 WC Dermatology SC Dermatology GA 295FR UT WOS:000330102500004 PM 24433180 ER PT J AU Rodriguez, EK Kwon, JY Herder, LM Appleton, PT AF Rodriguez, Edward K. Kwon, John Y. Herder, Lindsay M. Appleton, Paul T. TI Correlation of AO and Lauge-Hansen Classification Systems for Ankle Fractures to the Mechanism of Injury SO FOOT & ANKLE INTERNATIONAL LA English DT Article DE Lauge-Hansen classification system; YouTube; ankle fracture classification; injury videos; AO classification system ID OBSERVER VARIATION AB Background: Our aim was to assess whether the Lauge-Hansen (LH) and the Muller AO classification systems for ankle fractures radiographically correlate with in vivo injuries based on observed mechanism of injury. Methods: Videos of potential study candidates were reviewed on YouTube.com. Individuals were recruited for participation if the video could be classified by injury mechanism with a high likelihood of sustaining an ankle fracture. Corresponding injury radiographs were obtained. Injury mechanism was classified using the LH system as supination/external rotation (SER), supination/adduction (SAD), pronation/external rotation (PER), or pronation/abduction (PAB). Corresponding radiographs were classified by the LH system and the AO system. Results: Thirty injury videos with their corresponding radiographs were collected. Of the video clips reviewed, 16 had SAD mechanisms and 14 had PER mechanisms. There were 26 ankle fractures, 3 nonfractures, and 1 subtalar dislocation. Twelve fractures with SAD mechanisms had corresponding SAD fracture patterns. Five PER mechanisms had PER fracture patterns. Eight PER mechanisms had SER fracture patterns and 1 had SAD fracture pattern. When the AO classification was used, all 12 SAD type injuries had a 44A type fracture, whereas the 14 PER injuries resulted in nine 44B fractures, two 44C fractures, and three 43A fractures. Conclusion: When injury video clips of ankle fractures were matched to their corresponding radiographs, the LH system was 65% (17/26) consistent in predicting fracture patterns from the deforming injury mechanism. When the AO classification system was used, consistency was 81% (21/26). The AO classification, despite its development as a purely radiographic system, correlated with in vivo injuries, as based on observed mechanism of injury, more closely than did the LH system. C1 [Rodriguez, Edward K.; Herder, Lindsay M.] Beth Israel Deaconess Med Ctr, Dept Orthopaed Surg, Boston, MA 02215 USA. [Kwon, John Y.; Appleton, Paul T.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. RP Rodriguez, EK (reprint author), Beth Israel Deaconess Med Ctr, Dept Orthopaed Surg, 330 Brookline Ave,Stoneman 10, Boston, MA 02215 USA. EM ekrodrig@bidmc.harvard.edu FU AO Foundation [AO S-09-39R] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by an AO Foundation Startup Grant (AO S-09-39R). NR 10 TC 8 Z9 10 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1071-1007 EI 1944-7876 J9 FOOT ANKLE INT JI Foot Ankle Int. PD NOV PY 2013 VL 34 IS 11 BP 1516 EP 1520 DI 10.1177/1071100713491730 PG 5 WC Orthopedics SC Orthopedics GA 297YO UT WOS:000330291200008 PM 23729206 ER PT J AU Eicher, JD Powers, NR Miller, LL Akshoomoff, N Amaral, DG Bloss, CS Libiger, O Schork, NJ Darst, BF Casey, BJ Chang, L Ernst, T Frazier, J Kaufmann, WE Keating, B Kenet, T Kennedy, D Mostofsky, S Murray, SS Sowell, ER Bartsch, H Kuperman, JM Brown, TT Hagler, DJ Dale, AM Jernigan, TL St Pourcain, B Smith, GD Ring, SM Gruen, JR AF Eicher, J. D. Powers, N. R. Miller, L. L. Akshoomoff, N. Amaral, D. G. Bloss, C. S. Libiger, O. Schork, N. J. Darst, B. F. Casey, B. J. Chang, L. Ernst, T. Frazier, J. Kaufmann, W. E. Keating, B. Kenet, T. Kennedy, D. Mostofsky, S. Murray, S. S. Sowell, E. R. Bartsch, H. Kuperman, J. M. Brown, T. T. Hagler, D. J., Jr. Dale, A. M. Jernigan, T. L. St. Pourcain, B. Smith, G. Davey Ring, S. M. Gruen, J. R. TI Genome-wide association study of shared components of reading disability and language impairment SO GENES BRAIN AND BEHAVIOR LA English DT Article DE ALSPAC; dyslexia GWAS; language impairment; PING; reading disability; ZNF385D ID DEFICIT HYPERACTIVITY DISORDER; ALTERED BRAIN ACTIVATION; DEVELOPMENTAL DYSLEXIA; KIAA0319; SPEECH; DCDC2; GENE; CHILDREN; ATTENTION; REGIONS AB Written and verbal languages are neurobehavioral traits vital to the development of communication skills. Unfortunately, disorders involving these traitsspecifically reading disability (RD) and language impairment (LI)are common and prevent affected individuals from developing adequate communication skills, leaving them at risk for adverse academic, socioeconomic and psychiatric outcomes. Both RD and LI are complex traits that frequently co-occur, leading us to hypothesize that these disorders share genetic etiologies. To test this, we performed a genome-wide association study on individuals affected with both RD and LI in the Avon Longitudinal Study of Parents and Children. The strongest associations were seen with markers in ZNF385D (OR=1.81, P=5.45x10(-7)) and COL4A2 (OR=1.71, P=7.59x10(-7)). Markers within NDST4 showed the strongest associations with LI individually (OR=1.827, P=1.40x10(-7)). We replicated association of ZNF385D using receptive vocabulary measures in the Pediatric Imaging Neurocognitive Genetics study (P=0.00245). We then used diffusion tensor imaging fiber tract volume data on 16 fiber tracts to examine the implications of replicated markers. ZNF385D was a predictor of overall fiber tract volumes in both hemispheres, as well as global brain volume. Here, we present evidence for ZNF385D as a candidate gene for RD and LI. The implication of transcription factor ZNF385D in RD and LI underscores the importance of transcriptional regulation in the development of higher order neurocognitive traits. Further study is necessary to discern target genes of ZNF385D and how it functions within neural development of fluent language. C1 [Eicher, J. D.; Powers, N. R.; Gruen, J. R.] Yale Univ, Dept Genet, New Haven, CT 06520 USA. [Miller, L. L.; St. Pourcain, B.; Smith, G. Davey; Ring, S. M.] Univ Bristol, Sch Social & Community Med, MRC Integrat Epidemiol Unit IEU, Bristol, Avon, England. [Akshoomoff, N.; Brown, T. T.; Jernigan, T. L.] Univ Calif San Diego, Ctr Human Dev, La Jolla, CA 92093 USA. [Akshoomoff, N.; Dale, A. M.; Jernigan, T. L.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Amaral, D. G.] Univ Calif Davis, Dept Psychiat & Behav Sci, Davis, CA 95616 USA. [Bloss, C. S.; Libiger, O.; Schork, N. J.; Darst, B. F.; Murray, S. S.] Scripps Translat Sci Inst, Scripps Genom Med, La Jolla, CA USA. [Bloss, C. S.; Libiger, O.; Schork, N. J.; Darst, B. F.; Murray, S. S.] Scripps Hlth, La Jolla, CA USA. [Casey, B. J.] Weill Cornell Med Coll, Sackler Inst Dev Psychobiol, New York, NY USA. [Chang, L.; Ernst, T.; Keating, B.] Univ Hawaii, Dept Med, Honolulu, HI 96822 USA. [Chang, L.; Ernst, T.; Keating, B.] Queens Med Ctr, Honolulu, HI USA. [Frazier, J.; Kennedy, D.] Univ Massachusetts, Sch Med, Dept Psychiat, Boston, MA 02125 USA. [Kaufmann, W. E.; Mostofsky, S.] Kennedy Krieger Inst, Baltimore, MD USA. [Kaufmann, W. E.] Harvard Univ, Childrens Hosp, Dept Neurol, Sch Med, Boston, MA 02115 USA. [Kenet, T.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA. [Kenet, T.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Sowell, E. R.] Univ So Calif, Dept Pediat, Los Angeles, CA 90089 USA. [Sowell, E. R.] Childrens Hosp, Dev Cognit Neuroimaging Lab, Los Angeles, CA 90027 USA. [Bartsch, H.; Kuperman, J. M.; Brown, T. T.; Hagler, D. J., Jr.; Dale, A. M.] Univ Calif San Diego, Multimodal Imaging Lab, La Jolla, CA 92093 USA. [Kuperman, J. M.; Brown, T. T.; Dale, A. M.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Hagler, D. J., Jr.; Dale, A. M.; Jernigan, T. L.] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA. [Dale, A. M.; Jernigan, T. L.] Univ Calif San Diego, Dept Cognit Sci, La Jolla, CA 92093 USA. [St. Pourcain, B.] Univ Bristol, Sch Oral & Dent Sci, Bristol, Avon, England. [St. Pourcain, B.] Univ Bristol, Sch Expt Psych, Bristol, Avon, England. [Gruen, J. R.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA. [Gruen, J. R.] Yale Univ, Sch Med, Dept Investigat Med, New Haven, CT 06520 USA. RP Gruen, JR (reprint author), Yale Univ, Sch Med, Yale Child Hlth Res Ctr, Dept Pediat, POB 208064, New Haven, CT 06520 USA. EM jeffrey.gruen@yale.edu RI Davey Smith, George/A-7407-2013; OI Davey Smith, George/0000-0002-1407-8314; St Pourcain, Beate/0000-0002-4680-3517 FU The UK medical research council; Wellcome Trust [092731]; National Institute on Drug Abuse; Eunice Kennedy Shriver National Institute of Child Health & Human Development; National Institutes of Health [R01 NS043530, F31 DC012270] FX We thank all the families and participants who took part in these studies. We also wish to acknowledge the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK medical research council and the Wellcome Trust (Grant ref: 092731) and the University of Bristol provide core support for the ALSPAC. The GWAS genotyping of the ALSPAC children samples was supported by 23andMe. The authors gratefully thank the children, adolescents, adults and parents who participated in the PING study. Data collection and sharing for this project were funded by the PING Study (National Institutes of Health Grant RC2DA029475). PING is funded by the National Institute on Drug Abuse and the Eunice Kennedy Shriver National Institute of Child Health & Human Development. PING data are disseminated by the PING Coordinating Center at the Center for Human Development, University of California at San Diego. This research was specifically funded by the National Institutes of Health (Grant ref: R01 NS043530 awarded to J.R.G., and F31 DC012270 awarded to J.D.E.). NR 71 TC 20 Z9 21 U1 1 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1601-1848 EI 1601-183X J9 GENES BRAIN BEHAV JI Genes Brain Behav. PD NOV PY 2013 VL 12 IS 8 BP 792 EP 801 DI 10.1111/gbb.12085 PG 10 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 295FI UT WOS:000330101600005 PM 24024963 ER PT J AU Kawase, Y Honye, J Ota, H Miyake, T Kamikawa, S Kondo, H Okubo, M Tsuchiya, K Matsuo, H Jang, IK Ueno, K AF Kawase, Yoshiaki Honye, Junko Ota, Hideaki Miyake, Taiji Kamikawa, Shigeshi Kondo, Hiroki Okubo, Munenori Tsuchiya, Kunihiko Matsuo, Hitoshi Jang, Ik-Kyung Ueno, Katsumi TI Neointimal Calcification After Stenting and Chronic Kidney Disease SO INTERNATIONAL HEART JOURNAL LA English DT Article DE Calcification; In stent restenosis; Hemodialysis ID DRUG-ELUTING STENTS; CORONARY-ARTERY-DISEASE; OPTICAL COHERENCE TOMOGRAPHY; STAGE RENAL-DISEASE; BARE-METAL STENTS; RISK; NEOATHEROSCLEROSIS; INSUFFICIENCY; IMPLANTATION; PATHOLOGY AB The timing and incidence of neointimal calcification after stenting (NIC) is largely unknown. The purpose of our study was to elucidate the characteristics of NIC. The presence of NIC in patients who underwent intravascular ultrasound between June 30, 2009 and June 30, 2012 was analyzed. The patients were divided into two groups based on the follow-up period: <365 days or >= 365 days. A total of 181 images were analyzed. Those with MC had a lower estimated glomerular filtration rate [51 (6-60) versus 61 (52-72) mL/minute/1.73 m(2); P < 0.01] and longer time after stenting [3198 (1710-3684) versus 211 (180-516) days; P < 0.01] compared to those without NIC. NIC during short-term follow-up was observed only in patients who were on hemodialysis. On the other hand, NIC in the long-term follow-up was observed only in patients with bare metal stents. The development of NIC was related to renal function and time after stenting. MC in the short-term and the long-term follow-up was observed only in patients who were on hemodialysis and who were implanted with a bare metal stent, respectively. C1 [Kawase, Yoshiaki; Honye, Junko; Ota, Hideaki; Miyake, Taiji; Kamikawa, Shigeshi; Kondo, Hiroki; Okubo, Munenori; Tsuchiya, Kunihiko; Matsuo, Hitoshi; Ueno, Katsumi] Gifu Heart Ctr, Dept Cardiol, Gifu, Gifu 5008384, Japan. [Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. RP Kawase, Y (reprint author), Gifu Heart Ctr, Dept Cardiol, 4-14-4 Yabuta Minami, Gifu, Gifu 5008384, Japan. NR 25 TC 1 Z9 1 U1 0 U2 1 PU INT HEART JOURNAL ASSOC PI TOKYO PA UNIV TOKYO, GRADUATE SCHOOL MEDICINE, DEPT CARDIOVASCULAR MEDICINE, HONGO 7-3-1, BUNKYO-KU, TOKYO, 113-8655, JAPAN SN 1349-2365 EI 1349-3299 J9 INT HEART J JI Int. Heart J. PD NOV PY 2013 VL 54 IS 6 BP 341 EP 347 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 295WM UT WOS:000330147100002 PM 24309442 ER PT J AU Bruinsma, BG Berendsen, TA Izamis, ML Yarmush, ML Uygun, K AF Bruinsma, Bote G. Berendsen, Tim A. Izamis, Maria-Louisa Yarmush, Martin L. Uygun, Korkut TI Determination and extension of the limits to static cold storage using subnormothermic machine perfusion SO INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS LA English DT Article DE Liver; Transplantation; Machine perfusion; Preservation; Cold ischemia; Adenosine triphophate ID HEART-BEATING DONOR; ISCHEMIC RAT-LIVER; NORMOTHERMIC PERFUSION; UW SOLUTION; WARM ISCHEMIA; TRANSPLANTATION; PRESERVATION; GRAFTS; VIABILITY; HEPATOCYTES AB Background/Aims: Static cold storage (SCS) of the liver for transplantation is limited by time. Continuation of metabolic activity leads to depletion of energy stores and loss of cellular function, which results in poor post-transplant function. Machine perfusion (MP) applied at the end of preservation may improve the viability of marginal liver grafts and provides information on the quality of the organ. We attempt to define the limits to SCS in terms of easily measurable perfusion parameters and investigate whether MP can improve liver viability. Methods: Rat livers were cold-stored for 0, 24, 48, 72, and 120 h, after which they were treated with subnormothermic machine perfusion (SNMP). Livers cold-stored for 48 and 72 h were transplanted orthotopically with or without SNMP. During SNMP easily measurable parameters were monitored and adenosine triphosphate (ATP) content was measured following preservation and SNMP. Results: ATP increased significantly during SNMP, but the recovered ATP content deteriorated with increased duration of SCS, with minimal improvement after 72 h of SCS. Vascular resistance during SNMP increased with extended preservation. After 48 h of SCS, orthotopic transplantation survival increased significantly from 50% to 100% with SNMP, but did not improve after 72 h. Conclusions: Vascular resistance and ATP recovery suggest a decrease in viability after 48 h of SCS. Survival data confirms the loss of post-transplant graft function and supports the use of ATP and vascular resistance as useful indicators. Further, we show that the recoverability of a liver using SNMP is limited to 48 h of SCS. C1 [Bruinsma, Bote G.; Berendsen, Tim A.; Izamis, Maria-Louisa; Yarmush, Martin L.; Uygun, Korkut] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med,Dept Surg, Boston, MA 02114 USA. [Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ USA. RP Uygun, K (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med,Dept Surg, 51 Blossom St, Boston, MA 02114 USA. EM uygun.korkut@mgh.harvard.edu FU National Institutes of Health [R00DK080942, R01DK096075, R01EB008678]; Shriners Hospitals for Children FX Funding from the National Institutes of Health (R00DK080942, R01DK096075, R01EB008678), and the Shriners Hospitals for Children are gratefully acknowledged. NR 32 TC 11 Z9 12 U1 0 U2 7 PU WICHTIG EDITORE PI MILAN PA 72/74 VIA FRIULI, 20135 MILAN, ITALY SN 0391-3988 EI 1724-6040 J9 INT J ARTIF ORGANS JI Int. J. Artif. Organs PD NOV PY 2013 VL 36 IS 11 BP 775 EP 780 DI 10.5301/ijao.5000250 PG 6 WC Engineering, Biomedical; Transplantation SC Engineering; Transplantation GA 295BM UT WOS:000330091600004 PM 24338652 ER PT J AU Yee, LM Kaimal, AJ Nakagawa, S Houston, K Kuppermann, M AF Yee, Lynn M. Kaimal, Anjali J. Nakagawa, Sanae Houston, Kathryn Kuppermann, Miriam TI Predictors of Postpartum Sexual Activity and Function in a Diverse Population of Women SO JOURNAL OF MIDWIFERY & WOMENS HEALTH LA English DT Article DE breastfeeding; depression; mode of birth; postpartum sexual function ID CHILDBIRTH; DELIVERY; HEALTH; DEPRESSION; MODE; PREGNANCY; VERSION; TRAUMA; IMPACT; INDEX AB Introduction: The purpose of this study was to identify predictors of postpartum sexual activity and functioning in a diverse population of women using the Sexual Health Outcomes in Women Questionnaire (SHOW-Q). Methods: This was a prospective study of 160 postpartum women assessing relationships between demographic factors, mode of birth, depression, breastfeeding, and sexual activity and function. Questionnaires were administered over the telephone 8 to 10 weeks postpartum and in person 6 to 8 months postpartum. Primary outcomes were sexual activity at 8 to 10 weeks postpartum and global and subscale SHOW-Q scores at 6 to 8 months postpartum; the primary predictor was mode of birth. Associations were assessed using multiple linear and logistic regression analyses. Results: Seventy-five percent of this population (n = 140 at 8-10 weeks, n = 129 at 6-8 months) gave birth vaginally, and 60.7% resumed sexual activity by 8 to 10 weeks postpartum. Only multiparity was associated with increased odds of having resumed sexual activity by 8 to 10 weeks postpartum (adjusted odds ratio [aOR], 2.44; P = .03), whereas older age was associated with decreased odds (aOR, 0.92; P = .02) of having resumed sexual activity. Women who were depressed (effect estimate, -13.3; P = .01), older (-1.1, P = .01), or exclusively breastfeeding (-16.5, P < .001) had significantly poorer sexual satisfaction, whereas multiparous women reported better sexual satisfaction (11.1, P =. 03). A significant relationship between mode of birth and SHOW-Q scores did not emerge, although we did observe a trend toward lower SHOW-Q scores among women who underwent cesarean compared with those giving birth vaginally. Discussion: Multiparity and younger age predict early resumption of sexual activity, whereas depression and breastfeeding are associated with poorer postpartum sexual functioning. The relationship between mode of birth and resumed sexual activity or postpartum sexual function remains uncertain.(C) 2013 by the American College of Nurse-Midwives. C1 [Yee, Lynn M.] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA. [Yee, Lynn M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kaimal, Anjali J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nakagawa, Sanae; Houston, Kathryn; Kuppermann, Miriam] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA. RP Kuppermann, M (reprint author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, 3333 Calif St,Suite 335, San Francisco, CA 94143 USA. EM kuppermannm@obgyn.ucsf.edu FU NCRR NIH HHS [UL1 RR024131] NR 33 TC 5 Z9 5 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-9523 EI 1542-2011 J9 J MIDWIFERY WOM HEAL JI J. Midwifery Women Health PD NOV PY 2013 VL 58 IS 6 BP 654 EP 661 DI 10.1111/jmwh.12068 PG 8 WC Nursing SC Nursing GA 285YL UT WOS:000329430900006 PM 24325662 ER PT J AU DiMartini, A Cruz, RJ Dew, MA Myaskovsky, L Goodpaster, B Fox, K Kim, KH Fontes, P AF DiMartini, Andrea Cruz, Ruy J., Jr. Dew, Mary Amanda Myaskovsky, Larissa Goodpaster, Bret Fox, Kristen Kim, Kevin H. Fontes, Paulo TI Muscle Mass Predicts Outcomes Following Liver Transplantation SO LIVER TRANSPLANTATION LA English DT Article ID NUTRITIONAL ASSESSMENT; COMPUTED-TOMOGRAPHY; BODY-COMPOSITION; CIRRHOSIS; PREVALENCE; VALIDATION; MORTALITY; INDEX; AREA AB For patients with end-stage liver disease, commonly used indices of nutritional status (ie, body weight and body mass index) are often inflated because of fluid overload (ie, ascites and peripheral edema), and this results in an underdiagnosis of malnutrition. Because muscle is the largest protein reservoir in the body, an estimate of the muscle mass may be a more reliable and valid estimate of nutritional status. Therefore, we used pretransplant computed tomography data for 338 liver transplantation (LT) candidates to identify muscle and fat mass on the basis of a specific abdominal transverse section commonly used in body composition analyses, and we investigated the contribution of this measure to specific post-LT outcomes. We found that the majority of our patients (68%) could be defined as cachectic. For men, muscle mass predicted many important posttransplant outcomes, including intensive care unit (ICU) stay, total length of stay (LOS), and days of intubation. Muscle mass was a significant predictor of survival and also predicted disposition to home versus another facility. For women, muscle mass predicted ICU stay, total LOS, and days of intubation, but the effect was modest. Muscle mass did not predict survival or disposition for women. In conclusion, because pretransplant muscle mass is associated with many important postoperative outcomes, we discuss these findings in the context of possible pretransplant interventions for either improving or sustaining muscle mass before surgery. Liver Transpl 19:1172-1180, 2013. (c) 2013 AASLD. C1 [DiMartini, Andrea; Cruz, Ruy J., Jr.; Fontes, Paulo] Univ Pittsburgh, Med Ctr, Dept Transplantat Surg, Pittsburgh, PA USA. [DiMartini, Andrea; Dew, Mary Amanda; Myaskovsky, Larissa; Fox, Kristen] Univ Pittsburgh, Dept Psychiat, Med Ctr, Pittsburgh, PA USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Psychol, Med Ctr, Pittsburgh, PA 15260 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Epidemiol, Med Ctr, Pittsburgh, PA 15261 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Biostat, Med Ctr, Pittsburgh, PA 15261 USA. [Myaskovsky, Larissa; Goodpaster, Bret] Univ Pittsburgh, Dept Med, Med Ctr, Pittsburgh, PA USA. [Goodpaster, Bret] Univ Pittsburgh, Dept Hlth & Phys Educ, Med Ctr, Pittsburgh, PA USA. [Kim, Kevin H.] Univ Pittsburgh, Dept Educ Psychol, Med Ctr, Pittsburgh, PA USA. [DiMartini, Andrea; Cruz, Ruy J., Jr.; Fontes, Paulo] Univ Pittsburgh, Med Ctr, Starzl Transplant Inst, Pittsburgh, PA USA. [Myaskovsky, Larissa] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Kim, Kevin H.] Univ Pittsburgh, Joseph M Katz Grad Sch Business, Pittsburgh, PA 15260 USA. RP DiMartini, A (reprint author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA. EM dimartiniaf@upmc.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK066266, NOT-OD-09-056N]; National Center for Research Resources of the National Institutes of Health; National Institutes of Health Roadmap for Medical Research [5UL1 RR024153-04] FX This research was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (grant R01 DK066266 and administrative supplement NOT-OD-09-056N) and by the National Center for Research Resources (a component of the National Institutes of Health) and the National Institutes of Health Roadmap for Medical Research (grant 5UL1 RR024153-04). The contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Institute of Diabetes and Digestive and Kidney Diseases, the National Center for Research Resources, or the National Institutes of Health. Information on the National Center for Research Resources is available at http://www.ncrr.nih.gov. NR 17 TC 21 Z9 21 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD NOV PY 2013 VL 19 IS 11 BP 1172 EP 1180 DI 10.1002/lt.23724 PG 9 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA 295NE UT WOS:000330122000002 PM 23960026 ER PT J AU Stengel, A Mori, M Tache, Y AF Stengel, A. Mori, M. Tache, Y. TI The role of nesfatin-1 in the regulation of food intake and body weight: recent developments and future endeavors SO OBESITY REVIEWS LA English DT Article DE Food intake; hypothalamus; nesfatin-1; NUCB2 ID CENTRAL-NERVOUS-SYSTEM; CORTICOTROPIN-RELEASING HORMONE; GESTATIONAL DIABETES-MELLITUS; SATIETY MOLECULE NESFATIN-1; PITUITARY-ADRENAL AXIS; CORD BLOOD NESFATIN-1; OREXIN MESSENGER-RNA; INTER-MEAL INTERVALS; PARAVENTRICULAR NUCLEUS; INSULIN-SECRETION AB Nesfatin-1 was discovered in 2006 and introduced as a potential novel anorexigenic modulator of food intake and body weight. The past years have witnessed increasing evidence establishing nesfatin-1 as a potent physiological inhibitor of food intake and body weight and unravelled nesfatin-1's interaction with other brain transmitters to exert its food consumption inhibitory effect. As observed for other anorexigenic brain neuropeptides, nesfatin-1 is also likely to exert additional, if not pleiotropic, actions in the brain and periphery. Recent studies established the prominent expression of the nesfatin-1 precursor, nucleobindin2 (NUCB2), in the stomach and pancreas, where nesfatin-1 influences endocrine secretion. This review will highlight the current experimental state-of-knowledge on the effects of NUCB2/nesfatin-1 on food intake, body weight and glucose homeostasis. Potential implications in human obesity will be discussed in relation to the evidence of changes in circulating levels of NUCB2/nesfatin-1 in disease states, the occurrence of genetic NUCB2 polymorphisms and - in contrast to several other hormones - the independence of leptin signalling known to be blunted under conditions of chronically increased body weight. C1 [Stengel, A.] Charite, Charite Ctr Internal Med & Dermatol, Div Gen Internal & Psychosomat Med, D-13353 Berlin, Germany. [Mori, M.] Gunma Univ, Grad Sch Med, Dept Med & Mol Sci, Maebashi, Gumma 371, Japan. [Tache, Y.] Univ Calif Los Angeles, Dept Med, Div Digest Dis, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. [Tache, Y.] Univ Calif Los Angeles, Div Digest Dis, Ctr Neurobiol Stress, Los Angeles, CA USA. [Tache, Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Tache, Y (reprint author), VA GLA Healthcare Syst, CURE Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU NIDDK NIH HHS [R01 DK-33061, R37 DK033061, P30 DK041301, DK-41301, R01 DK033061] NR 100 TC 18 Z9 18 U1 2 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1467-7881 EI 1467-789X J9 OBES REV JI Obes. Rev. PD NOV PY 2013 VL 14 IS 11 BP 859 EP 870 DI 10.1111/obr.12063 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 295HJ UT WOS:000330106900001 PM 23980879 ER PT J AU Patel, M Shah, G Davies, JB Mittra, RA Eliott, D AF Patel, Mrinali Shah, Gaurav Davies, John B. Mittra, Robert A. Eliott, Dean TI Re-evaluating Our Perspective on Retinal Artery Occlusion from Carotid Dissection: A Report of Three Cases and Review of the Literature SO OPHTHALMIC SURGERY LASERS & IMAGING LA English DT Review ID SECONDARY AB BACKGROUND AND OBJECTIVE: Retinal artery occlusion from carotid dissection is rare and classically considered a post-traumatic phenomenon occurring in young patients and associated with additional symptoms of dissection such as neck pain, headache, or focal neurological deficits. PATIENTS AND METHODS: The authors report three cases of retinal artery occlusion due to carotid artery dissection and briefly review the literature. RESULTS: Antecedent trauma or neck injury was reported in only 42% (five of 12) of previously reported cases and in none of the three cases presented here. All three patients in this series initially denied symptoms such as headache or neck pain; however, one patient's wife later recalled her husband experiencing minor neck soreness several days prior to visual loss. In 17% (two of 12) of previously reported cases, no additional symptoms of carotid dissection were reported. CONCLUSION: These cases highlight the importance of considering carotid dissection in young patients with retinal artery occlusion, even in the absence of a report of recent trauma or associated symptoms such as pain. C1 [Patel, Mrinali; Eliott, Dean] Harvard Univ, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Retina Serv,Med Sch, Boston, MA 02114 USA. [Shah, Gaurav] Retina Inst, St Louis, MO USA. [Davies, John B.; Mittra, Robert A.] VitreoRetinal Surg, St Paul, MN USA. RP Eliott, D (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM dean_eliott@meei.harvard.edu NR 13 TC 2 Z9 2 U1 0 U2 2 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 1542-8877 EI 1938-2375 J9 OPHTHAL SURG LAS IM JI Ophthalmic Surg. Lasers Imaging PD NOV-DEC PY 2013 VL 44 IS 6 BP 555 EP 560 DI 10.3928/23258160-20130901-01 PG 6 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA 296NW UT WOS:000330192900007 PM 24094478 ER PT J AU Holman, KM Carr, JA Baddley, JW Hook, EW AF Holman, Katherine M. Carr, James Andrew Baddley, John W. Hook, Edward W., III TI Sexual History Taking and Sexually Transmitted Infection Screening in Patients Initiating Erectile Dysfunction Medication Therapy SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID RISK; HIV; SILDENAFIL; BEHAVIOR; DISEASES; ADULTS; MEN AB Background: Erectile dysfunction medications are being prescribed frequently; however, little is known about the amount of sexual health screening occurring in this setting. Methods: A retrospective cohort study evaluating sexual health and sexually transmitted infection screening occurring in veterans receiving initial erectile dysfunction medication prescription was conducted. Results: A total of 252 patients received initial erectile dysfunction medication prescriptions between October 1, 2009, and December 31, 2009; had at least 1 health care provider visit 12 months before the date of initial prescription; and had no documentation of previous erectile dysfunction medication use. Approximately 3% of these patients had any aspect of a sexual history recorded in the 24 months surrounding initial erectile dysfunction medication prescription. Sexually transmitted infection screening was 9.9% for syphilis, 4.8% for HIV, and 4.3% for gonorrhea/chlamydia before prescription, with only a slight increase in HIV screening after prescription. Conclusions: Minimal sexual health assessment is being performed during the time surrounding initial prescription of erectile dysfunction medication. Further work needs to evaluate patient and provider barriers to basic elements of sexual health care, such as taking sexual histories or screening for sexually transmitted infections. C1 [Holman, Katherine M.] Birmingham Vet Affairs Med Ctr, Dept Qual Management, Birmingham, AL USA. [Holman, Katherine M.; Baddley, John W.; Hook, Edward W., III] Birmingham Vet Affairs Med Ctr, Dept Med, Div Infect Dis, Birmingham, AL USA. [Holman, Katherine M.; Baddley, John W.] Univ Alabama Birmingham, Div Infect Dis, Dept Med, Birmingham, AL 35294 USA. [Carr, James Andrew] Birmingham Vet Affairs Med Ctr, Div Infect Dis, Dept Pharm, Birmingham, AL USA. [Carr, James Andrew] Birmingham Vet Affairs Med Ctr, Div Infect Dis, Dept Internal Med, Birmingham, AL USA. RP Holman, KM (reprint author), Univ Alabama Birmingham, Div Infect Dis, Dept Med, 1900 Univ Blvd THT 229, Birmingham, AL 35294 USA. EM holmkm@uab.edu NR 9 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2013 VL 40 IS 11 BP 836 EP 838 DI 10.1097/OLQ.0000000000000031 PG 3 WC Infectious Diseases SC Infectious Diseases GA 297FU UT WOS:000330241900002 PM 24113402 ER PT J AU Rassiwala, J Vaduganathan, M Kupershtok, M Castillo, FM Evert, J AF Rassiwala, Jasmine Vaduganathan, Muthiah Kupershtok, Mania Castillo, Frank M. Evert, Jessica TI Global Health Educational Engagement-A Tale of Two Models SO ACADEMIC MEDICINE LA English DT Article ID MEDICAL-EDUCATION; PROGRAMS; WORK; EXPERIENCES; CURRICULUM; PHYSICIANS; HUMILITY; STUDENTS; SCHOOLS; ETHICS AB Global health learning experiences for medical students sit at the intersection of capacity building, ethics, and education. As interest in global health programs during medical school continues to rise, Northwestern University Alliance for International Development, a student-led and -run organization at Northwestern University Feinberg School of Medicine, has provided students with the opportunity to engage in two contrasting models of global health educational engagement. Eleven students, accompanied by two Northwestern physicians, participated in a one-week trip to Matagalpa, Nicaragua, in December 2010. This model allowed learning within a familiar Western framework, facilitated high-volume care, and focused on hands-on experiences. This approach aimed to provide basic medical services to the local population. In July 2011, 10 other Feinberg students participated in a four-week program in Puerto Escondido, Mexico, which was coordinated by Child Family Health International, a nonprofit organization that partners with native health care providers. A longer duration, homestays, and daily language classes hallmarked this experience. An intermediary, third-party organization served to bridge the cultural and ethical gap between visiting medical students and the local population. This program focused on providing a holistic cultural experience for rotating students. Establishing comprehensive global health curricula requires finding a balance between providing medical students with a fulfilling educational experience and honoring the integrity of populations that are medically underserved. This article provides a rich comparison between two global health educational models and aims to inform future efforts to standardize global health education curricula. C1 [Rassiwala, Jasmine; Kupershtok, Mania] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Vaduganathan, Muthiah] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Castillo, Frank M.] Northwestern Univ, Dept Family & Community Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Evert, Jessica] Univ Calif San Francisco, Child Family Hlth Int, San Francisco, CA 94143 USA. [Evert, Jessica] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA. RP Evert, J (reprint author), 995 Market St,Suite 1104, San Francisco, CA 94103 USA. EM jevert@cfhi.org RI yan, liu/A-1822-2015 OI yan, liu/0000-0001-8517-1084 FU Child Family Health International FX Child Family Health International funded the Western institutional review board application fee for this program evaluation. NR 39 TC 11 Z9 11 U1 2 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD NOV PY 2013 VL 88 IS 11 BP 1651 EP 1657 DI 10.1097/ACM.0b013e3182a6d0b0 PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 292VB UT WOS:000329929500028 PM 24072106 ER PT J AU Cherniak, WA Drain, PK Brewer, TF AF Cherniak, William A. Drain, Paul K. Brewer, Timothy F. TI Educational Objectives for International Medical Electives: A Literature Review SO ACADEMIC MEDICINE LA English DT Review ID GLOBAL HEALTH ELECTIVES; CHILD HEALTH; PEDIATRIC RESIDENTS; EXPERIENCE; OPPORTUNITIES; STUDENTS; COMPETENCES; CURRICULUM; PROGRAM AB Purpose Although most medical schools and residency programs offer international medical electives (IMEs), little guidance on the educational objectives for these rotations exists; thus, the authors reviewed the literature to compile and categorize a comprehensive set of educational objectives for IMEs. Method In February and July 2012, the authors searched SciVerse Scopus online, which includes the Embase and MEDLINE databases, using specified terms. From the articles that met their inclusion criteria, they extracted the educational objectives of IMEs and sorted them into preelective, intraelective, and postelective objectives. Results The authors identified and reviewed 255 articles, 11 (4%) of which described 22 educational objectives. Among those 22 objectives, 5 (23%), 15 (68%), and 2 (9%) were, respectively, preelective, intraelective, and postelective objectives. Among preelective objectives, only cultural awareness appeared in more than 2 articles (3/11; 27%). Among intraelective objectives, the most commonly defined were enhancing clinical skills and understanding different health care systems (9/11; 82%). Learning to manage diseases rarely seen at home and increasing cultural awareness appeared in nearly half (5/11; 45%) of all articles. Among postelective objectives, reflecting on experiences through a written project was most common (9/11; 82%). Conclusions The authors identified 22 educational objectives for IMEs in the published literature, some of which were consistent across institutions. These consistencies, in conjunction with future research, can be used as a framework on which institutions can build their own IME curricula, ultimately helping to ensure that their medical trainees have a meaningful learning experience while abroad. C1 [Cherniak, William A.] Univ Toronto, Fac Med, Scarborough Hosp, Toronto, ON, Canada. [Drain, Paul K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Drain, Paul K.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Brewer, Timothy F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Cherniak, WA (reprint author), Dept Family & Community Med, 3000 Lawrence Ave East,Bldg A,2nd Floor, Scarborough, ON M1P 2V1, Canada. EM w.cherniak@mail.utoronto.ca OI Cherniak, William/0000-0003-3001-2400; Drain, Paul/0000-0003-3300-3817 FU Harvard Global Health Institute; Fogarty International Clinical Research Scholars and Fellows Program at Vanderbilt University [R24 TW007988]; Program for AIDS Clinical Research Training grant [T32 AI007433] FX Dr. Drain was supported by the Harvard Global Health Institute, the Fogarty International Clinical Research Scholars and Fellows Program at Vanderbilt University (R24 TW007988), and a Program for AIDS Clinical Research Training grant (T32 AI007433). NR 25 TC 6 Z9 6 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 EI 1938-808X J9 ACAD MED JI Acad. Med. PD NOV PY 2013 VL 88 IS 11 BP 1778 EP 1781 DI 10.1097/ACM.0b013e3182a6a7ce PG 4 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 292VB UT WOS:000329929500049 PM 24072105 ER PT J AU Marchbein, D AF Marchbein, Deane TI Humanitarian Surgery A Call to Action for Anesthesiologists SO ANESTHESIOLOGY LA English DT Editorial Material C1 [Marchbein, Deane] Doctors Borders, New York, NY USA. [Marchbein, Deane] Massachusetts Gen Hosp, Arlington, MA USA. [Marchbein, Deane] Cambridge Hlth Alliance, Arlington, MA USA. RP Marchbein, D (reprint author), Doctors Borders, New York, NY USA. EM deane.marchbein@newyork.msf.org NR 1 TC 3 Z9 3 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD NOV PY 2013 VL 119 IS 5 BP 1001 EP 1002 DI 10.1097/ALN.0b013e3182a950fb PG 2 WC Anesthesiology SC Anesthesiology GA 290ZS UT WOS:000329797900002 PM 24037317 ER PT J AU Tirumani, H Tirumani, SH AF Tirumani, Harika Tirumani, Sree Harsha TI Distal intestinal obstruction syndrome: a mimic of acute appendicitis SO EMERGENCY MEDICINE JOURNAL LA English DT Editorial Material C1 [Tirumani, Harika] SVS Med Coll, Mahabubnagar, India. [Tirumani, Sree Harsha] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, Boston, MA 02215 USA. RP Tirumani, SH (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02215 USA. EM tirumani.sreeharsha@gmail.com NR 1 TC 2 Z9 2 U1 0 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1472-0205 EI 1472-0213 J9 EMERG MED J JI Emerg. Med. J. PD NOV PY 2013 VL 30 IS 11 DI 10.1136/emermed-2012-202075 PG 1 WC Emergency Medicine SC Emergency Medicine GA 292OC UT WOS:000329910600013 PM 23345312 ER PT J AU Dana, R Miller, JW AF Dana, Reza Miller, Joan W. TI On the Edge The Clinician-Scientist in Ophthalmology SO JAMA OPHTHALMOLOGY LA English DT Editorial Material C1 [Dana, Reza; Miller, Joan W.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA. RP Dana, R (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. EM reza_dana@meei.harvard.edu NR 7 TC 3 Z9 3 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6165 EI 2168-6173 J9 JAMA OPHTHALMOL JI JAMA Ophthalmol. PD NOV PY 2013 VL 131 IS 11 BP 1401 EP 1402 DI 10.1001/jamaophthalmol.2013.4883 PG 2 WC Ophthalmology SC Ophthalmology GA 291RZ UT WOS:000329848300002 PM 24077531 ER PT J AU Haines, J McDonald, J O'Brien, A Sherry, B Bottino, CJ Schmidt, ME Taveras, EM AF Haines, Jess McDonald, Julia O'Brien, Ashley Sherry, Bettylou Bottino, Clement J. Schmidt, Marie Evans Taveras, Elsie M. TI Healthy Habits, Happy Homes Randomized Trial to Improve Household Routines for Obesity Prevention Among Preschool-Aged Children SO JAMA PEDIATRICS LA English DT Article ID BODY-MASS INDEX; CHILDHOOD OBESITY; SLEEP DURATION; US CHILDREN; FAMILY DINNER; RISK-FACTORS; EARLY-LIFE; OVERWEIGHT; INTERVENTION; TELEVISION AB IMPORTANCE Racial/ethnic and socioeconomic disparities exist across risk factors for childhood obesity. OBJECTIVE To examine the effectiveness of a home-based intervention to improve household routines known to be associated with childhood obesity among a sample of low-income, racial/ethnic minority families with young children. DESIGN Randomized trial. SETTING The intervention was delivered in the families' homes. PARTICIPANTS The study involved 121 families with children aged 2 to 5 years who had a television (TV) in the room where he or she slept; 111 (92%) had 6-month outcome data (55 intervention and 56 control). The mean (SD) age of the children was 4.0 (1.1) years; 45% were overweight/obese. Fifty-two percent of the children were Hispanic, 34% were black, and 14% were white/other. Nearly 60% of the families had household incomes of $20 000 or less. INTERVENTIONS The 6-month intervention promoted 4 household routines, family meals, adequate sleep, limiting TV time, and removing the TV from the child's bedroom, using (1) motivational coaching at home and by phone, (2) mailed educational materials, and (3) text messages. Control subjects were mailed materials focused on child development. MAIN OUTCOMES AND MEASURES Change in parent report of frequency of family meals (times/wk), child sleep duration (hours/d), child weekday and weekend day TV viewing (hours/d), and the presence of a TV in the room where the child slept from baseline to 6 months. A secondary outcome was change in age- and sex-adjusted body mass index (calculated as weight in kilograms divided by height in meters squared). RESULTS Compared with control subjects, intervention participants had increased sleep duration (0.75 hours/d; 95% CI, 0.06 to 1.44; P =.03), greater decreases in TV viewing on weekend days (-1.06 hours/d; 95% CI, -1.97 to -0.15; P =.02), and decreased body mass index (-0.40; 95% CI, -0.79 to 0.00; P =.05). No significant intervention effect was found for the presence of a TV in the room where the child slept or family meal frequency. CONCLUSIONS AND RELEVANCE Our results suggest that promoting household routines, particularly increasing sleep duration and reducing TV viewing, may be an effective approach to reduce body mass index among low-income, racial/ethnic minority children. Longer-term studies are needed to determine maintenance of behavior change. C1 [McDonald, Julia; O'Brien, Ashley; Taveras, Elsie M.] Harvard Univ, Sch Med, Dept Populat Med, Obes Prevent Program, Boston, MA USA. [McDonald, Julia; O'Brien, Ashley; Taveras, Elsie M.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Taveras, Elsie M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Haines, Jess] Univ Guelph, Dept Family Relat & Appl Nutr, Guelph, ON N1G 2W1, Canada. [Sherry, Bettylou] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Bottino, Clement J.; Schmidt, Marie Evans] Childrens Hosp Boston, Div Gen Pediat, Boston, MA USA. [Schmidt, Marie Evans] Childrens Hosp Boston, Ctr Media & Child Hlth, Boston, MA USA. RP Taveras, EM (reprint author), Massachusetts Gen Hosp Children, Div Gen Pediat, Dept Pediat, 100 Cambridge St,15th Fl,Mail Code M100C1570, Boston, MA 02114 USA. EM etaveras@partners.org FU Centers for Disease Control and Prevention; National Center for Chronic Disease Prevention and Health Promotion (Prevention Research Centers) [1U48DP00194] FX This work was supported by the Centers for Disease Control and Prevention and the National Center for Chronic Disease Prevention and Health Promotion (Prevention Research Centers grant 1U48DP00194). NR 45 TC 49 Z9 49 U1 7 U2 49 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD NOV PY 2013 VL 167 IS 11 BP 1072 EP 1079 DI 10.1001/jamapediatrics.2013.2356 PG 8 WC Pediatrics SC Pediatrics GA 291PX UT WOS:000329842300021 PM 24019074 ER PT J AU de Borst, MH Hajhosseiny, R Tamez, H Wenger, J Thadhani, R Goldsmith, DJA AF de Borst, Martin H. Hajhosseiny, Reza Tamez, Hector Wenger, Julia Thadhani, Ravi Goldsmith, David J. A. TI Active Vitamin D Treatment for Reduction of Residual Proteinuria: A Systematic Review SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; RENIN-ANGIOTENSIN SYSTEM; CONVERTING ENZYME-INHIBITORS; RANDOMIZED CONTROLLED-TRIAL; GLOMERULAR-FILTRATION-RATE; TYPE-2 DIABETIC-NEPHROPATHY; NONDIABETIC RENAL-DISEASE; D-RECEPTOR ACTIVATION; POST-HOC ANALYSIS; CARDIOVASCULAR EVENTS AB Despite renin-angiotensin-aldosterone system blockade, which retards progression of CKD by reducing proteinuria, many patients with CKD have residual proteinuria, an independent risk factor for disease progression. We aimed to address whether active vitamin D analogs reduce residual proteinuria. We systematically searched for trials published between 1950 and September of 2012 in the Medline, Embase, and Cochrane Library databases. All randomized controlled trials of vitamin D analogs in patients with CKD that reported an effect on proteinuria with sample size50 were selected. Mean differences of proteinuria change over time and odds ratios for reaching 15% proteinuria decrease from baseline to last measurement were synthesized under a random effects model. From 907 citations retrieved, six studies (four studies with paricalcitol and two studies with calcitriol) providing data for 688 patients were included in the meta-analysis. Most patients (84%) used an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker throughout the study. Active vitamin D analogs reduced proteinuria (weighted mean difference from baseline to last measurement was -16% [95% CI, -13% to -18%]) compared with controls (+6% [95% CI, 0% to +12%]; P<0.001). Proteinuria reduction was achieved more commonly in patients treated with an active vitamin D analog (204/390 patients) than control patients (86/298 patients; OR, 2.72 [95% CI, 1.82 to 4.07]; P<0.001). Thus, active vitamin D analogs may further reduce proteinuria in CKD patients in addition to current regimens. Future studies should address whether vitamin D therapy also retards progressive renal functional decline. C1 [de Borst, Martin H.] Univ Groningen, Univ Med Ctr Groningen, Dept Med, Div Nephrol, Groningen, Netherlands. [Hajhosseiny, Reza; Tamez, Hector; Wenger, Julia; Thadhani, Ravi] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA. [Hajhosseiny, Reza; Goldsmith, David J. A.] Guys Hosp, Kings Hlth Partners Acad Hlth Sci Ctr, Renal & Transplantat Dept, London SE1 9RT, England. RP Goldsmith, DJA (reprint author), Guys Hosp, Kings Hlth Partners Acad Hlth Sci Ctr, Renal & Transplantat Dept, 6th Floor,Borough Wing, London SE1 9RT, England. EM david.goldsmith@gstt.nhs.uk FU Dutch Kidney Foundation (NIGRAM Consortium) [CP10.11]; Dutch Kidney Foundation [KJPB.08.07] FX This work is supported by a consortium grant from the Dutch Kidney Foundation (NIGRAM Consortium, grant no CP10.11). The NIGRAM consortium (www.nigram.eu) consists of the following principal investigators: Piet ter Wee and Marc Vervloet (VU [Vrije Universiteit] Medical Center, Amsterdam, The Netherlands), Rene Bindels and Joost Hoenderop (Radboud University Medical Center, Nijmegen, The Netherlands), and Gerjan Navis, Jan-Luuk Hillebrands, and Martin de Borst (University Medical Center, Groningen, The Netherlands). M.H.d.B. was supported by the Dutch Kidney Foundation Grant KJPB.08.07. NR 52 TC 40 Z9 40 U1 2 U2 8 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD NOV PY 2013 VL 24 IS 11 BP 1863 EP 1871 DI 10.1681/ASN.2013030203 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 292OJ UT WOS:000329911300017 PM 23929770 ER PT J AU O'Seaghdha, CM Hwang, SJ Larson, MG Meigs, JB Vasan, RS Fox, CS AF O'Seaghdha, Conall M. Hwang, Shih-Jen Larson, Martin G. Meigs, James B. Vasan, Ramachandran S. Fox, Caroline S. TI Analysis of a Urinary Biomarker Panel for Incident Kidney Disease and Clinical Outcomes SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID GENERAL-POPULATION; HEART-FAILURE; NONCARDIOVASCULAR MORTALITY; NONVASCULAR MORTALITY; MULTIPLE BIOMARKERS; CARDIOVASCULAR RISK; INJURY MOLECULE-1; EPITHELIAL-CELLS; EXPRESSION; PREDICTION AB Whether novel biomarkers improve the assessment of incident kidney disease and related adverse outcomes remains to be tested in longitudinal observational studies. We tested 14 urinary biomarkers for association with incident kidney, cardiovascular, and mortality outcomes in 2948 Framingham Heart Study participants. Baseline examinations were performed between 1995 and 1998; mean follow-up was 10.1 years for renal outcomes and 11.2 years for survival analyses. Primary outcomes were incident CKD, incident albuminuria, incident cardiovascular disease, and all-cause mortality. Secondary analyses assessed incident congestive heart failure (CHF) and mortality with coexistent kidney disease. Biomarkers were tested for association with renal end points using logistic regression and incident cardiovascular and mortality outcomes in proportional hazards models; 1-microglobulin, Kim-1, and TFF-3 predicted all-cause mortality (hazard ratio per SD increase in log-transformed biomarker [HR] range, 1.15 to 1.21; 95% confidence interval [CI] range, 1.04 to 1.34; P values=0.007 to <0.001), whereas 1-microglobulin, 2-microglobulin, KIM-1, and TFF-3 associated with death with coexistent kidney disease (HR range, 1.72-2.25; 95% CI, 1.17 to 3.24; P values<0.01). KIM-1 also associated with the risk of incident CHF (HR, 1.32; 95% CI, 1.07 to 1.63; P=0.008). CTGF associated nominally with CKD (HR, 0.83; 95% CI, 0.71 to 0.98; P=0.03), but no other biomarkers associated with incident CKD or albuminuria. Addition of 1-microglobulin and TFF-3 resulted in a nonsignificant net reclassification index (NRI) of 3% for all-cause mortality beyond clinical risk factors. In conclusion, components of a panel of 14 subclinical biomarkers of kidney injury were associated with important clinical outcomes and merit additional investigation. C1 [O'Seaghdha, Conall M.; Hwang, Shih-Jen; Larson, Martin G.; Vasan, Ramachandran S.; Fox, Caroline S.] NHLBI, Framingham Heart Study, Framingham, MA 01702 USA. [O'Seaghdha, Conall M.; Hwang, Shih-Jen; Fox, Caroline S.] Ctr Populat Studies, Framingham, MA USA. [O'Seaghdha, Conall M.] Massachusetts Gen Hosp, Div Renal, Boston, MA 02114 USA. [Meigs, James B.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Fox, Caroline S.] Harvard Univ, Sch Med, Boston, MA USA. [O'Seaghdha, Conall M.] Beaumont Hosp, Div Renal, Dublin 9, Ireland. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Prevent Med & Epidemiol Sect, Boston, MA 02118 USA. [Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol, Boston, MA 02115 USA. RP Fox, CS (reprint author), NHLBI, Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA. EM foxca@nhlbi.nih.gov OI Ramachandran, Vasan/0000-0001-7357-5970 FU National Heart, Lung, and Blood Institute [N01-HC-25195] FX The Framingham Heart Study is supported by National Heart, Lung, and Blood Institute Grant N01-HC-25195. NR 46 TC 21 Z9 22 U1 1 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD NOV PY 2013 VL 24 IS 11 BP 1880 EP 1888 DI 10.1681/ASN.2013010019 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 292OJ UT WOS:000329911300019 PM 23990678 ER PT J AU Dyke, ML Cuffee, YL Halanych, JH McManus, RH Curtin, C Allison, JJ AF Dyke, Michelle L. Cuffee, Yendelela L. Halanych, Jewell H. McManus, Richard H. Curtin, Carol Allison, Jeroan J. TI The Relationship Between Coping Styles in Response to Unfair Treatment and Understanding of Diabetes Self-Care SO DIABETES EDUCATOR LA English DT Article ID CLINICAL COMORBIDITY INDEX; AFRICAN-AMERICANS; DECISION-MAKING; HEALTH; RACISM; DISCRIMINATION; PERSPECTIVES; RELIABILITY; STRATEGIES; VALIDATION AB Purpose This study examined the relationship between coping style and understanding of diabetes self-care among African American and white elders in a southern Medicare-managed care plan. Methods Participants were identified through a diabetes-related pharmacy claim or ICD-9 code and completed a computer-assisted telephone survey in 2006-2007. Understanding of diabetes self-care was assessed using the Diabetes Care Profile Understanding (DCP-U) scale. Coping styles were classified as active (talk about it/take action) or passive (keep it to yourself). Linear regression was used to estimate the associations between coping style with the DCP-U, adjusting for age, sex, education, and comorbidities. Based on the conceptual model, 4 separate categories were established for African American and white participants who displayed active and passive coping styles. Results Of 1420 participants, the mean age was 73 years, 46% were African American, and 63% were female. Most respondents (77%) exhibited active coping in response to unfair treatment. For African American participants in the study, active coping was associated with higher adjusted mean DCP-U scores when compared to participants with a passive coping style. No difference in DCP-U score was noted among white participants on the basis of coping style. Conclusions Active coping was more strongly associated with understanding of diabetes self-care among older African Americans than whites. Future research on coping styles may give new insights into reducing diabetes disparities among racial/ethnic minorities. C1 [Dyke, Michelle L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [McManus, Richard H.; Allison, Jeroan J.] Univ Massachusetts, Sch Med, Worcester, MA USA. [Cuffee, Yendelela L.] NYU, Sch Med, New York, NY 10014 USA. [Halanych, Jewell H.] Univ Alabama Birmingham, Birmingham, AL USA. [Curtin, Carol] Eunice Kennedy Shriver Ctr Mental Retardat Inc, Waltham, MA 02154 USA. RP Cuffee, YL (reprint author), NYU, Dept Populat Hlth, Sch Med, 227 East 30th St,6th Floor, New York, NY 10014 USA. EM yendelela.cuffee@nyumc.org OI Allison, Jeroan/0000-0003-4472-2112 FU NIMHD NIH HHS [P60 MD006912] NR 24 TC 2 Z9 2 U1 0 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0145-7217 EI 1554-6063 J9 DIABETES EDUCATOR JI Diabetes Educ. PD NOV PY 2013 VL 39 IS 6 BP 848 EP 855 DI 10.1177/0145721713507112 PG 8 WC Endocrinology & Metabolism; Public, Environmental & Occupational Health SC Endocrinology & Metabolism; Public, Environmental & Occupational Health GA 289FT UT WOS:000329667800010 PM 24096805 ER PT J AU Weitzman, PF Caballero, AE Millan-Ferro, A Becker, AE Levkoff, SE AF Weitzman, Patricia Flynn Caballero, A. Enrique Millan-Ferro, Andreina Becker, Anne E. Levkoff, Sue E. TI Bodily Aesthetic Ideals Among Latinas With Type 2 Diabetes Implications for Treatment Adherence, Access, and Outcomes SO DIABETES EDUCATOR LA English DT Article ID BODY-IMAGE; AFRICAN-AMERICANS; EATING-DISORDERS; ADULTS; SATISFACTION; OVERWEIGHT; EXPOSURE; PATIENT; OBESE; MEDIA AB Purpose The purpose of this study was to examine how attitudes and practices related to bodily aesthetic ideals and self-care might inform the engagement of Latinas with type 2 diabetes (T2DM). Methods Focus groups were used to collect qualitative data concerning bodily aesthetic ideals and diabetes management, including help-seeking experiences, from Latina women with T2DM (n = 29) receiving care through Latino Diabetes Initiative at the Joslin Diabetes Center. Focus groups were conducted in Spanish, audiotaped, transcribed, and content analyzed. Results Four main themes emerged: (1) a preference among participants for a larger than average body size, although perceptions of attractiveness were more closely linked to grooming than body size; bodily dissatisfaction centered on diabetes-induced skin changes, virilization, and fatigue rather than weight; (2) diabetic complications, especially foot pain, as a major obstacle to exercise; (3) fatalistic attitudes regarding the inevitability of diabetes and reversal of its complications; and (4) social burdens, isolation, and financial stressors as contributing to disease exacerbation. Conclusions Interventions that emphasize reduced body size may be less effective with Latinas who have T2DM than those that emphasize the benefits of exercise and weight loss for skin health, energy levels, and reduced virilization. C1 [Weitzman, Patricia Flynn; Levkoff, Sue E.] Environm & Hlth Grp, Cambridge, MA 02138 USA. [Caballero, A. Enrique; Millan-Ferro, Andreina] Harvard Univ, Sch Med, Joslin Diabet Ctr, Latino Diabet Initiat, Boston, MA 02115 USA. [Becker, Anne E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Levkoff, Sue E.] Univ S Carolina, Columbia, SC 29208 USA. RP Weitzman, PF (reprint author), Environm & Hlth Grp, 1280 Massachusetts Ave, Cambridge, MA 02138 USA. EM pat.weitzman@gmail.com FU NIH [DK069379-01] FX Research reported here was conducted while Dr Weitzman was assistant professor of psychology at Brigham & Women's Hospital/Harvard Medical School. It was supported by an NIH grant to Drs Weitzman and Caballero (DK069379-01). NR 38 TC 2 Z9 2 U1 3 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0145-7217 EI 1554-6063 J9 DIABETES EDUCATOR JI Diabetes Educ. PD NOV PY 2013 VL 39 IS 6 BP 856 EP 863 DI 10.1177/0145721713507113 PG 8 WC Endocrinology & Metabolism; Public, Environmental & Occupational Health SC Endocrinology & Metabolism; Public, Environmental & Occupational Health GA 289FT UT WOS:000329667800011 PM 24096804 ER PT J AU Alvarez, J Meyer, FL Granoff, DL Lundy, A AF Alvarez, Jean Meyer, Fremonta L. Granoff, David L. Lundy, Allan TI The Effect of EEG Biofeedback on Reducing Postcancer Cognitive Impairment SO INTEGRATIVE CANCER THERAPIES LA English DT Article DE cancer; oncology; chemobrain; chemofog; neurofeedback; EEG biofeedback; cognitive impairment; survivorship; brain-computer interface; fatigue ID QUALITY-OF-LIFE; BREAST-CANCER; ADJUVANT CHEMOTHERAPY; WHITE-MATTER; LONG-TERM; SURVIVORS AB Background and hypotheses. Postcancer cognitive impairment (PCCI) is observed in a substantial number of breast cancer survivors, persisting for as long as 20 years in some subgroups. Although compensatory strategies are frequently suggested, no restorative interventions have yet been identified. This study examined the feasibility of EEG biofeedback (neurofeedback) and its potential effectiveness in reducing PCCI as well as the fatigue, sleep disturbance, and psychological symptoms that frequently accompany PCCI. Study design. This was a 6-month prospective study with a waitlist control period followed by an active intervention. Participants were female breast cancer survivors (n = 23), 6 to 60 months postchemotherapy, with self-reported cognitive impairment. Methods. Four self-report outcome measures (Functional Assessment of Cancer Therapy-Cognitive Function [FACT-Cog], Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-Fatigue], Pittsburgh Sleep Quality Index [PSQI], and Brief Symptom Inventory [BSI]-18) were administered 3 times during a 10-week waitlist control period, 3 times during a 10-week (20-session) neurofeedback training regimen, and once at 4 weeks postneurofeedback. Results. All 23 participants completed the study, demonstrating the feasibility of EEG biofeedback in this population. Initially, the sample demonstrated significant dysfunction on all measures compared with general population norms. Repeated-measures ANOVAs revealed strongly significant improvements (P < .001) on all 4 cognitive measures (perceived cognitive impairment, comments from others, perceived cognitive abilities, and impact on quality of life [QOL]), the fatigue scale, and the 4 psychological scales (somatization, depression, anxiety and global severity index) as well as on 3 of 8 sleep scales (quality, daytime dysfunction, and global). Two of the other sleep scales (latency and disturbance) were significant at P < .01, and 1 (use of medication) at P < .05; 2 were not significant. Improvements were generally linear across the course of training, and were maintained at the follow-up testing. At the follow-up testing, the sample no longer differed significantly from normative populations on 3 of the 4 FACT-Cog measures (impairment, impact on QOL, and comments), FACIT-Fatigue, PSQI sleep quality and habitual efficiency, or any of the BSI-18 measures of psychological disturbance. Conclusions. Data from this limited study suggest that EEG biofeedback has potential for reducing the negative cognitive and emotional sequelae of cancer treatment as well as improving fatigue and sleep patterns. C1 [Alvarez, Jean] Appl Brain Res Fdn Ohio, Cleveland, OH 44111 USA. [Meyer, Fremonta L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Meyer, Fremonta L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Granoff, David L.] Lake Erie Brain Performance Inst, Beachwood, OH USA. RP Alvarez, J (reprint author), Appl Brain Res Fdn Ohio, 3430 Rocky River Dr, Cleveland, OH 44111 USA. EM jalvarez@ohiobrainresearch.org NR 43 TC 12 Z9 12 U1 3 U2 17 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1534-7354 EI 1552-695X J9 INTEGR CANCER THER JI Integr. Cancer Ther. PD NOV PY 2013 VL 12 IS 6 BP 475 EP 487 DI 10.1177/1534735413477192 PG 13 WC Oncology; Integrative & Complementary Medicine SC Oncology; Integrative & Complementary Medicine GA 287FA UT WOS:000329525900005 PM 23584550 ER PT J AU Stice, E Figlewicz, DP Gosnell, BA Levine, AS Pratt, WE AF Stice, Eric Figlewicz, Dianne P. Gosnell, Blake A. Levine, Allen S. Pratt, Wayne E. TI The contribution of brain reward circuits to the obesity epidemic SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS LA English DT Review DE Obesity; Feeding; Reward; Reinforcement; Mesolimbic dopamine system; Opioids; Food addiction; Drug addiction; Food abuse ID MU-OPIOID RECEPTORS; EXCESSIVE SUGAR INTAKE; DIET-INDUCED OBESITY; ENERGY REGULATORY SIGNALS; MEDIAL PREFRONTAL CORTEX; INDUCED DOPAMINE RELEASE; FOOD-SEEKING BEHAVIOR; NUCLEUS-ACCUMBENS; SUBTHALAMIC NUCLEUS; DORSAL STRIATUM AB One of the defining characteristics of the research of Ann E. Kelley was her recognition that the neuroscience underlying basic learning and motivation processes also shed significant light upon mechanisms underlying drug addiction and maladaptive eating patterns. In this review, we examine the parallels that exist in the neural pathways that process both food and drug reward, as determined by recent studies in animal models and human neuroimaging experiments. We discuss contemporary research that suggests that hyperphagia leading to obesity is associated with substantial neurochemical changes in the brain. These findings verify the relevance of reward pathways for promoting consumption of palatable, calorically dense foods, and lead to the important question of whether changes in reward circuitry in response to intake of such foods serve a causal role in the development and maintenance of some cases of obesity. Finally, we discuss the potential value for future studies at the intersection of the obesity epidemic and the neuroscience of motivation, as well as the potential concerns that arise from viewing excessive food intake as an "addiction". We suggest that it might be more useful to focus on overeating that results in frank obesity, and multiple health, interpersonal, and occupational negative consequences as a form of food "abuse". (C) 2012 Elsevier Ltd. All rights reserved. C1 [Stice, Eric] Oregon Res Inst, Eugene, OR 97403 USA. [Figlewicz, Dianne P.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Gosnell, Blake A.] Univ Minnesota, Dept Food Sci & Nutr, St Paul, MN 55108 USA. [Levine, Allen S.] Univ Minnesota, Coll Food Agr & Nat Resource Sci, St Paul, MN 55108 USA. [Pratt, Wayne E.] Wake Forest Univ, Dept Psychol, Winston Salem, NC 27109 USA. RP Pratt, WE (reprint author), Wake Forest Univ, Dept Psychol, POB 7778 Reynolda Stn, Winston Salem, NC 27109 USA. EM estice@ori.org; latte@u.washington.edu; bgosnell@umn.edu; aslevine@umn.edu; prattwe@wfu.edu FU NIH [R1MH064560A, DK080760, DK092468, DK40963]; NIH/NIDA [R01DA021280]; NIH/NIDDK [P30DK50456]; [DA030618] FX Eric Stice is a Senior Research Scientist at Oregon Research Institute; his research cited herein was supported by NIH grants R1MH064560A, DK080760, and DK092468. Dianne Figlewicz Lattemann is a Senior Research Career Scientist, Biomedical Laboratory Research Program, Department of Veterans Affairs Puget Sound Health Care System, Seattle, Washington; and her research cited in this paper has been supported by NIH grant DK40963. The research by Blake A. Gosnell and Allen S. Levine was supported by NIH/NIDA (R01DA021280) (ASL, BAG) and NIH/NIDDK (P30DK50456) (ASL). Wayne E. Pratt is currently supported by DA030618. NR 164 TC 58 Z9 60 U1 8 U2 55 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7634 EI 1873-7528 J9 NEUROSCI BIOBEHAV R JI Neurosci. Biobehav. Rev. PD NOV PY 2013 VL 37 IS 9 SI SI BP 2047 EP 2058 DI 10.1016/j.neubiorev.2012.12.001 PN A PG 12 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 292EE UT WOS:000329884200012 PM 23237885 ER PT J AU Martins, P Bruinsma, B Farmer, A Berendsen, T Izamis, ML Yeh, H Uygun, K AF Martins, Paulo Bruinsma, Bote Farmer, Adam Berendsen, Tim Izamis, Maria Louisa Yeh, Heidi Uygun, Korkut TI SUBNORMOTHERMIC MACHINE PERFUSION FOR RECOVERY AND VIABILITY TESTING OF THE DISCARDED HUMAN LIVER SO TRANSPLANT INTERNATIONAL LA English DT Meeting Abstract C1 [Martins, Paulo] UMass Mem, Worcester, MA 01605 USA. [Bruinsma, Bote; Farmer, Adam; Berendsen, Tim; Izamis, Maria Louisa; Yeh, Heidi; Uygun, Korkut] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0934-0874 EI 1432-2277 J9 TRANSPL INT JI Transpl. Int. PD NOV PY 2013 VL 26 SU 2 SI SI BP 316 EP 316 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 269HJ UT WOS:000328232002279 ER PT J AU Miller, JW AF Miller, Joan W. TI Treating Macular Degeneration: Looking to the Future SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY LA English DT Meeting Abstract C1 [Miller, Joan W.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1442-6404 EI 1442-9071 J9 CLIN EXP OPHTHALMOL JI Clin. Exp. Ophthalmol. PD NOV PY 2013 VL 41 SU 1 SI SI BP 3 EP 4 DI 10.1111/ceo.12222 PG 2 WC Ophthalmology SC Ophthalmology GA 286ZF UT WOS:000329507100006 ER PT J AU Wangelin, BC Powers, MB Smits, JAJ Tuerk, PW AF Wangelin, Bethany C. Powers, Mark B. Smits, Jasper A. J. Tuerk, Peter W. TI Enhancing exposure therapy for PTSD with yohimbine HCL: Protocol for a double-blind, randomized controlled study implementing subjective and objective measures of treatment outcome SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Randomized controlled trial; Posttraumatic stress disorder; Prolonged exposure; Yohimbine HCL; Skin conductance; Heart rate ID POSTTRAUMATIC-STRESS-DISORDER; PLACEBO-CONTROLLED TRIAL; UNIPOLAR MOOD DISORDERS; SCRIPT-DRIVEN IMAGERY; PROLONGED EXPOSURE; FEAR EXTINCTION; D-CYCLOSERINE; PSYCHOMETRIC PROPERTIES; VETERANS; CHECKLIST AB Prolonged exposure (PE) therapy is considered a gold standard protocol for the treatment of PTSD, and it is associated with large treatment effect sizes in combat veteran samples. However, considering high rates of PTSD in the present veteran population, ongoing research work is important toward improving treatment efficiency by decreasing time to symptom amelioration and increasing the amount of symptom amelioration. The proposed research aims to enhance exposure therapy outcomes for veterans with PTSD via combination treatment with PE and yohimbine hydrochloride (HCL), an alpha-2 adrenergic receptor antagonist. The proposed investigation entails a randomized, placebo-controlled trial investigating the effect of a single administration of,yohimbine HCL (paired with the first session of imaginal exposure) on outcome of PE in 40 veterans with PTSD. An additional goal is to establish a pragmatic method of tracking psychophysiological measures over the course of therapy for incorporation into future clinical psychotherapy trials. Thus, in addition to traditional self- and clinician-reported psychological outcomes, heart rate and skin conductance reactivity will be measured during a standard trauma-specific imagery task before, during, and after PE treatment. We will further investigate whether changes in psychophysiological measures predict changes in patient- and clinician-reported outcome measures. Published by Elsevier Inc. C1 [Wangelin, Bethany C.; Tuerk, Peter W.] Ralph H Johnson VA Med Ctr, Mental Hlth Serv Line, Charleston, SC 29401 USA. [Wangelin, Bethany C.; Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29401 USA. [Powers, Mark B.; Smits, Jasper A. J.] So Methodist Univ, Dept Psychol, Dallas, TX 75205 USA. RP Wangelin, BC (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St 116, Charleston, SC 29401 USA. EM wangelin@musc.edu RI Smits, Jasper/A-4350-2008; OI Smits, Jasper/0000-0001-7128-9807; Powers, Mark/0000-0001-7898-073X; Smits, Jasper/0000-0003-1633-9693 FU Career Development Award from the Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development (PI) [CDA-2] FX Dr. Tuerk's portion of this work was supported by a Career Development Award (CDA-2) from the Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development (PI: Peter W. Tuerk). NR 68 TC 5 Z9 5 U1 4 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD NOV PY 2013 VL 36 IS 2 BP 319 EP 326 DI 10.1016/j.cct.2013.08.003 PG 8 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 283RS UT WOS:000329265300001 PM 23939512 ER PT J AU Jeon, S Walkup, JT Woods, DW Peterson, A Piacentini, J Wilhelm, S Katsovich, L McGuire, JF Dziura, J Scahilli, L AF Jeon, Sangchoon Walkup, John T. Woods, Douglas W. Peterson, Alan Piacentini, John Wilhelm, Sabine Katsovich, Lily McGuire, Joseph F. Dziura, James Scahilli, Lawrence TI Detecting a clinically meaningful change in tic severity in Tourette syndrome: A comparison of three methods SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Tourette syndrome; Yale Global Tic Severity Scale; Clinical Global Impression; Cognitive behavioral intervention; Signal detection analysis; Mixture model ID SIGNAL-DETECTION ANALYSIS; OBSESSIVE-COMPULSIVE DISORDER; DEFINING TREATMENT RESPONSE; CONTROLLED-TRIAL; DOUBLE-BLIND; SCALE; DEPRESSION; BEHAVIOR; CHILDREN; PLACEBO AB Objective: To compare three statistical strategies for classifying positive treatment response based on a dimensional measure (Yale Global Tic Severity Scale [YGTSS]) and a categorical. measure (Clinical Global Impression Improvement [CGI-I] scale). Method: Subjects (N = 232; 69.4% male; ages 9-69 years) with Tourette syndrome or chronic tic disorder participated in one of two 10-week, randomized controlled trials comparing behavioral treatment to supportive therapy. The YGTSS and CGI-I were rated by clinicians blind to treatment assignment We examined the percent reduction in the YGTSS-Total Tic Score (TTS) against Much Improved or Very Much Improved on the CGI-I, computed a signal detection analysis (SDA) and built a mixture model to classify dimensional response based on the change in the YGTSS-TTS. Results: A 25% decrease on the YGTSS-TTS predicted positive response on the CGI-I during the trial. The SDA showed that a 25% reduction in the YGTSS-TI'S provided optimal sensitivity (87%) and specificity (84%) for predicting positive response. Using a mixture model without consideration of the CGI-I, the dimensional response was defined by 23% (or greater) reduction on the YGTSS-TTS. Theodds ratio (OR) of positive response (OR = 5.68,95% CI = [2.99, 10.78]) on the CGI-I for behavioral intervention was greater than the dimensional response (OR = 2.86, 95% Cl = [1.65, 4.99]). Conclusion: A 25% reduction on the YGTSS-TTS is highly predictive of positive response by all three analytic methods. For trained raters, however, tic severity alone does not drive the classification of positive response. Clinicaltrials.gov identifiers: NCT00218777; NCT00231985. (C) 2013 Elsevier Inc. All rights reserved. C1 [Jeon, Sangchoon] Yale Univ, Sch Nursing, New Haven, CT 06536 USA. [Walkup, John T.] Weill Cornell Med Coll, New York, NY USA. [Woods, Douglas W.] Univ Wisconsin, Dept Psychol, Milwaukee, WI 53201 USA. [Peterson, Alan] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Piacentini, John] Univ Calif Los Angeles, Los Angeles, CA USA. [Wilhelm, Sabine] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA USA. [Katsovich, Lily] Yale Univ, Sch Med, Yale Child Study Ctr, New Haven, CT USA. [McGuire, Joseph F.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA. [Dziura, James] Yale Ctr Clin Invest, New Haven, CT USA. [Scahilli, Lawrence] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. RP Scahilli, L (reprint author), Emory Univ, Sch Med, Marcus Ctr, 1920 Briarcliff Rd, Atlanta, GA 30029 USA. EM lawrence.scahill@emory.edu OI Scahill, Lawrence/0000-0001-5073-1707 FU Forest Laboratories; National Institutes of Health (NIH); Shire Pharmaceutical, Roche and Pfizer; Abbott for NIMH-funded; National Institute of Mental Health (NIMH) [5R01MH069877, RO1MH069874, RO1MH069875, NCT00231985]; National Institute of Mental Health [RO1MH070802, NCT00218777]; Yale University Clinical and Translational Sciences Award [UL1 RR024139 from The National Center for Research Resources]; NIH; Tourette Syndrome Association FX Drs. Wilhelm, Peterson, Piacentini, Woods, Walkup and Scahill report receiving royalties from Oxford University Press for treatment manuals on tic disorders. Drs. Wilhelm, Peterson, Piacentini, Woods, Walkup, and Scahill report receiving honoraria for continuing education presentations from the Tourette Syndrome Association. Drs. Piacentini, Woods, and Walkup receive royalties from Guilford Press for a book on Tourette disorder. Dr Wilhelm reports receiving support in the form of free medication and matching placebo from Forest Laboratories for clinical trials funded by the National Institutes of Health (NIH) and receiving book royalties from Guilford Publications, New Harbinger Publications, and Oxford University Press. Dr. Piacentini reports receiving royalties from Oxford University Press for treatment manuals on child obsessive-compulsive disorder. Dr. Woods reports receiving book royalties from New Harbinger and Springer Publications. Dr. Scahill has received royalties from Oxford University Press and American Psychiatric Press, has served as a consultant for BioMarin, Roche, Pfizer and Bracket and has had research support from Shire Pharmaceutical, Roche and Pfizer. Dr. Walkup reports receiving consulting fees from Shire Pharmaceuticals. He reports receiving free drug and matching placebo from Pfizer and Lilly and free drugs from Abbott for NIMH-funded clinical trials. Dr. Jeon, Ms. Katsovich and Mr McGuire report no financial interests.; This work was supported by grants from the National Institute of Mental Health (NIMH) to Drs. Wilhelm (5R01MH069877), Scahill (RO1MH069874), and Peterson (RO1MH069875) with subcontracts to Drs. Piacentini and Woods. Dr. Walkup consulted on this grant (clinicaltrials.gov identifier: NCT00231985). This work was also supported by grant RO1MH070802 (clinicaltrials.gov identifier: NCT00218777) from the National Institute of Mental Health to Dr. Piacentini, with subcontracts to Drs. Woods, Scahill, Wilhelm, Peterson, and Walkup. Drs. Scahill and Jeon receive support from the Yale University Clinical and Translational Sciences Award grant (UL1 RR024139) fromThe National Center for Research Resources, NIH. Role of the sponsor: The funding organization was not involved in the design or conduct of the study; collection, management analysis, and interpretation of the data or preparation, review, and approval of the manuscript. This study was also supported by the Tourette Syndrome Association to Dr. Scahill. NR 22 TC 24 Z9 24 U1 4 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD NOV PY 2013 VL 36 IS 2 BP 414 EP 420 DI 10.1016/j.cct2013.08.012 PG 7 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 283RS UT WOS:000329265300011 PM 24001701 ER PT J AU Huffman, JC Beach, SR Suarez, L Mastromauro, CA DuBois, CM Celano, CM Rollman, BL Januzzi, JL AF Huffman, Jeff C. Beach, Scott R. Suarez, Laura Mastromauro, Carol A. DuBois, Christina M. Celano, Christopher M. Rollman, Bruce L. Januzzi, James L. TI Design and baseline data from the Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized controlled trial SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Collaborative care; Depression; Anxiety; Coronary artery disease; Heart failure; Arrhythmia ID CORONARY-HEART-DISEASE; COGNITIVE-BEHAVIORAL THERAPY; QUALITY-OF-LIFE; PLACEBO-CONTROLLED TRIAL; PERSISTENT DEPRESSIVE SYMPTOMS; DISORDER SEVERITY SCALE; ACTIVITY STATUS INDEX; POST-CABG DEPRESSION; COLLABORATIVE CARE; PANIC DISORDER AB Background: Depression and anxiety in cardiac patients are independently associated with adverse cardiovascular outcomes, including mortality. Collaborative care (CC) programs, which use care managers to assess patients, coordinate care, and perform therapeutic interventions, have proven effective in managing depression in this population. However, no prior CC intervention has simultaneously managed depression and anxiety disorders, and there has been minimal study of CC in high-risk cardiac inpatients. Materials and methods: The Management of Sadness and Anxiety in Cardiology (MOSAIC) study was a prospective randomized trial of a low-intensity CC intervention, compared to enhanced usual care, for patients hospitalized for acute coronary syndrome, heart failure, or arrhythmia, and diagnosed with depression, generalized anxiety disorder (GAD), or panic disorder (PD). The primary outcome measure for MOSAIC was mental health-related quality of life (HRQoL), measured using the Medical Outcomes Study Short Form-12. Additional outcomes included psychological, functional, and medical outcomes, including rehospitalizations. Results: A total of 183 eligible participants were enrolled (92 collaborative care, 91 enhanced usual care); 94% of depressed patients reported being depressed for >1 month, and 53% of those with GAD reported clinically significant anxiety for >1 year. One hundred thirty-three patients had depression, 118 had GAD, and 19 had PD; 74 participants (40%) had two or more of the disorders. Conclusion: The MOSAIC trial will provide data regarding whether an intervention that concurrently manages these common psychiatric disorders results in meaningful improvements in HRQoL, psychiatric symptoms, and medical outcomes in cardiac patients at high risk for adverse outcomes. (C) 2013 Elsevier Inc. All rights reserved. C1 [Huffman, Jeff C.; Beach, Scott R.; Suarez, Laura; Mastromauro, Carol A.; DuBois, Christina M.; Celano, Christopher M.; Januzzi, James L.] Harvard Univ, Sch Med, Boston, MA USA. [Huffman, Jeff C.; Beach, Scott R.; Suarez, Laura; Mastromauro, Carol A.; DuBois, Christina M.; Celano, Christopher M.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Rollman, Bruce L.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA. [Januzzi, James L.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. RP Huffman, JC (reprint author), Massachusetts Gen Hosp, Blake 11,55 Fruit St, Boston, MA 02114 USA. EM jhuffman@partners.org NR 89 TC 11 Z9 11 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD NOV PY 2013 VL 36 IS 2 BP 488 EP 501 DI 10.1016/j.cct.2013.09.012 PG 14 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 283RS UT WOS:000329265300018 PM 24090821 ER PT J AU Meliga, E De Benedictis, M Chieffo, A Latib, A Park, SJ Kim, YH Onuma, Y Capranzano, P Jegere, S Makkar, R Palacios, I Buszman, P Bande, M Chakravarty, T Mehran, R Naber, C Scroccai, I Margey, R Leon, M Moses, J Fajadet, J Lefevre, T Morice, MC Erglis, A Colombo, A Alfieri, O Conte, MR Serruys, PW Colombo, A AF Meliga, Emanuele De Benedictis, Mauro Chieffo, Alaide Latib, Azeem Park, Seung Jung Kim, Young Hak Onuma, Yoshinobu Capranzano, Piera Jegere, Sanda Makkar, Raj Palacios, Igor Buszman, Pawel Bande, Marta Chakravarty, Tarun Mehran, Roxana Naber, Christoph Scrocca, Innocenzo Margey, Ronan Leon, Martin Moses, Jeffrey Fajadet, Jean Lefevre, Thierry Morice, Marie Claude Erglis, Andrejs Tamburinos, Corrado Alfieri, Ottavio Conte, Maria Rosa Serruys, Patrick W. Colombo, Antonio TI Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry SO EUROINTERVENTION LA English DT Article DE coronary artery bypass graft; diabetes; drug-eluting stents; unprotected left main coronary artery disease ID RANDOMIZED-TRIAL; FOLLOW-UP; REVASCULARIZATION; SURGERY; ANGIOPLASTY; STENOSIS; OUTCOMES; MELLITUS; IMPACT; LONG AB Aims: Data regarding the impact on clinical outcomes of PCI with DES implantation vs. CABG to treat unprotected left main coronary artery (ULMCA) disease in diabetic patients are still insufficient. The present study evaluated the short-term and long-term results of percutaneous and surgical revascularisation in diabetic patients with ULMCA disease in a large population. Methods and results: A total of 826 diabetic patients with ULMCA stenosis who received DES (n=520) or underwent CABG (n=306) were selected and analysed from the DELTA registry. In-hospital MACCE was significantly higher in the CABG group, mainly driven by a higher incidence of MI. At four-year follow-up, freedom from death and the composite endpoint of death, MI and cerebrovascular accident (CVA) was similar in the two treatment groups (CABG 87.4%, PCI 82.5%, p=0.124, and CABG 85.4%, PCI 78.9%, p=0.11, respectively). Conversely, freedom from TVR and MACCE was significantly higher in the CABG compared to the PCI group (CABG 95.4%, PCI 79.4%, p<0.001, and CABG 81.9%, PCI 64.7%, p<0.001). Conclusions: In diabetic patients with ULMCA disease with/without concomitant multivessel disease, PCI and CABG led to similar results in terms of death, MI and CVA. However, CABG was associated with less MACCE at long-term follow-up, primarily due to the higher repeat revascularisation rate with DES. C1 [Meliga, Emanuele; De Benedictis, Mauro; Scrocca, Innocenzo; Conte, Maria Rosa] AO Ordine Mauriziano Umberto 1, Intervent Cardiol Unit, Turin, Italy. [Chieffo, Alaide; Latib, Azeem; Alfieri, Ottavio; Colombo, Antonio] Ist Sci San Raffaele, Dept Cardiothorac & Vasc Dis, I-20132 Milan, Italy. [Park, Seung Jung; Kim, Young Hak] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Cardiol,Ctr Med Res & Informat, Seoul, South Korea. [Onuma, Yoshinobu; Serruys, Patrick W.] Erasmus MC, Thoraxctr, Rotterdam, Netherlands. [Capranzano, Piera; Tamburinos, Corrado] Univ Catania, Ferrarotto Hosp, Catania, Italy. [Jegere, Sanda; Erglis, Andrejs] Pauls Stradins Clin Univ Hosp, Latvian Ctr Cardiol, Riga, Latvia. [Jegere, Sanda; Erglis, Andrejs] Univ Latvia, Inst Cardiol, Riga, Latvia. [Makkar, Raj; Chakravarty, Tarun] Cedars Sinai Med Ctr, Cedars Sinai Heart Inst, Los Angeles, CA 90048 USA. [Palacios, Igor; Margey, Ronan] Massachusetts Gen Hosp, Cardiac Catheterizat Lab, Boston, MA 02114 USA. [Palacios, Igor; Margey, Ronan] Harvard Univ, Sch Med, Boston, MA USA. [Buszman, Pawel] Med Univ Silesia, Amer Heart Poland, Katowice, Poland. [Bande, Marta] San Donato Hosp, Intervent Cardiol Unit, San Donato Milanese, Italy. [Mehran, Roxana; Moses, Jeffrey] Columbia Univ, Med Ctr, New York, NY USA. [Mehran, Roxana; Moses, Jeffrey] Cardiovasc Res Fdn, New York, NY USA. [Naber, Christoph] Univ Hosp, Dept Cardiol, Essen, Germany. [Fajadet, Jean] Clin Pasteur, Toulouse, France. [Lefevre, Thierry; Morice, Marie Claude] Inst Hosp Jacques Cartier, Massy, France. RP Meliga, E (reprint author), Mauriziano Hosp, Intervent Cardiol Unit, Largo Filippo Turati 62, I-10128 Turin, Italy. EM emeliga@gmail.com OI TAMBURINO, Corrado/0000-0002-4940-9742 NR 24 TC 0 Z9 1 U1 0 U2 4 PU EUROPA EDITION PI TOULOUSE CEDEX 6 PA 19 ALLEES JEAN JAURES B P 61508, TOULOUSE CEDEX 6, 31015, FRANCE SN 1774-024X EI 1969-6213 J9 EUROINTERVENTION JI EuroIntervention PD NOV PY 2013 VL 9 IS 7 BP 803 EP 808 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 283RZ UT WOS:000329266000007 PM 24280156 ER PT J AU Mukete, BN Rosendorff, C AF Mukete, Bertrand N. Rosendorff, Clive TI Effects of low-dose thiazide diuretics on fasting plasma glucose And serum potassium-a meta-analysis SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Article DE Chlorthalidone; diuretics; glucose; hydrochlorothiazide; hypertension; hypokalemia; potassium; thiazide ID ISOLATED SYSTOLIC HYPERTENSION; LIPID-LOWERING TREATMENT; ATTACK TRIAL ALLHAT; BLOOD-PRESSURE; CLINICAL-TRIALS; ANTIHYPERTENSIVE EFFICACY; CARDIOVASCULAR EVENTS; ELDERLY PROGRAM; LONG-TERM; HYDROCHLOROTHIAZIDE AB This study is a meta-analysis of the metabolic profile (fasting plasma glucose and serum potassium) of low-dose thiazide and thiazide-like diuretics. The meta-analysis involved 10 randomized controlled clinical trials with a total sample size of 17,636 and 17,947 for the potassium and glucose arms respectively. The random effect model was used to calculate the odds ratio with 95 percent confidence interval. The cumulative mean change of fasting plasma glucose was +0.20 mmol/L (+3.6 mg/dL) for the diuretic arm versus +0.12 mmol/L (+2.2 mg/dL) for the comparator arm The cumulative mean change of serum potassium was -0.22 mmol/L (-0.22 mEq/L) for the diuretic arm versus +0.05 mmol/L (+0.05 mEq/L) for the comparator arm. The aggregate odds ratio for having higher fasting plasma glucose in subjects on low-dose thiazide versus non-thiazide antihypertensive was 1.22 (1.11 to 1.33; P < .01). The odds ratio for having a lower serum potassium in subjects on low-dose thiazide versus non-thiazide antihypertensive was 0.36 (0.27 to 0.49; P < .01). The magnitude of the observed change in fasting plasma glucose associated with low-dose thiazide diuretic use, while statistically significant, does not appear to place patients at clinically significant risk. On the other hand, the observed change in serum potassium was also statistically significant, and may be clinically significant in patients whose baseline potassium concentration is low or low-normal, and could predispose at-risk patients, such as those with ischemic heart disease, to ventricular arrhythmias. Published by Elsevier Inc. on behalf of American Society of Hypertension. C1 [Mukete, Bertrand N.] Mt Sinai Sch Med, Leon & Norma Hess Ctr Sci & Med, Cardiovasc Res Ctr, New York, NY USA. [Rosendorff, Clive] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY USA. RP Rosendorff, C (reprint author), Mt Sinai Sch Med, James J Peters VA Med Ctr, Dept Med, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM clive.rosendorff@va.gov NR 47 TC 10 Z9 10 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 EI 1878-7436 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD NOV-DEC PY 2013 VL 7 IS 6 BP 454 EP 466 DI 10.1016/j.jash.2013.05.004 PG 13 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 283UP UT WOS:000329272800008 PM 23800570 ER PT J AU Zhu, S Kozono, D Li, J Kushwaha, D Carter, B Chen, C AF Zhu, Shan Kozono, David Li, Jie Kushwaha, Deepa Carter, Bob Chen, Clark TI GENOME-WIDE shRNA SCREEN REVEALED SYNTHETIC LETHAL INTERACTION BETWEEN DOPAMINE RECEPTOR D2 (DRD2) AND EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITION IN GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Zhu, Shan; Kozono, David] Dana Farber Canc Inst, Boston, MA 02115 USA. [Li, Jie; Kushwaha, Deepa; Carter, Bob; Chen, Clark] Univ Calif San Diego, La Jolla, CA 92093 USA. RI Li, Jie/L-1737-2015 OI Li, Jie/0000-0002-0590-9817 NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 14 EP 14 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200057 ER PT J AU Gruber-Olipitz, M Dabral, S Ramkissoon, S Kung, A Pak, E Chung, J Theisen, M Sun, YP Monrose, V Franchetti, Y Sun, Y Shulman, D Redjal, N Tabak, B Beroukhim, R Zhao, J Buonamici, S Ligon, K Kelleher, J Segal, R AF Gruber-Olipitz, Mariella Dabral, Sukriti Ramkissoon, Shakti Kung, Andrew Pak, Ekaterina Chung, Jarom Theisen, Matthew Sun, Yanping Monrose, Valerie Franchetti, Yoko Sun, Yu Shulman, David Redjal, Navid Tabak, Barbara Beroukhim, Rameen Zhao, Jean Buonamici, Silvia Ligon, Keith Kelleher, Joseph Segal, Rosalind TI COORDINATE ACTIVATION OF Shh AND PI3 KINASE SIGNALING PATHWAYS IN PTEN-DEFICIENT GLIOBLASTOMA PRESENTS NEW OPPORTUNITIES FOR TARGETED THERAPY SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Gruber-Olipitz, Mariella; Dabral, Sukriti; Ramkissoon, Shakti; Kung, Andrew; Pak, Ekaterina; Chung, Jarom; Theisen, Matthew; Sun, Yanping; Monrose, Valerie; Franchetti, Yoko; Sun, Yu; Shulman, David; Tabak, Barbara; Beroukhim, Rameen; Zhao, Jean; Ligon, Keith; Segal, Rosalind] Dana Farber Canc Inst, Boston, MA 02115 USA. [Gruber-Olipitz, Mariella; Dabral, Sukriti; Kung, Andrew; Pak, Ekaterina; Chung, Jarom; Shulman, David; Segal, Rosalind] Boston Childrens Hosp, Boston, MA USA. [Ramkissoon, Shakti; Ligon, Keith] Harvard Med Sch, Boston, MA USA. [Redjal, Navid] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Buonamici, Silvia; Kelleher, Joseph] Novartis Inst Biomed Res, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 17 EP 17 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200070 ER PT J AU Tateishi, K Narita, Y Nakamura, T Cahill, D Kawahara, N Ichimura, K AF Tateishi, Kensuke Narita, Yoshitaka Nakamura, Taishi Cahill, Daniel Kawahara, Nobutaka Ichimura, Koichi TI MUTATIONS OF CD79B ARE COMMON EVENT IN PRIMARY CENTRAL NERVOUS SYSTEM B-CELL LYMPHOMA PATIENTS AND ARE ASSOCIATED WITH UNFAVORABLE PROGNOSIS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Tateishi, Kensuke; Cahill, Daniel; Ichimura, Koichi] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Tateishi, Kensuke; Narita, Yoshitaka; Nakamura, Taishi] Natl Canc Ctr, Tokyo 104, Japan. [Nakamura, Taishi; Kawahara, Nobutaka] Yokohama City Univ, Yokohama, Kanagawa 232, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 28 EP 28 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200117 ER PT J AU Zhu, W Begum, G Wang, QW Clark, P Yang, SS Lin, SH Kahle, K Kuo, J Sun, DD AF Zhu, Wen Begum, Gulnaz Wang, Qiwei Clark, Paul Yang, Sung-Sen Lin, Shih-Hua Kahle, Kristopher Kuo, John Sun, Dandan TI TEMOZOLOMIDE-TRIGGERED ACTIVATION OF THE NA(+)-K+-2CL(-) COTRANSPORTER NKCC1 VIA THE WNK1/OSR1 KINASE PATHWAY IN REGULATION OF GLIOMA MIGRATION SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Zhu, Wen; Begum, Gulnaz; Sun, Dandan] Univ Pittsburgh, Pittsburgh, PA USA. [Wang, Qiwei; Clark, Paul; Kuo, John] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Yang, Sung-Sen; Lin, Shih-Hua] Tri Serv Gen Hosp, Taipei, Taiwan. [Kahle, Kristopher] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kahle, Kristopher] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 31 EP 31 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200131 ER PT J AU Esaki, S Rabkin, S Martuza, R Wakimoto, H AF Esaki, Shinichi Rabkin, Samuel Martuza, Robert Wakimoto, Hiroaki TI COMBINATION THERAPY FOR CANCER STEM CELLS ISOLATED FROM RECURRENT GLIOBLASTOMA UTILIZING ONCOLYTIC HERPES SIMPLEX VIRUSES AND TRANSFORMING GROWTH FACTOR-beta INHIBITOR SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Esaki, Shinichi; Rabkin, Samuel; Martuza, Robert; Wakimoto, Hiroaki] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 42 EP 43 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200178 ER PT J AU Green, AL Ramkissoon, S McCauley, D Jones, K Perry, JA Ramkissoon, L Maire, C Shacham, S Ligon, KL Kung, AL AF Green, Adam L. Ramkissoon, Shakti McCauley, Dilara Jones, Kristen Perry, Jennifer A. Ramkissoon, Lori Maire, Cecile Shacham, Sharon Ligon, Keith L. Kung, Andrew L. TI THERAPEUTIC TARGETINGOFXPO1/CRM1 INADULT AND PEDIATRIC HIGH-GRADE GLIOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Green, Adam L.; Ramkissoon, Shakti; Jones, Kristen; Perry, Jennifer A.; Ramkissoon, Lori; Maire, Cecile; Ligon, Keith L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Green, Adam L.] Boston Childrens Hosp, Boston, MA USA. [Ramkissoon, Shakti; Ligon, Keith L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [McCauley, Dilara; Shacham, Sharon] Karyopharm Therapeut, Natick, MA USA. [Kung, Andrew L.] Columbia Univ, Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 44 EP 44 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200185 ER PT J AU Hingtgen, S Kasmieh, R Nesterenko, I Figueiredo, JL Dash, R Sarkar, D Fisher, P Shah, K AF Hingtgen, Shawn Kasmieh, Randa Nesterenko, Irina Figueiredo, Jose-Luiz Dash, Rupesh Sarkar, Devanand Fisher, Paul Shah, Khalid TI EXPLORING MULTIPLE ASPECTS OF STEM CELL-BASED THERAPY FOR CANCER USING NOVEL MULTI-FUNCTIONAL MOLECULES SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Hingtgen, Shawn; Kasmieh, Randa; Nesterenko, Irina; Figueiredo, Jose-Luiz; Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Dash, Rupesh; Sarkar, Devanand; Fisher, Paul] Virginia Commonwealth Univ, Richmond, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 46 EP 46 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200193 ER PT J AU Lee, WS Maire, C Kluk, M Aster, JC Ligon, K AF Lee, Wen-Shin Maire, Cecile Kluk, Michael Aster, Jon C. Ligon, Keith TI NOTCH PATHWAY ACTIVATION AND RESPONSE TO NOTCH INHIBITION THERAPY IS HETEROGENEOUS IN HUMAN GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Lee, Wen-Shin; Maire, Cecile; Ligon, Keith] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lee, Wen-Shin] Harvard Univ, Sch Med, Boston, MA USA. [Kluk, Michael; Aster, Jon C.; Ligon, Keith] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 50 EP 50 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200210 ER PT J AU Reardon, D Li, G Recht, L Fink, K Nabors, L Tran, D Desjardins, A Chandramouli, N Duic, JP Groves, M Clarke, A Hawthorne, T Green, J Yellin, M Sampson, J AF Reardon, David Li, Gordon Recht, Lawrence Fink, Karen Nabors, Louis Tran, David Desjardins, Annick Chandramouli, Nitin Duic, J. Paul Groves, Morris Clarke, Anne Hawthorne, Thomas Green, Jennifer Yellin, Michael Sampson, John TI ReACT: A PHASE II STUDYOF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Reardon, David] Dana Farber Canc Inst, Boston, MA 02115 USA. [Li, Gordon; Recht, Lawrence] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Fink, Karen] Baylor Res Inst, Dallas, TX USA. [Nabors, Louis] Univ Alabama Birmingham, Birmingham, AL USA. [Tran, David] Washington Univ, St Louis, MO USA. [Desjardins, Annick; Sampson, John] Duke Univ, Med Ctr, Durham, NC USA. [Chandramouli, Nitin] Utah Canc Specialists, Salt Lake City, UT USA. [Duic, J. Paul] Neurol Surg PC, Long Isl Brain Tumor Ctr, Lake Success, NY USA. [Groves, Morris] Texas Oncol, Austin, TX USA. [Clarke, Anne; Hawthorne, Thomas; Green, Jennifer; Yellin, Michael] Celldex Therapeut Inc, Needham, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 71 EP 72 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200297 ER PT J AU Nabors, LB Fink, KL Mikkelsen, T Grujicic, D Tarnawski, R Nam, DH Mazurkiewicz, M Salacz, M Ashby, L Thurzo, L Zagonel, V Depenni, R Perry, JR Henslee-Downey, J Picard, M Reardon, DA AF Nabors, Louis Burt Fink, Karen L. Mikkelsen, Tom Grujicic, Dana Tarnawski, Rafal Nam, Do-Hyun Mazurkiewicz, Maria Salacz, Michael Ashby, Lynn Thurzo, Laszlo Zagonel, Vittorina Depenni, Roberta Perry, James R. Henslee-Downey, Jean Picard, Martin Reardon, David A. TI CILENGITIDE IN COMBINATION WITH STANDARD TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH UNMETHYLATED O-6-METHYLGUANINE- DNA METHYLTRANSFERASE (MGMT) GENE PROMOTER: KEY RESULTS OF THE OPEN-LABEL, CONTROLLED, RANDOMIZED PHASE II CORE STUDY SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Nabors, Louis Burt] Univ Alabama Birmingham, Birmingham, AL USA. [Fink, Karen L.] Baylor Univ, Med Ctr, Dallas, TX USA. [Mikkelsen, Tom] Henry Ford Hlth Syst, Detroit, MI USA. [Grujicic, Dana] Clin Ctr Serbia, Inst Neurosurg, Belgrade, Serbia. [Tarnawski, Rafal] Maria Sklodowska Curie Mem Canc Ctr, Gliwice, Poland. [Tarnawski, Rafal] Inst Oncol, Gliwice Branch, Radiotherapy & Chemotherapy Clin, Gliwice, Poland. [Nam, Do-Hyun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea. [Mazurkiewicz, Maria] Ctr Onkol Ziemi Lubelskiej, Lublin, Poland. [Salacz, Michael] St Lukes Hosp, St Lukes Brain Tumor Ctr, Kansas City, MO USA. [Ashby, Lynn] Barrow Neurol Inst, Phoenix, AZ 85013 USA. [Thurzo, Laszlo] Szegedi Tudomanyegyet, Onkoterapias Int, Szeged, Hungary. [Zagonel, Vittorina] IRCCS, IOV, Med Oncol Unit 1, Padua, Italy. [Depenni, Roberta] Policlin Modena, Modena, Italy. [Perry, James R.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada. [Henslee-Downey, Jean; Picard, Martin] Merck KGaA, Darmstadt, Germany. [Reardon, David A.] Dana Farber Canc Inst, Boston, MA 02115 USA. RI zagonel, vittorina/F-4226-2014; Tarnawski, Rafal/N-7526-2016 OI zagonel, vittorina/0000-0002-0829-2525; NR 0 TC 1 Z9 1 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 80 EP 80 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200329 ER PT J AU Nambudiri, N Nayak, L LaFrankie, D Wen, P AF Nambudiri, Navya Nayak, Lakshmi LaFrankie, Debra Wen, Patrick TI AFLIBERCEPT INDUCED THROMBOTIC MICROANGIOPATHY IN A PATIENT WITH MALIGNANT GLIOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Nambudiri, Navya; Nayak, Lakshmi; LaFrankie, Debra; Wen, Patrick] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 80 EP 80 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200330 ER PT J AU Schiff, D Desjardins, A Cloughesy, T Mikkelsen, T Glantz, M Chamberlain, M Reardon, DA Wen, P AF Schiff, David Desjardins, Annick Cloughesy, Timothy Mikkelsen, Tom Glantz, Michael Chamberlain, Marc Reardon, David A. Wen, Patrick TI PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY AND PHARMACOKINETICS (PK) OF CABOZANTINIB (XL184) CONCURRENT WITH TEMOZOLOMIDE (TMZ) & RADIATION (RT) OR TMZ POST-RT IN NEWLY DIAGNOSED HIGH-GRADE GLIOMAS (HGG) SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Schiff, David] Univ Virginia, Sch Med, Dept Neurol, Neurooncol Ctr, Charlottesville, VA 22908 USA. [Desjardins, Annick] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Durham, NC USA. [Cloughesy, Timothy] Univ Calif Los Angeles, Neurooncol Program, Los Angeles, CA USA. [Mikkelsen, Tom] Henry Ford Hlth Syst, Detroit, MI USA. [Glantz, Michael] Penn State Coll Med, Milton S Hershey Med Ctr, Dept Neurosurg, Hershey, PA USA. [Chamberlain, Marc] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA. [Reardon, David A.; Wen, Patrick] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 81 EP 81 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200334 ER PT J AU Armstrong, T Yuan, Y Liu, D Acquaye, A Vera-Bolanos, E Diefes, K Heathcock, L Cahill, D Gilbert, M Aldape, K AF Armstrong, Terri Yuan, Ying Liu, Diane Acquaye, Alvina Vera-Bolanos, Elizabeth Diefes, Kristin Heathcock, Lindsey Cahill, Daniel Gilbert, Mark Aldape, Kenneth TI IMPACT OF TREATMENT ON OUTCOME IN PATIENTS WITH GRADE II AND III GLIOMAS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Armstrong, Terri] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Armstrong, Terri; Yuan, Ying; Liu, Diane; Acquaye, Alvina; Vera-Bolanos, Elizabeth; Diefes, Kristin; Heathcock, Lindsey; Gilbert, Mark; Aldape, Kenneth] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Cahill, Daniel] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 99 EP 99 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200399 ER PT J AU Arrillaga-Romany, I Ruddy, K Greenberg, S Nayak, L AF Arrillaga-Romany, Isabel Ruddy, Kathryn Greenberg, Steven Nayak, Lakshmi TI ERIBULIN INDUCED NEUROPATHY IN A PATIENT WITH PREVIOUSLY UNDIAGNOSED CHARCOT-MARIE-TOOTH (CMT) DISEASE SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Arrillaga-Romany, Isabel; Ruddy, Kathryn; Greenberg, Steven; Nayak, Lakshmi] Dana Farber Canc Inst, Boston, MA 02115 USA. [Arrillaga-Romany, Isabel] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ruddy, Kathryn; Nayak, Lakshmi] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 99 EP 100 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200400 ER PT J AU Blakeley, J Ye, XB Bergner, A Dombi, E Zalewski, C Follmer, K Halpin, C Fayad, L Jacobs, M Baldwin, A Langmead, S Whitcomb, T Jennings, D Widemann, B Plotkin, S AF Blakeley, Jaishri Ye, Xiaobu Bergner, Amanda Dombi, Eva Zalewski, Christopher Follmer, Krista Halpin, Chris Fayad, Laura Jacobs, Michael Baldwin, Andrea Langmead, Shannon Whitcomb, Trish Jennings, Dominique Widemann, Brigitte Plotkin, Scott TI BEVACIZUMAB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS TYPE 2 AND SYMPTOMATIC VESTIBULAR SCHWANNOMAS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Blakeley, Jaishri; Ye, Xiaobu; Bergner, Amanda; Follmer, Krista; Fayad, Laura; Jacobs, Michael; Langmead, Shannon] Johns Hopkins Univ, Baltimore, MD USA. [Halpin, Chris; Jennings, Dominique] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Dombi, Eva; Zalewski, Christopher; Baldwin, Andrea; Whitcomb, Trish; Widemann, Brigitte; Plotkin, Scott] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 101 EP 101 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200405 ER PT J AU Chamberlain, M Raizer, J Soffetti, R Ruda, R Brandsma, D Boogerd, W Taillibert, S Le Rhun, E Jaeckle, K van den Bent, M Wen, P AF Chamberlain, Marc' Raizer, Jeffrey Soffetti, Riccardo Ruda, Roberta Brandsma, Dieta Boogerd, Wilhelm Taillibert, Sophie Le Rhun, Emilie Jaeckle, Kurt van den Bent, Martin Wen, Patrick TI LEPTOMENINGEAL ASSESSMENT IN NEURO-ONCOLOGY (LANO): A RANO PROPOSED MODEL OF EVALUATION IN LEPTOMENINGEAL METASTASIS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Chamberlain, Marc'] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA. [Raizer, Jeffrey] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Soffetti, Riccardo; Ruda, Roberta] Univ Turin, San Giovanni Battista Hosp, Turin, Italy. [Brandsma, Dieta; Boogerd, Wilhelm] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands. [Taillibert, Sophie] Hosp Pitie Salpetriere, Paris, France. [Le Rhun, Emilie] Hosp Jean Bernard, Valenciennes, France. [Jaeckle, Kurt] Mayo Clin, Jacksonville, FL 32224 USA. [van den Bent, Martin] Dr Daniel Den Hoed Canc Ctr, NL-3008 AE Rotterdam, Netherlands. [Wen, Patrick] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 105 EP 105 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200421 ER PT J AU Cullen, J Winer, E Hochberg, F Sachs, G Jeyapalan, S AF Cullen, John Winer, Eric Hochberg, Fred Sachs, George Jeyapalan, Suriya TI HD-METHOTREXATE/LIPOSOMAL CYTARABINE/RITUXIMAB FOR THE TREATMENT OF A PATIENT WITH SECONDARY CNS LYMPHOMA, LYMPHOMATOUS MENINGITIS AND NEUROLYMPHOMATOSIS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Cullen, John; Winer, Eric; Sachs, George; Jeyapalan, Suriya] Brown Univ, Rhode Isl Hosp, Providence, RI 02903 USA. [Hochberg, Fred] Harvard Univ, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 106 EP 107 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200427 ER PT J AU Prust, M Kalpathy-Cramer, J Poloskova, P Jafari-Khouzani, K Gerstner, E Dietrich, J AF Prust, Morgan Kalpathy-Cramer, Jayashree Poloskova, Pavlina Jafari-Khouzani, Kourosh Gerstner, Elizabeth Dietrich, Jorg TI NEUROIMAGING OF TREATMENT ASSOCIATED NEUROTOXICITY IN GLIOBLASTOMA PATIENTS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Prust, Morgan; Dietrich, Jorg] Harvard Univ, Sch Med, Boston, MA USA. [Prust, Morgan; Kalpathy-Cramer, Jayashree; Poloskova, Pavlina; Jafari-Khouzani, Kourosh; Gerstner, Elizabeth] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Gerstner, Elizabeth; Dietrich, Jorg] Massachusetts Gen Hosp, Ctr Neurooncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 108 EP 108 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200432 ER PT J AU Kaley, T Barani, I Chamberlain, M McDermott, M Raizer, J Rogers, L Schiff, D Vogelbaum, M Weber, D Wen, P AF Kaley, Thomas Barani, Igor Chamberlain, Marc McDermott, Michael Raizer, Jeffrey Rogers, Leland Schiff, David Vogelbaum, Michael Weber, Damien Wen, Patrick TI HISTORICAL BENCHMARKS FOR MEDICAL THERAPY TRIALS IN SURGERY AND RADIATION REFRACTORY MENINGIOMA: A RANO REVIEW SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Kaley, Thomas] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Barani, Igor; McDermott, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Chamberlain, Marc] Univ Washington, Seattle, WA 98195 USA. [Raizer, Jeffrey] Northwestern Univ, Chicago, IL 60611 USA. [Rogers, Leland] Gamma West Canc Serv, Salt Lake City, UT USA. [Schiff, David] Univ Virginia, Charlottesville, VA USA. [Vogelbaum, Michael] Cleveland Clin, Cleveland, OH 44106 USA. [Weber, Damien] Univ Hosp Geneva, Geneva, Switzerland. [Wen, Patrick] Brigham & Womens Ctr, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 113 EP 114 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200455 ER PT J AU Kieran, M Hargrave, D Wen, PY Goldman, S Amakye, D Patton, M Tai, F Moreno, L AF Kieran, Mark Hargrave, Darren Wen, Patrick Y. Goldman, Stewart Amakye, Dereck Patton, Margaret Tai, Feng Moreno, Lucas TI A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ORAL SONIDEGIB (LDE225) VERSUS TEMOZOLOMIDE IN PATIENTS WITH HEDGEHOG PATHWAY-ACTIVATED RELAPSED MEDULLOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Kieran, Mark; Wen, Patrick Y.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hargrave, Darren] Great Ormond St Hosp Sick Children, London WC1N 3JH, England. [Goldman, Stewart] Childrens Hosp Chicago, Chicago, IL USA. [Amakye, Dereck; Patton, Margaret; Tai, Feng] Novartis Pharmaceut, E Hanover, NJ USA. [Moreno, Lucas] CNIO Hosp Nino Jesus, Madrid, Spain. OI Hargrave, Darren/0000-0001-8219-9807 NR 0 TC 0 Z9 0 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 115 EP 115 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200461 ER PT J AU Lee, E Reardon, D Schiff, D Drappatz, J Muzikansky, A Hammond, S Grimm, S Norden, A Beroukhim, R McCluskey, C Chi, A Batchelor, T Smith, K Gaffey, S Gerard, M Snodgras, S Raizer, J Wen, P AF Lee, Eudocia Reardon, David Schiff, David Drappatz, Jan Muzikansky, Alona Hammond, Samantha Grimm, Sean Norden, Andrew Beroukhim, Rameen McCluskey, Christine Chi, Andrew Batchelor, Tracy Smith, Katrina Gaffey, Sarah Gerard, Mary Snodgras, Susan Raizer, Jeffrey Wen, Patrick TI PHASE II STUDY OF PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Lee, Eudocia; Reardon, David; Hammond, Samantha; Norden, Andrew; Beroukhim, Rameen; McCluskey, Christine; Smith, Katrina; Gaffey, Sarah; Gerard, Mary; Wen, Patrick] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Schiff, David] Univ Virginia, Charlottesville, VA USA. [Drappatz, Jan] Univ Pittsburgh, Pittsburgh, PA USA. [Muzikansky, Alona; Chi, Andrew; Batchelor, Tracy] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Grimm, Sean] Univ Minnesota, Minneapolis, MN USA. [Snodgras, Susan] Novartis Pharmaceut, E Hanover, NJ USA. [Raizer, Jeffrey] Northwestern Univ, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 118 EP 118 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200472 ER PT J AU Merker, V Slusarz, K Muzikansky, A Francis, S Plotkin, S AF Merker, Vanessa Slusarz, Katie Muzikansky, Alona Francis, Sanjeev Plotkin, Scott TI LONG-TERM TOXICITY OF BEVACIZUMAB IN PATIENTS WITH NEUROFIBROMATOSIS 2 SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Merker, Vanessa; Slusarz, Katie; Muzikansky, Alona; Francis, Sanjeev; Plotkin, Scott] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 121 EP 121 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200485 ER PT J AU Nambudiri, N Arrilaga, I Dunn, I Folkerth, R Chi, SS Reardon, D AF Nambudiri, Navya Arrilaga, Isabel Dunn, Ian Folkerth, Rebecca Chi, Susan Reardon, David TI INTRACRANIAL GERM CELL TUMOR IN ASSOCIATION WITH MARFAN'S SYNDROME SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Nambudiri, Navya; Arrilaga, Isabel; Chi, Susan; Reardon, David] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA. [Dunn, Ian] Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA. [Folkerth, Rebecca] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Chi, Susan] Boston Childrens Hosp, Dept Hematol Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 122 EP 122 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200491 ER PT J AU Nayak, L Omuro, A DeAngelis, L Robins, HI Govindan, R Gadgeel, S Kelly, K Rigas, J Reimers, HJ Peereboom, D Rosenfeld, S Garst, J Ramnath, N Wing, P Zheng, M Urban, P Abrey, L Wen, P AF Nayak, Lakshmi Omuro, Antonio DeAngelis, Lisa Robins, H. Ian Govindan, Ramaswamy Gadgeel, Shirish Kelly, Karen Rigas, James Reimers, Hans-Joachim Peereboom, David Rosenfeld, Steven Garst, Jennifer Ramnath, Nithya Wing, Patricia Zheng, Ming Urban, Patrick Abrey, Lauren Wen, Patrick TI AN OPEN-LABEL, MULTI-CENTER, PHASE II STUDYOF PATUPILONE (EPO906), IN THE TREATMENT OF RECURRENT OR PROGRESSIVE BRAIN METASTASES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Nayak, Lakshmi; Wen, Patrick] Dana Farber Canc Inst, Boston, MA 02115 USA. [Omuro, Antonio; DeAngelis, Lisa; Abrey, Lauren] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Robins, H. Ian] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. [Govindan, Ramaswamy] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA. [Gadgeel, Shirish] Wayne State Univ, Wertz Clin Canc Ctr, Detroit, MI USA. [Kelly, Karen] Univ Calif Davis, Ctr Canc, Sacramento, CA USA. [Rigas, James] Darmouth Hitchcock Med Ctr, Lebanon, NH USA. [Reimers, Hans-Joachim] St Louis Univ, Ctr Canc, St Louis, MO 63103 USA. [Peereboom, David] Cleveland Clin Fdn, Cleveland, OH 44195 USA. [Rosenfeld, Steven] Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY USA. [Garst, Jennifer] Duke Univ, Med Ctr, Durham, NC USA. [Ramnath, Nithya] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Wing, Patricia; Zheng, Ming; Urban, Patrick] Novartis Pharmaceut, E Hanover, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 122 EP 123 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200492 ER PT J AU Nayak, L DeAngelis, LM Wen, PY Brandes, AA Soffietti, R Peereboom, DM Lin, NU Chamberlain, M Macdonald, D Galanis, E Perry, J Jaeckle, K Mehta, M Stupp, R van den Bent, M Reardon, DA AF Nayak, Lakshmi DeAngelis, Lisa M. Wen, Patrick Y. Brandes, Alba A. Soffietti, Riccardo Peereboom, David M. Lin, Nancy U. Chamberlain, Marc Macdonald, David Galanis, Evanthia Perry, James Jaeckle, Kurt Mehta, Minesh Stupp, Roger van den Bent, Martin Reardon, David A. TI THE NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE: A TOOL TO ASSESS NEUROLOGIC FUNCTION FOR INTEGRATION IN THE RADIOLOGIC ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Nayak, Lakshmi; Wen, Patrick Y.; Lin, Nancy U.; Reardon, David A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [DeAngelis, Lisa M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Brandes, Alba A.] Bellaria Maggiore Hosp, Bologna, Italy. [Soffietti, Riccardo] Univ Turin, Turin, Italy. [Soffietti, Riccardo] San Giovanni Battista Hosp, Turin, Italy. [Peereboom, David M.] Cleveland Clin Fdn, Cleveland, OH USA. [Chamberlain, Marc] Univ Washington, Sch Med, Seattle Canc Care Alliance, Seattle, WA USA. [Macdonald, David] Univ Western Ontario, London Reg Canc Program, London, ON, Canada. [Galanis, Evanthia] Mayo Clin, Rochester, MN USA. [Perry, James] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada. [Jaeckle, Kurt] Mayo Clin, Jacksonville, FL USA. [Mehta, Minesh] Northwestern Univ, Chicago, IL 60611 USA. [Stupp, Roger] Univ Lausanne, Lausanne, Switzerland. [van den Bent, Martin] Erasmus Univ Hosp, Daniel den Hoed Canc Ctr, Rotterdam, Netherlands. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 123 EP 123 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200493 ER PT J AU Norden, A Schiff, D Ahluwalia, M Lesser, G Nayak, L Lee, E Muzikansky, A Dietrich, J Smith, K Gaffey, S McCluskey, C Ligon, K Reardon, D Wen, P AF Norden, Andrew Schiff, David Ahluwalia, Manmeet Lesser, Glenn Nayak, Lakshmi Lee, Eudocia Muzikansky, Alona Dietrich, Jorg Smith, Katrina Gaffey, Sarah McCluskey, Christine Ligon, Keith Reardon, David Wen, Patrick TI PHASE II TRIAL OF TRIPLE RECEPTOR TYROSINE KINASE RECEPTOR INHIBITOR NINTEDANIB IN RECURRENT HIGH-GRADE GLIOMAS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Norden, Andrew; Nayak, Lakshmi; Lee, Eudocia; Smith, Katrina; Gaffey, Sarah; McCluskey, Christine; Ligon, Keith; Reardon, David; Wen, Patrick] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Schiff, David] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. [Ahluwalia, Manmeet] Cleveland Clin, Cleveland, OH 44106 USA. [Lesser, Glenn] Wake Forest Baptist Med Ctr, Winston Salem, NC USA. [Muzikansky, Alona; Dietrich, Jorg] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 123 EP 124 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200495 ER PT J AU Norden, A Hammond, S Drappatz, J Phuphanich, S Reardon, D Wong, E Plotkin, S Lesser, G Raizer, J Batchelor, T Lee, E Kaley, T Muzikansky, A Doherty, L LaFrankie, D Ruland, S Smith, K Gerard, M McCluskey, C Wen, P AF Norden, Andrew Hammond, Samantha Drappatz, Jan Phuphanich, Surasak Reardon, David Wong, Eric Plotkin, Scott Lesser, Glenn Raizer, Jeffrey Batchelor, Tracy Lee, Eudocia Kaley, Thomas Muzikansky, Alona Doherty, Lisa LaFrankie, Debra Ruland, Sandra Smith, Katrina Gerard, Mary McCluskey, Christine Wen, Patrick TI PHASE II STUDY OF MONTHLY PASIREOTIDE LAR (SOM230C) FOR RECURRENT OR PROGRESSIVE MENINGIOMA: FINAL RESULTS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Norden, Andrew; Hammond, Samantha; Reardon, David; Lee, Eudocia; Doherty, Lisa; LaFrankie, Debra; Ruland, Sandra; Smith, Katrina; Gerard, Mary; McCluskey, Christine; Wen, Patrick] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Drappatz, Jan] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Phuphanich, Surasak] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Wong, Eric] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Lesser, Glenn] Wake Forest Univ, Baptist Med Ctr, Winston Salem, NC 27109 USA. [Raizer, Jeffrey] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Plotkin, Scott; Batchelor, Tracy; Muzikansky, Alona] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Kaley, Thomas] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 123 EP 123 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200494 ER PT J AU Omuro, A Abrey, L Raizer, J Paleologos, N Forsyth, P DeAngelis, L Kaley, T Louis, D Cairncross, JG Matasar, M Mehta, J Grimm, S Moskowitz, C Sauter, C AF Omuro, Antonio Abrey, Lauren Raizer, Jeffrey Paleologos, Nina Forsyth, Peter DeAngelis, Lisa Kaley, Thomas Louis, David Cairncross, J. Gregory Matasar, Matthew Mehta, Jayesh Grimm, Sean Moskowitz, Craig Sauter, Craig TI TEMOZOLOMIDE FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT (HDC-ASCT) FOR NEWLY DIAGNOSED ANAPLASTIC OLIGODENDROGLIOMA (AO): CAN RADIOTHERAPY BE DEFERRED? SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Omuro, Antonio; Abrey, Lauren; DeAngelis, Lisa; Kaley, Thomas; Matasar, Matthew; Moskowitz, Craig; Sauter, Craig] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Raizer, Jeffrey; Mehta, Jayesh; Grimm, Sean] NW Mem Hosp, Chicago, IL 60611 USA. [Paleologos, Nina] Northshore Univ Hlth Syst, Evanston, IL USA. [Forsyth, Peter; Cairncross, J. Gregory] Univ Calgary, Calgary, AB, Canada. [Louis, David] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 125 EP 125 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200500 ER PT J AU Rahman, R Hempfling, K Norden, A Reardon, DA Nayak, L Rinne, M Doherty, L Ruland, S Rai, A Rifenburg, J LaFrankie, D Wen, P Lee, E AF Rahman, Rifaquat Hempfling, Kelly Norden, Andrew Reardon, David A. Nayak, Lakshmi Rinne, Mikael Doherty, Lisa Ruland, Sandra Rai, Arun Rifenburg, Jennifer LaFrankie, Debra Wen, Patrick Lee, Eudocia TI RETROSPECTIVE STUDY OF USING CARMUSTINE OR LOMUSTINE WITH BEVACIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS WHO HAVE FAILED PRIOR SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Rahman, Rifaquat] Harvard Univ, Sch Med, Boston, MA USA. [Hempfling, Kelly; Norden, Andrew; Reardon, David A.; Nayak, Lakshmi; Rinne, Mikael; Doherty, Lisa; Ruland, Sandra; Rifenburg, Jennifer; LaFrankie, Debra; Wen, Patrick; Lee, Eudocia] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA. [Rai, Arun] Boston Univ, Sch Med, Boston, MA 02118 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 126 EP 127 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200507 ER PT J AU Wen, P Yung, A Mellinghoff, I Lamborn, K Ramkissoon, S Cloughesy, T Rinne, M Omuro, A DeAngelis, L Gilbert, M Chi, A Batchelor, T Colman, H Chang, S Nayak, L Massacesi, C DiTomaso, E Prados, M Reardon, D Ligon, K AF Wen, Patrick Yung, Alfred Mellinghoff, Ingo Lamborn, Kathleen Ramkissoon, Shakti Cloughesy, Timothy Rinne, Mikael Omuro, Antonio DeAngelis, Lisa Gilbert, Mark Chi, Andrew Batchelor, Tracy Colman, Howard Chang, Susan Nayak, Lakshmi Massacesi, Cristian DiTomaso, Emmanuelle Prados, Michael Reardon, David Ligon, Keith TI PHASE II TRIAL OF THE PHOSPHATIDYINOSITOL-3 KINASE (PI3K) INHIBITOR BUPARLISIB (BKM120) IN RECURRENT GLIOBLASTOMA: AN IVY FOUNDATION EARLY PHASE CLINICAL TRIALS CONSORTIUM STUDY SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Wen, Patrick; Ramkissoon, Shakti; Rinne, Mikael; Nayak, Lakshmi; Reardon, David; Ligon, Keith] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Yung, Alfred; Gilbert, Mark] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Mellinghoff, Ingo; Omuro, Antonio; DeAngelis, Lisa] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Lamborn, Kathleen; Chang, Susan; Prados, Michael] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Cloughesy, Timothy] Univ Calif Los Angeles, Los Angeles, CA USA. [Chi, Andrew; Batchelor, Tracy] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Colman, Howard] Univ Utah, Salt Lake City, UT USA. [Massacesi, Cristian] Novartis Pharmaceut, Rueil Malmaison, France. [DiTomaso, Emmanuelle] Novartis Oncol, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 134 EP 134 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200537 ER PT J AU Wu, WT Galanis, E Wen, P Das, A Fine, H Cloughesy, T Sargent, D AF Wu, Wenting Galanis, Eva Wen, Patrick Das, Asha Fine, Howard Cloughesy, Tim Sargent, Dan TI RELATIONSHIP BETWEEN OVERALL SURVIVAL AND PROGRESSION-BASED ENDPOINTS IN BEV-INCLUDED RECURRENT GLIOBLASTOMA MULTIFORME TRIALS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Wu, Wenting; Galanis, Eva; Sargent, Dan] Mayo Clin, Rochester, MN USA. [Wen, Patrick] Dana Farber Canc Inst, Boston, MA 02115 USA. [Das, Asha] Genentech Inc, San Francisco, CA 94080 USA. [Fine, Howard] NYU, New York, NY USA. [Cloughesy, Tim] Univ Calif Los Angeles, Los Angeles, CA USA. UCSF, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 134 EP 135 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200540 ER PT J AU Kim, BYS Jiang, W Beiko, J Prabhu, S DeMonte, F Lang, F Gilbert, M Aldape, K Sawaya, R Cahill, D McCutcheon, I AF Kim, Betty Y. S. Jiang, Wen Beiko, Jason Prabhu, Sujit DeMonte, Franco Lang, Frederick Gilbert, Mark Aldape, Kenneth Sawaya, Raymond Cahill, Daniel McCutcheon, Ian TI IDH1 STATUS AS A DIAGNOSTIC AND PROGNOSTIC MARKER FOR MALIGNANT ASTROCYTOMAS WITH LIMITED HISTOLOGICAL SPECIMEN: THE ROLE OF SURGICAL RESECTION, PATHOLOGICAL ANALYSIS AND MOLECULAR TESTING SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Prabhu, Sujit; DeMonte, Franco; Lang, Frederick; Gilbert, Mark; Aldape, Kenneth; Sawaya, Raymond; McCutcheon, Ian] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Kim, Betty Y. S.] Mayo Clin, Jacksonville, FL 32224 USA. [Jiang, Wen] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Beiko, Jason] Univ Manitoba, Winnipeg, MB, Canada. [Cahill, Daniel] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 145 EP 145 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200581 ER PT J AU Loebel, F Curry, WT Barker, FG Lelic, N Chi, AS Cahill, DP AF Loebel, Franziska Curry, William T. Barker, Fred G. Lelic, Nina Chi, Andrew S. Cahill, Daniel P. TI PREDICTORS OF PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN IDH1-MUTANT GLIOMA PATIENTS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Loebel, Franziska; Curry, William T.; Barker, Fred G.; Lelic, Nina; Cahill, Daniel P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA USA. [Chi, Andrew S.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 146 EP 146 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200585 ER PT J AU Maire, C Francis, J Zhang, CZ Jung, J Manzo, V Adalsteinsson, V Homer, H Blumenstiel, B Pedamallu, CS Nickerson, E Ligon, A Love, C Meyerson, M Ligon, K AF Maire, Cecile Francis, Joshua Zhang, Cheng-Zhong Jung, Joonil Manzo, Veronica Adalsteinsson, Viktor Homer, Heather Blumenstiel, Brendan Pedamallu, Chandra Sekhar Nickerson, Elizabeth Ligon, Azra Love, Christopher Meyerson, Matthew Ligon, Keith TI SINGLE CELL SEQUENCING RESOLVES CLONAL AND SUBCLONAL ALTERATIONS IN GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Maire, Cecile; Francis, Joshua; Homer, Heather; Blumenstiel, Brendan; Pedamallu, Chandra Sekhar; Ligon, Azra; Meyerson, Matthew; Ligon, Keith] Dana Farber Canc Inst, Boston, MA 02115 USA. [Francis, Joshua; Zhang, Cheng-Zhong; Jung, Joonil; Manzo, Veronica; Adalsteinsson, Viktor; Pedamallu, Chandra Sekhar; Nickerson, Elizabeth; Love, Christopher; Meyerson, Matthew] Broad Inst Harvard & MIT, Cambridge, MA USA. [Adalsteinsson, Viktor; Love, Christopher] Davide H Koch Inst Intergart Canc Res, Cambridge, MA USA. [Ligon, Azra] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 146 EP 147 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200588 ER PT J AU Ozawa, T Riester, M Cheng, YK Huse, J Helmy, K Charles, N Squatrito, M Michor, F Holland, E AF Ozawa, Tatsuya Riester, Markus Cheng, Yu-Kang Huse, Jason Helmy, Karim Charles, Nikki Squatrito, Massimo Michor, Franziska Holland, Eric TI HUMAN NON-GCIMP GLIOBLASTOMA SUBTYPES EVOLVE FROM A COMMON PRONEURAL-LIKE PRECURSOR GLIOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Ozawa, Tatsuya; Huse, Jason; Helmy, Karim; Charles, Nikki; Holland, Eric] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Riester, Markus; Cheng, Yu-Kang; Michor, Franziska] Dana Farber Canc Inst, Boston, MA 02115 USA. [Squatrito, Massimo] Spanish Natl Canc Res Ctr, Madrid, Spain. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 149 EP 149 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200598 ER PT J AU Walston, S Williams, T Hamstra, D Oh, K Pelloski, C AF Walston, Steve Williams, Terence Hamstra, Daniel Oh, Kevin Pelloski, Christopher TI AMULTI-INSTITUTIONAL EXPERIENCE INPEDIATRIC HIGH GRADE GLIOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Walston, Steve; Williams, Terence; Pelloski, Christopher] Ohio State Univ, James Comprehens Canc Ctr, Dept Radiat Oncol, Columbus, OH 43210 USA. [Hamstra, Daniel] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA. [Oh, Kevin] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RI Williams, Terence/I-9614-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 171 EP 171 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200678 ER PT J AU Colen, R Vangel, M Gutman, D Hwang, S Wintermark, M Jain, R Jilwan-Nicolas, M Chen, J Raghavan, P Holder, C Rubin, D Huang, E Kirby, J Freymann, J Jaffe, C Flanders, A Zinn, P AF Colen, Rivka Vangel, Mark Gutman, David Hwang, Scott Wintermark, Max Jain, Rajan Jilwan-Nicolas, Manal Chen, James Raghavan, Prashant Holder, Chad Rubin, Daniel Huang, Eric Kirby, Justin Freymann, John Jaffe, Carl Flanders, Adam Zinn, Pascal TI IMAGING GENOMIC CORRELATION OF INVASIVE GENOMIC COMPOSITION AND PATIENT SURVIVAL DEMONSTRATES METABOLIC DYSFUNCTION: A TCGA GLIOMA PHENOTYPE RESEARCH GROUP PROJECT SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Colen, Rivka] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Vangel, Mark] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Gutman, David; Hwang, Scott; Holder, Chad] Emory Univ, Atlanta, GA 30322 USA. [Wintermark, Max; Jilwan-Nicolas, Manal; Raghavan, Prashant] Univ Virginia, Charlottesville, VA USA. [Jain, Rajan] Henry Ford, Detroit, MI USA. [Chen, James] Univ Calif San Diego Hlth Syst, San Diego, CA USA. [Chen, James] Univ Calif San Diego, San Diego Med Ctr, San Diego, CA 92103 USA. [Rubin, Daniel] Stanford Univ, Stanford, CA 94305 USA. [Huang, Eric; Kirby, Justin; Freymann, John] NCI, NIH, Bethesda, MD 20892 USA. [Jaffe, Carl] NCI, NIH, Rockville, MD USA. [Flanders, Adam] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. [Zinn, Pascal] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 193 EP 193 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200755 ER PT J AU Huang, R Rahman, R Hamdan, A Kane, C Chen, C Norden, A Reardon, D Mukundan, S Wen, P AF Huang, Raymond Rahman, Rifaquat Hamdan, Alhafidz Kane, Caroline Chen, Christina Norden, Andrew Reardon, David Mukundan, Srinivasan Wen, Patrick TI VOLUMETRIC ASSESSMENT AND STRATIFICATION OF PATIENT SURVIVAL WITH EARLY POST-TREATMENT MRI IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH BEVACIZUMAB SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Huang, Raymond; Mukundan, Srinivasan] Brigham & Womens Hosp, Boston, MA 02115 USA. [Hamdan, Alhafidz; Kane, Caroline; Norden, Andrew; Reardon, David; Wen, Patrick] Dana Farber Canc Inst, Boston, MA 02115 USA. [Huang, Raymond; Rahman, Rifaquat; Chen, Christina; Norden, Andrew; Reardon, David; Mukundan, Srinivasan] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 197 EP 197 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200773 ER PT J AU Nelson, S Lieberman, F Lupo, J Viziri, S Nabors, LB Crane, J Wen, P Cote, A Peereboom, D Wen, QT Cloughesy, T Robins, HI Fisher, J Desideri, S Grossman, S Ye, XB Blakeley, J AF Nelson, Sarah Lieberman, Frank Lupo, Janine Viziri, Sana Nabors, L. Burt Crane, Jason Wen, Patrick Cote, Andre Peereboom, David Wen, Qiuting Cloughesy, Timothy Robins, H. Ian Fisher, Joy Desideri, Serena Grossman, Stuart Ye, Xiaobu Blakeley, Jaishri TI FUNCTIONAL BRAIN MRI FOR ASSESSING EARLY ACTIVITY OF RAMUCIRUMAB AND OLARATUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Nelson, Sarah; Lupo, Janine; Viziri, Sana; Crane, Jason; Cote, Andre; Wen, Qiuting] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lieberman, Frank] Univ Pittsburgh, Pittsburgh, PA USA. [Nabors, L. Burt] Univ Alabama Birmingham, Birmingham, AL USA. [Wen, Patrick] Dana Farber Canc Ctr, Boston, MA USA. [Peereboom, David] Cleveland Clin, Cleveland, OH 44106 USA. [Cloughesy, Timothy] Univ Calif Los Angeles, Los Angeles, CA USA. [Robins, H. Ian] Univ Wisconsin, Madison, WI USA. [Fisher, Joy; Desideri, Serena; Grossman, Stuart; Ye, Xiaobu; Blakeley, Jaishri] Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 200 EP 200 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200787 ER PT J AU Rahman, R Akgoz, A You, H Hamdan, A Seethamraju, R Wen, P Young, G AF Rahman, Rifaquat Akgoz, Ayca You, Hui Hamdan, Alhafidz Seethamraju, Ravi Wen, Patrick Young, Geoffrey TI BASELINE SPIN-ECHO ECHO-PLANAR PERFUSION nCBV PRIOR TO CHEMORADIATION IS A STRONG INDEPENDENT PRE-THERAPY PREDICTOR OF PROGRESSION-FREE AND OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Rahman, Rifaquat; Wen, Patrick; Young, Geoffrey] Harvard Univ, Sch Med, Boston, MA USA. [Akgoz, Ayca; Young, Geoffrey] Brigham & Womens Hosp, Boston, MA 02115 USA. [You, Hui] Beijing Union Med Coll Hosp, Beijing, Peoples R China. [Hamdan, Alhafidz; Wen, Patrick] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA. [Seethamraju, Ravi] Siemens Med Syst Inc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 202 EP 202 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200793 ER PT J AU Martinez-Quintanilla, J Choi, SH Bhere, D Heidari, P He, D Mahmood, U Shah, K AF Martinez-Quintanilla, Jordi Choi, Sung-Hugh Bhere, Deepak Heidari, Pedram He, Derek Mahmood, Umar Shah, Khalid TI THERAPEUTIC EFFICACY AND FATE OF BIMODAL ENGINEERED STEM CELLS IN MICE MODELS OF MALIGNANT BRAIN TUMORS SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Martinez-Quintanilla, Jordi; Choi, Sung-Hugh; Bhere, Deepak; He, Derek; Shah, Khalid] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp,Mol Neurotherapy & Imaging, Boston, MA 02115 USA. [Heidari, Pedram; Mahmood, Umar] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol 2,Div Nucl Med & Mol Imaging, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 212 EP 212 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200831 ER PT J AU Tanaka, S Luk, S Chang, C Iafrate, J Cahill, D Martuza, R Rabkin, S Chi, A Wakimoto, H AF Tanaka, Shota Luk, Samantha Chang, Clarice Iafrate, John Cahill, Daniel Martuza, Robert Rabkin, Samuel Chi, Andrew Wakimoto, Hiroaki TI ESTABLISHMENT OF GENETICALLY DISTINCT BRAIN TUMOR STEM CELLS FROM GLIOBLASTOMA BEFORE AND AFTER MOLECULAR TARGETED THERAPY SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Tanaka, Shota; Luk, Samantha; Chang, Clarice; Iafrate, John; Cahill, Daniel; Martuza, Robert; Rabkin, Samuel; Chi, Andrew; Wakimoto, Hiroaki] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 216 EP 216 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200847 ER PT J AU Akers, J Ramakrishnan, V Kim, R Skog, J Nakano, I Pingle, S Kalinina, J Kesari, S Breakfield, X Hochberg, F Van Meir, E Carter, B Chen, C AF Akers, Johnny Ramakrishnan, Valya Kim, Ryan Skog, Johan Nakano, Ichiro Pingle, Sandeep Kalinina, Juliya Kesari, Santosh Breakfield, Xandra Hochberg, Fred Van Meir, Erwin Carter, Bob Chen, Clark TI miR-21 IN THE EXTRACELLULAR VESICLES (EVS) OF CEREBROSPINAL FLUID (CSF): A PLATFORM FOR GLIOBLASTOMA BIOMARKER DEVELOPMENT SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Akers, Johnny; Ramakrishnan, Valya; Kim, Ryan; Pingle, Sandeep; Kesari, Santosh; Carter, Bob; Chen, Clark] Univ Calif San Diego, La Jolla, CA 92093 USA. [Nakano, Ichiro] Ohio State Univ, Columbus, OH 43210 USA. [Breakfield, Xandra; Hochberg, Fred] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kalinina, Juliya; Van Meir, Erwin] Emory Univ, Atlanta, GA 30322 USA. [Skog, Johan] Exosome Diagnost, New York, NY USA. RI Kesari, Santosh/E-8461-2013 NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 218 EP 218 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200857 ER PT J AU Arvold, N Wang, Y Zigler, C Schrag, D Dominici, F AF Arvold, Nils Wang, Yun Zigler, Cory Schrag, Deborah Dominici, Francesca TI HOSPITALIZATION BURDEN AND SURVIVAL AMONG ELDERLY PATIENTS WITH GLIOBLASTOMA SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Arvold, Nils; Schrag, Deborah] Dana Farber Brigham Womens Canc Ctr, Boston, MA USA. [Wang, Yun; Zigler, Cory; Dominici, Francesca] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 226 EP 227 PG 2 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200887 ER PT J AU Plotkin, S James, M Kalamarides, M Zhao, WN Kim, J Stemmer-Rachamimov, A Haggarty, S Gusella, J Ramesh, V Nunes, F AF Plotkin, Scott James, Marianne Kalamarides, Michel Zhao, Wen-ning Kim, James Stemmer-Rachamimov, Anat Haggarty, Stephen Gusella, James Ramesh, Vijaya Nunes, Fabio TI CRITICAL ROLE FOR NF-kappa B INHIBITORS IN MENINGIOMA CELL DEATH SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Plotkin, Scott; James, Marianne; Zhao, Wen-ning; Kim, James; Stemmer-Rachamimov, Anat; Haggarty, Stephen; Gusella, James; Ramesh, Vijaya; Nunes, Fabio] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kalamarides, Michel] Hop La Pitie Salpetriere, Paris, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 238 EP 238 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200930 ER PT J AU Stiles, C Sun, Y Mehta, S Taylor, C Alberta, J AF Stiles, Charles Sun, Yu Mehta, Shwetal Taylor, Christopher Alberta, John TI HDAC INHIBITORS: A SYNTHETIC LETHALTOOL FOR TARGETED THERAPY OF PLGAs? SO NEURO-ONCOLOGY LA English DT Meeting Abstract CT 4th Quadrennial Meeting of the World-Federation-of-Neuro-Oncology (WFNO) held in conjunction with the 18th Annual Meeting of the Society-for-Neuro-Oncology (SNO) CY NOV 21-24, 2013 CL San Francisco, CA SP World Federat Neuro Oncol, Soc Neuro Oncol C1 [Stiles, Charles; Sun, Yu; Mehta, Shwetal; Taylor, Christopher; Alberta, John] Dana Farber Canc Inst, Boston, MA 02115 USA. [Stiles, Charles; Sun, Yu; Mehta, Shwetal; Taylor, Christopher; Alberta, John] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD NOV PY 2013 VL 15 SU 3 BP 240 EP 240 PG 1 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 258JT UT WOS:000327456200937 ER PT J AU Groen, SC Whiteman, NK Bahrami, AK Wilczek, AM Cui, JP Russell, JA Cibrian-Jaramillo, A Butler, IA Rana, JD Huang, GH Bush, J Ausubel, FM Pierce, NE AF Groen, Simon C. Whiteman, Noah K. Bahrami, Adam K. Wilczek, Amity M. Cui, Jianping Russell, Jacob A. Cibrian-Jaramillo, Angelica Butler, Ian A. Rana, Jignasha D. Huang, Guo-Hua Bush, Jenifer Ausubel, Frederick M. Pierce, Naomi E. TI Pathogen-Triggered Ethylene Signaling Mediates Systemic-Induced Susceptibility to Herbivory in Arabidopsis SO PLANT CELL LA English DT Article ID SYRINGAE PV. TOMATO; DEPENDENT CELL-DEATH; PSEUDOMONAS-SYRINGAE; SALICYLIC-ACID; DEFENSE RESPONSES; JASMONIC ACID; ACQUIRED-RESISTANCE; DISEASE RESISTANCE; PLANT DEFENSES; NICOTIANA-ATTENUATA AB Multicellular eukaryotic organisms are attacked by numerous parasites from diverse phyla, often simultaneously or sequentially. An outstanding question in these interactions is how hosts integrate signals induced by the attack of different parasites. We used a model system comprised of the plant host Arabidopsis thaliana, the hemibiotrophic bacterial phytopathogen Pseudomonas syringae, and herbivorous larvae of the moth Trichoplusia ni (cabbage looper) to characterize mechanisms involved in systemic-induced susceptibility (SIS) to T. ni herbivory caused by prior infection by virulent P. syringae. We uncovered a complex multilayered induction mechanism for SIS to herbivory. In this mechanism, antiherbivore defenses that depend on signaling via (1) the jasmonic acid-isoleucine conjugate (JA-Ile) and (2) other octadecanoids are suppressed by microbe-associated molecular pattern-triggered salicylic acid (SA) signaling and infection-triggered ethylene signaling, respectively. SIS to herbivory is, in turn, counteracted by a combination of the bacterial JA-Ile mimic coronatine and type III virulence-associated effectors. Our results show that SIS to herbivory involves more than antagonistic signaling between SA and JA-Ile and provide insight into the unexpectedly complex mechanisms behind a seemingly simple trade-off in plant defense against multiple enemies. C1 [Groen, Simon C.; Whiteman, Noah K.; Bahrami, Adam K.; Wilczek, Amity M.; Cui, Jianping; Russell, Jacob A.; Cibrian-Jaramillo, Angelica; Butler, Ian A.; Rana, Jignasha D.; Huang, Guo-Hua; Pierce, Naomi E.] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA. [Groen, Simon C.] Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England. [Whiteman, Noah K.] Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA. [Cui, Jianping; Ausubel, Frederick M.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Cui, Jianping; Bush, Jenifer; Ausubel, Frederick M.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. RP Pierce, NE (reprint author), Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA. EM npierce@oeb.harvard.edu RI Groen, Simon/G-2443-2012; Russell, Jacob/H-7996-2015 FU Kirschstein National Research Service Award from the National Institutes of Health [F32AI069732]; National Science Foundation [DEB-1256758, MCB-0519898, SES-0750480]; University of Arizona's Seed Grant for Faculty Research Program; National Institutes of Health [R37 GM48707, P30 DK040561]; Harvard University Microbial Sciences Initiative Postdoctoral Fellowship FX N. K. W. was supported by a Kirschstein National Research Service Award from the National Institutes of Health (F32AI069732), a grant from the National Science Foundation (DEB-1256758), and a grant from the University of Arizona's Seed Grant for Faculty Research Program. F. M. A. was supported by a grant from the National Science Foundation (MCB-0519898) and two grants from the National Institutes of Health (R37 GM48707 and P30 DK040561), and N. E. P. was supported by a grant from the National Science Foundation (SES-0750480). A. K. B. was supported by a Harvard University Microbial Sciences Initiative Postdoctoral Fellowship. N. K. W., S. C. G., F. M. A., and N. E. P. were supported by a grant from Harvard University's Provost Fund for Interfaculty Collaboration and a grant from the Harvard University Science and Engineering Committee Seed Fund for Interdisciplinary Science. We thank Suresh Gopalan (ReSurfX) for help with the analysis of microarray data. We thank the following members of the Pierce laboratory and others who volunteered to help with the caterpillar feeding assays (in alphabetical order): Deborah Anderson, Lina Arcila, Ashley Bae, Chris Baker, Katie Berry, Megan Berry, Leonora Bittleston, John Boyle, Andrew Brownjohn, Lian Bruno, Alanna Callendrello, Norma-Rashid Che Yusoff, Mark Cornwall, James Crall, Seth Donoghue, Rodney Eastwood, Marianne Espeland, Abby Finkelstein, Joshua Fries, Masaru Hojo, Jay Iwasaki, Zofia Kaliszewska, Sarah Kocher, Petra Kubikova, Bonnie Lei, Patrick McCormack, Bruno de Medeiros, John Mewherter, Gabriel Miller, Julianne Pelaez, Jon Sanders, Mariah Slone, Jared Squires, Lauren Tomkinson, and Brian Trippe. We thank the following people for their help and advice during the experiments and data analyses: Reddy Gali, Jennifer Couget, Claire Reardon (Harvard University Faculty of Arts and Sciences Systems Biology Core), Julia Dewdney, and Nicole Clay. We also thank Fumiaki Katagiri for nonglabrous coi1-1 seeds, Carol Bender for providing the COR-deficient mutants of Pto DC3000, and Alan Collmer and Brian Kvitko for the nonpolar hrc cfa6 cmaA mutant of Pto DC3000 Pto CUCPB5532. The manuscript was improved by comments from the editorial team at The Plant Cell and two anonymous reviewers. NR 84 TC 13 Z9 13 U1 2 U2 26 PU AMER SOC PLANT BIOLOGISTS PI ROCKVILLE PA 15501 MONONA DRIVE, ROCKVILLE, MD 20855 USA SN 1040-4651 EI 1532-298X J9 PLANT CELL JI Plant Cell PD NOV PY 2013 VL 25 IS 11 BP 4755 EP 4766 DI 10.1105/tpc.113.113415 PG 12 WC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology SC Biochemistry & Molecular Biology; Plant Sciences; Cell Biology GA 282LY UT WOS:000329174400034 PM 24285796 ER PT J AU Baggett, TP Lebrun-Harris, LA Rigotti, NA AF Baggett, Travis P. Lebrun-Harris, Lydie A. Rigotti, Nancy A. TI Homelessness, cigarette smoking and desire to quit: results from a US national study SO ADDICTION LA English DT Article DE Homeless persons; smoking cessation; tobacco use ID SERIOUS MENTAL-ILLNESS; UNITED-STATES; SOCIOECONOMIC-STATUS; RISK-FACTORS; NICOTINE DEPENDENCE; HEALTH-CARE; TOBACCO USE; LOS-ANGELES; INNER-CITY; POPULATION AB AimsWe determined whether or not homelessness is associated with cigarette smoking independent of other socio-economic measures and behavioral health factors, and whether homeless smokers differ from non-homeless smokers in their desire to quit. Design, setting and participantsWe analyzed data from 2678 adult respondents to the 2009 Health Center Patient Survey, a nationally representative cross-sectional survey of homeless and non-homeless individuals using US federally funded community health centers. MeasurementsWe used multivariable logistic regression to examine the association between homelessness and (i) current cigarette smoking among all adults, and (ii) past-year desire to quit among current smokers, adjusting for demographic, socio-economic and behavioral health characteristics. FindingsAdults with any history of homelessness were more likely than never homeless respondents to be current smokers (57 versus 27%, P<0.001). In multivariable models, a history of homelessness was associated independently with current smoking [adjusted odds ratio (AOR) 2.09; 95% confidence interval (CI)=1.49-2.93], even after adjusting for age, sex, race, veteran status, insurance, education, employment, income, mental illness and alcohol and drug abuse. Housing status was not associated significantly with past-year desire to stop smoking in unadjusted (P=0.26) or adjusted (P=0.60) analyses; 84% of currently homeless, 89% of formerly homeless and 82% of never homeless smokers reported wanting to quit. ConclusionsAmong patients of US health centers, a history of homelessness doubles the odds of being a current smoker independent of other socio-economic factors and behavioral health conditions. However, homeless smokers do not differ from non-homeless smokers in their desire to quit and should be offered effective interventions. C1 [Baggett, Travis P.; Rigotti, Nancy A.] Massachusetts Gen Hosp, Div Gen Med, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA. [Baggett, Travis P.; Rigotti, Nancy A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Baggett, Travis P.] Boston Hlth Care Homeless Program, Boston, MA USA. [Lebrun-Harris, Lydie A.] US Hlth Resources & Serv Adm, Rockville, MD 20857 USA. RP Baggett, TP (reprint author), Massachusetts Gen Hosp, Div Gen Med, Tobacco Res & Treatment Ctr, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM tbaggett@partners.org FU National Institute on Drug Abuse of the National Institutes of Health [K23DA034008] FX We thank Manaswi Sangraula for her assistance with the literature review for this paper. This study was funded by the National Institute on Drug Abuse of the National Institutes of Health under Award Number K23DA034008 to Dr Baggett. NR 71 TC 17 Z9 17 U1 3 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD NOV PY 2013 VL 108 IS 11 BP 2009 EP 2018 DI 10.1111/add.12292 PG 10 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 282AD UT WOS:000329141500021 PM 23834157 ER PT J AU Lin, TY Chin, CR Everitt, AR Clare, S Perreira, JM Savidis, G Aker, AM John, SP Sarlah, D Carreira, EM Elledge, SJ Kellam, P Brass, AL AF Lin, Tsai-Yu Chin, Christopher R. Everitt, Aaron R. Clare, Simon Perreira, Jill M. Savidis, George Aker, Aaron M. John, Sinu P. Sarlah, David Carreira, Erick M. Elledge, Stephen J. Kellam, Paul Brass, Abraham L. TI Amphotericin B Increases Influenza A Virus Infection by Preventing IFITM3-Mediated Restriction SO CELL REPORTS LA English DT Article ID POLYENE MACROLIDE ANTIBIOTICS; WEST NILE VIRUS; DENGUE VIRUS; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEINS; SEMLIKI FOREST; IFITM PROTEINS; CELL-MEMBRANE; FUSION; DERIVATIVES AB The IFITMs inhibit influenza A virus (IAV) replication in vitro and in vivo. Here, we establish that the antimycotic heptaen, amphotericin B (AmphoB), prevents IFITM3-mediated restriction of IAV, thereby increasing viral replication. Consistent with its neutralization of IFITM3, a clinical preparation of AmphoB, AmBisome, reduces the majority of interferon's protective effect against IAV in vitro. Mechanistic studies reveal that IFITM1 decreases host-membrane fluidity, suggesting both a possible mechanism for IFITM-mediated restriction and its negation by AmphoB. Notably, we reveal that mice treated with AmBisome succumbed to a normally mild IAV infection, similar to animals deficient in Ifitm3. Therefore, patients receiving antifungal therapy with clinical preparations of AmphoB may be functionally immunocompromised and thus more vulnerable to influenza, as well as other IFITM3-restricted viral infections. C1 [Lin, Tsai-Yu; Chin, Christopher R.; Perreira, Jill M.; Savidis, George; Aker, Aaron M.; Brass, Abraham L.] Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Worcester, MA 01655 USA. [Chin, Christopher R.; John, Sinu P.; Brass, Abraham L.] Massachusetts Gen Hosp, MIT, Ragon Inst, Charlestown, MA 02129 USA. [Chin, Christopher R.; John, Sinu P.; Brass, Abraham L.] Harvard Univ, Charlestown, MA 02129 USA. [Everitt, Aaron R.; Clare, Simon; Kellam, Paul] Wellcome Trust Sanger Inst, Hinxton CB10 1SA, England. [Sarlah, David; Carreira, Erick M.] ETH, Deutsch English Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland. [Elledge, Stephen J.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Elledge, Stephen J.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA. [Elledge, Stephen J.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. [Kellam, Paul] UCL, Div Infect & Immun, MRC UCL Ctr Med Mol Virol, London W1CE 6BT, England. RP Brass, AL (reprint author), Univ Massachusetts, Sch Med, Dept Microbiol & Physiol Syst, Albert Sherman Ctr, 368 Plantat St,8 1001, Worcester, MA 01655 USA. EM abraham.brass@umassmed.edu RI Lin, Tsai-Yu/B-8873-2016; OI Lin, Tsai-Yu/0000-0002-8076-1584; Carreira, Erick/0000-0003-1472-490X; Sarlah, David/0000-0002-8736-8953 FU National Institute of Allergy and Infectious Diseases of the National Institutes of Health [1R01AI091786]; Charles H. Hood Foundation; Burroughs Wellcome Fund; Bill and Melinda Gates Foundation; Phillip T. and Susan M. Ragon Foundation; Harvard Center for AIDS Research; UMMS Center for AIDS Research; Wellcome Trust FX We thank University of Massachusetts Medical School (UMMS) colleagues R. Fish, B. Hobbs, L. Benson, T. Brailey, and J. Barrett and Ragon Institute colleagues M. Boyarina, K. Donnelly, and P. Richtmeyer. We thank A. T. Chan (Massachusetts General Hospital), A. Quaresma and J. Nickerson (UMMS), J. White (University of Virginia), K. Weninger (North Carolina State University), and G. Melikian (Emory University) for helpful discussions and advice. This work was generously supported by a grant (1R01AI091786) from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (to A. L. B.). A. L. B. is grateful to the Charles H. Hood Foundation, the Burroughs Wellcome Fund, the Bill and Melinda Gates Foundation, the Phillip T. and Susan M. Ragon Foundation, and the Harvard and UMMS Centers for AIDS Research for their generous support. P. K, S. C., and A. R. E are supported by the Wellcome Trust. S.J.E. is a Howard Hughes Investigator. NR 45 TC 27 Z9 28 U1 2 U2 9 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REP JI Cell Reports PD NOV PY 2013 VL 5 IS 4 BP 895 EP 908 DI 10.1016/j.celrep.2013.10.033 PG 14 WC Cell Biology SC Cell Biology GA 269TY UT WOS:000328266000005 PM 24268777 ER PT J AU Varela, VS Zhou, ES Bober, SL AF Varela, Veronica Sanchez Zhou, Eric S. Bober, Sharon L. TI Management of sexual problems in cancer patients and survivors SO CURRENT PROBLEMS IN CANCER LA English DT Article ID QUALITY-OF-LIFE; LOCALIZED PROSTATE-CANCER; RADICAL RETROPUBIC PROSTATECTOMY; LONG-TERM SURVIVORS; ANDROGEN DEPRIVATION THERAPY; STEM-CELL TRANSPLANTATION; BRCA2 MUTATION CARRIERS; VERSUS-HOST-DISEASE; BILATERAL PROPHYLACTIC MASTECTOMY; SPONTANEOUS ERECTILE FUNCTION C1 [Varela, Veronica Sanchez] Rush Univ, Med Ctr, Dept Behav Sci, Chicago, IL 60612 USA. [Varela, Veronica Sanchez] Rush Univ, Med Ctr, Bone Marrow & Stem Cell Transplant Sect, Dept Internal Med, Chicago, IL USA. [Zhou, Eric S.] Dana Farber Canc Inst, Boston, MA USA. [Zhou, Eric S.; Bober, Sharon L.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Bober, Sharon L.] Dana Farber Canc Inst, Sexual Hlth Program, Boston, MA USA. RP Varela, VS (reprint author), Rush Univ, Med Ctr, Dept Behav Sci, Chicago, IL 60612 USA. NR 415 TC 5 Z9 5 U1 1 U2 13 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0147-0272 EI 1535-6345 J9 CURR PROB CANCER JI Curr. Probl. Cancer PD NOV-DEC PY 2013 VL 37 IS 6 BP 319 EP 352 DI 10.1016/j.currproblcancer.2013.10.009 PG 34 WC Oncology SC Oncology GA 280AF UT WOS:000329000300001 ER PT J AU Jarrett, RB Minhajuddin, A Gershenfeld, H Friedman, ES Thase, ME AF Jarrett, Robin B. Minhajuddin, Abu Gershenfeld, Howard Friedman, Edward S. Thase, Michael E. TI Preventing Depressive Relapse and Recurrence in Higher-Risk Cognitive Therapy Responders A Randomized Trial of Continuation Phase Cognitive Therapy, Fluoxetine, or Matched Pill Placebo SO JAMA PSYCHIATRY LA English DT Article ID MAJOR DEPRESSION; BEHAVIOR-THERAPY; FOLLOW-UP; ANTIDEPRESSANT MEDICATION; DISORDER; DESIGN; OUTPATIENTS; ACTIVATION; REMISSION; PHYSICIAN AB IMPORTANCE Strategies to improve the course of recurrent major depressive disorder have great public health relevance. To reduce the risk of relapse/recurrence after acute phase cognitive therapy (CT), a continuation phase model of therapy may improve outcomes. OBJECTIVES To test the efficacy of continuation phase CT (C-CT) and fluoxetine for relapse prevention in a pill placebo (PBO)-controlled randomized trial and compare the durability of prophylaxis after discontinuation of treatments. DESIGN A sequential, 3-stage design with an acute phase (all patients received 12 weeks of CT); 8-month experimental phase (responders at higher risk were randomized to C-CT, fluoxetine, or PBO); and 24 months of longitudinal, posttreatment follow-up. SETTING Two university-based specialty clinics. PATIENTS A total of 523 adults with recurrent major depressive disorder began acute phase CT, of which 241 higher-risk responders were randomized and 181 subsequently entered the follow-up. INTERVENTIONS Cognitive therapy responders at higher risk for relapse were randomized to receive 8 months of C-CT (n = 86), fluoxetine (n = 86), or PBO (n = 69). MAIN OUTCOMES AND MEASURES Survival analyses of relapse/recurrence rates, as determined by blinded evaluators using DSM-IV criteria and the Longitudinal Interval Follow-up Evaluation. RESULTS As predicted, the C-CT or fluoxetine groups were significantly less likely to relapse than the PBO group across 8 months. Relapse/recurrence rates for C-CT and fluoxetine were nearly identical during the 8 months of treatment, although C-CT patients were more likely to accept randomization, stayed in treatment longer, and attended more sessions than those in the fluoxetine and PBO groups. Contrary to prediction, relapse/recurrence rates following the discontinuation of C-CT and fluoxetine did not differ. CONCLUSIONS AND RELEVANCE Relapse risk was reduced by both C-CT and fluoxetine in an enriched randomization sampling only CT responders. The preventive effects of C-CT were not significantly more durable than those of fluoxetine after treatment was stopped, suggesting that some higher-risk patients may require alternate longer-term interventions. C1 [Jarrett, Robin B.; Gershenfeld, Howard] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Minhajuddin, Abu] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. [Friedman, Edward S.; Thase, Michael E.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA. [Thase, Michael E.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA. RP Jarrett, RB (reprint author), Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM robin.jarrett@utsouthwestern.edu FU National Institute of Mental Health [K24 MH001571, R01 MH058397, R01 MH069619, R01 MH058356, R01 MH069618]; Eli Lilly and Co FX This study was supported by grants K24 MH001571, R01 MH058397, and R01 MH069619 (Dr Jarrett) and by R01 MH058356 and R01 MH069618 (Dr Thase) from the National Institute of Mental Health. We acknowledge the unrestricted support of Eli Lilly and Co, which provided fluoxetine and matched pill placebo for the first 6 years of the study. Thereafter, study materials were purchased and prepared to appear identical for both sites by the pharmacy at The University of Texas Southwestern Medical Center. NR 54 TC 25 Z9 26 U1 4 U2 14 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD NOV PY 2013 VL 70 IS 11 BP 1152 EP 1160 DI 10.1001/jamapsychiatry.2013.1969 PG 9 WC Psychiatry SC Psychiatry GA 279GP UT WOS:000328948700007 PM 24005123 ER PT J AU Yildirim, M Ferhanoglu, O Kobler, J Zeitels, SM Ben-Yakar, A AF Yildirim, Murat Ferhanoglu, Onur Kobler, James Zeitels, Steven M. Ben-Yakar, Adela TI Parameters affecting ultrafast laser microsurgery of subepithelial voids for scar treatment in vocal folds SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE ultrafast lasers; ablation of tissue; endoscopic imaging; nonlinear microscopy; multiphoton processes; laser-induced damage; vocal fold scarring; scarring; tensile strength of tissue; mechanical properties of tissue ID FEMTOSECOND TIME SCALES; HAMSTER-CHEEK POUCH; 2ND-HARMONIC GENERATION; MECHANICAL-PROPERTIES; EXTRACELLULAR-MATRIX; OPTICAL-PROPERTIES; HYALURONIC-ACID; IN-VIVO; MULTIPHOTON MICROSCOPY; BIOLOGICAL TISSUES AB Toward developing a new method for restoring tissue viscoelasticity in scarred vocal folds, we previously proposed a method to localize biomaterials within subepithelial voids ablated using ultrafast laser pulses. The clinical implementation of this method necessitates the quantification of the laser parameters for ablating scarred tissue. Here, we present a comprehensive study of these parameters including ablation threshold and bubble lifetime in healthy and scarred tissues. We also present a new method for extracting tissue-specific ablation threshold and scattering lengths of different tissue layers. This method involves finding the ablation threshold at multiple depths and solving the equations based on Beer's law of light attenuation for each depth to estimate the unknown parameters. Measured threshold fluences were 1.75 J/cm(2) for vocal folds and 0.5 J/cm(2) for cheek pouches for 3-ps, 776nm laser pulses. Scarred pouches exhibited 30% lower threshold than healthy pouches, possibly due to the degraded mechanical properties of scarred collagen during wound healing. The analysis of tissue architecture indicated a direct correlation between the ablation threshold and tissue tensile strength and that the bubble lifetime is inversely related to tissue stiffness. Overall, this study sheds light on the required laser parameters for successful implementation of ultrafast laser ablation for phonosurgery. (C) 2013 Society of Photo-Optical Instrumentation Engineers (SPIE) C1 [Yildirim, Murat; Ferhanoglu, Onur; Ben-Yakar, Adela] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA. [Kobler, James; Zeitels, Steven M.] Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, Boston, MA 02114 USA. RP Ben-Yakar, A (reprint author), Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA. EM ben-yakar@mail.utexas.edu RI Ferhanoglu, Onur/I-9348-2014 OI Ferhanoglu, Onur/0000-0002-5381-533X FU National Science Foundation [IDR: CBET-1014953, CBET-0846868] FX Grants from the National Science Foundation (IDR: CBET-1014953 and Career Award: CBET-0846868) supported this work. We thank Raydiance, Inc. for use of their Discovery fiber laser, Dr. David Kleinfeld and his research group for the use of MPScan, as well as Dr. R. Rox Anderson, Dr. Christopher Hoy, Dr. Nicholas Durr, Dr. Richard Harrison, Dr. Aaron Friedman, Myoungkyu Lee, Navid Ghorashian, and Ki Hyun Kim for consultation. NR 61 TC 10 Z9 10 U1 0 U2 5 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 EI 1560-2281 J9 J BIOMED OPT JI J. Biomed. Opt. PD NOV PY 2013 VL 18 IS 11 AR 118001 DI 10.1117/1.JBO.18.11.118001 PG 14 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA 278MT UT WOS:000328895100049 PM 24193950 ER PT J AU Ricardo, JRD Medhi, J Pineda, R AF da Silva Ricardo, Jose Reinaldo Medhi, Jnanankar Pineda, Roberto TI Indications for and Outcomes of Deep Anterior Lamellar Keratoplasty in Mucopolysaccharidoses SO JOURNAL OF PEDIATRIC OPHTHALMOLOGY & STRABISMUS LA English DT Article ID MAROTEAUX-LAMY SYNDROME; SYSTEMIC MUCOPOLYSACCHARIDOSIS; SCHEIES-SYNDROME; OCULAR HISTOPATHOLOGY; CORNEA; TRANSPLANTATION; ENDOTHELIUM; BUBBLE AB Purpose: To describe the outcome of deep anterior lamellar keratoplasty (DALK) for visually significant corneal clouding in patients with mucopolysaccharidoses (MPS). Methods: A retrospective consecutive case series of patients with MPS and corneal clouding were analyzed at a tertiary eye hospital. A review of the English literature regarding MPS and DALK was performed. The main outcomes measures of the study were intraoperative surgical complications, change in visual acuity, and postoperative DALK-related complications. Results: Four eyes from 2 patients with MPS I (Hurler's syndrome and Hurler-Scheie syndrome) and a history of DALK met inclusion criteria for the case series. Using the "big-bubble" technique, DALK was performed successfully in all eyes. Completed Descemet's membrane baring was achieved in 3 or 4 eyes and a pre-Descemet's membrane dissection in 1 eye. The mean age at the time of DALK was 17.3 years (range: 15.4 to 19.5 years). Mean follow-up time after DALK was 16.7 months (range: 6 to 31 months). Mean visual acuity before DALK was 20/80 (0.59 +/- 0.12 logMAR). Mean visual acuity at the last visit for all 4 eyes was 20/50 (0.41 +/- 0.17 logMAR). Visual acuity improved in all eyes. Recurrence of MPS corneal clouding was not noted in any of the corneal grafts. Conclusions: DALK is a beneficial and preferable intervention in appropriate patients with significant corneal clouding due to MPS I. Improvement in vision can be obtained with stable, clear corneal grafts, although other ophthalmic manifestations may limit vision. C1 [da Silva Ricardo, Jose Reinaldo; Medhi, Jnanankar] Int Council Ophthalmol, Boston, MA USA. [da Silva Ricardo, Jose Reinaldo; Medhi, Jnanankar; Pineda, Roberto] Massachusetts Eye & Ear Infirm, Dept Cornea, Boston, MA 02114 USA. RP Ricardo, JRD (reprint author), Rua Marechal Deodoro 3025, BR-85810200 Cascavel, Parana, Brazil. EM jreinaldo2020@gmail.com.br NR 21 TC 1 Z9 1 U1 0 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0191-3913 EI 1938-2405 J9 J PEDIAT OPHTH STRAB JI J. Pediatr. Ophthalmol. Strabismus. PD NOV-DEC PY 2013 VL 50 IS 6 BP 376 EP 381 DI 10.3928/01913913-20131125-05 PG 6 WC Ophthalmology; Pediatrics SC Ophthalmology; Pediatrics GA 280IR UT WOS:000329022600012 ER PT J AU Planet, PJ LaRussa, SJ Dana, A Smith, H Xu, A Ryan, C Uhlemann, AC Boundy, S Goldberg, J Narechania, A Kulkarni, R Ratner, AJ Geoghegan, JA Kolokotronis, SO Prince, A AF Planet, Paul J. LaRussa, Samuel J. Dana, Ali Smith, Hannah Xu, Amy Ryan, Chanelle Uhlemann, Anne-Catrin Boundy, Sam Goldberg, Julia Narechania, Apurva Kulkarni, Ritwij Ratner, Adam J. Geoghegan, Joan A. Kolokotronis, Sergios-Orestis Prince, Alice TI Emergence of the Epidemic Methicillin-Resistant Staphylococcus aureus Strain USA300 Coincides with Horizontal Transfer of the Arginine Catabolic Mobile Element and speG-mediated Adaptations for Survival on Skin SO MBIO LA English DT Article ID INNATE ANTIMICROBIAL PEPTIDES; FIBRONECTIN-BINDING PROTEIN; BIOFILM FORMATION; HUMAN KERATINOCYTES; MAXIMUM-LIKELIHOOD; MIXED MODELS; POLYAMINES; FIBRINOGEN; INFECTIONS; VIRULENCE AB The arginine catabolic mobile element (ACME) is the largest genomic region distinguishing epidemic USA300 strains of methicillin-resistant Staphylococcus aureus (MRSA) from other S. aureus strains. However, the functional relevance of ACME to infection and disease has remained unclear. Using phylogenetic analysis, we have shown that the modular segments of ACME were assembled into a single genetic locus in Staphylococcus epidermidis and then horizontally transferred to the common ancestor of USA300 strains in an extremely recent event. Acquisition of one ACME gene, speG, allowed USA300 strains to with-stand levels of polyamines (e. g., spermidine) produced in skin that are toxic to other closely related S. aureus strains. speG-mediated polyamine tolerance also enhanced biofilm formation, adherence to fibrinogen/fibronectin, and resistance to antibiotic and keratinocyte-mediated killing. We suggest that these properties gave USA300 a major selective advantage during skin infection and colonization, contributing to the extraordinary evolutionary success of this clone. IMPORTANCE Over the past 15 years, methicillin-resistant Staphylococcus aureus (MRSA) has become a major public health problem. It is likely that adaptations in specific MRSA lineages (e. g., USA300) drove the spread of MRSA across the United States and allowed it to replace other, less-virulent S. aureus strains. We suggest that one major factor in the evolutionary success of MRSA may have been the acquisition of a gene (speG) that allows S. aureus to evade the toxicity of polyamines (e. g., spermidine and spermine) that are produced in human skin. Polyamine tolerance likely gave MRSA multiple fitness advantages, including the formation of more-robust biofilms, increased adherence to host tissues, and resistance to antibiotics and killing by human skin cells. C1 [Planet, Paul J.; LaRussa, Samuel J.; Smith, Hannah; Xu, Amy; Ryan, Chanelle; Goldberg, Julia; Kulkarni, Ritwij; Ratner, Adam J.; Prince, Alice] Columbia Univ, Dept Pediat, Div Pediat Infect Dis, Coll Phys & Surg, New York, NY 10027 USA. [Planet, Paul J.; Narechania, Apurva; Kolokotronis, Sergios-Orestis] Amer Museum Nat Hist, Sackler Inst Comparat Genom, New York, NY 10024 USA. [Dana, Ali] James J Peters Vet Affairs Med Ctr, Dept Dermatol, Bronx, NY USA. [Uhlemann, Anne-Catrin] Columbia Univ, Coll Phys & Surg, Dept Internal Med, Div Infect Dis, New York, NY USA. [Boundy, Sam] Virginia Commonwealth Univ, Sch Med, Dept Internal Med, Div Infect Dis, Richmond, VA USA. [Geoghegan, Joan A.] Trinity Coll Dublin, Moyne Inst Prevent Med, Dept Microbiol, Dublin, Ireland. [Kolokotronis, Sergios-Orestis] Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA. RP Planet, PJ (reprint author), Columbia Univ, Dept Pediat, Div Pediat Infect Dis, Coll Phys & Surg, New York, NY 10027 USA. EM pjp23@columbia.edu RI Kolokotronis, Sergios-Orestis/A-1910-2009; OI Kolokotronis, Sergios-Orestis/0000-0003-3309-8465; Boundy, Sam/0000-0003-0541-1776; Ratner, Adam/0000-0003-1761-794X FU [UL1 TR000040]; [NIH R01 HL079395]; [NIH RO1 AI 103854] FX This work was supported by grants to P.J.P. (UL1 TR000040) and A. S. P. (NIH R01 HL079395 and NIH RO1 AI 103854). NR 62 TC 27 Z9 27 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 2150-7511 J9 MBIO JI mBio PD NOV-DEC PY 2013 VL 4 IS 6 AR e00889-13 DI 10.1128/mBio.00889-13 PG 10 WC Microbiology SC Microbiology GA 282LZ UT WOS:000329174500037 PM 24345744 ER PT J AU Alba, GA Kelmenson, DA Noble, VE Murray, AF Currier, PF AF Alba, George A. Kelmenson, Daniel A. Noble, Vicki E. Murray, Alice F. Currier, Paul F. TI Faculty staff-guided versus self-guided ultrasound training for internal medicine residents SO MEDICAL EDUCATION LA English DT Article ID HAND-CARRIED ULTRASOUND; RANDOMIZED CONTROLLED-TRIAL; EMERGENCY PHYSICIANS; EDUCATION; FEEDBACK; PNEUMOTHORAX; PERFORMANCE; STUDENTS; IMPROVES; SKILLS AB ObjectivesUltrasonography is of growing importance within internal medicine (IM), but the optimal method of training doctors to use it is uncertain. In this study, the authors provide the first objective comparison of two approaches to training IM residents in ultrasonography. MethodsIn this randomised trial, a simulation-based ultrasound training curriculum was implemented during IM intern orientation at a tertiary care teaching hospital. All 72 incoming interns attended a lecture and were given access to online modules. Interns were then randomly assigned to a 4-hour faculty-guided (FG) or self-guided (SG) ultrasound training session in a simulation laboratory with both human and manikin models. Interns were asked to self-assess their competence in ultrasonography and underwent an objective structured clinical examination (OSCE) to assess their competence in basic and procedurally oriented ultrasound tasks. The primary outcome was the score on the OSCE. ResultsFaculty-guided training was superior to self-guided training based on the OSCE scores. Subjects in the FG training group achieved significantly higher OSCE scores on the two subsets of task completion (0.9-point difference, 95% confidence interval [CI] 0.27-1.54; p=0.008) and ultrasound image quality (2.43-point difference, 95% CI 1.5-3.36; p<0.001). Both training groups demonstrated an increase in self-assessed competence after their respective training sessions and there was little difference between the groups. Subjects rated the FG training group much more favourably than the SG training group. ConclusionsBoth FG and SG ultrasound training curricula can improve the self-reported competence of IM interns in ultrasonography. However, FG training was superior to SG training in both skills acquisition and intern preference. Incorporating mandatory ultrasound training into IM residencies can address the perceived need for ultrasound training, improve confidence and procedural skills, and may enhance patient safety. However, the optimal training method may require significant faculty input. Discuss ideas arising from the article at discuss' C1 [Alba, George A.; Kelmenson, Daniel A.; Currier, Paul F.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA. [Alba, George A.; Kelmenson, Daniel A.; Noble, Vicki E.; Murray, Alice F.; Currier, Paul F.] Harvard Univ, Sch Med, Boston, MA USA. [Noble, Vicki E.; Murray, Alice F.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Currier, Paul F.] Massachusetts Gen Hosp, Dept Pulm & Crit Care, Boston, MA 02114 USA. RP Kelmenson, DA (reprint author), Apartment 2,66 Myrtle St, Boston, MA 02114 USA. EM dkelmenson@gmail.com FU Partners Centers of Expertise in Medical Education trainee research grant through Partners Healthcare FX This study was supported by a Partners Centers of Expertise in Medical Education trainee research grant offered through Partners Healthcare. NR 41 TC 7 Z9 7 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0308-0110 EI 1365-2923 J9 MED EDUC JI Med. Educ. PD NOV PY 2013 VL 47 IS 11 BP 1099 EP 1108 DI 10.1111/medu.12259 PG 10 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 282EN UT WOS:000329153200010 PM 24117556 ER PT J AU Coker, J Tucker, J Estrada, C AF Coker, Joshua Tucker, Jesse Estrada, Carlos TI Nominal group technique: a tool for course evaluation SO MEDICAL EDUCATION LA English DT News Item C1 [Estrada, Carlos] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Estrada, C (reprint author), Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, 732 FOT 510 20th St South, Birmingham, AL 35294 USA. EM cestrada@uab.edu NR 1 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0308-0110 EI 1365-2923 J9 MED EDUC JI Med. Educ. PD NOV PY 2013 VL 47 IS 11 BP 1145 EP 1145 DI 10.1111/medu.12324 PG 1 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 282EN UT WOS:000329153200045 PM 24117592 ER PT J AU Sharma, A Gulbahce, N Pevzner, SJ Menche, J Ladenvall, C Folkersen, L Eriksson, P Orho-Melander, M Barabasi, AL AF Sharma, Amitabh Gulbahce, Natali Pevzner, Samuel J. Menche, Joerg Ladenvall, Claes Folkersen, Lasse Eriksson, Per Orho-Melander, Marju Barabasi, Albert-Laszlo TI Network-based Analysis of Genome Wide Association Data Provides Novel Candidate Genes for Lipid and Lipoprotein Traits SO MOLECULAR & CELLULAR PROTEOMICS LA English DT Article ID PROTEIN INTERACTION NETWORK; HUMAN-DISEASE; HDL-CHOLESTEROL; HYPERHOMOCYSTEINEMIA; PRIORITIZATION; SUSCEPTIBILITY; POLYMORPHISMS; INTERACTOME; METABOLISM; MUTATIONS AB Genome wide association studies (GWAS) identify susceptibility loci for complex traits, but do not identify particular genes of interest. Integration of functional and network information may help in overcoming this limitation and identifying new susceptibility loci. Using GWAS and comorbidity data, we present a network-based approach to predict candidate genes for lipid and lipoprotein traits. We apply a prediction pipeline incorporating interactome, co-expression, and comorbidity data to Global Lipids Genetics Consortium (GLGC) GWAS for four traits of interest, identifying phenotypically coherent modules. These modules provide insights regarding gene involvement in complex phenotypes with multiple susceptibility alleles and low effect sizes. To experimentally test our predictions, we selected four candidate genes and genotyped representative SNPs in the Malmo Diet and Cancer Cardiovascular Cohort. We found significant associations with LDL-C and total-cholesterol levels for a synonymous SNP (rs234706) in the cystathionine beta-synthase (CBS) gene (p = 1 x 10(-5) and adjusted-p = 0.013, respectively). Further, liver samples taken from 206 patients revealed that patients with the minor allele of rs234706 had significant dysregulation of CBS (p = 0.04). Despite the known biological role of CBS in lipid metabolism, SNPs within the locus have not yet been identified in GWAS of lipoprotein traits. Thus, the GWAS-based Comorbidity Module (GCM) approach identifies candidate genes missed by GWAS studies, serving as a broadly applicable tool for the investigation of other complex disease phenotypes. C1 [Sharma, Amitabh; Ladenvall, Claes; Orho-Melander, Marju] Lund Univ, Malmo Univ Hosp, Dept Clin Sci Diabet & Cardiovasc Dis, SE-20502 Malmo, Sweden. [Sharma, Amitabh; Gulbahce, Natali; Menche, Joerg; Barabasi, Albert-Laszlo] Northeastern Univ, Ctr Complex Network Res, Boston, MA 02115 USA. [Sharma, Amitabh; Gulbahce, Natali; Menche, Joerg; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Phys, Boston, MA 02115 USA. [Sharma, Amitabh; Gulbahce, Natali; Menche, Joerg; Barabasi, Albert-Laszlo] Harvard Univ, Sch Med, CCSB, Boston, MA 02115 USA. [Sharma, Amitabh; Gulbahce, Natali; Menche, Joerg; Barabasi, Albert-Laszlo] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Sharma, Amitabh; Gulbahce, Natali; Menche, Joerg; Barabasi, Albert-Laszlo] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Barabasi, Albert-Laszlo] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Gulbahce, Natali] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA. [Folkersen, Lasse; Eriksson, Per] Karolinska Inst, Dept Med, Atherosclerosis Res Unit, Stockholm, Sweden. [Pevzner, Samuel J.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA. [Pevzner, Samuel J.] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Sharma, A (reprint author), Lund Univ, Skania Univ Hosp, CRC Entrance 72,Bldg 91 Floor 12, SE-20502 Malmo, Sweden. EM amitabhsharma13@gmail.com; marju.orho-melander@med.lu.se RI Menche, Jorg/G-3994-2015; OI Menche, Jorg/0000-0002-1583-6404; Folkersen, Lasse/0000-0003-0708-9530 FU Swedish Research Council; Swedish Heart and Lung Foundation; Region Skane; Skane University Hospital; Novo Nordic Foundation; Albert Pahlsson Research Foundation; Crafoord foundation equipment grant from the Knut and Alice Wallenberg Foundation; Linneus for the Lund University Diabetes Center (LUDC); National Institutes of Health (NIH) [P50-HG004233 CEGS] FX This study is supported by the Swedish Research Council, the Swedish Heart and Lung Foundation, the Region Skane, the Skane University Hospital, the Novo Nordic Foundation, the Albert Pahlsson Research Foundation, the Crafoord foundation equipment grant from the Knut and Alice Wallenberg Foundation and by Linneus for the Lund University Diabetes Center (LUDC). MOM is a senior scientist at the Swedish Research Council. This work was supported by National Institutes of Health (NIH) grants P50-HG004233 CEGS. NR 49 TC 13 Z9 13 U1 0 U2 11 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 1535-9476 EI 1535-9484 J9 MOL CELL PROTEOMICS JI Mol. Cell. Proteomics PD NOV PY 2013 VL 12 IS 11 BP 3398 EP 3408 DI 10.1074/mcp.M112.024851 PG 11 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA 277JX UT WOS:000328816000031 PM 23882023 ER PT J AU Janssens, T Keil, B Serano, P Mareyam, A McNab, JA Wald, LL Vanduffel, W AF Janssens, Thomas Keil, Boris Serano, Peter Mareyam, Azma McNab, Jennifer A. Wald, Lawrence L. Vanduffel, Wim TI A 22-channel receive array with Helmholtz transmit coil for anesthetized macaque MRI at 3 T SO NMR IN BIOMEDICINE LA English DT Article DE RF receive coils; array coils; animal model study; macaque ID VISUAL-CORTEX; PHASED-ARRAY; HEAD COIL; MONKEYS; RESONANCE; BRAIN; FMRI; TESLA; FIELD; MICROSTIMULATION AB The macaque monkey is an important model for cognitive and sensory neuroscience that has been used extensively in behavioral, electrophysiological, molecular and, more recently, neuroimaging studies. However, macaque MRI has unique technical differences relative to human MRI, such as the geometry of highly parallel receive arrays, which must be addressed to optimize imaging performance. A 22-channel receive coil array was constructed specifically for rapid high-resolution anesthetized macaque monkey MRI at 3 T. A local Helmholtz transmit coil was used for excitation. Signal-to-noise ratios (SNRs) and noise amplification for parallel imaging were compared with those of single- and four-channel receive coils routinely used for macaque MRI. The 22-channel coil yielded significant improvements in SNR throughout the brain. Using this coil, the SNR in peripheral brain was 2.4 and 1.7 times greater than that obtained with single- or four-channel coils, respectively. In the central brain, the SNR gain was 1.5 times that of both the single- and four-channel coils. Finally, the performance of the array for functional, anatomical and diffusion-weighted imaging was evaluated. For all three modalities, the use of the 22-channel array allowed for high-resolution and accelerated image acquisition. Copyright (c) 2013 John Wiley & Sons, Ltd. C1 [Janssens, Thomas; Keil, Boris; Serano, Peter; Mareyam, Azma; McNab, Jennifer A.; Wald, Lawrence L.; Vanduffel, Wim] Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Janssens, Thomas; Vanduffel, Wim] KU Leuven Med Sch, Lab Neuro & Psychophysiol, Louvain, Belgium. [Keil, Boris; McNab, Jennifer A.; Wald, Lawrence L.; Vanduffel, Wim] Harvard Univ, Sch Med, Boston, MA USA. [McNab, Jennifer A.] Stanford Univ, Dept Radiol, RM Lucas Ctr Imaging, Stanford, CA 94305 USA. [Wald, Lawrence L.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Vanduffel, W (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Bldg 149,Room 2301,13th St, Charlestown, MA 02129 USA. EM wim@nmr.mgh.harvard.edu RI Keil, Boris/P-1411-2014; Wald, Lawrence/D-4151-2009 FU Inter University Attraction Pole [6/29, PFV/10/008, 10/19]; Fonds Wetenschappelijk Onderzoek (FWO)-Vlaanderen [G062208N10, G083111N10, G043912N]; National Science Foundation (NSF) [BCS-0745436]; National Center for Research Resources [P41RR14075] FX The authors thank H. Deng and R. Farivar for technical support during the scans. This work received support from Inter University Attraction Pole 6/29, Program Financing PFV/10/008, Geconcerteerde Onderzoeks Actie 10/19, Hercules funding, Fonds Wetenschappelijk Onderzoek (FWO)-Vlaanderen (G062208N10, G083111N10 and G043912N) and National Science Foundation (NSF) grant BCS-0745436. TJ is an aspirant of the FWO-Vlaanderen. The Martinos Center is supported by National Center for Research Resources grant P41RR14075. NR 42 TC 3 Z9 3 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0952-3480 EI 1099-1492 J9 NMR BIOMED JI NMR Biomed. PD NOV PY 2013 VL 26 IS 11 BP 1431 EP 1440 DI 10.1002/nbm.2970 PG 10 WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy GA 283DK UT WOS:000329225200011 PM 23703859 ER PT J AU Lin, AE Traum, AZ Sahai, I Keppler-Noreuil, K Kukolich, MK Adam, MP Westra, SJ Arts, HH AF Lin, Angela E. Traum, Avram Z. Sahai, Inderneel Keppler-Noreuil, Kim Kukolich, Mary K. Adam, Margaret P. Westra, Sjirk J. Arts, Heleen H. TI Sensenbrenner Syndrome (Cranioectodermal Dysplasia): Clinical and Molecular Analyses of 39 Patients Including Two New Patients SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE asphyxiating thoracic dystrophy; ciliopathy; cranioectodermal dysplasia; Jeune syndrome; sagittal craniosynostosis; Sensenbrenner syndrome; short rib-polydactyly syndromes ID ASPHYXIATING THORACIC DYSTROPHY; TUBULOINTERSTITIAL NEPHROPATHY; JOUBERT SYNDROME; GAPO SYNDROME; MUTATIONS; PHENOTYPE; CILIOPATHIES; DISEASE; CRANIOSYNOSTOSIS; ABNORMALITIES AB Sensenbrenner syndrome, also known as cranioectodermal dysplasia, is a rare multiple anomaly syndrome with distinctive craniofacial appearance, skeletal, ectodermal, connective tissue, renal, and liver anomalies. Dramatic advances with next-generation sequencing have expanded its phenotypic variability and molecular heterogeneity. We review 39 patients including two new patients, one with compound heterozygous novel mutations in WDR35 and a previously unreported multisutural craniosynostosis that may be a part of Sensenbrenner syndrome. In 14 of 25 (56.0%) patients pathogenic mutations have been identified in 4 different genes that regulate (intraflagellar) cilia transport. We compared Sensenbrenner syndrome to asphyxiating thoracic dystrophy-Jeune syndrome (ATD-JS) and other ciliopathies. Our analyses showed that the high anterior hairline, forehead bossing and dolichocephaly (accompanied by sagittal craniosynostosis in more than half of the patients) occur in almost all patients with Sensenbrenner syndrome. Metaphyseal dysplasia with narrow thorax, proximal limb shortness, and short fingers are typical of Sensenbrenner syndrome and ATD-JS. Respiratory complications have been reported in both syndromes, usually less severe with Sensenbrenner syndrome. Proposed diagnostic criteria for Sensenbrenner syndrome include the distinctive craniofacial appearance, ubiquitous brachydactyly and ectodermal anomalies, and sagittal craniosynostosis. Mild heart defects have been noted, but there have been no atrioventricular canal or heterotaxy defects that are common in Ellis-Van Creveld syndrome. We anticipate that the steady identification of molecularly defined patients may allow correlation of phenotype and genotype. Additional natural history data will improve genetic counseling and current guidelines. (c) 2013 Wiley Periodicals, Inc. C1 [Lin, Angela E.; Sahai, Inderneel] MassGen Hosp Children, Boston, MA USA. [Traum, Avram Z.] MassGeneral Hosp Children, Dept Pediat, Pediat Nephrol Unit, Boston, MA USA. [Keppler-Noreuil, Kim] NHGRI, Genet Dis Res Branch, Human Dev Sect, NIH, Bethesda, MD 20892 USA. [Kukolich, Mary K.] Cook Childrens Hosp, Clin Genet Serv, Ft Worth, TX USA. [Adam, Margaret P.] Univ Washington, Div Med Genet, Seattle, WA 98195 USA. [Westra, Sjirk J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Arts, Heleen H.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6525 ED Nijmegen, Netherlands. RP Lin, AE (reprint author), Genet Unit, 185 Cambridge St,CPZN 2222, Boston, MA 02114 USA. EM lin.angela@mgh.harvard.edu FU Dutch Kidney Foundation [CP11.18]; Netherlands Organization for Scientific Research [NWO Veni-91613008] FX H.H.A. is supported by grants from Dutch Kidney Foundation (CP11.18) and the Netherlands Organization for Scientific Research (NWO Veni-91613008). We express our deep gratitude to Dr. Friedhelm Hildebrandt from the Department of Pediatrics, University of Michigan (currently, Boston Children's Hospital, Boston, Massachusetts) for performing the molecular studies on the new patient 1. We thank Dr. Harald Jueppner, MD (Nephrology) and Barbara Luby, LICSW (Social Services) from the Mass-General Hospital for Children, and Meaghan Muir and her staff for research assistance at the Brigham and Women's Hospital. We thank Dr. Carlos Bacino from the Department of Molecular and Human Genetics, Baylor College of Medicine for assistance in interpreting the WES data on new patient 2. NR 38 TC 15 Z9 15 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 EI 1552-4833 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD NOV PY 2013 VL 161 IS 11 SI SI BP 2762 EP 2776 DI 10.1002/ajmg.a.36265 PG 15 WC Genetics & Heredity SC Genetics & Heredity GA 267ZP UT WOS:000328137500014 PM 24123776 ER PT J AU Duzkale, H Shen, J McLaughlin, H Alfares, A Kelly, MA Pugh, TJ Funke, BH Rehm, HL Lebo, MS AF Duzkale, H. Shen, J. McLaughlin, H. Alfares, A. Kelly, M. A. Pugh, T. J. Funke, B. H. Rehm, H. L. Lebo, M. S. TI A systematic approach to assessing the clinical significance of genetic variants SO CLINICAL GENETICS LA English DT Article DE (4-9) clinical interpretation; gain-of-function (GOF); genetic variant; loss of function (LOF); next-generation sequencing (NGS); sequence analysis; variant assessment; variant of uncertain significance (VUS) ID DE-NOVO MUTATIONS; HYPERTROPHIC CARDIOMYOPATHY; CYSTIC-FIBROSIS; DISEASE RISK; PATHOGENICITY; FREQUENCY; STANDARDS; DEAFNESS; RECOMMENDATIONS; CLASSIFICATION AB Molecular genetic testing informs diagnosis, prognosis, and risk assessment for patients and their family members. Recent advances in low-cost, high-throughput DNA sequencing and computing technologies have enabled the rapid expansion of genetic test content, resulting in dramatically increased numbers of DNA variants identified per test. To address this challenge, our laboratory has developed a systematic approach to thorough and efficient assessments of variants for pathogenicity determination. We first search for existing data in publications and databases including internal, collaborative and public resources. We then perform full evidence-based assessments through statistical analyses of observations in the general population and disease cohorts, evaluation of experimental data from in vivo or in vitro studies, and computational predictions of potential impacts of each variant. Finally, we weigh all evidence to reach an overall conclusion on the potential for each variant to be disease causing. In this report, we highlight the principles of variant assessment, address the caveats and pitfalls, and provide examples to illustrate the process. By sharing our experience and providing a framework for variant assessment, including access to a freely available customizable tool, we hope to help move towards standardized and consistent approaches to variant assessment. C1 [Duzkale, H.; Shen, J.; McLaughlin, H.; Alfares, A.] Harvard Univ, Sch Med, Genet Training Program, Boston, MA USA. [Duzkale, H.; Shen, J.; McLaughlin, H.; Alfares, A.; Kelly, M. A.; Pugh, T. J.; Funke, B. H.; Rehm, H. L.; Lebo, M. S.] Partners HealthCare Ctr Personalized Genet Med, Lab Mol Med, Cambridge, MA USA. [Shen, J.; Pugh, T. J.; Funke, B. H.; Rehm, H. L.; Lebo, M. S.] Massachusetts Gen Hosp, Dept Pathol, Brigham & Womans Hosp, Boston, MA 02114 USA. [Shen, J.; Pugh, T. J.; Funke, B. H.; Rehm, H. L.; Lebo, M. S.] Harvard Univ, Sch Med, Boston, MA USA. [Alfares, A.] Qassim Univ, Dept Pediat, Buraydah, Saudi Arabia. RP Lebo, MS (reprint author), 65 Landsdowne St, Cambridge, MA 02139 USA. EM mlebo@partners.org OI Lebo, Matthew/0000-0002-9733-5207 FU National Institutes of Health [HG006834, HG006500] FX We thank Jordan Lerner-Ellis, Sami Amr, and Mark Bowser for their help in developing and maintaining the VAT. We also thank all of our colleagues past and present at the LMM for their contributions to our variant assessment process over the past decade. This work was supported in part by National Institutes of Health grants HG006834 and HG006500. NR 44 TC 42 Z9 44 U1 0 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9163 EI 1399-0004 J9 CLIN GENET JI Clin. Genet. PD NOV PY 2013 VL 84 IS 5 BP 453 EP 463 DI 10.1111/cge.12257 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA 270PT UT WOS:000328331600006 PM 24033266 ER PT J AU Karakis, I Montouris, GD Piperidou, C San Luciano, M Meador, KJ Cole, AJ AF Karakis, Ioannis Montouris, Georgia D. Piperidou, Charitomeni San Luciano, Marta Meador, Kimford J. Cole, Andrew J. TI The effect of epilepsy surgery on caregiver quality of life SO EPILEPSY RESEARCH LA English DT Article DE Caregiver; Quality of life; Burden; Epilepsy; Surgery; SF36v2 ID CHILDREN; IMPACT; HEALTH; ADULTS; ADOLESCENTS; PREVALENCE; OUTCOMES; PARENTS; BURDEN; DETERMINANTS AB Purpose: Epilepsy surgery has been shown to improve patient quality of life (QOL). Little is known about its effect on caregiver QOL. Methods: The study population comprised of 26 persons with epilepsy (PWE) who underwent long term video EEG monitoring at Massachusetts General Hospital for presurgical evaluation along with 16 caregivers. The PWE completed epilepsy directed QOL (QOLIE-31) and psychological (Beck depression-BDI and anxiety inventory-BAI) questionnaires before and after surgery. Their participating caregivers completed generic health related QOL (SF36v2) and disease burden (Zarit caregiver burden inventory-ZCBI) questionnaires before and after surgery. Demographic data for all participants and disease/surgery related data for the PWE were collected. Statistical analysis was performed to compare PWE and caregiver QOL before and after surgery. Results: Mean patient age was 37 years. Most (77%) suffered from symptomatic partial epilepsy for approximately 18 years prior to surgery, averaging 4 seizures per month and 2.2 antiepileptic drugs (AEDs). 78% of them underwent an anterior temporal lobectomy and the rest extra-temporal resections. On follow up at approximately 9 months, 69% had a surgical outcome of Engel class I, 23% of class II and 8% class IV. Postoperatively, the PWE remained on average on 1.9 AEDs. There was a statistically significant improvement for both the aggregate QOLIE-31 score and all its subscales (except for medication effects) as well as the BAI scores. 96% of the PWE felt that the decision to go through surgery was worthwhile. Mean caregivers age was 47 years. Half of them were spouses to the PWE and the majority of the rest their parents. 50% of them stated that their overall time devoted to patient's care decreased after surgery and 50% that it remained unchanged. The mental component scale (SF36v2, MCS) of caregiver QOL showed statistically significant improvement. ZCBI score and the physical component scale of their QOL (SF36v2, PCS) did not significantly vary before and after surgery. 75% of caregivers deemed their QOL better post surgery vs 19% similar. 94% of the caregivers felt that the decision to go through surgery was worthwhile. Conclusions: Successful epilepsy surgery has a positive impact not only to patient QOL but also to their caregiver. To the best of our knowledge, this is the first pilot study to systematically address the impact of epilepsy surgery on caregivers providing additional support to epilepsy surgery as the optimal treatment modality in carefully selected patients. These findings call for further investigation on the caregiver quality of life in epilepsy and for its inclusion in the treatment plan and quality indicators for epilepsy surgery. (C) 2013 Elsevier B.V. All rights reserved. C1 [Karakis, Ioannis; Meador, Kimford J.] Emory Univ, Dept Neurol, Sch Med, Atlanta, GA 30303 USA. [Montouris, Georgia D.] Boston Univ, Sch Med, Boston Med Ctr, Dept Neurol, Boston, MA 02118 USA. [Piperidou, Charitomeni] Democritus Univ Thrace, Dept Neurol, Alexandroupolis, Greece. [San Luciano, Marta] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Cole, Andrew J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Epilepsy Serv, Boston, MA USA. RP Karakis, I (reprint author), Emory Univ, Sch Med, Fac Off Bldg & Grady Campus,49 Jesse Hill Jr Dr S, Atlanta, GA 30303 USA. EM ioannis.karakis@emory.edu NR 50 TC 4 Z9 4 U1 0 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-1211 EI 1872-6844 J9 EPILEPSY RES JI Epilepsy Res. PD NOV PY 2013 VL 107 IS 1-2 BP 181 EP 189 DI 10.1016/j.eplepsyres.2013.08.006 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA 273HB UT WOS:000328524800021 PM 24054427 ER PT J AU Inglessis, I Elmariah, S Rengifo-Moreno, PA Margey, R O'Callaghan, C Cruz-Gonzalez, I Baron, S Mehrotra, P Tan, TC Hung, J Demirjian, ZN Buonanno, FS Ning, MM Silverman, SB Cubeddu, RJ Pomerantsev, E Schainfeld, RM Dec, GW Palacios, IF AF Inglessis, Ignacio Elmariah, Sammy Rengifo-Moreno, Pablo A. Margey, Ronan O'Callaghan, Caitlin Cruz-Gonzalez, Ignacio Baron, Suzanne Mehrotra, Praveen Tan, Timothy C. Hung, Judy Demirjian, Zareh N. Buonanno, Ferdinando S. Ning, MingMing Silverman, Scott B. Cubeddu, Roberto J. Pomerantsev, Eugene Schainfeld, Robert M. Dec, G. William, Jr. Palacios, Igor F. TI Long-Term Experience and Outcomes With Transcatheter Closure of Patent Foramen Ovale SO JACC-CARDIOVASCULAR INTERVENTIONS LA English DT Article DE cerebral infarction; cryptogenic stroke; embolic stroke; paradoxical embolism; patent foramen ovale ID ATRIAL SEPTAL-DEFECT; PRESUMED PARADOXICAL EMBOLISM; RECURRENT NEUROLOGICAL EVENTS; SECONDARY STROKE PREVENTION; RANDOMIZED CLINICAL-TRIALS; PERCUTANEOUS CLOSURE; CRYPTOGENIC STROKE; MEDICAL THERAPY; DECOMPRESSION-SICKNESS; PLATYPNEA-ORTHODEOXIA AB Objectives This study sought to examine the frequency of indications for and the immediate and long-term clinical outcomes of transcatheter closure of patent foramen ovale (PFO). Background Transcatheter PFO closure is commonly performed for several indications, including cryptogenic stroke, despite conflicting data regarding the efficacy of this intervention. Methods We report the outcomes of 800 consecutive patients (52% male, 50 +/- 14 years of age) who underwent PFO closure at our institution after multidisciplinary evaluation over a 16-year period. Results Indications for closure included cryptogenic cerebrovascular event (94%), hypoxemia (2%), peripheral embolism (3%), and migraine headaches (2%). Procedural success was 99% with effective closure obtained in 93% of patients. At a mean follow-up of 42.7 +/- 33.4 months, 21 patients suffered a recurrent ischemic neurologic event (12 strokes, and 9 transient ischemic attacks) for an incidence rate of 0.79 events per 100 person-years and freedom from recurrent events of 91.6% at 10 years. There was no device-based difference in the rate of recurrent ischemic neurologic events (p = 0.82). Only Eustachian valve prominence (hazard ratio: 9.04; 95% confidence interval: 2.07 to 39.44; p = 0.0034) was associated with recurrent neurologic events. Conclusions Transcatheter PFO closure is safe and feasible in patients with several clinical indications. The long-term efficacy of this intervention in patients with paradoxical embolism appears superb in this observational study. Carefully selected patients with features suggestive of paradoxical embolism are the most likely to benefit from PFO closure and should be the focus of future investigation. (C) 2013 by the American College of Cardiology Foundation C1 [Inglessis, Ignacio; Elmariah, Sammy; Rengifo-Moreno, Pablo A.; Margey, Ronan; O'Callaghan, Caitlin; Cruz-Gonzalez, Ignacio; Baron, Suzanne; Mehrotra, Praveen; Tan, Timothy C.; Hung, Judy; Cubeddu, Roberto J.; Pomerantsev, Eugene; Schainfeld, Robert M.; Dec, G. William, Jr.; Palacios, Igor F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiol Div,Dept Med, Boston, MA USA. [Cruz-Gonzalez, Ignacio] Univ Hosp Salamanca, Div Cardiol, Salamanca, Spain. [Demirjian, Zareh N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Hematol & Oncol,Dept Med, Boston, MA USA. [Buonanno, Ferdinando S.; Ning, MingMing; Silverman, Scott B.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Cubeddu, Roberto J.] Aventura Med Ctr, Div Cardiol, Miami, FL USA. RP Palacios, IF (reprint author), Massachusetts Gen Hosp, 55 Fruit St,GRB 800, Boston, MA 02114 USA. EM ipalacios@partners.org NR 34 TC 13 Z9 13 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-8798 EI 1876-7605 J9 JACC-CARDIOVASC INTE JI JACC-Cardiovasc. Interv. PD NOV PY 2013 VL 6 IS 11 BP 1176 EP 1183 DI 10.1016/j.jcin.2013.06.013 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 272KB UT WOS:000328458100009 PM 24262618 ER PT J AU Monteiro, ANA Freedman, ML AF Monteiro, A. N. A. Freedman, M. L. TI Lessons from postgenome-wide association studies: functional analysis of cancer predisposition loci SO JOURNAL OF INTERNAL MEDICINE LA English DT Review DE cancer predisposition; eQTL; GWAS; SNPs; transcription ID HUMAN GENOME; GENE-EXPRESSION; OVARIAN-CANCER; RISK LOCI; CHROMOSOME CONFORMATION; SUSCEPTIBILITY LOCI; BREAST; VARIANTS; ANNOTATION; LANDSCAPE AB In the last few years, genome-wide association studies (GWASs) have identified hundreds of predisposition loci for several types of human cancers. Recent progress has been made in determining the underlying mechanisms through which different single-nucleotide polymorphisms (SNPs) affect predisposition to cancer. Although there has been much debate about the clinical utility of GWASs, less attention has been paid to how GWASs and post-GWASs functional analysis have contributed to understanding the aetiology of cancer. Most common variants associated with cancer risk are localized in nonprotein-coding regions highlighting transcriptional regulation as a common theme in the mechanism of cancer predisposition. Here, we outline strategies to functionally dissect predisposition loci and discuss their limitations as well as challenges for future studies. C1 [Monteiro, A. N. A.] H Lee Moffitt Canc Ctr & Res Inst, Canc Epidemiol Program, Tampa, FL 33612 USA. [Freedman, M. L.] Eli & Edythe L Broad Inst & Harvard, Cambridge, MA USA. [Freedman, M. L.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Monteiro, ANA (reprint author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA. EM alvaro.monteiro@moffitt.org; freedman@broadinstitute.org FU National Institutes of Health (NIH) post-GWASs initiative; NIH [1U19CA148112, 1U19CA148537, 1U19CA148065] FX The GAME-ON consortium is funded by the National Institutes of Health (NIH) post-GWASs initiative. Work in the authors' laboratories is funded by NIH awards (1U19CA148112, 1U19CA148537 and 1U19CA148065). We thank all investigators in the GAME-ON consortium for helpful discussions. We also sincerely thank all individuals who have contributed to cancer GWASs by providing DNA, tissues and clinical information. NR 57 TC 17 Z9 18 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0954-6820 EI 1365-2796 J9 J INTERN MED JI J. Intern. Med. PD NOV PY 2013 VL 274 IS 5 BP 414 EP 424 DI 10.1111/joim.12085 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 269ZP UT WOS:000328284700003 PM 24127939 ER PT J AU Landegger, LD Cohen, MS AF Landegger, L. D. Cohen, M. S. TI Congenital cholesteatoma in siblings SO JOURNAL OF LARYNGOLOGY AND OTOLOGY LA English DT Article DE Cholesteatoma; Pediatrics; Heredity ID PATHOGENESIS; EAR AB Introduction: The exact aetiology of congenital cholesteatoma, the less common form of this destructive disease, is still under debate. Case report: A two-year-old boy was referred to paediatric otolaryngology with persistent, bloody, left-sided otorrhoea refractory to oral and ototopical antibiotics. Prior to its onset at age 16months, all ear examinations on the affected side were normal. Physical examination, imaging with computed tomography and eventual tympanomastoidectomy revealed extensive cholesteatoma. The extent of the disease, age at onset of symptoms and absence of otological disease before initial presentation suggested the diagnosis of congenital cholesteatoma. Review of the family history revealed that the patient's older brother had undergone tympanomastoidectomy for a small, well-encapsulated, mesotympanic congenital cholesteatoma at two years of age. Discussion: This case joins a single, previous report describing congenital cholesteatoma in multiple family members, suggesting that in some cases, hereditary factors may play a role in the formation of the disease. C1 [Landegger, L. D.] Med Univ Vienna, Dept Otol & Laryngol, Vienna, Austria. [Cohen, M. S.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Cohen, MS (reprint author), Massachusetts Eye & Ear Infirm, Div Pediat Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM michael_cohen@meei.harvard.edu OI Landegger, Lukas D./0000-0002-9660-2625 NR 11 TC 0 Z9 0 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0022-2151 EI 1748-5460 J9 J LARYNGOL OTOL JI J. Laryngol. Otol. PD NOV PY 2013 VL 127 IS 11 BP 1143 EP 1144 DI 10.1017/S0022215113002284 PG 2 WC Otorhinolaryngology SC Otorhinolaryngology GA 272QW UT WOS:000328476300021 PM 24169145 ER PT J AU Buccheri, RK Trygstad, LN Buffum, MD Birmingham, P Dowling, GA AF Buccheri, Robin Kay Trygstad, Louise Nigh Buffum, Martha D. Birmingham, Patricia Dowling, Glenna A. TI Self-Management of Unpleasant Auditory Hallucinations A Tested Practice Model SO JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES LA English DT Article ID COMMAND HALLUCINATIONS; BEHAVIORAL-MANAGEMENT; SCHIZOPHRENIA; VOICES; HARM AB Individuals who experience auditory hallucinations (AH) frequently report hearing unpleasant voices saying disturbing things to them, making derogatory remarks about them, or commanding them to do something, including harming themselves or someone else. The Self-Management of Unpleasant Auditory Hallucinations Practice Model was developed to help psychiatric-mental health nurses in both inpatient and outpatient settings implement evidence-based nursing care for voice hearers who are distressed by unpleasant voices. The model's utility extends to nursing education, administration, and research. The model is comprised of three parts: (a) Assessment of Voice Hearer's Experience, (b) Nursing Interventions, and (c) Voice Hearer's Expected Positive Outcomes. These three parts of the model describe nursing assessments conducted with an interview guide and two self-report tools, nursing interventions that teach strategies to manage unpleasant AH in a 10-session course or individually, and evaluation of voice hearer outcomes with two self-report tools. Copyright (C) SLACK Incorporated C1 [Buccheri, Robin Kay; Trygstad, Louise Nigh] Univ San Francisco, Sch Nursing & Hlth Profess, San Francisco, CA 94117 USA. [Buffum, Martha D.; Birmingham, Patricia] San Francisco VA Med Ctr, San Francisco, CA USA. [Buffum, Martha D.] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Dowling, Glenna A.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA USA. RP Buccheri, RK (reprint author), Univ San Francisco, Sch Nursing & Hlth Profess, Cowell Hall 222,2130 Fulton St, San Francisco, CA 94117 USA. EM buccherir@usfca.edu NR 24 TC 2 Z9 2 U1 3 U2 13 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0279-3695 EI 1938-2413 J9 J PSYCHOSOC NURS MEN JI J. Psychosoc. Nurs. Ment. Health Serv. PD NOV PY 2013 VL 51 IS 11 BP 26 EP 34 DI 10.3928/02793695-20130731-02 PG 9 WC Nursing SC Nursing GA 276EW UT WOS:000328732000011 PM 23938067 ER PT J AU Kim, SC Gillet, VG Feldman, S Lii, HC Toh, S Brown, JS Katz, JN Solomon, DH Schneeweiss, S AF Kim, Seoyoung C. Gillet, Victoria G. Feldman, Sarah Lii, Huichuan Toh, Sengwee Brown, Jeffrey S. Katz, Jeffrey N. Solomon, Daniel H. Schneeweiss, Sebastian TI Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE pharmacoepidemiology; cervical dysplasia; cervical cancer; validity; claims data ID HUMAN-PAPILLOMAVIRUS; CYTOLOGY; VACCINE AB BackgroundHigh-grade cervical dysplasia or cervical intraepithelial neoplasia grade 2 or worse has been widely used as a surrogate endpoint in cervical cancer screening or prevention trials. MethodsTo identify high-grade cervical dysplasia and cervical cancer, we developed claims-based algorithms that incorporated a combination of diagnosis and procedure codes using the billing data in an electronic medical records database and assessed the validity of the algorithms in an independent administrative claims database. We calculated the positive predictive value (PPV) with the 95% confidence interval (CI) of each algorithm, using new cytologic or pathologic diagnosis of cervical intraepithelial neoplasia 2 or 3, carcinoma in situ, or cervical cancer as the gold standard. ResultsHaving 1 diagnosis code for high-grade cervical dysplasia or cervical cancer had a PPV of 57.1% (95%CI, 54.7-59.5%). By requiring 2 diagnoses for high-grade cervical dysplasia or cervical cancer, separated by 7-30days, the PPV increased to 60.2% (95%CI, 53.9-66.1%). At least two diagnoses and a procedure code within a month from the first diagnosis date yielded a PPV of 80.7% (95%CI, 73.6-86.2%). The algorithms had greater PPVs in identifying prevalent high-grade cervical dysplasia or cervical cancer. Overall, the PPVs of these algorithms were similar or slightly lower in the external claims data than in the sample used to derive the algorithms. ConclusionsUse of 2 diagnosis codes in combination with a procedure code appears to be a valid tool for studying high-grade cervical dysplasia and cervical cancer in both electronic medical record and administrative claims databases. Copyright (c) 2013 John Wiley & Sons, Ltd. C1 [Kim, Seoyoung C.; Gillet, Victoria G.; Solomon, Daniel H.; Schneeweiss, Sebastian] Harvard Univ, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Sch Med, Boston, MA 02115 USA. [Kim, Seoyoung C.; Katz, Jeffrey N.; Solomon, Daniel H.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02120 USA. [Feldman, Sarah] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lii, Huichuan; Toh, Sengwee; Brown, Jeffrey S.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Lii, Huichuan; Toh, Sengwee; Brown, Jeffrey S.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Katz, Jeffrey N.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Orthoped Surg, Boston, MA 02115 USA. RP Kim, SC (reprint author), Brigham & Womens Hosp, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA. EM skim62@partners.org RI Schneeweiss, Sebastian/C-2125-2013; Toh, Sengwee/D-7567-2017; OI Toh, Sengwee/0000-0002-5160-0810; Kim, Seoyoung/0000-0002-2517-3579 FU National Institutes of Health (NIH) [K23 AR059677, K24 AR055989, P60 AR047782, R01 AR056215]; NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Informed Medical Decisions Foundation; HMO Research Network Center for Education and Research on Therapeutics (AHRQ) [1U18HS016955-1]; HMO Research Network DEcIDE Center; Agency for Healthcare Research and Quality; NIH/NIAMS; US Food and Drug Administration; [P60 AR 047782] FX Kim is supported by the National Institutes of Health (NIH) grant K23 AR059677. Katz receives support from several NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) grants including P60 AR 047782 as well as the Informed Medical Decisions Foundation.; Brown receives funding from several federal agencies, including the HMO Research Network Center for Education and Research on Therapeutics (AHRQ, 1U18HS016955-1) and the HMO Research Network DEcIDE Center, both funded by the Agency for Healthcare Research and Quality.; Solomon is supported by the NIH grants K24 AR055989, P60 AR047782, and R01 AR056215. Schneeweiss is principal investigator of the Brigham and Women's Hospital DEcIDE Center on Comparative Effectiveness Research, funded by the Agency for Healthcare Research and Quality, and of the Harvard-Brigham Drug Safety and Risk Management Research Contract, funded by the US Food and Drug Administration. NR 15 TC 3 Z9 3 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD NOV PY 2013 VL 22 IS 11 BP 1239 EP 1244 DI 10.1002/pds.3520 PG 6 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 274OG UT WOS:000328615200006 PM 24027140 ER PT J AU Vassy, JL Green, RC Lehmann, LS AF Vassy, Jason L. Green, Robert C. Lehmann, Lisa Soleymani TI Genomic medicine in primary care: barriers and assets SO POSTGRADUATE MEDICAL JOURNAL LA English DT Editorial Material DE Genomics; Individualized Medicine; Primary Health Care ID CLINICAL-PRACTICE; GENETICS C1 [Vassy, Jason L.] VA Boston HealthCare Syst, Gen Internal Med Sect, Boston, MA USA. [Vassy, Jason L.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA. [Vassy, Jason L.; Green, Robert C.; Lehmann, Lisa Soleymani] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Green, Robert C.] G2P Res Program, Boston, MA USA. [Green, Robert C.] Partners Ctr Personalized Genet Med, Boston, MA USA. [Green, Robert C.] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA. [Green, Robert C.] Harvard Univ, Sch Med, Boston, MA USA. [Lehmann, Lisa Soleymani] Brigham & Womens Hosp, Ctr Bioeth, Div Gen Internal Med & Primary Care, Dept Med, Boston, MA 02115 USA. RP Vassy, JL (reprint author), 150 South Huntington Ave,152G, Boston, MA 02130 USA. EM jvassy@partners.org FU NHGRI NIH HHS [R01 HG005092, U01-HG006500, R01-HG005092, U01 HG006500]; NIA NIH HHS [K24 AG027841, K24-AG027841]; NIDDK NIH HHS [L30 DK089597, L30-DK089597] NR 9 TC 3 Z9 3 U1 0 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0032-5473 EI 1469-0756 J9 POSTGRAD MED J JI Postgrad. Med. J. PD NOV PY 2013 VL 89 IS 1057 BP 615 EP 616 DI 10.1136/postgradmedj-2013-132093 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 265CE UT WOS:000327926500001 PM 24129030 ER PT J AU Greer, DM Yang, JY Scripko, PD Sims, JR Cash, S Wu, O Hafler, JP Schoenfeld, DA Furie, KL AF Greer, David M. Yang, Jingyun Scripko, Patricia D. Sims, John R. Cash, Sydney Wu, Ona Hafler, Jason P. Schoenfeld, David A. Furie, Karen L. TI Clinical examination for prognostication in comatose cardiac arrest patients SO RESUSCITATION LA English DT Article DE Coma; Prognosis; Outcome; Cardiac arrest; Neurologic examination ID EMERGENCY CARDIOVASCULAR CARE; CARDIOPULMONARY-RESUSCITATION; THERAPEUTIC HYPOTHERMIA; PROSPECTIVE COHORT; MYOCLONIC STATUS; POSTANOXIC COMA; SURVIVORS; PREDICTION; PROGNOSIS; RECOVERY AB Objective: To build new algorithms for prognostication of comatose cardiac arrest patients using clinical examination, and investigate whether therapeutic hypothermia influences the value of the clinical examination. Methods: From 2000 to 2007, 500 consecutive patients in non-traumatic coma were prospectively enrolled, 200 of whom were post-cardiac arrest. Outcome was determined by modified Rankin Scale (mRS) score at 6 months, with mRS <= 3 indicating good outcome. The clinical examination was performed on days 0, 1, 3 and 7 post-arrest, and clinical variables analyzed for importance in prognostication of outcome. A classification and regression tree analysis (CART) was used to develop a predictive algorithm. Results: Good outcome was achieved in 9.9% of patients. In CART analysis, motor response was often chosen as a root node, and spontaneous eye movements, pupillary reflexes, eye opening and corneal reflexes were often chosen as splitting nodes. Over 8% of patients with absent or extensor motor response on day 3 achieved a good outcome, as did 2 patients with myoclonic status epilepticus. The odds of achieving a good outcome were lower in patients who suffered asystole (OR 0.187, 95% CI: 0.039-0.875, p = 0.033) compared with ventricular fibrillation or non-perfusing ventricular tachycardia, but some still achieved good outcome. The absence of pupillary and corneal reflexes on day 3 remained highly reliable for predicting poor outcome, regardless of therapeutic hypothermia utilization. Conclusion: The clinical examination remains central to prognostication in comatose cardiac arrest patients in the modern area. Future studies should incorporate the clinical examination along with modern technology for accurate prognostication. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Greer, David M.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06520 USA. [Greer, David M.; Scripko, Patricia D.; Cash, Sydney] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Yang, Jingyun] Penn State Univ, Methodol Ctr, University Pk, PA 16802 USA. [Sims, John R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Sims, John R.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Sims, John R.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Wu, Ona] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Hafler, Jason P.] Univ Cambridge, Addenbrookes Hosp, Juvenile Diabet Cambridge Inst Med Res, Cambridge CB2 1TN, England. [Schoenfeld, David A.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [Furie, Karen L.] Brown Univ, Warren Alpert Med Sch, Dept Neurol, Providence, RI 02912 USA. RP Greer, DM (reprint author), Yale Univ, Sch Med, Dept Neurol, LLCI 912,15 York St, New Haven, CT 06520 USA. EM david.greer@yale.edu FU National Institute on Drug Abuse [P50DA010075-16]; NIH/NCI [R01 CA168676] FX Dr. Yang is supported by Award Number P50DA010075-16 from the National Institute on Drug Abuse and NIH/NCI R01 CA168676. The content of this research is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Drug Abuse or the National Institute of Health. There were no other sources of funding or support for this research. NR 33 TC 21 Z9 21 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0300-9572 J9 RESUSCITATION JI Resuscitation PD NOV PY 2013 VL 84 IS 11 BP 1546 EP 1551 DI 10.1016/j.resuscitation.2013.07.028 PG 6 WC Critical Care Medicine; Emergency Medicine SC General & Internal Medicine; Emergency Medicine GA 275DA UT WOS:000328654800021 PM 23954666 ER PT J AU Mateen, FJ Black, RE AF Mateen, Farrah J. Black, Robert E. TI Expansion of acute flaccid paralysis surveillance: beyond poliomyelitis SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Editorial Material DE diphtheria; vaccination; rabies; paralysis; poliomyelitis C1 [Mateen, Farrah J.; Black, Robert E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Mateen, Farrah J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Mateen, FJ (reprint author), Massachusetts Gen Hosp, Dept Neurol, AC720,55 Fruit St, Boston, MA 02114 USA. EM fmateen@partners.org NR 7 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD NOV PY 2013 VL 18 IS 11 BP 1421 EP 1422 DI 10.1111/tmi.12181 PG 2 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 270PP UT WOS:000328331200014 PM 24033476 ER PT J AU Magill, SS Klompas, M Balk, R Burns, SM Deutschman, CS Diekema, D Fridkin, S Greene, L Guh, A Gutterman, D Hammer, B Henderson, D Hess, DR Hill, NS Horan, T Kollef, M Levy, M Septimus, E VanAntwerpen, C Wright, D Lipsett, P AF Magill, Shelley S. Klompas, Michael Balk, Robert Burns, Suzanne M. Deutschman, Clifford S. Diekema, Daniel Fridkin, Scott Greene, Linda Guh, Alice Gutterman, David Hammer, Beth Henderson, David Hess, Dean R. Hill, Nicholas S. Horan, Teresa Kollef, Marin Levy, Mitchell Septimus, Edward VanAntwerpen, Carole Wright, Don Lipsett, Pamela TI DEVELOPING A NEW, NATIONAL APPROACH TO SURVEILLANCE FOR VENTILATOR-ASSOCIATED EVENTS SO AMERICAN JOURNAL OF CRITICAL CARE LA English DT Article AB This article is an executive summary of a report from the Centers for Disease Control and Prevention Ventilator-Associated Pneumonia Surveillance Definition Working Group, entitled "Developing a New, National Approach to Surveillance for Ventilator-Associatied Events," C1 [Magill, Shelley S.; Fridkin, Scott; Guh, Alice; Horan, Teresa] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. [Klompas, Michael] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Klompas, Michael] Brigham & Womens Hosp, Infect Control Dept, Boston, MA 02115 USA. [Klompas, Michael] Soc Healthcare Epidemiol Amer, Arlington, VA USA. [Balk, Robert] Rush Univ, Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA. [Burns, Suzanne M.] Univ Virginia, Sch Nursing Crit & Acute Care, Charlottesville, VA USA. [Deutschman, Clifford S.] Univ Penn, Dept Anesthesiol & Crit Care, Perelman Sch Med, Philadelphia, PA 19104 USA. [Diekema, Daniel] Univ Iowa, Carver Coll Med, Div Infect Dis, Iowa City, IA USA. [Diekema, Daniel] Healthcare Infect Control Practices Advisory Comm, Atlanta, GA USA. [Greene, Linda] Rochester Gen Hlth Syst, Infect Prevent & Control Dept, Rochester, NY USA. [Greene, Linda] Assoc Profess Infect Control & Epidemiol, Washington, DC USA. [Gutterman, David] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Hammer, Beth] Zablocki VA Med Ctr, Dept Cardiol, Milwaukee, WI USA. [Henderson, David] NIH, Hosp Epidemiol & Qual Improvement, Ctr Clin, Bethesda, MD 20892 USA. [Hess, Dean R.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA. [Hess, Dean R.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA. [Hess, Dean R.] Amer Assoc Resp Care, Irving, TX USA. [Hill, Nicholas S.] Tufts Med Ctr, Div Pulm & Crit Care Med, Boston, MA USA. [Kollef, Marin] Washington Univ, Div Pulm & Crit Care Med, St Louis, MO USA. [Levy, Mitchell] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Pulm Crit Care & Sleep, Providence, RI 02903 USA. [Septimus, Edward] Texas A&M Hlth Sci Ctr, Dept Internal Med, College Stn, TX USA. [Septimus, Edward] Infect Dis Soc Amer, Arlington, VA USA. [VanAntwerpen, Carole] New York State Dept Hlth, Bur Healthcare Associated Infect, Albany, NY 12237 USA. [VanAntwerpen, Carole] Council State & Terr Epidemiologists, Atlanta, GA USA. [Wright, Don] US Dept HHS, Off Dis Prevent & Hlth Promot, Washington, DC 20201 USA. [Lipsett, Pamela] Johns Hopkins Univ, Sch Med, Dept Surg Anesthesiol & Crit Care Med, Baltimore, MD USA. RP Magill, SS (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-24, Atlanta, GA 30329 USA. EM smagill@cdc.gov FU Centers for Disease Control and Prevention (CDC), Atlanta, Georgia; CDC; US Food and Drug Administration; Office of the National Coordinator for Health Information Technology; National Institute of General Medical Sciences; Merck; Cerexa; bioMeriuex; PurThread Technologies; Pfizer; Society of Healthcare Epidemiologists of America; Elsevier; McGraw-Hill; Up-To-Date; Jones and Bartlett FX This work was supported by the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia. Dr Klompas received grant support from the CDC, US Food and Drug Administration, and the Office of the National Coordinator for Health Information Technology. Dr Balk received grant support from the CDC and bioMerieux for participation in the EPIC CAP study (CDC) and the Procalcitonin in ICU antibiotic stewardship study (CDC and bioMerieux). Dr Deutschman received grant support from the National Institute of General Medical Sciences. Dr Diekema received grant support from Merck, Cerexa, bioMeriuex, PurThread Technologies, and Pfizer. Ms Greene consults for INC. Dr. Hess consulted for Philips Respironics, ResMed, Pari, and Breathe and received honoraria from Covidien and Maquet. Ms Greene lectured for Premier, Advanced Sterilization Products, and APIC. Dr Burns lectured for AACN. Ms Greene presented speeches for Covidien and Maquet. Dr Septimus received an honorarium for a lecture. Dr. Klompas received support from the Society of Healthcare Epidemiologists of America for the development of educational presentations. Dr Deutschman received royalties from Elsevier for the textbook, Evidence-based Practice of Critical Care Medicine. Dr Burns receives royalties from McGraw-Hill for books endorsed by AACN. Ms Greene receives royalties from Up-To-Date, Jones and Bartlett, and McGraw-Hill. The remaining authors have disclosed that they do not have any potential conflicts of interest. NR 2 TC 10 Z9 10 U1 1 U2 3 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 1062-3264 EI 1937-710X J9 AM J CRIT CARE JI Am. J. Crit. Care PD NOV 1 PY 2013 VL 22 IS 6 BP 469 EP 473 DI 10.4037/ajcc2013893 PG 5 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA 268KB UT WOS:000328167700007 PM 24186816 ER PT J AU Barrios, CH Fay, AP AF Barrios, Carlos H. Fay, Andre P. TI MULTIDISCIPLINARY APPROACH TO LIVER METASTASIS IN BREAST CANCER SO BREAST LA English DT Meeting Abstract C1 [Barrios, Carlos H.] PUCRS Sch Med, Porto Alegre, RS, Brazil. [Fay, Andre P.] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA. RI Barrios, Carlos/G-8525-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0960-9776 EI 1532-3080 J9 BREAST JI Breast PD NOV PY 2013 VL 22 SU 3 BP S23 EP S24 PG 2 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 264VO UT WOS:000327909300015 ER PT J AU Zu, K Martin, NE Fiorentino, M Flavin, R Lis, RT Sinnott, JA Finn, S Penney, KL Ma, J Fazli, L Gleave, ME Bismar, TA Stampfer, MJ Pollak, MN Loda, M Mucci, LA Giovannucci, E AF Zu, Ke Martin, Neil E. Fiorentino, Michelangelo Flavin, Richard Lis, Rosina T. Sinnott, Jennifer A. Finn, Stephen Penney, Kathryn L. Ma, Jing Fazli, Ladan Gleave, Martin E. Bismar, Tarek A. Stampfer, Meir J. Pollak, Michael N. Loda, Massimo Mucci, Lorelei A. Giovannucci, Edward TI Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID TUMOR-SUPPRESSOR GENE; BINDING PROTEIN-3; RADICAL PROSTATECTOMY; CELL PROLIFERATION; GENOMIC DELETION; FACTOR (IGF)-I; ADVANCED-STAGE; GLEASON SCORE; RISK; PATHWAY AB Background: Loss of PTEN has been shown to be associated with aggressive behavior of prostate cancer. It is less clear that loss of PTEN also increases the risk of cancer mortality. We investigated the association between PTEN expression and prostate cancer mortality and the potential effect modification by IGF-IR, a direct activator of the phosphoinositide-3-kinase (PI3K) pathway. Methods: Protein expression in tumor was evaluated using tumor tissues obtained from 805 participants of the Physicians' Health and the Health Professionals Follow-up studies who were diagnosed with prostate cancer and underwent radical prostatectomy. Proportional hazard models were used to assess PTEN expression and its interaction with IGF-IR, in relation to lethal prostate cancer (cancer-specific death or distant metastases). Results: Low PTEN expression was associated with an increased risk of lethal prostate cancer [ HR, 1.7; 95% confidence interval (CI), 0.98-3.2; P-trend = 0.04]. The association was attenuated after adjustment for Gleason grade, tumor stage, and prostate-specific antigen (PSA) at diagnosis. A significant negative interaction between PTEN and IGF-IR was found (P-interaction = 0.03). Either reduction in PTEN or increase in IGF-IR expression was sufficient to worsen prognosis. Models including PTEN and IGF-IR expression offer additional predicting power to prostate cancer survival, compared to those only including demographic and clinical factors. Conclusions: Low PTEN protein expression significantly increases the risk of lethal prostate cancer, particularly when the IGF-IR expression remains at normal level. Impact: PTEN and IGF-IR expression in tumor are promising candidates for independent prognostic factors to predict lethal prostate cancer. (C) 2013 AACR. C1 [Zu, Ke; Stampfer, Meir J.; Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Martin, Neil E.; Penney, Kathryn L.; Stampfer, Meir J.; Mucci, Lorelei A.; Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Sinnott, Jennifer A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Sinnott, Jennifer A.; Penney, Kathryn L.; Ma, Jing; Stampfer, Meir J.; Mucci, Lorelei A.; Giovannucci, Edward] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Div Network Med,Dept Med, Boston, MA 02115 USA. [Martin, Neil E.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Fiorentino, Michelangelo; Flavin, Richard; Sinnott, Jennifer A.; Loda, Massimo] Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA. [Lis, Rosina T.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Fiorentino, Michelangelo] Univ Bologna, F Addarii Inst Oncol, Mol & Transplantat Pathol Lab, Bologna, Italy. [Mucci, Lorelei A.] Univ Iceland, Ctr Publ Hlth Sci, Reykjavik, Iceland. [Fazli, Ladan; Gleave, Martin E.] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC V5Z 1M9, Canada. [Bismar, Tarek A.] Univ Calgary, Dept Pathol & Lab Med & Oncol, Calgary, AB, Canada. [Pollak, Michael N.] McGill Univ, Jewish Gen Hosp, Dept Med, Montreal, PQ H3T 1E2, Canada. [Pollak, Michael N.] McGill Univ, Jewish Gen Hosp, Dept Oncol, Montreal, PQ H3T 1E2, Canada. RP Giovannucci, E (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 677 Huntington Ave, Boston, MA 02115 USA. EM egiovann@hsph.harvard.edu RI Martin, Neil/E-2193-2014; OI Martin, Neil/0000-0002-8164-8516; Finn, Stephen/0000-0002-8628-5814 FU NIH [R01 CA133891, CA136578, CA141298, UM1 CA167552]; US Army Prostate Cancer Program [W81XWH-05-1-0562]; National Cancer Institute [CA-34933, CA-40360, CA-091793]; National Heart, Lung, and Blood Institute, Bethesda, MD [HL-26490, HL-34595]; Prostate Cancer Foundation FX This project was funded by NIH R01 CA133891 (E.L. Giovannucci), CA136578 (L.A. Mucci), CA141298 (M.J. Stampfer), and US Army Prostate Cancer Program W81XWH-05-1-0562 (L.A. Mucci). The Physicians' Health Study is supported by grants CA-34933, CA-40360, and CA-091793 from the National Cancer Institute and grants HL-26490 and HL-34595 from the National Heart, Lung, and Blood Institute, Bethesda, MD. The Health Professionals Follow-up study is supported by NIH UM1 CA167552. N.E. Martin and L.A. Mucci are supported by the Prostate Cancer Foundation. NR 48 TC 14 Z9 14 U1 1 U2 7 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD NOV PY 2013 VL 22 IS 11 BP 1984 EP 1993 DI 10.1158/1055-9965.EPI-13-0349 PG 10 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 262ID UT WOS:000327726800007 PM 23983239 ER PT J AU Hiraki, LT Qu, CH Hutter, CM Baron, JA Berndt, SI Bezieau, S Brenner, H Caan, BJ Casey, G Chang-Claude, J Chanock, SJ Conti, DV Duggan, D Fuchs, CS Gallinger, S Giovannucci, EL Harrison, TA Hayes, RB Hazra, A Henderson, B Hoffmeister, M Hopper, JL Hudson, TJ Jenkins, MA Kury, SE Le Marchand, L Lemire, M Ma, J Manson, JE Nan, HM Newcomb, PA Ng, K Potter, JD Schoen, RE Schumacher, FR Seminara, D Slattery, ML Wactawski-Wende, J White, E Wu, KN Zanke, BW Kraft, P Peters, U Chan, AT AF Hiraki, Linda T. Qu, Conghui Hutter, Carolyn M. Baron, John A. Berndt, Sonja I. Bezieau, Stephane Brenner, Hermann Caan, Bette J. Casey, Graham Chang-Claude, Jenny Chanock, Stephen J. Conti, David V. Duggan, David Fuchs, Charles S. Gallinger, Steven Giovannucci, Edward L. Harrison, Tabitha A. Hayes, Richard B. Hazra, Aditi Henderson, Brian Hoffmeister, Michael Hopper, John L. Hudson, Thomas J. Jenkins, Mark A. Kuery, S. Ebastien Le Marchand, Loic Lemire, Mathieu Ma, Jing Manson, JoAnn E. Nan, Hongmei Newcomb, Polly A. Ng, Kimmie Potter, John D. Schoen, Robert E. Schumacher, Fredrick R. Seminara, Daniela Slattery, Martha L. Wactawski-Wende, Jean White, Emily Wu, Kana Zanke, Brent W. Kraft, Peter Peters, Ulrike Chan, Andrew T. TI Genetic Predictors of Circulating 25-Hydroxyvitamin D and Risk of Colorectal Cancer SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID GENOME-WIDE ASSOCIATION; VITAMIN-D-RECEPTOR; D-BINDING PROTEIN; COLON-CANCER; SUSCEPTIBILITY LOCI; ENVIRONMENT INTERACTIONS; CALCIUM SUPPLEMENTATION; METAANALYSIS; PREVENTION; GENOTYPE AB Background: Experimental evidence has demonstrated an antineoplastic role for vitamin D in the colon, and higher circulating 25-hydroxyvitamin D [25(OH)D] levels are consistently associated with a lower risk of colorectal cancer. Genome-wide association studies have identified loci associated with levels of circulating 25(OH)D. The identified single-nucleotide polymorphisms (SNPs) from four gene regions collectively explain approximately 5% of the variance in circulating 25(OH)D. Methods: We investigated whether five polymorphisms in GC, CYP2R1, CYP24A1, and DHCR7/NADSYN1, genes previously shown to be associated with circulating 25(OH)D levels, were associated with colorectal cancer risk in 10,061 cases and 12,768 controls drawn from 13 studies included in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) and Colon Cancer Family Registry (CCFR). We conducted a meta-analysis of crude and multivariate-adjusted logistic regression models to calculate odds ratios and associated confidence intervals for SNPs individually, SNPs simultaneously, and for a vitamin D additive genetic risk score (GRS). Results: We did not observe a statistically significant association between the 25(OH)D-associated SNPs and colorectal cancer marginally, conditionally, or as a GRS, or for colon or rectal cancer separately. Conclusions: Our findings do not support an association between SNPs associated with circulating 25(OH)D and risk of colorectal cancer. Additional work is warranted to investigate the complex relationship between 25 (OH)D and colorectal cancer risk. Impact: There was no association observed between genetic markers of circulating 25(OH)D and colorectal cancer. These genetic markers account for a small proportion of the variance in 25(OH)D. (C) 2013 AACR. C1 [Hiraki, Linda T.; Giovannucci, Edward L.; Hazra, Aditi; Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Program Mol & Genet Epidemiol, Boston, MA 02114 USA. [Giovannucci, Edward L.; Wu, Kana] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02114 USA. [Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02114 USA. [Fuchs, Charles S.; Manson, JoAnn E.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Giovannucci, Edward L.; Ma, Jing; Chan, Andrew T.] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA. [Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Fuchs, Charles S.; Hazra, Aditi; Manson, JoAnn E.; Ng, Kimmie] Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA. [Fuchs, Charles S.] Dana Farber Canc Inst, Gastrointestinal Malignancy Program, Boston, MA 02115 USA. [Ng, Kimmie] Dana Farber Canc Inst, Boston, MA 02115 USA. [Qu, Conghui; Hutter, Carolyn M.; Harrison, Tabitha A.; Newcomb, Polly A.; Potter, John D.; White, Emily; Peters, Ulrike] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Newcomb, Polly A.; Potter, John D.; White, Emily; Peters, Ulrike] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Baron, John A.] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Chapel Hill, NC USA. [Berndt, Sonja I.; Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Seminara, Daniela] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. [Nan, Hongmei] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Bezieau, Stephane; Kuery, S. Ebastien] CHU Nantes, Serv Genet Med, F-44035 Nantes 01, France. [Brenner, Hermann; Chang-Claude, Jenny; Hoffmeister, Michael] German Canc Res Ctr, Heidelberg, Germany. [Caan, Bette J.] Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA. [Casey, Graham; Conti, David V.; Henderson, Brian; Schumacher, Fredrick R.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Duggan, David] Translat Genom Res Inst, Phoenix, AZ USA. [Gallinger, Steven] Toronto Gen Hosp, Dept Surg, Toronto, ON, Canada. [Hudson, Thomas J.; Lemire, Mathieu] Ontario Inst Canc Res, Toronto, ON, Canada. [Hudson, Thomas J.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada. [Hudson, Thomas J.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada. [Zanke, Brent W.] Univ Ottawa, Fac Med, Ottawa, ON, Canada. [Hayes, Richard B.] NYU, Sch Med, Dept Environm Med, Div Epidemiol, New York, NY USA. [Wactawski-Wende, Jean] SUNY Buffalo, Dept Social & Prevent Med, New York, NY USA. [Hopper, John L.; Jenkins, Mark A.] Univ Melbourne, Melborne Sch Populat Hlth, Melbourne, Vic, Australia. [Le Marchand, Loic] Canc Res Ctr Hawaii, Program Epidemiol, Honolulu, HI USA. [Schoen, Robert E.] Univ Pittsburgh, Med Ctr, Dept Epidemiol, Pittsburgh, PA USA. [Slattery, Martha L.] Univ Utah, Hlth Sci Ctr, Dept Internal Med, Salt Lake City, UT USA. [Potter, John D.] Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand. RP Chan, AT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gastroenterol,Gastroenterol Associates, 55 Fruit St, Boston, MA 02114 USA. EM achan@partners.org RI Gallinger, Steven/E-4575-2013; Hoffmeister, Michael/B-5745-2012; KURY, Sebastien/G-5971-2015; Bezieau, stephane/G-5621-2015; Jenkins, Mark/P-7803-2015; Brenner, Hermann/B-4627-2017 OI Potter, John/0000-0001-5439-1500; Hayes, Richard/0000-0002-0918-661X; Hoffmeister, Michael/0000-0002-8307-3197; KURY, Sebastien/0000-0001-5497-0465; Bezieau, stephane/0000-0003-0095-1319; Jenkins, Mark/0000-0002-8964-6160; Brenner, Hermann/0000-0002-6129-1572 FU regional Programme Hospitalier de Recherche Clinique (PHRC); Regional Council of Pays de la Loire; Groupement des Entreprises Francaises dans la Lutte contre le Cancer (GEFLUC); Association Anne de Bretagne Genetique; Ligue Regionale Contre le Cancer (LRCC); National Cancer Institute, NIH under RFA [CA-95-011]; Australasian Colorectal Cancer Family Registry [U01 CA097735]; Seattle Colorectal Cancer Family Registry [U01 CA074794]; Ontario Registry for Studies of Familial Colorectal Cancer [U01 CA074783]; NIH [U01 CA074783, P01 CA 055075, UM1 CA167552, P50CA127003, R01 137178, P01 CA087969, CA42182]; Ontario Research Fund; Canadian Institutes of Health Research; Cancer Risk Evaluation (CaRE) Program grant from the Canadian Cancer Society Research Institute; Senior Investigator Awards from the Ontario Institute for Cancer Research , through Ontario Ministry of Research and Innovation; National Cancer Institute [R01 CA60987]; German Research Council (Deutsche Forschungsgemeinschaft) [BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH 117/1-1]; German Federal Ministry of Education and Research [01KH0404, 01ER0814]; National Cancer Institute, NIH, U. S. Department of Health and Human Services [R01 CA48998]; National Cancer Institute, NIH, U.S. Department of Health and Human Services [U01 CA137088, R01 CA059045]; Canadian Institute of Health Research (CIHR) Fellowship Award; Intramural Research Program of the Division of Cancer Epidemiology and Genetics; Division of Cancer Prevention, National Cancer Institute, NIH, DHHS; NIH, Genes, Environment and Health Initiative [NIH GEI] [Z01 CP 010200]; intramural resources of the National Cancer Institute; NIH GEI [U01 HG 004438]; NIH from the National Cancer Institute [K05 CA154337]; Office of Dietary Supplements; National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; [R37 CA54281]; [P01 CA033619]; [R01 CA63464]; [K24 DK098311] FX S. Bezieau and S. Kury are affiliated with ASTERISK which was funded by a regional Programme Hospitalier de Recherche Clinique (PHRC) and supported by the Regional Council of Pays de la Loire, the Groupement des Entreprises Francaises dans la Lutte contre le Cancer (GEFLUC), the Association Anne de Bretagne Genetique, and the Ligue Regionale Contre le Cancer (LRCC).; J.A. Baron, G. Casey, D.V. Conti, J.L. Hopper, M. A. Jenkins, P. A. Newcomb, and F.R. Schumacher are affiliated with CCFR which is supported by the National Cancer Institute, NIH under RFA # CA-95-011 and through cooperative agreements with members of the CCFR and principal investigators (P.I.s). This genome wide scan was supported by the National Cancer Institute, NIH by U01 CA122839. The content of this article does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the CFRs, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government or the CFR. The following CCFR centers contributed data to this article and were supported by the following sources: Australasian Colorectal Cancer Family Registry (U01 CA097735), Seattle Colorectal Cancer Family Registry (U01 CA074794), and Ontario Registry for Studies of Familial Colorectal Cancer (U01 CA074783).; S. Gallinger, T.J. Hudson, M. Lemire, and B.W. Zanke are affiliated with OFCCR which is supported by the NIH, through funding allocated to the Ontario Registry for Studies of Familial Colorectal Cancer (U01 CA074783); see CCFR section above. As subset of ARCTIC, OFCCR is supported by a GL2 grant from the Ontario Research Fund, the Canadian Institutes of Health Research, and the Cancer Risk Evaluation (CaRE) Program grant from the Canadian Cancer Society Research Institute. T.J. Hudson and B. W. Zanke are recipients of Senior Investigator Awards from the Ontario Institute for Cancer Research, through generous support from the Ontario Ministry of Research and Innovation.; B. Henderson and L. Le Marchand are affiliated with COLO2&3/MEC. COLO2&3 is supported by the National Cancer Institute (R01 CA60987). MEC is supported by R37 CA54281, P01 CA033619, and R01 CA63464.; H. Brenner, J. Chang-Claude, and M. Hoffmeister are affiliated with DACHS which was supported by grants from the German Research Council (Deutsche Forschungsgemeinschaft, BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, and CH 117/1-1), and the German Federal Ministry of Education and Research (01KH0404 and 01ER0814).; B.J. Caan, J.D. Potter, and M.L. Slattery are affiliated with DALS which was supported by the National Cancer Institute, NIH, U. S. Department of Health and Human Services (R01 CA48998 to M. L. Slattery).; T.A. Harrison, C.M. Hutter, U. Peters, and C. Qu are affiliated with GECCO which is supported by National Cancer Institute, NIH, U.S. Department of Health and Human Services (U01 CA137088). Funding for the genome-wide scan of DALS, PLCO, and WHI was provided by the National Cancer Institute, NIH, U. S. Department of Health and Human Services (R01 CA059045).; A.T. Chan, C.S. Fuchs, E.L. Giovannucci, L.T. Hiraki, A. Hazra, P. Kraft, H. Nan, K. Ng, and K. Wu are affiliated with HPFS, NHS, and PHS. HPFS was supported by the NIH (P01 CA 055075, UM1 CA167552, R01 137178, and P50CA127003), NHS by the NIH (R01 137178, P50CA127003, and P01 CA087969) and PHS by the NIH (CA42182). A.T. Chan is a Damon Runyon Clinical Investigator and also supported by K24 DK098311. L.T. Hiraki was supported by a Canadian Institute of Health Research (CIHR) Fellowship Award.; S.I. Berndt, S.J. Chanock, R.B. Hayes, and R.E. Schoen are affiliated with PLCO which was supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, NIH, DHHS. Control samples were genotyped as part of the Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer scan, supported by the Intramural Research Program of the National Cancer Institute. The datasets used in this analysis were accessed with appropriate approval through the dbGaP online resource (http://www.cgems.cancer.gov/data_acess.html) through dbGaP accession number 000207v.1p1.c1. [National Cancer Institute (2009) CGEMS data website. http://cgems.cancer.gov/data_access.html; ref. 75]. Control samples were also genotyped as part of the GWAS of Lung Cancer and Smoking [76]. Funding for this work was provided through the NIH, Genes, Environment and Health Initiative [NIH GEI] (Z01 CP 010200). The human subjects participating in the GWAS are derived from the Prostate, Lung, Colon and Ovarian Screening Trial and the study is supported by intramural resources of the National Cancer Institute. Assistance with genotype cleaning, as well as with general study coordination, was provided by the Gene Environment Association Studies, GENEVA Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information. Funding support for genotyping, which was conducted at the Center for Inherited Disease Research, Johns Hopkins University (Baltimore, MD) was provided by the NIH GEI (U01 HG 004438). The datasets used for the analyses described in this article were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number phs000093.; E. White is affiliated with VITAL which is supported in part by the NIH (K05 CA154337) from the National Cancer Institute and Office of Dietary Supplements.; J. Manson and J. Wactawski-Wende are affiliated with WHI. The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. NR 76 TC 11 Z9 11 U1 0 U2 13 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 EI 1538-7755 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD NOV PY 2013 VL 22 IS 11 BP 2037 EP 2046 DI 10.1158/1055-9965.EPI-13-0209 PG 10 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 262ID UT WOS:000327726800013 PM 23983240 ER PT J AU Ho, JE Hwang, SJ Wollert, KC Larson, MG Cheng, S Kempf, T Vasan, RS Januzzi, JL Wang, TJ Fox, CS AF Ho, Jennifer E. Hwang, Shih-Jen Wollert, Kai C. Larson, Martin G. Cheng, Susan Kempf, Tibor Vasan, Ramachandran S. Januzzi, James L. Wang, Thomas J. Fox, Caroline S. TI Biomarkers of Cardiovascular Stress and Incident Chronic Kidney Disease SO CLINICAL CHEMISTRY LA English DT Article ID GROWTH-DIFFERENTIATION FACTOR-15; AMERICAN-HEART-ASSOCIATION; RECEPTOR FAMILY-MEMBER; SOLUBLE ST2; MYOCARDIAL-INFARCTION; BETA SUPERFAMILY; MORTALITY; MICROALBUMINURIA; ATHEROSCLEROSIS; COMMUNITY AB BACKGROUND: Growth differentiation factor-15 (GDF-15), soluble ST2 (sST2), and high-sensitivity troponin I (hsTnI) are emerging predictors of adverse clinical outcomes. We examined whether circulating concentrations are related to the development of kidney disease in the community. METHODS: Plasma GDF-15, sST2, and hsTnI concentrations were measured in 2614 Framingham Offspring cohort participants (mean age 57 years, 54% women) at the sixth examination cycle (1995-1998). Associations of biomarkers with incident chronic kidney disease [CKD, eGFR <60 mL . min(-1) . (1.73 m(2))(-1), n = 276], microalbuminuria (urinary albumin to creatinine ratio >= 25 mg/g in women and 17 mg/g in men, n = 191), and rapid decline in renal function [decline in eGFR >= 3 mL . min(-1) . (1.73 m(2))(-1) per year, n = 237], were evaluated using multivariable logistic regression; P < 0.006 was considered statistically significant in primary analyses. RESULTS: Participants were followed over a mean of 9.5 years. Higher plasma GDF-15 was associated with incident CKD [multivariable-adjusted odds ratio (OR) 1.9 per 1-U increase in log-GDF-15, 95% CI 1.6 -2.3, P < 0.0001] and rapid decline in renal function (OR, 1.6; 95% CI, 1.3-1.8; P < 0.0001). GDF-15, sST2, and hsTnI had suggestive associations with incident microalbuminuria but did not meet the prespecified P-value threshold after multivariable adjustment. Adding plasma GDF-15 to clinical covariates improved risk prediction of incident CKD: the c-statistic increased from 0.826 to 0.845 (P = 0.0007), and categorical net reclassification was 6.3% (95% CI, 2.7-9.9%). CONCLUSIONS: Higher circulating GDF-15 is associated with incident renal outcomes and improves risk prediction of incident CKD. These findings may provide insights into the mechanisms of renal injury. (C) 2013 American Association for Clinical Chemistry C1 [Ho, Jennifer E.; Hwang, Shih-Jen; Larson, Martin G.; Cheng, Susan; Vasan, Ramachandran S.; Wang, Thomas J.; Fox, Caroline S.] NHLBI, Framingham Heart Study, Framingham, MA USA. [Ho, Jennifer E.; Hwang, Shih-Jen; Larson, Martin G.; Cheng, Susan; Vasan, Ramachandran S.; Wang, Thomas J.; Fox, Caroline S.] Boston Univ, Sch Med, Framingham, MA USA. [Ho, Jennifer E.; Hwang, Shih-Jen; Fox, Caroline S.] NHLBI, Ctr Populat Studies, Bethesda, MD 20892 USA. [Ho, Jennifer E.] Boston Univ, Med Ctr, Cardiovasc Med Sect, Dept Med, Boston, MA 02118 USA. [Wollert, Kai C.; Kempf, Tibor] Hannover Med Sch, Dept Cardiol & Angiol, Div Mol & Translat Cardiol, Hannover, Germany. [Larson, Martin G.] Boston Univ, Dept Math & Stat, Boston, MA 02118 USA. [Cheng, Susan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiol,Dept Med, Boston, MA 02115 USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Januzzi, James L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiol Div,Dept Med, Boston, MA USA. [Wang, Thomas J.] Vanderbilt Univ, Dept Med, Div Cardiovasc Med, Nashville, TN USA. [Fox, Caroline S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Metab & Diabet,Dept Med, Boston, MA 02115 USA. RP Ho, JE (reprint author), Boston Univ, Med Ctr, Cardiovasc Med Sect, 88 East Newton St,C-818, Boston, MA 02118 USA. EM jennifer.ho@bmc.org OI Ramachandran, Vasan/0000-0001-7357-5970 FU American Diabetes Association; Roche Diagnostics, Inc.; American Heart Association; National Institutes of Health [1K23-HL116780]; Roche Diagnostics; German Ministry of Education and Research (BMBF, BioChancePlus); Ellison Foundation; DeSanctis Clinical Scholar Endowment, Roche Diagnostics, and Critical Diagnostics; National Heart, Lung and Blood Institute's Framingham Heart Study [N01-HC-25195]; Roche Diagnostics, Inc; Critical Diagnostics, Inc FX The urinary albumin excretion assays were supported by a grant from the American Diabetes Association (Dr. James Meigs, not a co-author on this paper) and by donation of reagents by Roche Diagnostics, Inc. (Framingham Heart Study); J.E. Ho, American Heart Association, the National Institutes of Health (1K23-HL116780); K.C. Wollert, Roche Diagnostics and the German Ministry of Education and Research (BMBF, BioChancePlus); S. Cheng, the Ellison Foundation; J.L. Januzzi, the DeSanctis Clinical Scholar Endowment, Roche Diagnostics, and Critical Diagnostics. The National Heart, Lung and Blood Institute's Framingham Heart Study (contract no. N01-HC-25195 to Boston University). Measurement of sST2 was performed by Critical Diagnostics, Inc; GDF-15 assays were provided by Roche Diagnostics, Inc; measurement of hsTnI was performed by Singulex, Inc (T.J. Wang, J.L. Januzzi, R.S. Vasan, and K.C. Wollert). NR 39 TC 22 Z9 22 U1 2 U2 8 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 EI 1530-8561 J9 CLIN CHEM JI Clin. Chem. PD NOV PY 2013 VL 59 IS 11 BP 1613 EP 1620 DI 10.1373/clinchem.2013.205716 PG 8 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 269YT UT WOS:000328281800012 PM 23873716 ER PT J AU Townsend, MK Clish, CB Kraft, P Wu, C Souza, AL Deik, AA Tworoger, SS Wolpin, BM AF Townsend, Mary K. Clish, Clary B. Kraft, Peter Wu, Chen Souza, Amanda L. Deik, Amy A. Tworoger, Shelley S. Wolpin, Brian M. TI Reproducibility of Metabolomic Profiles among Men and Women in 2 Large Cohort Studies SO CLINICAL CHEMISTRY LA English DT Article ID POSTMENOPAUSAL WOMEN; BREAST-CANCER; MEASUREMENT ERROR; HORMONE LEVELS; BLOOD-SAMPLES; PLASMA; RISK; STABILITY; SERUM; BIOMARKERS AB BACKGROUND: Rigorous studies are necessary to demonstrate suitability of metabolomics platforms to profile metabolites in archived plasma within epidemiologic studies of human disease, for which attenuation of effect estimates due to measurement error is a key concern. METHODS: Using a liquid chromatography-tandem mass spectrometry platform, we quantified 257 metabolites from archived plasma to evaluate metabolite interassay reproducibility, reproducibility with delayed processing, and within-person reproducibility over time. Interassay reproducibility was assessed with CVs from 60 duplicate plasma samples donated by participants in the Nurses' Health Study and Health Professionals Follow-up Study, and 20 QC pool plasma replicates. Metabolite reproducibility over a 24- to 48-h processing delay (n = 48 samples) and within-person reproducibility over 1-2 years (n = 80 samples) were assessed using Spearman and intraclass correlation coefficients (ICCs). RESULTS: CVs were <20% for 92% of metabolites and generally were similar by plasma anticoagulant type (heparin or EDTA) and fasting time. Approximately 75% of metabolites were reproducible over delays in processing of blood samples (Spearman correlation or ICC >= 0.75, comparing immediate and 24-h delayed processing). Carbohydrates and purine/pyrimidine derivatives were most adversely affected by the processing delay. Ninety percent of metabolites were reproducible over 1-2 years within individuals (Spearman correlation or ICC >= 0.4). CONCLUSIONS: For potential use in epidemiologic studies, the majority of plasma metabolites had low CVs and were reproducible over a 24-h processing delay and within individuals over 1-2 years. Certain metabolites, such as carbohydrates and purine/pyrimidine derivatives, may be challenging to evaluate if samples have delayed processing. (C) 2013 American Association for Clinical Chemistry C1 [Townsend, Mary K.; Tworoger, Shelley S.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Townsend, Mary K.; Tworoger, Shelley S.; Wolpin, Brian M.] Harvard Univ, Sch Med, Boston, MA USA. [Clish, Clary B.; Souza, Amanda L.; Deik, Amy A.] Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA USA. [Kraft, Peter; Wu, Chen; Tworoger, Shelley S.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Wolpin, Brian M.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Wolpin, Brian M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Townsend, MK (reprint author), Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA. EM nhmkt@channing.harvard.edu OI Tworoger, Shelley/0000-0002-6986-7046 FU NIH [P01-CA87969, R01-CA49449, P01-CA055075]; National Cancer Institute [K07-CA140790]; American Society of Clinical Oncology Career Development Award; Howard Hughes Medical Institute Early Career Physician-Scientist Award; Lustgarten Foundation for Pancreatic Cancer Research FX NHS funded by NIH grants P01-CA87969 and R01-CA49449, HPFS funded by NIH grant P01-CA055075, Metabolite profiling supported by a gift from the Nestle Research Center to the Broad Institute; B.M. Wolpin, grant K07-CA140790 from the National Cancer Institute, American Society of Clinical Oncology Career Development Award, Howard Hughes Medical Institute Early Career Physician-Scientist Award, and the Lustgarten Foundation for Pancreatic Cancer Research. NR 34 TC 36 Z9 36 U1 0 U2 24 PU AMER ASSOC CLINICAL CHEMISTRY PI WASHINGTON PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA SN 0009-9147 EI 1530-8561 J9 CLIN CHEM JI Clin. Chem. PD NOV PY 2013 VL 59 IS 11 BP 1657 EP 1667 DI 10.1373/clinchem.2012.199133 PG 11 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 269YT UT WOS:000328281800017 PM 23897902 ER PT J AU Wisco, BE Pineles, SL Shipherd, JC Marx, BP AF Wisco, Blair E. Pineles, Suzanne L. Shipherd, Jillian C. Marx, Brian P. TI Attentional interference by threat and post-traumatic stress disorder: The role of thought control strategies SO COGNITION & EMOTION LA English DT Article DE Attention; PTSD; Information processing bias; Thought control; Thought suppression ID INDIVIDUAL-DIFFERENCES; CONTROL QUESTIONNAIRE; SOCIAL SUPPORT; SUPPRESSION; PTSD; DEPRESSION; PREDICTORS; ACCIDENTS; VALIDITY; ANXIETY AB Attentional interference by threat is associated with PTSD, but the mechanisms of this relationship remain unclear. Attentional interference might be related to increased use of maladaptive thought control strategies, such as suppressing unwanted thoughts (thought suppression) or replacing threatening thoughts with everyday concerns (worry), which increase PTSD risk. Conversely, attentional interference might be associated with reduced use of adaptive strategies, such as talking about threatening thoughts (social control), which decrease PTSD risk. This study tested if thought control strategies mediate the relationship between attentional interference and PTSD. Sixty-one male Vietnam-era veterans completed measures of PTSD symptoms and thought control strategies. Participants also completed a Visual Search Task measuring attentional interference, which required participants to identify a target letter string among a group of threat or neutral words. Attentional interference by threat was related to PTSD symptoms, and mediation analyses revealed significant indirect effects of attentional interference through thought suppression and worry. Attentional interference was related to re-experiencing and avoidance, but not hyperarousal, symptom clusters. Thought suppression was a unique mediator for re-experiencing, whereas thought suppression and worry both mediated the relationship with avoidance. These results offer evidence for maladaptive thought control strategies as a mechanism linking attentional biases for threat to PTSD. C1 [Wisco, Blair E.; Pineles, Suzanne L.; Shipherd, Jillian C.; Marx, Brian P.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA. [Wisco, Blair E.; Pineles, Suzanne L.; Shipherd, Jillian C.; Marx, Brian P.] Boston Univ, Sch Med, Boston, MA 02118 USA. RP Pineles, SL (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, 150 S Huntington Ave,116B-3, Boston, MA 02130 USA. EM Suzanne.Pineles@va.gov FU NIMH NIH HHS [T32 MH019836, T32MH019836] NR 28 TC 3 Z9 3 U1 7 U2 14 PU PSYCHOLOGY PRESS PI HOVE PA 27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND SN 0269-9931 EI 1464-0600 J9 COGNITION EMOTION JI Cogn. Emot. PD NOV 1 PY 2013 VL 27 IS 7 BP 1314 EP 1325 DI 10.1080/02699931.2013.775109 PG 12 WC Psychology, Experimental SC Psychology GA 264GM UT WOS:000327865000010 PM 23517445 ER PT J AU Mori, T Seeman, T Crandall, CJ Merkin, S Binkley, N Greendale, GA Karlamangla, AS AF Mori, T. Seeman, T. Crandall, C. J. Merkin, S. Binkley, N. Greendale, G. A. Karlamangla, A. S. TI ALLOSTATIC LOAD AND BONE STRENGTH: FINDINGS FROM THE MIDLIFE IN THE US STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Mori, T.] VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA. [Mori, T.; Seeman, T.; Merkin, S.; Greendale, G. A.; Karlamangla, A. S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA. [Crandall, C. J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90095 USA. [Binkley, N.] Univ Wisconsin, Osteoporosis Clin Ctr, Madison, WI USA. [Binkley, N.] Univ Wisconsin, Res Program, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 15 EP 16 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442101072 ER PT J AU Brown, RT Kiely, DK Bharel, M Mitchell, SL AF Brown, R. T. Kiely, D. K. Bharel, M. Mitchell, S. L. TI USE OF ACUTE CARE SERVICES AMONG OLDER HOMELESS ADULTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Brown, R. T.] Univ Calif San Francisco, Div Geriatr, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Kiely, D. K.; Mitchell, S. L.] Hebrew SeniorLife Inst Aging Res, Boston, MA USA. [Bharel, M.] Boston Hlth Care Homeless Program, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 37 EP 37 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442101188 ER PT J AU Gerhard, L Schoeps, D AF Gerhard, L. Schoeps, D. TI EXPANDING VETERAN-DIRECTED RESPITE (VDR) TO CAREGIVERS ENROLLED IN VA'S CSP SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Gerhard, L.] Adm Community Living, Washington, DC USA. [Schoeps, D.] US Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 126 EP 126 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102117 ER PT J AU Schoeps, D Gerhard, L AF Schoeps, D. Gerhard, L. TI THE VETERAN-DIRECTED HCBS PROGRAM AND REBALANCING VA'S LONG-TERM CARE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Schoeps, D.] US Dept Vet Affairs, Washington, DC USA. [Gerhard, L.] Adm Community Living, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 126 EP 126 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102116 ER PT J AU Taylor, L Henius, J Kabat, M AF Taylor, L. Henius, J. Kabat, M. TI IMPLEMENTATION OF VA'S CAREGIVER SUPPORT PROGRAM (CSP) SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Taylor, L.; Henius, J.; Kabat, M.] US Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 126 EP 126 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102118 ER PT J AU Taylor, L Henius, J Kabat, M AF Taylor, L. Henius, J. Kabat, M. TI RESULTS AND FINDINGS FROM AN EVALUATION OF VA'S CSP SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Taylor, L.; Henius, J.; Kabat, M.] US Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 126 EP 127 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102119 ER PT J AU Dzierzewski, JM Fung, C Jouldjian, S Alessi, C Irwin, M Martin, JL AF Dzierzewski, J. M. Fung, C. Jouldjian, S. Alessi, C. Irwin, M. Martin, J. L. TI DAYTIME SLEEP IS ASSOCIATED WITH 6-MONTH CHANGE IN COGNITIVE FUNCTIONING IN AT-RISK OLDER ADULTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Dzierzewski, J. M.; Fung, C.; Alessi, C.; Irwin, M.; Martin, J. L.] Univ Calif Los Angeles, Los Angeles, CA USA. [Dzierzewski, J. M.; Fung, C.; Jouldjian, S.; Alessi, C.; Irwin, M.; Martin, J. L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RI Irwin, Michael/H-4870-2013 OI Irwin, Michael/0000-0002-1502-8431 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 135 EP 136 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102160 ER PT J AU Brommelhoff, J Melrose, RJ Natta, LE Narvaez, TA Sultzer, DL AF Brommelhoff, J. Melrose, R. J. Natta, L. E. Narvaez, T. A. Sultzer, D. L. TI NEUROPSYCHOLOGICAL CORRELATES OF DEPRESSION IN ALZHEIMER'S DISEASE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Brommelhoff, J.; Melrose, R. J.; Natta, L. E.; Narvaez, T. A.; Sultzer, D. L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Melrose, R. J.; Sultzer, D. L.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 155 EP 155 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102243 ER PT J AU Nagel, CL Quinones, AR Liang, J Blaum, C Cigolle, C AF Nagel, C. L. Quinones, A. R. Liang, J. Blaum, C. Cigolle, C. TI COGNITIVE IMPAIRMENT, PROXY INTERVIEWS, AND INCONSISTENT LONGITUDINAL REPORTING OF CHRONIC DISEASE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Nagel, C. L.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA. [Quinones, A. R.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Quinones, A. R.] Portland VA Med Ctr, Portland, OR USA. [Liang, J.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Blaum, C.] NYU, Sch Med, New York, NY USA. [Cigolle, C.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA. [Cigolle, C.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Cigolle, C.] VA Ann Arbor Geriatr Res Educ & Clin Ctr GRECC, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 169 EP 170 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102302 ER PT J AU Garrido, MM Boockvar, K Prigerson, HG Penrod, JD AF Garrido, M. M. Boockvar, K. Prigerson, H. G. Penrod, J. D. TI CHOOSING WISELY: BENZODIAZEPINE AND SEDATIVE-HYPNOTIC USE AMONG OLDER SERIOUSLY ILL VETERANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Garrido, M. M.; Boockvar, K.; Penrod, J. D.] James J Peters VAMC, Bronx, NY USA. [Garrido, M. M.; Boockvar, K.; Penrod, J. D.] Icahn Sch Med Mt Sinai, New York, NY USA. [Boockvar, K.] Jewish Home Lifecare Res Inst Aging, Bronx, NY USA. [Prigerson, H. G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Prigerson, H. G.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 176 EP 176 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102327 ER PT J AU Vaillant, GE AF Vaillant, G. E. TI ANTECEDENTS OF COGNITIVE COMPETENCE AND DEMENTIA AT AGE 90:A 70 YEAR PROSPECTIVE STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Vaillant, G. E.] Mass Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 207 EP 208 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442103026 ER PT J AU Genes, N Shapiro, JS Abraham, G Grudzen, C Hwang, U Nassisi, D Baumlin, K AF Genes, N. Shapiro, J. S. Abraham, G. Grudzen, C. Hwang, U. Nassisi, D. Baumlin, K. TI GEDI WISE: HEALTH IT - ENHANCED GERIATRIC EMERGENCY DEPARTMENT SCREENING AND CARE COORDINATION SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Genes, N.; Shapiro, J. S.; Abraham, G.; Grudzen, C.; Hwang, U.; Nassisi, D.; Baumlin, K.] Icahn Sch Med Mt Sinai, New York, NY USA. [Hwang, U.] James J Peters VAMC, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 213 EP 213 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442103053 ER PT J AU Dodge, HH Mattek, NC Austin, D Hayes, T Kaye, J AF Dodge, H. H. Mattek, N. C. Austin, D. Hayes, T. Kaye, J. TI IN-HOME WALKING SPEEDS AND VARIABILITY TRAJECTORIES ASSOCIATED WITH MILD COGNITIVE IMPAIRMENT SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Dodge, H. H.; Mattek, N. C.; Austin, D.; Hayes, T.; Kaye, J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Dodge, H. H.] Univ Michigan, Ann Arbor, MI 48109 USA. [Dodge, H. H.] Univ Pittsburgh, Pittsburgh, PA USA. [Kaye, J.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 230 EP 230 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442103138 ER PT J AU Aldwin, CM Jeong, Y Igarashi, H Spiro, A AF Aldwin, C. M. Jeong, Y. Igarashi, H. Spiro, A. TI DO HASSLES AND UPLIFTS CHANGE WITH AGE? LONGITUDINAL FINDINGS FROM THE NORMATIVE AGING STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Aldwin, C. M.; Jeong, Y.; Igarashi, H.] Oregon State Univ, Corvallis, OR 97331 USA. [Spiro, A.] VA Boston Healthcare Syst, Boston, MA USA. [Spiro, A.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Spiro, A.] Boston Univ, Sch Med, Boston, MA 02118 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 255 EP 255 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442103259 ER PT J AU Lin, F Roiland, R Chen, D AF Lin, F. Roiland, R. Chen, D. TI EXECUTIVE FUNCTION, STRESS REGULATION, AND FRAILTY IN OLDER ADULTS WITH METABOLIC SYNDROME SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Lin, F.; Chen, D.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Roiland, R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 316 EP 317 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442104093 ER PT J AU Matura, L McDonough, A Carroll, DL AF Matura, L. McDonough, A. Carroll, D. L. TI IS SYMPTOM SEVERITY AND HEALTH STATUS DIFFERENT IN OLDER ADULTS WITH PULMONARY ARTERIAL HYPERTENSION? SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Matura, L.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [McDonough, A.] Univ Massachusetts, Dept Nursing, Lowell, MA USA. [Carroll, D. L.] Massachusetts Gen Hosp, Munn Ctr Nursing Res, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 387 EP 387 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442104421 ER PT J AU Bean, JF Paul, TM Holt, NE Percac-Lima, S Latham, N Ni, P Jette, A Leveille, SG AF Bean, J. F. Paul, T. M. Holt, N. E. Percac-Lima, S. Latham, N. Ni, P. Jette, A. Leveille, S. G. TI TRUNK MUSCLE EXTENSOR ENDURANCE, MOBILITY PERFORMANCE AND BACK PAIN STATUS AMONG OLDER PRIMARY CARE PATIENTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Bean, J. F.; Holt, N. E.] Spaulding Rehabil Hosp, Cambridge, MA USA. [Bean, J. F.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Paul, T. M.] Case Western Reserve, Cleveland, OH USA. [Bean, J. F.; Percac-Lima, S.] Mass Gen Hosp, Boston, MA USA. [Latham, N.; Ni, P.; Jette, A.] Boston Univ, Boston, MA 02215 USA. [Leveille, S. G.] UMASS Boston, Boston, MA USA. RI Bean, Jonathan/F-5798-2017 OI Bean, Jonathan/0000-0001-8385-8210 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 390 EP 390 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442104438 ER PT J AU Chodosh, J Connor, M Guzman, J Connor, KI Harrell, K Leff, A Castle, S AF Chodosh, J. Connor, M. Guzman, J. Connor, K. I. Harrell, K. Leff, A. Castle, S. TI MEETING THE CHALLENGE OF PROVIDING SPECIALTY DEMENTIA CARE TO RURAL VETERANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Chodosh, J.; Connor, M.; Guzman, J.; Connor, K. I.; Harrell, K.; Leff, A.; Castle, S.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chodosh, J.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 392 EP 392 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442104449 ER PT J AU Hung, WW Kramer, B Barczi, S Thielke, SM Rossi, MI Caprio, TV Howe, JL AF Hung, W. W. Kramer, B. Barczi, S. Thielke, S. M. Rossi, M. I. Caprio, T. V. Howe, J. L. TI A NOVEL PROGRAM TO LINK GERIATRIC TEAM TO RURAL CLINICS (GRECC CONNECT) SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hung, W. W.; Howe, J. L.] James J Peters VA Med Ctr, GRECC, Bronx, NY USA. [Hung, W. W.; Howe, J. L.] Mt Sinai Sch Med, New York, NY USA. [Kramer, B.] West Los Angeles VA Med Ctr, GRECC, Los Angeles, CA USA. [Barczi, S.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA. [Thielke, S. M.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Rossi, M. I.] VA Pittsburgh Hlth Care Syst, GRECC, Pittsburgh, PA USA. [Caprio, T. V.] Univ Rochester, Canandaigua Rochester VA Med Ctr, Rochester, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 392 EP 392 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442104448 ER PT J AU Chodosh, J Price, R Cadogan, M Osterweil, D Czerwinski, A Tan, ZS Miller-Martinez, D Frank, J AF Chodosh, J. Price, R. Cadogan, M. Osterweil, D. Czerwinski, A. Tan, Z. S. Miller-Martinez, D. Frank, J. TI IMPROVING NURSING FACILITY DEPRESSION CARE USING MENTORED PRACTICE IMPROVEMENT EDUCATION (PIE) SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Chodosh, J.] VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. [Chodosh, J.; Price, R.; Cadogan, M.; Osterweil, D.; Tan, Z. S.; Miller-Martinez, D.; Frank, J.] Univ Calif Los Angeles, Los Angeles, CA USA. [Osterweil, D.] Calif Assoc Long Term Care Med, Los Angeles, CA USA. [Czerwinski, A.] Lawson & Associates, Sacramento, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 412 EP 412 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442105022 ER PT J AU Rivas, DA Lessard, SJ Rice, NP So, K Parnell, LD Fielding, R AF Rivas, D. A. Lessard, S. J. Rice, N. P. So, K. Parnell, L. D. Fielding, R. TI IMPAIRED MICRORNA REGULATION IN OLDER MEN IN RESPONSE TO ACUTE HIGH-INTENSITY RESISTANCE EXERCISE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Rivas, D. A.; Rice, N. P.; So, K.; Fielding, R.] Tufts Univ, Nutr Exercise Physiol & Sarcopenia Lab HNRCA, Boston, MA 02111 USA. [Lessard, S. J.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. [Parnell, L. D.] Tufts Univ, Nutr Genom Lab HNRCA, Boston, MA 02111 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 425 EP 425 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442105085 ER PT J AU Lee, L Spiro, A AF Lee, L. Spiro, A. TI IMPACT OF EARLY LIFE EXPERIENCES ON LATER-LIFE PSYCHOLOGICAL OUTCOMES: THE VA NORMATIVE AGING STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Lee, L.; Spiro, A.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Lee, L.] VA Boston Healthcare Syst, Boston, MA USA. [Spiro, A.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Spiro, A.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 473 EP 473 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442105311 ER PT J AU Levenson, M Jeong, Y Aldwin, CM Igarashi, H Spiro, A AF Levenson, M. Jeong, Y. Aldwin, C. M. Igarashi, H. Spiro, A. TI DO HASSLES MEDIATE THE EFFECT OF PERSONALITY ON MORTALITY? FINDINGS FROM THE NORMATIVE AGING STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Levenson, M.; Jeong, Y.; Aldwin, C. M.; Igarashi, H.] Oregon State Univ, Corvallis, OR 97331 USA. [Spiro, A.] VA Boston Healthcare Syst, Boston, MA USA. [Spiro, A.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Spiro, A.] Boston Univ, Sch Med, Boston, MA 02118 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 475 EP 475 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442105318 ER PT J AU Spira, AP Covinsky, K Rebok, G Punjabi, N Redline, S Stone, KL Yaffe, K AF Spira, A. P. Covinsky, K. Rebok, G. Punjabi, N. Redline, S. Stone, K. L. Yaffe, K. TI SLEEP-DISORDERED BREATHING AND FUNCTIONAL DECLINE IN OLDER WOMEN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Spira, A. P.; Rebok, G.; Punjabi, N.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Covinsky, K.; Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Covinsky, K.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Punjabi, N.] Johns Hopkins Sch Med, Baltimore, MD USA. [Redline, S.] Harvard Univ, Sch Med, Boston, MA USA. [Stone, K. L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 488 EP 488 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442105371 ER PT J AU Quach, L Gagnon, DR Dugan, E AF Quach, L. Gagnon, D. R. Dugan, E. TI HOW DO FALLS BY OLDER ADULTS VARY BY RACE AND GENDER? FINDINGS FROM THE HEALTH AND RETIREMENT STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Quach, L.; Dugan, E.] Univ Massachusetts, Gerontol Dept, Boston, MA 02125 USA. [Quach, L.; Gagnon, D. R.] Massachussetts Veterancs Epidemiol Res & Informat, VA Boston Healthcare Syst, Boston, MA USA. [Gagnon, D. R.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 491 EP 491 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442105384 ER PT J AU Mahoney, DF LaRose, S Mahoney, E AF Mahoney, D. F. LaRose, S. Mahoney, E. TI DRESSING DIFFICULTIES IN DEMENTIA CAREGIVING: THE PRESERVATION OF SELF MODEL SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Mahoney, D. F.; LaRose, S.] MGH Inst Hlth Profess, Boston, MA USA. [LaRose, S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mahoney, E.] EEDEE Consulting, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 498 EP 498 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442105413 ER PT J AU Dodge, HH Bowman, M Mattek, NC Kaye, J AF Dodge, H. H. Bowman, M. Mattek, N. C. Kaye, J. TI CONVERSATIONAL ENGAGEMENT AS A MEANS TO ENHANCE COGNITIVE FUNCTIONS: A TECHNOLOGY-ENABLED RANDOMIZED CONTROLLED TRIAL SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Dodge, H. H.; Bowman, M.; Mattek, N. C.; Kaye, J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Dodge, H. H.] Univ Michigan, Ann Arbor, MI 48109 USA. [Dodge, H. H.] Univ Pittsburgh, Pittsburgh, PA USA. [Kaye, J.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 515 EP 515 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442105495 ER PT J AU Byers, AL Beristianos, M Neylan, TC Covinsky, K Yaffe, K AF Byers, A. L. Beristianos, M. Neylan, T. C. Covinsky, K. Yaffe, K. TI LATE-LIFE PTSD AND RISK OF MORTALITY: THE IMPORTANCE OF COMORBIDITIES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Byers, A. L.; Beristianos, M.; Neylan, T. C.; Yaffe, K.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Byers, A. L.; Beristianos, M.; Neylan, T. C.; Covinsky, K.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Beristianos, M.] Calif Sch Profess Psychol, San Francisco, CA USA. [Covinsky, K.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Yaffe, K.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, K.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 538 EP 538 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106042 ER PT J AU June, A Naik, AD Gosian, J Moye, J AF June, A. Naik, A. D. Gosian, J. Moye, J. TI DIFFERENT EXPERIENCES OF PAIN IN OLDER VERSUS YOUNGER CANCER SURVIVORS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [June, A.; Gosian, J.; Moye, J.] VA Boston Healthcare Syst, Boston, MA USA. [June, A.; Moye, J.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Naik, A. D.] Michael E DeBakey VAMC, HSR&D, Houston, TX USA. [Naik, A. D.] Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 2 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 538 EP 539 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106046 ER PT J AU Mulligan, EA Moye, J Bush, A Gosian, J Naik, AD AF Mulligan, E. A. Moye, J. Bush, A. Gosian, J. Naik, A. D. TI THE SOCIAL INTRUSIVENESS OF SIDE EFFECTS OF CANCER AND THEIR ASSOCIATIONS WITH DEPRESSIVE SYMPTOMS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Mulligan, E. A.; Moye, J.; Gosian, J.] VA Boston Healthcare Syst, Brockton, MA USA. [Mulligan, E. A.; Moye, J.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Bush, A.; Naik, A. D.] Michael E DeBakey VAMC, HSR&D Ctr Excellence, Houston, TX USA. [Bush, A.; Naik, A. D.] Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 538 EP 538 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106045 ER PT J AU Karel, MJ Martin, LA Mulligan, EA Walder, A Moye, J Naik, AD AF Karel, M. J. Martin, L. A. Mulligan, E. A. Walder, A. Moye, J. Naik, A. D. TI QUALITY OF LIFE VALUES AND GOALS AMONG VETERANS WITH ORAL-DIGESTIVE CANCERS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Karel, M. J.; Mulligan, E. A.; Moye, J.] VA Boston Healthcare Syst, Mental Hlth, Brockton, MA USA. [Karel, M. J.; Mulligan, E. A.; Moye, J.] Harvard Univ, Sch Med, Boston, MA USA. [Martin, L. A.; Walder, A.; Naik, A. D.] Michael E DeBakey VAMC, HSR&D, Houston, TX USA. [Martin, L. A.; Walder, A.; Naik, A. D.] Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 539 EP 539 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106047 ER PT J AU Norris-Bell, R Moye, J Mulligan, EA Herman, L Naik, AD AF Norris-Bell, R. Moye, J. Mulligan, E. A. Herman, L. Naik, A. D. TI STRESS-RELATED GROWTH AMONG OLDER VETERANS WITH CANCER SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Norris-Bell, R.; Moye, J.; Mulligan, E. A.] VA Boston Healthcare Syst, Brockton, MA USA. [Norris-Bell, R.; Moye, J.; Mulligan, E. A.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. [Herman, L.; Naik, A. D.] Michael E DeBakey VAMC, HSR&D Ctr Excellence, Houston, TX USA. [Herman, L.; Naik, A. D.] Baylor Coll Med, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 539 EP 539 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106048 ER PT J AU Ford, B Buys, DR Allman, RM Sawyer, P AF Ford, B. Buys, D. R. Allman, R. M. Sawyer, P. TI NEIGHBORHOOD DISADVANTAGE IS ASSOCIATED WITH HOSPITAL USE AMONG OLDER ADULTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Ford, B.; Buys, D. R.; Allman, R. M.; Sawyer, P.] Birmingham VA Med Ctr, GRECC, Birmingham, AL USA. [Ford, B.; Buys, D. R.; Allman, R. M.; Sawyer, P.] Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 542 EP 542 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106063 ER PT J AU Sheldon, G Rao, S Kinosian, B Stallard, P AF Sheldon, G. Rao, S. Kinosian, B. Stallard, P. TI SMALL AREA ESTIMATES OF CATASTROPHICALLY DISABLED VETERANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Sheldon, G.; Rao, S.; Kinosian, B.; Stallard, P.] US Dept Vet Affairs, Washington, DC USA. [Sheldon, G.] George Washington Univ, Dept Econ, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 555 EP 555 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106130 ER PT J AU Carr, D Prigerson, HG Boerner, K Moorman, SM AF Carr, D. Prigerson, H. G. Boerner, K. Moorman, S. M. TI CAN ADVANCE CARE PLANNING MINIMIZE DISTRESS AMONG THE BEREAVED? ASSESSING DEATH QUALITY PATHWAYS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Carr, D.] Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08903 USA. [Moorman, S. M.] Boston Coll, Boston, MA USA. [Prigerson, H. G.] Dana Farber Harvard Canc Ctr, Boston, MA USA. [Boerner, K.] Jewish Home Lifecare, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 558 EP 558 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106146 ER PT J AU Prigerson, HG Garrido, MM AF Prigerson, H. G. Garrido, M. M. TI WHAT ASPECTS OF TERMINAL CARE BEST PREDICT FAMILY CAREGIVERS' BEREAVEMENT ADJUSTMENT?: EVIDENCE FROM THE COPING WITH CANCER STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Prigerson, H. G.] Harvard Dana Farber, Med Oncol Psychosocial Onc, Boston, MA USA. [Garrido, M. M.] James J Peters VAMC, Bronx, NY USA. [Garrido, M. M.] Icahn Sch Med Mt Sinai, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 558 EP 559 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106148 ER PT J AU Beverly, EA Fitzgerald, SM Weinger, K AF Beverly, E. A. Fitzgerald, S. M. Weinger, K. TI SELF-CARE AND PSYCHOSOCIAL FACTORS IN OLDER ADULTS WITH DIABETES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Beverly, E. A.; Fitzgerald, S. M.; Weinger, K.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Beverly, E. A.; Weinger, K.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 569 EP 569 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106203 ER PT J AU Atri, A AF Atri, A. TI THE GOOD, BAD AND UGLY: EVIDENCE & UNCERTAINTIES IN COMBINATION THERAPY AND ANTIPSYCHOTICS USE IN AD SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Atri, A.] Bedford VA Med Ctr, GRECC, Bedford, MA USA. [Atri, A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 574 EP 574 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106230 ER PT J AU Rudolph, JL AF Rudolph, J. L. TI THE COGNITIVE AND FUNCTIONAL IMPACT OF ANTICHOLINERGIC MEDICATIONS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Rudolph, J. L.] VA Boston Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 574 EP 574 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106228 ER PT J AU Carrion, IV Nedjat-Haiem, FR Macip-Billbe, M AF Carrion, I. V. Nedjat-Haiem, F. R. Macip-Billbe, M. TI RESILIENCE AND COPING AMONG OLDER LATINO MEN AND WOMEN WITH A CANCER DIAGNOSIS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Carrion, I. V.; Macip-Billbe, M.] Univ S Florida, Tampa, FL USA. [Nedjat-Haiem, F. R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 579 EP 579 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106254 ER PT J AU McLean, RR Peters, KW Cawthon, P Fragala, M Kenny, A Castaneda-Sceppa, C Studenski, S Dam, TL AF McLean, R. R. Peters, K. W. Cawthon, P. Fragala, M. Kenny, A. Castaneda-Sceppa, C. Studenski, S. Dam, T. L. TI LONGITUDINAL ASSOCIATION OF FNIH SARCOPENIA CRITERIA AND INCIDENT MOBILITY IMPAIRMENT AND MORTALITY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [McLean, R. R.] Hebrew SeniorLife Inst Aging Res, Boston, MA USA. [McLean, R. R.] Harvard Univ, Sch Med, Boston, MA USA. [Peters, K. W.; Cawthon, P.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Fragala, M.; Kenny, A.] Univ Connecticut, Ctr Hlth, Farmington, CT USA. [Fragala, M.] Univ Cent Florida, Orlando, FL 32816 USA. [Castaneda-Sceppa, C.] Northeastern Univ, Bouve Coll Hlth Sci, Boston, MA 02115 USA. [Studenski, S.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Studenski, S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Dam, T. L.] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 594 EP 594 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106333 ER PT J AU Spiro, A Davison, EH AF Spiro, A. Davison, E. H. TI FROM LOSS TO LATR: REEVALUATING THE IMPACT OF EARLY-LIFE TRAUMA IN LATER LIFE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Spiro, A.] VA Boston, MAVERIC NAS, Boston, MA USA. [Spiro, A.; Davison, E. H.] Boston Univ, Boston, MA 02215 USA. [Davison, E. H.] VA Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 602 EP 602 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106375 ER PT J AU Stellman, JM Kaiser, AP Spiro, A AF Stellman, J. M. Kaiser, A. Pless Spiro, A. TI CAREER MILITARY SERVICE, FAMILY STRUCTURE AND WELL-BEING AMONG AGING WOMEN OF THE VIETNAM WAR SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Stellman, J. M.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. [Kaiser, A. Pless; Spiro, A.] VA Boston Healthcare Syst, Boston, MA USA. [Kaiser, A. Pless; Spiro, A.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Kaiser, A. Pless; Spiro, A.] Boston Univ, Sch Med, Boston, MA 02118 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 602 EP 602 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106373 ER PT J AU Howe, JL Griffith, JL AF Howe, J. L. Griffith, J. L. TI RURAL INTERDISCIPLINARY TEAM TRAINING (RITT): INFUSING GERIATRICS THROUGHOUT TEAM-BASED PRIMARY CARE CLINICS IN THE UNITED STATES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Howe, J. L.; Griffith, J. L.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Howe, J. L.; Griffith, J. L.] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 609 EP 609 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106405 ER PT J AU Newell, DA Kramer, B AF Newell, D. A. Kramer, B. TI VA GERIATRIC SCHOLARS PROGRAM: WEB-BASED EDUCATION IN KEY GERIATRICS TOPICS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Newell, D. A.] Soulut Consulting, Gainesville, FL USA. [Kramer, B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Kramer, B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 609 EP 609 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106408 ER PT J AU Amorosa, VK Luetkemeyer, A Kang, M Johnson, VA Umbleja, T Haas, DW Yesmin, S Bardin, MC Chung, RT Alston-Smith, B Tebas, P Peters, MG AF Amorosa, Valerianna K. Luetkemeyer, Anne Kang, Minhee Johnson, Victoria A. Umbleja, Triin Haas, David W. Yesmin, Suria Bardin, Matthew C. Chung, Ray T. Alston-Smith, Beverly Tebas, Pablo Peters, Marion G. TI Addition of Nitazoxanide to PEG-IFN and Ribavirin to Improve HCV Treatment Response in HIV-1 and HCV Genotype 1 Coinfected Persons Naive to HCV Therapy: Results of the ACTG A5269 Trial SO HIV CLINICAL TRIALS LA English DT Article DE genotype 1; hepatitis C; HIV; nitazoxanide; pegylated interferon; ribavirin ID CHRONIC HEPATITIS-C; HOMEOSTASIS MODEL ASSESSMENT; SIMPLE NONINVASIVE INDEX; VIROLOGICAL RESPONSE; SIGNIFICANT FIBROSIS; INSULIN-RESISTANCE; VIRUS; PROGRAM; PREDICT; PLASMA AB Background: We hypothesized that nitazoxanide (NTZ) added to pegylated interferon alfa-2a (PEG-IFN) and weight-based ribavirin (WBR) would improve hepatitis C virus (HCV) virologic responses in HCV treatment-nave HIV-1/HCV genotype 1 coinfected persons. Methods: Prospective, single-arm study in which subjects received 4-week lead-in (NTZ 500 mg twice daily) followed by 48 weeks of NTZ, PEG-IFN, and WBR. We compared the HCV virologic responses of these subjects to historical controls from the completed ACTG study A5178 who received PEG-IFN and WBR and had similar subject characteristics. Primary endpoints were early virologic response and complete early virologic response (EVR and cEVR). Results: Among 67 subjects (78% male; 48% Black; median age, 50 years), EVR was achieved in 65.7% (90% CI, 55.0%-75.3%), cEVR in 38.8% (28.8%-49.6%). and SVR in 32.8% (23.4%-43.5%). EVR was higher with NTZ (51.4% in A5178; P = .03), but the sustained virologic response (SVR) proportion was similar (27.3% in A5178; P = .24). In contrast to A5178, SVR was similar across IL28B genotypes. Overall, NTZ was safe and well-tolerated. Conclusion: Whereas EVR proportion improved significantly in this pilot study, the addition of NTZ to PEG-IFN/WBR did not significantly improve SVR compared to historical controls. NTZ may be associated with an attenuation of the effect of IL28B on HCV treatment response. C1 [Amorosa, Valerianna K.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Amorosa, Valerianna K.; Tebas, Pablo] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Luetkemeyer, Anne; Peters, Marion G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kang, Minhee; Umbleja, Triin] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Johnson, Victoria A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Johnson, Victoria A.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Haas, David W.] Vanderbilt Univ Sch Med, Nashville, TN USA. [Yesmin, Suria] ACTG Operat Ctr, Silver Spring, MD USA. [Bardin, Matthew C.] Romark Labs LC, Tampa, FL USA. [Chung, Ray T.] Harvard Univ, Sch Med, Boston, MA USA. [Alston-Smith, Beverly] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA. RP Amorosa, VK (reprint author), Philadelphia VAMC, Dept Med, Univ & Woodlawn Ave,8th Floor, Philadelphia, PA 19010 USA. EM valerianna.amorosa@uphs.upenn.edu FU National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health [UL1RR024989]; NIH Roadmap for Medical Research FX This publication was made possible by the Clinical and Translational Science Collaborative of Cleveland grant UL1RR024989 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. NR 17 TC 3 Z9 3 U1 0 U2 2 PU THOMAS LAND PUBLISHERS, INC PI ST LOUIS PA 255 JEFFERSON RD, ST LOUIS, MO 63119-3627 USA SN 1528-4336 EI 1945-5771 J9 HIV CLIN TRIALS JI HIV Clin. Trials PD NOV-DEC PY 2013 VL 14 IS 6 BP 274 EP 283 DI 10.1310/hct1408-274 PG 10 WC Infectious Diseases; Pharmacology & Pharmacy SC Infectious Diseases; Pharmacology & Pharmacy GA 272EQ UT WOS:000328443500002 PM 24334180 ER PT J AU Van Haren, K Tomooka, BH Kidd, BA Banwell, B Bar-Or, A Chitnis, T Tenembaum, SN Pohl, D Rostasy, K Dale, RC O'Connor, KC Hafler, DA Steinman, L Robinson, WH AF Van Haren, Keith Tomooka, Beren H. Kidd, Brian A. Banwell, Brenda Bar-Or, Amit Chitnis, Tanuja Tenembaum, Silvia N. Pohl, Daniela Rostasy, Kevin Dale, Russell C. O'Connor, Kevin C. Hafler, David A. Steinman, Lawrence Robinson, William H. TI Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis SO MULTIPLE SCLEROSIS JOURNAL LA English DT Article DE Pediatric disease; multiple sclerosis; acute disseminated encephalomyelitis; myelin; autoantibody; differential diagnosis; biomarker; immunoglobulin; autoimmune disease; immunoassay ID OLIGODENDROCYTE GLYCOPROTEIN ANTIBODIES; DEMYELINATING DISEASES; INTERFERON-BETA; PROTEIN; ANTIGEN; MICROARRAYS; RESPONSES; AUTOIMMUNITY; AUTOANTIGEN; SIGNATURES AB Background and objective: Acute disseminated encephalomyelitis (ADEM) and relapsing-remitting multiple sclerosis (RRMS) share overlapping clinical, radiologic and laboratory features at onset. Because autoantibodies may contribute to the pathogenesis of both diseases, we sought to identify autoantibody biomarkers that are capable of distinguishing them. Methods: We used custom antigen arrays to profile anti-myelin-peptide autoantibodies in sera derived from individuals with pediatric ADEM (n = 15), pediatric multiple sclerosis (Ped MS; n = 11) and adult MS (n = 15). Using isotype-specific secondary antibodies, we profiled both IgG and IgM reactivities. We used Statistical Analysis of Microarrays software to confirm the differences in autoantibody reactivity profiles between ADEM and MS samples. We used Prediction Analysis of Microarrays software to generate and validate prediction algorithms, based on the autoantibody reactivity profiles. Results: ADEM was characterized by IgG autoantibodies targeting epitopes derived from myelin basic protein, proteolipid protein, myelin-associated oligodendrocyte basic glycoprotein, and alpha-B-crystallin. In contrast, MS was characterized by IgM autoantibodies targeting myelin basic protein, proteolipid protein, myelin-associated oligodendrocyte basic glycoprotein and oligodendrocyte-specific protein. We generated and validated prediction algorithms that distinguish ADEM serum (sensitivity 62-86%; specificity 56-79%) from MS serum (sensitivity 40-87%; specificity 62-86%) on the basis of combined IgG and IgM anti-myelin autoantibody reactivity to a small number of myelin peptides. Conclusions: Combined profiles of serum IgG and IgM autoantibodies identified myelin antigens that may be useful for distinguishing MS from ADEM. Further studies are required to establish clinical utility. Further biological assays are required to delineate the pathogenic potential of these antibodies. C1 [Van Haren, Keith; Steinman, Lawrence] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Palo Alto, CA 94304 USA. [Van Haren, Keith] Lucile Packard Childrens Hosp, Div Child Neurol, Palo Alto, CA USA. [Tomooka, Beren H.; Kidd, Brian A.; Robinson, William H.] Stanford Univ, Sch Med, Dept Med, Palo Alto, CA 94304 USA. [Tomooka, Beren H.; Robinson, William H.] VA Palo Alto Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Palo Alto, CA USA. [Banwell, Brenda] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA. [Bar-Or, Amit] McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada. [Chitnis, Tanuja] Massachusetts Gen Hosp, Partners Pediat MS Ctr, Boston, MA 02114 USA. [Tenembaum, Silvia N.] Natl Pediat Hosp Dr Juan P Garrahan, Dept Neurol, Buenos Aires, DF, Argentina. [Pohl, Daniela] Univ Ottawa, Childrens Hosp Eastern Ontario, Ottawa, ON, Canada. [Rostasy, Kevin] Med Univ Innsbruck, Dept Pediat, Innsbruck, Germany. [Dale, Russell C.] Univ Sydney, Dept Paediat & Child Hlth, Sydney, NSW 2006, Australia. [O'Connor, Kevin C.; Hafler, David A.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA. RP Robinson, WH (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Bldg 101,Room C4-185,3801 Miranda Ave, Palo Alto, CA 94304 USA. EM wrobins@stanford.edu FU US National Institutes of Health (NIH) [R25-NS070698]; NIH Loan Repayment Program; Child Neurology Foundation; Lucile Packard Foundation Sprague/McHugh Multiple Sclerosis Fund; Canadian Multiple Sclerosis Scientific Research Foundation; Nancy Davis Foundation for Multiple Sclerosis; National Multiple Sclerosis Society; US NIH (NIAID) [U19-AI070352]; US NIH (NINDS) [R01-NS024247, P01-AI039671, P01-NS038037]; NIH (NINDS) [R01 NS55997]; NIH NHLBI Proteomics Center [N01-HV-00242]; Veteran's Administration (VA) Merit Award FX KVH's work was supported by funding from the US National Institutes of Health (NIH; grant number R25-NS070698), the NIH Loan Repayment Program, the Child Neurology Foundation and the Lucile Packard Foundation Sprague/McHugh Multiple Sclerosis Fund. BB and ABO's work was supported by the Canadian Multiple Sclerosis Scientific Research Foundation; BB was previously supported by the Wadsworth Foundation. KCO's work was supported by the Nancy Davis Foundation for Multiple Sclerosis and a Career Transition Fellowship from the National Multiple Sclerosis Society. DAH's work was supported by the US NIH (NIAID grant number U19-AI070352; NINDS grant numbers R01-NS024247, P01-AI039671 and P01-NS038037). LS's work was supported by the NIH (NINDS grant number R01 NS55997). WHR's work was supported by the NIH NHLBI Proteomics Center (contract N01-HV-00242) and a Veteran's Administration (VA) Merit Award. NR 39 TC 13 Z9 13 U1 0 U2 7 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD NOV PY 2013 VL 19 IS 13 BP 1726 EP 1733 DI 10.1177/1352458513485653 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 250YU UT WOS:000326893900010 PM 23612879 ER PT J AU Masuda, A Arisaka, Y Hara, S Matsumoto, I Takenaka, M Sakai, A Shiomi, H Matsuki, N Sugimoto, M Fujita, T Hayakumo, T Ku, Y Ogino, S Azuma, T Kutsumi, H AF Masuda, Atsuhiro Arisaka, Yoshifumi Hara, Shigeo Matsumoto, Ippei Takenaka, Mamoru Sakai, Arata Shiomi, Hideyuki Matsuki, Nobuyuki Sugimoto, Maki Fujita, Tsuyoshi Hayakumo, Takanobu Ku, Yonson Ogino, Shuji Azuma, Takeshi Kutsumi, Hiromu TI MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas SO PANCREATOLOGY LA English DT Article DE Mixed-type IPMN; MUC2 expression; High-grade dysplasia; Invasive carcinoma ID INTERNATIONAL CONSENSUS GUIDELINES; SURGICAL-MANAGEMENT; TUMORS; DUCT; CLASSIFICATION; FEATURES; SUBTYPES; MUC5AC AB Background/objectives: Morphological types and mucin protein expressions classify intraductal papillary mucinous neoplasms (IPMNs). Main duct (MD)-IPMN mostly consists of intestinal type (I-type), which expresses MUC2. Branch duct (BD)-IPMN mostly consists of gastric type (G-type), which does not express MUC2. However, the definition of mixed-type IPMN has yet to be clarified and it contains various histological types. The aim of this study was to investigate the relationship between MUC2 expression and the presence of high-grade dysplasia (HGD) and invasive carcinoma, especially in mixed-type IPMN. Methods: This retrospective study included 101 consecutive patients with surgically resected IPMNs between April 2001 and October 2012. All patients were morphologically classified into four distinct types (I-type, G-type, PB-type: pancreatobilliary, O-type: oncocytic) and immunohistochemical reactivity of various anti-mucin antibodies were investigated. Results: According to the classification of the 2012 international guidelines, the numbers (and histomorphological types: I/G/PB/O) of MD, mixed-type, and BD-IPMNs were 16 (12/4/0/0), 45 (16/28/1/0), and 40 (0/38/1/1). Prevalence of MUC2 expression in MD, mixed-type, and BD-IPMNs were 75% (12/16), 36% (16/45), and 0% (0/40). In mixed-type IPMN, the prevalence of HGD and/or invasive carcinoma in MUC2-positive IPMN was significantly higher than that of MUC2-negative IPMN (HGD + invasive carcinoma: 88% vs. 38%, p = 0.0017; invasive carcinoma: 50% vs. 21%, p = 0.042). Multivariate analysis showed that MUC2 expression is an independent predictive factor of HGD and invasive carcinoma in mixed IPMN (odds ratio 14.6, 95% CI 2.5-87.4, p = 0.003). Conclusions: In mixed-type IPMN, MUC2 expression clearly identified HGD and invasive carcinoma and may provide most appropriate surgical indication. Copyright (C) 2013, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. All rights reserved. C1 [Masuda, Atsuhiro; Arisaka, Yoshifumi; Takenaka, Mamoru; Sakai, Arata; Shiomi, Hideyuki; Matsuki, Nobuyuki; Sugimoto, Maki; Fujita, Tsuyoshi; Hayakumo, Takanobu; Azuma, Takeshi; Kutsumi, Hiromu] Kobe Univ, Grad Sch Med, Div Gastroenterol,Dept Internal Med, Chuo Ku, Kobe, Hyogo 6500017, Japan. [Hara, Shigeo] Kobe Univ, Grad Sch Med, Div Diagnost Pathol, Kobe, Hyogo 6500017, Japan. [Matsumoto, Ippei; Ku, Yonson] Kobe Univ, Grad Sch Med, Dept Surg, Div Hepatobillary Pancreat Surg, Kobe, Hyogo 6500017, Japan. [Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Ogino, Shuji] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Ogino, Shuji] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Cambridge, MA 02138 USA. RP Kutsumi, H (reprint author), Kobe Univ, Grad Sch Med, Div Gastroenterol,Dept Internal Med, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan. EM hkutsumi@med.kobe-u.ac.jp FU Ministry of Health, Labour, and Welfare of Japan FX This work was supported by a grant for the Research Committee of Intractable Pancreatic Diseases provided by the Ministry of Health, Labour, and Welfare of Japan (to A.M. and H.K.). The authors report that there are no conflicts of interest relevant to this publication. NR 23 TC 4 Z9 4 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1424-3903 EI 1424-3911 J9 PANCREATOLOGY JI Pancreatology PD NOV-DEC PY 2013 VL 13 IS 6 BP 583 EP 588 DI 10.1016/j.pan.2013.08.007 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 270JC UT WOS:000328313700006 PM 24280573 ER PT J AU Rakvongthai, Y Oraintara, S AF Rakvongthai, Yothin Oraintara, Soontorn TI Statistical texture retrieval in noise using complex wavelets SO SIGNAL PROCESSING-IMAGE COMMUNICATION LA English DT Article DE Texture retrieval in noise; Complex wavelets; Relative phase; Parameter estimation in noise ID SCALE MIXTURES; RELATIVE PHASE; CLASSIFICATION; TRANSFORM; DOMAIN; COEFFICIENTS AB This paper investigates the use of complex wavelets for statistical texture retrieval in a noisy environment, in which the query image is contaminated by noise. To account for the presence of noise, the feature extraction step is based on parameter estimation in noise where features are extracted from the noisy query image by modeling the magnitude and phase of complex subband coefficients of the clean image, and relating the model's parameters to the noisy coefficients. In addition to using only the magnitude or phase which is in the form of the relative phase, we incorporate both magnitude and phase information to further improve the accuracy rate. The simulation results show the retrieval rate improvement by estimating the clean parameters from the noisy query image instead of assuming that the query image is clean. Furthermore, using both magnitude and phase of complex coefficients improves the accuracy rate from using either magnitude or phase alone, and that using complex-valued wavelets yields higher rate than using real-valued wavelets. (C) 2013 Elsevier B.V. All rights reserved. C1 [Rakvongthai, Yothin; Oraintara, Soontorn] Univ Texas Arlington, Dept Elect Engn, Arlington, TX 76019 USA. RP Rakvongthai, Y (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Div Nucl Med & Mol Imaging,Med Sch, 55 Fruit St, Boston, MA 02114 USA. EM rakvongthai@pet.mgh.harvard.edu; oraintar@uta.edu NR 36 TC 2 Z9 3 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0923-5965 EI 1879-2677 J9 SIGNAL PROCESS-IMAGE JI Signal Process.-Image Commun. PD NOV PY 2013 VL 28 IS 10 SI SI BP 1494 EP 1505 DI 10.1016/j.image.2013.06.005 PG 12 WC Engineering, Electrical & Electronic SC Engineering GA 269HU UT WOS:000328233200021 ER PT J AU Liang, F Wamala, I Scalea, J Tena, A Cormack, T Pratts, S Duran-Struuck, R Elias, N Hertl, M Huang, CA Sachs, DH AF Liang, Fan Wamala, Isaac Scalea, Joseph Tena, Aseda Cormack, Taylor Pratts, Shannon Duran-Struuck, Raimon Elias, Nahel Hertl, Martin Huang, Christene A. Sachs, David H. TI Increased levels of anti-non-Gal IgG following pig-to-baboon bone marrow transplantation correlate with failure of engraftment SO XENOTRANSPLANTATION LA English DT Article DE antibody; anti-non-Gal; baboons; bone marrow; miniature swine; xenotransplantation ID NONLETHAL PREPARATIVE REGIMEN; GENE-KNOCKOUT PIGS; XENOGENEIC BARRIER; MEDIATED REJECTION; MIXED CHIMERISM; CELL TOLERANCE; SWINE; XENOTRANSPLANTATION; ANTIBODIES; DONOR AB BackgroundThe development of genetically modified pigs, which lack the expression of alpha 1-3 galactosyl transferase, (GalT-KO pigs) has facilitated the xenogeneic transplantation of porcine organs and tissues into primates by avoiding hyperacute rejection due to pre-existing antibodies against the Gal epitope. However, antibodies against other antigens (anti-non-Gal antibodies), are found at varying levels in the pre-transplant sera of most primates. We have previously found that baboons with high levels of pre-transplant anti-non-Gal IgG, conditioned with a non-myeloablative conditioning regimen, failed to engraft following pig-to-baboon bone marrow transplantation (Xenotransplantation, 17, 2010 and 300). Two baboons with low levels of pre-transplant anti-non-Gal IgG, conditioned with the same regimen, showed porcine bone marrow progenitors at 28days following transplantation, suggesting engraftment. These baboons also showed evidence of donor-specific hyporesponsiveness. This observation led us to investigate the hypothesis that selecting for baboon recipients with low pre-transplant anti-non-Gal IgG levels might improve engraftment levels following GalT-KO pig-to-baboon bone marrow transplantation. MethodsFive baboons, with low pre-transplant anti-non-Gal IgG levels, received transplantation of bone marrow cells (1-5x10(9)/kg of recipient weight) from GalT-KO pigs. They received a non-myeloablative conditioning regimen consisting of low-dose total body irradiation (TBI) (150cGy), thymic irradiation (700cGy), anti-thymocyte globulin (ATG), and tacrolimus. In addition, two baboons received Rituximab and Bortezomib (Velcade) treatment as well as extra-corporeal immunoadsorption using GalT-KO pig livers. Bone marrow engraftment was assessed by porcine-specific PCR on colony forming units (CFU) of day 28 bone marrow aspirates. Anti-non-Gal antibody levels were assessed by serum binding toward GalT-KO PBMC using flow cytometry (FACS). Peripheral macro-chimerism was measured by FACS using pig and baboon-specific antibodies and baboon anti-pig cellular responses were assessed by mixed lymphocyte reactions (MLR). ResultsAs previously reported, two of five baboons demonstrated detectable bone marrow engraftment at 4weeks after transplantation. Engraftment was associated with lack of an increase in anti-non-Gal IgG levels as well as cellular hyporesponsiveness toward pig. Three subsequent baboons with similarly low levels of pre-existing anti-non-Gal IgG showed no engraftment and an increase in anti-non-Gal IgG antibody levels following transplantation. Peripheral macrochimerism was only seen for a few days following transplantation regardless of antibody development. ConclusionsSelecting for baboon recipients with low levels of pre-transplant anti-non-Gal IgG did not ensure bone marrow engraftment. Failure to engraft was associated with an increase in anti-non-Gal IgG levels following transplantation. These results suggest that anti-non-Gal-IgG is likely involved in early bone marrow rejection and that successful strategies for combating anti-non-Gal IgG development may allow better engraftment. Since engraftment was only low and transient regardless of antibody development, innate immune, or species compatibility mechanisms will likely also need to be addressed to achieve long term engraftment. C1 [Liang, Fan; Wamala, Isaac; Scalea, Joseph; Tena, Aseda; Cormack, Taylor; Pratts, Shannon; Duran-Struuck, Raimon; Huang, Christene A.; Sachs, David H.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Dept Surg, Boston, MA 02129 USA. [Liang, Fan; Wamala, Isaac; Scalea, Joseph; Tena, Aseda; Cormack, Taylor; Pratts, Shannon; Duran-Struuck, Raimon; Elias, Nahel; Hertl, Martin; Huang, Christene A.; Sachs, David H.] Harvard Univ, Sch Med, Boston, MA USA. [Elias, Nahel; Hertl, Martin] Massachusetts Gen Hosp, Dept Surg, Transplant Unit, Boston, MA 02129 USA. RP Sachs, DH (reprint author), Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Bldg 149-9019,13th St, Boston, MA 02129 USA. EM david.sachs@tbrc.mgh.harvard.edu FU NCI NIH HHS [CO6RR020135-01]; NCRR NIH HHS [C06 RR020135]; NIAID NIH HHS [5P01AI45897, P01 AI045897] NR 25 TC 3 Z9 3 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0908-665X EI 1399-3089 J9 XENOTRANSPLANTATION JI Xenotransplantation PD NOV PY 2013 VL 20 IS 6 BP 458 EP 468 DI 10.1111/xen.12065 PG 11 WC Medicine, Research & Experimental; Transplantation SC Research & Experimental Medicine; Transplantation GA 259UQ UT WOS:000327552200007 PM 24289469 ER PT J AU Fasler-Kan, E Barteneva, NS Ketterer, S Wunderlich, K Reschner, A Nurzhanova, A Flammer, J Huwyler, J Meyer, P AF Fasler-Kan, Elizaveta Barteneva, Natasha S. Ketterer, Sylvia Wunderlich, Kerstin Reschner, Anca Nurzhanova, Asil Flammer, Josef Huwyler, Joerg Meyer, Peter TI Human cytokines activate JAK-STAT signaling pathway in porcine ocular tissue SO XENOTRANSPLANTATION LA English DT Article DE cytokine signaling; interferon; pig retina; STAT proteins; xenotransplantation ID HUMAN T-CELLS; ACUTE ALLOGRAFT-REJECTION; ENDOTHELIAL-CELLS; CORNEAL XENOTRANSPLANTATION; MOLECULAR CHARACTERIZATION; RETINITIS-PIGMENTOSA; INTERFERON-ALPHA; IMMUNE-RESPONSE; GENE-EXPRESSION; IN-VITRO AB BackgroundThe JAK/STAT (Janus Tyrosine Kinase, Signal Transducers and Activators of Transcription) pathway is associated with cytokine or growth factor receptors and it is critical for growth control, developmental regulation and homeostasis. The use of porcine ocular cells as putative xenotransplants appears theoretically possible. The aim of this study was to investigate the response of various porcine ocular cells in vitro to human cytokines in regard to the activation of JAK-STAT signaling pathways. MethodsPorcine lens epithelial cells, pigmented iris epithelial cells and pigmented ciliary body cells were used in this study. These cells were isolated from freshly enucleated porcine eyes by enzymatic digestion. Cultured cells between passages 3-8 were used in all experiments. Electromobility shift assay (EMSA), proliferation assay, immunofluorescence staining and flow cytometry were used to evaluate the JAK-STAT signaling pathway in these cells. ResultsJAK/STAT signaling pathways could be activated in porcine pigmented epithelial ciliary body cells, in pigmented iris epithelial cells and in lens epithelial cells in response to porcine and human interferons and cytokines. All cells showed very strong STAT1 activation upon stimulation with porcine interferon-gamma. Porcine ocular cells also respond to human cytokines; IFN-alpha induced strong activation of STAT1 in EMSA, flow cytometry and immunofluorescence experiments whereas activation of STAT3 was less strong in EMSA, but strong in flow cytometry and immunofluorescence. Human recombinant IL-6 activated STAT3 and human IL-4 activated STAT6. With the help of immunofluorescence assay and flow cytometry we observed nuclear localization of STAT proteins after activation of porcine ocular cells with cytokines and interferons. Human IFN- had an inhibitory effect on porcine ocular cells in proliferation assays. ConclusionOur study demonstrated that some types of human cytokines and interferon activate intracellular JAK-STAT signaling pathways in porcine ocular cells. We hypothesize that direct stimulation of the JAK-STAT pathway in porcine cells in response to human cytokines will lead to complications or failure, if pig-to-human ocular tissue xenotransplantation were to be carried out. For successful xenotransplantation among other obstacles there must be new approaches developed to regulate signaling pathways. C1 [Fasler-Kan, Elizaveta; Ketterer, Sylvia; Wunderlich, Kerstin; Reschner, Anca; Meyer, Peter] Univ Basel, Dept Biomed, CH-4031 Basel, Switzerland. [Fasler-Kan, Elizaveta; Ketterer, Sylvia; Wunderlich, Kerstin; Flammer, Josef; Meyer, Peter] Univ Basel Hosp, CH-4031 Basel, Switzerland. [Fasler-Kan, Elizaveta] Univ Appl Sci Northwestern Switzerland, Inst Chem & Bioanalyt, Muttenz, Switzerland. [Barteneva, Natasha S.] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. [Barteneva, Natasha S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Wunderlich, Kerstin; Flammer, Josef; Meyer, Peter] Univ Basel, Dept Ophthalmol, CH-4031 Basel, Switzerland. [Nurzhanova, Asil] Al Farabi Kazakh Natl Univ, Dept Educ & Sci, Alma Ata, Kazakhstan. [Huwyler, Joerg] Univ Basel, Dept Pharmaceut Sci, Div Pharmaceut Technol, CH-4031 Basel, Switzerland. RP Fasler-Kan, E (reprint author), Univ Basel, Dept Biomed, Hebelstr 20, CH-4031 Basel, Switzerland. EM e.fasler@unibas.ch; natasha.barteneva@childrens.harvard.edu FU University Hospital Basel; NB; Immune Disease Institute; Harvard Pilot Grant; University Eye Clinic (University Hospital Basel, Switzerland) FX EFK, NB provided the concept and design; AR, AN performed data analysis/interpretation; EFK, NB, JH -drafted the article; PM, JF provided critical revision of article, PM provided approval of article, JH performed statistics, and EFK, AR, SK, KW, AN collected the data. EFK was supported by University Hospital Basel and NB by Immune Disease Institute and Harvard Pilot Grant. PM received funding from the University Eye Clinic (University Hospital Basel, Switzerland). NR 69 TC 3 Z9 3 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0908-665X EI 1399-3089 J9 XENOTRANSPLANTATION JI Xenotransplantation PD NOV PY 2013 VL 20 IS 6 BP 469 EP 480 DI 10.1111/xen.12070 PG 12 WC Medicine, Research & Experimental; Transplantation SC Research & Experimental Medicine; Transplantation GA 259UQ UT WOS:000327552200008 PM 24289470 ER PT J AU Bagnell, ME LeardMann, CA McMaster, HS Boyko, EJ Smith, B Granado, NS Smith, TC AF Bagnell, Melissa E. LeardMann, Cynthia A. McMaster, Hope S. Boyko, Edward J. Smith, Besa Granado, Nisara S. Smith, Tyler C. TI The Association of Predeployment and Deployment-Related Factors on Dimensions of Postdeployment Wellness in US Military Service Members SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article DE Wellness; Health Promotion; Military Personnel; Physical Fitness; Combat; Prevention Research ID POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; READJUSTMENT RATING-SCALE; HEALTH-CARE UTILIZATION; MILLENNIUM COHORT; MENTAL-HEALTH; GENDER-DIFFERENCES; CIGARETTE-SMOKING; PSYCHOMETRIC PROPERTIES; LONGITUDINAL ASSESSMENT AB Purpose. To assess the effects of predeployment and deployment-related factors on dimensions of wellness following deployment. Design. Prospective longitudinal study. The dependent variable was dimensions of wellness. Independent variables were measured in terms of modifiable, nonmodifiable, and military factors, such as sex, race/ethnicity, service branch, smoking status, and combat experience. Setting. A large military cohort participating in the Millennium Cohort Study. Subjects. Included 10,228 participants who deployed in support of the operations in Iraq and Afghanistan. Measures. Dimensions of wellness were measured by using standardized instruments assessing self-reported physical health, mental health, and stress. Covariates were measured by using self-reported and electronic data. Analysis. Factors of postdeployment wellness were assessed by using ordinal logistic regression. Results. Most participants (78.7%) were categorized as "moderately well" post deployment. Significant modifiable predeployment predictors of postdeployment wellness included normal/underweight body mass index (odds ratio [OR] = 1.72, p < .05). Military factors significantly associated with wellness included not experiencing combat (OR = .56, p < .05), member of Air Force (OR = 2.02, p < .05) or Navy/Coast Guard (OR = 1.47, p < .05), and combat specialist occupation (OR = 1.22, p < .05). Conclusion. Multiple modifiable factors associated with postdeployment wellness were identified, which may help inform medical and military leadership on potential strategies to ensure a well force. Those trained in combat roles were more likely to be well post deployment though this apparent benefit was not conferred onto those reporting combat experiences. C1 [Bagnell, Melissa E.; LeardMann, Cynthia A.; McMaster, Hope S.; Smith, Besa; Granado, Nisara S.; Smith, Tyler C.] Naval Hlth Res Ctr, Dept Deployment Hlth Res, San Diego, CA 92106 USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Smith, Tyler C.] Natl Univ, Sch Hlth & Human Serv, Dept Community Hlth, San Diego, CA USA. RP LeardMann, CA (reprint author), Naval Hlth Res Ctr, Dept Deployment Hlth Res, 140 Sylvester Rd, San Diego, CA 92106 USA. EM leardmann@med.navy.mil NR 76 TC 0 Z9 0 U1 4 U2 10 PU AMER JOURNAL HEALTH PROMOTION INC PI TROY PA PO BOX 1254, TROY, MI 48099-1254 USA SN 0890-1171 EI 2168-6602 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD NOV-DEC PY 2013 VL 28 IS 2 BP E56 EP E66 DI 10.4278/ajhp.120727-QUAN-366 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 268UP UT WOS:000328196400008 PM 23621754 ER PT J AU Schlosser, RJ Soler, ZM AF Schlosser, Rodney J. Soler, Zachary M. TI Evidence-based treatment of chronic rhinosinusitis with nasal polyps SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article; Proceedings Paper CT North American Rhinology and Allergy Conference CY JAN 31-FEB 03, 2013 CL Fajardo, PR ID ENDOSCOPIC SINUS SURGERY; EXACERBATED RESPIRATORY-DISEASE; ASPIRIN DESENSITIZATION-TREATMENT; ALLERGIC FUNGAL RHINOSINUSITIS; RANDOMIZED CONTROLLED-TRIAL; MAXIMAL MEDICAL THERAPY; QUALITY-OF-LIFE; DOUBLE-BLIND; POSTOPERATIVE CARE; STEROID-THERAPY AB Background: Chronic rhinosinusitis with nasal polyps (CRSwNPs) is the most challenging form of CRS to treat. Clinical practices vary widely among physicians around the world, often with little evidence to support current therapies. Methods: This study evaluates various medical and surgical treatments with a focus on the highest levels of evidence. Recommendations for various therapies are provided based on consensus panels and evidence-based reviews. Results: Therapies with the strongest evidence and recommendations for CRSwNPs include oral steroids and topical nasal steroid sprays. There is also reasonable evidence for surgery, to include perioperative oral steroids and postoperative oral antibiotics for at least 2 weeks. There is little evidence to support other therapies, including commonly used modalities such as oral antibiotics, antihistamines, and immunotherapy. Conclusion: CRSwNPs is a heterogenous disorder that currently has very few therapies supported by strong evidence. It is likely that in the near future, a more refined understanding of CRSwNPs will permit clinicians to tailor therapies using high-level evidence with improved outcomes. C1 [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA. [Schlosser, Rodney J.; Soler, Zachary M.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. RP Schlosser, RJ (reprint author), 135 Rutledge Ave,Suite 1130,MSC 250550, Charleston, SC 29425 USA. EM schlossr@musc.edu NR 58 TC 8 Z9 8 U1 0 U2 6 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 EI 1945-8932 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD NOV-DEC PY 2013 VL 27 IS 6 BP 461 EP 466 DI 10.2500/ajra.2013.27.3982 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA 272HZ UT WOS:000328452400014 PM 24274220 ER PT J AU Auger, M Nayar, R Khalbuss, WE Barkan, GA Benedict, CC Tambouret, R Schwartz, MR Howell, LP Souers, RJ Hartley, DA Thomas, N Moriarty, AT AF Auger, Manon Nayar, Ritu Khalbuss, Walid E. Barkan, Gueliz A. Benedict, Cynthia C. Tambouret, Rosemary Schwartz, Mary R. Howell, Lydia P. Souers, Rhona J. Hartley, David A. Thomas, Nicole Moriarty, Ann T. TI Implementation of the Bethesda System for Reporting Thyroid Cytopathology Observations From the 2011 Thyroid Supplemental Questionnaire of the College of American Pathologists SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID FINE-NEEDLE-ASPIRATION; CYTOLOGIC DIAGNOSIS; SCIENCE CONFERENCE; NODULES; STATE; CELLS; RISK; FNA AB Context.-Although information about the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) has been widely disseminated since its inception in 2007, the extent of its implementation and impact on daily practice has not been formally evaluated. Objectives.-To assess the extent of uptake of TBSRTC across pathology laboratories and to evaluate its impact on daily practice by collating participant responses to the 2011 supplemental thyroid questionnaire of the College of American Pathologists. Design.-A questionnaire was designed to gather information about various aspects of TBSRTC and mailed in June 2011 to 2063 laboratories participating in the College of American Pathologists cytopathology interlaboratory comparison program. The participating laboratories' answers were collated and summarized. Results.-Seven hundred and seventy-seven laboratories (37.6%) returned the survey. Although 60.9% (n = 451) and 17.1% (n = 127) of laboratories reported using TBSRTC or planning to use it in the near future, respectively, 22% (n = 163) had no plans to implement TBSRTC. Of the latter, 32% (n = 70) stated that they were unaware of this classification system. The majority (78.3%, n = 343) of the laboratories used TBSRTC as published in the Thyroid Bethesda System atlas, whereas 21.7% (n = 95) used it with minor modifications. Most reported that the use of TBSRTC had caused either no change (n = 67, 15.2%) or only minor changes (n = 353, 80.2%) in the terminology and diagnostic criteria previously used in their laboratories. Conclusions.-According to the collected data, TBSRTC is generally well implemented in pathology laboratories. However, because approximately a third of those not using this terminology are not aware of it, additional educational efforts regarding TBSRTC are warranted. C1 [Auger, Manon] McGill Univ, Dept Pathol, Montreal, PQ H3A 2B4, Canada. [Auger, Manon] McGill Univ, Ctr Hlth, Montreal, PQ H3A 2B4, Canada. [Nayar, Ritu] Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA. [Nayar, Ritu] NW Mem Hosp, Chicago, IL 60611 USA. [Khalbuss, Walid E.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA. [Barkan, Gueliz A.] Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA. [Benedict, Cynthia C.] DCL Pathol LLC, Indianapolis, IN USA. [Tambouret, Rosemary] Harvard Univ, Dept Pathol, Boston, MA 02115 USA. [Tambouret, Rosemary] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Schwartz, Mary R.] Methodist Hosp, Dept Pathol & Genom Med, Houston, TX 77030 USA. [Howell, Lydia P.] Univ Calif, Dept Pathol, Sacramento, CA USA. [Howell, Lydia P.] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA. [Hartley, David A.; Thomas, Nicole] Coll Amer Pathologists, Northfield, IL USA. [Moriarty, Ann T.] AmeriPath Indiana, Esoter Testing, Indianapolis, IN USA. RP Auger, M (reprint author), McGill Univ, Dept Pathol, 3775 Univ St,Room 105, Montreal, PQ H3A 2B4, Canada. EM manon.auger@mcgill.ca NR 14 TC 4 Z9 4 U1 0 U2 0 PU COLL AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 EI 1543-2165 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD NOV PY 2013 VL 137 IS 11 BP 1555 EP 1559 DI 10.5858/arpa.2012-0658-CP PG 5 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 269SR UT WOS:000328262700007 PM 24168494 ER PT J AU Linskey, KR Gimbel, DC Zukerberg, LR Duncan, LM Sadow, PM Nazarian, RM AF Linskey, Katy R. Gimbel, Devon C. Zukerberg, Lawrence R. Duncan, Lyn M. Sadow, Peter M. Nazarian, Rosalynn M. TI BerEp4, Cytokeratin 14, and Cytokeratin 17 Immunohistochemical Staining Aid in Differentiation of Basaloid Squamous Cell Carcinoma From Basal Cell Carcinoma With Squamous Metaplasia SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID HUMAN-PAPILLOMAVIRUS; FOLLICULAR DIFFERENTIATION; BASOSQUAMOUS CARCINOMA; SKIN; HEAD; TRICHOBLASTOMA; RELIABILITY; EXPRESSION; DIAGNOSIS; BIOLOGY AB Context.-Basaloid squamous cell carcinoma (bSCC) is an uncommon variant of squamous cell carcinoma, which may overlap histologically with basal cell carcinoma with squamous metaplasia (BCCm). Objective.-To aid in the differentiation of these neoplasms using immunohistochemical staining because of the worse prognosis associated with bSCC. Design.-Using immunohistochemical techniques, we investigated BerEp4, cytokeratin 17 (CK17), and cytokeratin 14 (CK14) protein expression in 25 cases of bSCC (8 cutaneous [32%], 12 aerodigestive tract [48%], and 5 lymph nodemetastases [20%]) and 43 cases of BCCm(39 cutaneous [91%], and 4 metastases [9%]). An immunoreactivity score was assigned using the percentage of tumor cells staining and the pattern of expression. Interobserver agreement for 2 independent pathologists was assessed using a kappa coefficient. Results.-The mean percentage of staining was significantly higher in BCCm, compared with bSCC (BerEp4, P = .006; CK17, P < .001; CK14, P < . 001; unpaired t test), with 58% of BCCm cases (25 of 43) displaying diffuse staining for all markers, and nearly all (98%; 42 of 43) displaying diffuse staining for CK17 and CK14. In contrast, no bSCC cases (0%) displayed diffuse staining for all 3 markers, and only 8% (2 of 25) displayed diffuse staining for CK17 and CK14. High interobserver agreement was determined. Conclusions.-BerEp4 alone is unreliable for differentiation between BCCm and bSCC, and the addition of either CK14 or CK17 will augment the sensitivity and negative predictive value of BerEp4 staining in BCCm and bSCC diagnosis. C1 [Linskey, Katy R.; Gimbel, Devon C.; Zukerberg, Lawrence R.; Duncan, Lyn M.; Sadow, Peter M.; Nazarian, Rosalynn M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pathol Serv, Boston, MA USA. [Linskey, Katy R.; Gimbel, Devon C.; Duncan, Lyn M.; Nazarian, Rosalynn M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dermatopathol Unit, Boston, MA USA. RP Nazarian, RM (reprint author), Massachusetts Gen Hosp, Dermatopathol Unit, 55 Fruit St,Warren 829A, Boston, MA 02114 USA. EM rmnazarian@partners.org NR 41 TC 9 Z9 9 U1 1 U2 3 PU COLL AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 EI 1543-2165 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD NOV PY 2013 VL 137 IS 11 BP 1591 EP 1598 DI 10.5858/arpa.2012-0424-OA PG 8 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 269SR UT WOS:000328262700012 PM 24168496 ER PT J AU Dekker, J Duncan, LM AF Dekker, John Duncan, Lyn M. TI Lack of Standards for the Detection of Melanoma in Sentinel Lymph Nodes A Survey and Recommendations SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID CUTANEOUS MELANOMA; METASTATIC MELANOMA; MALIGNANT-MELANOMA; II MELANOMA; LESS-THAN-0.1 MM; STAGE-I; BIOPSY; MICROMETASTASES; RECURRENCE; PATHOLOGY AB Context.-Detection of microscopic melanoma metastases in sentinel lymph nodes drives clinical care; patients without metastases are observed, and patients with metastases are offered completion lymphadenectomy and adjuvant therapy. Objective.-We sought to determine common elements in currently used analytic platforms for sentinel lymph nodes in melanoma patients. Design.-An electronic survey was distributed to 83 cancer centers in North America. Results.-Seventeen responses (20%) were received. The number of sentinel lymph node mapping procedures for melanoma ranged from less than 11 to more than 100 patients per year, with 72% of institutions mapping more than 50 melanoma patients a year. Uniform practices included (1) processing all of the lymph node tissue rather than submitting representative sections and (2) use of immunohistochemical stains if no tumor was identified on the hematoxylin-eosin-stained sections. Significant variability existed regarding the method of sectioning lymph nodes at grossing and in the histology laboratory; most bisected nodes longitudinally (94%) and performed deeper levels into the block (67%), but these were not uniform practices. S-100 was the most commonly used immunohistochemical stain (78%), followed by Melan-A (56%), MART-1 (50%), HMB-45 (44%), tyrosinase (33%), MiTF (11%), and pan-melanoma (6%). Conclusions.-There is a need for a standardized platform for detecting melanoma in sentinel lymph nodes. Current practices by a majority of laboratories and findings in the reported literature support the following: histologic evaluation of all lymph node tissue, use of immunohistochemical stains, bisecting lymph nodes longitudinally, and performing deeper levels into the tissue block. C1 [Dekker, John; Duncan, Lyn M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. RP Duncan, LM (reprint author), Massachusetts Gen Hosp, MGH Dermatopathol Unit, WRN 825,55 Fruit St, Boston, MA 02114 USA. EM Duncan@helix.mgh.harvard.edu NR 33 TC 6 Z9 6 U1 0 U2 0 PU COLL AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 EI 1543-2165 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD NOV PY 2013 VL 137 IS 11 BP 1603 EP 1609 DI 10.5858/arpa.2012-0550-OA PG 7 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 269SR UT WOS:000328262700014 PM 24168497 ER PT J AU Kraft, S Antonescu, CR Rosenberg, AE Deschler, DG Nielsen, GP AF Kraft, Stefan Antonescu, Cristina R. Rosenberg, Andrew E. Deschler, Daniel G. Nielsen, G. Petur TI Primary Clear Cell Sarcoma of the Tongue SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID OSTEOCLAST-RICH TUMOR; SOFT PARTS; MALIGNANT-MELANOMA; GASTROINTESTINAL-TRACT; MOLECULAR ANALYSIS; TENDONS; APONEUROSES; FUSION; ABSENCE; GENE AB Clear cell sarcoma shares features with melanoma, but frequently shows EWSR1 rearrangements. It is an aggressive tumor typically occurring in the soft tissues of the extremities, with a gastrointestinal variant with less consistent melanocytic differentiation. It is extremely rare in the head and neck region, with no reported cases in the oral cavity. We report a case of an 82-year-old woman with a clear cell sarcoma arising in the tongue, with cervical lymph node metastases. Histologically, the tumor showed some features of gastrointestinal clear cell sarcoma. No osteoclast-type giant cells were present. The tumor cells were positive for S100 protein and negative for other melanocytic markers. Fluorescence in situ hybridization showed rearrangements of EWSR1 and ATF1. This case expands the spectrum of clear cell sarcoma with a gastrointestinal-like variant in a novel site, emphasizing the need to consider it as a differential diagnosis to melanoma in mucosal sites. C1 [Kraft, Stefan; Rosenberg, Andrew E.; Nielsen, G. Petur] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Kraft, Stefan; Rosenberg, Andrew E.; Deschler, Daniel G.; Nielsen, G. Petur] Harvard Univ, Sch Med, Boston, MA USA. [Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA. [Deschler, Daniel G.] Massachusetts Eye & Ear Infirm, Div Head & Neck Surg, Boston, MA 02114 USA. RP Nielsen, GP (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Francis St, Boston, MA 02114 USA. EM gnielsen@partners.org NR 16 TC 5 Z9 5 U1 0 U2 1 PU COLL AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 EI 1543-2165 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD NOV PY 2013 VL 137 IS 11 BP 1680 EP 1683 DI 10.5858/arpa.2012-0467-CR PG 4 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 269SR UT WOS:000328262700027 PM 24168510 ER PT J AU Olsen, RHJ Allen, CN Derkach, VA Phillips, TJ Belknap, JK Raber, J AF Olsen, Reid H. J. Allen, Charles N. Derkach, Victor A. Phillips, Tamara J. Belknap, John K. Raber, Jacob TI Impaired memory and reduced sensitivity to the circadian period lengthening effects of methamphetamine in mice selected for high methamphetamine consumption SO BEHAVIOURAL BRAIN RESEARCH LA English DT Article DE Circadian; Water maze; Methamphetamine; Glutamate receptors; GluA1/2; Spatial memory ID AMPA RECEPTOR SUBUNITS; SUPRACHIASMATIC NUCLEUS; DRUG-ADDICTION; ENHANCED LTP; MUTANT MICE; GLUTAMATE; MECHANISMS; RHYTHMS; GLUR2; VULNERABILITY AB Drug abuse runs in families suggesting the involvement of genetic risk factors. Differences in addiction-related neurobiological systems, including learning and memory and circadian rhythms, may exist prior to developing addiction. We characterized the cognitive phenotypes and the free-running circadian period of mouse lines selectively bred for high methamphetamine (MA) drinking (MA high drinking or MAHDR) and low MA drinking (MA low drinking or MALDR). MA-naive MALDR mice showed spatial memory retention while MAHDR mice did not. MA-naive MAHDR mice had elevated hippocampal levels of the AMPA receptor subunits GluA2 (old terminology: GluR2), but not GluA1 (old terminology: GluR1). There were no line differences in the free running period (tau) when only water was available. During a 25 mg/L MA solution access period (vs water), there was an increase in tau in MALDR but not MAHDR mice, although MAHDR mice consumed significantly more MA. During a 50 mg/L MA solution access period (vs water), both lines showed an increased tau. There was a positive correlation between MA consumption and tau from baseline in MALDR, but not MAHDR, mice. Thus, a heritable proclivity for elevated MA self-administration may be associated with impairments in hippocampus-dependent memory and reduced sensitivity to effects of MA on lengthening of the circadian period. (C) 2013 Elsevier B.V. All rights reserved. C1 [Olsen, Reid H. J.; Allen, Charles N.; Phillips, Tamara J.; Belknap, John K.; Raber, Jacob] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Allen, Charles N.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97239 USA. [Derkach, Victor A.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA. [Phillips, Tamara J.; Belknap, John K.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA. [Phillips, Tamara J.; Belknap, John K.; Raber, Jacob] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97239 USA. [Raber, Jacob] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Raber, Jacob] Oregon Hlth & Sci Univ, Div Neurosci ONPRC, Portland, OR 97239 USA. RP Raber, J (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, 8131 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM raberj@ohsu.edu FU Department of Veterans Affairs [NS036607, P50 DA018165] FX This work was supported by NS036607, P50 DA018165, the Department of Veterans Affairs, and the development account of Dr Raber. We thank Nathan Rogers for the graphical art. NR 42 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-4328 EI 1872-7549 J9 BEHAV BRAIN RES JI Behav. Brain Res. PD NOV 1 PY 2013 VL 256 BP 197 EP 204 DI 10.1016/j.bbr.2013.08.015 PG 8 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 267JO UT WOS:000328094100024 PM 23954232 ER PT J AU Stidd, DA Vogelsang, K Krahl, SE Langevin, JP Fellous, JM AF Stidd, David A. Vogelsang, Kimberly Krahl, Scott E. Langevin, Jean-Philippe Fellous, Jean-Marc TI Amygdala Deep Brain Stimulation Is Superior to Paroxetine Treatment in a Rat Model of Posttraumatic Stress Disorder SO BRAIN STIMULATION LA English DT Article DE Amygdala; Deep brain stimulation; Paroxetine; Posttraumatic stress disorder; Psychosurgery ID MEDIAL PREFRONTAL CORTEX; ELEVATED PLUS-MAZE; BLOOD-FLOW; PTSD; ANXIETY; VETERANS; PLACEBO; SERTRALINE; SEROTONIN; BEHAVIOR AB Background: Posttraumatic stress disorder (PTSD) is a very debilitating disease refractory to current treatment with selective serotonin reuptake inhibitors (SSRIs) in up to 30 percent of patients, illustrating the need for new treatments of PTSD. Neuroimaging studies have shown increased activity of the amygdala of patients with PTSD. Objective/hypothesis: To investigate amygdala deep brain stimulation (DBS) as a possible novel treatment for PTSD and compare it to current treatment with a commonly used SSRI, paroxetine, in a rat PTSD model. Methods: A PTSD model was created by subjecting rats to inescapable foot shocks in the presence of a conspicuous ball. Response to treatment was measured as a decreased burying behavior when presented with the same ball 1 and 2 weeks after the shocks. Rats were treated with either daily intraperitoneal paroxetine injections or amygdala DBS via an electrode implanted 1 week prior to shocks. Generalized anxiety was assessed using an elevated plus maze. Results: Animals treated with amygdala DBS showed less ball burying at 2 weeks relative to the animals treated with paroxetine. The animals treated with paroxetine, however, had a lower general anxiety level compared to the DBS-treated group. Conclusions: In this PTSD model, paroxetine was found to decrease the measured general anxiety level of rats that underwent the PTSD protocol, but did not counteract shock-induced hyper-vigilance toward the trauma-associated object (ball). Amygdala DBS, however, did decrease shock-induced hyper-vigilance as measured by a lower burying time, but had no effect on general anxiety assessed in the elevated plus maze. By attenuating amygdala function, DBS may act to treat the cause of PTSD, hyperactive amygdala function, and may be a promising novel alternative in cases of PTSD refractory to current pharmacological treatments. Published by Elsevier Inc. C1 [Stidd, David A.] Univ Arizona, Div Neurosurg, Tucson, AZ 85724 USA. [Vogelsang, Kimberly] Univ Arizona, Dept Physiol, Tucson, AZ 85724 USA. [Krahl, Scott E.; Langevin, Jean-Philippe] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Krahl, Scott E.; Langevin, Jean-Philippe] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA. [Fellous, Jean-Marc] Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA. [Fellous, Jean-Marc] Univ Arizona, Program Appl Math, Tucson, AZ 85721 USA. RP Langevin, JP (reprint author), VA Greater Los Angeles Healthcare Syst Surg & Per, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Jean-Philippe.Langevin@va.gov FU National Science Foundation/National Institutes of Health [CRCNS-IIS-1010172]; Department of Surgery, University of Arizona; VISN 18 New Investigator Award, Department of Veterans Affairs FX Financial disclosures: This work was supported by the National Science Foundation/National Institutes of Health grant CRCNS-IIS-1010172; a grant from the Department of Surgery, University of Arizona; and a VISN 18 New Investigator Award, Department of Veterans Affairs. NR 34 TC 13 Z9 14 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD NOV PY 2013 VL 6 IS 6 BP 837 EP 844 DI 10.1016/j.brs.2013.05.008 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 264VH UT WOS:000327908600002 PM 23835167 ER PT J AU Krieg, TD Salinas, FS Narayana, S Fox, PT Mogul, DJ AF Krieg, Todd D. Salinas, Felipe. S. Narayana, Shalini Fox, Peter T. Mogul, David J. TI PET-Based Confirmation of Orientation Sensitivity of TMS-Induced Cortical Activation in Humans SO BRAIN STIMULATION LA English DT Article DE TMS; Cortex; PET; MRI; Orientation; Cerebral blood flow ID TRANSCRANIAL MAGNETIC STIMULATION; HUMAN MOTOR CORTEX; DORSOLATERAL PREFRONTAL CORTEX; SURFACE-BASED ANALYSIS; ELECTRIC-FIELD; BRAIN-STIMULATION; MECHANISMS; EXCITABILITY; MODULATION; EXCITATION AB Background: Currently, it is difficult to predict precise regions of cortical activation in response to transcranial magnetic stimulation (TMS). Most analytical approaches focus on applied magnetic field strength in the target region as the primary factor, placing activation on the gyral crowns. However, imaging studies support M1 targets being typically located in the sulcal banks. Objective/hypothesis: To more thoroughly investigate this inconsistency, we sought to determine whether neocortical surface orientation was a critical determinant of regional activation. Methods: MR images were used to construct cortical and scalp surfaces for 18 subjects. The angle (theta) between the cortical surface normal and its nearest scalp normal for similar to 50,000 cortical points per subject was used to quantify cortical location (i.e., gyral vs. sulcal). TMS-induced activations of primary motor cortex (M1) were compared to brain activations recorded during a finger-tapping task using concurrent positron emission tomographic (PET) imaging. Results: Brain activations were primarily sulcal for both the TMS and task activations (P < 0.001 for both) compared to the overall cortical surface orientation. Also, the location of maximal blood flow in response to either TMS or finger-tapping correlated well using the cortical surface orientation angle or distance to scalp (P < 0.001 for both) as criteria for comparison between different neocortical activation modalities. Conclusion: This study provides further evidence that a major factor in cortical activation using TMS is the orientation of the cortical surface with respect to the induced electric field. The results show that, despite the gyral crown of the cortex being subjected to a larger magnetic field magnitude, the sulcal bank of M1 had larger cerebral blood flow (CBF) responses during TMS. (C) 2013 Elsevier Inc. All rights reserved. C1 [Krieg, Todd D.; Mogul, David J.] IIT, Dept Biomed Engn, Chicago, IL 60616 USA. [Salinas, Felipe. S.; Narayana, Shalini; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Narayana, Shalini] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Mogul, DJ (reprint author), IIT, Dept Biomed Engn, Wishnick Hall 314,3255 S Dearborn St, Chicago, IL 60616 USA. EM mogul@iit.edu RI Fox, Peter/B-4725-2010 OI Fox, Peter/0000-0002-0465-2028 FU Achievement Rewards for College Scientists (ARCS) Chicago chapter; Ruth L. Kirschstein National Research Service Award from the National Institute of Neurological Disorders and Stroke [NIH/NINDS F32 NS066694]; Veterans Administration Merit Award FX Partial support for this work was provided by Achievement Rewards for College Scientists (ARCS) Chicago chapter (to TDK), the Ruth L. Kirschstein National Research Service Award from the National Institute of Neurological Disorders and Stroke (NIH/NINDS F32 NS066694 to FSS), and the Veterans Administration Merit Award (to PTF). NR 57 TC 6 Z9 6 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD NOV PY 2013 VL 6 IS 6 BP 898 EP 904 DI 10.1016/j.brs.2013.05.007 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 264VH UT WOS:000327908600010 PM 23827648 ER PT J AU Borckardt, JJ Nahas, ZH Teal, J Lisanby, SH McDonald, WM Avery, D Durkalski, V Pavlicova, M Long, JM Sackeim, HA George, MS AF Borckardt, Jeffrey J. Nahas, Ziad H. Teal, John Lisanby, Sarah H. McDonald, William M. Avery, David Durkalski, Valerie Pavlicova, Martina Long, James M. Sackeim, Harold A. George, Mark S. TI The Painfulness of Active, but not Sham, Transcranial Magnetic Stimulation Decreases Rapidly Over Time: Results From the Double-Blind Phase of the OPT-TMS Trial SO BRAIN STIMULATION LA English DT Article DE TMS; Transcranial magnetic stimulation; Pain; Depression; OPT-TMS; Clinical trial; Sham ID PREFRONTAL CORTEX; PAIN; DEPRESSION; MOOD; RTMS; THERAPY AB Background: Daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) over several weeks is an FDA approved treatment for major depression. Although rTMS is generally safe when administered using the FDA guidelines, there are a number of side effects that can make it difficult for patients to complete a course of rTMS. Many patients report that rTMS is painful, although patients appear to accommodate to the initial painfulness. The reduction in pain is hypothesized to be due to prefrontal stimulation and is not solely explained by accommodation to the stimulation. Methods: In a recent 4 site randomized controlled trial (using an active electrical sham stimulation system) investigating the antidepressant effects of daily left dorsolateral prefrontal rTMS (Optimization of TMS, or OPT-TMS), the procedural painfulness of TMS was assessed before and after each treatment session. Computerized visual analog scale ratings were gathered before and after each TMS session in the OPT-TMS trial. Stimulation was delivered with an iron core figure-8 coil (Neuronetics) with the following parameters: 10 Hz, 120% MT (EMG-defined), 4 s pulse train, 26 s inter-train interval, 3000 pulses per session, one 37.5 min session per day. After each session, procedural pain (pain at the beginning of the TMS session, pain toward the middle, and pain toward then end of the session) ratings were collected at all 4 sites. From the 199 patients randomized, we had usable data from 142 subjects for the initial 15 TMS sessions (double-blind phase) delivered over 3 weeks (142 x 2 x 15 = 4260 rating sessions). Results: The painfulness of real TMS was initially higher than that of the active sham condition. Over the 15 treatment sessions, subjective reports of the painfulness of rTMS (during the beginning, middle and end of the session) decreased significantly 37% from baseline in those receiving active TMS, with no change in painfulness in those receiving sham. This reduction, although greatest in the first few days, continued steadily over the 3 weeks. Overall, there was a decay rate of 1.56 VAS points per session in subjective painfulness of the procedure in those receiving active TMS. Discussion: The procedural pain of left, prefrontal rTMS decreases over time, independently of other emotional changes, and only in those receiving active TMS. These data suggest that actual TMS stimulation of prefrontal cortex maybe related to the reduction in pain, and that it is not a non-specific accommodation to pain. This painfulness reduction softly corresponds with later clinical outcome. Further work is needed to better understand this phenomenon and whether acute within-session or over time painfulness changes might be used as short-term biomarkers of antidepressant response. (C) 2013 Elsevier Inc. All rights reserved. C1 [Borckardt, Jeffrey J.; Nahas, Ziad H.; Teal, John; George, Mark S.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29482 USA. [Borckardt, Jeffrey J.] Med Univ S Carolina, Dept Anesthesia & Perioperat Med, Charleston, SC 29482 USA. [Nahas, Ziad H.] Amer Univ Beirut, Dept Psychiat, Beirut, Lebanon. [Lisanby, Sarah H.] Duke Univ, Brain Stimulat & Neurophysiol Div, Dept Psychiat & Behav Sci, Durham, NC USA. [McDonald, William M.] Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA. [Avery, David] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Durkalski, Valerie] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29482 USA. [Pavlicova, Martina] Columbia Univ, Biostat Dept, New York, NY USA. [Long, James M.] James Long Co, Caroga Lake, NY USA. [Sackeim, Harold A.] Columbia Univ, Dept Psychiat, New York, NY USA. [Sackeim, Harold A.] Columbia Univ, Dept Radiol, New York, NY USA. [George, Mark S.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Borckardt, JJ (reprint author), Med Univ S Carolina, Brain Stimulat Lab BSL, Dept Psychiat & Behav Sci, 502 N IOP,67 President St, Charleston, SC 29482 USA. EM borckard@musc.edu FU NIMH [5R01MH069929, 5R01MH069887, 5R01MH069896, 5R01MH069895, 5R01MH069886] FX Supported by the NIMH as the Optimization of TMS for Depression Trial, (OPT-TMS) involving grants 5R01MH069929 PI: Avery, David, 5R01MH069887 PI: George, Mark, 5R01MH069896 PI: George, Mark, 5R01MH069895 PI: Lisanby, Sarah, 5R01MH069886 PI: McDonald, William. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. NR 16 TC 7 Z9 7 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD NOV PY 2013 VL 6 IS 6 BP 925 EP 928 DI 10.1016/j.brs.2013.04.009 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 264VH UT WOS:000327908600014 PM 23769413 ER PT J AU Shin, JY He, M Liu, YF Paredes, S Villanova, L Brown, K Qiu, XL Nabavi, N Mohrin, M Wojnoonski, K Li, P Cheng, HL Murphy, AJ Valenzuela, DM Luo, HZ Kapahi, P Krauss, R Mostoslavsky, R Yancopoulos, GD Alt, FW Chua, KF Chen, D AF Shin, Jiyung He, Ming Liu, Yufei Paredes, Silvana Villanova, Lidia Brown, Katharine Qiu, Xiaolei Nabavi, Noushin Mohrin, Mary Wojnoonski, Kathleen Li, Patrick Cheng, Hwei-Ling Murphy, Andrew J. Valenzuela, David M. Luo, Hanzhi Kapahi, Pankaj Krauss, Ronald Mostoslavsky, Raul Yancopoulos, George D. Alt, Frederick W. Chua, Katrin F. Chen, Danica TI SIRT7 Represses Myc Activity to Suppress ER Stress and Prevent Fatty Liver Disease SO CELL REPORTS LA English DT Article ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; HEPATIC STEATOSIS; C-MYC; METABOLIC DISEASE; LIPID HOMEOSTASIS; LIFE-SPAN; EXPRESSION; MICE; SIRTUINS AB Nonalcoholic fatty liver disease is the most common chronic liver disorder in developed countries. Its pathogenesis is poorly understood, and therapeutic options are limited. Here, we show that SIRT7, an NAD(+)-dependent H3K18Ac deacetylase, functions at chromatin to suppress ER stress and prevent the development of fatty liver disease. SIRT7 is induced upon ER stress and is stabilized at the promoters of ribosomal proteins through its interaction with the transcription factor Myc to silence gene expression and to relieve ER stress. SIRT7-deficient mice develop chronic hepatosteatosis resembling human fatty liver disease. Myc inactivation or pharmacological suppression of ER stress alleviates fatty liver caused by SIRT7 deficiency. Importantly, SIRT7 suppresses ER stress and reverts the fatty liver disease in diet-induced obese mice. Our study identifies SIRT7 as a cofactor of Myc for transcriptional repression and delineates a druggable regulatory branch of the ER stress response that prevents and reverts fatty liver disease. C1 [Shin, Jiyung; He, Ming; Brown, Katharine; Qiu, Xiaolei; Nabavi, Noushin; Mohrin, Mary; Luo, Hanzhi; Chen, Danica] Univ Calif Berkeley, Program Metab Biol Nutr Sci & Toxicol, Berkeley, CA 94720 USA. [He, Ming] Shanghai Jiao Tong Univ, Key Lab Cell Differentiat & Apoptosis, Minist Educ, Dept Pathophysiol,Sch Med, Shanghai 200025, Peoples R China. [Liu, Yufei] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA. [Paredes, Silvana; Villanova, Lidia; Chua, Katrin F.] Stanford Univ, Dept Med, Sch Med, Div Endocrinol Gerontol & Metab, Stanford, CA 94305 USA. [Paredes, Silvana; Villanova, Lidia; Chua, Katrin F.] VA Palo Alto Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Palo Alto, CA 94304 USA. [Villanova, Lidia] Univ Roma La Sapienza, Dept Expt Med, I-00161 Rome, Italy. [Wojnoonski, Kathleen; Krauss, Ronald] Childrens Hosp Oakland Res Inst, Dept Atherosclerosis Res, Oakland, CA 94609 USA. [Li, Patrick; Kapahi, Pankaj] Buck Inst Res Aging, Novato, CA 94945 USA. [Cheng, Hwei-Ling; Alt, Frederick W.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,CBR Inst Biomed Res, Boston, MA 02115 USA. [Cheng, Hwei-Ling; Alt, Frederick W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Murphy, Andrew J.; Valenzuela, David M.; Yancopoulos, George D.] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA. [Mostoslavsky, Raul] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. RP Alt, FW (reprint author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,CBR Inst Biomed Res, Boston, MA 02115 USA. EM alt@enders.tch.harvard.edu; kfchua@stanford.edu; danicac@berkeley.edu RI Villanova, Lidia/J-8273-2016; OI Villanova, Lidia/0000-0001-8668-9854; Murphy, Andrew/0000-0003-4152-4081 FU National Institutes of Health [R01AG040990, R01AG028867, 3T32DK007217-36S1, T32 AG000266]; Searle Scholars Program; Ellison Medical Foundation; Glenn Foundation; American Heart Association; UCOP TRDRP; Hellman Family Faculty Fund; National Science Foundation; Siebel Stem Cell Institute; Department of Veterans Affairs; Italian Foundation for Cancer Research; Associazione Italiana per la Ricerca sul Cancro FX We thank the Kay lab for reagents. This work was support by grants from the National Institutes of Health (R01AG040990 [to D.C.], R01AG028867 [to K.F.C.], training grant 3T32DK007217-36S1 [to S.P.], training grant T32 AG000266 [to M.M.]), the Searle Scholars Program (to D.C.), the Ellison Medical Foundation (to D.C. and K.F.C.), The Glenn Foundation (to D.C.), the American Heart Association (to D.C.), UCOP TRDRP (to D.C.), the Hellman Family Faculty Fund (D.C.), the National Science Foundation (to J.S.), the Siebel Stem Cell Institute (to D.C., M.M., N.N., and X.Q.), the Department of Veterans Affairs (to K.F.C., Merit Award), and the Italian Foundation for Cancer Research (to L.V.). F.A. is an Investigator of the Howard Hughes Medical Institute. A.J.M., D.M.V., and G.D.Y. are employees and shareholders of Regeneron Pharmaceuticals. NR 52 TC 57 Z9 59 U1 1 U2 8 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 2211-1247 J9 CELL REP JI Cell Reports PD NOV PY 2013 VL 5 IS 3 BP 654 EP 665 DI 10.1016/j.celrep.2013.10.007 PG 12 WC Cell Biology SC Cell Biology GA 269SY UT WOS:000328263400012 PM 24210820 ER PT J AU Kwon, CS Sheth, SA Walcott, BP Neal, J Eskandar, EN Ogilvy, CS AF Kwon, Churl-Su Sheth, Sameer A. Walcott, Brian P. Neal, Jonathan Eskandar, Emad N. Ogilvy, Christopher S. TI Long-term seizure outcomes following resection of supratentorial cavernous malformations SO CLINICAL NEUROLOGY AND NEUROSURGERY LA English DT Article DE Seizure; Cavernous malformation; Surgery; Epilepsy; Multivariate analysis ID NATURAL-HISTORY; EPILEPSY SURGERY; TUBEROUS SCLEROSIS; CLINICAL ARTICLE; NERVOUS-SYSTEM; ANGIOMAS; CHILDREN; SERIES; LESIONECTOMY; HEMANGIOMAS AB Objective: Symptomatic supratentorial cavernous malformations may present with seizure, headache, neurological deficit, or a combination thereof. Factors that contribute to treatment algorithms commonly include patient age, lesion size and location, lesion multiplicity, hemorrhage history, and the ability to control seizure activity with medication. A better appreciation of the impact of patient and lesion characteristics on post-operative seizure control may provide insight into management strategies. To determine long-term seizure outcomes following surgical resection of supratentorial cavernous malformations, the predictive value of characteristics including seizure duration and number, presence of generalized seizures, and lesion multiplicity and size on seizure control rate was evaluated. Methods: We performed a single institution retrospective review of consecutive patients with supratentorial cavernous malformations presenting with at least one seizure between 1995 and 2008. Univariate and multivariate analyses were used to determine the influence of patient and lesion characteristics on postoperative seizure control. Results: Fifty-six patients met inclusion criteria. Mean follow-up duration was 87.9 months. At last follow-up there were 46 patients (82.1%) that were free from impairing seizures (Engel Class 1). Ten patients (17.9%) were classified as Engel Class 2-4. Univariate analysis demonstrated that only the presence of multiple cavernomas was associated with worse post-operative seizure outcome (p = 0.006). Multivariate analysis demonstrated that multiple cavernomas remained a significant predictor for development of worse seizure outcome controlling for number and duration of seizures prior to operation, presence of generalized tonic-clonic seizures, and size (odds ratio, 0.17; 95% confidence interval, 0.03, 0.99). Conclusion: Resection of supratentorial cavernomas is associated with a high rate of postoperative seizure freedom. The presence of multiple cavernomas is predictive of seizure persistence following surgery. Published by Elsevier B.V. C1 Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Kwon, CS (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM churlsu.kwon@gmail.com NR 48 TC 7 Z9 7 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0303-8467 EI 1872-6968 J9 CLIN NEUROL NEUROSUR JI Clin. Neurol. Neurosurg. PD NOV PY 2013 VL 115 IS 11 BP 2377 EP 2381 DI 10.1016/j.clineuro.2013.08.024 PG 5 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 264TX UT WOS:000327905000013 PM 24075713 ER PT J AU Boockvar, K AF Boockvar, Kenneth TI Pain Therapeutics in Older Adults SO CLINICAL THERAPEUTICS LA English DT Editorial Material ID KNEE OSTEOARTHRITIS; MANAGEMENT; IMPACT; EFFICACY; MEDICATION; FRACTURES; MODERATE; FALLS; LIFE; CARE C1 [Boockvar, Kenneth] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Boockvar, Kenneth] Jewish Home Lifecare, Res Inst Aging, New York, NY USA. [Boockvar, Kenneth] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. RP Boockvar, K (reprint author), James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. OI Boockvar, Kenneth/0000-0003-1165-5558 NR 29 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD NOV PY 2013 VL 35 IS 11 BP 1656 EP 1658 DI 10.1016/j.clinthera.2013.09.024 PG 3 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 267LF UT WOS:000328098500002 PM 24139094 ER PT J AU Weiner, DK Moore, CG Morone, NE Lee, ES Kwoh, CK AF Weiner, Debra K. Moore, Charity G. Morone, Natalia E. Lee, Edward S. Kwoh, C. Kent TI Efficacy of Periosteal Stimulation for Chronic Pain Associated With Advanced Knee Osteoarthritis: A Randomized, Controlled Clinical Trial SO CLINICAL THERAPEUTICS LA English DT Article DE acupuncture; chronic pain; knee osteoarthritis; older adults; periosteal stimulation ID HEALTH SURVEY SF-36; PHYSICAL PERFORMANCE BATTERY; WESTERN-ONTARIO-UNIVERSITY; LOWER-EXTREMITY FUNCTION; ILLNESS RATING-SCALE; SELF-EFFICACY; ACUPUNCTURE ANALGESIA; CRITICAL-APPRAISAL; PLACEBO ANALGESIA; OLDER-ADULTS AB Background: Because of morbidity associated with painful knee osteoarthritis (OA) and commonly prescribed analgesics, patients often pursue complementary and alternative modalities (eg, acupuncture). Clinical trials have demonstrated modest therapeutic efficacy of traditional Chinese acupuncture for knee OA pain, and patients with advanced disease have largely been excluded. We have previously demonstrated preliminary short-term tolerability and efficacy of periosteal stimulation therapy (PST) (ie, electrical stimulation of the periosteum facilitated by acupuncture needles) for older adults with advanced knee OA. Objective: This study evaluated the sustained efficacy of PST and boosters for treating chronic pain with advanced knee OA. Methods: One hundred ninety participants age >50 years with Kellgren-Lawrence grade 3 or 4 knee OA and chronic pain were randomized to (1) PST (once a week for 10 weeks) followed by PST boosters for 6 months (once every 2 weeks 2 times, then once a month), (2) control PST (ie, periosteal needles and brief electrical stimulation of control points) once a week for 10 weeks, or (3) PST for 10 weeks followed by control PST boosters for 6 months. Change in the Western Ontario and McMaster Universities Osteoarthritis Index pain score immediately after the 10-week intervention and at 6-month follow-up (9 months after baseline) was the primary outcome. OMERACT-OARSI (Outcome Measures in Rheumatology Clinical Trials Osteoarthritis Research Society International) criteria also were evaluated. Secondary measures of outcome included (1) physical performance (Short Physical Performance Battery, gait speed, Timed Up and Go, and timed stair climb); (2) psychological factors (depressive symptoms measured with the Center for Epidemiologic Studies Depression scale, coping measured with the catastrophizing subscale of the Coping Strategies Questionnaire, and self-efficacy measured with the Arthritis Self-Efficacy Scale); (3) health-related quality of life measured with the Medical Outcomes Study 36-Item Short-Form Health Survey; (4) rescue pain medication use tracked with diaries; and (5) health care utilization and interim physical activity were monitored via monthly telephone calls. Results: After adjustment for pain at baseline, the PST and control booster did not differ from controls at 10 weeks (difference, 1.3; 95% CI, -0.10 to 2.8; P = 0.0683) or 9 months (difference, 1.1; 95% CI, -0.32 to 2.6; P = 0.13). The PST and PST booster group had similar improvement compared with controls at 10 weeks (baseline adjusted difference, 1.1; 95% CI, -0.34 to 2.5; P = 0.1369) but significantly more improvement at 9 months (baseline adjusted difference, 1.5; 95% CI, 0.069 to 3.0; P = 0.0401). Baseline depressive symptoms, low self-efficacy, higher difficulty performing daily activities, and greater knee stiffness predicted a lower likelihood of response. Conclusion: PST plus PST boosters in patients age >50 with advanced knee OA were well-tolerated and modestly reduced pain. Published by Elsevier HS Journals, Inc. C1 [Weiner, Debra K.; Morone, Natalia E.] Vet Adm Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Lee, Edward S.] Vet Adm Pittsburgh Healthcare Syst, Primary Care Serv Line, Pittsburgh, PA USA. [Weiner, Debra K.; Moore, Charity G.; Morone, Natalia E.; Lee, Edward S.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Weiner, Debra K.; Moore, Charity G.; Morone, Natalia E.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Kwoh, C. Kent] Univ Arizona, Div Rheumatol & Clin Immunol, Tucson, AZ USA. [Kwoh, C. Kent] Univ Arizona, Arthrit Ctr, Tucson, AZ USA. RP Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C, Pittsburgh, PA 15240 USA. EM debra.weiner@va.gov OI Moore, Charity/0000-0002-0060-0124 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. The contents of this report do not represent the views of the Department of Veterans Affairs or the US government. The authors thank David Mortell, LAc, for his participation in the intervention portion of the study; Ms. Kimberly Hayes, Ms. Lisa Gaston, Mr. Wilbert Schrader, Mr. Jonathan Squeglia, and Ms. Catherine Harris for their assistance with preparation of regulatory documents and data collection; Ms. Diane Comer for her assistance with data analysis; and Ms. Terry Sefcik for her assistance with data management and processing. NR 86 TC 8 Z9 9 U1 3 U2 15 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD NOV PY 2013 VL 35 IS 11 BP 1703 EP 1720 DI 10.1016/j.clinthera.2013.09.025 PG 18 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 267LF UT WOS:000328098500006 PM 24184053 ER PT J AU Morone, NE Weiner, DK AF Morone, Natalia E. Weiner, Debra K. TI Pain as the Fifth Vital Sign: Exposing the Vital Need for Pain Education SO CLINICAL THERAPEUTICS LA English DT Editorial Material ID LOW-BACK-PAIN; OLDER-ADULTS; UNITED-STATES; COMPLICATIONS; PROGRAMS; FRACTURE; SURGERY; RISK C1 [Morone, Natalia E.; Weiner, Debra K.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Morone, Natalia E.] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Div Gen Internal Med, Pittsburgh, PA USA. [Morone, Natalia E.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Div Geriatr, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA USA. RP Morone, NE (reprint author), 7180 Highland Dr,Mail Code 00GR H, Pittsburgh, PA 15206 USA. EM Natalia.Morone@va.gov FU NIA NIH HHS [R01 AG034078]; NIAID NIH HHS [HHSN271201100111U]; PHS HHS [HHSN271201100111U] NR 24 TC 12 Z9 15 U1 1 U2 5 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD NOV PY 2013 VL 35 IS 11 BP 1728 EP 1732 DI 10.1016/j.clinthera.2013.10.001 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 267LF UT WOS:000328098500008 PM 24145043 ER PT J AU Smith, KW Souter, I Dimitriadis, I Ehrlich, S Williams, PL Calafat, AM Hauser, R AF Smith, Kristen W. Souter, Irene Dimitriadis, Irene Ehrlich, Shelley Williams, Paige L. Calafat, Antonia M. Hauser, Russ TI Urinary Paraben Concentrations and Ovarian Aging among Women from a Fertility Center SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID IN-VITRO FERTILIZATION; ESTROGENIC ACTIVITY; REPRODUCTIVE DISORDERS; HUMAN HEALTH; PREGNANCY; EXPOSURE; RESERVE; HUMANS; PRESERVATIVES; EXPRESSION AB BACKGROUND: Parabens are preservatives commonly used in personal care products, pharmaceuticals, and foods. There is documented widespread human exposure to parabens, and some experimental data suggest that they act as estrogenic endocrine disruptors. As far as we are aware, no epidemiologic studies have assessed female reproductive health effects in relation to paraben exposure. OBJECTIVE: We examined the association of urinary paraben concentrations with markers of ovarian reserve in a prospective cohort study of women seeking fertility treatment at Massachusetts General Hospital, Boston, Massachusetts. METHODS: Measures of ovarian reserve were day-3 follicle-stimulating hormone (FSH), antral follicle count (AFC), and ovarian volume. Paraben concentrations [methyl-paraben (MP), propylparaben (PP), and butyl-paraben (BP)] were measured in spot urine samples collected prior to the assessment of outcome measures. We used linear and Poisson regression models to estimate associations of urinary paraben concentrations (in tertiles) with ovarian reserve measures. RESULTS: Of the women enrolled in 2004-2010, 192 had at least one ovarian reserve outcome measured (mean age +/- SD, 36.1 +/- 4.5 years; range, 21.0-46.7 years). MP and PP were detected in > 99% of urine samples and BP in > 75%. We found a suggestive trend of lower AFC with increasing urinary PP tertiles [mean percent change (95% CI) for tertiles 2 and 3 compared with tertile 1, respectively, were -5.0% (-23.7, 18.4) and -16.3% (-30.8, 1.3); trend p-value (p(trend)) = 0.07] as well as higher day-3 FSH with higher urinary PP tertiles [mean change (95% CI) for tertiles 2 and 3 compared with tertile 1 were 1.16 IU/L (-0.26, 2.57) and 1.02 IU/L (-0.40, 2.43); p(trend) = 0.16]. We found no consistent evidence of associations between urinary MP or BP and day-3 FSH or AFC, or between urinary MP, PP, or BP and ovarian volume. CONCLUSIONS: PP may be associated with diminished ovarian reserve. However, our results require confirmation in further studies. C1 [Smith, Kristen W.; Dimitriadis, Irene; Ehrlich, Shelley; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Souter, Irene; Dimitriadis, Irene; Hauser, Russ] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Obstet & Gynecol,Fertil Ctr,Div Reprod Endoc, Boston, MA USA. [Williams, Paige L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Hauser, R (reprint author), 665 Huntington Ave,Bldg 1,14th Floor, Boston, MA 02115 USA. EM rhauser@hsph.harvard.edu RI Ehrlich , Shelley/L-6991-2015 FU National Institute of Environmental Health Sciences, National Institutes of Health [ES009718, ES000002, T32ES007069] FX This work was supported by grants ES009718, ES000002, and T32ES007069 from the National Institute of Environmental Health Sciences, National Institutes of Health. NR 41 TC 15 Z9 16 U1 2 U2 27 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD NOV-DEC PY 2013 VL 121 IS 11-12 BP 1299 EP 1305 DI 10.1289/ehp.1205350 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 266ZA UT WOS:000328061900018 PM 23912598 ER PT J AU Kim, SW Heller, ES Hohman, MH Hadlock, TA Heaton, JT AF Kim, Sang W. Heller, Elizabeth S. Hohman, Marc H. Hadlock, Tessa A. Heaton, James T. TI Detection and Perceptual Impact of Side-to-Side Facial Movement Asymmetry SO JAMA FACIAL PLASTIC SURGERY LA English DT Article ID PARALYSIS; FACE; REANIMATION; EXPRESSION; MOTION; NERVE; SYMMETRY; EMOTION; SMILE AB IMPORTANCE In this study, we examined whether specific facial movements have different time-delay detection thresholds, and to what extent such side-to-side facial movement asymmetry affects subjective ratings of movement naturalness. Ratings of dynamic asymmetry in experimentally manipulated video recordings demonstrate that there are different side-to-side time-delay thresholds for distinct regions of the face, with a strong inverse correlation between naturalness rating and the length-of-time delay. These findings will be helpful for counseling patients with unilateral facial paralysis and guide the design of neural interfaces for facial reanimation. OBJECTIVE To determine the detection threshold of side-to-side facial movement timing asymmetry and measure its effect on perceived movement naturalness. DESIGN, SETTING, AND PARTICIPANTS Videos of 5 symmetrical facial movements (eye blink, rapid eyebrow raising, slow eyebrow raising, smiling, and lip depression) were edited to introduce 6 levels of side-to-side timing asymmetry, ranging from 33 to 267 milliseconds. Participants (N = 58) viewed video clips through an online survey service, indicating whether they noticed side-to-side asymmetry and judging movement naturalness on a 5-point scale. RESULTS There was a significant difference among facial movements in asymmetry detection threshold. There was a strong correlation between naturalness ratings and amount of delay across movements (R = 0.823), with greater asymmetry being judged as progressively less natural. Blink was judged as less natural at 33, 67, 100, and 133 milliseconds of side-to-side delay compared with all other movements (P < .005). CONCLUSIONS AND RELEVANCE Side-to-side asymmetry in blink timing is detected sooner and viewed as less natural compared with asymmetry of the eyebrow and lips. At 100 milliseconds of delay, nearly all movements are detected as asymmetric, although blink is judged as the least natural. These findings will help set timing goals for facial pacing technologies treating unilateral paralysis. C1 [Kim, Sang W.; Hohman, Marc H.; Hadlock, Tessa A.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. [Heller, Elizabeth S.; Heaton, James T.] MGH Inst Hlth Profess, Boston, MA USA. [Heaton, James T.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Hadlock, TA (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM tessa_hadlock@meei.harvard.edu FU NINDS NIH HHS [R01 NS071067] NR 25 TC 8 Z9 9 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6076 EI 2168-6092 J9 JAMA FACIAL PLAST SU JI JAMA Facial Plast. Surg. PD NOV-DEC PY 2013 VL 15 IS 6 BP 411 EP 416 DI 10.1001/jamafacial.2013.1227 PG 6 WC Surgery SC Surgery GA 268HY UT WOS:000328162200004 PM 23929221 ER PT J AU Cohen, BE Neylan, TC Yaffe, K Samuelson, KW Li, YM Barnes, DE AF Cohen, Beth E. Neylan, Thomas C. Yaffe, Kristine Samuelson, Kristin W. Li, Yongmei Barnes, Deborah E. TI Posttraumatic Stress Disorder and Cognitive Function: Findings From the Mind Your Heart Study SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID ADMINISTERED PTSD SCALE; DEPRESSIVE SYMPTOMS; ALZHEIMERS-DISEASE; SLEEP QUALITY; OLDER-ADULTS; PSYCHOMETRIC PROPERTIES; HEALTH BEHAVIORS; CATEGORY FLUENCY; RISK-FACTORS; US VETERANS AB Objective: Prior studies have found that the patients with posttraumatic stress disorder (PTSD) have poorer performance on cognitive tests than patients without PTSD, but the underlying mechanisms remain unknown. We examined the association between PTSD and cognitive function in a large cohort and evaluated the role of potential biological and behavioral mediators. Method: A cohort of 535 adult outpatients (<= 65 years) without dementia, stroke, or other neurologic disorders was recruited from 2 Veterans Affairs medical centers between February 2008 and June 2010. PTSD was assessed with the Clinician Administered PTSD Scale (CAPS) using DSM-IV-TR criteria. Cognitive function tests included processing speed, Trails A and B, letter fluency, category fluency, and verbal learning and recognition. Linear regression was used to evaluate the association between PTSD and cognitive function test scores and to assess potential mediators of the association. Results: For our analyses of PTSD and cognitive function, we combined 178 participants who met criteria for full PTSD and 18 who met criteria for partial PTSD and had a CAPS score > 40. After adjusting for demographics, these participants with PTSD scored significantly worse on processing speed (0.30 standard deviations [SDs], P <=.001), category fluency (0.23 SDs, P=.01), verbal learning (0.30 SDs, P=.001), and verbal recognition (0.18 SDs, P=.048) than those without PTSD. These associations were largely accounted for by health behaviors, vascular risk factors, and depression. Conclusions: In this cohort of veterans under age 65 years without known neurologic disease, patients with versus without PTSD had significantly poorer performance in several domains of cognitive function, particularly in tests involving processing speed, executive function, and learning. These cognitive deficits were largely explained by modifiable risk factors. Interventions targeted at these risk factors might minimize the impact of PTSD on cognitive decline and dementia risk as patients age. (C) Copyright 2013 Physicians Postgraduate Press, Inc. C1 [Cohen, Beth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Neylan, Thomas C.; Yaffe, Kristine; Samuelson, Kristin W.; Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine; Barnes, Deborah E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Cohen, Beth E.; Li, Yongmei] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Neylan, Thomas C.; Yaffe, Kristine; Samuelson, Kristin W.; Barnes, Deborah E.] Vet Affairs Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA. [Samuelson, Kristin W.] Alliant Int Univ, San Francisco, CA USA. RP Cohen, BE (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM Beth.Cohen@ucsf.edu FU National Heart, Lung, and Blood Institute [K23 HL 094765-0]; Irene Perstein Foundation; University of California, San Francisco; National Center for Research Resources through University of California, San Francisco; National Center for Advancing Translational Sciences, National Institutes of Health, through University of California, San Francisco; Clinical and Translational Science Institute [UL1 RR024131] FX The Mind Your Heart Study was supported by the National Heart, Lung, and Blood Institute (K23 HL 094765-0), by the Irene Perstein Foundation, and by departmental funds from the University of California, San Francisco. Publication of this article was also supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through University of California, San Francisco, Clinical and Translational Science Institute grant UL1 RR024131. NR 69 TC 14 Z9 15 U1 5 U2 21 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD NOV PY 2013 VL 74 IS 11 BP 1063 EP 1070 DI 10.4088/JCP.12m08291 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 268OL UT WOS:000328180300001 PM 24330891 ER PT J AU Emmons, KM Puleo, E Sprunck-Harrild, K Ford, J Ostroff, JS Hodgson, D Greenberg, M Diller, L de Moor, J Tyc, V AF Emmons, Karen M. Puleo, Elaine Sprunck-Harrild, Kim Ford, Jennifer Ostroff, Jamie S. Hodgson, David Greenberg, Mark Diller, Lisa de Moor, Janet Tyc, Vida TI Partnership for Health-2, A Web-Based Versus Print Smoking Cessation Intervention for Childhood and Young Adult Cancer Survivors: Randomized Comparative Effectiveness Study SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE cancer survivors; smoking cessation; cancer prevention ID TOBACCO-DEPENDENCE TREATMENTS; LONG-TERM SURVIVORS; MEDICAID COVERAGE; CONTROLLED-TRIAL; A-REPORT; INTERNET; OUTCOMES; ADOLESCENT; INITIATION; COHORT AB Background: Smoking among cancer survivors increases the risk of late effects and second cancers. This article reports on Partnership for Health-2 (PFH-2)-an effort to develop an effective and scalable version of Partnership for Health (PFH), which was a previously tested peer-delivered telephone counseling program that doubled smoking cessation rates among childhood cancer survivors who smoke. Objective: This paper presents results from a randomized controlled trial evaluating the effectiveness of PFH-2 in targeted and tailored Web-based versus print formats. The overall goal was to determine whether the intervention outcomes in these self-guided scalable formats approximate what was found in a more intensive telephone counseling program. Methods: This study was a randomized controlled trial with a 15-month follow-up that included 374 smokers who were survivors of childhood or young adult cancers, recruited from five survivorship clinics. Participants were randomly assigned to a Web-based or print format of the PFH intervention; all had access to free pharmacotherapy. The website was designed to provide new content at each log-on, and a peer counselor moderated a forum/chat feature. The primary outcome was smoking status at 15 months post randomization. Results: In total, 58.3% (77/132) of Web participants logged on at least once (mean visits 3.25). Using multiple imputation methods for missing data, there were similar rates of cessation in the two arms (print: 20/128, 15.6%; Web: 33/201, 6.4%), and no differences in quit attempts or readiness to quit. The quit rates were equivalent to those found in our previous telephone counseling intervention. There were high rates of satisfaction with both of the PFH-2 interventions. Conclusions: The print and Web formats yielded equivalent levels of success to those found with our telephone-delivered intervention and are comparable to other Internet treatment studies. This study provides important options for survivorship programs that may not have resources for interpersonal forms of cessation counseling. Efforts to increase patient use of the interventions may result in higher cessation rates. C1 [Emmons, Karen M.; Sprunck-Harrild, Kim; Diller, Lisa] Dana Farber Canc Inst, Boston, MA 02215 USA. [Emmons, Karen M.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Puleo, Elaine] Univ Massachusetts, Amherst, MA 01003 USA. [Ford, Jennifer; Ostroff, Jamie S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Hodgson, David] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Greenberg, Mark] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Diller, Lisa] Harvard Univ, Sch Med, Boston, MA USA. [de Moor, Janet] Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USA. [Tyc, Vida] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. RP Emmons, KM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,LW601, Boston, MA 02215 USA. EM Karen_M_Emmons@dfci.harvard.edu OI Ostroff, Jamie/0000-0003-2671-5680 FU National Cancer Institute [5R01CA106914-5, 1K05 CA124415] FX This study was supported by grants from the National Cancer Institute, (5R01CA106914-5 and 1K05 CA124415). The authors would like to acknowledge Martha Zorn for her work on the data management and Nancy Klockson for participation in the manuscript preparation. NR 59 TC 15 Z9 15 U1 1 U2 12 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD NOV PY 2013 VL 15 IS 11 AR UNSP e218 DI 10.2196/jmir.2533 PG 17 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA 268HA UT WOS:000328159800001 PM 24195867 ER PT J AU Garrett, LA Growdon, WB Goodman, A Boruta, DM Schorge, JO del Carmen, MG AF Garrett, Leslie A. Growdon, Whitfield B. Goodman, Annekathryn Boruta, David M. Schorge, John O. del Carmen, Marcela G. TI Endometriosis-Associated Ovarian Malignancy A Retrospective Analysis of Presentation, Treatment, and Outcome SO JOURNAL OF REPRODUCTIVE MEDICINE LA English DT Article; Proceedings Paper CT 13th Biennial Meeting of the International-Gynecologic-Cancer-Society CY OCT 23-26, 2010 CL Prague, CZECH REPUBLIC SP Int Gynecol Canc Soc DE chemotherapy; endometriosis; ovarian cancer; surgery ID CLEAR-CELL CARCINOMA; HOSPITAL DISCHARGE DIAGNOSIS; EPITHELIAL-CELLS; CANCER-RISK; HETEROZYGOSITY; TUMORS; CYSTS; TRANSFORMATION; CHEMOTHERAPY; INFERTILITY AB OBJECTIVE: To investigate the relationship of age and tumors associated with endometriosis and outcome of different histologies of epithelial ovarian cancer arising from endometriosis. STUDY DESIGN: We identified cases of epithelial ovarian cancers with clear cell, endometrioid, or mixed clear cell and endometrioid histologies from January 2001 to March 2009. Tumors were classified as either "arising in" endometriosis, "associated with" endometriosis or "controls" (not associated with endometriosis). We collected information regarding patient demographics, past medical history, presentation at diagnosis, treatment, and outcome. RESULTS: Of 140 patients identified, 42 (30.0%) had clear cell, 92 (65.7%) had endometrioid, and 6 (4.3%) had mixed. Of those, 28.6% of tumors were associated with endometriosis (n = 40), 37.1% were arising in endometriosis (n = 52), and 34.3% were controls (n = 48). Premenopausal women had tumors that were more likely arising from or associated with endometriosis as compared to tumors in postmenopausal women (p = 0.005). Premenopausal patients were also more likely to present with early stage disease as compared to postmenopausal women (80.4% vs. 63.6%, p = 0.04) and better overall survival (p < 0.008). Survival analyses of the entire cohort showed that improved survival was associated with stage (p < 0.001), grade (p < 0.001), endometrioid histology (p < 0.005), and with tumors associated with or arising in endometriosis (p < 0.04). Multivariate analysis controlling for menopausal status showed the presence of endometriosis was no longer associated with a survival advantage (p = 0.08). CONCLUSION: The association with endometriosis does appear, at least in endometrioid tumors, to provide a survival benefit. Overall, menopausal status, stage, and grade are more powerful variables associated with improved survival. C1 [Garrett, Leslie A.; Growdon, Whitfield B.; Goodman, Annekathryn; Boruta, David M.; Schorge, John O.; del Carmen, Marcela G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gynecol Oncol,Vincent Obstet & Gynecol, Boston, MA USA. RP del Carmen, MG (reprint author), Massachusetts Gen Hosp, Div Gynecol Oncol, Vincent Obstet & Gynecol, 55 Fruit St,Yawkey 9 E, Boston, MA 02114 USA. EM mdelcarmen@partners.org NR 52 TC 8 Z9 9 U1 0 U2 5 PU SCI PRINTERS & PUBL INC PI ST LOUIS PA PO DRAWER 12425 8342 OLIVE BLVD, ST LOUIS, MO 63132 USA SN 0024-7758 EI 1943-3565 J9 J REPROD MED JI J. Reprod. Med. PD NOV-DEC PY 2013 VL 58 IS 11-12 BP 469 EP 476 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 266GQ UT WOS:000328012500002 PM 24568040 ER PT J AU Tamae, D Byrns, M Marck, B Mostaghel, E Nelson, PS Lange, P Lin, D Taplin, ME Balk, S Ellis, W True, L Vessella, R Montgomery, B Blair, IA Penning, TM AF Tamae, Daniel Byrns, Michael Marck, Brett Mostaghel, Elahe Nelson, Peter S. Lange, Paul Lin, Daniel Taplin, Mary-Ellen Balk, Steven Ellis, William True, Larry Vessella, Robert Montgomery, Bruce Blair, Ian A. Penning, Trevor M. TI Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY LA English DT Article DE Prostate cancer; Androgen metabolome; Mass spectrometry ID RESISTANT PROSTATE-CANCER; TANDEM MASS-SPECTROMETRY; HELIX-POMATIA JUICE; I CLINICAL-TRIAL; ABIRATERONE ACETATE; TESTOSTERONE; CASTRATION; DIHYDROTESTOSTERONE; SURVIVAL; CHEMOTHERAPY AB Prostate cancer is the most frequently diagnosed form of cancer in males in the United States. The disease is androgen driven and the use of orchiectomy or chemical castration, known as androgen deprivation therapy (ADT) has been employed for the treatment of advanced prostate cancer for over 70 years. Agents such as GnRH agonists and non-steroidal androgen receptor antagonists are routinely used in the clinic, but eventually relapse occurs due to the emergence of castration-resistant prostate cancer. With the appreciation that androgen signaling still persists in these patients and the development of new therapies such as abiraterone and enzalutamide that further suppresses androgen synthesis or signaling, there is a renewed need for sensitive and specific methods to quantify androgen precursor and metabolite levels to assess drug efficacy. We describe the development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization selected reaction monitoring mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of serum keto-androgens and their sulfate and glucuronide conjugates using Girard-T oxime derivatives. The method is robust down to 0.2-4 pg on column, depending on the androgen metabolite quantified, and can also quantify dehydroepiandrosterone sulfate (DHEA-S) in only 1 mu L of serum. The clinical utility of this method was demonstrated by analyzing serum androgens from patients enrolled in a clinical trial assessing combinations of pharmacological agents to maximally suppress gonadal and adrenal androgens (Targeted Androgen Pathway Suppression, TAPS clinical trial). The method was validated by correlating the results obtained with a hydroxylamine derivatization procedure coupled with tandem mass spectrometry using selected reaction monitoring that was conducted in an independent laboratory. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Tamae, Daniel; Byrns, Michael; Blair, Ian A.; Penning, Trevor M.] Univ Penn, Dept Pharmacol, Perelman Sch Med, Ctr Excellence Environm Toxicol, Philadelphia, PA 19104 USA. [Tamae, Daniel; Byrns, Michael; Blair, Ian A.; Penning, Trevor M.] Univ Penn, Dept Pharmacol, Perelman Sch Med, Ctr Canc Pharmacol, Philadelphia, PA 19104 USA. [Marck, Brett; Mostaghel, Elahe] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Marck, Brett; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA. [Mostaghel, Elahe; Nelson, Peter S.; Montgomery, Bruce] Univ Washington, Dept Med, Seattle, WA USA. [Lange, Paul; Lin, Daniel; Ellis, William; Vessella, Robert] Univ Washington, Dept Urol, Seattle, WA 98195 USA. [True, Larry] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Taplin, Mary-Ellen; Balk, Steven] Harvard Univ, Sch Med, Dana Farber Harvard Canc Ctr, Boston, MA USA. [Taplin, Mary-Ellen; Balk, Steven] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Penning, TM (reprint author), Univ Penn, Dept Pharmacol, Perelman Sch Med, 1315 BRBII-3,421 Curie Blvd, Philadelphia, PA 19104 USA. EM penning@upenn.edu OI Penning, Trevor/0000-0002-3937-1066 FU National Institutes of Health [P30-ES013508, R01-CA90744]; Prostate Cancer Foundation; NCI [5R25-CA101871]; [P01-CA163227-01A1] FX This work was supported by National Institutes of Health grants, P30-ES013508 and R01-CA90744 (and ARRA supplement) awarded to TMP; P01-CA163227-01A1 and a Prostate Cancer Foundation Challenge Award grant awarded to SB, PSB, BM and TMP; and an NCI Cancer Pharmacology postdoctoral fellowship to DT funded by 5R25-CA101871. NR 32 TC 13 Z9 14 U1 0 U2 22 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0960-0760 J9 J STEROID BIOCHEM JI J. Steroid Biochem. Mol. Biol. PD NOV PY 2013 VL 138 BP 281 EP 289 DI 10.1016/j.jsbmb.2013.06.014 PG 9 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 264UK UT WOS:000327906300030 PM 23851165 ER PT J AU Ivanova, T Alves-Rodrigues, I Gomez-Escoda, B Dutta, C DeCaprio, JA Rhind, N Hidalgo, E Ayte, J AF Ivanova, Tsvetomira Alves-Rodrigues, Isabel Gomez-Escoda, Blanca Dutta, Chaitali DeCaprio, James A. Rhind, Nick Hidalgo, Elena Ayte, Jose TI The DNA damage and the DNA replication checkpoints converge at the MBF transcription factor SO MOLECULAR BIOLOGY OF THE CELL LA English DT Article ID S-PHASE ARREST; FISSION YEAST; CELL-CYCLE; G(1)/S TRANSCRIPTION; G1/S GENES; KINASE; CDC10+; START; CHK1; COMPLEX AB In fission yeast cells, Cds1 is the effector kinase of the DNA replication checkpoint. We previously showed that when the DNA replication checkpoint is activated, the repressor Yox1 is phosphorylated and inactivated by Cds1, resulting in activation of MluI-binding factor (MBF)-dependent transcription. This is essential to reinitiate DNA synthesis and for correct G1-to-S transition. Here we show that Cdc10, which is an essential part of the MBF core, is the target of the DNA damage checkpoint. When fission yeast cells are treated with DNA-damaging agents, Chk1 is activated and phosphorylates Cdc10 at its carboxy-terminal domain. This modification is responsible for the repression of MBF-dependent transcription through induced release of MBF from chromatin. This inactivation of MBF is important for survival of cells challenged with DNA-damaging agents. Thus Yox1 and Cdc10 couple normal cell cycle regulation in unperturbed conditions and the DNA replication and DNA damage checkpoints into a single transcriptional complex. C1 [Ivanova, Tsvetomira; Alves-Rodrigues, Isabel; Gomez-Escoda, Blanca; Hidalgo, Elena; Ayte, Jose] Univ Pompeu Fabra, Oxidat Stress & Cell Cycle Grp, Barcelona 08003, Spain. [Dutta, Chaitali; Rhind, Nick] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA. [DeCaprio, James A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Ayte, J (reprint author), Univ Pompeu Fabra, Oxidat Stress & Cell Cycle Grp, Barcelona 08003, Spain. EM jose.ayte@upf.edu RI Alves-Rodrigues, I/I-7602-2014; Hidalgo, Elena/K-2919-2014; Ayte, Jose/L-5217-2014; OI Alves-Rodrigues, I/0000-0002-8280-2079; Hidalgo, Elena/0000-0002-3768-6785; Ayte, Jose/0000-0002-6354-0536; Rhind, Nicholas/0000-0003-1758-7736 FU Spanish Ministry of Science and Innovation [BFU2009-07453, BFU2012-31939]; PLAN E and FEDER from Generalitat de Catalunya [Consolider-Ingenio 2007-0020, SGR2009-195]; ICREA Academia Awards (Generalitat de Catalunya) FX We thank Paul Nurse and Paul Russell for strains, Gabriel Gil for reagents and critical reading of the manuscript, and members of the Oxidative Stress and Cell Cycle group for helpful discussions. We acknowledge the technical support of Merce Carmona. This work was supported by grants from the Spanish Ministry of Science and Innovation (BFU2009-07453 and BFU2012-31939), PLAN E and FEDER, Consolider-Ingenio 2007-0020, and SGR2009-195 from the Generalitat de Catalunya. J.A. and E.H. are recipients of ICREA Academia Awards (Generalitat de Catalunya). NR 37 TC 6 Z9 6 U1 1 U2 7 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 EI 1939-4586 J9 MOL BIOL CELL JI Mol. Biol. Cell PD NOV 1 PY 2013 VL 24 IS 21 BP 3350 EP 3357 DI 10.1091/mbc.E13-05-0257 PG 8 WC Cell Biology SC Cell Biology GA 267UR UT WOS:000328124300016 PM 24006488 ER PT J AU Azcutia, V Routledge, M Williams, MR Newton, G Frazier, WA Manica, A Croce, KJ Parkos, CA Schmider, AB Turman, MV Soberman, RJ Luscinskas, FW AF Azcutia, Veronica Routledge, Matthew Williams, Marcie R. Newton, Gail Frazier, William A. Manica, Andre Croce, Kevin J. Parkos, Charles A. Schmider, Angela B. Turman, Melissa V. Soberman, Roy J. Luscinskas, Francis W. TI CD47 plays a critical role in T-cell recruitment by regulation of LFA-1 and VLA-4 integrin adhesive functions SO MOLECULAR BIOLOGY OF THE CELL LA English DT Article ID CONDITIONS IN-VITRO; SHEAR-FLOW; P-SELECTIN; ALPHA(4)BETA(1)-INTEGRIN ACTIVATION; TRANSENDOTHELIAL MIGRATION; LYMPHOCYTE ARREST; PROTEIN CD47; ENDOTHELIUM; AFFINITY; CONFORMATION AB CD47 plays an important but incompletely understood role in the innate and adaptive immune responses. CD47, also called integrin-associated protein, has been demonstrated to associate in cis with beta 1 and beta 3 integrins. Here we test the hypothesis that CD47 regulates adhesive functions of T-cell alpha 4 beta 1 (VLA-4) and alpha L beta 2 (LFA-1) in in vivo and in vitro models of inflammation. Intravital microscopy studies reveal that CD47(-/-) Th1 cells exhibit reduced interactions with wild-type (WT) inflamed cremaster muscle microvessels. Similarly, murine CD47(-/-) Th1 cells, as compared with WT, showed defects in adhesion and transmigration across tumor necrosis factor-alpha (TNF-alpha)-activated murine endothelium and in adhesion to immobilized intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion protein 1 (VCAM-1) under flow conditions. Human Jurkat T-cells lacking CD47 also showed reduced adhesion to TNF-alpha-activated endothelium and ICAM-1 and VCAM-1. In cis interactions between Jurkat T-cell beta 2 integrins and CD47 were detected by fluorescence lifetime imaging microscopy. Unexpectedly, Jurkat CD47 null cells exhibited a striking defect in beta 1 and beta 2 integrin activation in response to Mn2+ or Mg2+/ethylene glycol tetraacetic acid treatment. Our results demonstrate that CD47 associates with beta 2 integrins and is necessary to induce high-affinity conformations of LFA-1 and VLA-4 that recognize their endothelial cell ligands and support leukocyte adhesion and transendothelial migration. C1 [Azcutia, Veronica; Routledge, Matthew; Williams, Marcie R.; Newton, Gail; Luscinskas, Francis W.] Brigham & Womens Hosp, Dept Pathol, Ctr Excellence Vasc Biol, Boston, MA 02115 USA. [Manica, Andre; Croce, Kevin J.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA. [Azcutia, Veronica; Williams, Marcie R.; Croce, Kevin J.; Schmider, Angela B.; Turman, Melissa V.; Soberman, Roy J.; Luscinskas, Francis W.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Frazier, William A.] Washington Univ, Dept Biochem & Mol Biophys, St Louis, MO 63130 USA. [Manica, Andre] Fundacao Univ Cardiol, Inst Cardiol Rio Grande do Sul, BR-90010395 Porto Alegre, RS, Brazil. [Parkos, Charles A.] Emory Univ, Sch Med, Div Gastrointestinal Pathol, Atlanta, GA 30322 USA. [Schmider, Angela B.; Turman, Melissa V.; Soberman, Roy J.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA. RP Luscinskas, FW (reprint author), Brigham & Womens Hosp, Dept Pathol, Ctr Excellence Vasc Biol, 75 Francis St, Boston, MA 02115 USA. EM fluscinskas@partners.org RI Azcutia, Veronica/A-7704-2017; OI Azcutia, Veronica/0000-0003-2160-5175; Vaught, Melissa/0000-0001-7627-8330 FU National Institutes of Health [PO1 HL36028, F32 HL105016, K08 HL086672, HL53192, R01s DK079392, DK072564, R01 AI068871, K01 DK089145-01A1, R01 AI068871-04S1, 1S10RR027931, 1R01HL097796, T32 DK007540-22]; American Heart Association [11POST7730055]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil FX This work was supported by awards PO1 HL36028 (F.W.L.), F32 HL105016 (M.R.W.), K08 HL086672 (K.J.C.), HL53192 (W.A.F.), R01s DK079392 and DK072564 (C.A.P.), R01 AI068871 (R.J.S. and A.M.B.), K01 DK089145-01A1 (A. B. S.), R01 AI068871-04S1 (M. V. T., R.J.S.), 1S10RR027931 (R.J.S.), 1R01HL097796 (R.J.S., A.M.B.), and T32 DK007540-22 (A.B.S., M.V.T.) from the National Institutes of Health. V.A. was supported by Fellowship Award 11POST7730055 from the American Heart Association. A.M was supported by a fellowship from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil. We thank Kay Case and Vannessa Davis for providing human umbilical vein endothelium and the Labor and Delivery Service at the Brigham and Women's Hospital for providing umbilical cords for isolation of endothelial cells. NR 38 TC 19 Z9 22 U1 0 U2 7 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 EI 1939-4586 J9 MOL BIOL CELL JI Mol. Biol. Cell PD NOV 1 PY 2013 VL 24 IS 21 BP 3358 EP 3368 DI 10.1091/mbc.E13-01-0063 PG 11 WC Cell Biology SC Cell Biology GA 267UR UT WOS:000328124300017 PM 24006483 ER PT J AU DesRoches, CM Gaudet, J Perloff, J Donelan, K Iezzoni, LI Buerhaus, P AF DesRoches, Catherine M. Gaudet, Jennifer Perloff, Jennifer Donelan, Karen Iezzoni, Lisa I. Buerhaus, Peter TI Using Medicare data to assess nurse practitioner-provided care SO NURSING OUTLOOK LA English DT Article DE Advanced practice nurse; Medicare; Patient characteristics ID PHYSICIAN WORKFORCE; ADMINISTRATIVE DATA; SATISFACTION; DIRECTIONS; EXPANSION; OUTCOMES; QUALITY AB Background: To mitigate shortages of primary care physicians and ensure access to health care services for a growing number of Medicare beneficiaries, some policy makers have recommended expanding the supply and roles of nurse practitioners (NPs). Little is known about the number of NPs billing Medicare or their practice patterns. Purpose: This study examines the geographic distribution and county characteristics of NPs billing Medicare, compares the types and quantities of primary care services provided to Medicare beneficiaries by NPs and primary care physicians, and analyzes the characteristics of beneficiaries receiving primary care from each type of clinician. Methods: We performed a cross-sectional analysis of 2008 Medicare administrative data from 959,848 aged and/or disabled beneficiaries continuously enrolled in fee-for-service Medicare during the study period. Outcome measures included geographic distribution of NPs measured by the rate of NPs per 1,000 Medicare beneficiaries by state, average utilization, and patient characteristics. Discussion: States with the highest rate of NPs billing were rural. Over 80% of the payments received by both NPs and primary care physicians were for evaluation and management services. Beneficiaries assigned to an NP were more likely to be female, to be dually eligible for Medicare and Medicaid, and to have qualified for Medicare because of a disability. NPs with assigned beneficiaries were significantly more likely than similar primary care physicians to practice in federally designated primary care shortage areas. Conclusions: Approximately 45,000 NPs were providing services to beneficiaries and billing under their own provider numbers in 2008. Aspects of NP practice patterns were different from primary care physicians, and NPs appeared more likely to provide services to disadvantaged Medicare beneficiaries. C1 [DesRoches, Catherine M.] Math Policy Res, Cambridge, MA 02139 USA. [Gaudet, Jennifer; Perloff, Jennifer] Brandeis Univ, Heller Sch, Waltham, MA 02254 USA. [Donelan, Karen; Iezzoni, Lisa I.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Buerhaus, Peter] Vanderbilt Univ, Sch Med, Inst Med & Publ Hlth, Nashville, TN 37212 USA. RP DesRoches, CM (reprint author), Math Policy Res, 955 Massachusetts Ave,Suite 801, Cambridge, MA 02139 USA. EM cdesroches@mathematica-mpr.com FU Robert Wood Johnson Foundation; Gordon and Betty Moore Foundation; Johnson and Johnson's Campaign for Nursing's Future; Johnson and Johnson' Campaign for Nursing's Future FX Supported by the Robert Wood Johnson Foundation, the Gordon and Betty Moore Foundation, and Johnson and Johnson' Campaign for Nursing's Future. Drs. DesRoches, Perloff, Gaudet, and Buerhaus received grant support from Johnson and Johnson's Campaign for Nursing's Future. NR 43 TC 12 Z9 12 U1 0 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0029-6554 EI 1528-3968 J9 NURS OUTLOOK JI Nurs. Outlook PD NOV-DEC PY 2013 VL 61 IS 6 BP 400 EP 407 DI 10.1016/j.outlook.2013.05.005 PG 8 WC Nursing SC Nursing GA 268PH UT WOS:000328182500006 PM 23870733 ER PT J AU Walsh, K Nugent, NR Kotte, A Amstadter, AB Wang, S Guille, C Acierno, R Kilpatrick, DG Resnick, HS AF Walsh, Kate Nugent, Nicole R. Kotte, Amelia Amstadter, Ananda B. Wang, Sheila Guille, Constance Acierno, Ron Kilpatrick, Dean G. Resnick, Heidi S. TI Cortisol at the emergency room rape visit as a predictor of PTSD and depression symptoms over time SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Cortisol; Hypothalamic-pituitary-adrenal axis; Sexual assault; Early intervention; PTSD ID POSTTRAUMATIC-STRESS-DISORDER; VEHICLE ACCIDENT VICTIMS; NATIONAL SAMPLE; SALIVARY CORTISOL; SEXUAL ASSAULT; MEDICAL-CARE; TRAUMA; WOMEN; RESPONSES; CHILD AB Background: Dysregulation of the hypothalamic-pituitary-adrenal axis, typically reflected by alterations in cortisol responsivity, has been associated with exposure to traumatic events and the development of stress-related disorders such as posttraumatic stress disorder (PTSD) and depression. Methods: Serum cortisol was measured at the time of a post sexual assault medical exam among a sample of 323 female victims of recent sexual assault. Analyses were conducted among 235 participants who provided data regarding history of previous assault as well as PTSD and depression symptoms during at least one of the three follow-ups. Results: Growth curve models suggested that prior history of assault and serum cortisol were positively associated with the intercept and negatively associated with the slope of PTSD and depression symptoms after controlling for covariates. Prior history of assault and serum cortisol also interacted to predict the intercept and slope of PTSD and depression symptoms such that women with a prior history of assault and lower ER cortisol had higher initial symptoms that decreased at a slower rate relative to women without a prior history and those with higher ER cortisol. Conclusions: Prior history of assault was associated with diminished acute cortisol responsivity at the emergency room visit. Prior assault history and cortisol both independently and interactively predicted PTSD and depression symptoms at first follow-up and over the course a 6-month follow-up. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Walsh, Kate] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Nugent, Nicole R.] Hasbro Childrens Res Ctr, DPHB Alpert Brown Med Sch, Providence, RI USA. [Nugent, Nicole R.] Hasbro Childrens Res Ctr, RIH Bradley, Providence, RI USA. [Kotte, Amelia] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Kotte, Amelia] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Amstadter, Ananda B.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Dept Psychiat, Richmond, VA USA. [Wang, Sheila] Childrens Mem Hosp, Feinberg Sch Med, Dept Pediat, Chicago, IL 60614 USA. [Guille, Constance; Acierno, Ron; Kilpatrick, Dean G.; Resnick, Heidi S.] Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP Resnick, HS (reprint author), Dept Psychiat & Behav Sci, 67 President St,S Bldg Suite 200, Charleston, SC 29425 USA. EM resnickh@musc.edu OI Kotte, Amelia/0000-0002-0198-7914 FU NIH [5M01 RR01070]; National Institute on Drug Abuse [R01 DA023099]; NIMH [T32 MH018869] FX NIH sponsored Medical University of South Carolina General Clinical Research Center Supported Study, 5M01 RR01070.; Manuscript preparation was supported by National Institute on Drug Abuse Grant No. R01 DA023099 Prevention of Postrape Drug Abuse: Replication Study (PI: Heidi Resnick, Ph.D.).; Manuscript preparation was supported by NIMH Grant T32 MH018869 (PI: Kilpatrick). NR 48 TC 14 Z9 15 U1 3 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD NOV PY 2013 VL 38 IS 11 BP 2520 EP 2528 DI 10.1016/j.psyneuen.2013.05.017 PG 9 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA 268MT UT WOS:000328175700013 PM 23806832 ER PT J AU Chuang, JH Tung, LC Yin, Y Lin, YS AF Chuang, Jen-Hua Tung, Li-Chu Yin, Yi Lin, Yenshou TI Differentiation of glutamatergic neurons from mouse embryonic stem cells requires raptor S6K signaling SO STEM CELL RESEARCH LA English DT Article ID RAPAMYCIN PATHWAY; MTOR; GROWTH; DROSOPHILA; DISEASE; TARGET; KINASE; AUTOPHAGY; REVEALS; MODELS AB Although the mammalian target of rapamycin complex 1 (mTORC1) functions as an important signaling complex in many cellular processes, the role of mTORC1 in neurons derived from embryonic stem cells (ESCs) has been less explored. Here, using a modified protocol to differentiate mouse ESCs (mESCs) into almost uniform glutamatergic neurons, we explored the importance of raptor/mTORC1 in the differentiation of mESCs. Raptor gene-trap mESCs, and raptor-knockdown mESCs formed smaller-sized embryonic bodies than the wild type and failed to undergo neuronal differentiation. Treatment with 1 rapamycin starting at the point when neuronal precursors began to differentiate from mESCs caused the gradual loss of neurites, shrinkage of soma, and a decreased ratio of neurite length to cell number over 48 to 72 h of treatment. This change was accompanied by activation of caspase-3 and S6 kinase (S6K), but not 4E-binding protein 1 (4EBP1). Knockdown of raptor during neuronal differentiation from mESCs also resulted in gradual loss of neurites and shrinkage of cell bodies. Loss of neurite density resulting from rapamycin treatment could be reversed by overexpression of S6K T389E. Taken together, these data demonstrate that raptor/mTORC1/S6K plays a critical role in the differentiation and survival of neurons derived from mESCs. (C) 2013 Elsevier B.V. All rights reserved. C1 [Chuang, Jen-Hua; Tung, Li-Chu; Lin, Yenshou] Natl Taiwan Normal Univ, Dept Life Sci, Taipei 116, Taiwan. [Yin, Yi] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA. [Yin, Yi] Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA. [Yin, Yi] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. RP Lin, YS (reprint author), Natl Taiwan Normal Univ, Dept Life Sci, Sect 4, 88 Ting Chou Rd, Taipei 116, Taiwan. EM yenshoulin@ntnu.edu.tw FU National Science Council, Taiwan [NSC98-2311-B-003-MY3, NSC101-2311-B-003-005] FX This work was partially supported by a grant (NSC98-2311-B-003-MY3 and NSC101-2311-B-003-005) to Y. Lin from the National Science Council, Taiwan. We are grateful for the help from the Molecular Imaging Core Facility of National Taiwan Normal University and National RNAi Core Facility Platform of Academia Sinica (Taipei, Taiwan). We would like to thank Drs. Joseph Avruch and Sara Ortiz-Vega of Massachusetts General Hospital (Boston, MA, USA) for the critical reading of the manuscript and technical assistance. NR 33 TC 4 Z9 4 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1873-5061 EI 1876-7753 J9 STEM CELL RES JI Stem Cell Res. PD NOV PY 2013 VL 11 IS 3 BP 1117 EP 1128 DI 10.1016/j.scr.2013.08.003 PG 12 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA 264UA UT WOS:000327905300013 PM 23988668 ER PT J AU Ossip, DJ Chang, YC Nabi-Burza, E Drehmer, J Finch, S Hipple, B Rigotti, NA Klein, JD Winickoff, JP AF Ossip, Deborah J. Chang, Yuchiao Nabi-Burza, Emara Drehmer, Jeremy Finch, Stacia Hipple, Bethany Rigotti, Nancy A. Klein, Jonathan D. Winickoff, Jonathan P. TI Strict Smoke-free Home Policies Among Smoking Parents in Pediatric Settings SO ACADEMIC PEDIATRICS LA English DT Article DE environmental tobacco smoke; parental smoking; secondhand smoke; smoking ID ENVIRONMENTAL TOBACCO-SMOKE; 4 COUNTRY SURVEY; UNITED-STATES; HOUSEHOLD SMOKING; THIRDHAND SMOKE; NATIONAL-SURVEY; CHILDREN; EXPOSURE; BANS; ADOLESCENTS AB OBJECTIVE: To examine strict smoke-free home policies among smoking parents assessed in pediatric offices. METHODS: We analyzed baseline parental survey data from 10 control practices in a national trial of pediatric office-based tobacco control interventions (Clinical Effort Against Second-hand Smoke Exposure, CEASE). We used logistic regression models with generalized estimating equations to examine factors associated with strict smoke-free home policies. RESULTS: Subjects were 952 parents who were current smokers. Just over half (54.3%) reported strict smoke-free home policies. Few reported being asked (19.9%) or advised (17.1%) regarding policies by pediatricians. Factors associated with higher odds of policies were child 5 years or younger (adjusted odds ratio [aOR] 2.43, 95% confidence interval [CI] 1.53, 3.86), nonblack race/ethnicity (aORs 2.17-2.60, 95% CIs 1.25-5.00), non-Medicaid (HMO/private (aOR 1.84, 95% CI 1.31, 2.58); self-pay/other aOR 1.76, 95% CI 1.12, 2.78); well-child versus sick child visit (aOR 1.61, 95% CI 1.11, 2.34), fewer than 10 cigarettes per day (aOR 1.80, 95% CI 1.31, 2.47), no other home smokers (aOR 1.68, 95% CI 1.26, 2.25), only father smoking (aOR 1.73, 95% CI 1.06, 2.83), and strict smoke-free car policy (aOR 3.51, 95% CI 2.19, 5.64). CONCLUSIONS; Nearly half of smoking parents did not have strict smoke-free home policies. Parents were less likely to report policies if they were heavier smokers, black, living with other smokers, or attending a sick child visit; if they did not have a young child or smoke-free car policy; if they had a child on Medicaid; and if anyone other than only the father smoked. Few pediatricians addressed or recommended strict smoke-free home policies in an office visit. The pediatric office encounter represents a currently missed opportunity to intervene regarding smoke-free homes, particularly for high-risk groups. C1 [Ossip, Deborah J.] Univ Rochester, Med Ctr, Dept Publ Hlth Sci, Rochester, NY 14642 USA. [Klein, Jonathan D.] Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA. [Chang, Yuchiao; Rigotti, Nancy A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen Med, Boston, MA USA. [Nabi-Burza, Emara; Hipple, Bethany; Winickoff, Jonathan P.] Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Res & Policy, Boston, MA 02114 USA. [Nabi-Burza, Emara; Hipple, Bethany; Rigotti, Nancy A.; Winickoff, Jonathan P.] Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA. [Drehmer, Jeremy; Finch, Stacia] Amer Acad Pediat, Pediat Res Off Settings, Elk Grove Village, IL USA. [Klein, Jonathan D.; Winickoff, Jonathan P.] Amer Acad Pediat, AAP Richmond Ctr Excellence, Elk Grove Village, IL USA. RP Ossip, DJ (reprint author), Univ Rochester, Med Ctr, Dept Publ Hlth Sci, 265 Crittenden Blvd,CU 420644, Rochester, NY 14642 USA. EM deborah_ossip@urmc.rochester.edu OI Drehmer, Jeremy/0000-0002-5022-5836 FU National Institutes of Health NCI [R01-CA127127]; National Institute on Drug Abuse; Agency for Healthcare Research and Quality; Flight Attendant Medical Research Institute to the AAP Julius B. Richmond Center; Pediatric Research in Office Settings (PROS) Network; HRSA MCHB [HRSA 5-UA6-10-001]; AAP FX This study was supported by the National Institutes of Health NCI grant R01-CA127127 (to Dr Winickoff), the National Institute on Drug Abuse, and the Agency for Healthcare Research and Quality. This study was also partially supported by a grant from the Flight Attendant Medical Research Institute to the AAP Julius B. Richmond Center, and the Pediatric Research in Office Settings (PROS) Network, which receives core funding from the HRSA MCHB (HRSA 5-UA6-10-001) and the AAP. NR 41 TC 4 Z9 5 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 EI 1876-2867 J9 ACAD PEDIATR JI Acad. Pediatr. PD NOV-DEC PY 2013 VL 13 IS 6 BP 517 EP 523 PG 7 WC Pediatrics SC Pediatrics GA 261TX UT WOS:000327688600007 PM 24238677 ER PT J AU McCormick, MC Co, JPT Dougherty, D AF McCormick, Marie C. Co, John Patrick T. Dougherty, Denise TI Quality Improvement in Pediatric Health Care: Introduction to the Supplement SO ACADEMIC PEDIATRICS LA English DT Editorial Material C1 [Dougherty, Denise] Agcy Healthcare Res & Qual, Rockville, MD 20850 USA. [McCormick, Marie C.] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA. [Co, John Patrick T.] MassGen Hosp Children, Dept Pediat, MGH Ctr Child & Adolescent Hlth Res Policy, Boston, MA USA. RP Dougherty, D (reprint author), Agcy Healthcare Res & Qual, 540 Gaither Rd, Rockville, MD 20850 USA. EM denise.dougherty@ahrq.hhs.gov NR 19 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 EI 1876-2867 J9 ACAD PEDIATR JI Acad. Pediatr. PD NOV-DEC PY 2013 VL 13 IS 6 SU S BP S1 EP S4 PG 4 WC Pediatrics SC Pediatrics GA 261TY UT WOS:000327688700001 PM 24268076 ER PT J AU Nizamoglu, S Gather, MC Yun, SH AF Nizamoglu, Sedat Gather, Malte C. Yun, Seok Hyun TI All-Biomaterial Laser Using Vitamin and Biopolymers SO ADVANCED MATERIALS LA English DT Article DE laser; biomaterial; biomolecule; vitamin; biopolymer; superhydrophobic ID SINGLE; MICRODROPLETS; WATER; DNA; FLAVINS; PROTEIN; FIBERS; ACID C1 [Nizamoglu, Sedat; Gather, Malte C.; Yun, Seok Hyun] Harvard Univ, Sch Med, Cambridge, MA 02139 USA. [Nizamoglu, Sedat; Gather, Malte C.; Yun, Seok Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA 02139 USA. [Yun, Seok Hyun] Korea Adv Inst Sci & Technol, WCU Grad Sch Nanosci & Technol, Taejon 305701, South Korea. [Gather, Malte C.] Tech Univ Dresden, Inst Angew Photophys, D-01062 Dresden, Germany. RP Yun, SH (reprint author), Harvard Univ, Sch Med, 65 Landsdowne St,UP 5, Cambridge, MA 02139 USA. EM syun@hms.harvard.edu OI Gather, Malte/0000-0002-4857-5562 FU Bullock-Wellman Fellowship; National Science Foundation [ECS-1101947]; Center for Nanoscale Systems (CNS); NSF [ECS-0335765] FX The authors thank Turgut Fettah Kosar for discussions on superhydrophobic surfaces and to Kyung-bok Lee for SEM images. Sedat Nizamoglu acknowledges financial support from the Bullock-Wellman Fellowship. This work was supported in part by a grant from the National Science Foundation (ECS-1101947) and by the Center for Nanoscale Systems (CNS), a member of the National Nanotechnology Infrastructure Network (NNIN), which is supported under NSF award no. ECS-0335765. CNS is part of Harvard University. NR 34 TC 26 Z9 26 U1 5 U2 73 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY SN 0935-9648 EI 1521-4095 J9 ADV MATER JI Adv. Mater. PD NOV PY 2013 VL 25 IS 41 BP 5943 EP 5947 DI 10.1002/adma201300818 PG 5 WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter SC Chemistry; Science & Technology - Other Topics; Materials Science; Physics GA 261VO UT WOS:000327692900016 PM 24425626 ER PT J AU Hammond, TG Stodieck, L Birdsall, HH Becker, JL Koenig, P Hammond, JS Gunter, MA Allen, PL AF Hammond, Timothy G. Stodieck, Louis Birdsall, Holly H. Becker, Jeanne L. Koenig, Paul Hammond, Jeffrey S. Gunter, Margaret A. Allen, Patricia L. TI Effects of Microgravity on the Virulence of Listeria monocytogenes, Enterococcus faecalis, Candida albicans, and Methicillin-Resistant Staphylococcus aureus SO ASTROBIOLOGY LA English DT Article ID NEMATODE CAENORHABDITIS-ELEGANS; ENTERICA SEROVAR TYPHIMURIUM; ROTATING-WALL VESSEL; GENE-EXPRESSION; INNATE IMMUNITY; SPACE-FLIGHT; SPACEFLIGHT; GROWTH; WEIGHTLESSNESS; CLINOSTAT AB To evaluate effects of microgravity on virulence, we studied the ability of four common clinical pathogensListeria monocytogenes, methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, and Candida albicansto kill wild type Caenorhabditis elegans (C. elegans) nematodes at the larval and adult stages. Simultaneous studies were performed utilizing spaceflight, clinorotation in a 2-D clinorotation device, and static ground controls. The feeding rate of worms for killed E. coli was unaffected by spaceflight or clinorotation. Nematodes, microbes, and growth media were separated until exposed to true or modeled microgravity, then mixed and grown for 48h. Experiments were terminated by paraformaldehyde fixation, and optical density measurements were used to assay residual microorganisms. Spaceflight was associated with reduced virulence for Listeria, Enterococcus, MRSA, and Candida for both larval and adult C. elegans. These are the first data acquired with a direct in vivo assay system in space to demonstrate virulence. Clinorotation reproduced the effects of spaceflight in some, but not all, virulence assays: Candida and Enterococcus were less virulent for larval worms but not adult worms, whereas virulence of MRSA and Listeria were unaffected by clinorotation in tests with both adult and larval worms. We conclude that four common clinical microorganisms are all less virulent in space. Key Words: VirulenceSpaceflightNematodesClinorotationMicrogravityMicroorganism. Astrobiology 13, 1081-1090. C1 [Hammond, Timothy G.; Allen, Patricia L.] Duke Univ, Sch Med, Durham VA Med Ctr, Res & Dev Serv, Durham, NC USA. [Hammond, Timothy G.] Duke Univ, Sch Med, Div Nephrol, Dept Internal Med, Durham, NC USA. [Hammond, Timothy G.; Birdsall, Holly H.] US Dept Vet Affairs, Off Res & Dev, Washington, DC 20420 USA. [Hammond, Timothy G.] Vet Affairs Med Ctr, Washington, DC 20422 USA. [Hammond, Timothy G.] George Washington Sch Med, Dept Internal Med, Nephrol Sect, Washington, DC USA. [Stodieck, Louis; Koenig, Paul] Univ Colorado, Boulder, CO 80309 USA. [Birdsall, Holly H.] Baylor Coll Med, Dept Otorhinolaryngol, Houston, TX 77030 USA. [Birdsall, Holly H.] Baylor Coll Med, Dept Immunol & Psychiat, Houston, TX 77030 USA. [Becker, Jeanne L.] Astrogenetix LLC, Austin, TX USA. [Hammond, Jeffrey S.] Inst Med Res, Durham, NC USA. [Gunter, Margaret A.] Georgia Dept Publ Hlth, Macon, GA USA. RP Hammond, TG (reprint author), US Dept Vet Affairs, Off Res & Dev, Vet Hlth Adm, 810 Vermont Ave 10P9, Washington, DC 20420 USA. EM Timothy.Hammond@va.gov FU SpaceHab/Astrotech; Astrogenetix Inc.; International Space Station National Lab Pathfinder program FX These studies were supported by SpaceHab/Astrotech and Astrogenetix Inc. We thank NASA for spaceflight access under the auspices of the International Space Station National Lab Pathfinder program. We thank Anthony Johnson for technical assistance. NR 35 TC 4 Z9 6 U1 0 U2 12 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1531-1074 EI 1557-8070 J9 ASTROBIOLOGY JI Astrobiology PD NOV 1 PY 2013 VL 13 IS 11 BP 1081 EP 1090 DI 10.1089/ast.2013.0986 PG 10 WC Astronomy & Astrophysics; Biology; Geosciences, Multidisciplinary SC Astronomy & Astrophysics; Life Sciences & Biomedicine - Other Topics; Geology GA 258CA UT WOS:000327434900006 PM 24283929 ER PT J AU Hu, Y Zheng, M Gali, R Tian, Z Gorgun, GT Munshi, NC Mitsiades, CS Anderson, KC AF Hu, Y. Zheng, M. Gali, R. Tian, Z. Goerguen, G. Topal Munshi, N. C. Mitsiades, C. S. Anderson, K. C. TI A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice SO BLOOD CANCER JOURNAL LA English DT Article DE multiple myeloma (MM); cMYC; KRAS12V; retroviral transduction and transplantation; BALB/c mouse; plasmacytoma ID B-CELL LINE; MULTIPLE-MYELOMA; C-MYC; BONE-MARROW; MOLECULAR PATHOGENESIS; MYELOGENOUS LEUKEMIA; V-RAF; EXPRESSION; GENE; DIFFERENTIATION AB Our goal is to develop a rapid and scalable system for functionally evaluating deregulated genes in multiple myeloma (MM). Here, we forcibly expressed human cMYC and KRAS12V in mouse T2 B cells (IgM(+)B220(+)CD38(+)IgD(+)) using retroviral transduction and transplanted these cells into lethally irradiated recipient mice. Recipients developed plasmacytomas with short onset (70 days) and high penetrance, whereas neither cMYC nor KRAS12V alone induced disease in recipient mice. Tumor cell morphology and cell surface biomarkers (CD138(+)B220(-)IgM(-)GFP(+)) indicate a plasma cell neoplasm. Gene set enrichment analysis further confirms that the tumor cells have a plasma cell gene expression signature. Plasmacytoma cells infiltrated multiple loci in the bone marrow, spleen and liver; secreted immunoglobulins; and caused glomerular damage. Our findings therefore demonstrate that deregulated expression of cMYC with KRAS12V in T2 B cells rapidly generates a plasma cell disease in mice, suggesting utility of this model both to elucidate molecular pathogenesis and to validate novel targeted therapies. C1 [Hu, Y.; Tian, Z.; Goerguen, G. Topal; Munshi, N. C.; Mitsiades, C. S.; Anderson, K. C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Dept Med Oncol, Boston, MA 02215 USA. [Hu, Y.; Gali, R.; Tian, Z.; Goerguen, G. Topal; Munshi, N. C.; Mitsiades, C. S.; Anderson, K. C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02215 USA. [Zheng, M.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Gali, R.] Harvard Univ, Sch Med, Bioinformat Team C3, Countway Lib, Boston, MA 02215 USA. RP Anderson, KC (reprint author), Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA. EM kenneth_anderson@dfci.harvard.edu FU National Institutes of Health [P50-100707, P01-78378, RO1-50947] FX We thank Weihua Song, Teru Hideshima and Yu-Tzu Tai for scientific discussion; as well as the Microarray Core and the Flow Cytometry Core Facilities at Dana-Farber Cancer Institute for outstanding technical support. This study was supported in part by National Institutes of Health Grants P50-100707, P01-78378 and RO1-50947. KCA is an American Cancer Society Clinical Research Professor. NR 49 TC 4 Z9 4 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2044-5385 J9 BLOOD CANCER J JI Blood Cancer J. PD NOV PY 2013 VL 3 AR UNSP e156 DI 10.1038/bcj.2013.53 PG 11 WC Oncology SC Oncology GA 267BO UT WOS:000328069400002 PM 24185503 ER PT J AU Garvey, KC Wolpert, HA Laffel, LM Rhodes, ET Wolfsdorf, JI Finkelstein, JA AF Garvey, Katharine C. Wolpert, Howard A. Laffel, Lori M. Rhodes, Erinn T. Wolfsdorf, Joseph I. Finkelstein, Jonathan A. TI HEALTH CARE TRANSITION IN YOUNG ADULTS WITH TYPE 1 DIABETES: BARRIERS TO TIMELY ESTABLISHMENT OF ADULT DIABETES CARE SO ENDOCRINE PRACTICE LA English DT Article ID GLYCEMIC CONTROL; FOLLOW-UP; ADOLESCENTS; SYSTEMS; SERVICES; CHILDREN; PROGRAM; PEOPLE; TRENDS; COHORT AB Objective: To examine barriers to health care transition reported by young adults with type 1 diabetes and associations between barriers and prolonged gaps between pediatric and adult diabetes care. Methods: We surveyed young adults aged 22 to 30 years with type 1 diabetes about their transition experiences, including barriers to timely establishment of adult diabetes care. We evaluated relationships between barriers and gaps in care using multivariate logistic regression. Results: The response rate was 53% (258 of 484 eligible subjects). Respondents (62% female) were 26.7 +/- 2.4 years old and transitioned to adult diabetes care at 19.5 +/- 2.9 years. Reported barriers included lack of specific adult provider referral name (47%) or contact information (27%), competing life priorities (43%), difficulty getting an appointment (41%), feeling upset about leaving pediatrics (24%), and insurance problems (10%). In multivariate analysis, barriers most strongly associated with gaps in care >6 months were lack of adult provider name (odds ratio [OR], 6.1; 95% confidence interval [CI], 3.0-12.7) or contact information (OR, 5.3; 95% CI, 2.0-13.9), competing life priorities (OR, 5.2; 95% CI, 2.7-10.3), and insurance problems (OR, 3.5; 95% CI, 1.2-10.3). Overall, respondents reporting >= 1 moderate/major barrier (48%) had 4.7-fold greater adjusted odds of a gap in care >6 months (95% CI, 2.8-8.7). Conclusion: Significant barriers to transition, such as a lack of specific adult provider referrals, may be addressed with more robust preparation by pediatric providers and care coordination. Further study is needed to evaluate strategies to improve young adult self-care in the setting of competing life priorities. C1 [Garvey, Katharine C.; Laffel, Lori M.; Rhodes, Erinn T.; Wolfsdorf, Joseph I.] Boston Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA. [Wolpert, Howard A.] Joslin Diabet Ctr, Adult Sect, Boston, MA 02215 USA. [Laffel, Lori M.] Joslin Diabet Ctr, Pediat Adolescent & Young Adult Sect, Boston, MA 02215 USA. [Finkelstein, Jonathan A.] Boston Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA. [Finkelstein, Jonathan A.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA. RP Garvey, KC (reprint author), Boston Childrens Hosp, Div Endocrinol, 300 Longwood Ave, Boston, MA 02115 USA. EM katharine.garvey@childrens.harvard.edu FU Agency for Healthcare Research and Quality [T32-HS000063]; National Institute of Diabetes and Digestive and Kidney Diseases [T32DK007699-30, K12-DK094721]; William Randolph Hearst Foundation; National Institute for Child Health and Human Development [K24-HD060786]; National Institute for Diabetes and Digestive and Kidney Diseases [K12-DK094721]; Katherine Adler Astrove Youth Education Fund; Eleanor Chesterman Beatson Fund FX Dr. Garvey was supported by grants from the Agency for Healthcare Research and Quality (T32-HS000063), the National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007699-30 and K12-DK094721), and the William Randolph Hearst Foundation. Dr. Finkelstein's work on this project was funded by a grant from the National Institute for Child Health and Human Development (K24-HD060786). Dr. Laffel's work on this project was funded by a grant from the National Institute for Diabetes and Digestive and Kidney Diseases (K12-DK094721) and by the Katherine Adler Astrove Youth Education and Eleanor Chesterman Beatson Funds. The authors presented results of this study in abstract form at the 73rd American Diabetes Association Scientific Sessions, June 2012, Philadelphia, PA. NR 33 TC 15 Z9 15 U1 1 U2 6 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD NOV-DEC PY 2013 VL 19 IS 6 BP 946 EP 952 DI 10.4158/EP13109.OR PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 261EB UT WOS:000327645900014 PM 23807526 ER PT J AU Routhier, CA Mochel, MC Lynch, K Dias-Santagata, D Louis, DN Hoang, MP AF Routhier, Caitlin Ann Mochel, Mark C. Lynch, Kerry Dias-Santagata, Dora Louis, David N. Hoang, Mai P. TI Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas SO HUMAN PATHOLOGY LA English DT Article DE BRAF V600E; Immunohistochemistry; VE1; Anti-B-Raf; Melanoma; Thyroid carcinoma; Glioma ID HAIRY-CELL LEUKEMIA; IMPROVED SURVIVAL; MEK INHIBITION; MUTANT BRAF; CANCER; GENE; VEMURAFENIB; THERAPY; PROTEIN; TUMORS AB BRAF mutation is seen in a variety of human neoplasms including cutaneous malignant melanoma, papillary thyroid carcinoma, colorectal carcinoma, non small cell lung carcinoma, pleomorphic xanthoastrocytoma, and others. Currently, there are 2 commercially available monoclonal antibodies for the detection of BRAF V600E mutation; however, a full and practical comparison of their performance in various tumor types on an automated staining platform has not been done. We investigated their sensitivity and specificity in detecting the BRAF V600E mutation in a series of 152 tumors including 31 malignant melanomas, 25 lung carcinomas, 32 gastrointestinal carcinomas, 23 thyroid carcinomas, 35 gliomas, and 6 other malignancies. In this series, the concordance rate between immunohistochemistry (IHC) and mutational analyses was 97% (148/152) for VE1 and 88% (131/149) for anti-B-Rat The sensitivity and specificity were 98% (60/61) and 97% (88/91) for monoclonal VE1 and 95% (58/61) and 83% (73/88) for anti-B-Raf, respectively. There were 4 cases with discordant IHC and mutational results for monoclonal VE1 in contrast to 18 cases for anti-B-Raf. Our studies showed that IHC with monoclonal VE1 has a better performance compared with anti-B-Raf in an automated staining platform and confirmed that clone VE1 provides excellent sensitivity and specificity for detecting the BRAF V600E mutation in a variety of tumor types in a clinical setting. (C) 2013 Elsevier Inc. All rights reserved. C1 [Hoang, Mai P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Hoang, MP (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. EM mhoang@partners.org NR 36 TC 49 Z9 49 U1 1 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0046-8177 EI 1532-8392 J9 HUM PATHOL JI Hum. Pathol. PD NOV PY 2013 VL 44 IS 11 BP 2563 EP 2570 DI 10.1016/j.humpath.2013.06.018 PG 8 WC Pathology SC Pathology GA 261SB UT WOS:000327683800024 PM 24071017 ER PT J AU Hall, YN Choi, AI Xu, P Smith, NL Boyko, EJ AF Hall, Yoshio N. Choi, Andy I. Xu, Ping Smith, Nicholas L. Boyko, Edward J. TI Predictors of End-stage Renal Disease in the Urban Poor SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE End-stage renal disease; chronic kidney disease; urban poor; race or ethnicity; public health care; disparities ID CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR EVENTS; RACIAL-DIFFERENCES; RISK-FACTORS; PROTEINURIA; HIV; OUTCOMES; ASSOCIATION; DISPARITIES; PROGRESSION AB We sought to examine the influence of social and clinical factors on risk of progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD) in the urban poor. We studied 15,353 individuals with moderate-to-advanced CKD who received ambulatory care within a large public health system during 1996-2005. The primary outcome was progression to ESRD. Overall, 559 cases of ESRD occurred over a median follow-up of 2.8 years. Among traditional predictors of ESRD, younger age, male sex, non-White race/ethnicity, public health insurance coverage, diabetes, lower kidney function, higher proteinuria, lower hemoglobin level, and lower serum albumin concentration were significantly associated with a higher adjusted ESRD risk (p<.001 for all). There was no significant association between HIV/AIDS (p=.07), viral hepatitis (p=.11), or non-English language (p=.27) and ESRD risk. Our results highlight the importance of addressing traditional risk factors for progressive CKD to reduce the disproportionate burden of ESRD among disadvantaged populations. C1 [Hall, Yoshio N.; Xu, Ping] Univ Washington, Kidney Res Inst, Dept Med, Seattle, WA 98104 USA. [Choi, Andy I.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Choi, Andy I.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Choi, Andy I.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Hall, Yoshio N.; Smith, Nicholas L.; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Hall, YN (reprint author), Univ Washington, Kidney Res Inst, 325 9th Ave, Seattle, WA 98104 USA. EM ynhall@u.washington.edu FU NCRR NIH HHS [UL1 RR024131, KL2 RR024130]; NIDDK NIH HHS [K23 DK087900, K23 DK080645, K23 DK 087900, K23 DK 080645] NR 39 TC 6 Z9 6 U1 3 U2 6 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 EI 1548-6869 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD NOV PY 2013 VL 24 IS 4 BP 1686 EP 1700 PG 15 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 251CG UT WOS:000326904800025 PM 24185164 ER PT J AU Sun, L Pan, JP Peng, YZ Wu, Y Li, JH Liu, X Qin, YW Bauman, WA Cardozo, C Zaidi, M Qin, WP AF Sun, Li Pan, Jiangping Peng, Yuanzhen Wu, Yong Li, Jianghua Liu, Xuan Qin, Yiwen Bauman, William A. Cardozo, Christopher Zaidi, Mone Qin, Weiping TI Anabolic steroids reduce spinal cord injury-related bone loss in rats associated with increased Wnt signaling SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Spinal cord injuries; Nandrolone; Androgens; Hypogonadism; Bone loss; Wnt signaling ID EXPRESSION; DIFFERENTIATION; ANDROGENS; TURNOVER; CELLS; GENE AB Background: Spinal cord injury (SCI) causes severe bone loss. At present, there is no practical treatment to delay or prevent bone loss in individuals with motor-complete SCI. Hypogonadism is common in men after SCI and may exacerbate bone loss. The anabolic steroid nandrolone reduces bone loss due to microgravity or nerve transection. Objective: To determine whether nandrolone reduced bone loss after SCI and, if so, to explore the mechanisms of nandrolone action. Methods: Male rats with complete transection of the spinal cord were administered nandrolone combined with a physiological replacement dose of testosterone, or vehicle, beginning on day 29 after SCI and continued for 28 days. Results: SCI reduced distal femoral and proximal tibial bone mineral density (BMD) by 25 and 16%, respectively, at 56 days. This bone loss was attenuated by nandrolone. In ex vivo osteoclasts cultures, SCI increased mRNA levels for tartrate-resistant acid phosphatase (TRAP) and calcitonin receptor; nandrolone-normalized expression levels of these transcripts. In ex vivo osteoblast cultures, SCI increased receptor activator of NF-kB ligand (RANKL) mRNA levels but did not alter osteoprotegerin (OPG) mRNA expression; nandrolone-increased expression of OPG and OPG/RANKL ratio. SCI reduced mRNA levels of Wnt signaling-related genes Wnt3a, low-density lipoprotein receptor-related protein 5 (LRP5), Fzd5, Tcf7, and ectodermal-neural cortex 1 (ENC1) in osteoblasts, whereas nandrolone increased expression of each of these genes. Conclusions: The results demonstrate that nandrolone reduces bone loss after SCI. A potential mechanism is suggested by our findings wherein nandrolone modulates genes for differentiation and activity of osteoclasts and osteoblasts, at least in part, through the activation of Wnt signaling. C1 [Sun, Li; Peng, Yuanzhen; Li, Jianghua; Liu, Xuan; Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY USA. [Pan, Jiangping; Wu, Yong; Qin, Yiwen; Bauman, William A.; Cardozo, Christopher; Qin, Weiping] James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, Bronx, NY 10468 USA. [Bauman, William A.; Cardozo, Christopher; Qin, Weiping] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP Qin, WP (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Weiping.qin@mssm.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service [B3347K, B4616R, B4162C]; Department of Defense [SC090504]; NIH [AG23176, DK 70525, DK 80459] FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service Grants B3347K, B4616R, and B4162C, the Department of Defense Grant SC090504, and NIH Grants (AG23176, DK 70525, and DK 80459). NR 19 TC 15 Z9 15 U1 1 U2 7 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD NOV PY 2013 VL 36 IS 6 BP 616 EP 622 DI 10.1179/2045772312Y.0000000020 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 264JC UT WOS:000327871900006 PM 24090150 ER PT J AU Locatelli, SM LaVela, SL Hogan, TP Goldstein, B AF Locatelli, Sara M. LaVela, Sherri L. Hogan, Timothy P. Goldstein, Barry TI Influenza infection control guidance provided to staff at Veterans Affairs facilities for veterans with spinal cord injury during a pandemic SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Infection control; Hygiene; Vaccination; Immunization; Patient education; Veterans; Spinal cord injuries; Paraplegia; Tetraplegia; Influenza; Human; Pandemics; Access to care ID DEATH; CONTAMINATION; VACCINATION; ENVIRONMENT AB Context/objective: To assess guidance provided to staff at Veterans Affairs (VA) healthcare facilities on H1N1 influenza infection control for veterans with spinal cord injuries and disorders (SCI/D). Study design: Cross-sectional qualitative semi-structured interviews. Setting: Thirty-three VA healthcare facilities from throughout the United States that provide care to veterans with SCI/D. Participants: Thirty-three infection control key informants, each representing a VA healthcare facility. Interventions: None. Outcome measures: Infection control practices, including vaccination practices, hospital preparedness, and recommendations for future pandemics, both in general and specifically to SCI/D. Results: Most (n = 26, 78.8%) infection control key informants believed veterans with SCI/D were at increased risk for influenza and complications, but only 17 (51.5%) said veterans with SCI/D were treated as a priority group for vaccination at their facilities. There was little special guidance provided for treating veterans with SCI/D, and most (n = 28, 84.8%) informants said that infection control procedures and recommendations were applied universally. Yet, 10 key informants discussed 'unique challenges' to infection control in the SCI/D population. Informants discussed the potential for infectious agents to be spread through shared and common use equipment and the necessity of including caregivers in any vaccination or educational campaigns. Conclusion: Greater input by experts knowledgeable about SCI/D is recommended to adequately address pandemic influenza within healthcare facilities where individuals with SCI/D receive care. C1 [Locatelli, Sara M.; LaVela, Sherri L.] Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA. [Locatelli, Sara M.; LaVela, Sherri L.; Goldstein, Barry] Edward Hines Jr VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL USA. [LaVela, Sherri L.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA. [Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. [Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Adm Hosp, eHlth Qual Enhancement Res Initiat, Natl eHlth QUERI Coordinating Ctr, Bedford, MA 01730 USA. [Hogan, Timothy P.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Worcester, MA USA. [Goldstein, Barry] VA Puget Sound Healthcare Syst, SCI Healthcare Grp, Seattle, WA USA. RP Locatelli, SM (reprint author), 5000 S 5th Ave 151H, Hines, IL 60141 USA. EM Sara.Locatelli@va.gov FU Office of Research and Development, Health Services Research and Development; Spinal Cord Injury Quality Enhancement Research Initiative, of the Department of Veterans Affairs [RRP 10-046] FX This material is based on work supported by the Office of Research and Development, Health Services Research and Development, and Spinal Cord Injury Quality Enhancement Research Initiative, of the Department of Veterans Affairs (Project number: RRP 10-046). This study reflects only the authors' opinions and does not necessarily reflect the official position of the Department of Veterans Affairs. NR 26 TC 2 Z9 2 U1 1 U2 2 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD NOV PY 2013 VL 36 IS 6 BP 666 EP 671 DI 10.1179/2045772313Y.0000000112 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 264JC UT WOS:000327871900013 PM 24090346 ER PT J AU Masrur, S Smith, EE Saver, JL Reeves, MJ Bhatt, DL Zhao, X Olson, D Pan, WQ Hernandez, AF Fonarow, GC Schwamm, LH AF Masrur, Shihab Smith, Eric E. Saver, Jeffrey L. Reeves, Mathew J. Bhatt, Deepak L. Zhao, Xin Olson, DaiWai Pan, Wenqin Hernandez, Adrian F. Fonarow, Gregg C. Schwamm, Lee H. TI Dysphagia Screening and Hospital-acquired Pneumonia in Patients with Acute Ischemic Stroke: Findings from Get with the Guidelines-Stroke SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES LA English DT Article DE Acute stroke; pneumonia; dysphagia screening ID ASPIRATION; CARE; RISK; COMPLICATIONS; ASSOCIATION; ATTACK AB Background: National guidelines recommend dysphagia screening (DS) before oral intake in stroke patients to reduce hospital-acquired pneumonia (HAP). We examined the relationship between DS and HAP after ischemic stroke. Methods: Get with the Guidelines-Stroke defines HAP as postadmission diagnosis of pneumonia requiring antibiotics, and DS as the use of bedside swallow screening prior to oral intake. Univariable and multivariable analyses examined the relationship between DS and HAP. Results: Among 314,007 ischemic stroke patients at 1244 Get with the Guidelines-Stroke hospitals from 2003-2009 who were eligible for DS and had completed HAP data, a total of 216,372 (68.9%) underwent DS and a total of 17,906 (5.7%) developed HAP. When compared with patients without HAP, patients with HAP were older, had admission National Institutes of Health Stroke Scale (NIHSS) score (median NIHSS score: 10 versus 4), were more likely to undergo DS (75.5% versus 68.5%), and had increased length of stay and in-hospital mortality (12.4% versus 2.3%). In multivariable analyses, factors independently associated with a lower risk of HAP were female gender (odds ratio [OR] 0.84), dyslipidemia (OR 0.84), and hypertension (OR 0.94). DS was associated with a higher adjusted OR for HAP (OR 1.40), but the OR was greatly attenuated after adding NIHSS score to the model (OR 1.10). Conclusions: HAP occurs in 1 of 17 hospitalized stroke patients and is associated with a greater than 5-fold increase in mortality. DS did not occur in 31.1% of eligible patients, with increased screening among those with more severe strokes and those who developed HAP. The attenuation of the relationship between DS and HAP risk when controlling for NIHSS score suggests the association between screening and pneumonia is confounded by severity. Controlled trials are needed to determine DS effectiveness. C1 [Masrur, Shihab] Berkshire Med Ctr, Dept Med, Pittsfield, MA 01201 USA. [Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada. [Saver, Jeffrey L.; Fonarow, Gregg C.] Ronald Reagan Univ Calif Los Angeles Med Ctr, Los Angeles, CA USA. [Reeves, Mathew J.] Michigan State Univ, E Lansing, MI 48824 USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, Dept Cardiol, Dept Vet Affairs Boston Healthcare Syst, Boston, MA 02115 USA. [Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA. [Zhao, Xin; Olson, DaiWai; Pan, Wenqin; Hernandez, Adrian F.] Duke Clin Res Inst, Durham, NC USA. [Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Masrur, S (reprint author), Berkshire Med Ctr, Dept Med, 725 North St, Pittsfield, MA 01201 USA. EM shihabmasrur@hotmail.com RI Smith, Eric/C-5443-2012; Hernandez, Adrian F./A-7818-2016 OI Smith, Eric/0000-0003-3956-1668; Saver, Jeffrey/0000-0001-9141-2251; Schwamm, Lee/0000-0003-0592-9145; Hernandez, Adrian F./0000-0003-3387-9616 NR 27 TC 9 Z9 9 U1 2 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1052-3057 EI 1532-8511 J9 J STROKE CEREBROVASC JI J. Stroke Cerebrovasc. Dis. PD NOV PY 2013 VL 22 IS 8 BP E301 EP E309 DI 10.1016/j.jstrokecerebrovasdis.2012.11.013 PG 9 WC Neurosciences; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 262FF UT WOS:000327719000007 PM 23305674 ER PT J AU Mitchell, DG Javitt, MC Glanc, P Bennett, GL Brown, DL Dubinsky, T Harisinghani, MG Harris, RD Horowitz, NS Pandharipande, PV Pannu, HK Podrasky, AE Royal, HD Shipp, TD Siegel, CL Simpson, L Wong-You-Cheong, JJ Zelop, CM AF Mitchell, Donald G. Javitt, Marcia C. Glanc, Phyllis Bennett, Genevieve L. Brown, Douglas L. Dubinsky, Theodore Harisinghani, Mukesh G. Harris, Robert D. Horowitz, Neil S. Pandharipande, Pari V. Pannu, Harpreet K. Podrasky, Ann E. Royal, Henry D. Shipp, Thomas D. Siegel, Cary Lynn Simpson, Lynn Wong-You-Cheong, Jade J. Zelop, Carolyn M. TI ACR Appropriateness Criteria Staging and Follow-up of Ovarian Cancer SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Appropriateness criteria; ovarian cancer; cancer staging; FDG-PET; MRI; CT ID POSITRON-EMISSION-TOMOGRAPHY; SUBOPTIMAL PRIMARY CYTOREDUCTION; IMAGE-GUIDED BIOPSY; COMPUTED-TOMOGRAPHY; DIAGNOSTIC-ACCURACY; FDG-PET/CT; PERITONEAL CARCINOMATOSIS; HISTOPATHOLOGIC FINDINGS; TRANSVAGINAL SONOGRAPHY; 2ND-LOOK LAPAROTOMY AB Imaging is used to detect and characterize adnexal masses and to stage ovarian cancer both before and after initial treatment, although the role for imaging in screening for ovarian cancer has not been established. CT and MRI have been used to determine the resectability of tumors, the candidacy of patients for effective cytoreductive surgery, the need for postoperative chemotherapy if debulking is suboptimal, and the need for referral to a gynecologic oncologist. Radiographic studies such as contrast enema and urography have been replaced by CT and other cross-sectional imaging for staging ovarian cancer. Contrast-enhanced CT is the procedure of choice for preoperative staging of ovarian cancer. MRI without and with contrast may be useful after equivocal CT, but is usually not the best initial procedure for ovarian cancer staging. Fluorine-18-2-fluoro-2-deoxy-D-glucose-PET/CT may not be needed preoperatively, but its use is appropriate for detecting and defining post-treatment recurrence. Ultrasound is useful for evaluating adnexal disease, but has limited utility for staging ovarian cancer. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. C1 [Mitchell, Donald G.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. [Javitt, Marcia C.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA. [Glanc, Phyllis] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada. [Bennett, Genevieve L.] NYU, Med Ctr, New York, NY 10016 USA. [Brown, Douglas L.] Mayo Clin, Rochester, MN USA. [Dubinsky, Theodore] Univ Washington, Sch Med, Seattle, WA USA. [Harisinghani, Mukesh G.; Pandharipande, Pari V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Harris, Robert D.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [Horowitz, Neil S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Horowitz, Neil S.] Soc Gynecol Oncol, Chicago, IL USA. [Pannu, Harpreet K.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Podrasky, Ann E.] Baptist Hosp Miami, South Miami Ctr Women & Infants, Miami, FL USA. [Royal, Henry D.; Siegel, Cary Lynn] Washington Univ, Med Ctr, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA. [Royal, Henry D.] Soc Nucl Med, Reston, VA USA. [Shipp, Thomas D.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Shipp, Thomas D.; Simpson, Lynn; Zelop, Carolyn M.] Amer Coll Obstetricians & Gynecologists, Washington, DC USA. [Simpson, Lynn] Columbia Univ, New York, NY USA. [Wong-You-Cheong, Jade J.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Zelop, Carolyn M.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. RP Mitchell, DG (reprint author), 1891 Preston White Dr, Reston, VA 20191 USA. EM donald.mitchell@jefferson.edu NR 69 TC 17 Z9 17 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD NOV PY 2013 VL 10 IS 11 BP 822 EP 827 DI 10.1016/j.jacr.2013.07.017 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 257WI UT WOS:000327418100008 PM 24183551 ER PT J AU Wintermark, M Sanelli, PC Albers, GW Bello, JA Derdeyn, CP Hetts, SW Johnson, MH Kidwell, CS Lev, MH Liebeskind, DS Rowley, HA Schaefer, PW Sunshine, JL Zaharchuk, G Meltzer, CC AF Wintermark, Max Sanelli, Pina C. Albers, Gregory W. Bello, Jacqueline A. Derdeyn, Colin P. Hetts, Steven W. Johnson, Michele H. Kidwell, Chelsea S. Lev, Michael H. Liebeskind, David S. Rowley, Howard A. Schaefer, Pamela W. Sunshine, Jeffrey L. Zaharchuk, Greg Meltzer, Carolyn C. TI Imaging Recommendations for Acute Stroke and Transient Ischemic Attack Patients SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Stroke; thrombolysis; computed tomography; magnetic resonance imaging; catheter angiography ID TISSUE-PLASMINOGEN ACTIVATOR; HEALTH-CARE PROFESSIONALS; INTRACRANIAL HEMORRHAGE; AMERICAN-ACADEMY; DIFFUSION; THROMBOLYSIS; MRI; ASSOCIATION; ECASS; REPERFUSION AB In the article entitled "Imaging Recommendations for Acute Stroke and Transient Ischemic Attack Patients: A Joint Statement by the American Society of Neuroradiology, the American College of Radiology and the Society of NeuroInterventional Surgery", we are proposing a simple, pragmatic approach that will allow the reader to develop an optimal imaging algorithm for stroke patients at their institution. C1 [Wintermark, Max] Univ Virginia, Div Neuroradiol, Charlottesville, VA 22903 USA. [Sanelli, Pina C.] NewYork Presbyterian Hosp, Weill Cornell Med Coll, Dept Radiol, New York, NY USA. [Albers, Gregory W.] Stanford Univ, Stanford Stroke Ctr, Stanford, CA 94305 USA. [Bello, Jacqueline A.] Montefiore Med Ctr, Albert Einstein Coll Med, Div Neuroradiol, Bronx, NY 10467 USA. [Derdeyn, Colin P.] Washington Univ, Med Ctr, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA. [Derdeyn, Colin P.] Washington Univ, Sch Med, Stroke & Cerebrovasc Ctr, St Louis, MO USA. [Hetts, Steven W.] Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA USA. [Hetts, Steven W.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Johnson, Michele H.] Yale Univ, Sch Med, Div Neuroradiol, New Haven, CT USA. [Kidwell, Chelsea S.] Georgetown Univ, Med Ctr, Stroke Ctr, Washington, DC 20007 USA. [Lev, Michael H.; Schaefer, Pamela W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA. [Schaefer, Pamela W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Neuroradiol, Boston, MA USA. [Liebeskind, David S.] Univ Calif Los Angeles, Dept Neurol, Stroke Ctr, Los Angeles, CA 90024 USA. [Rowley, Howard A.] Univ Wisconsin, Sch Med & Publ Hlth, Div Neuroradiol, Madison, WI USA. [Sunshine, Jeffrey L.] Case Western Reserve Univ, Div Neuroradiol, Cleveland, OH 44106 USA. [Sunshine, Jeffrey L.] Univ Hosp Cleveland, Cleveland, OH 44106 USA. [Zaharchuk, Greg] Stanford Univ, Div Neuroradiol, Stanford, CA 94305 USA. [Meltzer, Carolyn C.] Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA. RP Wintermark, M (reprint author), Univ Virginia, Dept Radiol, 1215 Lee St,Room 1826, Charlottesville, VA 22903 USA. EM max.wintermark@gmail.com RI Demchuk, Andrew/E-1103-2012; OI Demchuk, Andrew/0000-0002-4930-7789; Wintermark, Max/0000-0002-6726-3951 FU NINDS NIH HHS [K24 NS072272] NR 31 TC 16 Z9 16 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD NOV PY 2013 VL 10 IS 11 BP 828 EP 832 DI 10.1016/j.jacr.2013.06.019 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 257WI UT WOS:000327418100009 PM 23948676 ER PT J AU Heller, MT Harisinghani, M Neitlich, JD Yeghiayan, P Berland, LL AF Heller, Matthew T. Harisinghani, Mukesh Neitlich, Jeffrey D. Yeghiayan, Paula Berland, Lincoln L. TI Managing Incidental Findings on Abdominal and Pelvic CT and MRI, Part 3: White Paper of the ACR Incidental Findings Committee II on Splenic and Nodal Findings SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE Incidental findings; incidentaloma; ACR; consensus; CT; MRI; splenic lesion; adenopathy ID RADIOLOGIC-PATHOLOGICAL CORRELATION; SYSTEMIC-LUPUS-ERYTHEMATOSUS; LYMPH-NODES; IMAGING FINDINGS; LESIONS; LYMPHADENOPATHY; SPLEEN; HAMARTOMA; CRITERIA; CANCER AB This white paper describes splenic and nodal incidental findings found on CT and MRI. Recommendations for management are included. This represents the third of 4 such papers from the ACR Incidental Findings Committee II, which used a consensus method based on repeated reviews and revisions and a collective review and interpretation of relevant literature. Topics include descriptions of appearances of several types of splenic lesions and, the importance of size and distribution of lymph nodes. Flowcharts are provided for reference. C1 [Heller, Matthew T.] Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA USA. [Heller, Matthew T.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Harisinghani, Mukesh] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Neitlich, Jeffrey D.] Third Eye Teleradiol, Dept Radiol, Sequim, WA USA. [Yeghiayan, Paula] Wyckoff Hts Med Ctr, Dept Radiol, Brooklyn, NY USA. [Berland, Lincoln L.] Univ Alabama Birmingham, Dept Radiol, Birmingham, AL 35249 USA. RP Berland, LL (reprint author), Univ Alabama Birmingham, Dept Radiol, 619 S 19th St,N454, Birmingham, AL 35249 USA. EM lberland@uabmc.edu NR 31 TC 27 Z9 27 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD NOV PY 2013 VL 10 IS 11 BP 833 EP 839 DI 10.1016/j.jacr.2013.05.020 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 257WI UT WOS:000327418100010 PM 24183552 ER PT J AU Favinger, J Bastawrous, S Bhargava, P AF Favinger, Jennifer Bastawrous, Sarah Bhargava, Puneet TI Management of Acute Contrast Media Reactions: Assessing Preparedness of a Tertiary Care Veterans Affairs Medical Center SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material C1 [Favinger, Jennifer; Bastawrous, Sarah; Bhargava, Puneet] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA. [Bastawrous, Sarah; Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA 98108 USA. [Bastawrous, Sarah; Bhargava, Puneet] Univ Washington, Sch Med, Seattle, WA USA. RP Bhargava, P (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,Mail Box 358280, Seattle, WA 98108 USA. EM bhargp@uw.edu OI Bastawrous, Sarah/0000-0002-7690-3121; Bhargava, Puneet/0000-0002-3849-9666 NR 6 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD NOV PY 2013 VL 10 IS 11 BP 872 EP 874 DI 10.1016/j.jacr.2012.12.019 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 257WI UT WOS:000327418100018 PM 23433785 ER PT J AU Gee, MS Bittman, M Epelman, M Vargas, SO Lee, EY AF Gee, Michael S. Bittman, Mark Epelman, Monica Vargas, Sara O. Lee, Edward Y. TI Magnetic Resonance Imaging of the Pediatric Kidney Benign and Malignant Masses SO MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA LA English DT Article DE Children; Pediatric; Kidney; Mass; Magnetic resonance imaging ID RENAL-CELL CARCINOMA; WILMS-TUMOR; MEDULLARY CARCINOMA; MESOBLASTIC NEPHROMA; CYSTIC NEPHROMA; CHILDREN; CT; CHILDHOOD; LESIONS; ANGIOMYOLIPOMA AB The differential diagnosis of renal masses in pediatric patients includes benign and malignant tumors, as well as nonneoplastic mass-like lesions mimicking tumors. fAlthough the spectrum of renal masses in children has some overlap with that of adults, it is important to understand the renal pathologic processes specific to the pediatric population, as well as their characteristic imaging appearances and clinical presentations. This article reviews benign and malignant renal masses in children, with an emphasis on magnetic resonance imaging and clinical features that are specific to each lesion type. C1 [Gee, Michael S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Bittman, Mark] North Shore Long Isl Jewish Med Ctr, Cohen Childrens Med Ctr New York, Dept Radiol, New Hyde Pk, NY 11040 USA. [Epelman, Monica] Nemours Childrens Hosp, Dept Radiol, Orlando, FL 32827 USA. [Vargas, Sara O.] Boston Childrens Hosp, Dept Pathol, Boston, MA 02115 USA. [Lee, Edward Y.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Thorac Imaging,Dept Radiol, Boston, MA 02115 USA. RP Lee, EY (reprint author), Harvard Univ, Sch Med, Boston Childrens Hosp, Div Thorac Imaging,Dept Radiol, 300 Longwood Ave, Boston, MA 02115 USA. EM Edward.Lee@childrens.harvard.edu OI Bittman, Mark/0000-0003-4627-8860 NR 54 TC 1 Z9 1 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1064-9689 EI 1557-9786 J9 MAGN RESON IMAGING C JI Magn. Reson. Imaging Clin. N. Am. PD NOV PY 2013 VL 21 IS 4 BP 697 EP + DI 10.1016/j.mric.2013.06.001 PG 21 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 260CT UT WOS:000327573300006 PM 24183521 ER PT J AU Epelman, M Dinan, D Gee, MS Servaes, S Lee, EY Darge, K AF Epelman, Monica Dinan, David Gee, Michael S. Servaes, Sabah Lee, Edward Y. Darge, Kassa TI Mullerian Duct and Related Anomalies in Children and Adolescents SO MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA LA English DT Article DE Mullerian anomalies; Children; Uterine anomalies; Vaginal anomalies ID CONGENITAL UTERINE ANOMALIES; OBSTRUCTED UTEROVAGINAL ANOMALIES; IPSILATERAL RENAL AGENESIS; WERNER-WUNDERLICH-SYNDROME; GENITOURINARY ABNORMALITIES; 3-DIMENSIONAL ULTRASOUND; VAGINAL ANOMALIES; IMAGING FINDINGS; GENITAL-TRACT; DIAGNOSIS AB Although many Mullerian duct anomalies do not require treatment, surgical intervention is sometimes necessary to enable sexual activity or to preserve fertility. The identification of these anomalies is important for optimal clinical management or surgical treatment. Magnetic resonance (MR) imaging is a robust method for adequately evaluating and characterizing uterine and vaginal anomalies. The information provided by MR imaging allows for a more complete understanding of the malformation, facilitating management decisions and potentially changing the outcome. In this article, the embryology, classification, and MR imaging findings of Mullerian duct and related anomalies in children and adolescents are reviewed. C1 [Epelman, Monica; Dinan, David] Nemours Childrens Hosp, Dept Med Imaging, Orlando, FL 32827 USA. [Gee, Michael S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Sect Pediat Imaging,Dept Radiol, Boston, MA 02114 USA. [Gee, Michael S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Sect Abdominal Imaging & Intervent,Dept Radiol, Boston, MA 02114 USA. [Servaes, Sabah] Univ Penn, Perelman Sch Med, Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA. [Lee, Edward Y.] Boston Childrens Hosp, Dept Radiol, Div Thorac Imaging, Boston, MA 02115 USA. [Lee, Edward Y.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Darge, Kassa] Univ Penn, Perelman Sch Med, Childrens Hosp Philadelphia, Div Body Imaging,Dept Radiol, Philadelphia, PA 19104 USA. RP Epelman, M (reprint author), Nemours Childrens Hosp, Dept Med Imaging, 13535 Nemours Pkwy, Orlando, FL 32827 USA. EM Monica.Epelman@nemours.org NR 64 TC 6 Z9 9 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1064-9689 EI 1557-9786 J9 MAGN RESON IMAGING C JI Magn. Reson. Imaging Clin. N. Am. PD NOV PY 2013 VL 21 IS 4 BP 773 EP + DI 10.1016/j.mric.2013.04.011 PG 19 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 260CT UT WOS:000327573300010 PM 24183525 ER PT J AU Bagheri, A Delmonico, FL AF Bagheri, Alireza Delmonico, Francis L. TI Guest editorial: Organ trafficking and transplant tourism: a call for international collaboration SO MEDICINE HEALTH CARE AND PHILOSOPHY LA English DT Editorial Material C1 [Bagheri, Alireza] Univ Tehran Med Sci, Tehran, Iran. [Delmonico, Francis L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplant Ctr, Boston, MA USA. RP Bagheri, A (reprint author), Univ Tehran Med Sci, Tehran, Iran. EM bagheria@yahoo.com NR 8 TC 1 Z9 1 U1 0 U2 7 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1386-7423 EI 1572-8633 J9 MED HEALTH CARE PHIL JI Med. Health Care Philos. PD NOV PY 2013 VL 16 IS 4 BP 885 EP 886 DI 10.1007/s11019-013-9503-3 PG 2 WC Ethics; History & Philosophy Of Science SC Social Sciences - Other Topics; History & Philosophy of Science GA 253ZE UT WOS:000327128500028 PM 23860691 ER PT J AU Bagheri, A Delmonico, FL AF Bagheri, Alireza Delmonico, Francis L. TI Global initiatives to tackle organ trafficking and transplant tourism SO MEDICINE HEALTH CARE AND PHILOSOPHY LA English DT Review DE Organ transplantation; Organ trafficking; Transplant tourism; Istanbul Declaration; Asian Task Force; International guidelines ID DONATION; DECLARATION; ISTANBUL; TRADE AB The increasing gap between organ supply and demand has opened the door for illegal organ sale, trafficking of human organs, tissues and cells, as well as transplant tourism. Currently, underprivileged and vulnerable populations in resource-poor countries are a major source of organs for rich patient-tourists who can afford to purchase organs at home or abroad. This paper presents a summary of international initiatives, such as World Health Organization's Principle Guidelines, The Declaration of Istanbul, Asian Task Force Recommendations, as well as UNESCO's and the United Nation's initiatives against trafficking of human organs, tissues, cells, and transplant tourism. Beyond the summary, it calls for more practical measures to be taken to implement the existing guidelines and recommendations, in order to prevent exploitation of the poor as organ providers. The paper suggests that an international legally binding agreement in criminalizing organ trafficking would be a step forward to bring a change in the global picture of organ trafficking and transplant tourism. C1 [Bagheri, Alireza] Univ Tehran Med Sci, Sch Med, Tehran, Iran. [Delmonico, Francis L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplant Ctr, Boston, MA USA. RP Bagheri, A (reprint author), Univ Tehran Med Sci, Sch Med, 23,16th Azar St,Keshavarz Blvd, Tehran, Iran. EM bagheria@yahoo.com NR 22 TC 7 Z9 7 U1 1 U2 17 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1386-7423 EI 1572-8633 J9 MED HEALTH CARE PHIL JI Med. Health Care Philos. PD NOV PY 2013 VL 16 IS 4 BP 887 EP 895 DI 10.1007/s11019-013-9493-1 PG 9 WC Ethics; History & Philosophy Of Science SC Social Sciences - Other Topics; History & Philosophy of Science GA 253ZE UT WOS:000327128500029 PM 23749286 ER PT J AU Walker, MA Slate, N Lax, T Alejos, A Volpi, S Sweetser, D Sims, K Walter, JE AF Walker, Melissa A. Slate, Nancy Lax, Timothy Alejos, Alexandra Volpi, Stefano Sweetser, David Sims, Katherine Walter, Jolan E. TI Predisposition to infection and SIRS in oxidative phosphorylation disorders: 8 years' experience of a New England cohort at Massachusetts General Hospital and partners affiliates SO MITOCHONDRION LA English DT Meeting Abstract C1 [Walker, Melissa A.] MassGen Hosp Children, Dept Pediat, Boston, MA USA. [Slate, Nancy] MGH, Dept Mol Biol, Boston, MA USA. [Lax, Timothy; Alejos, Alexandra; Walter, Jolan E.] MassGen Hosp Children, Dept Allergy & Immunol, Boston, MA USA. [Volpi, Stefano] Childrens Hosp, Dept Allergy & Immunol, Boston, MA 02115 USA. [Sweetser, David] MGHfC, Dept Genet, Boston, MA USA. [Sims, Katherine] MGHfC, Dept Neurol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1567-7249 EI 1872-8278 J9 MITOCHONDRION JI Mitochondrion PD NOV PY 2013 VL 13 IS 6 MA 23 BP 905 EP 905 DI 10.1016/j.mito.2013.07.021 PG 1 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA 255ZY UT WOS:000327280500061 ER PT J AU Sheldon, CA Polyak, E Tsukikawa, M McCormick, E Place, E Consugar, M Pierce, E Gai, XW Falk, MJ AF Sheldon, Claire A. Polyak, Erzsebet Tsukikawa, Mai McCormick, Elizabeth Place, Emily Consugar, Marc Pierce, Eric Gai, Xiaowu Falk, Marni J. TI BCoR-L1: an X-linked transcriptional co-repressor in which mutations cause multi-systemic mitochondrial disease with mtDNA depletion SO MITOCHONDRION LA English DT Meeting Abstract C1 [Sheldon, Claire A.; Polyak, Erzsebet; Tsukikawa, Mai; McCormick, Elizabeth; Place, Emily; Falk, Marni J.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA. [Sheldon, Claire A.; Polyak, Erzsebet; Tsukikawa, Mai; McCormick, Elizabeth; Place, Emily; Falk, Marni J.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Place, Emily; Consugar, Marc; Pierce, Eric] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Ocular Genom Inst, Boston, MA 02114 USA. [Gai, Xiaowu] Loyola Univ, Stritch Sch Med, Dept Mol Pharmacol & Therapeut, Mayfield, IL 60153 USA. RI Falk, Marni/K-1997-2014 NR 0 TC 0 Z9 0 U1 2 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1567-7249 EI 1872-8278 J9 MITOCHONDRION JI Mitochondrion PD NOV PY 2013 VL 13 IS 6 MA 107 BP 937 EP 937 DI 10.1016/j.mito.2013.07.099 PG 1 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA 255ZY UT WOS:000327280500139 ER PT J AU Gai, XW Ghezzi, D Johnson, MA Biagosch, C Shamseldin, H Tsukikawa, M Sheldon, C Srinivasan, S Haack, T Gorza, M Wieland, T Strom, T Polyak, E Place, E Consugar, M Ostrovsky, J Vidoni, S Reyes, A Wong, LJ Sondheimer, N Salih, M Al-Jishi, E Freisinger, P Furlan, F Lamperti, C Rodenburg, R Pierce, E Smeitink, J Prokisch, H Alkuraya, F Zeviani, M Falk, MJ AF Gai, Xiaowu Ghezzi, Daniele Johnson, Mark A. Biagosch, Caroline Shamseldin, Hanah Tsukikawa, Mai Sheldon, Claire Srinivasan, Satish Haack, Tobias Gorza, Matteo Wieland, Thomas Strom, Tim Polyak, Erzsebet Place, Emily Consugar, Mark Ostrovsky, Julian Vidoni, Sara Reyes, Aurelio Wong, Lee-Jun Sondheimer, Neal Salih, Mustafa Al-Jishi, Emtethal Freisinger, Peter Furlan, Francesca Lamperti, Costanza Rodenburg, Richard Pierce, Eric Smeitink, Jan Prokisch, Holger Alkuraya, Fowzan Zeviani, Massimo Falk, Marni J. TI FBXL4 is a mitochondria-localized protein in which autosomal recessive mutations cause multiple respiratory chain multisystem disease commonly involving cortical atrophy and leukodystrophy SO MITOCHONDRION LA English DT Meeting Abstract C1 [Gai, Xiaowu] Loyola Univ, Stritch Sch Med, Dept Mol Pharmacol & Therapeut, Mayfield, IL 60153 USA. [Ghezzi, Daniele; Lamperti, Costanza; Zeviani, Massimo] Inst Neurol Besta, Dept Mol Neurogenet, Milan, Italy. [Johnson, Mark A.; Vidoni, Sara; Reyes, Aurelio; Zeviani, Massimo] Univ Cambridge, MRC Mitochondrial Biol Unit, Cambridge CB2 1TN, England. [Biagosch, Caroline; Haack, Tobias; Gorza, Matteo; Wieland, Thomas; Strom, Tim; Prokisch, Holger] Tech Univ Munich, Inst Human Genet, D-81675 Munich, Germany. [Biagosch, Caroline; Haack, Tobias; Gorza, Matteo; Wieland, Thomas; Strom, Tim; Prokisch, Holger] Helmholtz Zentrum Munich, D-81675 Munich, Germany. [Shamseldin, Hanah] King Faisal Specialist Hosp & Res Ctr, Dept Genet, Riyadh 11211, Saudi Arabia. [Tsukikawa, Mai; Sheldon, Claire; Polyak, Erzsebet; Place, Emily; Ostrovsky, Julian; Sondheimer, Neal; Falk, Marni J.] Childrens Hosp Philadelphia, Dept Pediat, Div Human Genet, Philadelphia, PA 19104 USA. [Tsukikawa, Mai; Sheldon, Claire; Polyak, Erzsebet; Place, Emily; Ostrovsky, Julian; Sondheimer, Neal; Falk, Marni J.] Childrens Hosp Philadelphia, Dept Pediat, Div Metab Dis, Philadelphia, PA 19104 USA. [Tsukikawa, Mai; Sheldon, Claire; Polyak, Erzsebet; Place, Emily; Ostrovsky, Julian; Sondheimer, Neal; Falk, Marni J.] Univ Penn, Perleman Sch Med, Philadelphia, PA 19104 USA. [Srinivasan, Satish] Univ Penn, Dept Anim Biol, Sch Vet Med, Philadelphia, PA 19104 USA. [Place, Emily; Consugar, Mark; Pierce, Eric] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Ocular Genom Inst, Boston, MA 02114 USA. [Wong, Lee-Jun] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA. [Salih, Mustafa] King Khalid Univ Hosp, Dept Pediat, Riyadh 11472, Saudi Arabia. [Salih, Mustafa] King Saud Univ, Coll Med, Riyadh 11461, Saudi Arabia. [Al-Jishi, Emtethal] Arabian Gulf Univ, Manama, Bahrain. [Freisinger, Peter] Klinikum Reutlingen, Dept Pediat, D-72764 Reutlingen, Germany. [Furlan, Francesca] Fdn MBBM San Gerardo Univ Hosp, Unit Metab Disorders, Dept Pediat, Monza, Italy. [Rodenburg, Richard; Smeitink, Jan] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mitochondrial Disorders, Dept Pediat, NL-6525 ED Nijmegen, Netherlands. [Alkuraya, Fowzan] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia. RI Falk, Marni/K-1997-2014; Zeviani, Massimo/K-2891-2014; Smeitink, Jan/C-1351-2013; Rodenburg, Richard/N-3579-2014; Ghezzi, Daniele/J-7873-2016 OI Rodenburg, Richard/0000-0001-5227-3527; NR 0 TC 0 Z9 0 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1567-7249 EI 1872-8278 J9 MITOCHONDRION JI Mitochondrion PD NOV PY 2013 VL 13 IS 6 MA 113 BP 939 EP 940 DI 10.1016/j.mito.2013.07.104 PG 2 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA 255ZY UT WOS:000327280500144 ER PT J AU Thang, CL Boye, JI Shi, HN Zhao, X AF Thang, Cin L. Boye, Joyce I. Shi, Hai Ning Zhao, Xin TI Effects of supplementing different ratios of omega-3 and omega-6 fatty acids in western-style diets on cow's milk protein allergy in a mouse model SO MOLECULAR NUTRITION & FOOD RESEARCH LA English DT Article DE beta-Lactoglobulin; Food allergy; Mouse model; Omega 3 fatty acids; Western-style diet ID RANDOMIZED CONTROLLED-TRIAL; FISH-OIL SUPPLEMENTATION; BETA-LACTOGLOBULIN; RESOLVIN E1; HIGH-RISK; DISEASE; PREGNANCY; INFANTS; MICE; SENSITIZATION AB ScopeThis study investigated the effects of supplementing different ratios of omega-6 and omega-3 fatty acids (O6H = 10:1, O3O6 = 4:1, and O3H = 1:4) to western-style diets on cow -lactoglobulin (BLG) induced allergic reactions in Balb/c mice. Methods and resultsThree-week-old mice were randomly assigned to three diet groups (n = 20/group). At 9 wk of age, half of the mice from each dietary treatment (n = 10) were intraperitoneally (i.p.) sensitized with three weekly doses of BLG and alum while the remaining half from each group was sham sensitized (controls). One week after the final sensitization, all mice were orally challenged with BLG. Elevated BLG-specific serum Igs were observed in all sensitized and challenged mice. IFN-, MCP-1, and IL-12p40 concentrations from lymphocytes of mesenteric lymph nodes were highest in O3H mice, compared to O3O6 and O6H mice. O6H mice had the highest IL-4 concentrations from splenic lymphocytes and a significantly lower rectal temperature after the challenge in comparison to O3O6 and O3H mice. ConclusionsOur results suggest that the -3 PUFA rich diets alleviated the severity of allergic reactions, and may modulate immune response toward T helper cell (Th)1-favoured immune response while the -6 PUFA rich diet exhibited no allergy alleviation with a stronger Th2 polarized immune response. C1 [Thang, Cin L.; Zhao, Xin] McGill Univ, Dept Anim Sci, Lakeshore, PQ, Canada. [Boye, Joyce I.] Agr & Agri Food Canada, Food Res & Dev Ctr, St Hyacinthe, PQ, Canada. [Shi, Hai Ning] Massachusetts Gen Hosp, Mucosal Immunol Lab, Charlestown, MA USA. RP Zhao, X (reprint author), McGill Univ, Dept Anim Sci, Fac Agr & Environm Sci, Macdonald Campus,21,111 Lakeshore Rd, Ste Anne De Bellevue, PQ H9X 3V9, Canada. EM xin.zhao@mcgill.ca FU Agriculture and Agri-Food Canada FX This study was supported by funding from Agriculture and Agri-Food Canada to Dr. Joyce I. Boye and James McGill Professorship to Dr. Xin Zhao. The authors thank Drs. Arif Mustafa and Baurhoo Bushansingh for their help in serum fatty acid analyses. C.L.T. designed and conducted the study, acquired the data, and drafted the manuscript. J.I.B. and H.N.S. were involved in planning the study and revising the manuscript. X.Z. designed the study, interpreted the data, and revised the manuscript critically. All authors have read and approved the final manuscript. NR 39 TC 1 Z9 1 U1 7 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1613-4125 EI 1613-4133 J9 MOL NUTR FOOD RES JI Mol. Nutr. Food Res. PD NOV PY 2013 VL 57 IS 11 BP 2029 EP 2038 DI 10.1002/mnfr.201300061 PG 10 WC Food Science & Technology SC Food Science & Technology GA 261MI UT WOS:000327668800014 PM 23780918 ER PT J AU Buvall, L Rashmi, P Lopez-Rivera, E Andreeva, S Weins, A Wallentin, H Greka, A Mundel, P AF Buvall, Lisa Rashmi, Priyanka Lopez-Rivera, Esther Andreeva, Svetlana Weins, Astrid Wallentin, Hanna Greka, Anna Mundel, Peter TI Proteasomal degradation of Nck1 but not Nck2 regulates RhoA activation and actin dynamics SO NATURE COMMUNICATIONS LA English DT Article ID ADAPTER PROTEINS; KIDNEY PODOCYTES; ARP2/3 COMPLEX; CYTOSKELETON; SYNAPTOPODIN; KINASE; FAMILY; PHOSPHORYLATION; ALPHA; UBIQUITINATION AB The ubiquitously expressed adapter proteins Nck1/2 interact with a multitude of effector molecules to regulate diverse cellular functions including cytoskeletal dynamics. Here we show that Nck1, but not Nck2, is a substrate of c-Cbl-mediated ubiquitination. We uncover lysine 178 in Nck1 as the evolutionarily conserved ubiquitin acceptor site. We previously reported that synaptopodin, a proline-rich actin-binding protein, induces stress fibres by blocking the Smurf1-mediated ubiquitination of RhoA. We now find that synaptopodin competes with c-Cbl for binding to Nck1, which prevents the ubiquitination of Nck1 by c-Cbl. Gene silencing of c-Cbl restores Nck1 protein abundance and stress fibres in synaptopodin knockdown cells. Similarly, expression of c-Cbl-resistant Nck1(K178R) or Nck2 containing the SH3 domain 2 of Nck1 restores stress fibres in synaptopodin-depleted podocytes through activation of RhoA signalling. These findings reveal proteasomal regulation as a key factor in the distinct and non-redundant effects of Nck on RhoA-mediated actin dynamics. C1 [Buvall, Lisa; Rashmi, Priyanka; Andreeva, Svetlana; Weins, Astrid; Wallentin, Hanna; Greka, Anna; Mundel, Peter] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02129 USA. [Lopez-Rivera, Esther] Mt Sinai Sch Med, Dept Otolaryngol, New York, NY 10029 USA. [Weins, Astrid] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Greka, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02129 USA. EM greka.anna@mgh.harvard.edu; mundel.peter@mgh.harvard.edu OI Buvall, Lisa/0000-0002-0599-8581 FU Swedish Research Council; Swedish Governmental Agency for Innovation Systems; NIH [DK093783, DK083511, DK057683, DK062472, DK091218]; American Society of Nephrology FX We thank Wei Li (University of Southern California, Los Angeles, CA, USA) for Nck1 and Nck2 cDNAs, Stanley Lipkowitz (National Cancer Institute, Bethesda, MD, USA) for c-Cbl cDNA and Keiji Tanaka (Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan) for Ubiquitin cDNA. L. B. was supported by the Swedish Research Council and The Swedish Governmental Agency for Innovation Systems, A. W. by NIH grant DK093783, A. G. by NIH grant DK083511 and a Carl W. Gottschalk Research Scholar Grant from the American Society of Nephrology, P. M. by NIH grants DK057683, DK062472 and DK091218. NR 41 TC 13 Z9 13 U1 1 U2 8 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD NOV PY 2013 VL 4 AR UNSP 2863 DI 10.1038/ncomms3863 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 266MS UT WOS:000328028700002 PM 24287595 ER PT J AU Goldberg, SB Oxnard, GR Digumarthy, S Muzikansky, A Jackman, DM Lennes, IT Sequist, LV AF Goldberg, Sarah B. Oxnard, Geoffrey R. Digumarthy, Subba Muzikansky, Alona Jackman, David M. Lennes, Inga T. Sequist, Lecia V. TI Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors SO ONCOLOGIST LA English DT Article DE Non-small cell lung cancer; Epidermal growth factor receptor; Protein kinase inhibitor; Drug resistance ID RANDOMIZED PHASE-II; FORMER SMOKERS; BREAST-CANCER; GEFITINIB; TRIAL; CARBOPLATIN; PACLITAXEL; COMBINATION; TUMORS; DISCONTINUATION AB Purpose. Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer has an oncogene-addicted biology that confers sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Published data suggest that EGFR addiction persists after development of TKI acquired resistance, leading many clinicians to continue TKI with subsequent chemotherapy; however, this strategy has not been formally evaluated. Methods. We retrospectively reviewed an institutional database to identify patients with advanced EGFR mutation with acquired resistance who subsequently received chemotherapy. Patients were classified as receiving chemotherapy with continued erlotinib or chemotherapy alone. We assessed differences in outcomes between the two strategies. Results. Seventy-eight patients were included, 34 treated with chemotherapy and erlotinib and 44 treated with chemotherapy alone. Objective response rate was evaluable in 57 patients and was 41% for those treated with chemotherapy and erlotinib and 18% for those treated with chemotherapy alone. After adjusting for chemotherapy regimen and length of initial TKI course, the odds ratio for the response rate was 0.20 (95% confidence interval: 0.05-0.78; p = .02) favoring treatment with chemotherapy and erlotinib. The median progression-free survival was 4.4 months on chemotherapy and erlotinib and 4.2 months on chemotherapy alone (adjusted hazard ratio = 0.79; 95% confidence interval: 0.48-1.29; p = .34). There was no difference in overall survival. Conclusion. This is the first study, to our knowledge, to demonstrate that continuation of EGFR TKI with chemotherapy in patients with acquired resistance improves outcomes compared with chemotherapy alone. We observed an improved response rate but no difference in progression-free survival or overall survival. A larger prospective clinical trial is needed to evaluate this promising strategy further. C1 [Goldberg, Sarah B.; Lennes, Inga T.; Sequist, Lecia V.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Goldberg, Sarah B.; Oxnard, Geoffrey R.; Digumarthy, Subba; Muzikansky, Alona; Jackman, David M.; Lennes, Inga T.; Sequist, Lecia V.] Harvard Univ, Sch Med, Boston, MA USA. [Oxnard, Geoffrey R.; Jackman, David M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Oxnard, Geoffrey R.; Jackman, David M.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Digumarthy, Subba] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Muzikansky, Alona] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA. RP Goldberg, SB (reprint author), Yale Canc Ctr, 333 Cedar St,FMP-130, New Haven, CT 06520 USA. EM Sarah.Goldberg@yale.edu FU Conquer Cancer Foundation of the American Society of Clinical Oncology; National Cancer Institute [P50-CA090578] FX This work was supported in part by the Conquer Cancer Foundation of the American Society of Clinical Oncology and by the National Cancer Institute (P50-CA090578). NR 34 TC 50 Z9 51 U1 0 U2 3 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD NOV PY 2013 VL 18 IS 11 BP 1214 EP 1220 DI 10.1634/theoncologist.2013-0168 PG 7 WC Oncology SC Oncology GA 262ZN UT WOS:000327776500011 PM 24072220 ER PT J AU Yao, J Lagunes, DR Kulke, MH AF Yao, James Lagunes, Diane Reidy Kulke, Matthew H. TI Are Targeted Therapies a Consideration in Poorly Differentiated Neuroendocrine Tumors? Reply SO ONCOLOGIST LA English DT Letter ID PROGNOSTIC-FACTORS; FOLLOW-UP; CLASSIFICATION; DIAGNOSIS; CARCINOMAS; NEOPLASMS C1 [Yao, James] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Lagunes, Diane Reidy] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Kulke, Matthew H.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Yao, J (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Div Canc Med, 1515 Holcombe Blvd, Houston, TX 77030 USA. EM jyao@mdanderson.org NR 10 TC 0 Z9 0 U1 0 U2 0 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD NOV PY 2013 VL 18 IS 11 BP 1240 EP 1241 DI 10.1634/theoncologist.2013-0242 PG 2 WC Oncology SC Oncology GA 262ZN UT WOS:000327776500015 PM 24218002 ER PT J AU O'Toole, J Jammallo, LS Miller, CL Skolny, MN Specht, MC Taghian, AG AF O'Toole, Jean Jammallo, Lauren S. Miller, Cynthia L. Skolny, Melissa N. Specht, Michelle C. Taghian, Alphonse G. TI Standardized Approach to Lymphedema Screening Reply SO ONCOLOGIST LA English DT Letter ID CANCER-RELATED LYMPHEDEMA; BREAST-CANCER; SPECTROSCOPY; BIOIMPEDANCE; PEROMETRY; VOLUME C1 [O'Toole, Jean] Massachusetts Gen Hosp, Dept Phys Therapy, Boston, MA 02114 USA. [Jammallo, Lauren S.; Miller, Cynthia L.; Skolny, Melissa N.; Taghian, Alphonse G.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Specht, Michelle C.] Massachusetts Gen Hosp, Dept Surg Oncol, Boston, MA 02114 USA. RP Taghian, AG (reprint author), Massachusetts Gen Hosp, Ctr Canc, Breast Canc Res Program, 100 Blossom St, Boston, MA 02114 USA. EM ataghian@partners.org NR 8 TC 0 Z9 0 U1 0 U2 0 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD NOV PY 2013 VL 18 IS 11 BP 1243 EP 1244 DI 10.1634/theoncologist.2013-0261 PG 2 WC Oncology SC Oncology GA 262ZN UT WOS:000327776500017 PM 24218004 ER PT J AU Clancy, TE Meyerhardt, JA AF Clancy, Thomas E. Meyerhardt, Jeffrey A. TI Perioperative Chemotherapy for Colorectal Cancer Liver Metastases SO ONCOLOGY-NEW YORK LA English DT Editorial Material ID PREOPERATIVE CHEMOTHERAPY; HEPATIC RESECTION; SURGERY; HEPATECTOMY; RECURRENCE; SURVIVAL C1 [Clancy, Thomas E.; Meyerhardt, Jeffrey A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Clancy, Thomas E.; Meyerhardt, Jeffrey A.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Clancy, Thomas E.; Meyerhardt, Jeffrey A.] Harvard Univ, Sch Med, Boston, MA USA. RP Clancy, TE (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. NR 17 TC 1 Z9 1 U1 0 U2 0 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD NOV PY 2013 VL 27 IS 11 BP 1088 EP 1090 PG 3 WC Oncology SC Oncology GA 261TQ UT WOS:000327687900005 PM 24575536 ER PT J AU Retamozo, S Brito-Zeron, P Bosch, X Stone, JH Ramos-Casals, M AF Retamozo, Soledad Brito-Zeron, Pilar Bosch, Xavier Stone, John H. Ramos-Casals, Manuel TI Cryoglobulinemic Disease SO ONCOLOGY-NEW YORK LA English DT Review ID HEPATITIS-C VIRUS; II MIXED CRYOGLOBULINEMIA; PRELIMINARY CLASSIFICATION CRITERIA; RANDOMIZED CONTROLLED-TRIAL; PRIMARY SJOGRENS-SYNDROME; OF-THE-LITERATURE; INTERFERON-ALPHA; VASCULITIS DATA; LONG-TERM; PROGNOSTIC-FACTORS AB "Cryoglobulinemia" refers to the presence of cryoglobulins (immunoglobulins that precipitate at variable temperatures < 37 degrees C [98.6 degrees F]) in serum. Monoclonal cryoglobulinemia (type I) involves a single type of monoclonal immunoglobulin, while mixed cryoglobulinemia involves a mixture either of polyclonal immunoglobulin (Ig) G and monoclonal IgM (type II), or of polyclonal IgG and polyclonal IgM (type III); both monoclonal and polyclonal IgM have rheumatoid factor activity. Cryoglobulinemia is a unique model of human disease for several reasons: (1) cryoglobulins are detected using a simple technical approach that is based on in vitro laboratory observation of cold precipitation in serum; (2) cryoglobulinemic organ damage may be produced by two different etiopathogenic mechanisms (accumulation of cryoglobulins and autoimmune-mediated vasculitic damage); and (3) cryoglobulinemia is associated with a wide range of etiologies, symptoms, and outcomes, and is considered a disease that combines elements of autoimmune and lymphoproliferative diseases. There are three main broad treatment strategies in cryoglobulinemia-conventional immunosuppression, antiviral treatment, and biologic therapy. Some agents, such as corticosteroids and rituximab, have been successfully used in all types of cryoglobulinemia; however, treatment should be modulated according to the underlying associated disease (chronic viral infections, autoimmune diseases, or cancer), the predominant etiopathogenic damage (vasculitis vs hyperviscosity), and the severity of internal organ involvement. C1 [Retamozo, Soledad; Brito-Zeron, Pilar; Ramos-Casals, Manuel] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Lab Autoimmune Dis Josep Font, Dept Autoimmune Dis,CELLEX, E-08036 Barcelona, Spain. [Bosch, Xavier] Hosp Clin Barcelona, Dept Internal Med, Clin Inst Med & Dermatol, E-08036 Barcelona, Spain. [Stone, John H.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Clin Immunol, Boston, MA 02114 USA. RP Ramos-Casals, M (reprint author), Hosp Clin Barcelona, Serv Malalties Autoimmunes, C Villarroel 170, E-08036 Barcelona, Spain. EM mramos@clinic.ub.es RI brito zeron, pilar/L-6551-2014 OI brito zeron, pilar/0000-0003-1016-5055 FU "Ajut per a la Recerca Josep Font" from Hospital Clinic-Barcelona FX The work of Dr. Brito-Zeron is supported by "Ajut per a la Recerca Josep Font" from Hospital Clinic-Barcelona 2012-2015. NR 60 TC 14 Z9 15 U1 0 U2 1 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD NOV PY 2013 VL 27 IS 11 BP 1098 EP + PG 15 WC Oncology SC Oncology GA 261TQ UT WOS:000327687900007 PM 24575538 ER PT J AU Lee, LJ Jhingran, A Kidd, E Cardenes, HR Elshaikh, MA Erickson, B Mayr, NA Moore, D Puthawala, AA Rao, GG Small, W Varia, MA Wahl, AO Wolfson, AH Yashar, CM Yuh, W Gaffney, DK AF Lee, Larissa J. Jhingran, Anuja Kidd, Elizabeth Cardenes, Higinia Rosa Elshaikh, Mohamed A. Erickson, Beth Mayr, Nina A. Moore, David Puthawala, Ajmel A. Rao, Gautam G. Small, William, Jr. Varia, Mahesh A. Wahl, Andrew O. Wolfson, Aaron H. Yashar, Catheryn M. Yuh, William Gaffney, David K. TI ACR APPROPRIATENESS CRITERIA (R) Management of Vaginal Cancer SO ONCOLOGY-NEW YORK LA English DT Review ID SQUAMOUS-CELL CARCINOMA; POSITRON-EMISSION-TOMOGRAPHY; CERVICAL-CANCER; RADIATION-THERAPY; PROGNOSTIC-FACTORS; TREATMENT MODALITIES; PELVIC RADIATION; RADIOTHERAPY; EXPERIENCE; BRACHYTHERAPY AB Due to its rarity, treatment guidelines for vaginal cancer are extrapolated from institutional reports and prospective studies of cervical and anal cancer. An expert panel was convened to reach consensus on the selection of imaging and therapeutic modalities. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) used by the panel to rate the appropriateness of imaging and treatment procedures. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. Four variants were developed to represent clinical scenarios in vaginal cancer management. Group members reached consensus on the appropriateness of the pretreatment evaluation and therapeutic interventions. This article represents the consensus opinion of an expert panel and may be used to inform clinical recommendations in vaginal cancer management. C1 [Lee, Larissa J.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Jhingran, Anuja] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Kidd, Elizabeth] Stanford Canc Ctr, Stanford, CA USA. [Cardenes, Higinia Rosa] Indiana Univ, Med Ctr, Indianapolis, IN USA. [Elshaikh, Mohamed A.] Henry Ford Hlth Syst, Detroit, MI USA. [Erickson, Beth] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Mayr, Nina A.] Univ Washington, Seattle, WA 98195 USA. [Moore, David] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Puthawala, Ajmel A.] Long Beach Mem Med Ctr, Long Beach, CA USA. [Rao, Gautam G.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Small, William, Jr.] Loyola Univ Hlth Syst, Chicago, IL USA. [Varia, Mahesh A.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Wahl, Andrew O.] Univ Nebraska Med Ctr, Omaha, NE USA. [Wolfson, Aaron H.] Univ Miami, Miami, FL USA. [Yashar, Catheryn M.] Univ Calif San Diego, San Diego, CA 92103 USA. [Yuh, William] Ohio State Univ, Columbus, OH 43210 USA. [Gaffney, David K.] Univ Utah, Med Ctr, Salt Lake City, UT USA. RP Lee, LJ (reprint author), Amer Coll Radiol, 1891 Preston White Dr, Reston, VA 20191 USA. EM llee@lroc.harvard.edu NR 49 TC 4 Z9 4 U1 0 U2 1 PU UBM MEDICA PI NORWALK PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA SN 0890-9091 J9 ONCOLOGY-NY JI Oncology-NY PD NOV PY 2013 VL 27 IS 11 BP 1166 EP 1173 PG 8 WC Oncology SC Oncology GA 261TQ UT WOS:000327687900016 PM 24575547 ER PT J AU Patra, KC Hay, N AF Patra, Krushna C. Hay, Nissim TI Hexokinase 2 as oncotarget SO ONCOTARGET LA English DT Editorial Material C1 [Patra, Krushna C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02114 USA. [Hay, Nissim] Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL USA. [Hay, Nissim] Jesse Brown VA Med Ctr, Res & Dev Sect, Chicago, IL USA. RP Patra, KC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02114 USA. EM kpatra@mgh.har-vard.edu; nhay@uic.edu FU NIA NIH HHS [R01 AG016927] NR 5 TC 7 Z9 9 U1 0 U2 3 PU IMPACT JOURNALS LLC PI ALBANY PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA SN 1949-2553 J9 ONCOTARGET JI Oncotarget PD NOV PY 2013 VL 4 IS 11 BP 1862 EP 1863 PG 2 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 261KW UT WOS:000327664900003 PM 24196563 ER PT J AU Manchikanti, L Helm, S Singh, V Hirsch, JA AF Manchikanti, Laxmaiah Helm, Standiford, II Singh, Vijay Hirsch, Joshua A. TI Accountable Interventional Pain Management: A Collaboration Among Practitioners, Patients, Payers, and Government SO PAIN PHYSICIAN LA English DT Review DE Accountable interventional pain management; Medicare; Medicare Evidence Development & Coverage Advisory Committee; epidural injections; facet joint interventions; sacroiliac joint injections; payment policies ID LOW-BACK-PAIN; EPIDURAL STEROID INJECTIONS; BONE MORPHOGENETIC PROTEIN-2; PERIPHERAL-NERVE STIMULATION; RANDOMIZED-CONTROLLED TRIALS; OUTCOMES RESEARCH-INSTITUTE; HEALTH-CARE-UTILIZATION; EVIDENCE-BASED MEDICINE; LUMBAR-DISK HERNIATION; CERVICAL-SPINE SURGERY AB The prevalence, costs, and disability associated with chronic pain continue to escalate. So too, the numerous modalities of treatments applied in managing these patients continue to increase as well. In the period from 2000 to 2011 interventional techniques increased 228%. In addition, analysis of utilization trends and expenditures for spinal interventional techniques alone from 2000 to 2008 illustrated an increase in Medicare fee-for-service expenditures of 240% in terms of dollars spent in the United States. The Office of Inspector General (OIG) of the Department of Health and Human Services showed an increase in facet joint and transforaminal epidural injections, with a significant proportion of these services did not meet the medical necessity criteria. The increasing utilization of interventional techniques is also associated with significant variations among specialty groups and regional variations among states. Overall procedures have increased by 173%, with rate of 130% per 100,000 Medicare beneficiaries for epidural injections; 383%, with a rate of 308% for facet joint interventions; and overall 410%, or a rate of 331% for sacroiliac joint interventions. Certain high volume interventions such as lumbar transforaminal epidural injections and lumbar facet joint neurolysis have actually increased a staggering 806% and 662%. Coverage policies across ambulatory settings and by multiple payers are highly variable. Apart from variability in the development of coverage policies, payments also substantially vary by site of service. In general, amongst the various ambulatory settings the highest payments are made to hospital outpatient departments (HOPDs) the lowest to in-office procedures, and payment to ambulatory surgery centers (ASCs) falling somewhere in the middle. This manuscript describes the many differences that exist between the various settings, and includes suggestions for accountable interventional pain management with coverage for techniques with evidence, addressing excessive use of specific techniques, and equalizing payments across multiple ambulatory settings. C1 [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY USA. [Manchikanti, Laxmaiah] Univ Louisville, Louisville, KY 40292 USA. [Helm, Standiford, II] Helm Ctr Pain Management, Laguna Hills, CA USA. [Singh, Vijay] Spine Pain Diagnost Associates, Niagara, WI USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, Endovasc Neurosurg & Neuroendovascu Program, Boston, MA 02114 USA. [Hirsch, Joshua A.] Harvard Univ, Sch Med, Boston, MA USA. RP Manchikanti, L (reprint author), 2831 Lone Oak Rd, Paducah, KY 42003 USA. EM drlm@thepainmd.com FU Cephalon/Teva; AstraZeneca; Purdue Pharma, LP FX Dr. Helm is a clinical investigator with Epimed and receives research support from Cephalon/Teva, AstraZeneca, and Purdue Pharma, LP. He has attended an advisory group meeting for Activas. NR 190 TC 40 Z9 40 U1 0 U2 4 PU AM SOC INTERVENTIONAL PAIN PHYSICIANS PI PADUCAH PA 81 LAKEVIEW DR, PADUCAH, KY 42001 USA SN 1533-3159 J9 PAIN PHYSICIAN JI Pain Physician PD NOV-DEC PY 2013 VL 16 IS 6 BP E635 EP E670 PG 36 WC Anesthesiology; Clinical Neurology SC Anesthesiology; Neurosciences & Neurology GA 259TG UT WOS:000327548600001 PM 24284849 ER PT J AU Murakami, Y Notomi, S Hisatomi, T Nakazawa, T Ishibashib, T Miller, JW Vavvas, DG AF Murakami, Yusuke Notomi, Shoji Hisatomi, Toshio Nakazawa, Toru Ishibashib, Tatsuro Miller, Joan W. Vavvas, Demetrios G. TI Photoreceptor cell death and rescue in retinal detachment and degenerations SO PROGRESS IN RETINAL AND EYE RESEARCH LA English DT Article DE Retina; Macula; Degenerations; Necrosis; Apoptosis; Autophagy; Neuroprotection; Neuroregeneration ID APOPTOSIS-INDUCING FACTOR; NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; RECEPTOR-INTERACTING PROTEIN; MITOCHONDRIAL PERMEABILITY TRANSITION; BCL-X-L; EPITHELIUM-DERIVED FACTOR; AGGREGATE-PRONE PROTEINS; ISOLATED RAT HEPATOCYTES; FAS-MEDIATED APOPTOSIS AB Photoreceptor cell death is the ultimate cause of vision loss in various retinal disorders, including retinal detachment (RD). Photoreceptor cell death has been thought to occur mainly through apoptosis, which is the most characterized form of programmed cell death. The caspase family of cysteine proteases plays a central role for inducing apoptosis, and in experimental models of RD, dying photoreceptor cells exhibit caspase activation; however, there is a paradox that caspase inhibition alone does not provide a sufficient protection against photoreceptor cell loss, suggesting that other mechanisms of cell death are involved. Recent accumulating evidence demonstrates that non-apoptotic forms of cell death, such as autophagy and necrosis, are also regulated by specific molecular machinery, such as those mediated by autophagy-related proteins and receptor-interacting protein kinases, respectively. Here we summarize the current knowledge of cell death signaling and its roles in photoreceptor cell death after RD and other retinal degenerative diseases. A body of studies indicate that not only apoptotic but also autophagic and necrotic signaling are involved in photoreceptor cell death, and that combined targeting of these pathways may be an effective neuroprotective strategy for retinal diseases associated with photoreceptor cell loss. (C) 2013 Published by Elsevier Ltd. C1 [Murakami, Yusuke; Notomi, Shoji; Miller, Joan W.; Vavvas, Demetrios G.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Angiogenesis Lab,Dept Ophthalmol, Boston, MA 02114 USA. [Murakami, Yusuke; Notomi, Shoji; Hisatomi, Toshio; Ishibashib, Tatsuro] Kyushu Univ, Dept Ophthalmol, Grad Sch Med Sci, Fukuoka 8128582, Japan. [Nakazawa, Toru] Tohoku Univ, Dept Ophthalmol, Grad Sch Med, Sendai, Miyagi 9808574, Japan. RP Vavvas, DG (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Angiogenesis Lab,Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. EM demetrios_vavvas@meei.harvard.edu RI U-ID, Kyushu/C-5291-2016; OI Vavvas, Demetrios/0000-0002-8622-6478 FU NIH [R21EY023079-01A1]; Research to Prevent Blindness; Foundation Lions Eye Research Fund; Yeatts Family Foundation; Rena Family Foundation; NEI [EY014104]; Japanese Ministry of Education, Culture, Sports, Science, and Technology [25861637] FX We thank Wendy Chao for her critical review and support for the manuscript. This work was supported by Harvard Ophthalmology Department Support (DGV), NIH grant R21EY023079-01A1 (DGV), Research to Prevent Blindness Physician Scientist Award (DGV), Foundation Lions Eye Research Fund (DGV), The Yeatts Family Foundation (JWM, DGV) and Rena Family Foundation (JWM, DGV), NEI grant EY014104 (MEEI Core Grant), and the Japanese Ministry of Education, Culture, Sports, Science, and Technology grant 25861637 (YM). NR 351 TC 28 Z9 29 U1 0 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1350-9462 J9 PROG RETIN EYE RES JI Prog. Retin. Eye Res. PD NOV PY 2013 VL 37 BP 114 EP 140 DI 10.1016/j.preteyeres.2013.08.001 PG 27 WC Ophthalmology SC Ophthalmology GA 264VI UT WOS:000327908700006 PM 23994436 ER PT J AU Johnson, JM Nachtigall, LB Stern, TA AF Johnson, Justin M. Nachtigall, Lisa B. Stern, Theodore A. TI The Effect of Testosterone Levels on Mood in Men: A Review SO PSYCHOSOMATICS LA English DT Review ID PLASMA PRODUCTION-RATES; HYPOGONADAL MEN; AGING MEN; ANDROGEN DEFICIENCY; SEXUAL FUNCTION; LONG-TERM; YOUNG MEN; DEPRESSION; REPLACEMENT; DISORDER AB Background: The effects of both high and low levels of testosterone are wide ranging and can include changes in mood, often overlapping with symptoms of mood disorders. Objective: We sought to review the literature on the correlation of high and low levels of testosterone on mood disorders in men. Results: Based on limited studies, high levels of testosterone are related to increased rates of depression as well as hypomania whereas low levels of testosterone are related to depressive disorders in certain subpopulations of patients. There is insufficient evidence to conclude that low testosterone level routinely leads to major depressive disorder in men. Conclusions: Physicians should consider screening for low testosterone levels in certain subgroups of depressed men. C1 [Johnson, Justin M.; Nachtigall, Lisa B.; Stern, Theodore A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Johnson, JM (reprint author), 15 Parkman St,WACC 812, Boston, MA 02114 USA. NR 31 TC 14 Z9 14 U1 2 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0033-3182 J9 PSYCHOSOMATICS JI Psychosomatics PD NOV-DEC PY 2013 VL 54 IS 6 BP 509 EP 514 PG 6 WC Psychiatry; Psychology SC Psychiatry; Psychology GA 258XM UT WOS:000327492000001 PM 24016385 ER PT J AU Yeh, ED Jacene, HA Bellon, JR Nakhlis, F Birdwell, RL Georgian-Smith, D Giess, CS Hirshfield-Bartek, J Overmoyer, B Van den Abbeele, AD AF Yeh, Eren D. Jacene, Heather A. Bellon, Jennifer R. Nakhlis, Faina Birdwell, Robyn L. Georgian-Smith, Dianne Giess, Catherine S. Hirshfield-Bartek, Judi Overmoyer, Beth Van den Abbeele, Annick D. TI What Radiologists Need to Know about Diagnosis and Treatment of Inflammatory Breast Cancer: A Multidisciplinary Approach SO RADIOGRAPHICS LA English DT Article ID EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; NEOADJUVANT CHEMOTHERAPY; PATHOLOGICAL RESPONSE; F-18-FDG PET/CT; E-CADHERIN; CARCINOMA; EXPRESSION; SURVIVAL; MRI; ANGIOGENESIS AB Inflammatory breast cancer (IBC) is a rare breast cancer with a highly virulent course and low 5-year survival rate. Trimodality treatment that includes preoperative chemotherapy, mastectomy, and radiation therapy is the therapeutic mainstay and has been shown to improve prognosis. Proper diagnosis and staging of IBC is critical to treatment planning and requires a multidisciplinary approach that includes imaging. Patients with IBC typically present with rapid onset of breast erythema, edema, and peau d'orange. Both tissue diagnosis of malignancy and clinical findings of inflammatory disease are required to confirm diagnosis of IBC. Imaging is used to identify a biopsy target; direct biopsy; stage IBC; differentiate curable from incurable (stage IV) disease; and help plan chemotherapy, surgical management, and radiation therapy. Comparison of baseline and posttreatment images helps confirm and quantitate disease response. When imaging is used early in the course of therapy to noninvasively predict treatment response, optimal tailored strategies for management of IBC can be implemented. Imaging is vital to diagnosis and treatment planning for patients with IBC, and radiologists are an integral part of the multidisciplinary patient care team. C1 [Yeh, Eren D.; Birdwell, Robyn L.; Georgian-Smith, Dianne; Giess, Catherine S.] Brigham & Womens Hosp, Dept Radiol, Div Breast Imaging, Boston, MA 02115 USA. [Yeh, Eren D.; Birdwell, Robyn L.; Georgian-Smith, Dianne; Giess, Catherine S.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Jacene, Heather A.; Van den Abbeele, Annick D.] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA. [Bellon, Jennifer R.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Nakhlis, Faina] Dana Farber Canc Inst, Dept Surg, Boston, MA 02115 USA. [Overmoyer, Beth] Dana Farber Canc Inst, Dept Breast Oncol, Boston, MA 02115 USA. [Yeh, Eren D.; Jacene, Heather A.; Bellon, Jennifer R.; Nakhlis, Faina; Hirshfield-Bartek, Judi; Overmoyer, Beth] Dana Farber Canc Inst, Inflammatory Breast Canc Program, Boston, MA 02115 USA. RP Yeh, ED (reprint author), Brigham & Womens Hosp, Dept Radiol, Div Breast Imaging, 75 Francis St,RA Bldg,RA 014, Boston, MA 02115 USA. EM eyeh@partners.org NR 46 TC 3 Z9 3 U1 0 U2 4 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0271-5333 J9 RADIOGRAPHICS JI Radiographics PD NOV-DEC PY 2013 VL 33 IS 7 BP 2003 EP 2017 DI 10.1148/rg.337135503 PG 15 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 262TG UT WOS:000327759900015 PM 24224593 ER PT J AU Tirumani, SH Shanbhogue, AKP Prasad, SR AF Tirumani, Sree Harsha Shanbhogue, Alampady K. P. Prasad, Srinivasa R. TI Current Concepts in the Diagnosis and Management of Endometrial and Cervical Carcinomas SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Endometrial carcinoma; Cervical carcinoma; Magnetic resonance imaging; International Federation of Gynecologic Oncology (FIGO) ID LYMPH-NODE METASTASIS; POSITRON-EMISSION-TOMOGRAPHY; MYOMETRIAL INVASION; GYNECOLOGIC MALIGNANCIES; COMPUTED-TOMOGRAPHY; CLINICAL IMPACT; SALINE INFUSION; F-18-FDG PET; HELICAL CT; STAGE-I AB Cross-sectional imaging modalities play a pivotal role in the diagnosis and multidisciplinary management of patients with endometrial and cervical carcinomas. Ultrasonography, including sonohysterography, permits evaluation of endometrial abnormalities and characterization of adnexal masses. Computed tomography, particularly in conjunction with (18F)-fluorodeoxyglucose positron emission tomography, is increasingly used to stage the cancers and to detect disease recurrence. Magnetic resonance imaging plays a major role in accurate locoregional staging of these cancers, and significantly influences treatment decisions and outcomes. This article discusses the role of imaging modalities in the diagnosis, management, and surveillance of these cancers. C1 [Tirumani, Sree Harsha] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Dept Imaging, Boston, MA 02215 USA. [Shanbhogue, Alampady K. P.] Beth Israel Deaconess Med Ctr, Dept Radiol, New York, NY 10003 USA. [Prasad, Srinivasa R.] Univ Texas MD Anderson Canc Ctr, Dept Radiol, Houston, TX 77030 USA. RP Prasad, SR (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Radiol, 1400 Pressler St, Houston, TX 77030 USA. EM sprasad2@mdanderson.org NR 71 TC 9 Z9 9 U1 3 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 EI 1557-8275 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD NOV PY 2013 VL 51 IS 6 BP 1087 EP + DI 10.1016/j.rcl.2013.07.003 PG 25 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 261QR UT WOS:000327680200011 PM 24210446 ER PT J AU Lalwani, N Moshiri, M Lee, JH Bhargava, P Dighe, MK AF Lalwani, Neeraj Moshiri, Mariam Lee, Jean H. Bhargava, Puneet Dighe, Manjiri K. TI Magnetic Resonance Imaging of Pelvic Floor Dysfunction SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Pelvic floor dysfunction; MR defecography; Cystocele; Rectocele; Incontinence; Constipation; Anismus; Descending perineal syndrome ID FLUOROSCOPIC CYSTOCOLPOPROCTOGRAPHY; EVACUATION PROCTOGRAPHY; MR DEFECOGRAPHY; ORGAN PROLAPSE; DISORDERS; SUPINE; DIAGNOSIS; POSITIONS; DESCENT AB Pelvic floor dysfunction is largely a complex problem of multiparous and postmenopausal women and is associated with pelvic floor or organ descent. Physical examination can underestimate the extent of the dysfunction and misdiagnose the disorders. Functional magnetic resonance (MR) imaging is emerging as a promising tool to evaluate the dynamics of the pelvic floor and use for surgical triage and operative planning. This article reviews the anatomy and pathology of pelvic floor dysfunction, typical imaging findings, and the current role of functional MR imaging. C1 [Lalwani, Neeraj] Univ Washington, Dept Radiol, Seattle, WA 98104 USA. [Moshiri, Mariam; Lee, Jean H.; Dighe, Manjiri K.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA 98108 USA. RP Lalwani, N (reprint author), Univ Washington, Dept Radiol, Box 359728,325 9th Ave, Seattle, WA 98104 USA. EM neerajl@uw.edu RI Lalwani, Neeraj/A-3490-2011; OI Lalwani, Neeraj/0000-0001-5514-2805; Bhargava, Puneet/0000-0002-3849-9666 NR 40 TC 12 Z9 17 U1 3 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 EI 1557-8275 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD NOV PY 2013 VL 51 IS 6 BP 1127 EP + DI 10.1016/j.rcl.2013.07.004 PG 15 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 261QR UT WOS:000327680200013 PM 24210448 ER PT J AU Stuckey, DW Shah, K AF Stuckey, Daniel W. Shah, Khalid TI TRAIL on trial: preclinical advances in cancer therapy SO TRENDS IN MOLECULAR MEDICINE LA English DT Review DE TRAIL; apoptesis; cancer; targeted therapy; stem cells ID APOPTOSIS-INDUCING LIGAND; MESENCHYMAL STEM-CELLS; IN-VIVO; MONOCLONAL-ANTIBODY; TUMORICIDAL ACTIVITY; DOWN-REGULATION; GLIOMA-CELLS; SOLID TUMORS; PHASE-I; DEATH AB Tumor necrosis factor (TNF)-related apoptosis-inducing ligand, or TRAIL, is a promising anticancer agent as it can induce apoptosis in a wide range of cancers whilst generally sparing non-malignant cells. However, the translation of TRAIL into the clinic has been confounded by its short half-life, inadequate delivery methods, and TRAIL-resistant cancer cell populations. In this review, we discuss how TRAIL has been functionalized to diversify its traditional tumor-killing role and novel strategies to facilitate its effective deployment in preclinical cancer models. The successes and failures of the most recent clinical trials using TRAIL agonists are highlighted and we provide a perspective for improving its clinical implementation. C1 [Stuckey, Daniel W.; Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02114 USA. [Stuckey, Daniel W.; Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA. [Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA. [Shah, Khalid] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. RP Shah, K (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02114 USA. EM kshah@mgh.harvard.edu FU James S. McDonnell Foundation; [R01CA138922]; [R01CA173077] FX We apologize to all colleagues whose work could not be cited owing to space limitations. This work was supported by R01CA138922, R01CA173077, and the James S. McDonnell Foundation. NR 80 TC 76 Z9 82 U1 3 U2 19 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1471-4914 EI 1471-499X J9 TRENDS MOL MED JI Trends Mol. Med PD NOV PY 2013 VL 19 IS 11 BP 685 EP 694 DI 10.1016/j.molmed.2013.08.007 PG 10 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 265BA UT WOS:000327923500005 PM 24076237 ER PT J AU Wilhelm, CJ Hashimoto, JG Roberts, ML Loftis, JM Wiren, KM AF Wilhelm, C. J. Hashimoto, J. G. Roberts, M. L. Loftis, J. M. Wiren, K. M. TI Immune response to chronic alcohol predicts neurotoxicity and is dependent on sex SO ALCOHOL LA English DT Meeting Abstract CT Alcohol-and-Immunology-Research-Interest-Group (AIRIG) Meeting on Alcohol and Inflammatory Responses CY NOV 22, 2013 CL Loyola Univ Chicago, Hlth Sci Campus, Dept Surg, Maywood, IL SP Alcohol & Immunol Res Interest Grp HO Loyola Univ Chicago, Hlth Sci Campus, Dept Surg C1 Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-8329 EI 1873-6823 J9 ALCOHOL JI Alcohol PD NOV PY 2013 VL 47 IS 7 MA 33 BP 576 EP 576 PG 1 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA 260FX UT WOS:000327581500042 ER PT J AU Vergallo, R Yonetsu, T Uemura, S Park, SJ Lee, S Kato, K Jia, HB Abtahian, F Tian, JW Hu, SN Lee, H McNulty, I Prasad, A Yu, B Zhang, SS Porto, I Biasucci, LM Crea, F Jang, IK AF Vergallo, Rocco Yonetsu, Taishi Uemura, Shiro Park, Seung-Jung Lee, Stephen Kato, Koji Jia, Haibo Abtahian, Farhad Tian, Jinwei Hu, Sining Lee, Hang McNulty, Iris Prasad, Abhiram Yu, Bo Zhang, Shaosong Porto, Italo Biasucci, Luigi M. Crea, Filippo Jang, Ik-Kyung TI Correlation Between Degree of Neointimal Hyperplasia and Incidence and Characteristics of Neoatherosclerosis as Assessed by Optical Coherence Tomography SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID BARE-METAL STENTS; DRUG-ELUTING STENTS; CORONARY-ARTERIES; FOLLOW-UP; IMPLANTATION; RESTENOSIS AB Emerging evidence suggests that neointimal degenerative changes with development of neoatherosclerosis (NA) may represent an important mechanism for late stent failure. The aim of the present study was to investigate the relation between degree of neointimal hyperplasia and incidence and characteristics of NA using optical coherence tomography. We identified a total of 252 stents with mean neointimal thickness (NIT) >100 mu m in 212 patients: 100 bare metal stents (BMSs) and 152 drug-eluting stents (DESs). Based on the values of mean NIT, we divided stents into tertiles and compared neointimal characteristics among the 3 groups. NA was defined as the presence of lipid-laden intima and/or calcification inside the stent. In both BMS and DES, there was a difference in the prevalence of lipid-laden intima among the tertiles (18.2% vs 36.4% vs 47.1%, p = 0.042 [BMS]; 19.6% vs 56.9% vs 88.0%, p < 0.001 [DES]). However, no difference in the prevalence of in-stent calcification was observed (21.2% vs 21.2% vs 2.9%, p = 0.053 [BMS]; 5.9% vs 9.8% vs 2.0%, p = 0.252 [DES]). In a multivariate model adjusting for stent type, follow-up duration, conventional coronary risk factors, statin, and angiotensin-converting enzyme inhibitor or angiotensin II receptor blockade use, mean NIT was independently associated with the presence of NA (odds ratio 2.53, 95% confidence interval 1.96 to 3.27, p < 0.001). This study demonstrates the presence of a positive correlation between degree of neointimal hyperplasia after stent implantation and presence of lipid-laden intima. This association is independent from stent type and time from implantation and suggests a possible pathogenic link between the two processes. (C) 2013 Elsevier Inc. All rights reserved. C1 [Vergallo, Rocco; Yonetsu, Taishi; Kato, Koji; Jia, Haibo; Abtahian, Farhad; Tian, Jinwei; Hu, Sining; McNulty, Iris; Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA. [Uemura, Shiro] Nara Med Univ, Dept Med 1, Nara, Japan. [Park, Seung-Jung] Asan Med Ctr, Seoul, South Korea. [Lee, Stephen] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China. [Jia, Haibo; Tian, Jinwei; Hu, Sining; Yu, Bo] Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Key Lab Myocardial Ischemia,Chinese Minist Educ, Harbin, Peoples R China. [Lee, Hang] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Biostat, Boston, MA USA. [Prasad, Abhiram] Mayo Clin, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN USA. [Zhang, Shaosong] St Jude Med Inc, LightLab Imaging Inc, Westford, MA USA. [Porto, Italo] San Donato Hosp, Cardiovasc & Neurol Dept, Arezzo, Italy. [Biasucci, Luigi M.; Crea, Filippo] Univ Cattolica Sacro Cuore, Dept Cardiovasc Med, I-00168 Rome, Italy. RP Jang, IK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA. EM ijang@partners.org OI biasucci, luigi m/0000-0002-6921-6497 FU Light Lab Imaging/St. Jude Medical FX Dr. Jang received grant support and consulting fees from Light Lab Imaging/St. Jude Medical. Dr. Zhang is an employee of Light Lab Imaging/St. Jude Medical. The other authors have no conflicts of interest to disclose. NR 20 TC 11 Z9 12 U1 1 U2 5 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD NOV 1 PY 2013 VL 112 IS 9 BP 1315 EP 1321 DI 10.1016/j.amjcard.2013.05.076 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 253QJ UT WOS:000327104100008 PM 23891431 ER PT J AU Toteberg-Harms, M Rhee, DJ AF Toeteberg-Harms, Marc Rhee, Douglas J. TI Selective Laser Trabeculoplasty Following Failed Combined Phacoemulsification Cataract Extraction and Ab Interno Trabeculectomy SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID OPEN-ANGLE GLAUCOMA; INTRAOCULAR-PRESSURE; OCULAR HYPERTENSION; TREATMENT OUTCOMES; PSEUDOPHAKIC EYES; EFFICACY; TRIAL; INTERVENTION; THERAPY; AGIS AB PURPOSE: To assess the effect of selective laser trabeculoplasty (SLT) following failed phacoemulsification cataract extraction combined with ab interno trabeculectomy (AIT) using the Trabectome (phaco-trabectome). DESIGN: Randomized, interventional case series. METHODS: Retrospectively, the medical records of patients who underwent SLT between March 2010 and July 2012 by 1 surgeon at a single center after a failed phaco-AIT were evaluated. Inclusion criteria were age >= 18 years with no upper limit and prior failed phaco-AIT attributable to glaucoma progression. Exclusion criterion was performance of any additional glaucoma procedure with influence on intraocular pressure (TOP) during follow-up and a follow-up after surgery of <3 months. Success was defined by reduction of TOP of >3 mm Hg and 20% and number of antiglaucoma medications equal to or less than baseline. Main outcome measures were TOP, antiglaucoma medications, time to failure, and Kaplan-Meier survival curve. RESULTS: Fourteen eyes of 13 subjects were included. Mean follow-up after SLT was 12.9 +/- 8.7 months. Total laser energy was 59.5 +/- 8.7 mJ. Baseline TOP was 17.9 +/- 3.3 mm Hg and number of antiglaucoma medications at baseline was 2.0 +/- 1.0. All SLT procedures failed. Median time to failure after SLT was 3.6 +/- 0.8 (range 2.1-5.1) months. Number of antiglaucoma medications did not change. CONCLUSIONS: In eyes in which the IOP was no longer controlled following phaco-trabectome, SLT had a limited duration of significant TOP-lowering effect. Other alternatives, such as incisional filtration surgery, should be considered following failed phaco-trabectome. (C) 2013 by Elsevier Inc. All rights reserved. C1 [Toeteberg-Harms, Marc; Rhee, Douglas J.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA. RP Rhee, DJ (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA. EM DougRhee@aol.com OI Toeteberg-Harms, Marc/0000-0002-2134-1336 FU Swiss National Science Foundation (SNSF) [PBZHP3_141457]; Alcon; Aquesys; Merck FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST. Financial disclosures are as follows: M.T.H.: personal funding by the Swiss National Science Foundation (SNSF Project No. PBZHP3_141457); D.J.R.: research funding from Alcon, Aquesys, Merck; ad hoc consultant, Aerie, Alcon, Allergan, Aquesys, Merck, Santen. Contributions of authors: design of the study (M.T.H., D.J.R.); conduct of the study (M.T.H., D.J.R.); collection, management, analysis, and interpretation of the data (M.T.H., D.J.R.); and preparation, review, and approval of the manuscript (M.T.H., D.J.R.). NR 32 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 EI 1879-1891 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD NOV PY 2013 VL 156 IS 5 BP 936 EP 940 DI 10.1016/j.ajo.2013.05.044 PG 5 WC Ophthalmology SC Ophthalmology GA 250NJ UT WOS:000326859200011 PM 23932217 ER PT J AU Yoon, MK Jakobiec, FA Mendoza, PR AF Yoon, Michael K. Jakobiec, Frederick A. Mendoza, Pia R. TI Canaliculops: Clinicopathologic Features and Treatment With Marsupialization SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID DACRYOPS; SYSTEM AB PURPOSE: To report the features of the rare and under-recognized condition of canaliculops (or canaliculocele) of the eyelid, which is a dilation of the canaliculus, and to evaluate treatment with marsupialization. DESIGN: Retrospective interventional case series. METHODS: The records of 2 patients with canaliculops from the Massachusetts Eye and Ear Infirmary were reviewed. Data collected included clinical history, surgical technique, histopathologic analysis, and comparative immunohistochemical analysis of a range of cyto-keratins in normal conjunctival epithelium, normal canalicular epithelium, and canaliculops epithelium. RESULTS: Two women, 53 and 66 years of age, experienced chronic, noninflammatory, painless medial eyelid and eyelid margin fluctuant swelling after earlier trauma or eyelid surgery. The external mass was accompanied by a whitish opalescent or bluish discoloration of a palpebral surface bulge. Biopsy revealed multilaminar (up to 12 cells thick), nonkeratinizing, tightly packed small squamous epithelial cells that surmounted a highly regimented basal layer with a picket fence arrangement. No goblet cells or subepithelial inflammation were present. Immunohistochemistry revealed only superficial CK7 immunostaining and positive patchy suprabasilar CK17 staining in the canaliculops epithelium, contrasting with their full-thickness positivity and negativity, respectively, in normal conjunctival epithelium. Marsupialization achieved resolution of the condition in each patient. CONCLUSIONS: An improved awareness of the normal canalicular epithelial structure and its immunohistochemical features can definitively separate canaliculops from conjunctival cysts. Previous treatment of canaliculops has involved complete excisions. Canaliculops may, however, be effectively treated with less invasive marsupialization while obtaining an adequate biopsy specimen for histopathologic diagnosis. (C) 2013 by Elsevier Inc. All rights reserved. C1 [Yoon, Michael K.] Massachusetts Eye & Ear Infirm, Ophthalm Plast Surg Serv, Dept Ophthalmol, Boston, MA 02114 USA. [Jakobiec, Frederick A.; Mendoza, Pia R.] Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, Dept Ophthalmol, Boston, MA 02114 USA. [Yoon, Michael K.; Jakobiec, Frederick A.; Mendoza, Pia R.] Harvard Univ, Sch Med, Boston, MA USA. RP Jakobiec, FA (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, 243 Charles St Suite 328, Boston, MA 02114 USA. EM Fred_Jakobiec@meei.harvard.edu NR 13 TC 6 Z9 6 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 EI 1879-1891 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD NOV PY 2013 VL 156 IS 5 BP 1062 EP 1068 DI 10.1016/j.ajo.2013.06.008 PG 7 WC Ophthalmology SC Ophthalmology GA 250NJ UT WOS:000326859200028 PM 23938123 ER PT J AU Marcus, EA Vagin, O Tokhtaeva, E Sachs, G Scott, DR AF Marcus, Elizabeth A. Vagin, Olga Tokhtaeva, Elmira Sachs, George Scott, David R. TI Helicobacter pylori impedes acid-induced tightening of gastric epithelial junctions SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE Helicobacter pylori; gastric epithelium; apical acidity ID CANCER CELL-LINES; GENE-EXPRESSION; INTERCELLULAR SPACES; ENVIRONMENTAL PH; BARRIER FUNCTION; BETA-CATENIN; INFECTION; UREASE; ACTIVATION; INTERLEUKIN-8 AB Gastric infection by Helicobacter pylori is the most common cause of ulcer disease and gastric cancer. The mechanism of progression from gastritis and inflammation to ulcers and cancer in a fraction of those infected is not definitively known. Significant acidity is unique to the gastric environment and is required for ulcer development. The interplay between gastric acidity and H. pylori pathogenesis is important in progression to advanced disease. The aim of this study was to characterize the impact of acid on gastric epithelial integrity and cytokine release and how H. pylori infection alters these responses. Human gastric epithelial (HGE-20) cells were grown on porous inserts, and survival, barrier function, and cytokine release were studied at various apical pH levels in the presence and absence of H. pylori. With apical acidity, gastric epithelial cells demonstrate increased barrier function, as evidenced by increased transepithelial electrical resistance (TEER) and decreased paracellular permeability. This effect is reduced in the presence of wild-type, but not urease knockout, H. pylori. The epithelial inflammatory response is also modulated by acidity and H. pylori infection. Without H. pylori, epithelial IL-8 release decreases in acid, while IL-6 release increases. In the presence of H. pylori, acidic pH diminishes the magnitude of the previously reported increase in IL-8 and IL-6 release. H. pylori interferes with the gastric epithelial response to acid, contributing to altered barrier function and inflammatory response. H. pylori diminishes acid-induced tightening of cell junctions in a urease-dependent manner, suggesting that local pH elevation promotes barrier compromise and progression to mucosal damage. C1 [Marcus, Elizabeth A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90073 USA. [Vagin, Olga; Tokhtaeva, Elmira; Sachs, George; Scott, David R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. [Sachs, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. [Marcus, Elizabeth A.; Vagin, Olga; Tokhtaeva, Elmira; Sachs, George; Scott, David R.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Scott, DR (reprint author), Univ Calif Los Angeles, DGSOM, VA GLAHS, 11301 Wilshire Blvd,Bldg 113,Rm 324, Los Angeles, CA 90073 USA. EM dscott@UCLA.edu FU National Institutes of Health [K12 HD-034610, P30 DK-41301, DK-053642]; Department of Veterans Affairs [1I01BX001006] FX This work was supported by National Institutes of Health Grants K12 HD-034610 (E. A. Marcus), P30 DK-41301 (E. A. Marcus), and DK-053642 (G. Sachs) and Department of Veterans Affairs Grant 1I01BX001006 (G. Sachs). NR 74 TC 6 Z9 6 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 EI 1522-1547 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD NOV PY 2013 VL 305 IS 10 BP G731 EP G739 DI 10.1152/ajpgi.00209.2013 PG 9 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 257OD UT WOS:000327393400008 PM 23989011 ER PT J AU Brawner, BM Volpe, EM Stewart, JM Gomes, MM AF Brawner, Bridgette M. Volpe, Ellen M. Stewart, Jennifer M. Gomes, Melissa M. TI Attitudes and beliefs toward biobehavioural research participation: voices and concerns of urban adolescent females receiving outpatient mental health treatment SO ANNALS OF HUMAN BIOLOGY LA English DT Article DE Biological specimens; research subject recruitment; research ethics ID PLANNED BEHAVIOR; DEPRESSIVE SYMPTOMS; PSYCHIATRIC-DISORDERS; CLINICAL DEPRESSION; RISK BEHAVIORS; CONDOM USE; HEART-RATE; BIOMARKERS; ASSOCIATION; DISEASE AB Background: Biobehavioural research methodology can be invasive and burdensome for participants - particularly adolescents with mental illnesses. Human biological researchers should consider how methodological impositions may hinder adolescent research participation. However, literature on adolescent's voices and concerns toward biobehavioural research participation is virtually non-existent. Aim: This study was designed to determine adolescents' perceptions of participation in research involving the collection of biomarkers via blood, saliva and/or urine samples. Subjects and methods: Urban adolescent females (aged 12-19) receiving outpatient mental health treatment (n = 37) participated in focus groups with concurrent survey administration to explore attitudes, beliefs and willingness/intentions toward biobehavioural research participation. Results: Participants had favourable attitudes toward biobehavioural research and were amenable to provide each specimen type. Mistrust for research emerged, however, and concerns related to privacy and confidentiality were expressed. Conclusion: Participant recruitment is a critical component in study design and implementation; this includes knowledge of population-specific recruitment barriers and facilitators. This innovative paper provides a context for the research participants' decision-making process, strategies to allay fears and concerns and concrete areas to target in research-related interventions. Although the findings are from a specific, US-based sample, the implications warrant replication of the research in other geosocial settings. C1 [Brawner, Bridgette M.; Volpe, Ellen M.; Stewart, Jennifer M.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA. [Gomes, Melissa M.] Virginia Commonwealth Univ, Sch Nursing, Dept Family & Community Hlth Nursing, Richmond, VA USA. RP Brawner, BM (reprint author), Univ Penn, Sch Nursing, Nursing Ctr Hlth Equity Res, Ctr Global Womens Hlth, Curie Blvd,Room 419, Philadelphia, PA 19104 USA. EM brawnerb@nursing.upenn.edu FU Distinguished Postdoctoral Fellowship at the University of Pennsylvania; NIH [T32NR007100]; National Institute of Nursing Research FX This research was supported by the Distinguished Postdoctoral Fellowship at the University of Pennsylvania awarded to Dr Bridgette M. Brawner and the NIH Award Number T32NR007100, Research on Vulnerable Women, Children and Families from the National Institute of Nursing Research to Drs Volpe, Stewart and Gomes. The authors thank the participants for generously giving of their time to participate in the study. The authors also wish to acknowledge Ehriel Fannin, Kristine Quiambao, Janaiya Reason, Jazz Robinson, Margaret Tait and Danielle Stevenson for their assistance with data collection. NR 60 TC 6 Z9 6 U1 3 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0301-4460 EI 1464-5033 J9 ANN HUM BIOL JI Ann. Hum. Biol. PD NOV-DEC PY 2013 VL 40 IS 6 BP 485 EP 495 DI 10.3109/03014460.2013.806590 PG 11 WC Anthropology; Biology; Public, Environmental & Occupational Health SC Anthropology; Life Sciences & Biomedicine - Other Topics; Public, Environmental & Occupational Health GA 255SH UT WOS:000327259600004 PM 23822716 ER PT J AU Janne, PA AF Jaenne, P. A. TI NEW STRATEGIES TO TREAT EGFR KINASE INHIBITOR RESISTANT CANCERS SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 11th Annual Meeting of the Japanese-Society-of-Medical-Oncology CY AUG 29-31, 2013 CL Sendai, JAPAN SP Japanese Soc Med Oncol C1 [Jaenne, P. A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD NOV PY 2013 VL 24 SU 9 BP 18 EP 18 DI 10.1093/annonc/mdt446.1 PG 1 WC Oncology SC Oncology GA 259EV UT WOS:000327511100031 ER PT J AU Janne, PA AF Jaenne, P. A. TI USE OF GENOMICS TO GUIDE THERAPY FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 11th Annual Meeting of the Japanese-Society-of-Medical-Oncology CY AUG 29-31, 2013 CL Sendai, JAPAN SP Japanese Soc Med Oncol C1 [Jaenne, P. A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD NOV PY 2013 VL 24 SU 9 DI 10.1093/annonc/mdt436.3 PG 1 WC Oncology SC Oncology GA 259EV UT WOS:000327511100007 ER PT J AU Kang, YK Xu, J Komatsu, Y Im, SA Li, J Nishida, T Quek, R Kappeler, C Kuss, I Demetri, GD Takimoto, R AF Kang, Y. -K. Xu, J. Komatsu, Y. Im, S. -A. Li, J. Nishida, T. Quek, R. Kappeler, C. Kuss, I. Demetri, G. D. Takimoto, R. TI SUBGROUP ANALYSIS OF ASIAN PATIENTS IN THE PHASE III TRIAL (GRID) OF REGORAFENIB IN PRETREATED METASTATIC GIST SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 11th Annual Meeting of the Japanese-Society-of-Medical-Oncology CY AUG 29-31, 2013 CL Sendai, JAPAN SP Japanese Soc Med Oncol C1 [Kang, Y. -K.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea. [Xu, J.] 307 Hosp PLA, Beijing, Peoples R China. [Komatsu, Y.] Hokkaido Univ Hosp, Sapporo, Hokkaido 060, Japan. [Im, S. -A.] Seoul Natl Univ Hosp, Seoul 110744, South Korea. [Li, J.] Fudan Univ, Canc Hosp, Dept Med Oncol, Shanghai 200433, Peoples R China. [Nishida, T.] Osaka Police Hosp, Dept Surg, Osaka, Japan. [Quek, R.] Natl Canc Ctr Singapore, Dept Med Oncol, Singapore, Singapore. [Kappeler, C.] Bayer Healthcare, Berlin, Germany. [Kuss, I.] Bayer Pharma AG, Berlin, Germany. [Demetri, G. D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Demetri, G. D.] Harvard Univ, Sch Med, Boston, MA USA. [Takimoto, R.] Sapporo Med Univ, Sch Med, Dept Med Oncol Hematol, Sapporo, Hokkaido, Japan. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD NOV PY 2013 VL 24 SU 9 DI 10.1093/annonc/mdt435.2 PG 1 WC Oncology SC Oncology GA 259EV UT WOS:000327511100004 ER PT J AU Nokihara, H Hirsh, V Blackhall, F Kim, DW Besse, B Han, JY Wilner, K Reisman, A Iyer, S Shaw, A AF Nokihara, H. Hirsh, V. Blackhall, F. Kim, D. -W. Besse, B. Han, J. -Y. Wilner, K. Reisman, A. Iyer, S. Shaw, A. TI PHASE III STUDY OF CRIZOTINIB VS. CHEMOTHERAPY IN ADVANCED ALK plus NSCLC: PATIENT-REPORTED SYMPTOMS AND QUALITY OF LIFE SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 11th Annual Meeting of the Japanese-Society-of-Medical-Oncology CY AUG 29-31, 2013 CL Sendai, JAPAN SP Japanese Soc Med Oncol C1 [Nokihara, H.] Natl Canc Ctr, Div Internal Med & Thorac Oncol, Tokyo, Japan. [Hirsh, V.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. [Blackhall, F.] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England. [Kim, D. -W.] Seoul Natl Univ Hosp, Seoul 110744, South Korea. [Besse, B.] Inst Gustave Roussy, Villejuif, France. [Han, J. -Y.] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea. [Wilner, K.] Pfizer Oncol, La Jolla, CA USA. [Reisman, A.] Pfizer Specialty Care, New York, NY USA. [Iyer, S.] Pfizer Oncol, New York, NY USA. [Shaw, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD NOV PY 2013 VL 24 SU 9 DI 10.1093/annonc/mdt459.53 PG 1 WC Oncology SC Oncology GA 259EV UT WOS:000327511100101 ER PT J AU Ou, SHI Kim, DW Camidge, R Riely, GJ Salgia, R Shapiro, G Clark, JW Tye, L Iafrate, AJ Shaw, A AF Ou, S. -H. I. Kim, D. -W. Camidge, R. Riely, G. J. Salgia, R. Shapiro, G. Clark, J. W. Tye, L. Iafrate, A. J. Shaw, A. TI CRIZOTINIB TREATMENT IN PATIENTS (PTS) WITH ADVANCED ROS1-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 11th Annual Meeting of the Japanese-Society-of-Medical-Oncology CY AUG 29-31, 2013 CL Sendai, JAPAN SP Japanese Soc Med Oncol C1 [Ou, S. -H. I.] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA. [Kim, D. -W.] Seoul Natl Univ Hosp, Seoul 110744, South Korea. [Camidge, R.] Univ Colorado, Ctr Canc, Aurora, CO USA. [Riely, G. J.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Salgia, R.] Univ Chicago, Chicago, IL 60637 USA. [Shapiro, G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Clark, J. W.; Iafrate, A. J.; Shaw, A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Tye, L.] Pfizer Oncol, La Jolla, CA USA. NR 0 TC 1 Z9 1 U1 3 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD NOV PY 2013 VL 24 SU 9 DI 10.1093/annonc/mdt459.54 PG 1 WC Oncology SC Oncology GA 259EV UT WOS:000327511100102 ER PT J AU Simcha, DM Younes, L Aryee, MJ Geman, D AF Simcha, David M. Younes, Laurent Aryee, Martin J. Geman, Donald TI Identification of direction in gene networks from expression and methylation SO BMC SYSTEMS BIOLOGY LA English DT Article DE Gene regulation; Methylation; Microarrays; Bayesian networks ID TUMOR CLASSIFICATION; REGULATORY NETWORKS; CANCER; INFERENCE; PROFILES; MODELS AB Background: Reverse-engineering gene regulatory networks from expression data is difficult, especially without temporal measurements or interventional experiments. In particular, the causal direction of an edge is generally not statistically identifiable, i.e., cannot be inferred as a statistical parameter, even from an unlimited amount of non-time series observational mRNA expression data. Some additional evidence is required and high-throughput methylation data can viewed as a natural multifactorial gene perturbation experiment. Results: We introduce IDEM (Identifying Direction from Expression and Methylation), a method for identifying the causal direction of edges by combining DNA methylation and mRNA transcription data. We describe the circumstances under which edge directions become identifiable and experiments with both real and synthetic data demonstrate that the accuracy of IDEM for inferring both edge placement and edge direction in gene regulatory networks is significantly improved relative to other methods. Conclusion: Reverse-engineering directed gene regulatory networks from static observational data becomes feasible by exploiting the context provided by high-throughput DNA methylation data. An implementation of the algorithm described is available at http://code.google.com/p/idem/. C1 [Simcha, David M.] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA. [Younes, Laurent] Johns Hopkins Univ, Dept Appl Math, Baltimore, MD 21218 USA. [Aryee, Martin J.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Aryee, Martin J.] Massachusetts Gen Hosp, Dept Pathol, Charlestown, MA 02129 USA. [Geman, Donald] Johns Hopkins Univ, Dept Appl Math & Stat, Baltimore, MD 21218 USA. [Geman, Donald] Johns Hopkins Univ, Inst Computat Med, Baltimore, MD 21218 USA. RP Simcha, DM (reprint author), Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA. EM dsimcha@gmail.com FU NIH-NCRR [UL1 RR 025005] FX The work of DS and DG was partially supported by NIH-NCRR Grant UL1 RR 025005. NR 37 TC 1 Z9 1 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1752-0509 J9 BMC SYST BIOL JI BMC Syst. Biol. PD NOV 1 PY 2013 VL 7 AR 118 DI 10.1186/1752-0509-7-118 PG 15 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA 259CF UT WOS:000327504300001 PM 24182195 ER PT J AU Zhang, Y Dong, Y Zheng, H Shie, V Wang, H Busscher, JJ Yue, Y Xu, Z Xie, Z AF Zhang, Y. Dong, Y. Zheng, H. Shie, V. Wang, H. Busscher, J. J. Yue, Y. Xu, Z. Xie, Z. TI Sevoflurane Inhibits Neurogenesis and the Wnt-Catenin Signaling Pathway in Mouse Neural Progenitor Cells SO CURRENT MOLECULAR MEDICINE LA English DT Article DE Sevoflurane; neurogenesis; wnt ID CENTRAL-NERVOUS-SYSTEM; BETA-PROTEIN-LEVELS; ADULT NEUROGENESIS; BIRTH COHORT; STEM-CELLS; LEARNING-DISABILITIES; EARLY EXPOSURE; DENTATE GYRUS; ANESTHESIA; PROLIFERATION AB Recent population studies suggest that children who receive anesthesia and surgery could be at an increased risk for developing learning disabilities. The underlying reason for this clinical observation is largely unknown. Whether undergoing anesthesia contributes to learning disability development, or if the need for anesthesia and surgery is a marker for other unidentified factors that contribute to the development of learning disabilities, remains to be determined. Neurogenesis, regulated by the Wnt-catenin signaling pathway, has been shown to be involved in learning and memory, and sevoflurane is the most commonly used inhalation anesthetic in children. We therefore set out to determine the effects of sevoflurane on neurogenesis and the Wnt-catenin signaling pathway in mouse neural progenitor cells (NPCs) using immunofluorescence and Western blot analysis. Here we show for the first time that 4.1%, but not 2.0%, sevoflurane reduced mouse NPC proliferation, increased Glycogen synthase kinase-3 beta (GSK-3 beta) levels, and decreased levels of beta-Catenin in mouse NPCs. The GSK-3 beta inhibitor Lithium attenuated the sevoflurane-induced reduction in mouse NPC proliferation. The data suggest that sevoflurane may reduce neurogenesis through the Wnt-catenin signaling pathway. These findings would promote further studies to investigate the effects of anesthesia on neurogenesis and function of learning and memory, as well as the underlying mechanisms in vitro and in vivo. Ultimately these efforts would lead to safer anesthesia care and better postoperative outcomes in children. C1 [Zhang, Y.; Dong, Y.; Zheng, H.; Shie, V.; Wang, H.; Busscher, J. J.; Xu, Z.; Xie, Z.] Massachusetts Gen Hosp, Geriatr Anesthesia Res Unit, Dept Anesthesia Crit Care & Pain Med, Charlestown, MA 02129 USA. [Zhang, Y.; Dong, Y.; Zheng, H.; Shie, V.; Wang, H.; Busscher, J. J.; Xu, Z.; Xie, Z.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Yue, Y.] Capital Med Univ, Beijing Chaoyang Hosp, Dept Anesthesia, Beijing 100020, Peoples R China. RP Xie, Z (reprint author), Massachusetts Gen Hosp, Geriatr Anesthesia Res Unit, Dept Anesthesia Crit Care & Pain Med, 149 13th St,Room 4310, Charlestown, MA 02129 USA. EM zxie@partners.org FU National Institutes of Health (Bethesda, Maryland) [R21 AG029856, R01 GM088801]; American Geriatrics Society Jahnigen Award (New York, NY); Investigator-Initiated Research Grant from Alzheimer's Association (Chicago, IL); National Science Foundation, P.R. China [NSF30928026] FX This study was supported by National Institutes of Health grants (Bethesda, Maryland) (R21 AG029856 and R01 GM088801); American Geriatrics Society Jahnigen Award (New York, NY); Investigator-Initiated Research Grant from Alzheimer's Association (Chicago, IL) (to Z.X.). National Science Foundation Oversea young scholar collaboration research award NSF30928026, P.R. China (to Z. X. and Y. Y.). The Department of Anesthesia, Critical Care and Pain Medicine at Massachusetts General Hospital and Harvard Medical School provided the cost of inhalation anesthetic sevoflurane. NR 49 TC 14 Z9 16 U1 0 U2 10 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1566-5240 EI 1875-5666 J9 CURR MOL MED JI Curr. Mol. Med. PD NOV PY 2013 VL 13 IS 9 BP 1446 EP 1454 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 258GC UT WOS:000327446300005 PM 23971735 ER PT J AU Hu, X Zhang, F Leak, RK Zhang, W Iwai, M Stetler, RA Dai, Y Zhao, A Gao, Y Chen, J AF Hu, X. Zhang, F. Leak, R. K. Zhang, W. Iwai, M. Stetler, R. A. Dai, Y. Zhao, A. Gao, Y. Chen, J. TI Transgenic Overproduction of Omega-3 Polyunsaturated Fatty Acids Provides Neuroprotection and Enhances Endogenous Neurogenesis After Stroke SO CURRENT MOLECULAR MEDICINE LA English DT Article DE Oligodendrogenesis; omega-3 polyunsaturated fatty acids; neurogenesis; neuroprotection; stroke ID FOCAL CEREBRAL-ISCHEMIA; NEURAL STEM-CELLS; DOCOSAHEXAENOIC ACID; FISH CONSUMPTION; AGED RATS; BRAIN; IMPROVES; RISK; OMEGA-3-FATTY-ACIDS; TRANSPLANTATION AB Strokes are devastating as there are no current therapies to prevent the long term neurological deficits that they cause. Soon after ischemic stroke, there is proliferation and differentiation of neural stem/progenitor cells as an important mechanism for neuronal restoration. However, endogenous neurogenesis by itself is insufficient for effective brain repair after stroke as most newborn neurons do not survive. One fascinating strategy for stroke treatment would thus be maintaining the survival and/or promoting the differentiation of endogenous neural stem/progenitor cells. Using transgenic (Tg) mice over-expressing the C. elegans fat-1 gene encoding an enzyme that converts endogenous omega-6 to omega-3 polyunsaturated fatty acids (n-3 PUFAs), we showed that fat-1 Tg mice with chronically elevated brain levels of n-3 PUFAs exhibited less brain damage and significantly improved long-term neurological performance compared to wild type littermates. Importantly, post-stroke neurogenesis occurred more robustly in fat-1 Tg mice after focal ischemia. This was manifested by enhanced neural stem cell proliferation/differentiation and increased migration of neuroblasts to the ischemic sites where neuroblasts matured into resident neurons. Moreover, these neurogenic effects were accompanied by significantly increased oligodendrogenesis. Our results suggest that n-3 PUFA supplementation is a potential neurogenic and oligodendrogenic treatment to naturally improve post-stroke brain repair and long-term functional recovery. C1 [Hu, X.; Zhang, F.; Stetler, R. A.; Chen, J.] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. [Hu, X.; Zhang, F.; Zhang, W.; Stetler, R. A.; Gao, Y.; Chen, J.] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Hu, X.; Zhang, F.; Zhang, W.; Stetler, R. A.; Gao, Y.; Chen, J.] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China. [Leak, R. K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA. [Dai, Y.; Zhao, A.] Nanjing Med Univ, Ctr Metab Dis Res, Nanjing, Jiangsu, Peoples R China. [Hu, X.; Zhang, F.; Iwai, M.; Stetler, R. A.; Chen, J.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Hu, X.; Zhang, F.; Iwai, M.; Stetler, R. A.; Chen, J.] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. EM yqgao@shmu.edu.cn; chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016; OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417; Zhang, Feng/0000-0001-7275-9989 FU VA RRD Merit Review; NIH [NS036736, NS045048, NS056118]; AHA [13SDG14570025, 10SDG2560122]; Chinese Natural Science Foundation [30670642, 30870794, 81020108021]; VA Career Research Scientist Award; RK Mellon Endowed Chair for Cerebrovascular Disease Research at the University of Pittsburgh FX X.H. and F.Z. contributed equally to the study. This work was supported by the VA RR&D Merit Review (to J.C.), NIH grants NS036736, NS045048, and NS056118 (to J.C.), and AHA grants 13SDG14570025 (to X. H.) and 10SDG2560122 (to F.Z.). Y.G. was supported by Chinese Natural Science Foundation grants no. 30670642, 30870794, and 81020108021. J.C. is a recipient of the VA Career Research Scientist Award and also supported by the RK Mellon Endowed Chair for Cerebrovascular Disease Research at the University of Pittsburgh. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 27 TC 13 Z9 13 U1 0 U2 9 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1566-5240 EI 1875-5666 J9 CURR MOL MED JI Curr. Mol. Med. PD NOV PY 2013 VL 13 IS 9 BP 1465 EP 1473 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 258GC UT WOS:000327446300007 PM 23971733 ER PT J AU Rengifo-Moreno, P Palacios, IF Junpaparp, P Witzke, CF Morris, DL Romero-Corral, A AF Rengifo-Moreno, Pablo Palacios, Igor F. Junpaparp, Parichart Witzke, Christian F. Morris, D. Lynn Romero-Corral, Abel TI Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials SO EUROPEAN HEART JOURNAL LA English DT Article DE PFO; Stroke; Transcatheter closure ID CRYPTOGENIC STROKE; EMBOLISM; QUALITY AB Background In patients with cryptogenic stroke, transcatheter (TC) closure of a patent foramen ovale (PFO) has not been shown to better prevent recurrent vascular events than medical therapy. However, randomized controlled trials (RCT) to date have included few vascular events, and lack of power has been raised as an important concern. Objective To conduct a systematic review and meta-analysis of existing RCT published studies assessing the recurrence of vascular events after TC PFO closure when compared to medical therapy. Methods Using the search terms patent foramen ovale, PFO, stroke, percutaneous closure and transcatheter closure, Medline, Pubmed, Embase, and Cochrane databases were reviewed from inception through April 2013, with no language restrictions. Only studies in adult humans were considered. Additional references were obtained from the bibliographies of studies reviewed. The following criteria were used for study selection: 1) randomized controlled trial, 2) subjects were adult patients with cryptogenic stroke who were randomized to TC PFO closure or medical treatment (antiplatelet therapy and/or anticoagulation), and 3) reported outcomes included cardiac death, all death, stroke, transient ischemic attack, and peripheral embolism. Methodological and descriptive data, adverse events (including raw data and risk estimates), as well as procedural success and complications were abstracted in duplicate from each study independently, and agreement was tested. We followed rigorously the recommended guidelines for reporting and conducting and assessing quality of meta-analysis of RCT. The primary endpoints pre-specified in advance were recurrent vascular events, and composite endpoint of death, and recurrent vascular events. Results Three studies were identified as meeting selection criteria. These included a total of 2,303 patients, with 1,150 patients randomized to TC PFO closure and 1,153 patients randomized to medical therapy. Mean follow-up was 3.5 years. Baseline characteristics (age, sex, and cardiovascular risk factors) were similar across studies. Intention-to-treat analyses showed a statistically significant risk reduction in stroke and/or transient ischemic attack in the TC PFO closure group when compared to medical treatment, pooled HR 0.59, 95%CI (0.36-0.97), P 0.04. The combined outcome of death, and vascular events, showed a borderline statistically significant benefit for TC PFO closure when compared to medical treatment, pooled HR 0.67, 95CI (0.441.00), P 0.05 Subjects with a substantial PFO shunt seem to benefit the most with TC PFO closure, pooled HR 0.35, 95%CI (0.121.03), P 0.06, however, it did not reach statistical significance. Conclusion These results suggest that in patients with cryptogenic stroke, TC PFO closure may be beneficial in reducing the risk of recurrent vascular events when compared to medical treatment. The benefit of TC PFO closure may be greater in patients with a substantial shunt. C1 [Rengifo-Moreno, Pablo; Witzke, Christian F.; Morris, D. Lynn; Romero-Corral, Abel] Albert Einstein Med Ctr, Inst Heart & Vasc Hlth & Cardiovasc Dis, Philadelphia, PA 19141 USA. [Palacios, Igor F.] Massachusetts Gen Hosp, Serv Cardiol, Boston, MA 02114 USA. [Palacios, Igor F.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Junpaparp, Parichart] Albert Einstein Med Ctr, Dept Internal Med, Philadelphia, PA 19141 USA. [Morris, D. Lynn] Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA. [Romero-Corral, Abel] Albert Einstein Med Ctr, Div Cardiovasc Dis, Philadelphia, PA 19141 USA. RP Romero-Corral, A (reprint author), Albert Einstein Med Ctr, Inst Heart & Vasc Hlth & Cardiovasc Dis, Philadelphia, PA 19141 USA. EM romeroab@einstein.edu NR 20 TC 54 Z9 54 U1 0 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD NOV PY 2013 VL 34 IS 43 BP 3342 EP 3352 DI 10.1093/eurheartj/eht285 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 257QH UT WOS:000327400000006 PM 23847132 ER PT J AU An, NF Janech, MG Bland, AM Lazarchick, J Arthur, JM Kang, YB AF An, Ningfei Janech, Michael G. Bland, Alison M. Lazarchick, John Arthur, John M. Kang, Yubin TI Proteomic analysis of murine bone marrow niche microenvironment identifies thioredoxin as a novel agent for radioprotection and for enhancing donor cell reconstitution SO EXPERIMENTAL HEMATOLOGY LA English DT Article ID HEMATOPOIETIC STEM-CELLS; OXIDATIVE STRESS; NOD/SCID MICE; MAMMALIAN THIOREDOXIN; PROGENITOR CELLS; LIFE-SPAN; G-CSF; ENGRAFTMENT; DISEASE; REPOPULATION AB Hematopoiesis is regulated by the bone marrow (BM) niche microenvironment. We recently found that posttransplant administration of AMD3100 (a specific and reversible CXCR4 antagonist) enhanced donor cell engraftment and promoted recovery of all donor cell lineages in a congeneic mouse transplant model. We hypothesized that AMD3100 enhances donor cell reconstitution in part by modulating the levels and constitution of soluble factors in the niche microenviromnent. In the current study, the effects of the BM extracellular fluid (supernatant) from AMD3100-treated transplant recipient mice on colony-forming units (CFUs) were examined. A semiquantitative, mass spectrometry-based proteomics approach was used to screen for differentially expressed proteins between the BM supernatants of PBS-treated transplant mice and AMD3100-treated transplant mice. A total of 178 proteins were identified in the BM supernatants. Thioredoxin was among the 32 proteins that displayed greater than a twofold increase in spectral counts in the BM supernatant of AMD3100-treated transplant mice. We found that thioredoxin increased CFUs in a dose-dependent manner. Thioredoxin improved hematopoiesis in irradiated mice and protected mice from radiation-related death. Furthermore, ex vivo exposure to thioredoxin for 24 hours enhanced the long-term repopulation of hematopoietic stem cells. Additionally, combined posttransplant administration of thioredoxin and AMD3100 improved hematologic recovery in primary and secondary transplant recipient mice. Our studies demonstrated that factors in the BM niche microenvironment play a critical role in hematopoiesis. Identifying these factors provides clues on potential novel targets that can be used to enhance hematologic recovery in hematopoietic stem cell transplan'tation. (C) 2013 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. C1 [An, Ningfei; Kang, Yubin] Med Univ S Carolina, Div Hematol Oncol, Charleston, SC 29425 USA. [Janech, Michael G.; Bland, Alison M.; Arthur, John M.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Lazarchick, John] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Arthur, John M.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Kang, YB (reprint author), Med Univ S Carolina, Dept Med, Div Hematol Oncol, Hollings Canc Ctr, 86 Jonathan Lucas St,Room HO307, Charleston, SC 29425 USA. EM kangy@musc.edu OI Janech, Michael/0000-0002-3202-4811 FU MUSC Hollings Cancer Center; Hollings Cancer Center ACS IRG; ASCO Conquer Cancer Foundation; National Institutes of Health [1K08HL 103780-01A1, 3P30CA138313-01S3] FX We thank Richard Peppler and Haiqun Zeng at the HCC Flow Cytometry Core for performing flow cytometry analysis and Henning Schade and Dzmitry Haviazheu for their technical assistance. This work is supported by MUSC Hollings Cancer Center Startup Fund, Hollings Cancer Center ACS IRG, ASCO Conquer Cancer Foundation Career Development Award, National Institutes of Health grants 1K08HL 103780-01A1 and 3P30CA138313-01S3. This manuscript is the result of work supported with resources and the use of facilities at the Ralph H. Johnson VA Medical Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funding agents. NR 53 TC 2 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0301-472X EI 1873-2399 J9 EXP HEMATOL JI Exp. Hematol. PD NOV PY 2013 VL 41 IS 11 BP 944 EP 956 DI 10.1016/j.exphem.2013.08.004 PG 13 WC Hematology; Medicine, Research & Experimental SC Hematology; Research & Experimental Medicine GA 257VU UT WOS:000327416700004 PM 23994289 ER PT J AU Oba, K Paoletti, X Alberts, S Bang, YJ Benedetti, J Bleiberg, H Catalano, P Lordick, F Michiels, S Morita, S Ohashi, Y Pignon, JP Rougier, P Sasako, M Sakamoto, J Sargent, D Shitara, K Cutsem, EV Buyse, M Burzykowski, T AF Oba, Koji Paoletti, Xavier Alberts, Steven Bang, Yung-Jue Benedetti, Jacqueline Bleiberg, Harry Catalano, Paul Lordick, Florian Michiels, Stefan Morita, Satoshi Ohashi, Yasuo Pignon, Jean-pierre Rougier, Philippe Sasako, Mitsuru Sakamoto, Junichi Sargent, Daniel Shitara, Kohei Cutsem, Eric Van Buyse, Marc Burzykowski, Tomasz CA GASTRIC Grp TI Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Review ID PHASE-III TRIAL; RANDOMIZED CONTROLLED-TRIAL; INDIVIDUAL-PATIENT-DATA; END-POINTS; CLINICAL-TRIAL; PLUS TEGAFUR; MITOMYCIN-C; CHEMOTHERAPY; SURGERY; 5-FLUOROURACIL AB In investigations of the effectiveness of surgery and adjuvant chemotherapy for gastric cancers, overall survival (OS) is considered the gold standard endpoint. However, the disadvantage of using OS as the endpoint is that it requires an extended follow-up period. We sought to investigate whether disease-free survival (DFS) is a valid surrogate for OS in trials of adjuvant chemotherapy for gastric cancer. The GASTRIC group initiated a meta-analysis of individual patient data collected in randomized clinical trials comparing adjuvant chemotherapy vs surgery alone for patients with curatively resected gastric cancer. Surrogacy of DFS was assessed through the correlation between the endpoints as well as through the correlation between the treatment effects on the endpoints. External validation of the prediction based on DFS was also evaluated. Individual patient data from 14 randomized clinical trials that included a total of 3288 patients were analyzed. The rank correlation coefficient between DFS and OS was 0.974 (95% confidence interval [CI] 0.971 to 0.976). The coefficient of determination between the treatment effects on DFS and on OS was as high as 0.964 (95% CI 0.926 to 1.000), and the surrogate threshold effect based on adjusted regression analysis was 0.92. In external validation, the six hazard ratios for OS predicted according to DFS were in very good agreement with those actually observed for OS. DFS is an acceptable surrogate for OS in trials of cytotoxic agents for gastric cancer in the adjuvant setting. C1 [Oba, Koji] Hokkaido Univ Hosp, Translat Res & Clin Trial Ctr, Sapporo, Hokkaido 060, Japan. [Paoletti, Xavier] Inst Curie, Biostat Dpt, INSEM U900, Paris, France. [Alberts, Steven; Sargent, Daniel] Mayo Clin, Rochester, MN USA. [Bang, Yung-Jue] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea. [Benedetti, Jacqueline] SWOG Stat Ctr, Seattle, WA USA. [Catalano, Paul] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Catalano, Paul] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Lordick, Florian] Univ Clin Leipzig, Univ Canc Ctr, Leipzig, Germany. [Michiels, Stefan; Pignon, Jean-pierre] Univ Paris 11, Inst Gustave Roussy, Biostat & Epidemiol Dept, Villejuif, France. [Morita, Satoshi] Yokohama City Univ, Dept Biostat, Yokohama, Kanagawa 232, Japan. [Ohashi, Yasuo] Univ Tokyo, Sch Publ Hlth, Grad Sch Med, Dept Biostat, Tokyo, Japan. [Rougier, Philippe] Univ Hosp Europeen Georges Pompidou, Gastroenterol Dept, Paris, France. [Sasako, Mitsuru] Hyogo Coll Med, Dept Surg, Nishinomiya, Hyogo 6638501, Japan. [Sakamoto, Junichi] Tokai Cent Hosp, Kakumuhara, Japan. [Shitara, Kohei] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan. [Cutsem, Eric Van] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium. [Buyse, Marc; Burzykowski, Tomasz] Int Inst Drug Dev, Louvain, Belgium. [Buyse, Marc; Burzykowski, Tomasz] Hasselt Univ, I BioStat, Diepenbeek, Belgium. RP Oba, K (reprint author), Hokkaido Univ Hosp, Translat Res & Clin Trial Ctr, Kita Ku, Kita 14,Nishi 5, Sapporo, Hokkaido 0608648, Japan. EM k.oba@huhp.hokudai.ac.jp RI Bang, Yung Jue/J-2759-2012; Michiels, Stefan/L-1516-2013; OI Michiels, Stefan/0000-0002-6963-2968; Sargent, Daniel/0000-0002-2684-4741 FU French Institut National du Cancer (grant PHRC GASTRIC); Clinical Research Support Unit; Epidemiological and Clinical Research Information Network; GlaxoSmithKline; Banyu Fellowship Program; Banyu Life Science Foundation International FX This work was partially supported by the French Institut National du Cancer (grant PHRC GASTRIC), the Clinical Research Support Unit, and the Epidemiological and Clinical Research Information Network. A meeting was supported financially by unrestricted grants from GlaxoSmithKline. The funders were not present at the meeting, were not involved in the analysis of the data, and did not comment on the present paper. KO was supported by the Banyu Fellowship Program, which is sponsored by the Banyu Life Science Foundation International. NR 32 TC 25 Z9 25 U1 1 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD NOV PY 2013 VL 105 IS 21 BP 1600 EP 1607 DI 10.1093/jnci/djt270 PG 8 WC Oncology SC Oncology GA 251ZL UT WOS:000326973900006 PM 24108812 ER PT J AU Pilarski, R Burt, R Kohlman, W Pho, L Shannon, KM Swisher, E AF Pilarski, Robert Burt, Randall Kohlman, Wendy Pho, Lana Shannon, Kristen M. Swisher, Elizabeth TI Cowden Syndrome and the PTEN Hamartoma Tumor Syndrome: Systematic Review and Revised Diagnostic Criteria SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID RILEY-RUVALCABA-SYNDROME; AUTISM SPECTRUM DISORDERS; LHERMITTE-DUCLOS-DISEASE; CORE-NEEDLE-BIOPSY; GENOTYPE-PHENOTYPE CORRELATIONS; LIFETIME CANCER-RISKS; GERMLINE PTEN; MULTIPLE HAMARTOMA; BREAST-CANCER; GASTROINTESTINAL POLYPOSIS AB Background PTEN hamartoma tumor syndrome (PHTS) refers to a spectrum of disorders caused by mutations in the phosphatase and tensin homolog (PTEN) gene. Diagnostic criteria for Cowden syndrome, the principal PTEN-related disorder, were first established in 1996 before the identification of the PTEN gene and the ability to molecularly confirm a clinical diagnosis. These consortium criteria were based on clinical experience and case reports in the existing literature, with their inherent selection biases. Although it was initially reported that approximately 80% of patients with Cowden syndrome had an identifiable germline PTEN mutation, more recent work has shown these diagnostic criteria to be far less specific. In addition, increasing evidence has documented the association of a broader spectrum of clinical features with PTEN mutations. Our goal was to develop revised, evidence-based diagnostic criteria and to include features of the broader spectrum of PTEN-related clinical syndromes. Methods We performed a systematic search and review of the medical literature related to clinical features reported in individuals with a PTEN mutation and/or a related clinical diagnosis. Results We found no sufficient evidence to support inclusion of benign breast disease, uterine fibroids, or genitourinary malformations as diagnostic criteria. There was evidence to include autism spectrum disorders, colon cancer, esophageal glycogenic acanthosis, penile macules, renal cell carcinoma, testicular lipomatosis, and vascular anomalies. Conclusions We propose revised, evidence-based criteria covering the spectrum of PTEN-related clinical disorders. Additional research on clinical features associated with PTEN mutations is warranted. C1 [Pilarski, Robert] Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43240 USA. [Pilarski, Robert] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43240 USA. [Burt, Randall; Kohlman, Wendy; Pho, Lana] Huntsman Canc Inst, Salt Lake City, UT USA. [Burt, Randall; Kohlman, Wendy] Univ Utah, Sch Med, Salt Lake City, UT USA. [Pho, Lana] Univ Utah, Dept Dermatol, Salt Lake City, UT USA. [Shannon, Kristen M.] Massachusetts Gen Hosp, Ctr Canc, Ctr Canc Risk Assessment, Boston, MA USA. [Swisher, Elizabeth] Univ Washington, Med Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA. RP Pilarski, R (reprint author), Ohio State Univ, Clin Canc Genet Program, 2001 Polaris Pkwy, Columbus, OH 43240 USA. EM robert.pilarski@osumc.edu RI Pilarski, Robert/E-3871-2011 NR 116 TC 85 Z9 86 U1 1 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD NOV PY 2013 VL 105 IS 21 BP 1607 EP 1616 DI 10.1093/jnci/djt277 PG 11 WC Oncology SC Oncology GA 251ZL UT WOS:000326973900007 PM 24136893 ER PT J AU Hong, FX Simon, R AF Hong, Fangxin Simon, Richard TI Run-In Phase III Trial Design With Pharmacodynamics Predictive Biomarkers SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID RANDOMIZED CLINICAL-TRIALS; DISCONTINUATION DESIGN; PHYSICIANS HEALTH; CARCINOMA CELLS; DENDRITIC CELLS; EFFICIENCY; PLACEBO; FUSIONS; BREAST AB Developments in biotechnology have stimulated the use of predictive biomarkers to identify patients who are likely to benefit from a targeted therapy. Several randomized phase III designs have been introduced for development of a targeted therapy using a diagnostic test. Most such designs require biomarkers measured before treatment. In many cases, it has been very difficult to identify such biomarkers. Promising candidate biomarkers can sometimes be effectively measured after a short run-in period on the new treatment. We introduce a new design for phase III trials with a candidate predictive pharmacodynamic biomarker measured after a short run-in period. Depending on the therapy and the biomarker performance, the trial would either randomize all patients but perform a separate analysis on the biomarker-positive patients or only randomize marker-positive patients after the run-in period. We evaluate the proposed design compared with the conventional phase III design and discuss how to design a run-in trial based on phase II studies. The proposed design achieves a major sample size reduction compared with the conventional randomized phase III design in many cases when the biomarker has good sensitivity (0.7) and specificity (0.7). This requires that the biomarker be measured accurately and be indicative of drug activity. However, the proposed design loses some of its advantage when the proportion of potential responders is large (> 50%) or the effect on survival from run-in period is substantial. Incorporating a pharmacodynamic biomarker requires careful consideration but can expand the capacity of clinical trials to personalize treatment decisions and enhance therapeutics development. C1 [Hong, Fangxin] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. [Hong, Fangxin] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Computat Biol, Boston, MA 02115 USA. [Simon, Richard] NCI, Biometr Res Branch, Bethesda, MD 20892 USA. RP Simon, R (reprint author), NCI, Biometr Res Branch, Bethesda, MD 20892 USA. EM rsimon@mail.nih.gov FU Department of Biostatistics and Computational Biology Research Scientist Fund FX This work was supported by the Department of Biostatistics and Computational Biology Research Scientist Fund (to FH). NR 20 TC 2 Z9 2 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-. Natl. Cancer Inst. PD NOV PY 2013 VL 105 IS 21 BP 1628 EP 1633 DI 10.1093/jnci/djt265 PG 6 WC Oncology SC Oncology GA 251ZL UT WOS:000326973900009 PM 24096624 ER PT J AU Paoletti, X Oba, K Bang, YJ Bleiberg, H Boku, N Bouche, O Catalano, P Fuse, N Michiels, S Moehler, M Morita, S Ohashi, Y Ohtsu, A Roth, A Rougier, P Sakamoto, J Sargent, D Sasako, M Shitara, K Thuss-Patience, P Van Cutsem, E Burzykowski, T Buyse, M AF Paoletti, Xavier Oba, Koji Bang, Yung-Jue Bleiberg, Harry Boku, Narikazu Bouche, Olivier Catalano, Paul Fuse, Nozomu Michiels, Stefan Moehler, Markus Morita, Satoshi Ohashi, Yasuo Ohtsu, Atsushi Roth, Arnaud Rougier, Philippe Sakamoto, Junichi Sargent, Daniel Sasako, Mitsuru Shitara, Kohei Thuss-Patience, Peter Van Cutsem, Eric Burzykowski, Tomasz Buyse, Marc CA GASTRIC Grp TI Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID RANDOMIZED PHASE-II; ADVANCED ESOPHAGOGASTRIC CANCER; INDIVIDUAL-PATIENT-DATA; HIGH-DOSE METHOTREXATE; GASTROESOPHAGEAL ADENOCARCINOMA; 1ST-LINE THERAPY; END-POINTS; INFUSION FLUOROURACIL; EUROPEAN-ORGANIZATION; COMPARING MITOMYCIN AB The traditional endpoint for assessing efficacy of chemotherapies for advanced/recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. We investigated whether progression-free survival (PFS) is a valid surrogate for OS. Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was assessed through the correlation between the endpoints and through the correlation between the treatment effects on the endpoints. External validation of the prediction based on PFS was also evaluated. Individual data from 4069 patients in 20 randomized trials were analyzed. The rank correlation coefficient between PFS and OS was 0.853 (95% confidence interval [CI] = 0.852 to 0.854). The R-2 between treatment effects on PFS and on OS was 0.61 (95% CI = 0.04 to 1.00). Treatment effects on PFS and on OS were only moderately correlated, and we could not confirm the validity of PFS as a surrogate endpoint for OS in advanced/recurrent gastric cancer. C1 [Paoletti, Xavier] Inst Curie, INSERM, U900, Biostat Dept, F-75005 Paris, France. [Oba, Koji] Hokkaido Univ Hosp, Translat Res & Clin Trial Ctr, Sapporo, Hokkaido, Japan. [Bang, Yung-Jue] Seoul Natl Univ Coll Med, Div Oncol, Seoul, South Korea. [Bleiberg, Harry] Jules Bordet Hosp, Brussels, Belgium. [Boku, Narikazu] St Marianna Univ Sch Med, Kawasaki, Kanagawa, Japan. [Bouche, Olivier] Hop Robert Debre, Dept Clin Oncol, Reims, France. [Catalano, Paul] Dana Farber Canc Inst, Boston, MA 02115 USA. [Catalano, Paul] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Fuse, Nozomu; Ohtsu, Atsushi] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan. [Michiels, Stefan] Univ Paris 11, Inst Gustave Roussy, Biostat & Epidemiol Dept, Villejuif, France. [Moehler, Markus] Johannes Gutenberg Univ Mainz, Dept Med, D-55122 Mainz, Germany. [Morita, Satoshi] Yokohama City Univ, Dept Biostat & Epidemiol, Yokohama, Kanagawa, Japan. [Ohashi, Yasuo] Univ Tokyo, Tokyo, Japan. [Roth, Arnaud] Univ Hosp, Dept Surg, Geneva, Switzerland. [Rougier, Philippe] Univ Hosp Europeen Georges Pompidou, Gastroenterol Dept, Paris, France. [Sakamoto, Junichi] Tokai Cent Hosp, Sohara, Japan. [Sargent, Daniel] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN USA. [Sasako, Mitsuru] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan. [Shitara, Kohei] Aichi Canc Ctr Hosp, Dept Gastrointestinal Oncol, Aichi, Japan. [Thuss-Patience, Peter] Charite, Dept Haematol Oncol & Tumorimmunol, D-13353 Berlin, Germany. [Van Cutsem, Eric] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium. [Burzykowski, Tomasz; Buyse, Marc] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat, Diepenbeek, Belgium. [Buyse, Marc] Int Inst Drug Dev, Louvain, Belgium. RP Paoletti, X (reprint author), Inst Curie, INSERM, U900, Bisotat Dept, 26 Rue Ulm, F-75005 Paris, France. EM xavier.paoletti@curie.net RI Bang, Yung Jue/J-2759-2012; Michiels, Stefan/L-1516-2013; OI Michiels, Stefan/0000-0002-6963-2968; Sargent, Daniel/0000-0002-2684-4741 FU French Institut National du Cancer (grant PHRC GASTRIC); Clinical Research Support Unit; Epidemiological and Clinical Research Information Network; GlaxoSmithKline FX This work was partially supported by the French Institut National du Cancer (grant PHRC GASTRIC); the Clinical Research Support Unit; and the Epidemiological and Clinical Research Information Network. A meeting was supported financially by unrestricted grants from GlaxoSmithKline. The funders were not present at the meeting, were not involved in the analyses of the data, and did not comment on the present paper. NR 40 TC 18 Z9 18 U1 1 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD NOV PY 2013 VL 105 IS 21 BP 1667 EP 1670 DI 10.1093/jnci/djt269 PG 4 WC Oncology SC Oncology GA 251ZL UT WOS:000326973900013 PM 24108811 ER PT J AU De Luca, G Gibson, MC van't Hof, AWJ Cutlip, D Zeymer, U Noc, M Maioli, M Zorman, S Gabriel, MH Secco, GG Emre, A Dudek, D Rakowski, T Gyongyosi, M Huber, K Bellandi, F AF De Luca, Giuseppe Gibson, Michael C. van't Hof, Arnoud W. J. Cutlip, Donald Zeymer, Uwe Noc, Marko Maioli, Mauro Zorman, Simona Gabriel, Mesquita H. Secco, Gioel Gabrio Emre, Ayse Dudek, Dariusz Rakowski, Tomasz Gyongyosi, Maryann Huber, Kurt Bellandi, Francesco CA EGYPT Cooperation TI Impact of time-to-treatment on myocardial perfusion after primary percutaneous coronary intervention with Gp IIb-IIIa inhibitors SO JOURNAL OF CARDIOVASCULAR MEDICINE LA English DT Article DE Gp IIb-IIIa; myocardial perfusion; ST-segment elevation myocardial infarction; time-to-treatment ID ST-SEGMENT ELEVATION; META-REGRESSION ANALYSIS; PRIMARY ANGIOPLASTY; RANDOMIZED-TRIALS; INFARCT SIZE; MECHANICAL REPERFUSION; DATA METAANALYSIS; SYMPTOM-ONSET; RISK PROFILE; ABCIXIMAB AB BackgroundPrimary angioplasty has been shown to be superior to thrombolysis. However, previous reports have shown a negative impact of longer time-to-treatment on myocardial perfusion and survival even with mechanical reperfusion. However, these deleterious effects might potentially be overcome by an extensive use of glycoprotein (Gp) IIb-IIIa inhibitors. Thus, the aim of the current study was to evaluate the prognostic role of the interval from symptoms onset to reperfusion in a large cohort of patients undergoing primary angioplasty with Gp IIb-IIIa inhibitors.MethodsOur population is represented by 1560 patients undergoing primary angioplasty for ST-segment elevation myocardial infarction (STEMI) included in the EGYPT (Early Glycoprotein IIb-IIIa Inhibitors in Primary Angiography) database. Myocardial perfusion was evaluated by angiography or ST-segment resolution, whereas infarct size was estimated by using peak creatine kinase and creatine kinase-MB (CK-MB). Follow-up data were collected between 30 days and 1 year after primary angioplasty.ResultsTime-to-treatment was significantly associated with age and female sex, diabetes and previous myocardial infarction (MI), but inversely related to smoking. Time-to-treatment affected the rate of postprocedural thrombolysis in myocardial infarction (TIMI) 3 flow (P<0.0001), myocardial blush grade 2-3 (P=0.052), complete ST-resolution (P<0.0001) and distal embolization (P=0.038). This relationship was confirmed after correction for baseline confounding factors for postprocedural TIMI 3 flow (P=0.008) and complete ST-segment resolution (P=0.003). Furthermore, time-to-treatment significantly affected enzymatic infarct size, even after correction for baseline confounding factors [odds ratio (OR) 95% confidence interval (95% CI)=1.002 (1.001-1.003), P=0.004]. At 208160 days follow-up, time-to-treatment was associated with a significantly higher mortality (P=0.006). The impact was confirmed when time-to-treatment was evaluated as a continuous variable (P<0.001), even after correction for baseline confounding factors [age, sex, diabetes, smoking, hypertension, previous myocardial infarction (MI), preprocedural TIMI 3 flow, multivessel disease, coronary stenting and early Gp IIb-IIIa inhibitors] (P=0.001).ConclusionThis study showed that time-to-treatment is a major determinant of mortality in ST-segment elevation myocardial infarction patients undergoing primary angioplasty. Impaired epicardial and myocardial perfusion and larger infarct size associated with longer ischemia time contribute to explain this finding. C1 [De Luca, Giuseppe; Secco, Gioel Gabrio] Eastern Piedmont Univ, Maggiore della Carita Hosp, Div Cardiol, Novara, Italy. [Gibson, Michael C.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA. [van't Hof, Arnoud W. J.] Hosp Weezenlanden, Div Cardiol, Zwolle, Netherlands. [Cutlip, Donald] Beth Israel Deaconess Med Ctr, Intervent Cardiol Sect, Boston, MA 02215 USA. [Noc, Marko; Zorman, Simona] Univ Med Ctr, Ctr Intens Internal Med, Ljubljana, Slovenia. [Maioli, Mauro; Bellandi, Francesco] Prato Hosp, Prato, Italy. [Zeymer, Uwe] Herzzentrum Ludwigshafen, Div Cardiol, Ludwigshafen, Germany. [Gabriel, Mesquita H.] Hosp Santa Maria, Div Cardiol, Lisbon, Portugal. [Emre, Ayse] Siyami Ersek Thorac & Cardiovasc Surg Ctr, Istanbul, Turkey. [Dudek, Dariusz; Rakowski, Tomasz] Jagiellonian Univ, Inst Cardiol, Dept Cardiol 2, Krakow, Poland. [Gyongyosi, Maryann] Med Univ Vienna, Dept Cardiol, Vienna, Austria. [Huber, Kurt] Wilhelminenspital Stadt Wien, Dept Med Cardiol & Emergency Med 3, Vienna, Austria. RP De Luca, G (reprint author), Eastern Piedmont Univ, Maggiore della Carita Hosp, Div Cardiol, Novara, Italy. EM giuseppe.deluca@maggioreosp.novara.it NR 38 TC 3 Z9 3 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1558-2027 EI 1558-2035 J9 J CARDIOVASC MED JI J. Cardiovasc. Med. PD NOV PY 2013 VL 14 IS 11 BP 815 EP 820 DI 10.2459/JCM.0b013e32835fcb38 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 256JK UT WOS:000327306100007 PM 23519096 ER PT J AU Diem, SJ Ruppert, K Cauley, JA Lian, YJ Bromberger, JT Finkelstein, JS Greendale, GA Solomon, DH AF Diem, Susan J. Ruppert, Kristine Cauley, Jane A. Lian, YinJuan Bromberger, Joyce T. Finkelstein, Joel S. Greendale, Gail A. Solomon, Daniel H. TI Rates of Bone Loss Among Women Initiating Antidepressant Medication Use in Midlife SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID SEROTONIN-REUPTAKE INHIBITORS; MINERAL DENSITY CHANGES; OLDER WOMEN; DEPRESSIVE SYMPTOMS; POSTMENOPAUSAL WOMEN; PHYSICAL-ACTIVITY; HIP-FRACTURES; IN-VITRO; RISK; TRANSPORTER AB Context: Concern has been raised that medications that block serotonin reuptake may affect bone metabolism, resulting in bone loss. Objective: The aim of the study was to compare annual bone mineral density(BMD) changes among new users of selective serotonin reuptake inhibitors (SSRIs), new users of tricyclic antidepressants (TCAs), and nonusers of antidepressant medications. Design and Setting: We conducted a prospective cohort study at five clinical centers in the United States. Participants: The study included 1972 community-dwelling women, aged 42 years and older, enrolled in the Study of Women's Health Across the Nation (SWAN). Exposure: The use of antidepressant medications was assessed by interview and verified from medication containers at annual visits. Subjects were categorized as nonusers (no SSRI or TCA use at any examination), SSRI users (initiated SSRI use after the baseline SWAN visit), or TCA users (initiated TCA use after the baseline visit), using a computerized dictionary to categorize type of medication. Main Outcome Measures: BMD at the lumbar spine, total hip, and femoral neck was measured using dual-energy x-ray absorptiometry at annual visits. Results: BMD was compared among 311 new users of SSRIs, 71 new users of TCAs, and 1590 nonusers. After adjustment for potential confounders, including age, race, body mass index, menopausal status, and hormone therapy use, mean lumbar spine BMD decreased on average 0.68% per year in nonusers, 0.63% per year in SSRI users (P = .37 for comparison to nonusers), and 0.40% per year in TCA users (P = .16 for comparison to nonusers). At the total hip and femoral neck, there was also no evidence that SSRI or TCA users had an increased rate of bone loss compared with nonusers. Results were similar in subgroups of women stratified by the Center for Epidemiologic Studies Depression Scale (<16 vs >= 16). Conclusions: In this cohort of middle-aged women, use of SSRIs and TCAs was not associated with an increased rate of bone loss at the spine, total hip, or femoral neck. C1 [Diem, Susan J.] Univ Minnesota, Dept Med, Minneapolis, MN 55415 USA. [Diem, Susan J.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55415 USA. [Ruppert, Kristine; Cauley, Jane A.; Lian, YinJuan; Bromberger, Joyce T.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Bromberger, Joyce T.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. [Finkelstein, Joel S.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Greendale, Gail A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Solomon, Daniel H.] Brigham & Womens Hosp, Div Rheumatol, Boston, MA 02115 USA. [Solomon, Daniel H.] Brigham & Womens Hosp, Div Pharmacoepidemiol, Boston, MA 02115 USA. RP Diem, SJ (reprint author), 1100 Washington Ave South,Suite 201, Minneapolis, MN 55415 USA. EM sdiem@umn.edu RI Ruppert, Kristine/C-2555-2016; OI Ruppert, Kristine/0000-0002-3008-6584; Cauley, Jane A/0000-0003-0752-4408 FU National Institutes of Health [K24 AR055989]; Eli Lilly; Amgen; Pfizer FX D.H.S. receives support from National Institutes of Health Grant K24 AR055989 and grant support from Eli Lilly and Amgen for unrelated projects and serves in unpaid roles on two Pfizer-sponsored trials of analgesics. All other authors have nothing to disclose. NR 52 TC 13 Z9 13 U1 1 U2 8 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD NOV PY 2013 VL 98 IS 11 BP 4355 EP 4363 DI 10.1210/jc.2013-1971 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 254QP UT WOS:000327180700046 PM 24001746 ER PT J AU Dwyer, AA Sykiotis, GP Hayes, FJ Boepple, PA Lee, H Loughlin, KR Dym, M Sluss, PM Crowley, WF Pitteloud, N AF Dwyer, Andrew A. Sykiotis, Gerasimos P. Hayes, Frances J. Boepple, Paul A. Lee, Hang Loughlin, Kevin R. Dym, Martin Sluss, Patrick M. Crowley, William F., Jr. Pitteloud, Nelly TI Trial of Recombinant Follicle-Stimulating Hormone Pretreatment for GnRH-Induced Fertility in Patients with Congenital Hypogonadotropic Hypogonadism SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID GONADOTROPIN-DEFICIENT BOYS; SERTOLI-CELLS; GERM-CELLS; HUMAN FSH; SPERMATOGENESIS; TESTIS; RATS; MEN; PROLIFERATION; PREDICTORS AB Context and Objective: The optimal strategy for inducing fertility in men with congenital hypogonadotropic hypogonadism (CHH) is equivocal. Albeit a biologically plausible approach, pretreatment with recombinant FSH (rFSH) before GnRH/human chorionic gonadotropin administration has not been sufficiently assessed. The objective of the study was to test this method. Design and Setting: This was a randomized, open-label treatment protocol at an academic medical center. Patients and Interventions: GnRH-deficient men (CHH) with prepubertal testes (similar to 4 mL), no cryptorchidism, and no prior gonadotropin therapy were randomly assigned to either 24 months of pulsatile GnRH therapy alone (inducing endogenous LH and FSH release) or 4 months of rFSH pretreatment followed by 24 months of GnRH therapy. Patients underwent serial testicular biopsies, ultrasound assessments of testicular volume, serumhormonemeasurements, andseminal fluid analyses. Results: rFSH treatment increased inhibin B levels into the normal range (from 29 +/- 9 to 107 +/- 41 pg mL, P =.05) and doubled testicular volume (from 1.1 +/- 0.2 to 2.2 +/- 0.3 mL, P +/-.005). Histological analysis showed proliferation of both Sertoli cells (SCs) and spermatogonia, a decreased SC to germ cell ratio (from 0.74 to 0.35), and SC cytoskeletal rearrangements. With pulsatile GnRH, the groups had similar hormonal responses and exhibited significant testicular growth. All men receiving rFSH pretreatment developed sperm in their ejaculate (7 of 7 vs 4 of 6 in the GnRH-only group) and showed trends toward higher maximal sperm counts. Conclusions: rFSH pretreatment followed by GnRH is successful in inducing testicular growth and fertility in men with CHH with prepubertal testes. rFSH not only appears to maximize the SC population but also induces morphologic changes, suggesting broader developmental roles. C1 [Dwyer, Andrew A.; Sykiotis, Gerasimos P.; Hayes, Frances J.; Boepple, Paul A.; Sluss, Patrick M.; Crowley, William F., Jr.; Pitteloud, Nelly] Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr, Boston, MA 02114 USA. [Dwyer, Andrew A.; Sykiotis, Gerasimos P.; Hayes, Frances J.; Boepple, Paul A.; Sluss, Patrick M.; Crowley, William F., Jr.; Pitteloud, Nelly] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA. [Lee, Hang] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Lee, Hang] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA. [Lee, Hang] Massachusetts Gen Hosp, Gen Clin Res Ctr, Boston, MA 02114 USA. [Dwyer, Andrew A.; Pitteloud, Nelly] CHU Vaudois, Endocrine Diabet & Metab Serv, CH-1011 Lausanne, Switzerland. [Sykiotis, Gerasimos P.] Univ Patras, Sch Med, Dept Internal Med, Div Endocrinol, Patras 26500, Greece. [Loughlin, Kevin R.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Dym, Martin] Georgetown Univ, Sch Med, Dept Cell Biol, Washington, DC 20057 USA. [Sluss, Patrick M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Pitteloud, N (reprint author), CHU Vaudois, Endocrine Diabet & Metab Serv, Rue Bugnon 46, CH-1011 Lausanne, Switzerland. EM nelly.pitteloud@chuv.ch RI Dwyer, Andrew/D-8099-2012; PITTELOUD, Nelly/K-2709-2014; OI Dwyer, Andrew/0000-0002-7023-6794; Sykiotis, Gerasimos/0000-0002-9565-4941 FU National Institutes of Health [R01 HD15788, R01 HD33728, M01-RR-01066]; National Center for Research Resources; General Clinical Research Centers Program FX This work was supported by Grants R01 HD15788 (to W.F.C.), R01 HD33728 (to M.D.), and M01-RR-01066 from the National Institutes of Health, National Center for Research Resources, General Clinical Research Centers Program. NR 20 TC 23 Z9 23 U1 1 U2 4 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD NOV PY 2013 VL 98 IS 11 BP E1790 EP E1795 DI 10.1210/jc.2013-2518 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 254QP UT WOS:000327180700013 PM 24037890 ER PT J AU Georgopoulos, NA Karagiannidou, E Koika, V Roupas, ND Armeni, A Marioli, D Papadakis, E Welt, CK Panidis, D AF Georgopoulos, Neoklis A. Karagiannidou, Eleni Koika, Vasiliki Roupas, Nikolaos D. Armeni, Anastasia Marioli, Dimitra Papadakis, Efstathios Welt, C. K. Panidis, Dimitrios TI Increased Frequency of the Anti-Mullerian-Inhibiting Hormone Receptor 2 (AMHR2) 482 A > G Polymorphism in Women With Polycystic Ovary Syndrome: Relationship to Luteinizing Hormone Levels SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID MOUSE OVARY; GENE AB Context: The polycystic ovary syndrome (PCOS) is a common and complex disease without a clear pattern of inheritance. Anti-Mullerian hormone (AMH) has an inhibitory effect on FSH-stimulated follicle growth. Serum AMH levels are higher in women with PCOS than in normo-ovulatory women. The elevated AMH levels may reflect abnormalities in AMH signaling. Objective: The purpose of this study was to evaluate the association of the anti-Mullerian hormone receptor 2 (AMHR2) - 482 A - G polymorphism (rs2002555) with the pathophysiology of PCOS. Design: AMHR2 -482A - Gpolymorphism genotyping were performed in a large cohort ofwomen with PCOS and in a healthy control group. Setting/ Subjects: A total of 858 Caucasian Greek women with PCOS and 309 healthy control women were studied. Interventions: Genotyping and hormonal measurements were preformed. Main Outcome Measures: Hormone levels in women with PCOS were analyzed. Results: TheAMHR2polymorphismwasmorecommoninwomenwithPCOSthan in controlwomen (P =.026). Homozygous AMHR2 - 482 A - G gene polymorphisms (GG) were associated with decreased levels of LH (P =.003) and lower LH to FSH ratios (P =.01) in women with PCOS, as well as with lower prolactin levels (P =.004). No other associations related to AMHR2 - 482 A - G polymorphisms were observed in women with PCOS or control women. Conclusion: In this study, the role of the AMHR2 - 482 A - G gene polymorphism in the pathogenesis of PCOS was suggested by the association of the variant with PCOS risk. Thus, further research is needed to elucidate a possible association of the AMHR2 - 482 A - G gene polymorphism with AMH signaling and impaired ovarian function and its clinical significance in women with PCOS. C1 [Georgopoulos, Neoklis A.; Karagiannidou, Eleni; Koika, Vasiliki; Roupas, Nikolaos D.; Armeni, Anastasia; Marioli, Dimitra] Univ Patras, Sch Med, Dept Obstet & Gynecol, Div Reprod Endocrinol, Patras 26500, Greece. [Papadakis, Efstathios; Panidis, Dimitrios] Aristotle Univ Thessaloniki, Div Endocrinol & Human Reprod, Dept Obstet & Gynecol 2, Thessaloniki 54621, Greece. [Welt, C. K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Reprod Endocrine Unit,Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Harvard Reprod Endocrine Sci Ctr, Boston, MA 02115 USA. RP Georgopoulos, NA (reprint author), Univ Patras, Sch Med, Dept Obstet & Gynecol, Div Reprod Endocrinol,Univ Hosp, Patras 26500, Greece. EM neoklisg@hol.gr OI Welt, Corrine/0000-0002-8219-5504 FU NICHD NIH HHS [R01 HD065029] NR 17 TC 3 Z9 5 U1 0 U2 3 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD NOV PY 2013 VL 98 IS 11 BP E1866 EP E1870 DI 10.1210/jc.2013-2458 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 254QP UT WOS:000327180700024 PM 23969185 ER PT J AU Ledoux, WR Shofer, JB Cowley, MS Ahroni, JH Cohen, V Boyko, EJ AF Ledoux, William R. Shofer, Jane B. Cowley, Matthew S. Ahroni, Jessie H. Cohen, Victoria Boyko, Edward J. TI Diabetic foot ulcer incidence in relation to plantar pressure magnitude and measurement location SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Plantar pressure; Diabetic foot ulcer; Hallux; Heel; Metatarsal; Epidemiology ID RISK; NEUROPATHY; REGRESSION; VETERANS; EVENTS; SHEAR AB Aims: We prospectively examined the relationship between site-specific peak plantar pressure (PPP) and ulcer risk. Researchers have previously reported associations between diabetic foot ulcer and elevated plantar foot pressure, but the effect of location-specific pressures has not been studied. Methods: Diabetic subjects (n = 591) were enrolled from a single VA hospital. Five measurements of in-shoe plantar pressure were collected using F-Scan. Pressures were measured at 8 areas: heel, lateral midfoot, medial midfoot, first metatarsal, second through fourth metatarsal, fifth metatarsal, hallux, and other toes. The relationship between incident plantar foot ulcer and PPP or pressure-time integral (PTI) was assessed using Cox regression. Results: During follow-up (2.4 years), 47 subjects developed plantar ulcers (10 heel, 12 metatarsal, 19 hallux, 6 other). Overall mean PPP was higher for ulcer subjects (219 vs. 194 kPa), but the relationship differed by site (the metatarsals with ulcers had higher pressure, while the opposite was true for the hallux and heel). A statistical analysis was not performed on the means, but hazard ratios from a Cox survival analysis were nonsignificant for PPP across all sites and when adjusted for location. However, when the metatarsals were considered separately, higher baseline PPP was significantly associated with greater ulcer risk; at other sites, this relationship was nonsignificant. Hazard ratios for all PTI data were nonsignificant. Conclusions: Location must be considered when assessing the relationship between PPP and plantar ulceration. Published by Elsevier Inc. C1 [Ledoux, William R.; Shofer, Jane B.; Cowley, Matthew S.] VA Puget Sound Hlth Care Syst, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Seattle, WA USA. [Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. [Ahroni, Jessie H.] VA Puget Sound Hlth Care Syst, Dept Surg, Seattle, WA USA. [Ahroni, Jessie H.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Cohen, Victoria; Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA USA. RP Ledoux, WR (reprint author), VA Puget Sound, MS 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 FU Department of Veterans Affairs, RRD service [A2661C, A4843C, A99-1499A] FX This work was supported in part by the Department of Veterans Affairs, RR&D service grant numbers A2661C, A4843C and A99-1499A. NR 26 TC 14 Z9 15 U1 3 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD NOV-DEC PY 2013 VL 27 IS 6 BP 621 EP 626 DI 10.1016/j.jdiacomp.2013.07.004 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 257UZ UT WOS:000327414600016 PM 24012295 ER PT J AU Boyko, EJ AF Boyko, Edward J. TI Observational research - opportunities and limitations SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Review DE Epidemiology; Bias; Causal Inference; Confounding; Pharmacoepidemiology; Randomized Controlled Trial ID PROPENSITY SCORE METHODS; PHYSICIAN DECISION THRESHOLDS; TYPE-2 DIABETES-MELLITUS; BLOOD-GLUCOSE CONTROL; SURROGATE END-POINTS; CARDIOVASCULAR-DISEASE; MENDELIAN RANDOMIZATION; CONTROLLED-TRIALS; CAUSAL INFERENCE; RISK AB Medical research continues to progress in its ability to identify treatments and characteristics associated with benefits and adverse outcomes. The principal engine for the evaluation of treatment efficacy is the randomized controlled trial (RCT). Due to the cost and other considerations, RCTs cannot address all clinically important decisions. Observational research often is used to address issues not addressed or not addressable by RCTs. This article provides an overview of the benefits and limitations of observational research to serve as a guide to the interpretation of this category of research designs in diabetes investigations. The potential for bias is higher in observational research but there are design and analysis features that can address these concerns although not completely eliminate them. Pharmacoepidemiologic research may provide important information regarding relative safety and effectiveness of diabetes pharmaceuticals. Such research must effectively address the important issue of confounding by indication in order to produce clinically meaningful results. Other methods such as instrumental variable analysis are being employed to enable stronger causal inference but these methods also require fulfillment of several key assumptions that may or may not be realistic. Nearly all clinical decisions involve probabilistic reasoning and confronting uncertainly, so a realistic goal for observational research may not be the high standard set by RCTs but instead the level of certainty needed to influence a diagnostic or treatment decision. Published by Elsevier Inc. C1 [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Boyko, Edward J.] Univ Washington, Sch Med, Seattle, WA USA. RP Boyko, EJ (reprint author), 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM eboyko@uw.edu FU VA Epidemiologic Research and Information Center; Diabetes Research Center at the University of Washington [DK-017047] FX Grant Support: VA Epidemiologic Research and Information Center; the Diabetes Research Center at the University of Washington (DK-017047). NR 50 TC 5 Z9 5 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD NOV-DEC PY 2013 VL 27 IS 6 BP 642 EP 648 DI 10.1016/j.jdiacomp.2013.07.007 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 257UZ UT WOS:000327414600020 PM 24055326 ER PT J AU Carlson, RM Dux, K Stuck, RM AF Carlson, Russell M. Dux, Katherine Stuck, Rodney M. TI Ultrasound Imaging for Diagnosis of Plantar Plate Ruptures of the Lesser Metatarsophalangeal Joints: A Retrospective Case Series SO JOURNAL OF FOOT & ANKLE SURGERY LA English DT Article DE magnetic resonance image; metatarsal; sensitivity and specificity; toe ID INSTABILITY; MRI AB Tears of the plantar plate can be a source of significant forefoot pain, leading to alterations of foot function and gait. The objective of the present retrospective study was to further determine the value of ultrasound imaging in diagnosing plantar plate tears after clinical evaluation through a comparison of the ultrasound and intraoperative examination findings. Eight patients were identified who, had undergone surgical intervention for a painful lesser metatarsophalangeal joint after ultrasound examination to diagnose a plantar plate pathologic entity. The intraoperative examination findings were used to calculate the sensitivity, specificity, and positive and negative predictive values of ultrasound in the diagnosis of plantar plate tears. The sensitivity and specificity of the ultrasound examination was 1 and 0.6, respectively. The positive and negative predictive value was 0.6 and 1, respectively. An ultrasound examination in the diagnosis of lesser metatarsophalangeal joint plantar plate tears displayed comparable sensitivity in identifying the pathologic features when compared with magnetic resonance imaging, with considerably less financial cost for the examination. (C) 2013 by the American College of Foot and Ankle Surgeons. All rights reserved. C1 [Carlson, Russell M.] ORA Orthoped, Moline, IL 61265 USA. [Dux, Katherine; Stuck, Rodney M.] Loyola Univ, Stritch Sch Med, Dept Orthoped Surg & Rehabil, Maywood, IL 60153 USA. [Stuck, Rodney M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Surg Serv, Hines, IL 60141 USA. RP Carlson, RM (reprint author), ORA Orthoped, 520 Valley View Dr,100, Moline, IL 61265 USA. EM russell.carlson32@gmail.com NR 13 TC 2 Z9 2 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1067-2516 EI 1542-2224 J9 J FOOT ANKLE SURG JI J. Foot Ankle Surg. PD NOV-DEC PY 2013 VL 52 IS 6 BP 786 EP 788 DI 10.1053/j.jfas.2013.05.009 PG 3 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 251DT UT WOS:000326908700019 PM 23870658 ER PT J AU Mulready-Shick, J Flanagan, KM Banister, GE Mylott, L Curtin, LJ AF Mulready-Shick, JoAnn Flanagan, Kathleen M. Banister, Gaurdia E. Mylott, Laura Curtin, Linda J. TI Evaluating Dedicated Education Units for Clinical Education Quality SO JOURNAL OF NURSING EDUCATION LA English DT Article ID REALIST EVALUATION; SAFETY EDUCATION; IMPROVEMENT; FRAMEWORK; NURSES; CARE AB Dedicated education units (DEUs) have emerged as an important clinical education innovation within academic practice partnerships. However, rigorous evaluation has not been conducted previously. This article presents findings from a randomized, controlled, multiyear, multisite study comparing the clinical education quality for students educated in either the DEU innovation or traditional clinical education model within the same nursing course. The evaluation occurred within a larger study focusing on teaching capacity, faculty work life, and educational quality at one large, urban university collaborating with three agency partners. To examine learning outcomes, the question posed was, "In what ways, if any, does the DEU intervention, when compared to traditional clinical education, enhance educational quality?" Results indicate that educational quality and learning gains are significantly more positive for students clinically instructed in DEUs. Findings will be of interest to education and practice leaders seeking to enhance the quality of clinical teaching, learning, and nursing practice. C1 [Mulready-Shick, JoAnn] Univ Massachusetts, Coll Nursing & Hlth Sci, Boston, MA 02125 USA. [Flanagan, Kathleen M.; Banister, Gaurdia E.] Massachusetts Gen Hosp, Inst Patient Care, Boston, MA 02114 USA. [Mylott, Laura] Northeastern Univ, Bouve Coll Hlth Sci, Boston, MA 02115 USA. [Curtin, Linda J.] Steward Good Samaritan Med Ctr, Brockton, MA USA. [Mylott, Laura] Brigham & Womens Hosp, Ctr Nursing Excellence, Boston, MA 02115 USA. RP Mulready-Shick, J (reprint author), Univ Massachusetts, Coll Nursing & Hlth Sci, 100 Morrissey Blvd, Boston, MA 02125 USA. EM joann.mulreadyshick@umb.edu FU Robert Wood Johnson Foundation's Evaluating Innovations in Nursing Education National Program Office FX Support for this study was provided to Dr. Mulready-Shick and the University of Massachusetts Boston, College of Nursing and Health Sciences, in the form of a grant from the Robert Wood Johnson Foundation's Evaluating Innovations in Nursing Education National Program Office. NR 24 TC 9 Z9 9 U1 3 U2 18 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0148-4834 EI 1938-2421 J9 J NURS EDUC JI J. Nurs. Educ. PD NOV PY 2013 VL 52 IS 11 BP 606 EP 614 DI 10.3928/01484834-20131014-07 PG 9 WC Nursing SC Nursing GA 257YB UT WOS:000327422600002 PM 24127181 ER PT J AU Hammermeister, K Bronsert, M Henderson, WG Coombs, L Hosokawa, P Brandt, E Bryan, C Valuck, R West, D Liaw, W Ho, M Pace, W AF Hammermeister, Karl Bronsert, Michael Henderson, William G. Coombs, Letoynia Hosokawa, Patrick Brandt, Elias Bryan, Cathy Valuck, Robert West, David Liaw, Winston Ho, Michael Pace, Wilson TI Risk-Adjusted Comparison of Blood Pressure and Low-Density Lipoprotein (LDL) Noncontrol in Primary Care Offices SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE LA English DT Article DE Blood Pressure; Cholesterol; Clinical Practice Guideline; Electronic Health Records; Feedback; Health Information Management ID AFFAIRS SURGICAL RISK; CARDIAC-SURGERY; ACHIEVABLE BENCHMARKS; HEART-DISEASE; OF-CARE; QUALITY; IMPROVEMENT; OUTCOMES; METAANALYSIS; CHOLESTEROL AB Objectives: Population-level control of modifiable cardiovascular disease (CVD) risk factors is suboptimal. The objectives of this study were (1) to demonstrate the use of electronically downloaded electronic health record (EHR) data to assess guideline concordance in a large cohort of primary care patients, (2) to provide a contemporary assessment of blood pressure (BP) and low-density lipoprotein (LDL) noncontrol in primary care, and (3) to demonstrate the effect of risk adjustment of rates of noncontrol of BP and LDL for differences in patient mix on these clinic-level performance measures. Methods: This was an observational comparative effectiveness study that included 232,172 adult patients >= 18 years old with >= 1 visit within 2 years in 33 primary care clinics with EHRs. The main measures were rates of BP and LDL noncontrol based on current guidelines and were calculated from electronically downloaded EHR data. Rates of noncontrol were risk-adjusted using multivariable models of patient-level variables. Results: Overall, 16.0% of the 227,122 patients with known BP and 14.9% of the 136,771 patients with known LDL were uncontrolled. Clinic-level, risk-adjusted BP noncontrol ranged from 7.7% to 26.5%, whereas that for LDL ranged from 5.8% to 23.6%. Rates of noncontrol exceeded an achievable benchmark for 85% (n = 28) and 79% (n = 26) of the 33 clinics for BP and LDL, respectively. Risk adjustment significantly influences clinic rank order for rate of noncontrol. Conclusions: We demonstrated that the use of electronic collection of data from a large cohort of patients from fee-for-service primary care clinics is feasible for the audit of and feedback on BP and LDL noncontrol. Rates of noncontrol for most clinics are substantially higher than those achievable. Risk adjustment of noncontrol rates results in a rank-order of clinics very different from that achieved with nonadjusted data. C1 [Hammermeister, Karl; Bronsert, Michael; Henderson, William G.; Hosokawa, Patrick; West, David; Pace, Wilson] Univ Colorado, Sch Med, Colorado Hlth Outcomes Program, Aurora, CO USA. [Hammermeister, Karl; Ho, Michael] Univ Colorado, Sch Med, Div Cardiol, Aurora, CO USA. [Coombs, Letoynia; West, David; Pace, Wilson] Univ Colorado, Sch Med, Dept Family Med, Aurora, CO USA. [Henderson, William G.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. [Brandt, Elias; Pace, Wilson] Amer Acad Family Phys, Natl Res Network, Leawood, KS USA. [Bryan, Cathy] DI Consulting, Dallas, TX USA. [Valuck, Robert] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Clin Pharm, Aurora, CO USA. [Liaw, Winston] Virginia Commonwealth Univ, Fairfax Family Med Residency Program, Fairfax, VA USA. [Ho, Michael] Denver VA Med Ctr, Denver, CO USA. RP Hammermeister, K (reprint author), Colorado Hlth Outcomes Program, Mail Stop F443,UPI Bldg,13199 East Montview Blvd,, Aurora, CO 80045 USA. EM karl.hammermeister@ucdenver.edu FU National Institutes of Health, National Heart, Lung, and Blood Institute [1RC1HL101071-01] FX This work was supported by The National Institutes of Health, National Heart, Lung, and Blood Institute Grant no. 1RC1HL101071-01. NR 30 TC 3 Z9 3 U1 1 U2 5 PU AMER BOARD FAMILY MEDICINE PI LEXINGTON PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA SN 1557-2625 EI 1558-7118 J9 J AM BOARD FAM MED JI J. Am. Board Fam. Med. PD NOV-DEC PY 2013 VL 26 IS 6 BP 658 EP E8 DI 10.3122/jabfm.2013.06.130017 PG 19 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 251KV UT WOS:000326928500008 PM 24204062 ER PT J AU Master, S Guzman, M Dowdall, J AF Master, Suely Guzman, Marco Dowdall, Jayme TI Vocal Economy in Vocally Trained Actresses and Untrained Female Subjects SO JOURNAL OF VOICE LA English DT Article DE Vocal economy; Impact stress; Vocal loading; Contact quotient; Actors ID OUTPUT-COST-RATIO; FOLD IMPACT STRESS; VOICE PRODUCTION; PHONATION; PRESSURE; FREQUENCY; INTENSITY; QUOTIENT; SPECTRUM; QUALITY AB Objectives. Vocally trained actresses are expected to have more vocal economy than nonactresses. Therefore, we hypothesize that there will be differences in the electroglottogram-based voice economy parameter quasi-output cost ratio (QOCR) between actresses and nonactresses. This difference should remain across different levels of intensity. Methods. A total of 30 actresses and 30 nonactresses were recruited for this study. Participants from both groups were required to sustain the vowels /a/, /i/, and /u/, in habitual, moderate, and high intensity levels. Acoustic variables such as sound pressure level (SPL), fundamental frequency (F0), and glottal contact quotient (CQ) were obtained. The QOCR was then calculated. Results. There were no significant differences among the groups for QOCR. Positive correlations were observed for QOCR versus SPL and QOCR versus F0 in all intensity levels. Negative correlation was found between QOCR and CQ in all intensity levels. Considering the differences among intensity levels, from habitual to moderate and from moderate to loud, only the CQ did not differ significantly. The QOCR, SPL, and F0 presented significant differences throughout the different intensity levels. Conclusion. The QOCR did not reflect the level of vocal training when comparing trained and nontrained female subjects in the present study. Both groups demonstrated more vocal economy in moderate and high intensity levels owing to more voice output without an increase in glottal adduction. C1 [Master, Suely] UNESP Univ Estadual Paulista, Dept Performing Arts, BR-01423040 Sao Paulo, Brazil. [Guzman, Marco] Univ Chile, Sch Commun Sci, Santiago, Chile. [Dowdall, Jayme] Harvard Univ, Brigham & Womens Hosp, Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol,Med Sch, Boston, MA 02115 USA. RP Master, S (reprint author), UNESP Univ Estadual Paulista, Dept Performing Arts, Campus Sao Paulo,R Dr Bento Teobaldo Ferraz 27, BR-01423040 Sao Paulo, Brazil. EM suely.master@uol.com.br RI Master, Suely/C-1585-2012 NR 28 TC 3 Z9 3 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0892-1997 EI 1873-4588 J9 J VOICE JI J. Voice PD NOV PY 2013 VL 27 IS 6 BP 698 EP 704 DI 10.1016/j.jvoice.2013.05.005 PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA 254EC UT WOS:000327146200006 PM 23932309 ER PT J AU Gupta, H Gupta, PK Schuller, D Fang, X Miller, WJ Modrykamien, A Wichman, TO Morrow, LE AF Gupta, Himani Gupta, Prateek K. Schuller, Dan Fang, Xiang Miller, Weldon J. Modrykamien, Ariel Wichman, Tammy O. Morrow, Lee E. TI Development and Validation of a Risk Calculator for Predicting Postoperative Pneumonia SO MAYO CLINIC PROCEEDINGS LA English DT Article ID AFFAIRS SURGICAL RISK; PULMONARY COMPLICATIONS; MULTIVARIATE-ANALYSIS; ABDOMINAL-SURGERY; HOSPITAL COSTS; CARDIAC RISK; SMOKING; CARE; QUALITY; DETERMINANTS AB Objective: To identify preoperative factors associated with an increased risk of postoperative pneumonia and subsequently develop and validate a risk calculator. Patients and Methods: The American College of Surgeons' National Surgical Quality Improvement Program, a multicenter, prospective data set (2007-2008) was used. Univariate and multivariate logistic regression analyses were performed. The 2007 data set (N = 211,410) served as the training set, and the 2008 data set (N = 257,385) served as the validation set. Results: In the training set, 3825 patients (1.8%) experienced postoperative pneumonia. Patients who experienced postoperative pneumonia had a significantly higher 30-day mortality (17.0% vs 1.5%; P<.001). On multivariate logistic regression analysis, 7 preoperative predictors of postoperative pneumonia were identified: age, American Society of Anesthesiologists class, chronic obstructive pulmonary disease, dependent functional status, preoperative sepsis, smoking before operation, and type of operation. The risk model based on the training data set was subsequently validated on the validation data set, with model performance being very similar (C statistic: 0.860 and 0.855, respectively). The high C statistic indicates excellent predictive performance. The risk model was used to develop an interactive risk calculator. Conclusion: Preoperative variables associated with an increased risk of postoperative pneumonia include age, American Society of Anesthesiologists class, chronic obstructive pulmonary disease, dependent functional status, preoperative sepsis, smoking before operation, and type of operation. The validated risk calculator provides a risk estimate for postoperative pneumonia and is anticipated to aid in surgical decision making and informed patient consent. (C) 2013 Mayo Foundation for Medical Education and Research C1 [Gupta, Himani] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA. [Gupta, Prateek K.] Univ Wisconsin Hosp & Clin, Dept Surg, Madison, WI 53792 USA. [Schuller, Dan; Modrykamien, Ariel; Wichman, Tammy O.; Morrow, Lee E.] Creighton Univ, Div Pulm Crit Care & Sleep Med, Dept Med, Omaha, NE 68178 USA. [Fang, Xiang] Creighton Univ, Omaha, NE 68178 USA. [Miller, Weldon J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Morrow, Lee E.] VA Nebraska & Western Iowa Hlth Care Syst, Omaha, NE USA. RP Gupta, PK (reprint author), Univ Wisconsin Hosp & Clin, Dept Surg, Madison, WI 53792 USA. EM pgupta@uwhealth.org NR 38 TC 20 Z9 20 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD NOV PY 2013 VL 88 IS 11 BP 1241 EP 1249 DI 10.1016/j.mayocp.2013.06.027 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 258TA UT WOS:000327480400014 PM 24182703 ER PT J AU Shampo, MA Kyle, RA Steensma, DP AF Shampo, Marc A. Kyle, Robert A. Steensma, David P. TI James B. Collip-Member of the Canadian Team That Isolated Insulin SO MAYO CLINIC PROCEEDINGS LA English DT Editorial Material C1 [Shampo, Marc A.; Kyle, Robert A.] Mayo Clin, Rochester, MN 55905 USA. [Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Shampo, MA (reprint author), Mayo Clin, Rochester, MN 55905 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD NOV PY 2013 VL 88 IS 11 BP E139 EP E140 DI 10.1016/j.mayocp.2012.01.033 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 258TA UT WOS:000327480400004 PM 24182713 ER PT J AU Aslam, MI Hettmer, S Abraham, J LaTocha, D Soundararajan, A Huang, ET Goros, MW Michalek, JE Wang, SY Mansoor, A Druker, BJ Wagers, AJ Tyner, JW Keller, C AF Aslam, M. Imran Hettmer, Simone Abraham, Jinu LaTocha, Dorian Soundararajan, Anuradha Huang, Elaine T. Goros, Martin W. Michalek, Joel E. Wang, Shuyu Mansoor, Atiya Druker, Brian J. Wagers, Amy J. Tyner, Jeffrey W. Keller, Charles TI Dynamic and Nuclear Expression of PDGFR alpha and IGF-1R in Alveolar Rhabdomyosarcoma SO MOLECULAR CANCER RESEARCH LA English DT Article ID TUMOR-INITIATING CELLS; FACTOR-I RECEPTOR; CANCER-CELLS; EGF RECEPTOR; LUNG-CANCER; STEM-CELLS; IDENTIFICATION; TRAFFICKING; INHIBITION; MECHANISMS AB Since the advent of tyrosine kinase inhibitors as targeted therapies in cancer, several receptor tyrosine kinases (RTK) have been identified as operationally important for disease progression. Rhabdomyosarcoma (RMS) is a malignancy in need of new treatment options; therefore, better understanding of the heterogeneity of RTKs would advance this goal. Here, alveolar RMS (aRMS) tumor cells derived from a transgenic mouse model expressing two such RTKs, platelet-derived growth factor (PDGFR)alpha and insulin-like growth factor (IGF)-1R, were investigated by fluorescence-activated cell sorting (FACS). Sorted subpopulations that were positive or negative for PDGFR alpha and IGF-1R dynamically altered their cell surface RTK expression profiles as early as the first cell division. Interestingly, a difference in total PDGFRa expression and nuclear IGF-1R expression was conserved in populations. Nuclear IGF-1R expression was greater than cytoplasmic IGF-1R in cells with initially high cell surface IGF-1R, and cells with high nuclear IGF-1R established tumors more efficiently in vivo. RNA interference-mediated silencing of IGF-1R in the subpopulation of cells initially harboring higher cell surface and total IGF-1R resulted in significantly reduced anchorage-independent colony formation as compared with cells with initially lower cell surface and total IGF-1R expression. Finally, in accordance with the findings observed in murine aRMS, human aRMS also had robust expression of nuclear IGF-1R. (C) 2013 AACR. C1 [Aslam, M. Imran; LaTocha, Dorian; Druker, Brian J.; Tyner, Jeffrey W.] Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR USA. [Mansoor, Atiya] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA. [Aslam, M. Imran; Hettmer, Simone; Druker, Brian J.; Wagers, Amy J.] Howard Hughes Med Inst, Portland, OR USA. [Soundararajan, Anuradha] Greehey Childrens Canc Res Inst, San Antonio, TX USA. [Goros, Martin W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Hettmer, Simone; Wagers, Amy J.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Hettmer, Simone; Wagers, Amy J.] Joslin Diabet Ctr, Cambridge, MA USA. [Hettmer, Simone; Michalek, Joel E.] Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Div Pediat Hematol Oncol, Boston, MA USA. [Wang, Shuyu] Harvard Univ, Cambridge, MA 02138 USA. RP Keller, C (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,MC L321, Portland, OR 97239 USA. EM amy.wagers@joslin.harvard.edu; tynerj@ohsu.edu; keller@ohsu.edu OI Tyner, Jeffrey/0000-0002-2133-0960 FU Alex's Lemonade Stand; William Lawrence and Blanche Hughes Foundation; Leukemia & Lymphoma Society; National Cancer Institute; [5R01CA133229-05]; [5R01CA133229-06] FX This work was supported by 5R01CA133229-05 and -06 to C. Keller. The studies were also supported, in part, from a gift from the Ethan Jostad Foundation for Childhood Cancer. Pilot studies leading to this work were supported by an innovation award from Alex's Lemonade Stand. J.W. Tyner is supported by grants from the William Lawrence and Blanche Hughes Foundation, Leukemia & Lymphoma Society, and the National Cancer Institute. M.I. Aslam is a Howard Hughes Medical Institute Medical Research Fellow. B.J. Druker is an investigator of the Howard Hughes Medical Institute. NR 34 TC 6 Z9 6 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1541-7786 EI 1557-3125 J9 MOL CANCER RES JI Mol. Cancer Res. PD NOV PY 2013 VL 11 IS 11 BP 1303 EP 1313 DI 10.1158/1541-7786.MCR-12-0598 PG 11 WC Oncology; Cell Biology SC Oncology; Cell Biology GA 258CE UT WOS:000327435400002 PM 23928059 ER PT J AU Rost, NS AF Rost, Natalia S. TI Clinical Neurogenetics: Stroke SO NEUROLOGIC CLINICS LA English DT Article DE Cerebrovascular disease; Genetics; Stroke subtype; Ischemic stroke; Intracerebral hemorrhage; White matter hyperintensity; Phenotype; Genome-wide association study ID MATTER HYPERINTENSITY VOLUME; CEREBRAL AMYLOID ANGIOPATHY; ACUTE ISCHEMIC-STROKE; LOBAR INTRACEREBRAL HEMORRHAGE; GENOME-WIDE ASSOCIATION; INFLAMMATORY-BOWEL-DISEASE; ENVIRONMENTAL RISK-FACTORS; HEALTH-CARE PROFESSIONALS; APOLIPOPROTEIN-E GENOTYPE; GENETIC ASSOCIATION AB Understanding the genetic architecture of cerebrovascular disease holds promise of novel stroke prevention strategies and therapeutics that are both safe and effective. Apart from a few single-gene disorders associated with cerebral ischemia or intracerebral hemorrhage, stroke is a complex genetic phenotype that requires careful ascertainment and robust association testing for discovery and validation analyses. The recently uncovered shared genetic contribution between clinically manifest stroke syndromes and closely related intermediate cerebrovascular phenotypes offers effective and efficient approaches to complex trait analysis. C1 Massachusetts Gen Hosp, Dept Neurol, JP Kistler Stroke Res Ctr, Boston, MA 02114 USA. RP Rost, NS (reprint author), Massachusetts Gen Hosp, Dept Neurol, JP Kistler Stroke Res Ctr, 175 Cambridge St,Suite 300, Boston, MA 02114 USA. EM nrost@partners.org FU National Institute of Neurological Disorders and Stroke (NINDS) [K23NS064052] FX Dr Natalia S. Rost is supported by the National Institute of Neurological Disorders and Stroke (NINDS) (K23NS064052). NR 104 TC 2 Z9 2 U1 0 U2 9 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8619 EI 1557-9875 J9 NEUROL CLIN JI Neurol. Clin. PD NOV PY 2013 VL 31 IS 4 BP 915 EP + DI 10.1016/j.ncl.2013.05.001 PG 15 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 261QP UT WOS:000327680000003 PM 24176416 ER PT J AU Waugh, JL Sharma, N AF Waugh, Jeffrey L. Sharma, Nutan TI Clinical Neurogenetics Dystonia From Phenotype to Genotype SO NEUROLOGIC CLINICS LA English DT Article DE Dystonia; Myoclonus; Parkinsonism; Paroxysmal dyskinesia ID DEEP-BRAIN-STIMULATION; KINASE-ASSOCIATED NEURODEGENERATION; DYT6 PRIMARY DYSTONIA; CERVICAL DYSTONIA; FOCAL DYSTONIA; ONSET DYSTONIA; MYOCLONUS-DYSTONIA; TARDIVE DYSTONIA; PSYCHIATRIC-DISORDERS; PALLIDAL STIMULATION AB Dystonia can arise from genetic syndromes or can be secondary to nongenetic injuries; both causes can produce pure dystonia, dystonia plus other movement disorders, or paroxysmal mixed movement disorders. Genetic causes of dystonia are inherited through dominant, recessive, X-linked, and mitochondrial mechanisms, may show anticipation, are variably penetrant, and may be limited to small ethnic populations or single families. In this article, the genetic causes of dystonia, an algorithm for their diagnosis and management, information on common medications and surgical treatments, and resources for affected families and those interested in advancing research are presented. C1 [Waugh, Jeffrey L.; Sharma, Nutan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Cambridge, MA 02138 USA. [Waugh, Jeffrey L.] Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA. RP Waugh, JL (reprint author), Boston Childrens Hosp, Dept Neurol, Fegan 11,300 Longwood Ave, Boston, MA 02115 USA. EM jeff.waugh@childrens.harvard.edu OI Waugh, Jeff/0000-0001-7526-1342 FU Bachmann-Strauss, Silverman Family Fellowship; American Academy of Neurology Clinical Research Training Fellowship; NINDS [P50 NS037409] FX This work was supported by the Bachmann-Strauss, Silverman Family Fellowship (JW); the American Academy of Neurology Clinical Research Training Fellowship (JW); and NINDS P50 NS037409 (NS). NR 74 TC 1 Z9 1 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0733-8619 EI 1557-9875 J9 NEUROL CLIN JI Neurol. Clin. PD NOV PY 2013 VL 31 IS 4 BP 969 EP + DI 10.1016/j.ncl.2013.04.002 PG 19 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 261QP UT WOS:000327680000006 PM 24176419 ER PT J AU Hughes, C Howard, IM AF Hughes, Christina Howard, Ileana M. TI Spasticity Management in Multiple Sclerosis SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA LA English DT Article DE Spasticity; Multiple sclerosis; Antispasticity; Chemodenervation; Intrathecal baclofen ID SHOCK-WAVE THERAPY; ALTERNATIVE MEDICINE USE; TOXIN TYPE-A; INTRATHECAL BACLOFEN; ELECTRICAL-STIMULATION; CEREBRAL-PALSY; MUSCLE STRETCH; CHRONIC STROKE; DOUBLE-BLIND; FOLLOW-UP AB Spasticity is a prevalent and potentially disabling symptom common in individuals with multiple sclerosis. Adequate evaluation and management of spasticity requires a careful assessment of the patient's history to determine functional impact of spasticity and potential exacerbating factors, and physical examination to determine the extent of the condition and culpable muscles. A host of options for spasticity management are available: therapeutic exercise, physical modalities, complementary/alternative medicine interventions, oral medications, chemodenervation, and implantation of an intrathecal baclofen pump. Choice of treatment hinges on a combination of the extent of symptoms, patient preference, and availability of services. C1 [Hughes, Christina] Virginia Mason Med Ctr, Dept Phys Med & Inpatient Neuro Rehabil, Seattle, WA 98111 USA. [Howard, Ileana M.] Vet Affairs Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA. RP Hughes, C (reprint author), Virginia Mason Med Ctr, Dept Phys Med & Inpatient Neuro Rehabil, Mailstop H4-469,1100 9th Ave, Seattle, WA 98111 USA. EM pmrdoc@mac.com NR 40 TC 11 Z9 11 U1 4 U2 19 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1047-9651 EI 1558-1381 J9 PHYS MED REH CLIN N JI Phys. Med. Rehabil. Clin. N. Am. PD NOV PY 2013 VL 24 IS 4 BP 593 EP + DI 10.1016/j.pmr.2013.07.003 PG 13 WC Rehabilitation SC Rehabilitation GA 261QN UT WOS:000327679800004 PM 24314678 ER PT J AU Sylvia, LG Iosifescu, D Friedman, ES Bernstein, EE Bowden, CL Ketter, TA Reilly-Harrington, NA Leon, AC Calabrese, JR Ostacher, MJ Rabideau, DJ Thase, ME Nierenberg, AA AF Sylvia, Louisa G. Iosifescu, Dan Friedman, Edward S. Bernstein, Emily E. Bowden, Charles L. Ketter, Terence A. Reilly-Harrington, Noreen A. Leon, Andrew C. Calabrese, Joseph R. Ostacher, Michael J. Rabideau, Dustin J. Thase, Michael E. Nierenberg, Andrew A. TI Use of Treatment Services in a Comparative Effectiveness Study of Bipolar Disorder SO PSYCHIATRIC SERVICES LA English DT Article ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; GENERAL MEDICAL CONDITIONS; HEALTH-CARE UTILIZATION; I-DISORDER; INSURED POPULATION; BEHAVIORAL-MODEL; VETERANS; COMORBIDITIES; OBESITY; ACCESS AB Objective: Bipolar disorder is a severe, chronic mental illness with a high incidence of medical and psychological comorbidities that make treatment and prevention of future episodes challenging. This study investigated the use of services among outpatients with bipolar disorder to further understanding of how to maximize and optimize personalization and accessibility of services for this difficult-to-treat population. Methods: The Lithium Treatment-Moderate Dose Use Study (LiTMUS) was a six-month multisite, comparative effectiveness trial that randomly assigned 283 individuals to receive lithium plus optimized care-defined as personalized, guideline-informed care-or optimized care without lithium. Relationships between treatment service utilization, captured by the Cornell Service Index, and demographic and illness characteristics were examined with generalized linear marginal models. Results: Analyses with complete data (week 12, N=246; week 24, N=236) showed that increased service utilization was related to more severe bipolar disorder symptoms, physical side effects, and psychiatric and general medical comorbidities. Middle-aged individuals and those living in the United States longer tended to use more services than younger individuals or recent immigrants, respectively. Conclusions: These data suggest that not all individuals with bipolar disorder seek treatment services at the same rate. Instead, specific clinical or demographic features may affect the degree to which one seeks treatment, conveying clinical and public health implications and highlighting the need for specific approaches to correct such discrepancies. Future research is needed to elucidate potential moderators of service utilization in bipolar disorder to ensure that those most in need of additional services utilize them. C1 [Sylvia, Louisa G.; Bernstein, Emily E.; Reilly-Harrington, Noreen A.; Nierenberg, Andrew A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Rabideau, Dustin J.] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA. [Iosifescu, Dan] Mt Sinai Sch Med, Dept Psychiat & Neurosci, New York, NY USA. [Friedman, Edward S.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Bowden, Charles L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Ketter, Terence A.; Ostacher, Michael J.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Leon, Andrew C.] Cornell Univ, Dept Psychiat, Weill Med Coll, New York, NY 10021 USA. [Calabrese, Joseph R.] Case Western Reserve Univ, Dept Psychiat, Cleveland, OH 44106 USA. [Thase, Michael E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Sylvia, LG (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 55 Fruit St, Boston, MA 02114 USA. EM lsylvia2@partners.org OI Bernstein, Emily/0000-0001-8609-3153; Ostacher, Michael/0000-0003-0353-7535 FU National Institute of Mental Health [NO1MH80001]; AstraZeneca Pharmaceuticals; Medtronics; Novartis; Repligen; Roche; St. Jude Medical; Takeda; AstraZeneca; Cephalon; Eli Lilly and Company; Pfizer; Sunovion Pharmaceuticals; Allergan; Avanir Pharmaceuticals; Bristol-Myers Squibb Company; Forest Pharmaceuticals; Janssen Pharmaceutica Products; Merck Co.; Sunovion; Teva Pharmaceuticals; Brain and Behavior Research Foundation; Cleveland Foundation; Stanley Medical Research Institute; Abbott; GlaxoSmithKline; Janssen; Eli Lilly; Lundbeck; Bristol-Myers Squibb; Merck; Alkermes; Forest; Otsuka; PharmaNeuroboost; Cederroth; Cyberonics; Elan; Lichtwer Pharma; Mylan; Pamlabs; Shire; Stanley Foundation; Wyeth-Ayerst FX This study was funded by contract NO1MH80001 from the National Institute of Mental Health.; Dr. Sylvia was a shareholder in Concordant Rater Systems and serves as a consultant for United Biosource Corporation and Clintara. She receives royalties from New Harbinger. Dr. Iosifescu is a consultant for CNS Response and Servier. Dr. Friedman receives grant support from AstraZeneca Pharmaceuticals, Medtronics, Novartis, Repligen, Roche, St. Jude Medical, and Takeda. He receives royalties from Springer. Dr. Ketter receives research support from AstraZeneca, Cephalon, Eli Lilly and Company, Pfizer, and Sunovion Pharmaceuticals. He receives consultant fees from Allergan, Avanir Pharmaceuticals, Bristol-Myers Squibb Company, Cephalon, Forest Pharmaceuticals, Janssen Pharmaceutica Products, Merck & Co., Sunovion, and Teva Pharmaceuticals. He has received lecture honoraria from Abbott Laboratories, AstraZeneca, GlaxoSmithKline, and Otsuka Pharmaceuticals and receives publication royalties from American Psychiatric Publishing. In addition, Dr. Ketter's spouse is an employee of and holds stock in Janssen. Dr. Reilly-Harrington receives royalties from Oxford University Press and the American Psychological Association and serves as a consultant for United Biosource Corporation. Dr. Leon served on independent data and safety monitoring boards for AstraZeneca, Sunovion, and Pfizer. He served as a consultant and advisor to MedAvante and Roche and had equity in MedAvante. Dr. Calabrese receives research funding or grants from the following private industries or nonprofit funds: Brain and Behavior Research Foundation (formerly NARSAD), Cleveland Foundation, and Stanley Medical Research Institute; he receives research grants from Abbott, AstraZeneca, Cephalon, GlaxoSmithKline, Janssen, Eli Lilly, and Lundbeck; he serves on the advisory boards of Abbott, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Forest, France Foundation, GlaxoSmithKline, Janssen, Neuro-Search, OrthoMcNeil, Repligen, Schering-Plough, Servier, Solvay/Wyeth, Takeda, and Supernus Pharmaceuticals; and he reports continuing medical education activities with AstraZeneca, Bristol-Myers Squibb, France Foundation, GlaxoSmithKline, Janssen, Johnson & Johnson, Schering-Plough, and Solvay/Wyeth. Dr. Ostacher has served as a consultant for Alexza Pharmaceuticals, Bristol Myers Squibb, Eli Lilly, Janssen, Otsuka, and Sunovion. Dr. Thase has, during the past three years, been an advisor or consultant to Alkermes, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, GlaxoSmithKline, Janssen, Lundbeck, MedAvante, Merck, Mylan, Neuronetics, Otsuka, Pamlab, Pfizer, PharmaNeuroboost, Roche, Shire, Sunovion, Takeda, and Teva. During the same time frame, he received honoraria for continuing education talks that were supported by AstraZeneca, Bristol-Myers Squibb, Merck, and Pfizer, and he has received research grants from Alkermes, AstraZeneca, Eli Lilly, Forest, GlaxoSmithKline, Otsuka, PharmaNeuroboost, and Roche. Dr. Nierenberg is a consultant for Abbott Laboratories, AstraZeneca, Basilea, BrainCells Inc., Brandeis University, Bristol-Myers Squibb, Cephalon, Corcept, Eli Lilly, Forest, Genaissance, GlaxoSmithKline, Innapharma, Janssen, Jazz Pharmaceuticals, Lundbeck, Merck, Novartis, PamLabs, Pfizer, PGx Health, Ridge Diagnostics, Roche, Sepracor, Schering-Plough, Shire, Somerset, Sunovion, Takeda, Targacept, and Teva. He is a stakeholder in Appliance Computing, Inc. (MindSite); Brain Cells, Inc.; and InfoMed (potential share of income).; He receives research support from Brain and Behavior Research Foundation, Bristol-Myers Squibb, Cederroth, Cyberonics, Elan, Forest Pharmaceuticals, GlaxoSmithKline, Janssen, Lichtwer Pharma, Eli Lilly, Mylan, Pamlabs, Pfizer, Shire, Stanley Foundation, and Wyeth-Ayerst. Honoraria include MGH Psychiatry Academy. He receives other income from CRICO for legal case reviews, from MBL Publishing for past services as Editor-in-Chief of CNS Spectrums, from Slack Inc. for services as associate editor of Psychiatric Annals, and from Belvoir Publications for serving on the editorial board of Mind Mood Memory. He has joint copyright ownership with MGH for the Structured Clinical Interview for MADRS and Clinical Positive Affect Scale. He receives additional honoraria from ADURS, American Society for Clinical Psychopharmacology, AstraZeneca, Biomedical Development, Brandeis University, East Asian Bipolar Forum, Eli Lilly, Forest, Harold Grinspoon Charitable Foundation, Health New England, International Society for Bipolar Disorder, Janssen, Mid-Atlantic Permanente Research Institute, University of Pisa, University Texas Southwest at Dallas, University of Wisconsin-Madison, Up-to-Date, and Zucker Hillside Hospital. The other authors report no competing interests. NR 40 TC 1 Z9 1 U1 4 U2 7 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD NOV PY 2013 VL 64 IS 11 BP 1119 EP 1126 DI 10.1176/appi.ps.201200479 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 256IS UT WOS:000327303800008 PM 23945956 ER PT J AU Tuerk, PW Wangelin, B Rauch, SAM Dismuke, CE Yoder, M Myrick, H Eftekhari, A Acierno, R AF Tuerk, Peter W. Wangelin, Bethany Rauch, Sheila A. M. Dismuke, Clara E. Yoder, Matthew Myrick, Hugh Eftekhari, Afsoon Acierno, Ron TI Health Service Utilization Before and After Evidence-Based Treatment for PTSD SO PSYCHOLOGICAL SERVICES LA English DT Article DE PTSD; prolonged exposure; veterans; service utilization; cost ID POSTTRAUMATIC-STRESS-DISORDER; PROLONGED EXPOSURE THERAPY; COCAINE-DEPENDENT INDIVIDUALS; MALE VIETNAM VETERANS; AFGHANISTAN VETERANS; RANDOMIZED-TRIAL; IRAQ; SYMPTOMS; WAR; DIAGNOSES AB Posttraumatic stess disorder (PTSD) is associated with functional impairment, co-occurring diagnoses, and increased health care utilization. Associated high demand for health care services is an important contributor to the large public-health cost of PTSD. Treatments incorporating exposure therapy are efficacious in ameliorating or eliminating PTSD symptoms. Accordingly, the Veterans Health Administration has made significant investments toward nationwide dissemination of a manualized exposure therapy protocol, prolonged exposure (PE). PE is effective with veterans; however, the relationship between PE and mental health service utilization is unknown. The current study investigates PE as it relates to actual tracked mental health service utilization in an urban VA medical center. A sample of 60 veterans with a diagnosis of PTSD was used to examine mental health service utilization in the 12-months prior to and 12-months after being offered PE. Hierarchical Linear Models and traditional repeated-measures ANOVA were used to estimate R-2- and d-type effect sizes for service utilization. Associated estimated cost saving are reported. PE was associated with large reductions in symptoms and diagnosis remission. Treatment was also associated with statistically significant, large reductions in mental health service utilization for veterans who completed treatment. Findings suggest that expanding access to PE can increase access to mental health services in general by decreasing ongoing demand for specialty care clinical services. C1 [Tuerk, Peter W.; Wangelin, Bethany; Yoder, Matthew; Myrick, Hugh; Acierno, Ron] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv Line, Charleston, SC USA. [Tuerk, Peter W.; Wangelin, Bethany; Yoder, Matthew; Myrick, Hugh; Acierno, Ron] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Rauch, Sheila A. M.] Ann Arbor Healthcare Syst, Vet Affairs, Res Serv, Ann Arbor, MI USA. [Rauch, Sheila A. M.] Ann Arbor Healthcare Syst, Vet Affairs, Mental Hlth Serv, Ann Arbor, MI USA. [Rauch, Sheila A. M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. [Dismuke, Clara E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Eftekhari, Afsoon] Vet Affairs Palo Alto Hlth Care Syst, Natl Ctr Posttraumat Stress Disorder, Disseminat & Training Div, Palo Alto, CA USA. RP Tuerk, PW (reprint author), RHJ VAMC, 109 Bee St, Charleston, SC 29401 USA. EM Tuerk@musc.edu RI Rauch, Sheila/K-4450-2015 OI Rauch, Sheila/0000-0001-9686-4011 NR 54 TC 20 Z9 20 U1 0 U2 4 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD NOV PY 2013 VL 10 IS 4 BP 401 EP 409 DI 10.1037/a0030549 PG 9 WC Psychology, Clinical SC Psychology GA 254QZ UT WOS:000327182400006 PM 23148769 ER PT J AU Harris, AHS Ellerbe, L Reeder, RN Bowe, T Gordon, AJ Hagedorn, H Oliva, E Lembke, A Kivlahan, D Trafton, JA AF Harris, Alex H. S. Ellerbe, Laura Reeder, Rachelle N. Bowe, Thomas Gordon, Adam J. Hagedorn, Hildi Oliva, Elizabeth Lembke, Anna Kivlahan, Daniel Trafton, Jodie A. TI Pharmacotherapy for Alcohol Dependence: Perceived Treatment Barriers and Action Strategies Among Veterans Health Administration Service Providers SO PSYCHOLOGICAL SERVICES LA English DT Article DE alcohol dependence; health care providers; medications; pharmacotherapy; veterans ID USE DISORDERS; ADDICTION TREATMENT; MEDICATIONS; NALTREXONE; PHYSICIAN; ATTITUDES AB Although access to and consideration of pharmacological treatments for alcohol dependence are consensus standards of care, receipt of these medications by patients is generally rare and highly variable across treatment settings. The goal of the present project was to survey and interview the clinicians, managers, and pharmacists affiliated with addiction treatment programs within Veterans Health Administration (VHA) facilities to learn about their perceptions of barriers and facilitators regarding greater and more reliable consideration of pharmacological treatments for alcohol dependence. Fifty-nine participants from 19 high-adopting and 11 low-adopting facilities completed the survey (facility-level response rate = 50%) and 23 participated in a structured interview. The top 4 barriers to increased consideration and use of pharmacotherapy for alcohol dependence were consistent across high- and low-adopting facilities and included perceived low patient demand, pharmacy procedures or formulary restrictions, lack of provider skills or knowledge regarding pharmacotherapy for alcohol dependence, and lack of confidence in treatment effectiveness. Low patient demand was rated as the most important barrier for oral naltrexone and disulfiram, whereas pharmacy or formulary restrictions were rated as the most important barrier for acamprosate and extended-release naltrexone. The 4 strategies rated across low-and high-adopting facilities as most likely to facilitate consideration and use of pharmacotherapy for alcohol dependence were more education to patients about existing medications, more education to health care providers about medications, increased involvement of physicians in treatment for alcohol dependence, and more compelling research on existing medications. This knowledge provides a foundation for designing, deploying, and evaluating targeted implementation efforts. C1 [Harris, Alex H. S.; Ellerbe, Laura; Reeder, Rachelle N.; Bowe, Thomas] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. [Harris, Alex H. S.; Ellerbe, Laura; Reeder, Rachelle N.; Bowe, Thomas; Oliva, Elizabeth; Trafton, Jodie A.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Gordon, Adam J.] VA Pittsburgh Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. [Hagedorn, Hildi] VA Minneapolis Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Oliva, Elizabeth; Trafton, Jodie A.] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA. [Lembke, Anna] Stanford Univ, Dept Psychiat, Stanford, CA 94305 USA. [Kivlahan, Daniel] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Kivlahan, Daniel] Univ Washington, Sch Med, Seattle, WA 98195 USA. RP Harris, AHS (reprint author), VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM Alexander.Harris2@va.gov NR 30 TC 15 Z9 15 U1 2 U2 7 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD NOV PY 2013 VL 10 IS 4 BP 410 EP 419 DI 10.1037/a0030949 PG 10 WC Psychology, Clinical SC Psychology GA 254QZ UT WOS:000327182400007 PM 23356858 ER PT J AU Miller, MW Wolf, EJ Kilpatrick, D Resnick, H Marx, BP Holowka, DW Keane, TM Rosen, RC Friedman, MJ AF Miller, Mark W. Wolf, Erika J. Kilpatrick, Dean Resnick, Heidi Marx, Brian P. Holowka, Darren W. Keane, Terence M. Rosen, Raymond C. Friedman, Matthew J. TI The Prevalence and Latent Structure of Proposed DSM-5 Posttraumatic Stress Disorder Symptoms in US National and Veteran Samples SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE DSM-5; Posttraumatic Stress Disorder; Diagnosis ID COMORBIDITY SURVEY REPLICATION; CONFIRMATORY FACTOR-ANALYSIS; ADMINISTERED PTSD SCALE; PSYCHOMETRIC PROPERTIES; CHECKLIST; MODEL AB The Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) is currently undergoing revisions in advance of the next edition, DSM-5. The DSM-5 posttraumatic stress disorder workgroup has proposed numerous changes to the PTSD diagnosis. These include the addition of new symptoms, revision of existing ones, and a new four-cluster organization (Friedman, Resick, Bryant, & Brewin, 2011). We conducted two Internet-based surveys to provide preliminary information about how proposed changes might impact PTSD prevalence and clarify the latent structure of the new symptom set. We used a newly developed instrument to assess event exposure and lifetime and current DSM-5 PTSD symptoms among a nationally representative sample of American adults (N = 2,953) and a clinical convenience sample of U.S. military veterans (N = 345). Results from both samples indicated that the originally proposed DSM-5 symptom criteria (i.e., requiring 1 B, 1 C, 3 D, and 3 E symptoms) yielded considerably lower PTSD prevalence estimates compared with DSM-IV estimates. These estimates were more comparable when the DSM-V D and E criteria were relaxed to 2 symptoms each (i.e., the revised proposal). Confirmatory factor analyses (CFA) indicated that the factor structure implied by the four-symptom criteria provided adequate fit to the data in both samples, and a DSM-5 version of a dysphoria model (Simms, Watson, & Doebbeling, 2002) yielded modest improvement in fit. Item-response theory and CFA analyses indicated that the psychogenic amnesia and new reckless/self-destructive behavior symptom deviated from the others in their respective symptom clusters. Implications for final formulations of DSM-5 PTSD criteria are discussed. C1 [Miller, Mark W.; Wolf, Erika J.; Marx, Brian P.; Holowka, Darren W.; Keane, Terence M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA. [Miller, Mark W.; Wolf, Erika J.; Marx, Brian P.; Holowka, Darren W.; Keane, Terence M.] Boston Univ, Sch Med, Boston, MA 02215 USA. [Kilpatrick, Dean; Resnick, Heidi] Med Univ S Carolina, Dept Psychiat, Charleston, SC USA. [Rosen, Raymond C.] New England Res Inst, Watertown, MA 02172 USA. [Friedman, Matthew J.] White River Junct VA Med Ctr, Natl Ctr PTSD, Hanover, NH USA. [Friedman, Matthew J.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA. RP Miller, MW (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, 150 S Huntington Ave 116B-2, Boston, MA 02130 USA. EM mark.miller5@va.gov RI Miller, Mark/G-7322-2011; OI Miller, Mark/0000-0001-6393-8563; Wolf, Erika/0000-0003-2666-2435 NR 27 TC 59 Z9 59 U1 2 U2 20 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 EI 1942-969X J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD NOV PY 2013 VL 5 IS 6 BP 501 EP 512 DI 10.1037/a0029730 PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 259UR UT WOS:000327552300001 ER PT J AU Cook, JM Thompson, R Harb, GC Ross, RJ AF Cook, Joan M. Thompson, Richard Harb, Gerlinde C. Ross, Richard J. TI Cognitive-Behavioral Treatment for Posttraumatic Nightmares: An Investigation of Predictors of Dropout and Outcome SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE stress disorders; posttraumatic; psychotherapy; nightmares; treatment outcome; dropout ID IMAGERY REHEARSAL THERAPY; SEXUAL ASSAULT SURVIVORS; RANDOMIZED CONTROLLED-TRIAL; SLEEP QUALITY INDEX; STRESS-DISORDER; CLINICAL-TRIAL; PTSD; VETERANS; INSOMNIA; EXPOSURE AB This study examined factors predicting treatment dropout and outcome in 124 male Vietnam War veterans with chronic, severe posttraumatic stress disorder treated in a randomized controlled trial of two cognitive-behavioral group therapies for combat-related nightmares. Though significant bivariate predictors of dropout in the imagery rehearsal condition included non-African American race, use of selective serotonin reuptake inhibitors, more traumas, and lower perceived treatment credibility, none of these variables uniquely predicted dropout in multivariate analyses. In the sleep and nightmare management condition, only low avoidance symptoms predicted dropout. Use of benzodiazepines and higher reexperiencing symptoms predicted posttreatment nightmare frequency in imagery rehearsal; although baseline sleep quality and higher avoidance symptoms predicted posttreatment sleep quality. In sleep and nightmare management, only poorer sleep quality predicted posttreatment nightmares, although poorer baseline sleep quality and higher avoidance symptoms predicted posttreatment sleep quality. Practical and clinical implications, including the use of "socialization" strategies (e.g., patient testimonials, in-depth explanation of treatment rationale), are discussed. C1 [Cook, Joan M.] Yale Sch Med, Dept Psychiat, West Haven, CT 06516 USA. [Cook, Joan M.] Natl Ctr PTSD, West Haven, CT USA. [Thompson, Richard] Univ Illinois, Juvenile Justice Ctr, Chicago, IL USA. [Harb, Gerlinde C.] Philadelphia Dept Vet Affairs, Dept Behav Hlth, Philadelphia, PA USA. [Ross, Richard J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Ross, Richard J.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Cook, JM (reprint author), Yale Sch Med, Dept Psychiat, 950 Campbell Ave,NEPEC 182, West Haven, CT 06516 USA. EM joan.cook@yale.edu NR 57 TC 1 Z9 1 U1 2 U2 11 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 EI 1942-969X J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD NOV PY 2013 VL 5 IS 6 BP 545 EP 553 DI 10.1037/a0030724 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 259UR UT WOS:000327552300006 ER PT J AU Brusasco, C Corradi, F Vargas, M Bona, M Bruno, F Marsili, M Simonassi, F Santori, G Severgnini, P Kacmarek, RM Pelosi, P AF Brusasco, Claudia Corradi, Francesco Vargas, Maria Bona, Margherita Bruno, Federica Marsili, Maria Simonassi, Francesca Santori, Gregorio Severgnini, Paolo Kacmarek, Robert M. Pelosi, Paolo TI In Vitro Evaluation of Heat and Moisture Exchangers Designed for Spontaneously Breathing Tracheostomized Patients SO RESPIRATORY CARE LA English DT Article DE tracheostomized patients; absolute humidity; inspiratory air temperature; air conditioning; heat and moisture exchangers ID 48 HOURS RATHER; MICROBIOLOGICAL EVALUATION; TEMPERATURE DYNAMICS; TOTAL LARYNGECTOMY; SYSTEM FILTERS; CHANGING HEAT; WATER-VAPOR; HUMIDIFICATION; HUMIDITY; PERFORMANCE AB BACKGROUND: Heat and moisture exchangers (HMEs) are commonly used in chronically tracheostomized spontaneously breathing patients, to condition inhaled air, maintain lower airway function, and minimize the viscosity of secretions. Supplemental oxygen (O-2) can be added to most HMEs designed for spontaneously breathing tracheostomized patients. We tested the efficiency of 7 HMEs designed for spontaneously breathing tracheostomized patients, in a normothermic model, at different minute ventilations ((V) over dot(E)) and supplemental O-2 flows. METHODS: HME efficiency was evaluated using an in vitro lung model at 2 (V) over dot(E) (5 and 15 L/min) and 4 supplemental O-2 flows (0, 3, 6, and 12 L/min). Wet and dry temperatures of the inspiratory flow were measured, and absolute humidity was calculated. In addition, HME efficiency at 0, 12, and 24 h use was evaluated, as well as resistance to flow at 0 and 24 h. RESULTS: The progressive increase in O-2 flow from 0 to 12 L/min was associated with a reduction in temperature and absolute humidity. Under the same conditions, this effect was greater at lower (V) over dot(E). The HME with the best performance provided an absolute humidity of 26 mg H2O/L and a temperature of 27.8 degrees C. No significant changes in efficiency or resistance were detected during the 24 h evaluation. CONCLUSIONS: The efficiency of HMEs in terms of temperature and absolute humidity is significantly affected by O-2 supplementation and (V) over dot(E). (C) 2013 Daedalus Enterprises C1 [Brusasco, Claudia; Vargas, Maria; Bona, Margherita; Bruno, Federica; Marsili, Maria; Simonassi, Francesca; Pelosi, Paolo] Univ Genoa, Ist Ricovero & Cura Carattere Sci, Azienda Osped Univ San Martino,Sez Anestesia & Ri, Dipartimento Sci Chirurg & Diagnost Integrate, I-16132 Genoa, Italy. [Santori, Gregorio] Univ Genoa, Ist Ricovero & Cura Carattere Sci, Azienda Osped Univ San Martino, Dipartimento Sci Chirurg & Diagnost Integrate, I-16132 Genoa, Italy. [Corradi, Francesco] Azienda Ospedaliero Univ Parma, Sez Terapia Intens Cardiochirurg, Dipartimento Cardionefropolmonare, I-43100 Parma, Italy. [Severgnini, Paolo] Univ Insubria, Dipartimento Sci & Alta Tecnol, Sez Ambiente Salute Sicurezza Terr, Varese, Italy. [Kacmarek, Robert M.] Massachusetts Gen Hosp, Resp Care Serv, Boston, MA 02114 USA. [Vargas, Maria] Univ Naples Federico II, Dipartimento Anestesia & Terapia Intens, Naples, Italy. RP Brusasco, C (reprint author), Univ Genoa, Dipartimento Sci Chirurg & Diagnost Integrate, Largo Rosanna Benzi 8, I-16132 Genoa, Italy. EM claudia.brusasco@gmail.com RI Vargas, Maria/H-6876-2014; Brusasco, Claudia/C-3064-2015; Corradi, Francesco/C-5207-2009; OI Vargas, Maria/0000-0001-7652-970X; Severgnini, Paolo/0000-0001-8027-0059 NR 28 TC 0 Z9 0 U1 0 U2 10 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD NOV PY 2013 VL 58 IS 11 BP 1878 EP 1885 DI 10.4187/respcare.02405 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 252JZ UT WOS:000327002300007 PM 23674812 ER PT J AU Magill, SS Klompas, M Balk, R Burns, SM Deutschman, CS Diekema, D Friclkin, S Greene, L Guh, A Gutterman, D Hammer, B Henderson, D Hess, DR Hill, NS Horan, T Kollef, M Levy, M Septimus, E Van Antwerpen, C Wright, D Lipsett, P AF Magill, Shelley S. Klompas, Michael Balk, Robert Burns, Suzanne M. Deutschman, Clifford S. Diekema, Daniel Friclkin, Scott Greene, Linda Guh, Alice Gutterman, David Hammer, Beth Henderson, David Hess, Dean R. Hill, Nicholas S. Horan, Teresa Kollef, Marin Levy, Mitchell Septimus, Edward Van Antwerpen, Carole Wright, Don Lipsett, Pamela TI Developing a New, National Approach to Surveillance for Ventilator-Associated Events: Executive Summary SO RESPIRATORY CARE LA English DT Article DE ventilator-associated pneumonia; ICU; epidemiology; public health; critical care; mechanicalventilation C1 [Magill, Shelley S.; Friclkin, Scott; Guh, Alice; Horan, Teresa] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. [Klompas, Michael] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Klompas, Michael] Brigham & Womens Hosp, Infect Control Dept, Boston, MA 02115 USA. [Klompas, Michael] Soc Healthcare Epidemiol Amer, Arlington, VA USA. [Balk, Robert] Rush Univ, Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA. [Burns, Suzanne M.] Univ Virginia, Sch Nursing Crit & Acute Care, Charlottesville, VA USA. [Deutschman, Clifford S.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. [Diekema, Daniel] Univ Iowa, Carver Coll Med, Div Infect Dis, Iowa City, IA USA. [Diekema, Daniel] Healthcare Infect Control Practices Advisory Comm, Atlanta, GA USA. [Greene, Linda] Rochester Gen Hlth Syst, Infect Prevent & Control Dept, Rochester, NY USA. [Greene, Linda] Assoc Profess Infect Control & Epidemiol, Washington, DC USA. [Gutterman, David] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Hammer, Beth] Zablocki VA Med Ctr, Dept Cardiol, Milwaukee, WI USA. [Henderson, David] NIH, Hosp Epidemiol & Qual Improvement, Ctr Clin, Bethesda, MD 20892 USA. [Hess, Dean R.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA. [Hess, Dean R.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA. [Hess, Dean R.] Amer Assoc Resp Care, Irving, TX USA. [Hill, Nicholas S.] Tufts Med Ctr, Div Pulm & Crit Care Med, Boston, MA USA. [Kollef, Marin] Washington Univ, Div Pulm & Crit Care Med, St Louis, MO USA. [Levy, Mitchell] Brown Univ, Rhode Isl Hosp, Div Pulm Crit Care & Sleep, Warren Alpert Med Sch, Providence, RI 02903 USA. [Septimus, Edward] Texas A&M Hlth Sci Ctr, Dept Internal Med, College Stn, TX USA. [Septimus, Edward] Infect Dis Soc Amer, Arlington, VA USA. [Van Antwerpen, Carole] New York State Dept Hlth, Dept Hlth, Bur Healthcare Associated Infect, Albany, NY USA. [Van Antwerpen, Carole] Council State & Terr Epidemiologists, Atlanta, GA USA. [Wright, Don] US Dept HHS, Off Dis Prevent & Hlth Promot, Washington, DC 20201 USA. [Lipsett, Pamela] Johns Hopkins Univ, Sch Med, Dept Surg Anesthesiol & Crit Care Med, Baltimore, MD USA. RP Magill, SS (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-24, Atlanta, GA 30329 USA. EM smagill@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX The work described herein was supported by the Centers for Disease Control and Prevention (CDC). NR 2 TC 2 Z9 2 U1 0 U2 2 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD NOV PY 2013 VL 58 IS 11 BP 1985 EP 1989 DI 10.4187/respcare.02759 PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 252JZ UT WOS:000327002300021 ER PT J AU Shi, J Longo, FM Massa, SM AF Shi, Jian Longo, Frank M. Massa, Stephen M. TI A Small Molecule p75(NTR) Ligand Protects Neurogenesis After Traumatic Brain Injury SO STEM CELLS LA English DT Article DE Traumatic brain injury; Neurotrophin; Neurogenesis; Hippocampus ID P75 NEUROTROPHIN RECEPTOR; CELL-ADHESION MOLECULE; REGULATES HIPPOCAMPAL NEUROGENESIS; NERVE GROWTH-FACTOR; SPINAL-CORD-INJURY; DENTATE GYRUS; IN-VITRO; PROGENITOR CELLS; UP-REGULATION; EXPRESSION PATTERNS AB The p75 neurotrophin receptor (p75(NTR)) influences the proliferation, survival, and differentiation of neuronal precursors and its expression is induced in injured brain, where it regulates cell survival. Here, we test the hypotheses that pharmacologic modulation of p75(NTR) signaling will promote neural progenitor survival and proliferation, and improve outcomes of traumatic brain injury (TBI). LM11A-31, an orally available, blood-brain barrier-permeant small-molecule p75(NTR) signaling modulator, significantly increased proliferation and survival, and decreased JNK phosphorylation, in hippocampal neural stem/progenitor cells in culture expressing wild-type p75(NTR), but had no effect on cells expressing a mutant neurotrophin-unresponsive form of the receptor. The compound also enhanced the production of mature neurons from adult hippocampal neural progenitors in vitro. In vivo, intranasal administration of LM11A-31 decreased postinjury hippocampal and cortical neuronal death, neural progenitor cell death, gliogenesis, and microglial activation, and enhanced long-term hippocampal neurogenesis and reversed spatial memory impairments. LM11A-31 diminished the postinjury increase of SOX2-expressing early progenitor cells, but protected and increased the proliferation of endogenous polysialylated-neural cell adhesion molecule positive intermediate progenitors, and restored the long-term production of mature granule neurons. These findings suggest that modulation of p75(NTR) actions using small molecules such as LM11A-31 may constitute a potent therapeutic strategy for TBI. Stem Cells2013;31:2561-2574 C1 [Shi, Jian; Massa, Stephen M.] Dept Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA USA. [Shi, Jian; Massa, Stephen M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Longo, Frank M.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. RP Massa, SM (reprint author), San Francisco VA Med Ctr, Dept Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA. EM Stephen.Mas-sa@ucsf.edu FU Department of Defense [DOD DAMD17-03-1-0532]; Veterans Administration FX These studies were supported by the Department of Defense (DOD DAMD17-03-1-0532 to SMM); and the Veterans Administration (SMM). NR 76 TC 18 Z9 20 U1 1 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5099 EI 1549-4918 J9 STEM CELLS JI Stem Cells PD NOV PY 2013 VL 31 IS 11 BP 2561 EP 2574 DI 10.1002/stem.1516 PG 14 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA 252QY UT WOS:000327025600025 PM 23940017 ER PT J AU Breitner, J Baker, L Drye, L Evans, D Lyketsos, C Ryan, L Zandi, P Baker, L Breitner, J Saucedo, HH Anau, J Cholerton, B Kramer, K Zandi, P Drye, L Casper, AS Meinert, C Martin, B Jenkins, G McCaffrey, L Meinert, J Vaidya, V Ahuja, A May, P Ryan, L Lyketsos, CG Steinberg, M Brandt, J Pedroso, JJ Bergey, A Gogel, C Smith, L Kraus, J Stern, RA Green, RC Gavett, B Mwicigi, J Baldwin, L McGowan, T Johnson, P Qiu, W Frederick, J Raghavan, S Rossi, C Mandell, A Dinizo, D Roth, MT Porsteinsson, A Ismail, MS Weber, M Brand, C Richard, J Stear, K Schepp, S Cosman, K Martin, K Craft, S Baker, L Dahl, D Garrett, G Tidwell, J Thielke, S Smith, L Arbuckle, M Strong, W Ladenberg, J Callaghan, M Watson, S Skinner, J Bowton, K Sabbagh, M Belden, C Liebsack, C Davis, K Arnieri, L Malek-Ahmadi, M Nicholson, L Jacobson, S Schwartz, E Mullan, M Luis, C Parrish, J Faircloth, M Ervin, T Girard, J Burke, D Keegan, A Evans, D AF Breitner, John Baker, Laura Drye, Lea Evans, Denis Lyketsos, Constantine Ryan, Laurie Zandi, Peter Baker, Laura Breitner, John Saucedo, Hector Hernandez Anau, Jane Cholerton, Brenna Kramer, Kirise Zandi, Peter Drye, Lea Casper, Anne Shanklin Meinert, Curtis Martin, Barbara Jenkins, Gabrielle McCaffrey, Lee Meinert, Jill Vaidya, Vijay Ahuja, Alka May, Pat Ryan, Laurie Lyketsos, Constantine G. Steinberg, Martin Brandt, Jason Pedroso, Julia J. Bergey, Alyssa Gogel, Carol Smith, Lynn Kraus, Jennifer Stern, Robert A. Green, Robert C. Gavett, Brandon Mwicigi, Jane Baldwin, Lorraine McGowan, Theresa Johnson, Patricia Qiu, Wendy Frederick, Jamie Raghavan, Sumati Rossi, Carol Mandell, Alan Dinizo, Daniella Roth, Mary Tara Porsteinsson, Anton Ismail, M. Saleem Weber, Miriam Brand, Connie Richard, Jennifer Stear, Kelly Schepp, Sue Cosman, Kelly Martin, Kimberly Craft, Suzanne Baker, Laura Dahl, Deborah Garrett, Grace Tidwell, Jamie Thielke, Stephen Smith, Lauren Arbuckle, Matthew Strong, William Ladenberg, Juliet Callaghan, Maureen Watson, Stennis Skinner, Jeannine Bowton, Kaysha Sabbagh, Marwan Belden, Christine Liebsack, Carolyn Davis, Kathryn Arnieri, Lauren Malek-Ahmadi, Michael Nicholson, Lisa Jacobson, Sandra Schwartz, Elliot Mullan, Michael Luis, Cheryl Parrish, Julia Faircloth, Marlee Ervin, Terry Girard, Janette Burke, Deborah Keegan, Andrew Evans, Denis CA Alzheimer's Dis Antiinflammatory TI Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) The Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group SO ALZHEIMERS & DEMENTIA LA English DT Article DE Prevention; Clinical trial; Alzheimer's disease; Nonsteroidal anti-inflammatory drug; Naproxen; Celecoxib ID DOUBLE-BLIND; DRUGS; ROFECOXIB; NAPROXEN; PLACEBO; INHIBITION; CELECOXIB; ASPIRIN; DESIGN; NSAIDS AB Objectives: The Alzheimer's Disease Anti-inflammatory Prevention Trial Follow-up Study (ADAPT-FS) was designed to evaluate the efficacy of naproxen and celecoxib for the primary prevention of Alzheimer's disease (AD) several years after cessation of treatment in ADAPT. Methods: ADAPT was a randomized, double-masked, multicenter clinical trial of naproxen or celecoxib vs placebo (1:1:1.5 assignment ratio) at six U.S.-based clinics. The trial enrolled 2528 people between 2001 and 2004. Treatments were discontinued in December 2004 and participants were monitored regularly until 2007. In 2010 and 2011, ADAPT-FS screened 1537 participants by telephone and, if indicated, examined them in person using standardized clinical assessments. The primary outcome was time to diagnosis of AD. Death index searches were performed for participants not located. Results: Eighty-nine additional AD events were identified (24 celecoxib, 25 naproxen, and 40 placebo) yielding a total of 161 events (48 [6.6% of randomized participants] celecoxib, 43 [6.0%] naproxen, and 70 [6.5%] placebo) across ADAPT and ADAPT-FS. Adjusted hazard ratios (HRs) comparing each treatment with placebo showed no overall reduction in risk of AD: HR celecoxib vs placebo, 1.03 (95% confidence interval [CI], 0.72-1.50; P = .86); HR naproxen vs placebo, 0.92 (95% CI, 0.62-1.35; P = .66). There were 349 deaths (110 [15.2%] celecoxib, 96 [13.4%] naproxen, and 143 [13.2%] placebo). Risk of death was similar for the naproxen- and placebo-assigned groups (HR, 0.99; 95% CI, 0.76-1.28; P = .93) and slightly higher for celecoxib compared with the placebo-assigned group (HR, 1.15; 95% CI, 0.90-1.48; P = .27). Conclusions: These results acquired during a follow-up of approximately 7 years (which included a median of less than 1.5 years of treatment) do not support the hypothesis that celecoxib or naproxen prevent AD in adults with a family history of dementia. 2013 The Alzheimer's Association. All rights reserved. C1 [Breitner, John; Baker, Laura; Breitner, John] Douglas Mental Hlth Univ Inst, Ctr Studies Prevent Alzheimers Dis, Montreal, PQ, Canada. [Breitner, John; Baker, Laura; Breitner, John] McGill Univ, Montreal, PQ, Canada. [Baker, Laura; Porsteinsson, Anton; Ismail, M. Saleem; Weber, Miriam; Brand, Connie; Richard, Jennifer; Stear, Kelly; Schepp, Sue; Cosman, Kelly; Martin, Kimberly] Veteran Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Baker, Laura; Zandi, Peter; Porsteinsson, Anton; Ismail, M. Saleem; Weber, Miriam; Brand, Connie; Richard, Jennifer; Stear, Kelly; Schepp, Sue; Cosman, Kelly; Martin, Kimberly] Univ Washington, Sch Med, Seattle, WA USA. [Drye, Lea; Zandi, Peter; Saucedo, Hector Hernandez; Anau, Jane; Cholerton, Brenna; Kramer, Kirise] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Evans, Denis; Mullan, Michael; Luis, Cheryl; Parrish, Julia; Faircloth, Marlee; Ervin, Terry; Girard, Janette; Burke, Deborah; Keegan, Andrew; Evans, Denis] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA. [Lyketsos, Constantine; Ryan, Laurie] Johns Hopkins Sch Med, Baltimore, MD 60612 USA. [Ryan, Laurie] NIA, Bethesda, MD 20892 USA. [Zandi, Peter] Vet Affairs Puget Sound Hlth Care Syst, Res Grp Resource Ctr Chairmans Off, Seattle, WA USA. [Zandi, Peter; Drye, Lea; Casper, Anne Shanklin; Meinert, Curtis; Martin, Barbara; Jenkins, Gabrielle; McCaffrey, Lee; Meinert, Jill; Vaidya, Vijay; Ahuja, Alka; May, Pat] NIA, Project Off, Bethesda, MD 20892 USA. [Lyketsos, Constantine G.; Steinberg, Martin; Brandt, Jason; Pedroso, Julia J.; Bergey, Alyssa; Gogel, Carol; Smith, Lynn; Kraus, Jennifer] Boston Univ, Sch Med, Boston, MA 02118 USA. [Stern, Robert A.; Green, Robert C.; Gavett, Brandon; Mwicigi, Jane; Baldwin, Lorraine; McGowan, Theresa; Johnson, Patricia; Qiu, Wendy; Frederick, Jamie; Raghavan, Sumati; Rossi, Carol; Mandell, Alan; Dinizo, Daniella; Roth, Mary Tara] Univ Rochester, Sch Med, Rochester, NY USA. [Craft, Suzanne; Baker, Laura; Dahl, Deborah; Garrett, Grace; Tidwell, Jamie; Thielke, Stephen; Smith, Lauren; Arbuckle, Matthew; Strong, William; Ladenberg, Juliet; Callaghan, Maureen; Watson, Stennis; Skinner, Jeannine; Bowton, Kaysha] Sun Hlth Res Inst, Sun City, AZ USA. [Sabbagh, Marwan; Belden, Christine; Liebsack, Carolyn; Davis, Kathryn; Arnieri, Lauren; Malek-Ahmadi, Michael; Nicholson, Lisa; Jacobson, Sandra; Schwartz, Elliot] Roskamp Inst Memory Clin, Tampa, FL USA. RP Breitner, J (reprint author), Douglas Mental Hlth Univ Inst, Ctr Studies Prevent Alzheimers Dis, Montreal, PQ, Canada. EM ldrye@jhsph.edu FU National Institute on Aging (NIA) [U01 AG15477, 2U01 AG015477-06A2]; N. Bud Grossman Center for Memory Research and Care; Minnesota Medical Foundation FX Funding for this study was provided by the National Institute on Aging (NIA) U01 AG15477 and 2U01 AG015477-06A2, the N. Bud Grossman Center for Memory Research and Care, and the Minnesota Medical Foundation. NR 28 TC 25 Z9 25 U1 1 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD NOV PY 2013 VL 9 IS 6 BP 714 EP 723 DI 10.1016/j.jalz.2012.11.012 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 254NP UT WOS:000327172700012 ER PT J AU Zhu, CW Livote, EE Scarmeas, N Albert, M Brandt, J Blacker, D Sano, M Stern, Y AF Zhu, Carolyn W. Livote, Elayne E. Scarmeas, Nikolaos Albert, Marilyn Brandt, Jason Blacker, Deborah Sano, Mary Stern, Yaakov TI Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease SO ALZHEIMERS & DEMENTIA LA English DT Article DE Alzheimer's disease; Cholinesterase inhibitors; Memantine; Outcomes; Longitudinal studies ID OPEN-LABEL; NATURAL-HISTORY; DONEPEZIL; MULTICENTER; EFFICACY; EXTENSION; DEMENTIA; MODERATE; GALANTAMINE; PREDICTORS AB Objectives: To examine in an observational study (1) relationships between cholinesterase inhibitors (ChEI) and memantine use, and functional and cognitive end points and mortality in patients with Alzheimer's disease (AD); (2) relationships between other patient characteristics and these clinical end points; and (3) whether effects of the predictors change across time. Methods: The authors conducted a multicenter, natural history study that included three university-based AD centers in the United States. A total of 201 patients diagnosed with probable AD with modified Mini-Mental State Examination (MMSE) scores >= 30 at study entry were monitored annually for 6 years. Discrete-time hazard analyses were used to examine relationships between ChEI and memantine use during the previous 6 months reported at each assessment, and time to cognitive (MMSE score <= 10) and functional (Blessed Dementia Rating Scale score >= 10) end points and mortality. Analyses controlled for clinical characteristics, including baseline cognition, function, and comorbid conditions, and presence of extrapyramidal signs and psychiatric symptoms at each assessment interval. Demographic characteristics included baseline age, sex, education, and living arrangement at each assessment interval. Results: ChEI use was associated with delayed time in reaching the functional end point and death. Memantine use was associated with delayed time to death. Different patient characteristics were associated with different clinical end points. Conclusions: Results suggest long-term beneficial effects of ChEI and memantine use on patient outcomes. As for all observational cohort studies, observed relationships should not be interpreted as causal effects. (C) 2013 The Alzheimer's Association. All rights reserved. C1 [Zhu, Carolyn W.; Livote, Elayne E.; Scarmeas, Nikolaos] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Stern, Yaakov] Taub Inst Res Alzheimers Dis & Aging Brain, Cognit Neurosci Div, New York, NY USA. [Scarmeas, Nikolaos; Stern, Yaakov] Columbia Univ, Med Ctr, Gertrude H Sergievsky Ctr, New York, NY USA. [Scarmeas, Nikolaos; Stern, Yaakov] Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA. [Albert, Marilyn; Brandt, Jason] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD USA. [Blacker, Deborah] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Sano, Mary] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Scarmeas, Nikolaos] Univ Athens, Sch Med, Dept Neurol, Athens 11528, Greece. RP Zhu, CW (reprint author), Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA. EM carolyn.zhu@mssm.edu OI Brandt, Jason/0000-0001-7381-6244 FU Department of Veterans Affairs, Veterans Health Administration; [AG07370]; [RR00645]; [U01AG010483] FX The Predictors Study is supported by federal grant AG07370, with additional support from federal grants, RR00645, and U01AG010483. Dr Sano is supported by the Department of Veterans Affairs, Veterans Health Administration. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. The authors all certify that they have no conflict of interest to report in this manuscript. The sponsor had no role in the design, methods, subject recruitment, data collections, analysis, and preparation of this article. NR 38 TC 20 Z9 20 U1 0 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD NOV PY 2013 VL 9 IS 6 BP 733 EP 740 DI 10.1016/j.jalz.2012.09.015 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 254NP UT WOS:000327172700014 PM 23332671 ER PT J AU Pearson, SD Ollendorf, DA Colby, JA AF Pearson, Steven D. Ollendorf, Daniel A. Colby, Jennifer A. CA ICER Alzheimer's Diagnostics TI Biomarker tests for the diagnosis of Alzheimer's disease: Generating evidence to inform insurance coverage determinations SO ALZHEIMERS & DEMENTIA LA English DT Editorial Material DE Alzheimer's disease; Diagnostic tests; Insurance coverage; Research recommendations; Evidence-based medicine; Evidence hierarchies AB Outside of their uses in drug development and clinical research trials, the current clinical value of performing any type of formal biomarker testing for the diagnosis or exclusion of Alzheimer's disease (AD) is controversial, and most biomarker tests for AD are not covered by public or private insurers. This situation raises the issue of how insurers determine whether there is "adequate" evidence to justify a positive coverage determination in this area. This article, a focused condensation of a larger white paper, is the product of an initiative led by the Institute for Clinical and Economic Review to convene a multiple-stakeholder AD Diagnostics Policy Development Group composed of patient advocates, clinicians, clinical researchers, manufacturers, and insurers. The larger white paper was the basis for the evidence review presented to the Medicare Evidence Development and Coverage Advisory Committee meeting on January 30, 2013, as part of its deliberations on positron emission tomography-amyloid imaging. Herein we focus on the description of the core elements of what insurers will be looking for in evidence on all potential diagnostic tests for AD. Corresponding research recommendations are also included, framed to serve as a guide for future AD diagnostics research. (C) 2013 The Alzheimer's Association. All rights reserved. C1 [Pearson, Steven D.; Ollendorf, Daniel A.; Colby, Jennifer A.; ICER Alzheimer's Diagnostics] Massachusetts Gen Hosp, Inst Technol Assessment, Inst Clin & Econ Review, Boston, MA 02114 USA. RP Pearson, SD (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, Inst Clin & Econ Review, Boston, MA 02114 USA. EM spearson@icer-review.org NR 7 TC 1 Z9 2 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD NOV PY 2013 VL 9 IS 6 BP 745 EP 752 DI 10.1016/j.jalz.2013.06.002 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 254NP UT WOS:000327172700016 PM 24094912 ER PT J AU Chen, YW Chhabra, N Liu, YCC Arnold, JE Rezaee, RP AF Chen, Yunwei Chhabra, Nipun Liu, Yi-Chun Carol Arnold, James E. Rezaee, Rod P. TI Foreign body impaction of the vertebral canal SO AMERICAN JOURNAL OF OTOLARYNGOLOGY LA English DT Article ID BODIES; ESOPHAGUS; TRACT; BONE AB Foreign body impactions in the aerodigestive tract are common, but have the potential for serious complications. A foreign body may disrupt the mucosal lining and migrate regionally thereby risking impingement or injury to critical neurovascular structures in the cervical region. It is important to recognize potential complications that may arise from luminal compromise. In such cases, expeditious surgical treatment is warranted. (C) 2013 Elsevier Inc. All rights reserved. C1 [Chen, Yunwei] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. [Chhabra, Nipun] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA. [Liu, Yi-Chun Carol; Arnold, James E.; Rezaee, Rod P.] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Ear Nose & Throat Inst, Cleveland, OH 44106 USA. RP Liu, YCC (reprint author), Ear Nose & Throat Inst, Dept Otolaryngol Head & Neck Surg, 11100 Euclid Ave, Cleveland, OH 44106 USA. EM yichun.liu@uhhospitals.org NR 11 TC 0 Z9 0 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0196-0709 EI 1532-818X J9 AM J OTOLARYNG JI Am. J. Otolaryngol. PD NOV-DEC PY 2013 VL 34 IS 6 BP 724 EP 726 DI 10.1016/j.amjoto.2013.05.003 PG 3 WC Otorhinolaryngology SC Otorhinolaryngology GA 252YH UT WOS:000327048300019 PM 23810084 ER PT J AU Bhatt, SP Dransfield, MT AF Bhatt, Surya P. Dransfield, Mark T. TI AECOPD: Acute Exacerbations of Chronic Obstructive Cardiopulmonary Disease? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID ARTERIAL STIFFNESS; PULMONARY-DISEASE; MYOCARDIAL-INFARCTION; COPD; MORTALITY; RISK; STROKE C1 [Bhatt, Surya P.; Dransfield, Mark T.] Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL 35294 USA. [Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Bhatt, SP (reprint author), Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL 35294 USA. NR 19 TC 2 Z9 3 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD NOV 1 PY 2013 VL 188 IS 9 BP 1046 EP 1048 DI 10.1164/rccm.201309-1651ED PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 251WJ UT WOS:000326962700003 PM 24180438 ER PT J AU Miravitlles, M Anzueto, A AF Miravitlles, Marc Anzueto, Antonio TI Antibiotics for Acute and Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE exacerbations of chronic obstructive pulmonary disease; antibiotics; bacteria; prevention; colonization ID CHRONIC BRONCHIAL INFECTION; PLACEBO-CONTROLLED TRIAL; ACUTE EXACERBATIONS; CYSTIC-FIBROSIS; PSEUDOMONAS-AERUGINOSA; INHALED TOBRAMYCIN; SPUTUM PURULENCE; TRACT INFECTIONS; SEVERE COPD; AZITHROMYCIN AB Prevention and effective treatment of exacerbations are major objectives in the management of patients with chronic obstructive pulmonary disease (COPD). Antibiotics are mainstay treatment for patients with severe COPD with an acute exacerbation that includes increased sputum purulence and worsening shortness of breath. Although such treatment is associated with clinical benefit, treatment failure and relapse rates may be high, particularly in cases of inadequate antibiotic therapy through incomplete resolution of the initial exacerbation and persistent bacterial infection. These aspects have led to recommendations for a stratified approach to antibiotic therapy based on patient characteristics associated with increased risk factors for failure. Patients at greatest risk for poor outcome (i.e., those with severe COPD) are likely to derive greatest benefit from early treatment with antibiotics. Long-term or intermittent antibiotic treatment has been shown to prevent COPD exacerbations and hospitalizations. These effects may be achieved by reducing bacterial load in the airways in stable state and/or bronchial inflammation. Although systemic antibiotics are likely to remain the core treatment for patients with moderate to severe exacerbated COPD, inhaled antibiotics may represent a more optimal approach for the treatment and prevention of COPD exacerbations in the future. Regardless of the route of administration, further studies are required to evaluate the potential long-term adverse events of antibiotics and the development of bacterial resistance. C1 [Miravitlles, Marc] Hosp Univ Vall dHebron, Dept Pneumol, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Barcelona, Spain. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm Dis Crit Care Med, San Antonio, TX 78229 USA. [Anzueto, Antonio] Audie L Murphy Mem Vet Hosp Div, South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Anzueto, A (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, Pulm Dis Sect 111E, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. EM anzueto@uthscsa.edu OI Miravitlles, Marc/0000-0002-9850-9520 NR 64 TC 13 Z9 18 U1 0 U2 8 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD NOV 1 PY 2013 VL 188 IS 9 BP 1052 EP 1057 DI 10.1164/rccm.201302-0289PP PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 251WJ UT WOS:000326962700006 PM 23924286 ER PT J AU Tse, SM Li, LL Butler, MG Fung, V Kharbanda, EO Larkin, EK Vollmer, WM Miroshnik, I Rusinak, D Weiss, ST Lieu, T Wu, AC AF Tse, Sze Man Li, Lingling Butler, Melissa G. Fung, Vicki Kharbanda, Elyse O. Larkin, Emma K. Vollmer, William M. Miroshnik, Irina Rusinak, Donna Weiss, Scott T. Lieu, Tracy Wu, Ann Chen TI Statin Exposure Is Associated with Decreased Asthma-related Emergency Department Visits and Oral Corticosteroid Use SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE HMG-CoA reductase inhibitors; asthma therapy; exacerbations ID PROPENSITY SCORE METHODS; INHALED CORTICOSTEROIDS; AIRWAY INFLAMMATION; ALLERGIC-ASTHMA; SIMVASTATIN; LUNG; HYPERRESPONSIVENESS; ATORVASTATIN AB Rationale: Statins, or HMG-CoA reductase inhibitors, may aid in the treatment of asthma through their pleiotropic antiinflammatory effects. Objectives: To examine the effect of statin therapy on asthma-related exacerbations using a large population-based cohort. Methods: Statin users aged 31 years or greater with asthma were identified from the Population-Based Effectiveness in Asthma and Lung population, which includes data from five health plans. Statin exposure and asthma exacerbations were assessed over a 24-month observation period. Statin users with a statin medication possession ratio greater than or equal to 80% were matched to non-statin users by age, baseline asthma therapy, site of enrollment, season at baseline, and propensity score, which was calculated based on patient demographics and Deyo-Charlson conditions. Asthma exacerbations were defined as two or more oral corticosteroid dispensings, asthma-related emergency department visits, or asthma-related hospitalizations. The association between statin exposure and each of the three outcome measures was assessed using conditional logistic regression. Measurements and Main Results: Of the 14,566 statin users, 8,349 statin users were matched to a nonuser. After adjusting for Deyo-Charlson conditions that remained unbalanced after matching, among statin users, statin exposure was associated with decreased odds of having asthma-related emergency department visits (odds ratio [OR], 0.64; 95% confidence interval [CI], 0.53-0.77; P, 0.0001) and two or more oral corticosteroid dispensings (OR, 0.90; 95% CI, 0.81-0.99; P = 0.04). There were no differences in asthma-related hospitalizations (OR, 0.91; 95% CI, 0.66-1.24; P = 0.52). Conclusions: Among statin users with asthma, statin exposure was associated with decreased odds of asthma-related emergency department visits and oral corticosteroid dispensings. C1 [Tse, Sze Man; Weiss, Scott T.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Tse, Sze Man; Fung, Vicki; Weiss, Scott T.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Tse, Sze Man] Massachusetts Gen Hosp, Dept Pediat, Div Pediat Pulm Med, Boston, MA 02114 USA. [Li, Lingling; Miroshnik, Irina; Rusinak, Donna; Lieu, Tracy; Wu, Ann Chen] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Ctr Child Hlth Care Studies, Boston, MA USA. [Butler, Melissa G.] Kaiser Permanente Georgia, Ctr Hlth Res Southeast, Atlanta, GA USA. [Fung, Vicki] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Kharbanda, Elyse O.] HealthPartners Inst Educ & Res, Minneapolis, MN USA. [Larkin, Emma K.] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA. [Vollmer, William M.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Lieu, Tracy] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Lieu, Tracy; Wu, Ann Chen] Childrens Hosp, Dept Pediat, Boston, MA 02115 USA. RP Tse, SM (reprint author), Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA. EM reszt@channing.harvard.edu FU NHLBI [R01 HS019669, K08 HL088046-01A2] FX Supported by NHLBI (R01 HS019669; PI: S. B. Soumerai). A. W. was supported by K08 HL088046-01A2 from NHLBI. NR 23 TC 15 Z9 15 U1 0 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD NOV 1 PY 2013 VL 188 IS 9 BP 1076 EP 1082 DI 10.1164/rccm.201306-1017OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 251WJ UT WOS:000326962700009 PM 24093599 ER PT J AU Boronat, S Van Eeghen, AM Shinnick, JE Newberry, P Thiele, EA AF Boronat, Susana Van Eeghen, Agnies M. Shinnick, Julianna E. Newberry, Peter Thiele, Elizabeth A. TI Stressor-related disorders in tuberous sclerosis SO ANNALS OF CLINICAL PSYCHIATRY LA English DT Article DE adjustment disorder; anxiety; seizures; posttraumatic stress disorder; trauma; tuberous sclerosis ID TRAUMA; COMPLEX; TRIAL; PTSD; EXTINCTION; VETERANS; EXPOSURE; CHILDREN; PLACEBO AB BACKGROUND: Patients with tuberous sclerosis complex (TSC) have high rates of psychiatric comorbidity, including mood and anxiety disorders. The aim of this study is to identify patients with stressor-related disorders such as posttraumatic stress disorder (PTSD) or adjustment disorder (AD) and to describe their clinical picture in the setting of TSC. METHODS: Retrospective review of medical charts of TSC patients referred for a stressor-related disorder to a TSC psychiatric clinic. RESULTS: We identified 7 females and 2 males (3 PTSD, 6 AD), including 4 children. Two patients with severe intellectual disabffity presented with aggression and the remaining patients presented with avoidance. The mean duration of symptoms at the time of the study was 21 months (range: 7 to 48 months) and 7 of the 9 patients still were having trauma-related symptoms. All the patients who received an initial diagnosis of AD had their diagnosis changed to another category because their symptoms lasted >6 months. In most cases, selective serotonin reuptalce inhibitors improved the symptoms. CONCLUSIONS: Stressor-related disorders in TSC frequently linger beyond 6 months and may appear with triggering events that typically are not viewed as trauma in a normal population. C1 [Boronat, Susana; Van Eeghen, Agnies M.; Shinnick, Julianna E.; Thiele, Elizabeth A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Boronat, Susana] Univ Autonoma Barcelona, Dept Pediat Neurol, Vall dHebron Hosp, E-08193 Barcelona, Spain. [Newberry, Peter] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Thiele, EA (reprint author), Massachusetts Gen Hosp, Pediat Epilepsy Program, 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM ethiele@partners.org FU NIH/NINDS [P01 NS024279]; Carlos III Institute in Spain FX The authors thank all the patients with TSC and their family members for participating in this study and to Herscot Center for Tuberous Sclerosis Complex, NIH/NINDS P01 NS024279 and Carlos III Institute in Spain for funding this study. NR 32 TC 0 Z9 0 U1 0 U2 5 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 1040-1237 EI 1547-3325 J9 ANN CLIN PSYCHIATRY JI Ann. Clin. Psychiatry PD NOV PY 2013 VL 25 IS 4 BP 243 EP 249 PG 7 WC Psychiatry SC Psychiatry GA 252IE UT WOS:000326997600002 PM 23926580 ER PT J AU Freeman, MP Toth, TL Cohen, LS AF Freeman, Marlene P. Toth, Thomas L. Cohen, Lee S. TI Assisted reproduction and risk of depressive relapse: Considerations for treatment SO ANNALS OF CLINICAL PSYCHIATRY LA English DT Review DE infertility; pregnancy; antidepressants; depression ID IN-VITRO FERTILIZATION; COGNITIVE-BEHAVIORAL THERAPY; MAJOR DEPRESSION; RECURRENT DEPRESSION; ANTIDEPRESSANT TREATMENT; PSYCHOLOGICAL REACTIONS; MAINTENANCE THERAPIES; HPA AXIS; WOMEN; INFERTILITY AB BACKGROUND: At present, there is a lack of systematic data regarding the risk of relapse of psychiatric disorders in women undergoing infertility treatment. Clinicians would benefit from a systematic study of the biological sequelae of stress and the clinical implications for women with histories of depression or anxiety disorders undergoing treatment for infertility. Women with histories of major depressive disorder may be vulnerable to the stress involved in the process of assisted reproduction, and treatment changes during this time in anticipation of a pregnancy may affect relapse rates. METHODS: We have highlighted the elements important to the care of women undergoing assisted reproduction with histories of depression in the following case report and review of the relevant literature. RESULTS: No clinical guidelines currently exist for prevention of depressive relapse in women seeking infertility treatment. Due to concerns about medication exposure during a potential pregnancy, many women will avoid antidepressants. CONCLUSIONS: The profession needs to identify women at risk of depressive relapse and create evidence-based treatment guidelines for their management. Similarly, among patients who may be pregnant, providers should monitor mood, psychotherapeutic approaches, and collaborative decision-making about medication use carefully. C1 [Freeman, Marlene P.; Cohen, Lee S.] Massachusetts Gen Hosp, Perinatal & Reprod Psychiat Program, Boston, MA 02114 USA. [Toth, Thomas L.] Massachusetts Gen Hosp, Vincent Vitro Fertilizat Unit, Boston, MA 02114 USA. RP Freeman, MP (reprint author), Massachusetts Gen Hosp, Perinatal & Reprod Psychiat Program, 185 Cambridge St,2nd Floor, Boston, MA 02114 USA. EM mfreeman@partners.org FU GlaxoSmithKline; AstraZeneca; Bristol-Myers Squibb; Cephalon; National Institute on Aging; National Institute of Mental health; Ortho-McNeil; Janssen; Sunovion FX Dr. Freeman receives grant/research support from GlaxoSmithKline; is a consultant to Johnson and Johnson, Otsuka, Takeda/Lundbeck, and Genentech. Dr. Toth reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products. Dr. Cohen receives research support from AstraZeneca, Bristol-Myers Squibb, Cephalon, GlaxoSmithKline, the National Institute on Aging, the National Institute of Mental health, Ortho-McNeil, Janssen, and Sunovion; and is a consultant to Noven Pharmaceutical. NR 30 TC 3 Z9 3 U1 1 U2 7 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 1040-1237 EI 1547-3325 J9 ANN CLIN PSYCHIATRY JI Ann. Clin. Psychiatry PD NOV PY 2013 VL 25 IS 4 BP 283 EP 288 PG 6 WC Psychiatry SC Psychiatry GA 252IE UT WOS:000326997600008 PM 24199219 ER PT J AU Robinson, E Daly, M Kirby, A Ruparel, K Qiu, HJ Lehner, T Gur, R Hakonarson, H Gur, R AF Robinson, Elise Daly, Mark Kirby, Andrew Ruparel, Kosha Qiu, Haijun Lehner, Thomas Gur, Ruben Hakonarson, Hakon Gur, Raquel TI Common genetic influences identify cognitive and behavioral networks in the Philadelphia Neurodevelopmental Cohort SO BEHAVIOR GENETICS LA English DT Meeting Abstract CT 43rd Annual Meeting of the Behavior-Genetics-Association CY JUN 28-JUL 02, 2013 CL Marseille, FRANCE SP Behav Genet Assoc C1 [Robinson, Elise; Daly, Mark; Kirby, Andrew] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ruparel, Kosha; Gur, Ruben; Gur, Raquel] Univ Penn, Philadelphia, PA 19104 USA. [Qiu, Haijun; Hakonarson, Hakon] Childrens Hosp Philadelphia, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-8244 EI 1573-3297 J9 BEHAV GENET JI Behav. Genet. PD NOV PY 2013 VL 43 IS 6 BP 538 EP 538 PG 1 WC Behavioral Sciences; Genetics & Heredity; Psychology, Multidisciplinary SC Behavioral Sciences; Genetics & Heredity; Psychology GA 250ZH UT WOS:000326895400122 ER PT J AU Taylor, M Charman, T Robinson, E Hayiou-Thomas, M Dale, P Ronald, A AF Taylor, Mark Charman, Tony Robinson, Elise Hayiou-Thomas, Marianna Dale, Philip Ronald, Angelica TI Language and autistic traits are aetiologically distinct: Evidence from a community-based twin study SO BEHAVIOR GENETICS LA English DT Meeting Abstract CT 43rd Annual Meeting of the Behavior-Genetics-Association CY JUN 28-JUL 02, 2013 CL Marseille, FRANCE SP Behav Genet Assoc C1 [Robinson, Elise] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hayiou-Thomas, Marianna] Univ York, York YO10 5DD, N Yorkshire, England. [Dale, Philip] Univ New Mexico, Albuquerque, NM 87131 USA. RI Charman, Tony/A-2085-2014; Dale, Philip/A-2254-2009 OI Charman, Tony/0000-0003-1993-6549; Dale, Philip/0000-0002-7697-8510 NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-8244 EI 1573-3297 J9 BEHAV GENET JI Behav. Genet. PD NOV PY 2013 VL 43 IS 6 BP 543 EP 543 PG 1 WC Behavioral Sciences; Genetics & Heredity; Psychology, Multidisciplinary SC Behavioral Sciences; Genetics & Heredity; Psychology GA 250ZH UT WOS:000326895400138 ER PT J AU Gallagher, MW Payne, LA White, KS Shear, KM Woods, SW Gorman, JM Barlow, DH AF Gallagher, Matthew W. Payne, Laura A. White, Kamila S. Shear, Katherine M. Woods, Scott W. Gorman, Jack M. Barlow, David H. TI Mechanisms of change in cognitive behavioral therapy for panic disorder: The unique effects of self-efficacy and anxiety sensitivity SO BEHAVIOUR RESEARCH AND THERAPY LA English DT Article DE Panic disorder; Mechanisms of change; CBT; Self-efficacy; Anxiety sensitivity; Latent difference score ID LONGITUDINAL DATA; CATASTROPHIC MISINTERPRETATION; NEGATIVE COGNITIONS; BODILY SENSATIONS; SEVERITY SCALE; DEPRESSION; PSYCHOTHERAPY; MEDIATION; MODELS; VULNERABILITY AB The present study examined temporal dependencies of change of panic symptoms and two promising mechanisms of change (self-efficacy and anxiety sensitivity) during an 11-session course of cognitive-behavior therapy (CBT) for Panic Disorder (PD). 361 individuals with a principal diagnosis of PD completed measures of self-efficacy, anxiety sensitivity, and PD symptoms at each session during treatment. Effect size analyses indicated that the greatest changes in anxiety sensitivity occurred early in treatment, whereas the greatest changes in self-efficacy occurred later in treatment. Results of parallel process latent growth curve models indicated that changes in self-efficacy and anxiety sensitivity across treatment uniquely predicted changes in PD symptoms. Bivariate and multivariate latent difference score models indicated, as expected, that changes in anxiety sensitivity and self-efficacy temporally preceded changes in panic symptoms, and that intraindividual changes in anxiety sensitivity and self-efficacy independently predicted subsequent intraindividual changes in panic symptoms. These results provide strong evidence that changes in self-efficacy and anxiety sensitivity during CBT influence subsequent changes in panic symptoms, and that self-efficacy and anxiety sensitivity may therefore be two distinct mechanisms of change of CBT for PD that have their greatest impact at different stages of treatment. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Gallagher, Matthew W.; Barlow, David H.] Boston Univ, Ctr Anxiety & Related Disorders, Boston, MA 02215 USA. [Payne, Laura A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [White, Kamila S.] Univ Missouri, St Louis, MO 63121 USA. [Shear, Katherine M.] Columbia Univ, Sch Social Work, New York, NY 10027 USA. [Woods, Scott W.] Yale Univ, New Haven, CT 06520 USA. RP Gallagher, MW (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B2, Behav Sci Div, 150 South Huntington Ave, Boston, MA 02130 USA. EM mwg@bu.edu FU NIMH NIH HHS [R01 MH045964, R10 MH045965, MH45965, R01 MH45963, MH45964, MH45966, R01 MH045965, R01 MH045966] NR 61 TC 19 Z9 19 U1 7 U2 40 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0005-7967 EI 1873-622X J9 BEHAV RES THER JI Behav. Res. Ther. PD NOV PY 2013 VL 51 IS 11 BP 767 EP 777 DI 10.1016/j.brat.2013.09.001 PG 11 WC Psychology, Clinical SC Psychology GA 253AA UT WOS:000327052800008 PM 24095901 ER PT J AU Gress, RE Miller, JS Battiwalla, M Bishop, MR Giralt, SA Hardy, NM Kroger, N Wayne, AS Landau, DA Wu, CJ AF Gress, Ronald E. Miller, Jeffrey S. Battiwalla, Minoo Bishop, Michael R. Giralt, Sergio A. Hardy, Nancy M. Kroeger, Nicolaus Wayne, Alan S. Landau, Dan A. Wu, Catherine J. TI Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of Relapse after Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Stem cell transplantation; Relapse; Allogeneic; Prevention; Biology; Treatment ID NATURAL-KILLER-CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; T-CELLS; INTENSIVE CHEMOTHERAPY; MULTIPLE-MYELOMA; CLONAL EVOLUTION; BREAST-CANCER; NK CELLS; CYTOMEGALOVIRUS; RECONSTITUTION AB In the National Cancer Institute's Second Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on the Biology of Relapse discussed recent advances in understanding some of the host-, disease-, and transplantation-related contributions to relapse, emphasizing concepts with potential therapeutic implications. Relapse after hematopoietic stem cell transplantation (HSCT) represents tumor escape, from the cytotoxic effects of the conditioning regimen and from immunologic control mediated by reconstituted lymphocyte populations. Factors influencing the biology of the therapeutic graft-versus-malignancy (GVM) effect-and relapse-include conditioning regimen effects on lymphocyte populations and homeostasis, immunologic niches, and the tumor microenvironment; reconstitution of lymphocyte populations and establishment of functional immune competence; and genetic heterogeneity within the malignancy defining potential for clonal escape. Recent developments in T cell and natural killer cell homeostasis and reconstitution are reviewed, with implications for prevention and treatment of relapse, as is the application of modern genome sequencing to defining the biologic basis of GVM, clonal escape, and relapse after HSCT. Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation. C1 [Gress, Ronald E.; Hardy, Nancy M.] NCI, Expt Transplantat & Immunol Branch, NIH, Ctr Canc Res, Bethesda, MD 20892 USA. [Miller, Jeffrey S.] Univ Minnesota, Ctr Canc, Minneapolis, MN USA. [Battiwalla, Minoo] NHLBI, Hematol Branch, Bethesda, MD 20892 USA. [Bishop, Michael R.] Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA. [Giralt, Sergio A.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA. [Kroeger, Nicolaus] Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany. [Wayne, Alan S.] NCI, Pediat Oncol Branch, NIH, Ctr Canc Res, Bethesda, MD 20892 USA. [Landau, Dan A.; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. [Landau, Dan A.; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Hardy, NM (reprint author), NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, Hatfield Clin Res Ctr, 10 Ctr Dr,Room 3E-3330, Bethesda, MD 20892 USA. EM hardyn@mail.nih.gov OI Miller, Jeffrey S/0000-0002-0339-4944 FU National Institutes of Health: the National Cancer Institute/Center for Cancer Research; National Institutes of Health: National Heart, Lung and Blood Institute FX Supported in part by the Intramural Research Programs of the National Institutes of Health: the National Cancer Institute/Center for Cancer Research and the National Heart, Lung and Blood Institute. NR 48 TC 8 Z9 8 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD NOV PY 2013 VL 19 IS 11 BP 1537 EP 1545 DI 10.1016/j.bbmt.2013.08.010 PG 9 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 250KL UT WOS:000326851600004 PM 24018395 ER PT J AU Lee, SJ Storer, B Wang, HL Lazarus, HM Waller, EK Isola, LM Klumpp, TR Umejiego, JBC Savani, BN Loren, AW Cairo, MS Camitta, BM Cutler, CS George, B Khoury, HJ Marks, DI Rizzieri, DA Copelan, EA Gupta, V Liesveld, JL Litzow, MR Miller, AM Schouten, HC Gale, RP Cahn, JY Weisdorf, DJ AF Lee, Stephanie J. Storer, Barry Wang, Hailin Lazarus, Hillard M. Waller, Edmund K. Isola, Luis M. Klumpp, Thomas R. Umejiego, John Bosco C. Savani, Bipin N. Loren, Alison W. Cairo, Mitchell S. Camitta, Bruce M. Cutler, Corey S. George, Biju Khoury, H. Jean Marks, David I. Rizzieri, David A. Copelan, Edward A. Gupta, Vikas Liesveld, Jane L. Litzow, Mark R. Miller, Alan M. Schouten, Harry C. Gale, Robert Peter Cahn, Jean-Yves Weisdorf, Daniel J. TI Providing Personalized Prognostic Information for Adult Leukemia Survivors SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Leukemia-free survival; Chronic graft-versus-host disease; Landmark analysis; Survivorship; Prognosis ID STEM-CELL TRANSPLANTATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; VERSUS-HOST-DISEASE; ACUTE MYELOGENOUS LEUKEMIA; 1ST COMPLETE REMISSION; CHRONIC GRAFT; MYELODYSPLASTIC SYNDROMES; POSTREMISSION THERAPY; DONOR AB Prediction of subsequent leukemia-free survival (LFS) and chronic graft-versus-host disease (GVHD) in adults with acute leukemia who survived at least 1 year after allogeneic hematopoietic cell transplantation is difficult. We analyzed 3339 patients with acute myeloid leukemia and 1434 patients with acute lymphoblastic leukemia who received myeloablative conditioning and related or unrelated stem cells from 1990 to 2005. Most clinical factors predictive of LFS in 1-year survivors were no longer significant after 2 or more years. For acute myeloid leukemia, only disease status (beyond first complete remission) remained a significant adverse risk factor for LFS 2 or more years after transplantation. For lymphoblastic leukemia, only extensive chronic GVHD remained a significant adverse predictor of LFS in the second and subsequent years. For patients surviving for 1 year without disease relapse or extensive chronic GVHD, the risk of developing extensive chronic GVHD in the next year was 4% if no risk factors were present and higher if noncyclosporine-based GVHD prophylaxis, an HLA-mismatched donor, or peripheral blood stem cells were used. Estimates for subsequent LFS and extensive chronic GVHD can be derived for individual patients or populations using an online calculator (http://www.cibmtr.org/LeukemiaCalculators). This prognostic information is more relevant for survivors than estimates provided before transplantation. (C) 2013 American Society for Blood and Marrow Transplantation. C1 [Lee, Stephanie J.; Storer, Barry] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Wang, Hailin] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. [Waller, Edmund K.; Khoury, H. Jean] Emory Univ Hosp, Bone Marrow & Stem Cell Transplant Ctr, Atlanta, GA 30322 USA. [Isola, Luis M.] Mt Sinai Med Ctr, Bone Marrow Transplant Program, New York, NY 10029 USA. [Klumpp, Thomas R.] Temple Univ, Bone Marrow Transplant Program, Philadelphia, PA 19122 USA. [Umejiego, John Bosco C.] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA. [Savani, Bipin N.] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Loren, Alison W.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Cairo, Mitchell S.] New York Med Coll, Maria Fareri Childrens Hosp, New York, NY USA. [Camitta, Bruce M.] Med Coll Wisconsin, Midwest Ctr Canc & Blood Disorders, Milwaukee, WI 53226 USA. [Camitta, Bruce M.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA. [Cutler, Corey S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [George, Biju] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India. [Marks, David I.] Bristol Childrens Hosp, Adult BMT Unit, Bristol, Avon, England. [Rizzieri, David A.] Duke Univ, Med Ctr, Durham, NC USA. [Copelan, Edward A.] Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA. [Gupta, Vikas] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada. [Liesveld, Jane L.] Univ Rochester, Med Ctr, Strong Mem Hosp, Rochester, NY 14642 USA. [Litzow, Mark R.] Mayo Clin Rochester, Rochester, MN USA. [Miller, Alan M.] Baylor Univ, Med Ctr, Dallas, TX USA. [Schouten, Harry C.] Acad Ziekenhuis Maastricht, Maastricht, Netherlands. [Gale, Robert Peter] Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Sect Haematol, London, England. [Cahn, Jean-Yves] Univ Hosp, Dept Hematol, Grenoble, France. [Weisdorf, Daniel J.] Univ Minnesota, Med Ctr, Bone Marrow Transplant Program, Minneapolis, MN 55455 USA. RP Lee, SJ (reprint author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,D5-290, Seattle, WA 98109 USA. EM sjlee@fhcrc.org RI Cahn, Jean-Yves/M-6493-2014 FU Public Health Service from the National Cancer Institute (NCI) [U24-CA76518]; National Heart, Lung and Blood Institute (NHLBI) [5U01HL069294]; National Institute of Allergy and Infectious Diseases; NCI; Health Resources and Services Administration [HHSH234200637015C]; Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]; Allos, Inc.; Amgen, Inc.; Angioblast FX The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration; 2 grants (N00014-06-1-0704 and N00014-08-1-0058) from the Office of Naval Research; and grants from Allos, Inc.; Amgen, Inc.; Angioblast; anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and Blue Shield Association; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children's Leukemia Research Association; Fresenius-Biotech North America, Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Genzyme Corporation; GlaxoSmithKline; HistoGenetics, Inc.; Kiadis Pharma; The Leukemia & Lymphoma Society; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; RemedyMD; Sanofi; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; Tarix Pharmaceuticals; Teva Neuroscience, Inc.; THERAKOS, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government. NR 28 TC 5 Z9 5 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD NOV PY 2013 VL 19 IS 11 BP 1600 EP 1607 DI 10.1016/j.bbmt.2013.08.013 PG 8 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 250KL UT WOS:000326851600011 PM 24018394 ER PT J AU Savic, RM Cowan, MJ Dvorak, CC Pai, SY Pereira, L Bartelink, IH Boelens, JJ Bredius, RGM Wynn, RF Cuvelier, GDE Shaw, PJ Slatter, MA Long-Boyle, J AF Savic, Radojka M. Cowan, Morton J. Dvorak, Christopher C. Pai, Sung-Yun Pereira, Luis Bartelink, Imke H. Boelens, Jaap J. Bredius, Robbert G. M. Wynn, Rob F. Cuvelier, Geoff D. E. Shaw, Peter J. Slatter, Mary A. Long-Boyle, Janel TI Effect of Weight and Maturation on Busulfan Clearance in Infants and Small Children Undergoing Hematopoietic Cell Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Busulfan; Hematopoietic cell transplantation; Pharmacokinetics; Pediatrics ID SEVERE COMBINED IMMUNODEFICIENCY; INTRAVENOUS BUSULFAN; PHARMACOKINETIC BEHAVIOR; PEDIATRIC-PATIENTS; YOUNG-CHILDREN; RECIPIENTS; AGE; PHARMACOGENETICS; DISPOSITION; DISEASE AB Little information is currently available regarding the pharmacokinetics (PK) of busulfan in infants and small children to help guide decisions for safe and efficacious drug therapy. The objective of this study was to develop an algorithm for individualized dosing of i.v. busulfan in infants and children weighing <= 12 kg, that would achieve targeted exposure with the first dose of busulfan. Population PK modeling was conducted using intensive time-concentration data collected through the routine therapeutic drug monitoring of busulfan in 149 patients from 8 centers. Busulfan PK was well described by a 1-compartment base model with linear elimination. The important clinical covariates affecting busulfan PK were actual body weight and age. Based on our model, the predicted clearance of busulfan increases approximately 1.7-fold between 6 weeks to 2 years of life. For infants age <5 months, the model-predicted doses (mg/kg) required to achieve a therapeutic concentration at steady state of 600-900 ng/mL (area under the curve range, 900-1350 mu M.min) were much lower compared with standard busulfan doses of 1.1 mg/kg. These results could help guide clinicians and inform better dosing decisions for busulfan in young infants and small children undergoing hematopoietic cell transplantation. (C) 2013 American Society for Blood and Marrow Transplantation. C1 [Savic, Radojka M.; Bartelink, Imke H.] Univ Calif San Francisco, Dept Bioengn & Therapeut, San Francisco, CA 94143 USA. [Cowan, Morton J.; Dvorak, Christopher C.] Univ Calif San Francisco, Dept Pediat, UCSF Benioff Childrens Hosp, San Francisco, CA 94143 USA. [Pai, Sung-Yun] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Pereira, Luis] Harvard Univ, Sch Med, Pharmacometr Res Core, Boston Childrens Hosp, Boston, MA USA. [Boelens, Jaap J.] Univ Med Ctr Utrecht, Pediat Blood & Marrow Transplantat Program, Utrecht, Netherlands. [Bredius, Robbert G. M.] Leiden Univ, Med Ctr, Dept Pediat, Leiden, Netherlands. [Wynn, Rob F.] Royal Manchester Childrens Hosp, Dept Blood & Marrow Transplant, Manchester M27 1HA, Lancs, England. [Cuvelier, Geoff D. E.] Univ Manitoba, Dept Pediat Hematol Oncol BMT, CancerCare Manitoba, Winnipeg, MB, Canada. [Shaw, Peter J.] Childrens Hosp Westmead, Dept Paediat & Child Hlth, Sydney, NSW, Australia. [Slatter, Mary A.] Newcastle Upon Tyne Hosp NHS Fdn Trust, Dept Paediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England. [Long-Boyle, Janel] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA. RP Long-Boyle, J (reprint author), Univ Calif San Francisco, Dept Clin Pharm, Sch Pharm, 521 Parnassus Ave,C-152,Box 0622, San Francisco, CA 94143 USA. EM long-boylej@pharmacy.ucsf.edu OI Boelens, Jaap Jan/0000-0003-2232-6952 FU National Institute of Allergies and Infectious Diseases [U54 AI082973, R13 AI094943] FX This work was supported in part by National Institute of Allergies and Infectious Diseases Grants U54 AI082973 (to M.J.C. and C.C.D.) and R13 AI094943 (to M.J.C.). NR 43 TC 17 Z9 17 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD NOV PY 2013 VL 19 IS 11 BP 1608 EP 1614 DI 10.1016/j.bbmt.2013.08.014 PG 7 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 250KL UT WOS:000326851600012 PM 24029650 ER PT J AU Costa, LJ Zhang, MJ Zhong, XB Dispenzieri, A Lonial, S Krishnan, A Freytes, C Vesole, D Gale, RP Anderson, K Wirk, B Savani, BN Waller, EK Schouten, H Lazarus, H Meehan, K Sharma, M Kamble, R Vij, R Kumar, S Nishihori, T Kindwall-Keller, T Saber, W Hari, PN AF Costa, Luciano J. Zhang, Mei-Jie Zhong, Xiaobo Dispenzieri, Angela Lonial, Sagar Krishnan, Amrita Freytes, Cesar Vesole, David Gale, Robert Peter Anderson, Kenneth Wirk, Baldeep Savani, Bipin N. Waller, Edmund K. Schouten, Harry Lazarus, Hillard Meehan, Kenneth Sharma, Manish Kamble, Rammurti Vij, Ravi Kumar, Shaji Nishihori, Taiga Kindwall-Keller, Tamila Saber, Wael Hari, Parameswaran N. TI Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Multiple myeloma; Autologous stem cell transplantation; Population study; Survival ID STEM-CELL TRANSPLANTATION; INTERNATIONAL STAGING SYSTEM; LONG-TERM SURVIVAL; CONSOLIDATION THERAPY; PLUS DEXAMETHASONE; RANDOMIZED PHASE-3; BORTEZOMIB; INDUCTION; TRIAL; THALIDOMIDE AB The impact of novel drugs for treating multiple myeloma (MM) on the utilization and outcomes of autologous hematopoietic progenitor cell transplantation (AHPCT) is unknown. We reviewed characteristics and outcomes of 20,278 patients who underwent AHPCT within 12 months of diagnosis of MM in the United States and Canada and registered at the Center for International Blood and Marrow Transplant Research (CIBMTR) in 3 time cohorts reflecting the increasing availability of novel drugs: 1995 to 1999 (n = 2226), 2000 to 2004 (n = 6408), and 2005 to 2010 (n = 11,644). In the United States, the number of AHPCTs performed increased at a greater rate than new MM cases. Patients in recent cohorts were older, less likely to have stage 3 MM, and more likely to have received previous thalidomide, lenalidomide, or bortezomib. On multivariate analysis, AHPCT in the 2000 to 2004 cohort (HR = 0.77) or in the 2005 to 2010 cohort (HR = 0.68) were associated with lower risk of death. Survival at 60 months post-AHPCT improved from 47% in 1995 to 1999 to 55% in 2000 to 2004 and to 57% in 2005 to 2010, owing less to improvement in progression-free survival (50% versus 55% versus 57% at 24 months) than to postrelapse/progression survival (58% versus 65% versus 72% at 24 months). AHPCT and new biological agents are complementary, nonredundant therapies and should be combined in the management of MM in suitable patients. (C) 2013 American Society for Blood and Marrow Transplantation. C1 [Costa, Luciano J.] Med Univ S Carolina, Dept Med, Charleston, SC 29414 USA. [Zhang, Mei-Jie; Zhong, Xiaobo; Saber, Wael; Hari, Parameswaran N.] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Dispenzieri, Angela; Kumar, Shaji] Mayo Clin, Div Hematol & Internal Med, Rochester, MN USA. [Lonial, Sagar; Waller, Edmund K.] Emory Univ Hosp, Div Hematol & Oncol, Atlanta, GA 30322 USA. [Krishnan, Amrita] City Hope Natl Med Ctr, Dept Hematol Oncol, Duarte, CA 91010 USA. [Freytes, Cesar] South Texas Hlth Care Syst, San Antonio, TX USA. [Freytes, Cesar] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Vesole, David] Hackensack Univ, Med Ctr, Multiple Myeloma Div, Hackensack, NJ USA. [Gale, Robert Peter] Univ London Imperial Coll Sci Technol & Med, Sect Hematol, London, England. [Anderson, Kenneth] Dana Farber Canc Inst, Boston, MA 02115 USA. [Wirk, Baldeep] Univ Florida, Dept Hematol Oncol, Gainesville, FL USA. [Savani, Bipin N.] Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Nashville, TN USA. [Schouten, Harry] Acad Ziekenhuis Maastricht, Maastricht, Netherlands. [Lazarus, Hillard] Univ Hosp Case Med Ctr, Dept Hematol & Oncol, Cleveland, OH USA. [Meehan, Kenneth] Dartmouth Hitchcock Med Ctr, Blood & Marrow Transplant Program, Lebanon, NH 03766 USA. [Sharma, Manish] Fox Chase Canc Ctr, Temple Bone Marrow Transplant Program, Philadelphia, PA 19111 USA. [Kamble, Rammurti] Baylor Coll Med, Dept Hematol Oncol, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. [Vij, Ravi] Barnes Jewish Hosp, Dept BMT & Leukemia, St Louis, MO 63110 USA. [Nishihori, Taiga] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL 33612 USA. [Kindwall-Keller, Tamila] Univ Virginia, Dept Hematol Oncol, Charlottesville, VA USA. RP Costa, LJ (reprint author), Med Univ S Carolina, 96 Jonathan Lucas St, Charleston, SC 29414 USA. EM costalj@musc.edu RI Kumar, Shaji/A-9853-2008; OI Kumar, Shaji/0000-0001-5392-9284; Hari, Parameswaran/0000-0002-8800-297X; Dispenzieri, Angela/0000-0001-8780-9512 FU Public Health Service from the National Cancer Institute (NCI) [U24-CA76518]; National Heart, Lung, and Blood Institute (NHLBI); National Institute of Allergy and Infectious Diseases (NIAID); NHLBI; NCI [5U01HL069294]; Health Resources and Services Administration (HRSA/DHHS) [HHSH234200637015C]; Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]; AABB; Allos Inc; Amgen Inc FX The CIBMTR is supported by the Public Health Service (grant/cooperative agreement U24-CA76518) from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); NHLBI and NCI (grant/cooperative agreement 5U01HL069294); Health Resources and Services Administration (HRSA/DHHS; contract HHSH234200637015C); the Office of Naval Research (grants N00014-06-1-0704 and N00014-08-1-0058); and by grants from AABB; Allos Inc; Amgen Inc; anonymous donation to the Medical College of Wisconsin; Astellas Pharma US Inc; Be the Match Foundation; Biogen IDEC; BioMarin Pharmaceutical Inc; Biovitrum AB; Blood Center of Wisconsin; Blue Cross and Blue Shield Association; Bone Marrow Foundation; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix GmbH; Children's Leukemia Research Association; ClinImmune Labs; CTI Clinical Trial and Consulting Services; Eisai Inc; Genentech Inc; Genzyme Corporation; Histogenetics Inc; HKS Medical Information Systems; Hospira Inc.; Kirin Brewery Co Ltd; The Leukemia & Lymphoma Society; Merck & Company; The Medical College of Wisconsin; Millennium Pharmaceuticals Inc; Miller Pharmacal Group; Milliman USA Inc; Miltenyi Biotec Inc; National Marrow Donor Program; Nature Publishing Group; Novartis Oncology; Oncology Nursing Society; Osiris Therapeutics Inc; Otsuka America Pharmaceutical Inc; Pall Life Sciences; Pfizer Inc; Schering Corporation; Sigma-Tau Pharmaceuticals; Soligenix Inc; StemCyte Inc; Stem Soft Software Inc; Sysmex America Inc; THERAKOS Inc; Vidacare Corporation; ViraCor Laboratories; ViroPharma Inc; and Wellpoint Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the US government. NR 34 TC 35 Z9 35 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD NOV PY 2013 VL 19 IS 11 BP 1615 EP 1624 DI 10.1016/j.bbmt.2013.08.002 PG 10 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 250KL UT WOS:000326851600013 PM 23939198 ER PT J AU Wood, WA Chai, X Weisdorf, D Martin, PJ Cutler, C Inamoto, Y Wolff, D Pavletic, SZ Pidala, J Palmer, JM Arora, M Arai, S Jagasia, M Storer, B Lee, SJ Mitchell, S AF Wood, W. A. Chai, X. Weisdorf, D. Martin, P. J. Cutler, C. Inamoto, Y. Wolff, D. Pavletic, S. Z. Pidala, J. Palmer, J. M. Arora, M. Arai, S. Jagasia, M. Storer, B. Lee, S. J. Mitchell, S. TI Comorbidity burden in patients with chronic GVHD SO BONE MARROW TRANSPLANTATION LA English DT Article DE chronic GVHD; comorbidities; outcomes; allogeneic hematopoietic cell transplantation ID HEMATOPOIETIC-CELL TRANSPLANTATION; VERSUS-HOST-DISEASE; REPORTED OUTCOMES; REDUCED-INTENSITY; PHYSICAL FUNCTION; INDEX; LYMPHOMA; MORTALITY; SEVERITY; LEUKEMIA AB Chronic GVHD (cGVHD) is associated with mortality, disability and impaired quality of life. Understanding the role of comorbidity in patients with cGVHD is important both for prognostication and potentially for tailoring treatments based on mortality risks. In a prospective cohort study of patients with cGVHD (n = 239), we examined the performance of two comorbidity scales, the Functional Comorbidity Index (FCI) and the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI). Both scales detected a higher number of comorbidities at cGVHD cohort enrollment than pre-hematopoietic cell transplant (HCT) (P<0.001). Higher HCT-CI scores at the time of cGVHD cohort enrollment were associated with higher non-relapse mortality (HR: 1.21:1.04-1.42, P = 0.01). For overall mortality, we detected an interaction with platelet count. Higher HCT-CI scores at enrollment were associated with an increased risk of overall mortality when the platelet count was <= 100 000/mu L (HR: 2.01:1.20-3.35, P = 0.01), but not when it was >100 000/mu L (HR: 1.05:0.90-1.22, P = 0.53). Comorbidity scoring may help better to predict survival outcomes in patients with cGVHD. Further studies to understand vulnerability unrelated to cGVHD activity in this patient population are needed. C1 [Wood, W. A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Chai, X.; Martin, P. J.; Inamoto, Y.; Storer, B.; Lee, S. J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Weisdorf, D.; Arora, M.] Univ Minnesota, Blood & Marrow Transplant Program, Minneapolis, MN USA. [Cutler, C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Wolff, D.] Univ Regensburg, Dept Hematol & Clin Oncol, D-93053 Regensburg, Germany. [Pavletic, S. Z.; Mitchell, S.] NCI, NIH, Bethesda, MD 20892 USA. [Pidala, J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Palmer, J. M.] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA. [Arai, S.] Stanford Univ, Med Ctr, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA. [Jagasia, M.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. RP Wood, WA (reprint author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Phys Off Bldg,170 Manning Dr, Chapel Hill, NC 27599 USA. EM wawood@med.unc.edu OI Wood, William/0000-0001-7439-2543 FU National Institutes of Health/National Cancer Institute [CA 118953, KL2TR000084] FX This work was supported by National Institutes of Health/National Cancer Institute grant CA 118953 as well as grant KL2TR000084. NR 22 TC 8 Z9 8 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 EI 1476-5365 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD NOV PY 2013 VL 48 IS 11 BP 1429 EP 1436 DI 10.1038/bmt.2013.70 PG 8 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 250WR UT WOS:000326887900010 PM 23665819 ER PT J AU Lin, NU Freedman, RA Ramakrishna, N Younger, J Storniolo, AM Bellon, JR Come, SE Gelman, RS Harris, GJ Henderson, MA MacDonald, SM Mahadevan, A Eisenberg, E Ligibel, JA Mayer, EL Moy, B Eichler, AF Winer, EP AF Lin, Nancy U. Freedman, Rachel A. Ramakrishna, Naren Younger, Jerry Storniolo, Anna Maria Bellon, Jennifer R. Come, Steven E. Gelman, Rebecca S. Harris, Gordon J. Henderson, Mark A. MacDonald, Shannon M. Mahadevan, Anand Eisenberg, Emily Ligibel, Jennifer A. Mayer, Erica L. Moy, Beverly Eichler, April F. Winer, Eric P. TI A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Breast cancer; Brain metastases; Lapatinib; Whole brain radiotherapy ID MINI-MENTAL STATE; NERVOUS-SYSTEM METASTASES; PLUS CAPECITABINE; TRASTUZUMAB; COMBINATION; SURVIVAL; RADIOSENSITIZATION; CARCINOMA; OUTGROWTH; GW572016 AB Brain metastases are common in patients with advanced, Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer. We evaluated the maximum tolerated dose (MTD) and feasibility of lapatinib given concurrently with whole brain radiotherapy (WBRT). Eligible patients had (HER2)-positive breast cancer and a parts per thousand yen1 brain metastasis. Patients received lapatinib 750 mg twice on day one followed by 1000, 1250, or 1500 mg once daily. WBRT (37.5 Gy, 15 fractions) began 1-8 days after starting lapatinib. Lapatinib was continued through WBRT. Following WBRT, patients received trastuzumab 2 mg/kg weekly and lapatinib 1000 mg once daily. The regimen would be considered feasible if < 3/27 pts treated at the MTD experienced a dose-limiting toxicity (DLT). Thirty-five patients were enrolled; 17 % had central nervous disease (CNS) only. During dose escalation, no patients receiving 1,000 or 1,250 mg and two of five patients receiving 1,500 mg experienced DLTs (grade 3 mucositis and rash). Overall, 7/27 patients at 1,250 mg (MTD) had DLTs: grade 3 rash (n = 2), diarrhea (n = 2), hypoxia (n = 1), and grade 4 pulmonary embolus (n = 2). Among 28 evaluable patients, the CNS objective response rate (ORR) was 79 % [95% confidence interval (CI) 59-92 %] by pre-specified volumetric criteria; 46 % remained progression-free (CNS or non-CNS) at 6 months. The study did not meet the pre-defined criteria for feasibility because of toxicity, although the relationship between study treatment and some DLTs was uncertain. Given the high ORR, concurrent lapatinib-WBRT could still be considered for future study with careful safety monitoring. C1 [Lin, Nancy U.; Freedman, Rachel A.; Gelman, Rebecca S.; Eisenberg, Emily; Ligibel, Jennifer A.; Mayer, Erica L.; Winer, Eric P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Ramakrishna, Naren] MD Anderson Canc Ctr Orlando, Orlando, FL USA. [Younger, Jerry; MacDonald, Shannon M.; Moy, Beverly; Eichler, April F.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Storniolo, Anna Maria; Henderson, Mark A.] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA. [Bellon, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bellon, Jennifer R.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Come, Steven E.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Harris, Gordon J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mahadevan, Anand] Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA. RP Freedman, RA (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA. EM nlin@partners.org; rafreedman@partners.org; Naren.Ramakrishna@orlandohealth.com; jyounger@partners.org; astornio@iupui.edu; jbellon@partners.org; scome@bidmc.harvard.edu; gelman@jimmy.harvard.edu; gjharris@partners.org; mahender@iupui.edu; smacdonald@partners.org; amahadev@bidmc.harvard.edu; eeisenberg@partners.org; jligibel@partners.org; emayer@partners.org; bmoy@partners.org; aeichler@partners.org; ewiner@partners.org FU American Society of Clinical Oncology Career Development Award; Breast Cancer Research Foundation; Nancy and Randy Berry Junior Faculty Award; Dana-Farber/Harvard Cancer Center [CA006516]; GlaxoSmithKline FX The authors thank all of the patients who participated on this study and who shared their quality of life experiences. In addition, we thank Trinity Urban and the DF/HCC Tumor Imaging Metrics Core (www.tumormetrics.org) for their assistance in central radiology review. We acknowledge the following grant support: American Society of Clinical Oncology Career Development Award, Breast Cancer Research Foundation [NL], the Nancy and Randy Berry Junior Faculty Award [NL], and the Dana-Farber/Harvard Cancer Center Grant CA006516, GlaxoSmithKline. NR 31 TC 16 Z9 17 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 EI 1573-7217 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD NOV PY 2013 VL 142 IS 2 BP 405 EP 414 DI 10.1007/s10549-013-2754-0 PG 10 WC Oncology SC Oncology GA 253JB UT WOS:000327079800015 PM 24197661 ER PT J AU Pagani, O Gelber, S Colleoni, M Price, KN Simoncini, E AF Pagani, Olivia Gelber, Shari Colleoni, Marco Price, Karen N. Simoncini, Edda TI Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93 SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Breast cancer; Treatment adherence; Tamoxifen; Toremifene; Selective estrogen receptor modulators; Endocrine treatment ID ADJUVANT ENDOCRINE THERAPY; PATIENT ADHERENCE; DRUG-THERAPY; EARLY DISCONTINUATION; AROMATASE INHIBITORS; TAMOXIFEN THERAPY; OLDER WOMEN; NONADHERENCE; MEDICATION; PREDICTORS AB The degree of adherence to oral anticancer agents may influence treatment efficacy. Tamoxifen and toremifene usage data from two International Breast Cancer Study Group (IBCSG) studies were used to evaluate the impact of treatment adherence on the efficacy of these two selective estrogen receptor modulators (SERMs). Between 1993 and 1999, IBCSG Trial 13-93 randomized premenopausal women with node-positive disease to tamoxifen or no endocrine therapy and IBCSG Trial 14-93 compared tamoxifen and toremifene in postmenopausal women with node-positive disease. 690 women with estrogen-receptor positive enrolled in these two trials were alive and disease-free 4 years after the start of SERM. The median follow up for this analysis was 9.0 years. Using a Kaplan-Meier landmark analysis at 4 years, the 609 women completing at least 4 years of SERM had improved 10-year disease-free survival (DFS) (71 %) compared with the 81 women taking less than 4 years (64 %), but these differences did not reach statistical significance [DFS hazard ratio (< 4 year/4+ year) 1.31, 95 % CI 0.86-1.98), p value = 0.20]. Women who completed less than 4 years of SERM treatment (12 %) appeared not to have achieved the full benefit from their therapy. These results suggest that more effort should be made to educate women regarding the benefits of a full course of treatment. This is especially important in light of the results of the recently reported ATLAS and aTTom trials which suggest a benefit of 10 years of tamoxifen. C1 [Pagani, Olivia] Osped San Giovanni Bellinzona, Inst Oncol Southern Switzerland, CH-6500 Bellinzona, Switzerland. [Pagani, Olivia] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland. [Gelber, Shari; Price, Karen N.] Dana Farber Canc Inst, Int Breast Canc Study Grp Stat Ctr, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Colleoni, Marco] European Inst Oncol, Div Med Senol, Milan, Italy. [Simoncini, Edda] Spedali Civil Brescia, Breast Unit, I-25125 Brescia, Italy. RP Pagani, O (reprint author), Osped San Giovanni Bellinzona, Inst Oncol Southern Switzerland, CH-6500 Bellinzona, Switzerland. EM Olivia.Pagani@ibcsg.org; price@jimmy.harvard.edu FU International Breast Cancer Study Group (IBCSG); Swedish Cancer Society; Cancer Council Australia; Australia and New Zealand Breast Cancer Trials Group (National Health and Medical Research Council); Frontier Science and Technology Research Foundation; Swiss Group for Clinical Cancer Research (SAKK); Swiss Cancer League; United States National Institutes of Health [CA-75362] FX We thank the patients, physicians, nurses, and data managers who participate in the International Breast Cancer Study Group trials. This work was partially funded by the International Breast Cancer Study Group (IBCSG), which receives funding from the Swedish Cancer Society; The Cancer Council Australia; Australia and New Zealand Breast Cancer Trials Group (National Health and Medical Research Council); the Frontier Science and Technology Research Foundation; the Swiss Group for Clinical Cancer Research (SAKK); the Swiss Cancer League; and the United States National Institutes of Health (CA-75362). NR 32 TC 6 Z9 7 U1 1 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 EI 1573-7217 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD NOV PY 2013 VL 142 IS 2 BP 455 EP 459 DI 10.1007/s10549-013-2757-x PG 5 WC Oncology SC Oncology GA 253JB UT WOS:000327079800020 PM 24197662 ER PT J AU Magill, SS Klompas, M Balk, R Burns, SM Deutschman, CS Diekema, D Fridkin, S Greene, L Guh, A Gutterman, D Hammer, B Henderson, D Hess, DR Hill, NS Horan, T Kollef, M Levy, M Septimus, E VanAntwerpen, C Wright, D Lipsett, P AF Magill, Shelley S. Klompas, Michael Balk, Robert Burns, Suzanne M. Deutschman, Clifford S. Diekema, Daniel Fridkin, Scott Greene, Linda Guh, Alice Gutterman, David Hammer, Beth Henderson, David Hess, Dean R. Hill, Nicholas S. Horan, Teresa Kollef, Marin Levy, Mitchell Septimus, Edward VanAntwerpen, Carole Wright, Don Lipsett, Pamela TI Developing a New, National Approach to Surveillance for Ventilator-Associated Events Executive Summary SO CHEST LA English DT Article C1 [Fridkin, Scott; Guh, Alice; Horan, Teresa] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA. [Klompas, Michael] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Klompas, Michael] Brigham & Womens Hosp, Infect Control Dept, Boston, MA 02115 USA. [Klompas, Michael] Soc Healthcare Epidemiol Amer, Arlington, VA USA. [Balk, Robert] Rush Univ, Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA. [Balk, Robert; Burns, Suzanne M.; Deutschman, Clifford S.; Gutterman, David; Hammer, Beth; Hill, Nicholas S.; Kollef, Marin; Levy, Mitchell; Lipsett, Pamela] Amer Thorac Soc, Soc Crit Care Med, Crit Care Soc Collaborat Amer Assoc Crit Care Nur, Amer Coll Chest Phys, Philadelphia, PA USA. [Burns, Suzanne M.] Univ Virginia, Sch Nursing Crit & Acute Care, Charlottesville, VA USA. [Deutschman, Clifford S.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA. [Diekema, Daniel] Univ Iowa, Carver Coll Med, Div Infect Dis, Iowa City, IA USA. [Diekema, Daniel] Healthcare Infect Control Practices Advisory Comm, Surveillance Working Grp, Atlanta, GA USA. [Greene, Linda] Rochester Gen Hlth Syst, Infect Prevent & Control Dept, Rochester, NY USA. [Greene, Linda] Assoc Professionals Infect Control & Epidemiol, Washington, DC USA. [Gutterman, David] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA. [Hammer, Beth] Zablocki VA Med Ctr, Dept Cardiol, Milwaukee, WI USA. [Henderson, David] NIH, Hosp Epidemiol & Qual Improvement, Ctr Clin, Bethesda, MD 20892 USA. [Hess, Dean R.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA. [Hess, Dean R.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA USA. [Hess, Dean R.] Amer Assoc Resp Care, Irving, TX USA. [Hill, Nicholas S.] Tufts Med Ctr, Div Pulm & Crit Care Med, Boston, MA USA. [Kollef, Marin] Washington Univ, Div Pulm & Crit Care Med, St Louis, MO USA. [Levy, Mitchell] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Pulm Crit Care & Sleep, Providence, RI 02903 USA. [Septimus, Edward] Texas A&M Hlth Sci Ctr, Dept Internal Med, College Stn, TX USA. [Septimus, Edward] Infect Dis Soc Amer, Arlington, VA USA. [VanAntwerpen, Carole] New York State Dept Hlth, Bur Healthcare Associated Infect, Albany, NY USA. [VanAntwerpen, Carole] Council State & Territorial Epidemiologists, Atlanta, GA USA. [Wright, Don] US Dept Hlth & Human Serv, Off Dis Prevent & Hlth Promot, Washington, DC USA. [Lipsett, Pamela] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA. RP Magill, SS (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-24, Atlanta, GA 30329 USA. EM smagill@cdc.gov OI Diekema, Daniel/0000-0003-1273-0724 NR 2 TC 6 Z9 6 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD NOV PY 2013 VL 144 IS 5 BP 1448 EP 1452 DI 10.1378/chest.13-1640 PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 254DI UT WOS:000327143700010 PM 24189858 ER PT J AU Rubin, E Courtwright, A AF Rubin, Emily Courtwright, Andrew TI Medical Futility Procedures What More Do We Need to Know? SO CHEST LA English DT Article ID TEXAS ADVANCE DIRECTIVES; LIFE-SUSTAINING TREATMENT; PRECAUTIONARY PRINCIPLE; ETHICS CONSULTATION; CARE; END; EXPERIENCE; DECISIONS; RESOLUTION; HOSPITALS AB Unilateral medical futility policies, which allow health-care providers to limit or withdraw life-sustaining treatment over patient or surrogate objections, are increasingly designed around a procedural approach. Medical or ethics committees follow a prespecified process, the culmination of which is a justified decision about whether ongoing treatment should be withheld or withdrawn. These procedures have three stages. First, health-care providers must decide to refer patients for consideration of whether ongoing treatment is futile. Second, the committees involved must decide whether ongoing treatment is actually futile. Third, there is a clinical outcome that often is, but not always, patient death. We review the available data on procedure-based futility policies, arguing that there is limited information on their potential harms and how these harms are distributed. We consider the ethical implications of policy-making under informational uncertainty, invoking the precautionary principle-in the absence of clear data, if a policy has significant risk of significant harm, the burden of proof that it is not harmful falls on those recommending the policy-as the guiding moral standard for hospitals and professional organizations considering whether to adopt a procedural approach to medical futility. On the basis of this principle, we argue that any new futility guideline must include a significant commitment to collecting prospective data on its application. C1 [Rubin, Emily] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA. [Rubin, Emily] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Courtwright, Andrew] Massachusetts Gen Hosp, Inst Patient Care, Boston, MA 02114 USA. [Courtwright, Andrew] Brigham & Womens Hosp, Dept Pulm & Crit Care Med, Boston, MA 02115 USA. RP Courtwright, A (reprint author), Massachusetts Gen Hosp, Inst Patient Care, Founders House,3rd Floor,55 Fruit St, Boston, MA 02114 USA. EM acourtwright@partners.org NR 29 TC 6 Z9 6 U1 2 U2 6 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD NOV PY 2013 VL 144 IS 5 BP 1707 EP 1711 DI 10.1378/chest.13-1240 PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 254DI UT WOS:000327143700042 PM 24189864 ER PT J AU Rice, MB Bernstein, AS AF Rice, Mary B. Bernstein, Aaron S. TI Climate Change, Air Pollution, and COPD Outcomes Too Many Factors to Be Considered, Even Barometric Pressure! Response SO CHEST LA English DT Letter C1 [Rice, Mary B.] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA. [Bernstein, Aaron S.] Harvard Univ, Sch Publ Hlth, Ctr Hlth & Global Environm, Cambridge, MA 02138 USA. [Bernstein, Aaron S.] Boston Childrens Hosp, Div Gen Med, Boston, MA USA. RP Rice, MB (reprint author), Massachusetts Gen Hosp, Pulm & Crit Care Unit, Bullfinch 148,55 Fruit St, Boston, MA 02114 USA. EM mrice2@partners.org NR 4 TC 0 Z9 0 U1 0 U2 7 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD NOV PY 2013 VL 144 IS 5 BP 1732 EP 1732 DI 10.1378/chest.13-1692 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 254DI UT WOS:000327143700048 PM 24189871 ER PT J AU Kabrhel, C Jaff, MR Channick, RN Baker, JN Rosenfi, K AF Kabrhel, Christopher Jaff, Michael R. Channick, Richard N. Baker, Joshua N. Rosenfi, Kenneth TI A Multidisciplinary Pulmonary Embolism Response Team SO CHEST LA English DT Letter C1 [Kabrhel, Christopher] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA. [Jaff, Michael R.; Rosenfi, Kenneth] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol & Vasc Med, Boston, MA USA. [Channick, Richard N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Pulm Crit Care,Dept Med, Boston, MA USA. [Baker, Joshua N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Div Cardiac Surg, Boston, MA 02115 USA. RP Kabrhel, C (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 0 Emerson Pl,Ste 3B, Boston, MA 02114 USA. EM ckabrhel@partners.org OI Kabrhel, Christopher/0000-0002-8699-7176 NR 4 TC 11 Z9 11 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD NOV PY 2013 VL 144 IS 5 BP 1738 EP 1739 DI 10.1378/chest.13-1562 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 254DI UT WOS:000327143700057 PM 24189880 ER PT J AU Nunes, MCP Hung, J Barbosa, MM Esteves, WA Carvalho, VT Lodi-Junqueira, L Neto, CPF Tan, TC Levine, RA AF Nunes, Maria Carmo P. Hung, Judy Barbosa, Marcia M. Esteves, William A. Carvalho, Vinicius T. Lodi-Junqueira, Lucas Fonseca Neto, Cirilo P. Tan, Timothy C. Levine, Robert A. TI Impact of Net Atrioventricular Compliance on Clinical Outcome in Mitral Stenosis SO CIRCULATION-CARDIOVASCULAR IMAGING LA English DT Article DE compliance; hypertension; pulmonary; mitral valve stenosis; outcome assessment (health care) ID PRESSURE HALF-TIME; LEFT ATRIAL COMPLIANCE; HEART-DISEASE; PULMONARY-HYPERTENSION; EXERCISE CAPACITY; VALVE AREA; ECHOCARDIOGRAPHY; FLOW; VELOCITY; MODERATE AB Background Net atrioventricular compliance (C-n) has been reported to be an important determinant of pulmonary hypertension in mitral stenosis (MS). We hypothesized that it may be useful in assessing prognosis because C-n reflects hemodynamic consequences of MS. To date, limited data with an assumed C-n cutoff have indicated the need for larger prospective studies. This prospective study was designed to determine the impact of C-n on clinical outcome and its contribution to pulmonary pressure in MS. In addition, we aimed to identify a cutoff value of C-n for outcome prediction in this setting. Methods and Results A total of 128 patients with rheumatic MS without other significant valve disease were prospectively enrolled. Comprehensive echocardiography was performed and Doppler-derived C-n estimated using a previously validated equation. The end point was either mitral valve intervention or death. C-n was an important predictor of pulmonary pressure, regardless of classic measures of MS severity. During a median follow-up of 22 months, the end point was reached in 45 patients (35%). Baseline C-n predicted outcome, adding prognostic information beyond that provided by mitral valve area and functional status. C-n 4 mL/mm Hg best predicted unfavorable outcome in derivation and validation sets. A subgroup analysis including only initially asymptomatic patients with moderate to severe MS without initial indication for intervention (40.6% of total) demonstrated that baseline C-n predicted subsequent adverse outcome even after adjustment for classic measures of hemodynamic MS severity (hazard ratio, 0.33; 95% confidence interval, 0.14-0.79; P=0.013). Conclusions C-n contributes to pulmonary hypertension beyond stenosis severity itself. In a wide spectrum of MS severity, C-n is a powerful predictor of adverse outcome, adding prognostic value to clinical data and mitral valve area. Importantly, baseline C-n predicts a progressive course with subsequent need for intervention in initially asymptomatic patients. C-n assessment therefore has potential value for clinical risk stratification and monitoring in MS patients. C1 [Nunes, Maria Carmo P.; Barbosa, Marcia M.; Esteves, William A.; Carvalho, Vinicius T.; Lodi-Junqueira, Lucas; Fonseca Neto, Cirilo P.] Univ Fed Minas Gerais, Sch Med, BR-30130100 Belo Horizonte, MG, Brazil. [Nunes, Maria Carmo P.; Hung, Judy; Tan, Timothy C.; Levine, Robert A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Ultrasound Lab, Boston, MA USA. RP Nunes, MCP (reprint author), Univ Fed Minas Gerais, Sch Med, Dept Internal Med, Av Prof Alfredo Balena 190, BR-30130100 Belo Horizonte, MG, Brazil. EM mcarmo@waymail.com.br FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Brasilia, Brazil); National Institutes of Health/National Heart, Lung, and Blood Institute [R01 HL092101, K24 HL67434, R01 HL109506]; Leducq Transatlantic Mitral Network (Paris, France) FX This study was partly supported by grants from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (Brasilia, Brazil); by National Institutes of Health/National Heart, Lung, and Blood Institute grants R01 HL092101 (J. Hung), K24 HL67434, and R01 HL109506 (R.A. Levine); and by the Leducq Transatlantic Mitral Network (Paris, France; R.A. Levine). NR 35 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-9651 EI 1942-0080 J9 CIRC-CARDIOVASC IMAG JI Circ.-Cardiovasc. Imaging PD NOV PY 2013 VL 6 IS 6 BP 1001 EP 1008 DI 10.1161/CIRCIMAGING.112.000328 PG 8 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 253UI UT WOS:000327114400027 PM 24097419 ER PT J AU Karaosmanoglu, AD Butros, SR Scott, J Blake, MA AF Karaosmanoglu, Ali D. Butros, Selim R. Scott, James Blake, Michael A. TI PET and PET-CT imaging findings of peritoneal and omental involvement in patients with lymphoma SO CLINICAL IMAGING LA English DT Article DE PET-CT; CT; Lymphoma; Peritoneum; Omentum ID CARCINOMATOSIS; PITFALLS AB A retrospective institutional-review-board-approved study was performed evaluating positron emission tomography (PET)-computed tomography (CT) imaging findings of peritoneal and omental involvement of lymphoma. Twelve patients were identified with a wide spectrum of imaging findings on PET-CT including but not limited to peritoneal thickening, ascites, and serosal involvement. Lymphoma is among the rare causes of malignant peritoneal or omental involvement. The most common manifestations of peritoneal lymphomatosis are peritoneal 2-[fluorine 18] fluoro-2-deoxy-n-glucose uptake with corresponding peritoneal thickening and nonobstructive serosal masses on CT. (C) 2013 Elsevier Inc. All rights reserved. C1 [Karaosmanoglu, Ali D.; Butros, Selim R.; Blake, Michael A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Div Abdominal Imaging & Intervent, Boston, MA 02114 USA. [Scott, James] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Div Nucl Med, Boston, MA 02114 USA. RP Butros, SR (reprint author), Massachussetts Gen Hosp, Dept Radiol, Div Abdominal Imaging & Intervent, 55 Fruit St, Boston, MA 02114 USA. EM sbutros@partners.org RI Karaosmanoglu, Ali/D-8624-2015 OI Karaosmanoglu, Ali/0000-0003-0027-9593 NR 14 TC 2 Z9 2 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0899-7071 EI 1873-4499 J9 CLIN IMAG JI Clin. Imaging PD NOV-DEC PY 2013 VL 37 IS 6 BP 1089 EP 1093 DI 10.1016/j.clinimag.2013.07.002 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 250NE UT WOS:000326858700019 PM 23938141 ER PT J AU Taneja, AK Neto, LP Skaf, A AF Taneja, Atul Kumar Pecci Neto, Luis Skaf, Abdalla TI Bilateral anterior glenohumeral dislocation and coracoid processes fracture after seizure: acute MRI findings of this rare association SO CLINICAL IMAGING LA English DT Article DE Shoulder dislocation; Coracoid process; Fracture; Seizure; MRI ID SHOULDER DISLOCATION; INSTABILITY AB We report a rare case of bilateral anterior shoulder dislocation associated with coracoid processes fracture after a seizure episode in a 37-year-old woman. This combination of findings is rare, especially by the presence of bilateral coracoid processes fracture. Possible mechanisms related are direct trauma of humeral heads over the coracoid processes or sudden pull of biceps short head attachment site during uncontrolled contractures. Few reports published similar combination of injuries, and to our knowledge, this is the first to demonstrate its acute features by magnetic resonance imaging. A review of the literature is also presented. (C) 2013 Elsevier Inc. All rights reserved. C1 [Taneja, Atul Kumar; Pecci Neto, Luis; Skaf, Abdalla] Hosp Coracao HCor, Dept Radiol Musculoesquelet, Sao Paulo, Brazil. [Taneja, Atul Kumar; Pecci Neto, Luis; Skaf, Abdalla] Teleimagem, Sao Paulo, Brazil. [Taneja, Atul Kumar] Massachusetts Gen Hosp, Musculoskeletal Imaging & Intervent Div, Boston, MA 02114 USA. [Taneja, Atul Kumar] Harvard Univ, Sch Med, Boston, MA USA. [Pecci Neto, Luis; Skaf, Abdalla] Alta Diagnost, Sao Paulo, Brazil. RP Taneja, AK (reprint author), Hosp Coracao HCor, Dept Radiol Musculoesquelet, Rua Desembargador Eliseu Guilherme, Sao Paulo, Brazil. EM tanejamsk@gmail.com RI Taneja, Atul/N-3133-2014 OI Taneja, Atul/0000-0002-4655-2033 NR 7 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0899-7071 EI 1873-4499 J9 CLIN IMAG JI Clin. Imaging PD NOV-DEC PY 2013 VL 37 IS 6 BP 1131 EP 1134 DI 10.1016/j.clinimag.2013.08.007 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 250NE UT WOS:000326858700029 PM 24050938 ER PT J AU Rigotti, NA Clair, C AF Rigotti, Nancy A. Clair, Carole TI Managing tobacco use: the neglected cardiovascular disease risk factor SO EUROPEAN HEART JOURNAL LA English DT Review DE Tobacco use; Cigarette smoking; Secondhand smoke exposure; Cardiovascular disease; Coronary heart disease; Prevention; Treatment ID CORONARY-HEART-DISEASE; SUSTAINED-RELEASE BUPROPION; RANDOMIZED CONTROLLED-TRIAL; ACUTE MYOCARDIAL-INFARCTION; CURRENT CIGARETTE-SMOKING; RECEPTOR PARTIAL AGONIST; UNITED-STATES; TRANSDERMAL NICOTINE; REDUCES MORTALITY; OXIDATIVE STRESS AB Cigarette smoking is a major risk factor for cardiovascular disease (CVD) and the leading avoidable cause of death worldwide. Exposure to secondhand smoke (SHS) increases the risk of CVD among non-smokers. Smoking cessation benefits all smokers, regardless of age or amount smoked. The excess risk of CVD is rapidly reversible, and stopping smoking after a myocardial infarction reduces an individuals risk of CVD mortality by 36 over 2 years. Smoking cessation is a key component of primary and secondary CVD prevention strategies, but tobacco use often receives less attention from cardiologists than other risk factors, despite the availability of proven treatments that improve smoking cessation rates. Both psychosocial counselling and pharmacotherapy are effective methods to help smokers quit, but they are most effective when used together. The first-line medications licensed to aid smoking cessation, nicotine replacement therapy, bupropion and varenicline, are effective in and appropriate for patients with CVD. An evidence-based approach for physicians is to routinely ask all patients about smoking status and SHS exposure, advise all smokers to quit and all patients to adopt smoke-free policies for their home and car, and offer all smokers in the office or hospital brief counselling, smoking cessation pharmacotherapy, and referral to local programmes where psychosocial support can be sustained in person or by telephone. Like other chronic diseases, tobacco use requires a long-term management strategy. It deserves to be managed as intensively as other CVD risk factors. C1 [Rigotti, Nancy A.] Harvard Univ, Sch Med, Div Gen Med, Boston, MA 02115 USA. [Rigotti, Nancy A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Tobacco Res & Treatment Ctr, Boston, MA USA. [Clair, Carole] Univ Lausanne, Dept Ambulatory Care & Community Med, Lausanne, Switzerland. RP Rigotti, NA (reprint author), Harvard Univ, Sch Med, Div Gen Med, 50 Staniford St,9th Floor, Boston, MA 02115 USA. EM nrigotti@partners.org RI Clair, Carole/D-9786-2014 OI Clair, Carole/0000-0001-5281-0943 FU Pfizer FX N.A.R. reported having consulted without pay about smoking cessation for Pfizer and Allere Wellbeing, Inc. and having conducted research projects sponsored by Pfizer. NR 94 TC 24 Z9 26 U1 2 U2 22 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0195-668X EI 1522-9645 J9 EUR HEART J JI Eur. Heart J. PD NOV PY 2013 VL 34 IS 42 BP 3259 EP 3267 DI 10.1093/eurheartj/eht352 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 251XL UT WOS:000326967200008 PM 24014389 ER PT J AU Berg, JS Amendola, LM Eng, C Van Allen, E Gray, SW Wagle, N Rehm, HL DeChene, ET Dulik, MC Hisama, FM Burke, W Spinner, NB Garraway, L Green, RC Plon, S Evans, JP Jarvik, GP AF Berg, Jonathan S. Amendola, Laura M. Eng, Christine Van Allen, Eliezer Gray, Stacy W. Wagle, Nikhil Rehm, Heidi L. DeChene, Elizabeth T. Dulik, Matthew C. Hisama, Fuki M. Burke, Wylie Spinner, Nancy B. Garraway, Levi Green, Robert C. Plon, Sharon Evans, James P. Jarvik, Gail P. CA CSER Actionability Return Results TI Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium SO GENETICS IN MEDICINE LA English DT Article DE actionability; actionable genes; clinical sequencing; genomic medicine; incidental findings ID MEDICINE; RETURN AB As genomic and exomic testing expands in both the research and clinical arenas, determining whether, how, and which incidental findings to return to the ordering clinician and patient becomes increasingly important. Although opinion is varied on what should be returned to consenting patients or research participants, most experts agree that return of medically actionable results should be considered. There is insufficient evidence to fully inform evidencebased clinical practice guidelines regarding return of results from genome-scale sequencing, and thus generation of such evidence is imperative, given the rapidity with which genome-scale diagnostic tests are being incorporated into clinical care. We present an overview of the approaches to incidental findings by members of the Clinical Sequencing Exploratory Research network, funded by the National Human Genome Research Institute, to generate discussion of these approaches by the clinical genomics community We also report specific lists of "medically actionable" genes that have been generated by a subset of investigators in order to explore what types of findings have been included or excluded in various contexts. A discussion of the general principles regarding reporting of novel variants, challenging cases (genes for which consensus was difficult to achieve across Clinical Sequencing Exploratory Research network sites), solicitation of preferences from participants regarding return of incidental findings, and the timing and context of return of incidental findings are provided. C1 [Berg, Jonathan S.; Evans, James P.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA. [Berg, Jonathan S.; Evans, James P.] Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC USA. [Berg, Jonathan S.; Evans, James P.] Univ N Carolina, Ctr Genom & Soc, Chapel Hill, NC USA. [Berg, Jonathan S.; Evans, James P.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Amendola, Laura M.; Hisama, Fuki M.; Burke, Wylie; Jarvik, Gail P.] Univ Washington, Dept Med, Div Genet, Seattle, WA 98195 USA. [Eng, Christine; Plon, Sharon] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA. [Van Allen, Eliezer; Garraway, Levi] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Van Allen, Eliezer; Gray, Stacy W.; Wagle, Nikhil] Dana Farber Canc Inst, Boston, MA 02115 USA. [Van Allen, Eliezer] Broad Inst MIT & Harvard, Canc Program, Cambridge, MA USA. [Gray, Stacy W.; Rehm, Heidi L.] Harvard Univ, Sch Med, Boston, MA USA. [Gray, Stacy W.; Wagle, Nikhil] Brigham & Womens Hosp, Dept Med, Div Oncol, Boston, MA 02115 USA. [Wagle, Nikhil; Garraway, Levi; Green, Robert C.] Broad Inst, Cambridge, MA USA. [Rehm, Heidi L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Rehm, Heidi L.] Partners Healthcare Ctr Personalized Genet Med, Mol Med Lab, Boston, MA USA. [DeChene, Elizabeth T.; Dulik, Matthew C.; Spinner, Nancy B.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [DeChene, Elizabeth T.; Dulik, Matthew C.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Burke, Wylie] Univ Washington, Dept Bioeth, Seattle, WA 98195 USA. [Garraway, Levi] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Green, Robert C.] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA. [Plon, Sharon] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Jarvik, Gail P.] Univ Washington, Seattle, WA 98195 USA. RP Jarvik, GP (reprint author), Univ Washington, Dept Med, Div Genet, Seattle, WA 98195 USA. EM gjarvik@medicine.washington.edu RI Jarvik, Gail/N-6476-2014 OI Jarvik, Gail/0000-0002-6710-8708 FU National Institutes of Health [RFA-HG-11-003, 5R01HG006600-02, 5R01HG006615-02, RFA-HG-10-017, 1U01HG006485, 1U01HG006487, 1U01HG006492, 1U01HG006500, 1U01HG006507, 1U01HG006546]; State of Washington Life Sciences Discovery Award FX This work was funded by the National Institutes of Health RFA-HG-11-003 grants 5R01HG006600-02 and 5R01HG006615-02 and the National Institutes of Health RFA-HG-10-017 grants 1U01HG006485, 1U01HG006487, 1U01HG006492, 1U01HG006500, 1U01HG006507, and 1U01HG006546. Other support was provided by a State of Washington Life Sciences Discovery Award to the Northwest Institute of Genetic Medicine. NR 9 TC 38 Z9 38 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD NOV PY 2013 VL 15 IS 11 BP 860 EP 867 DI 10.1038/gim.2013.133 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 250LB UT WOS:000326853200004 PM 24195999 ER PT J AU Ramoni, RB McGuire, AL Robinson, JO Morley, DS Plon, SE Joffe, S AF Ramoni, Rachel B. McGuire, Amy L. Robinson, Jill Oliver Morley, Debra S. Plon, Sharon E. Joffe, Steven TI Experiences and attitudes of genome investigators regarding return of individual genetic test results SO GENETICS IN MEDICINE LA English DT Article DE incidental findings; return of results ID INCIDENTAL FINDINGS; RESEARCH PARTICIPANTS; PERSPECTIVES; RESEARCHER; DISCLOSURE; VARIANTS; FEEDBACK; CONSENT; MATTERS; CANCER AB Purpose: Whether and how to return individual genetic results to study participants is among the most contentious policy issues in contemporary genomic research. Methods: We surveyed corresponding authors of genome-wide association studies, identified through the National Human Genome Research Institute's Catalog of Published Genome-Wide Association Studies, to describe the experiences and attitudes of these stakeholders. Results: Of 357 corresponding authors, 200 (56%) responded. One hundred twenty-six (63%) had been responsible for primary data and sample collection, whereas 74 (37%) had performed secondary analyses. Only 7 (4%) had returned individual results within their index genome-wide association studies. Most (69%) believed that return of results to individual participants was warranted under at least some circumstances. Most respondents identified a desire to benefit participants' health (63%) and respect for participants' desire for information (57%) as major motivations for returning results. Most also identified uncertain clinical utility (76%), the possibility that participants will misunderstand results (74%), the potential for emotional harm (61%), the need to ensure access to trained clinicians (59%), and the potential for loss of confidentiality (51%) as major barriers to return of results. Conclusion: Investigators have limited experience returning individual results from genome-scale research, yet most are motivated to do so in at least some circumstances. C1 [Ramoni, Rachel B.] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA USA. [McGuire, Amy L.; Robinson, Jill Oliver] Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA. [Morley, Debra S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Plon, Sharon E.] Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr, Houston, TX 77030 USA. [Joffe, Steven] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Joffe, Steven] Boston Childrens Hosp, Dept Med, Boston, MA USA. RP Joffe, S (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. EM steven_joffe@dfci.harvard.edu OI Joffe, Steven/0000-0002-0667-7384 FU National Institute of Dental and Craniofacial Research [K08DE016956]; Baylor College of Medicine Clinical and Translational Research Program; Baylor Annual Fund; National Human Genome Research Institute [U01HG006485-01] FX The work of R.B.R. on this study was supported by a grant from the National Institute of Dental and Craniofacial Research (K08DE016956). A.L.M., S.E.P., and J.O.R. acknowledge research support from the Baylor College of Medicine Clinical and Translational Research Program and the Baylor Annual Fund. S.E.P. acknowledges a grant from the National Human Genome Research Institute (U01HG006485-01). The investigators also acknowledge the Survey and Data Management Core at the Dana-Farber Cancer Institute for assistance with fielding the investigator survey. NR 26 TC 20 Z9 20 U1 3 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD NOV PY 2013 VL 15 IS 11 BP 882 EP 887 DI 10.1038/gim.2013.58 PG 6 WC Genetics & Heredity SC Genetics & Heredity GA 250LB UT WOS:000326853200008 PM 23639901 ER PT J AU Everett, C Thorpe, C Palta, M Carayon, P Bartels, C Smith, MA AF Everett, Christine Thorpe, Carolyn Palta, Mari Carayon, Pascale Bartels, Christie Smith, Maureen A. TI Physician Assistants And Nurse Practitioners Perform Effective Roles On Teams Caring For Medicare Patients With Diabetes SO HEALTH AFFAIRS LA English DT Article ID PRIMARY-CARE; AMBULATORY-CARE; UNITED-STATES; OUTCOMES; MANAGEMENT; QUALITY; SYSTEMS; HEALTH; TIME AB One approach to the patient-centered medical home, particularly for patients with chronic illnesses, is to include physician assistants (PAs) and nurse practitioners (NPs) on primary care teams. Using Medicare claims and electronic health record data from a large physician group, we compared outcomes for two groups of adult Medicare patients with diabetes whose conditions were at various levels of complexity: those whose care teams included PAs or NPs in various roles, and those who received care from physicians only. Outcomes were generally equivalent in thirteen comparisons. In four comparisons, outcomes were superior for the patients receiving care from PAs or NPs, but in three other comparisons the outcomes were superior for patients receiving care from physicians only. Specific roles performed by PAs and NPs were associated with different patterns in the measure of the quality of diabetes care and use of health care services. No role was best for all outcomes. Our findings suggest that patient characteristics, as well as patients' and organizations' goals, should be considered when determining when and how to deploy PAs and NPs on primary care teams. Accordingly, training and policy should continue to support role flexibility for these health professionals. C1 [Everett, Christine] Duke Univ, Sch Med, Dept Community & Family Med, Physician Assistant Program, Durham, NC 27705 USA. [Thorpe, Carolyn] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Thorpe, Carolyn] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA 15260 USA. [Palta, Mari; Carayon, Pascale; Smith, Maureen A.] Univ Wisconsin, Madison, WI 53706 USA. [Bartels, Christie] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. RP Everett, C (reprint author), Duke Univ, Sch Med, Dept Community & Family Med, Physician Assistant Program, Durham, NC 27705 USA. EM christine.everett@duke.edu FU Agency for Healthcare Research and Quality [R21 HS017646, R01 HS018368]; Health Innovation Program; Clinical and Translational Science Award program of the National Institutes of Health's National Center for Advancing Translational Sciences [UL1TR000427]; University of Wisconsin School of Medicine and Public Health from the Wisconsin Partnership Program; Agency for Healthcare Research and Quality/National Research Service Award T32 Institutional Training Program [5-T32-HS00083]; American Academy of Physician Assistants Breitman-Dorn Fellowship; National Insititute of Arthritis and Musculoskeletal and Skin Diseases [K23 AR062381-01] FX This material was presented at IMPACT, the American Academy of Physician Assistants' 2013 Physician Assistant Conference, in Washington, D. C., May 2013. Funding for this project was provided by the Agency for Healthcare Research and Quality (Grant Nos. R21 HS017646 and R01 HS018368). Additional support was provided by the Health Innovation Program by providing assistance with Institutional Review Board application, Medicare data management, creation of variables, and manuscript formatting; the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (Grant No. UL1TR000427 from the Clinical and Translational Science Award program of the National Institutes of Health's National Center for Advancing Translational Sciences); and the University of Wisconsin School of Medicine and Public Health from the Wisconsin Partnership Program, which provided funding to the Health Innovation Program. Christine Everett was supported by the Agency for Healthcare Research and Quality/National Research Service Award T32 Institutional Training Program (Grant No. 5-T32-HS00083) and the American Academy of Physician Assistants Breitman-Dorn Fellowship. Christie Bartels was supported by the National Insititute of Arthritis and Musculoskeletal and Skin Diseases (Grant No. K23 AR062381-01). No other funding source had a role in the design or conduct; data collection, management, analysis or interpretation; or preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the National Institutes of Health, Department of Veterans Affairs, or the US government. NR 30 TC 16 Z9 16 U1 0 U2 14 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD NOV PY 2013 VL 32 IS 11 BP 1942 EP 1948 DI 10.1377/hlthaff.2013.0506 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 250HN UT WOS:000326841400013 PM 24191084 ER PT J AU Bachhuber, MA Cunningham, CO AF Bachhuber, Marcus A. Cunningham, Chinazo O. TI For-Profit Treatment Of Opioid Addiction SO HEALTH AFFAIRS LA English DT Letter C1 [Bachhuber, Marcus A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Cunningham, Chinazo O.] Albert Einstein Coll Med, Bronx, NY 10467 USA. RP Bachhuber, MA (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. OI Bachhuber, Marcus/0000-0002-5610-8382 FU NIDA NIH HHS [R34 DA031066, R01 DA032110, R25 DA023021] NR 3 TC 0 Z9 0 U1 0 U2 2 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD NOV PY 2013 VL 32 IS 11 BP 2060 EP 2060 DI 10.1377/hlthaff.2013.1100 PG 1 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 250HN UT WOS:000326841400036 PM 24191105 ER PT J AU Gheorghiade, M Vaduganathan, M Fonarow, GC Greene, SJ Greenberg, BH Liu, PP Massie, BM Mehra, MR Metra, M Zannad, F Cleland, JGF van Veldhuisen, DJ Shah, AN Butler, J AF Gheorghiade, Mihai Vaduganathan, Muthiah Fonarow, Gregg C. Greene, Stephen J. Greenberg, Barry H. Liu, Peter P. Massie, Barry M. Mehra, Mandeep R. Metra, Marco Zannad, Faiez Cleland, John G. F. van Veldhuisen, Dirk J. Shah, Ami N. Butler, Javed TI Anticoagulation in heart failure: current status and future direction SO HEART FAILURE REVIEWS LA English DT Article DE Heart failure; Anticoagulants; Atrial fibrillation; Sudden cardiac death ID LEFT-VENTRICULAR DYSFUNCTION; QUALITY-OF-CARE; ACUTE MYOCARDIAL-INFARCTION; ACUTE CORONARY SYNDROMES; NONVALVULAR ATRIAL-FIBRILLATION; MORBIDITY CHARM PROGRAM; ASSOCIATION TASK-FORCE; SUDDEN CARDIAC DEATH; EJECTION FRACTION; ANTITHROMBOTIC THERAPY AB Despite therapeutic advances, patients with worsening heart failure (HF) requiring hospitalization have unacceptably high post-discharge mortality and re-admission rates soon after discharge. Evidence suggests a hypercoagulable state is present in patients with HF. Although thromboembolism as a direct consequence of HF is not frequently clinically recognized, it may contribute to mortality and morbidity. Additionally, many patients with HF have concomitant disorders conferring additional thrombotic risk, including atrial fibrillation (AF) and coronary artery disease (CAD). Acute coronary syndrome (ACS), a known consequence of coronary thrombosis, is a common precipitating factor for worsening HF. Coronary thrombosis may also cause sudden death in patients with HF and CAD. Because data are largely derived from observational studies or trials of modest size, guideline recommendations on anticoagulation for HF vary between organizations. The recently presented Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial of HF patients in sinus rhythm suggested anticoagulation reduces the risk of stroke, although rates of the combined primary endpoint (death, ischemic stroke, or intracerebral hemorrhage) were similar for acetylsalicylic acid and warfarin. Newer oral anticoagulants dabigatran, apixaban, and rivaroxaban have successfully completed trials for the prevention of stroke in patients with AF and have shown benefits in the subpopulation of patients with concomitant HF. Positive results of the Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) trial of rivaroxaban in ACS are also encouraging. These data suggest there is a need to assess the potential role for these newer agents in the management of patients hospitalized for HF who continue to have a high post-discharge event rate despite available therapies. C1 [Gheorghiade, Mihai; Greene, Stephen J.; Shah, Ami N.] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA. [Vaduganathan, Muthiah] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA. [Fonarow, Gregg C.] Ahmanson UCLA Cardiomyopathy Ctr, UCLA Div Cardiol, Los Angeles, CA USA. [Greenberg, Barry H.] Univ Calif San Diego, Sulpizio Cardiovasc Ctr, Div Cardiovasc Med, San Diego, CA 92103 USA. [Liu, Peter P.] Univ Toronto, Univ Hlth Network, Heart & Stroke Richard Lewar Ctr, Toronto, ON, Canada. [Liu, Peter P.] Univ Toronto, Univ Hlth Network, Peter Munk Cardiac Ctr, Toronto, ON, Canada. [Massie, Barry M.] Univ Calif San Francisco, Div Cardiol, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Mehra, Mandeep R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Metra, Marco] Univ Brescia, Dept Expt & Appl Med, Brescia, Italy. [Zannad, Faiez] Nancy Univ, Ctr Hosp Univ, Dept Cardiol, INSERM,Ctr Invest Clin 9501, Nancy, France. [Zannad, Faiez] Nancy Univ, Ctr Hosp Univ, Unite 961, Nancy, France. [Cleland, John G. F.] Univ Hull, Postgrad Med Inst, Acad Unit, Dept Cardiol, Kingston Upon Hull, Yorks, England. [van Veldhuisen, Dirk J.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Butler, Javed] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA. RP Gheorghiade, M (reprint author), Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, 645 N Michigan Ave,Suite 1006, Chicago, IL 60611 USA. EM m-gheorghiade@northwestern.edu RI van Veldhuisen, Dirk Jan/E-8967-2014; OI Metra, Marco/0000-0001-6691-8568; Mehra, Mandeep/0000-0001-8683-7044; Cleland, John/0000-0002-1471-7016 FU Bayer HealthCare Pharmaceuticals; Janssen Pharmaceuticals, Inc. FX The authors would like to acknowledge Joanne McGrail, who provided medical writing services with funding from Bayer HealthCare Pharmaceuticals and Janssen Pharmaceuticals, Inc. NR 108 TC 12 Z9 12 U1 0 U2 13 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1382-4147 EI 1573-7322 J9 HEART FAIL REV JI Heart Fail. Rev. PD NOV PY 2013 VL 18 IS 6 SI SI BP 797 EP 813 DI 10.1007/s10741-012-9343-x PG 17 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 251AC UT WOS:000326897600009 PM 22987320 ER PT J AU Vaduganathan, M Greene, SJ Butler, J Sabbah, HN Shantsila, E Lip, GYH Gheorghiade, M AF Vaduganathan, Muthiah Greene, Stephen J. Butler, Javed Sabbah, Hani N. Shantsila, Eduard Lip, Gregory Y. H. Gheorghiade, Mihai TI The immunological axis in heart failure: importance of the leukocyte differential SO HEART FAILURE REVIEWS LA English DT Article DE Heart failure; Immune activation; Inflammation; Prognosis; Outcomes ID RELATIVE LYMPHOCYTE COUNT; TUMOR-NECROSIS-FACTOR; ACUTE MYOCARDIAL-INFARCTION; BLOOD-CELL COUNT; IDIOPATHIC DILATED CARDIOMYOPATHY; VENTRICULAR DYSFUNCTION SOLVD; ELEVATED CIRCULATING LEVELS; CARDIAC MAST-CELLS; EJECTION FRACTION; FACTOR-ALPHA AB The important role of the immune system and inflammation in the pathophysiology of heart failure (HF) is becoming increasingly appreciated. We have reviewed the prognostic significance of under-recognized aspects of the leukocyte differential in HF, including lymphocytes, monocytes, eosinophils and mast cells. Studies to date evaluating lymphocyte counts in both chronic and hospitalized HF patients have consistently shown worse prognosis associated with low lymphocyte counts, despite widely heterogeneous study designs. Limited data suggest elevations in monocyte-derived cytokines and serum monocyte count may be predictive of poor outcomes in HF. Further data are required to better define the relationship between eosinophils, mast cells and HF. Leukocyte differentials are widely available, simple, inexpensive and appear to have independent prognostic significance, beyond traditional risk factors. Enhanced sympathetic activation and increased circulating cytokine levels (particularly tumor necrosis factor) have been implicated in the variability of leukocyte subpopulations. To date, immune-modulators targeting these mediators have been largely unsuccessful in improving cardiovascular outcomes in HF. Given the potential role of the immunological axis in HF, there may be an unmet need for novel therapeutic agents that can safely and effectively ameliorate these leukocyte derangements and perhaps improve the unacceptably high event rate in this population. Variations in leukocyte differentials may identify a high-risk subset of patients that may benefit from tailored immune therapies. C1 [Vaduganathan, Muthiah] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Greene, Stephen J.; Gheorghiade, Mihai] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA. [Butler, Javed] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA. [Sabbah, Hani N.] Henry Ford Hosp, Dept Med, Detroit, MI 48202 USA. [Shantsila, Eduard; Lip, Gregory Y. H.] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham, W Midlands, England. RP Gheorghiade, M (reprint author), Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, 645 North Michigan Ave,Suite 1006, Chicago, IL 60611 USA. EM m-gheorghiade@northwestern.edu OI Shantsila, Eduard/0000-0002-2429-6980 NR 71 TC 13 Z9 14 U1 0 U2 5 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1382-4147 EI 1573-7322 J9 HEART FAIL REV JI Heart Fail. Rev. PD NOV PY 2013 VL 18 IS 6 SI SI BP 835 EP 845 DI 10.1007/s10741-012-9352-9 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 251AC UT WOS:000326897600011 PM 23054221 ER PT J AU Heaton, JT Knox, CJ Malo, JS Kobler, JB Hadlock, TA AF Heaton, James T. Knox, Christopher J. Malo, Juan S. Kobler, James B. Hadlock, Tessa A. TI A System for Delivering Mechanical Stimulation and Robot-Assisted Therapy to the Rat Whisker Pad During Facial Nerve Regeneration SO IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING LA English DT Article DE Facial nerve; facial paralysis; nerve regeneration; rehabilitation; reinnervation; robotic; vibrissae; whisking ID IMPROVES FUNCTIONAL RECOVERY; MANUAL STIMULATION; VIBRISSAL MUSCLES; RECONSTRUCTIVE SURGERY; AXON REGENERATION; PERIPHERAL-NERVES; RODENT WHISKING; MOTOR RECOVERY; SENSORY INPUT; INJURY AB Functional recovery is typically poor after facial nerve transection and surgical repair. In rats, whisking amplitude remains greatly diminished after facial nerve regeneration, but can recover more completely if the whiskers are periodically mechanically stimulated during recovery. Here we present a robotic "whisk assist" system for mechanically driving whisker movement after facial nerve injury. Movement patterns were either preprogrammed to reflect natural amplitudes and frequencies, or movements of the contralateral (healthy) side of the face were detected and used to control real-time mirror-like motion on the denervated side. In a pilot study, 20 rats were divided into nine groups and administered one of eight different whisk assist driving patterns (or control) for 5-20 minutes, five days per week, across eight weeks of recovery after unilateral facial nerve cut and suture repair. All rats tolerated the mechanical stimulation well. Seven of the eight treatment groups recovered average whisking amplitudes that exceeded controls, although small group sizes precluded statistical confirmation of group differences. The potential to substantially improve facial nerve recovery through mechanical stimulation has important clinical implications, and we have developed a system to control the pattern and dose of stimulation in the rat facial nerve model. C1 [Heaton, James T.; Kobler, James B.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Heaton, James T.; Knox, Christopher J.; Malo, Juan S.; Kobler, James B.; Hadlock, Tessa A.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Knox, Christopher J.; Malo, Juan S.; Hadlock, Tessa A.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. RP Heaton, JT (reprint author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. EM james.heaton@mgh.harvard.edu; tessa_hadlock@meei.harvard.edu FU [R01NS071067] FX The work of T. A. Hadlock and J. T. Heaton was supported by R01NS071067. NR 67 TC 1 Z9 1 U1 0 U2 14 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1534-4320 EI 1558-0210 J9 IEEE T NEUR SYS REH JI IEEE Trans. Neural Syst. Rehabil. Eng. PD NOV PY 2013 VL 21 IS 6 BP 928 EP 937 DI 10.1109/TNSRE.2013.2244911 PG 10 WC Engineering, Biomedical; Rehabilitation SC Engineering; Rehabilitation GA 253MM UT WOS:000327091400007 PM 23475376 ER PT J AU Vartholomeos, P Bergeles, C Qin, L Dupont, PE AF Vartholomeos, Panagiotis Bergeles, Christos Qin, Lei Dupont, Pierre E. TI An MRI-powered and controlled actuator technology for tetherless robotic interventions SO INTERNATIONAL JOURNAL OF ROBOTICS RESEARCH LA English DT Article DE MRI; magnetic actuation; medical robotics ID IMAGE-GUIDED INTERVENTIONS; MAGNETIC-RESONANCE; VISIBLE MARKERS; LOCALIZATION; NAVIGATION; TRACKING; FORCE; BRACHYTHERAPY; FEASIBILITY; SYSTEMS AB This paper presents a novel actuation technology for robotically assisted MRI-guided interventional procedures. In the proposed approach, the MRI scanner is used to deliver power, estimate actuator state and perform closed-loop control. The actuators themselves are compact, inexpensive and wireless. Using needle driving as an example application, actuation principles and force production capabilities are examined. Actuator stability and performance are analyzed for the two cases of state estimation at the input versus the output of the actuator transmission. Closed-loop needle position control is achieved by interleaving imaging pulse sequences to estimate needle position (transmission output estimation) and propulsion pulse sequences to drive the actuator. A prototype needle driving robot is used to validate the proposed approach in a clinical MRI scanner. C1 [Vartholomeos, Panagiotis; Bergeles, Christos; Dupont, Pierre E.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Cardiovasc Surg, Boston, MA USA. [Qin, Lei] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Dupont, PE (reprint author), Boston Childrens Hosp, Dept Cardiovasc Surg, 300 Longwood Ave, Boston, MA 02115 USA. EM pierre.dupont@childrens.harvard.edu OI Bergeles, Christos/0000-0002-9152-3194; Dupont, Pierre/0000-0001-7294-640X FU National Science Foundation [IIS-1208509]; Wyss Institute for Biologically Inspired Engineering; National Institutes of Health [R01HL073647] FX This work was supported by the National Science Foundation (grant number IIS-1208509), the Wyss Institute for Biologically Inspired Engineering and the National Institutes of Health (grant number R01HL073647). NR 35 TC 20 Z9 20 U1 2 U2 15 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0278-3649 EI 1741-3176 J9 INT J ROBOT RES JI Int. J. Robot. Res. PD NOV PY 2013 VL 32 IS 13 BP 1536 EP 1552 DI 10.1177/0278364913500362 PG 17 WC Robotics SC Robotics GA 257HL UT WOS:000327374100002 ER PT J AU Croymans, DM Paparisto, E Lee, MM Brandt, N Le, BK Lohan, D Lee, CC Roberts, CK AF Croymans, Daniel M. Paparisto, Ergit Lee, Mary M. Brandt, Nina Le, Brian K. Lohan, Derek Lee, Cathy C. Roberts, Christian K. TI Resistance training improves indices of muscle insulin sensitivity and beta-cell function in overweight/obese, sedentary young men SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE insulin sensitivity; strength training; exercise; OGTT; glucose tolerance ID GLUCOSE-TOLERANCE TEST; RANDOMIZED CONTROLLED-TRIAL; SKELETAL-MUSCLE; DIABETES-MELLITUS; GLYCEMIC CONTROL; GENE-EXPRESSION; FATTY LIVER; WEIGHT-LOSS; OLDER MEN; EXERCISE AB We examined the effects of RT on oral glucose tolerance test (OGTT)-derived indices of muscle insulin sensitivity, hepatic insulin resistance, beta-cell function, and skeletal muscle proteins related to glucose transport in overweight/obese, sedentary young men. Twenty-eight participants [median body mass index (BMI) 30.9 kg/m(2); age 22 yr] completed 12 wk of RT (3 sessions/wk) and were assessed for changes in OGTT-derived indices, resting metabolic rate, body composition, serum adipokines, and skeletal muscle protein content [hexokinase 2 (HK2), glucose transporter type 4 (GLUT4), RAC-beta serine/threonine-protein kinase (AKT2), glycogen synthase kinase 3 beta, and insulin receptor substrate 1]. Individualized responses to RT were also evaluated. RT significantly improved insulin and glucose area under the curve (both P < 0.03). With the use of OGTT indices of insulin action, we noted improved muscle insulin sensitivity index (mISI; P = 0.03) and oral disposition index (P = 0.03). BMI, lean body mass (LBM), and relative strength also increased (all P < 0.03), as did skeletal muscle protein content of HK2, GLUT4, and AKT2 (26-33%; all P < 0.02). Hepatic insulin resistance index, adiponectin, leptin, and total amylin did not change. Further analysis demonstrated the presence of highly individualized responsiveness to RT for glucose tolerance and other outcomes. RT improved oral indices of muscle insulin sensitivity and beta-cell function but not hepatic insulin resistance in overweight/obese young men. In addition to the increase in LBM, the improvements in insulin action may be due, in part, to increases in key insulin signaling proteins. C1 [Croymans, Daniel M.; Lee, Cathy C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Croymans, Daniel M.; Paparisto, Ergit; Lee, Mary M.; Brandt, Nina; Le, Brian K.; Roberts, Christian K.] Univ Calif Los Angeles, Exercise & Metab Dis Res Lab, Translat Sci Sect, Sch Nursing, Los Angeles, CA 90095 USA. [Lohan, Derek] Galway Univ Hosp, Galway, Ireland. [Lee, Cathy C.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Lee, Cathy C.] Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. RP Roberts, CK (reprint author), Univ Calif Los Angeles, Exercise & Metab Dis Res Lab, Translat Sci Sect, Sch Nursing, 700 Tiverton Ave, Los Angeles, CA 90095 USA. EM croberts@ucla.edu FU American Heart Association (BGIA) [0765139Y]; National Heart, Lung, and Blood Institute [P50 HL105188]; National Institute of Diabetes and Digestive and Kidney Diseases [DK090406]; National Center for Advancing Translational Sciences through UCLA Clinical and Translational Science Institute (CTSI) [UL1TR000124] FX Support for this work was provided by the American Heart Association (BGIA #0765139Y to C. K. Robers), National Heart, Lung, and Blood Institute (P50 HL105188 to C. K. Roberts), National Institute of Diabetes and Digestive and Kidney Diseases (DK090406 to C. K. Roberts), and National Center for Advancing Translational Sciences through UCLA Clinical and Translational Science Institute (CTSI) Grant UL1TR000124. NR 49 TC 9 Z9 9 U1 1 U2 17 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD NOV PY 2013 VL 115 IS 9 BP 1245 EP 1253 DI 10.1152/japplphysiol.00485.2013 PG 9 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 246XV UT WOS:000326576000005 PM 23970530 ER PT J AU Kelly, VJ Sands, SA Harris, RS Venegas, JG Brown, NJ Stuart-Andrews, CR King, GG Thompson, BR AF Kelly, Vanessa J. Sands, Scott A. Harris, R. Scott Venegas, Jose G. Brown, Nathan J. Stuart-Andrews, Christopher R. King, Gregory G. Thompson, Bruce R. TI Respiratory system reactance is an independent determinant of asthma control SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE airway closure; airway heterogeneity; peripheral airway dysfunction; asthma symptoms; forced oscillation technique; nomenclature ID FORCED OSCILLATION TECHNIQUE; AIRWAY HYPERRESPONSIVENESS; VENTILATION HETEROGENEITY; LUNG-VOLUMES; ADULTS; MECHANICS; DISEASE; CLOSURE; MRI; STANDARDIZATION AB The mechanisms underlying not well-controlled (NWC) asthma remain poorly understood, but accumulating evidence points to peripheral airway dysfunction as a key contributor. The present study tests whether our recently described respiratory system reactance (Xrs) assessment of peripheral airway dysfunction reveals insight into poor asthma control. The aim of this study was to investigate the contribution of Xrs to asthma control. In 22 subjects with asthma, we measured Xrs (forced oscillation technique), spirometry, lung volumes, and ventilation heterogeneity (inert-gas washout), before and after bronchodilator administration. The relationship between Xrs and lung volume during a deflation maneuver yielded two parameters: the volume at which Xrs abruptly decreased (closing volume) and Xrs at this volume (Xrscrit). Lowered (more negative) Xrscrit reflects reduced apparent lung compliance at high lung volumes due, for example, to heterogeneous airway narrowing and unresolved airway closure or near closure above the critical lung volume. Asthma control was assessed via the 6-point Asthma Control Questionnaire (ACQ6). NWC asthma was defined as ACQ6 > 1.0. In 10 NWC and 12 well-controlled subjects, ACQ6 was strongly associated with postbronchodilator (post-BD) Xrscrit (R-2 = 0.43, P < 0.001), independent of all measured variables, and was a strong predictor of NWC asthma (receiver operator characteristic area = 0.94, P < 0.001). By contrast, Xrs measures at lower lung volumes were not associated with ACQ6. Xrscrit itself was significantly associated with measures of gas trapping and ventilation heterogeneity, thus confirming the link between Xrs and airway closure and heterogeneity. Residual airway dysfunction at high lung volumes assessed via Xrscrit is an independent contributor to asthma control. C1 [Kelly, Vanessa J.; Harris, R. Scott] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA. [Kelly, Vanessa J.; Sands, Scott A.; Harris, R. Scott; Venegas, Jose G.] Harvard Univ, Sch Med, Boston, MA USA. [Kelly, Vanessa J.; Thompson, Bruce R.] Monash Univ, Dept Med Nursing & Hlth Sci, Clayton, Vic, Australia. [Kelly, Vanessa J.; Stuart-Andrews, Christopher R.; Thompson, Bruce R.] Alfred Hosp, Dept Allergy Immunol & Resp Med, Prahran, Vic 3181, Australia. [Sands, Scott A.] Brigham & Womens Hosp, Div Sleep Med, Boston, MA 02115 USA. [Venegas, Jose G.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Brown, Nathan J.; King, Gregory G.] Woolcock Inst Med Res, Glebe, NSW, Australia. [Brown, Nathan J.; King, Gregory G.; Thompson, Bruce R.] Cooperat Res Ctr Asthma & Airways, Glebe, NSW, Australia. RP Kelly, VJ (reprint author), Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, 55 Fruit St,Edwards 4-440, Boston, MA 02114 USA. EM vjkelly@partners.org RI Brown, Nathan/H-4317-2011; OI Brown, Nathan/0000-0001-7149-8895; Thompson, Bruce/0000-0002-5885-0652 FU National Health and Medical Research Council of Australia; Cooperative Research Centre for Asthma; Airways, Hills Foundation Asthma NSW Grant; American Australian Association [12POST11820025, 11POST7360012] FX This study was supported by the National Health and Medical Research Council of Australia, Cooperative Research Centre for Asthma and Airways, Hills Foundation Asthma NSW Grant, and the American Australian Association. VK and SS were supported by American Heart Association Postdoctoral Fellowships (12POST11820025 and 11POST7360012). NR 52 TC 8 Z9 8 U1 0 U2 7 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD NOV PY 2013 VL 115 IS 9 BP 1360 EP 1369 DI 10.1152/japplphysiol.00093.2013 PG 10 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 246XV UT WOS:000326576000017 PM 23990243 ER PT J AU Baryza, MJ Hinson, M Conway, J Ryan, CM AF Baryza, Mary Jo Hinson, Michelle Conway, Jennifer Ryan, Colleen M. TI Five-Year Experience With Burns From Glass Fireplace Doors in the Pediatric Population SO JOURNAL OF BURN CARE & RESEARCH LA English DT Article ID CONTACT BURNS; PALM BURNS; CHILDREN AB Burns from contact with glass doors of gas fireplaces have been previously reported. The purpose of this study is to examine the incidence and severity of this injury in our population. Patients were identified for inclusion in the retrospective chart review study using the National Trauma Registry of the American College of Surgeons (NTRACS) and our local outpatient database. Criteria for inclusion were burn injuries sustained from contact with fireplace glass doors treated at our pediatric burn center from 2007 through 2011. Fifty children met these criteria, including two children whose burns were caused by electric fireplace glass doors. BSA burned was 1.5 +/- 1.5% (mean +/- SD), range 0.5 to 10%. Age was 27.2 +/- 27.3 months, range 8 months to 13 years. Forty-five children (90%) had hand burns; of these, 18 children had bilateral hand involvement. Facial burns were found in three children (6%), and eight children (16%) had other areas burned. One patient developed cellulitis. Two patients required surgery. Six children (12%) required hospitalization; mean length of stay was 5.8 +/- 5 days, range 1 to 5 days. Although the number of inpatient admissions was relatively few, 329 outpatient visits and 309 rehabilitation visits were required for treatment of these children. Nineteen patients (38%) required splints and six patients (12%) required scar treatment with pressure garments. Burns from contact with fireplace glass doors are a recurring problem. Toddlers are most at risk. Directed preventive strategies including parent education, safety warnings, and design modifications such as temperature sensors and barrier screens could be potentially helpful in reducing the incidence of this injury. C1 [Baryza, Mary Jo; Hinson, Michelle; Conway, Jennifer] Shriners Hosp Children Boston, Patient Care Serv, Boston, MA USA. [Ryan, Colleen M.] Shriners Hosp Children Boston, Acute Surg Serv, Boston, MA USA. [Ryan, Colleen M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Burns,Dept Surg,Sumner Redstone Burn Ctr, Boston, MA 02114 USA. RP Ryan, CM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Burns,Dept Surg,Sumner Redstone Burn Ctr, Bigelow 1302,Fruit St, Boston, MA 02114 USA. FU Department of Education, National Institute on Disability and Rehabilitation Research [H133A120034]; Shriners Hospitals for Children Research Grant [84080] FX The contents of this report were developed under partial support from a grant from the Department of Education, National Institute on Disability and Rehabilitation Research grant number H133A120034. This work was supported in part by the Shriners Hospitals for Children Research Grant 84080. NR 15 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1559-047X EI 1559-0488 J9 J BURN CARE RES JI J. Burn Care Res. PD NOV-DEC PY 2013 VL 34 IS 6 BP 607 EP 611 DI 10.1097/BCR.0b013e3182a2a887 PG 5 WC Emergency Medicine; Dermatology; Surgery SC Emergency Medicine; Dermatology; Surgery GA 250ZN UT WOS:000326896100013 PM 24043229 ER PT J AU Schneider, JC Tan, WH Goldstein, R Mix, JM Niewczyk, P DiVita, MA Ryan, CM Gerrard, PB Kowalske, K Zafonte, R AF Schneider, Jeffrey C. Tan, Wei-Han Goldstein, Richard Mix, Jacqueline M. Niewczyk, Paulette DiVita, Margaret A. Ryan, Colleen M. Gerrard, Paul B. Kowalske, Karen Zafonte, Ross TI Time to Rehabilitation in the Burn Population: Incidence of Zero Onset Days in the UDSMR National Dataset SO JOURNAL OF BURN CARE & RESEARCH LA English DT Article ID LENGTH-OF-STAY; FUNCTIONAL INDEPENDENCE MEASURE; HEALTH-CARE COSTS; MEDICAL REHABILITATION; DECLINING LENGTH; OUTCOMES; INJURY; MORTALITY; TRENDS; READMISSIONS AB A preliminary investigation of the burn rehabilitation population found a large variability of zero onset day frequency between facilities. Onset days is defined as the time from injury to inpatient rehabilitation admission; this variable has not been investigated in burn patients previously. This study explored if this finding was a facility-based phenomena or characteristic of burn inpatient rehabilitation patients. This study was a secondary analysis of Uniform Data System for Medical Rehabilitation (UDSmr((R))) data from 2002 to 2007 examining inpatient rehabilitation characteristics among patients with burn injuries. Exclusion criteria were age less than 18 years and discharge against medical advice. Comparisons of demographic, medical and functional data were made between facilities with a high frequency of zero onset days versus facilities with a low frequency of zero onset days. A total of 4738 patients from 455 inpatient rehabilitation facilities were included. Twenty-three percent of the population exhibited zero onset days (n = 1103). Sixteen facilities contained zero onset patients; two facilities accounted for 97% of the zero onset subgroup. Facilities with a high frequency of zero onset day patients demonstrated significant differences in demographic, medical, and functional variables compared to the remainder of the study population. There were significantly more zero onset day admissions among burn patients (23%) than other diagnostic groups (0.5- 3.6%) in the Uniform Data System for Medical Rehabilitation database, but the majority (97%) came from two inpatient rehabilitation facilities. It is unexpected for patients with significant burn injury to be admitted to a rehabilitation facility on the day of injury. Future studies investigating burn rehabilitation outcomes using the Uniform Data System for Medical Rehabilitation database should exclude facilities with a high percentage of zero onset days, which are not representative of the burn inpatient rehabilitation population. C1 [Schneider, Jeffrey C.; Tan, Wei-Han; Goldstein, Richard; Gerrard, Paul B.; Zafonte, Ross] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA USA. [Mix, Jacqueline M.; Niewczyk, Paulette; DiVita, Margaret A.] Uniform Data Syst Med Rehabil, Amherst, NY USA. [Niewczyk, Paulette] Daemen Coll, Hlth Care Studies Dept, Amherst, NY USA. [Ryan, Colleen M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Sumner Redstone Burn Ctr,Surg Serv, Boston, MA USA. [Ryan, Colleen M.] Shriners Burns Hosp, Boston, MA USA. [Kowalske, Karen] Univ Texas SW Med Ctr Dallas, Dept Phys Med & Rehabil, Dallas, TX 75390 USA. RP Schneider, JC (reprint author), Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA USA. OI Gerrard, Paul/0000-0003-0654-5354; DiVita, Margaret/0000-0002-4878-2959 NR 25 TC 9 Z9 9 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1559-047X EI 1559-0488 J9 J BURN CARE RES JI J. Burn Care Res. PD NOV-DEC PY 2013 VL 34 IS 6 BP 666 EP 673 DI 10.1097/BCR.0b013e31827d1f52 PG 8 WC Emergency Medicine; Dermatology; Surgery SC Emergency Medicine; Dermatology; Surgery GA 250ZN UT WOS:000326896100022 PM 23511282 ER PT J AU Venteicher, AS Walcott, BP Sheth, SA Snuderl, M Patel, AP Curry, WT Nahed, BV AF Venteicher, Andrew S. Walcott, Brian P. Sheth, Sameer A. Snuderl, Matija Patel, Anoop P. Curry, William T. Nahed, Brian V. TI Clinical features of brain metastasis from salivary gland tumors SO JOURNAL OF CLINICAL NEUROSCIENCE LA English DT Article DE Brain tumor; Metastasis; Parotid; Radiation; Salivary; Submandibular; Surgery ID ADENOID CYSTIC CARCINOMA; IN-SITU HYBRIDIZATION; PAROTID-GLAND; DUCT CARCINOMAS; HER-2/NEU GENE; IMMUNOHISTOCHEMISTRY; EXPRESSION; PROTEIN; CANCER; NECK AB Salivary gland tumors comprise a group of 24 tumor subtypes with a wide range of clinical behaviors and propensities for metastasis. Several prognostic factors have been identified that help predict the development of systemic metastases, most commonly to the lung, liver, or bone. Metastases to the brain are rare. To better understand the behavior of salivary gland tumors that metastasise to the brain, we performed a retrospective cohort analysis on a series of patients to highlight features of their medical and surgical management. From 2007 to 2011, a database of 4117 elective craniotomies were queried at a single institution to identify patients surgically treated for salivary gland metastases to the brain. Three patients were identified. Histologic subtypes included salivary duct carcinoma, poorly differentiated carcinoma, and papillary mucinous adenocarcinoma. They had all undergone previous treatment for their primary malignancy. The mean time to intracranial metastasis was 48 months from initial diagnosis (range, 14-91 months). Treatment for intracranial metastases included surgical resection, whole brain radiation, stereotactic radiosurgery, and chemotherapy. Intracranial metastases from salivary gland tumors are rare, present years after diagnosis of the primary tumor, and are treatable with multimodality therapy. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Venteicher, Andrew S.; Walcott, Brian P.; Sheth, Sameer A.; Patel, Anoop P.; Curry, William T.; Nahed, Brian V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA 02114 USA. [Snuderl, Matija] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA. RP Walcott, BP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, 55 Fruit St,White Bldg Room 502, Boston, MA 02114 USA. EM brian.walcott@mgh.harvard.edu OI Snuderl, Matija/0000-0003-0752-0917 FU NINDS NIH HHS [R25 NS065743] NR 24 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0967-5868 EI 1532-2653 J9 J CLIN NEUROSCI JI J. Clin. Neurosci. PD NOV PY 2013 VL 20 IS 11 BP 1533 EP 1537 DI 10.1016/j.jocn.2012.11.024 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 251CW UT WOS:000326906400012 PM 23685104 ER PT J AU Strong, C Yanamadala, V Khanna, A Walcott, BP Nahed, BV Borges, LF Coumans, JVCE AF Strong, Christian Yanamadala, Vijay Khanna, Arjun Walcott, Brian P. Nahed, Brian V. Borges, Lawrence F. Coumans, Jean-Valery C. E. TI Surgical treatment options and management strategies of metastatic renal cell carcinoma to the lumbar spinal nerve roots SO JOURNAL OF CLINICAL NEUROSCIENCE LA English DT Article DE Cauda equine; Intradural; Metastasis; Nerve root; Renal; Spine ID VON-HIPPEL-LINDAU; OF-THE-LITERATURE; PHASE-III TRIAL; CORD METASTASIS; CAUDA-EQUINA; CEREBELLAR HEMANGIOBLASTOMA; INTERFERON-ALPHA; DOUBLE-BLIND; DISEASE; RARE AB Spinal nerve root metastasis of renal cell carcinoma is a rare occurrence. In addition to treatment of the primary lesion, surgical resection of the nerve root metastasis, occasionally with sacrifice of the involved nerve, is the accepted standard of treatment. Resection often resolves presenting motor and pain symptoms due to relief of neural compression. We describe two patients with nerve root metastasis of renal cell carcinoma and their management. While locally advanced and metastatic renal cell carcinoma has been shown to be chemo- and radio-resistant, immunotherapy is a promising treatment. Given the high prevalence of systemic disease in patients with intradural metastases, systemic (and possibly intracranial) imaging can be used to identify other potential areas of disease. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Walcott, Brian P.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Walcott, BP (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St, Boston, MA 02115 USA. EM Walcott.Brian@mgh.harvard.edu FU NINDS NIH HHS [R25 NS065743] NR 37 TC 4 Z9 4 U1 1 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0967-5868 EI 1532-2653 J9 J CLIN NEUROSCI JI J. Clin. Neurosci. PD NOV PY 2013 VL 20 IS 11 BP 1546 EP 1549 DI 10.1016/j.jocn.2013.02.014 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 251CW UT WOS:000326906400014 PM 23931936 ER PT J AU Verrier, RL Malik, M AF Verrier, Richard L. Malik, Marek TI Electrophysiology of T-wave alternans: Mechanisms and pharmacologic influences SO JOURNAL OF ELECTROCARDIOLOGY LA English DT Article DE T-wave alternans; Heterogeneity of repolarization; Arrhythmia trigger ID SUDDEN CARDIAC DEATH; VENTRICULAR-FIBRILLATION; MYOCARDIAL-ISCHEMIA; VULNERABILITY; TRACKING; HEART AB Extensive experimental evidence indicates a fundamental link between T-wave alternans (TWA) and arrhythmogenesis. Diverse physiologic and pathophysiologic influences alter TWA magnitude in parallel with their effects on vulnerability to ventricular tachyarrhythmias. Specifically, interventions that impede intracellular calcium handling, such as elevated heart rate, heightened adrenergic activity, myocardial ischemia, and heart failure, predispose to greater levels of TWA, reflecting heightened risk for arrhythmias. Conversely, vagus nerve stimulation, blockade of beta-adrenergic receptors and late sodium and L-type calcium channels, and sympathetic denervation decrease TWA magnitude, reflecting the potential of these interventions to reduce risk for ventricular tachycardia and fibrillation. TWA thus appears able to detect the influence of pathophysiologically relevant triggers as well as the efficacy of antiarrhythmic drugs without reducing the predictive capacity of the phenomenon. (C) 2013 Elsevier Inc. All rights reserved. C1 [Verrier, Richard L.] Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Boston, MA 02215 USA. [Malik, Marek] St Pauls Cardiac Electrophysiol, London, England. [Malik, Marek] Univ London, London, England. RP Verrier, RL (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc Med,Harvard Thorndike Electrophysi, 99 Brookline Ave,RN-301, Boston, MA 02215 USA. EM rverrier@bidmc.harvard.edu FU Gilead Sciences, Inc. FX RLV receives post-market royalties from Georgetown University and Beth Israel Deaconess Medical Center for the Modified Moving Average algorithm for TWA measurement, which is licensed to GE Healthcare. He also receives research grant support from Gilead Sciences, Inc., for experimental investigations on ranolazine. NR 20 TC 6 Z9 6 U1 0 U2 9 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0022-0736 EI 1532-8430 J9 J ELECTROCARDIOL JI J. Electrocardiol. PD NOV-DEC PY 2013 VL 46 IS 6 BP 580 EP 584 DI 10.1016/j.jelectrocard.2013.07.003 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 250MO UT WOS:000326857100019 PM 23948521 ER PT J AU Verrier, RL Malik, M AF Verrier, Richard L. Malik, Marek TI Clinical applications of T-wave alternans assessed during exercise stress testing and ambulatory ECG monitoring SO JOURNAL OF ELECTROCARDIOLOGY LA English DT Article DE T-wave alternans; Sudden cardiac death; Cardiovascular mortality ID LEFT-VENTRICULAR DYSFUNCTION; SUDDEN CARDIAC DEATH; HEART-FAILURE; MYOCARDIAL-INFARCTION; INTERNATIONAL SOCIETY; RISK STRATIFICATION; TRIAL; CARDIOMYOPATHY; ARRHYTHMIAS; HOLTER AB Analytical methods to measure T-wave alternans (TWA), a beat-to-beat fluctuation in the morphology of the ST-segment and T wave in the electrocardiogram (ECG), have been developed to address the unmet challenge of identifying individuals at increased risk for sudden cardiac death. Conventional noninvasive markers including left ventricular ejection fraction have significant limitations as many individuals who die suddenly have relatively preserved ventricular mechanical function. TWA is an attractive marker as it is closely linked to ECG heterogeneity and abnormalities in calcium handling, key factors in arrhythmogenesis. The objectives of this review are to summarize the clinical evidence supporting use of TWA in risk stratification and to discuss its current and potential applications in guiding device and medical therapy. (C) 2013 Elsevier Inc. All rights reserved. C1 [Verrier, Richard L.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Boston, MA 02215 USA. [Malik, Marek] St Pauls Cardiac Electrophysiol, London, England. [Malik, Marek] Univ London, London, England. RP Verrier, RL (reprint author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc Med Harvard Thorndike Electrophysi, 99 Brookline Ave,RN-301, Boston, MA 02215 USA. EM rverrier@bidmc.harvard.edu NR 27 TC 3 Z9 3 U1 0 U2 8 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0022-0736 EI 1532-8430 J9 J ELECTROCARDIOL JI J. Electrocardiol. PD NOV-DEC PY 2013 VL 46 IS 6 BP 585 EP 590 DI 10.1016/j.jelectrocard.2013.06.006 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 250MO UT WOS:000326857100020 PM 23870659 ER PT J AU Race, E LaRocque, KF Keane, MM Verfaellie, M AF Race, Elizabeth LaRocque, Karen F. Keane, Margaret M. Verfaellie, Mieke TI Medial Temporal Lobe Contributions to Short-Term Memory for Faces SO JOURNAL OF EXPERIMENTAL PSYCHOLOGY-GENERAL LA English DT Article DE working memory; episodic memory; hippocampus; amnesia ID VERBAL WORKING-MEMORY; BILATERAL HIPPOCAMPAL LESIONS; MATCHING-TO-SAMPLE; LONG-TERM; PERIRHINAL CORTEX; RELATIONAL MEMORY; RECOGNITION MEMORY; LOCATION ASSOCIATIONS; SELECTIVE ATTENTION; ACTIVE MAINTENANCE AB The role of the medial temporal lobes (MTL) in short-term memory (STM) remains a matter of debate. Whereas imaging studies commonly show hippocampal activation during short-delay memory tasks, evidence from amnesic patients with MTL lesions is mixed. It has been argued that apparent STM impairments in amnesia may reflect long-term memory (LTM) contributions to performance. We challenge this conclusion by demonstrating that MTL amnesic patients show impaired delayed matching-to-sample (DMS) for faces in a task that meets both a traditional delay-based and a recently proposed distractor-based criterion for classification as an STM task. In Experiment 1, we demonstrate that our face DMS task meets the proposed distractor-based criterion for STM classification, in that extensive processing of delay-period distractor stimuli disrupts performance of healthy individuals. In Experiment 2, MTL amnesic patients with lesions extending into anterior subhippocampal cortex, but not patients with lesions limited to the hippocampus, show impaired performance on this task without distraction at delays as short as 8 s, within temporal range of delay-based STM classification, in the context of intact perceptual matching performance. Experiment 3 provides support for the hypothesis that STM for faces relies on configural processing by showing that the extent to which healthy participants' performance is disrupted by interference depends on the configural demands of the distractor task. Together, these findings are consistent with the notion that the amnesic impairment in STM for faces reflects a deficit in configural processing associated with subhippocampal cortices and provide novel evidence that the MTL supports cognition beyond the LTM domain. C1 [Race, Elizabeth; LaRocque, Karen F.; Keane, Margaret M.; Verfaellie, Mieke] VA Boston Healthcare Syst, Memory Disorders Res Ctr, Boston, MA 02130 USA. [Race, Elizabeth; LaRocque, Karen F.; Verfaellie, Mieke] Boston Univ, Sch Med, Boston, MA 02215 USA. [Keane, Margaret M.] Wellesley Coll, Dept Psychol, Boston, MA USA. RP Race, E (reprint author), VA Boston Healthcare Syst, Memory Disorders Res Ctr, 150 South Huntington Ave 151-A, Boston, MA 02130 USA. EM race@bu.edu OI LaRocque, Karen/0000-0002-6058-2706 FU NINDS NIH HHS [F32NS073212, F32 NS073212] NR 91 TC 8 Z9 8 U1 4 U2 22 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0096-3445 EI 1939-2222 J9 J EXP PSYCHOL GEN JI J. Exp. Psychol.-Gen. PD NOV PY 2013 VL 142 IS 4 BP 1309 EP 1322 DI 10.1037/a0033612 PG 14 WC Psychology, Experimental SC Psychology GA 253RY UT WOS:000327108200024 PM 23937185 ER PT J AU Calligaris, D Norton, I Feldman, DR Ide, JL Dunn, IF Eberlin, LS Cooks, RG Jolesz, FA Golby, AJ Santagata, S Agar, NY AF Calligaris, David Norton, Isaiah Feldman, Daniel R. Ide, Jennifer L. Dunn, Ian F. Eberlin, Livia S. Cooks, R. Graham Jolesz, Ferenc A. Golby, Alexandra J. Santagata, Sandro Agar, Nathalie Y. TI Mass spectrometry imaging as a tool for surgical decision-making SO JOURNAL OF MASS SPECTROMETRY LA English DT Article DE DESI-MSI; brain tumors; real-time diagnosis; surgery; image-guided therapy ID DESORPTION ELECTROSPRAY-IONIZATION; ASSISTED-LASER-DESORPTION/IONIZATION; MOTOR FUNCTIONAL MRI; HUMAN BRAIN-TUMORS; ATMOSPHERIC-PRESSURE; IN-VIVO; TISSUE-SECTIONS; FLOW-CYTOMETRY; PHARMACEUTICAL COMPOUNDS; BIOMARKER DISCOVERY AB Despite significant advances in image-guided therapy, surgeons are still too often left with uncertainty when deciding to remove tissue. This binary decision between removing and leaving tissue during surgery implies that the surgeon should be able to distinguish tumor from healthy tissue. In neurosurgery, current image-guidance approaches such as magnetic resonance imaging (MRI) combined with neuronavigation offer a map as to where the tumor should be, but the only definitive method to characterize the tissue at stake is histopathology. Although extremely valuable information is derived from this gold standard approach, it is limited to very few samples during surgery and is not practically used for the delineation of tumor margins. The development and implementation of faster, comprehensive, and complementary approaches for tissue characterization are required to support surgical decision-making - an incremental and iterative process with tumor removed in multiple and often minute biopsies. The development of atmospheric pressure ionization sources makes it possible to analyze tissue specimens with little to no sample preparation. Here, we highlight the value of desorption electrospray ionization as one of many available approaches for the analysis of surgical tissue. Twelve surgical samples resected from a patient during surgery were analyzed and diagnosed as glioblastoma tumor or necrotic tissue by standard histopathology, and mass spectrometry results were further correlated to histopathology for critical validation of the approach. The use of a robust statistical approach reiterated results from the qualitative detection of potential biomarkers of these tissue types. The correlation of the mass spectrometry and histopathology results to MRI brings significant insight into tumor presentation that could not only serve to guide tumor resection, but that is also worthy of more detailed studies on our understanding of tumor presentation on MRI. Copyright (c) 2013 John Wiley & Sons, Ltd. C1 [Calligaris, David; Norton, Isaiah; Ide, Jennifer L.; Dunn, Ian F.; Golby, Alexandra J.; Agar, Nathalie Y.] Harvard Univ, Brigham & Womens Hosp, Dept Neurosurg, Sch Med, Boston, MA 02115 USA. [Feldman, Daniel R.; Santagata, Sandro] Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA. [Eberlin, Livia S.; Cooks, R. Graham] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA. [Eberlin, Livia S.; Cooks, R. Graham] Purdue Univ, Ctr Analyt Instrumentat Dev, W Lafayette, IN 47907 USA. [Jolesz, Ferenc A.; Golby, Alexandra J.; Agar, Nathalie Y.] Harvard Univ, Brigham & Womens Hosp, Dept Radiol, Sch Med, Boston, MA 02115 USA. [Agar, Nathalie Y.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. RP Agar, NY (reprint author), Harvard Univ, Brigham & Womens Hosp, Dept Neurosurg, Sch Med, Boston, MA 02115 USA. EM Nathalie_Agar@dfci.harvard.edu FU Daniel E. Ponton fund for the Neurosciences; DFCI Pediatric Low-Grade Astrocytoma program; NIH Director's New Innovator Award [1DP2OD007383-01]; Klarman Family Foundation; NIH [K08NS064168]; U.S. National Institute of Health [1R21EB009459]; National Center for Research Resources; National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health [P41EB015898, P41RR019703] FX The work received support from Daniel E. Ponton fund for the Neurosciences, the DFCI Pediatric Low-Grade Astrocytoma program, and the NIH Director's New Innovator Award (grant 1DP2OD007383-01 to N.Y.R. Agar); the Klarman Family Foundation (A.J. Golby). S. S. is supported by NIH grant K08NS064168. LSE, and RGC also thank the U.S. National Institute of Health (Grant 1R21EB009459). This project was supported by the National Center for Research Resources and the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health through Grant Numbers P41EB015898 and P41RR019703. NR 87 TC 17 Z9 17 U1 4 U2 46 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1076-5174 EI 1096-9888 J9 J MASS SPECTROM JI J. Mass Spectrom. PD NOV PY 2013 VL 48 IS 11 BP 1178 EP 1187 DI 10.1002/jms.3295 PG 10 WC Biochemical Research Methods; Chemistry, Analytical; Spectroscopy SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy GA 254HZ UT WOS:000327157100006 PM 24259206 ER PT J AU Gebhart, G Gamez, C Holmes, E Robles, J Garcia, C Cortes, M de Azambuja, E Fauria, K Van Dooren, V Aktan, G Coccia-Portugal, MA Kim, SB Vuylsteke, P Cure, H Eidtmann, H Baselga, J Piccart, M Flamen, P Di Cosimo, S AF Gebhart, Geraldine Gamez, Cristina Holmes, Eileen Robles, Javier Garcia, Camilo Cortes, Montserrat de Azambuja, Evandro Fauria, Karine Van Dooren, Veerle Aktan, Gursel Coccia-Portugal, Maria Antonia Kim, Sung-Bae Vuylsteke, Peter Cure, Herve Eidtmann, Holger Baselga, Jose Piccart, Martine Flamen, Patrick Di Cosimo, Serena TI F-18-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE F-18-FDG-PET/CT; early response assessment; anti-HER2 drugs ID POSITRON-EMISSION-TOMOGRAPHY; PATHOLOGICAL COMPLETE RESPONSE; CHEMOTHERAPY PLUS TRASTUZUMAB; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; PREOPERATIVE CHEMOTHERAPY; OPEN-LABEL; PHASE-II; TRIAL; RECEPTOR AB Molecular imaging receives increased attention for selecting patients who will benefit from targeted anticancer therapies. Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) enrolled 455 women with invasive human epidermal growth factor receptor 2 (HER2) positive breast cancer and compared rates of pathologic complete response (pCR) to neoadjuvant lapatinib, trastuzumab, and their combination. Each anti-HER2 therapy was given alone for 6 wk, followed by 12 wk of the same therapy plus weekly paclitaxel. The early metabolic effects of the anti-HER2 therapies on the primary tumors and their predictive values for pCR were assessed in a subset of patients. Methods: Eighty-six patients underwent F-18-FDG PET/CT at baseline and weeks 2 and 6 of anti-HER2 treatment. An imaging core laboratory provided central validation, and 2 independent reviewers, masked to assigned treatment arm and clinical outcomes, performed consensus F-18-FDG PET/CT readings. Maximum standardized uptake value (SUVmax) reductions from baseline were used to measure metabolic response. Results: Seventy-seven of the 86 enrolled patients presented an evaluable baseline F-18-FDG PET/CT scan; of these, 68 and 66 were evaluable at weeks 2 and 6, respectively. Metabolic responses in the primary tumors were evident after 2 wk of targeted therapy and correlated highly with metabolic responses at week 6 (R-2 = 0.81). pCRs were associated with greater SUVmax reductions at both time points. Mean SUVmax reductions for pCR and non-pCR, respectively, were 54.3% versus 32.8% at week 2 (P = 0.02) and 61.5% versus 34.1% at week 6 (P = 0.02). F-18-FDG PET/CT metabolic response rates at weeks 2 and 6 were 71.6% and 60%, respectively using European Organization for Research and Treatment of Cancer criteria; pCR rates were twice as high for F-18-FDG PET/CT responders than nonresponders (week 2: 42% vs. 21%, P = 0.12; week 6: 44% vs. 19%, P = 0.05). Conclusion: Early metabolic assessment using F-18-FDG PET/CT can identify patients with an increased likelihood of pCR after neoadjuvant trastuzumab, lapatinib, or their combination when given with chemotherapy. C1 [Gebhart, Geraldine; Garcia, Camilo; de Azambuja, Evandro; Flamen, Patrick] Univ Libre Brussels, Inst Jules Bordet, Dept Nucl Med, Brussels, Belgium. [Gamez, Cristina; Robles, Javier; Cortes, Montserrat] Hosp Univ Bellvitge IDIBELL, PET Unit, IDI, Barcelona, Spain. [Holmes, Eileen] Frontier Sci Scotland FSS Ltd, Kincraig, Scotland. [de Azambuja, Evandro; Van Dooren, Veerle] Breast European Adjuvant Study Team, Brussels, Belgium. [Fauria, Karine; Baselga, Jose; Di Cosimo, Serena] SOLTI Breast Canc Res Grp, Barcelona, Spain. [Aktan, Gursel] GlaxoSmithKline, Philadelphia, PA USA. [Coccia-Portugal, Maria Antonia] Eastleigh Breast Care Ctr, Pretoria, South Africa. [Kim, Sung-Bae] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea. [Vuylsteke, Peter] Clin St Elizabeth, Dept Med Oncol, Namur, Belgium. [Cure, Herve] Inst Jean Godinot, Reims, France. [Eidtmann, Holger] Univ Hosp Kiel, Kiel, Germany. [Baselga, Jose] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA. [Piccart, Martine] Univ Libre Brussels, Inst Jules Bordet, Dept Med, Brussels, Belgium. [Di Cosimo, Serena] Ist Nazl Tumori, Dept Oncol, I-20133 Milan, Italy. RP Gebhart, G (reprint author), Inst Jules Bordet, Dept Nucl Med, 121 Blvd Waterloo, B-1000 Brussels, Belgium. EM geraldine.gebhart@bordet.be RI Serena, Di Cosimo/E-9418-2017 OI Serena, Di Cosimo/0000-0002-4666-8052 FU GlaxoSmithKline FX The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This trial was funded by GlaxoSmithKline. No other potential conflict of interest relevant to this article was reported. NR 34 TC 51 Z9 53 U1 0 U2 9 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD NOV 1 PY 2013 VL 54 IS 11 BP 1862 EP 1868 DI 10.2967/jnumed.112.119271 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 250TF UT WOS:000326876800008 PM 24092940 ER PT J AU Cypess, AM Doyle, AN Sass, CA Huang, TL Mowschenson, PM Rosen, HN Tseng, YH Palmer, EL Kolodny, GM AF Cypess, Aaron M. Doyle, Ashley N. Sass, Christina A. Huang, Tian Lian Mowschenson, Peter M. Rosen, Harold N. Tseng, Yu-Hua Palmer, Edwin L., III Kolodny, Gerald M. TI Quantification of Human and Rodent Brown Adipose Tissue Function Using 99mTc-Methoxyisobutylisonitrile SPECT/CT and 18F-FDG PET/CT SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article DE brown fat; blood flow; glucose uptake ID TC-99M-SESTAMIBI UPTAKE; F-18-FDG PET/CT; COLD-EXPOSURE; ADULT HUMANS; IN-VIVO; USA-FAT; EXPRESSION; TL-201; THERMOGENESIS; LOCALIZATION AB For brown adipose tissue (BAT) to be effective at consuming calories, its blood flow must increase enough to provide sufficient fuel to sustain energy expenditure and also transfer the heat created to avoid thermal injury. Here we used a combination of human and rodent models to assess changes in BAT blood flow and glucose utilization. Methods: Tc-99m-methoxyisobutylisonitrile (MIBI) SPECT (n = 7) and SPECT/CT (n = 74) scans done in adult humans for parathyroid imaging were reviewed for uptake in regions consistent with human BAT. Site-directed biopsies of subcutaneous and deep neck fat were obtained for electron microscopy and gene expression profiling. In mice, tissue perfusion was measured with Tc-99m-MIBI (n = 16) and glucose uptake with (18)FFDG (n = 16). Animals were kept fasting overnight, anesthetized with pentobarbital, and given intraperitoneally either the beta(3)-adrenergic receptor agonist CL-316,243, 1 mg/kg (n = 8), or saline (n = 8) followed by radiotracer injection 5 min later. After 120 min, the mice were imaged using SPECT/CT or PET/CT. Vital signs were recorded over 30 min during the imaging. BAT, white adipose tissue (WAT), muscle, liver, and heart were resected, and tissue uptake of both Tc-99m-MIBI and F-18-FDG was quantified by percentage injected dose per gram of tissue and normalized to total body weight. Results: In 5.4% of patients (4/74), Tc-99m-MIBI SPECT/CT showed increased retention in cervical and supraclavicular fat that displayed multilocular lipid droplets, dense capillary investment, and a high concentration of ovoid mitochondria. Expression levels of the tissue-specific uncoupling protein-1 were 180 times higher in BAT than in subcutaneous WAT (P < 0.001). In mice, BAT tissue perfusion increased by 61% (P < 0.01), with no significant changes in blood flow to WAT, muscle, heart, or liver. CL-316,243 increased glucose uptake in BAT even more, by 440% (P < 0.01). Conclusion: Pharmacologic activation of BAT requires increased blood flow to deliver glucose and oxygen for thermogenesis. However, the glucose consumption far exceeds the vascular response. These findings demonstrate that activated BAT increases glucose uptake beyond what might occur by increased blood flow alone and suggest that activated BAT likely uses glucose for nonthermogenic purposes. C1 [Cypess, Aaron M.; Sass, Christina A.; Huang, Tian Lian; Tseng, Yu-Hua] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Integrat Physiol & Metab,Res Div, Boston, MA 02115 USA. [Doyle, Ashley N.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Harvard Thorndike Clin Res Ctr, Boston, MA 02215 USA. [Mowschenson, Peter M.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Surg, Boston, MA 02215 USA. [Rosen, Harold N.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol,Dept Med, Boston, MA 02215 USA. [Palmer, Edwin L., III] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nucl Med,Dept Radiol, Boston, MA USA. [Kolodny, Gerald M.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Nucl Med,Dept Radiol, Boston, MA 02215 USA. RP Cypess, AM (reprint author), Joslin Diabet Ctr, Div Res, Sect Integrat Physiol & Metab, 1 Joslin Pl, Boston, MA 02215 USA. EM aaron.cypess@joslin.harvard.edu FU NIH from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [DK087317, DK081604, DK046200, DK077097, RR025757, P30 DK036836, UL1 RR 025758]; Clinical Translational Science Award [UL1RR025758]; National Center for Research Resources, Harvard Catalyst; Harvard University FX The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This work was supported by NIH grants DK087317, DK081604, DK046200, DK077097, RR025757, and P30 DK036836 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Clinical Translational Science Award UL1RR025758 to Harvard University and BIDMC from the National Center for Research Resources, Harvard Catalyst. The Harvard Clinical and Translational Science Center (NIH award UL1 RR 025758 and financial contributions from Harvard University and its affiliated academic health care centers), the Clinical Investigator Training Program (Beth Israel Deaconess Medical Center-Harvard/MIT Health Sciences and Technology, in collaboration with Pfizer and Merck), and the Eli Lilly Foundation. No other potential conflict of interest relevant to this article was reported. NR 39 TC 14 Z9 16 U1 2 U2 15 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA SN 0161-5505 EI 1535-5667 J9 J NUCL MED JI J. Nucl. Med. PD NOV 1 PY 2013 VL 54 IS 11 BP 1896 EP 1901 DI 10.2967/jnumed.113.121012 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 250TF UT WOS:000326876800013 PM 24071505 ER PT J AU Huynh, TN Walling, AM Le, TX Kleerup, EC Liu, HH Wenger, NS AF Huynh, Thanh N. Walling, Anne M. Le, Thuy X. Kleerup, Eric C. Liu, Honghu Wenger, Neil S. TI Factors Associated with Palliative Withdrawal of Mechanical Ventilation and Time to Death after Withdrawal SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID INTENSIVE-CARE-UNIT; OF-LIFE CARE; CRITICALLY-ILL; HOSPITALIZED-PATIENTS; END; SUPPORT; ICU AB Background: In imminently dying patients, mechanical ventilation withdrawal is often a comfort measure and avoids prolonging the dying process. Objective: The aim of the study was to identify factors associated with palliative withdrawal of mechanical ventilation and time to death after extubation. Methods: Logistic regression models were used to identify factors associated with palliative withdrawal of mechanical ventilation. Cox proportional hazards models were used to determine factors associated with time to death after extubation. We retrospectively evaluated 322 patients who died on mechanical ventilation or after palliative ventilator withdrawal at a single tertiary care center. Results: Of the 322 ventilated deaths, 159 patients had palliative withdrawal of mechanical ventilation and 163 patients died on the ventilator. Clinical service was associated with palliative withdrawal of mechanical ventilation: Patients withdrawn from the ventilator were less likely to be on the surgery service and more likely to be on the neurology/neurosurgical service. The median time to death was 0.9 hours (range 0-165 hours). Fraction of inspired oxygen (FIO2) greater than 70% (hazard ratio [HR] 1.92, 95% confidence interval [CI ]1.24-2.99) and a requirement for vasopressors (HR 2.06, 95% CI 1.38-3.09) were associated with shorter time to death. Being on the neurology/neurosurgical service at the time of ventilator withdrawal was associated with a longer time to death (HR 0.60, 95% CI 0.39-0.92). Conclusions: Palliative withdrawal of mechanical ventilation was performed in only half of dying mechanically ventilated patients. Because clinical service rather than physiologic parameters are associated with withdrawal, targeted interventions may improve withdrawal decisions. Considering FIO2 and vasopressor requirements may facilitate counseling families about anticipated time to death. C1 [Huynh, Thanh N.; Kleerup, Eric C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. [Walling, Anne M.; Wenger, Neil S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Le, Thuy X.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Liu, Honghu] Univ Calif Los Angeles, Sch Dent, Div Publ Hlth & Community Dent, Los Angeles, CA 90024 USA. [Walling, Anne M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Walling, Anne M.] RAND Hlth, Santa Monica, CA USA. RP Huynh, TN (reprint author), Dept Med, Div Pulm & Crit Care Med, Box 951690,37-131 CHS, Los Angeles, CA 90095 USA. EM thuynh@mednet.ucla.edu FU Kennamer Fellowship; NIH Loan Repayment Program; National Palliative Care Research Center Career Development Award FX This project was supported by a donation from Mary Kay Farley to RAND Health. Dr. Huynh was supported by the Kennamer Fellowship and the NIH Loan Repayment Program. Dr. Walling was supported by a National Palliative Care Research Center Career Development Award. NR 18 TC 7 Z9 7 U1 1 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD NOV 1 PY 2013 VL 16 IS 11 BP 1368 EP 1374 DI 10.1089/jpm.2013.0142 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 250VQ UT WOS:000326884800013 PM 24083651 ER PT J AU Ahmad, R Mullen, JT AF Ahmad, Rima Mullen, John T. TI Career Outcomes of Nondesignated Preliminary General Surgery Residents at an Academic Surgical Program SO JOURNAL OF SURGICAL EDUCATION LA English DT Article DE nondesignated preliminary residents; general surgery; professional goals; career; surgical education ID ATTRITION; POSITION AB PURPOSE: There remains a debate as to whether non-designated preliminary (NDP) positions in surgery ultimately translate into successful surgical careers for those who pursue them. We sought to identify the success with which our NDP residents were able to transition to their desired career and what, if any, factors contributed to their success. METHODS: The records of all NDP residents accepted into the Massachusetts General Hospital General Surgery Residency Program from 1995 to 2010 were examined and long-term follow-up was completed. RESULTS: Thirty-four NDP residents were identified, including 26.5% US graduates and 73.5% international medical graduates. At the end of the initial preliminary year, 30 (88%) got placed in a postgraduate residency program, whereas 4 (12%) pursued other career paths. Of those who got placed, 25 (83%) attained surgical residency positions, including 17 (57%) who continued as preliminary residents at our institution and 8 (27%) who got placed in categorical surgical positions at other programs. After multiple preliminary years, 15 of 17 achieved a categorical position, of which, 93% were in surgical fields. Overall, 64.7% of all entering NDP residents eventually went on to have careers in general surgery (50%) or surgical subspecialties (14.7%), and 24 of 34 (71%) fulfilled their desired career goals. No factor predicted success. From 1995 to 2012 there have been 15 midlevel (11 postgraduate year 4) vacancies in our program, 4 of which were filled by preliminary residents, 2 from our program and 2 from elsewhere. All have gone on to board certifications and careers in surgery. CONCLUSIONS: More than 70% of NDP residents in our program successfully transitioned to their desired career paths, many achieving categorical surgical positions and academic surgical careers, thus demonstrating the benefit of this track to both residency programs and trainees. ((C) 2013 Association of Program Directors in Surgery. Published by Elsevier Inc. All rights reserved.) C1 [Ahmad, Rima; Mullen, John T.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Mullen, JT (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA. EM jmullen@partners.org NR 9 TC 2 Z9 2 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1931-7204 EI 1878-7452 J9 J SURG EDUC JI J. Surg. Educ. PD NOV-DEC PY 2013 VL 70 IS 6 BP 690 EP 695 DI 10.1016/j.jsurg.2013.09.004 PG 6 WC Education, Scientific Disciplines; Surgery SC Education & Educational Research; Surgery GA 253QM UT WOS:000327104400002 PM 24209641 ER PT J AU George, BC Teitelbaum, EN DaRosa, DA Hungness, ES Meyerson, SL Fryer, JP Schuller, M Zwischenberger, JB AF George, Brian C. Teitelbaum, Ezra N. DaRosa, Debra A. Hungness, Eric S. Meyerson, Shari L. Fryer, Jonathan P. Schuller, Mary Zwischenberger, Joseph B. TI Duration of Faculty Training Needed to Ensure Reliable OR Performance Ratings SO JOURNAL OF SURGICAL EDUCATION LA English DT Article DE frame-of-reference training; rater training; faculty development; measurement; evaluation; surgical education ID ACCURACY AB OBJECTIVES: The American Board of Surgery has mandated intraoperative assessment of general surgery residents, yet the time required to train faculty to accurately and reliably complete operating room performance evaluation forms is unknown. Outside of surgical education, frame-of-reference (FOR) training has been shown to be an effective training modality to teach raters the specific performance indicators associated with each point on a rating scale. Little is known, however, about what form and duration of FOR training is needed to accomplish reliable ratings among surgical faculty. DESIGN: Two groups of surgical faculty separately underwent either an accelerated 1-hour (n = 10) or immersive four-hour (n = 34) FOR faculty development program. Both programs included a formal presentation and a facilitated discussion of sample behaviors for each point on the Zwisch operating room performance rating scale (see DaRosa et al.(8)). The immersive group additionally participated in a small group exercise that included additional practice. After training, both groups were tested using 10 video clips of trainees at various levels. Responses were scored against expert consensus rating. The 2-sided Mann-Whitney U test was used to compare between group means. SETTING AND PARTICIPANTS: All trainees were faculty members in the Department of Surgery of a large mid-western private medical school. RESULTS: Faculty undergoing the 1-hour FOR training program did not have a statistically different mean correct response rate on the video test when compared with those undergoing the 4-hour training program (88% vs 80%; p = 0.07). CONCLUSIONS: One-hour FOR training sessions are likely sufficient to train surgical faculty to reliably use a simple evaluation instrument for the assessment of intraoperative performance. Additional research is needed to determine how these results generalize to different assessment instruments. ((C) 2013 Association of Program Directors in Surgery. Published by Elsevier Inc. All rights reserved.) C1 [George, Brian C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA USA. [Teitelbaum, Ezra N.; DaRosa, Debra A.; Hungness, Eric S.; Meyerson, Shari L.; Fryer, Jonathan P.; Schuller, Mary] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. [Zwischenberger, Joseph B.] Univ Kentucky, Coll Med, Dept Surg, Lexington, KY USA. RP George, BC (reprint author), 55 Fruit St GRB-425, Boston, MA 02114 USA. EM bcgeorge@partners.org NR 10 TC 7 Z9 7 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1931-7204 EI 1878-7452 J9 J SURG EDUC JI J. Surg. Educ. PD NOV-DEC PY 2013 VL 70 IS 6 BP 703 EP 708 DI 10.1016/j.jsurg.2013.06.015 PG 6 WC Education, Scientific Disciplines; Surgery SC Education & Educational Research; Surgery GA 253QM UT WOS:000327104400005 PM 24209644 ER PT J AU Davis, NJ Ma, Y Delahanty, LM Hoffman, HJ Mayer-Davis, E Franks, PW Brown-Friday, J Isonaga, M Kriska, AM Venditti, EM Wylie-Rosett, J AF Davis, Nichola J. Ma, Yong Delahanty, Linda M. Hoffman, Heather J. Mayer-Davis, Elizabeth Franks, Paul W. Brown-Friday, Janet Isonaga, Mae Kriska, Andrea M. Venditti, Elizabeth M. Wylie-Rosett, Judith CA Diabet Prevention Program Res Grp TI Predictors of Sustained Reduction in Energy and Fat Intake in the Diabetes Prevention Program Outcomes Study Intensive Lifestyle Intervention SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS LA English DT Article DE Diet; Lifestyle intervention; Diabetes prevention; Dietary intake; Dietary change ID WEIGHT-LOSS; FOLLOW-UP; BASE-LINE; RISK; INDIVIDUALS; INVENTORY; METFORMIN; LOSSES; COHORT AB Background Few lifestyle intervention studies examine long-term sustainability of dietary changes. Objective To describe sustainability of dietary changes over 9 years in the Diabetes Prevention Program and its outcomes study, the Diabetes Prevention Program Outcomes Study, among participants receiving the intensive lifestyle intervention. Design One thousand seventy-nine participants were enrolled in the intensive lifeStyle intervention arm of the Diabetes Prevention Program; 910 continued participation in the Diabetes Prevention Program Outcomes Study. Fat and energy intake derived from food frequency questionnaires at baseline and post-randomization Years 1 and 9 were examined. Parsimonious models determined whether baseline characteristics and intensive lifestyle intervention session participation predicted sustainability. Results Self-reported energy intake was reduced from a median of 1,876 kcal/day (interquartile range [IQR]=1,452 to 2,549 kcal/day) at baseline to 1,520 kcal/day (IQR=1,192 to 1,986 kcal/day) at Year 1, and 1,560 kcal/day (IQR=1,223 to 2,026 kcal/ day) at Year 9. Dietary fat was reduced from a median of 70.4 g (IQR=49.3 to 102.5 g) to 45 g (IQR=32.2 to 63.8 g) at Year 1 and increased to 61.0 g (IQR=44.6 to 82.7 g) at Year 9. Percent energy from fat was reduced from a median of 34.4% (IQR=29.6% to 38.5%) to 27.1% (IQR=23.1% to 31.5%) at Year 1 but increased to 35.3% (IQR=29.7% to 40.2%) at Year 9. Lower baseline energy intake and Year 1 dietary reduction predicted lower energy and fat gram intake at Year 9. Higher leisure physical activity predicted lower fat gram intake but not energy intake. Conclusions Intensive lifestyle intervention can result in reductions in total energy intake for up to 9 years. Initial success in achieving reductions in fat and energy intake and success in attaining activity goals appear to predict long-term success at maintaining changes. C1 [Davis, Nichola J.; Brown-Friday, Janet; Wylie-Rosett, Judith] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Ma, Yong; Hoffman, Heather J.] George Washington Univ, Washington, DC USA. [Delahanty, Linda M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Delahanty, Linda M.] Harvard Univ, Sch Med, Boston, MA USA. [Mayer-Davis, Elizabeth] Univ N Carolina, Chapel Hill, NC USA. [Franks, Paul W.] Lund Univ, Malmo, Sweden. [Franks, Paul W.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Isonaga, Mae] Univ Hawaii, Honolulu, HI 96822 USA. [Kriska, Andrea M.; Venditti, Elizabeth M.] Univ Pittsburgh, Pittsburgh, PA USA. RP Wylie-Rosett, J (reprint author), George Washington Univ, Ctr Biostat, 6110 Execut Blvd,Suite 750, Rockville, MD 20852 USA. EM dppmail@biostat.bsc.gwu.edu OI Kriska, Andrea/0000-0002-3522-0869; Franks, Paul/0000-0002-0520-7604 FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health FX The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health provided funding to the clinical centers and the Coordinating Center for the design and conduct of the study, and collection, management, analysis, and interpretation of the data (grant no. U01 DK048489). The Southwestern American Indian Centers were supported directly by the NIDDK, including its Intramural Research Program, and the Indian Health Service. The General Clinical Research Center Program, National Center for Research Resources, and the Department of Veterans Affairs supported data collection at many of the clinical centers. Funding was also provided by the National Institute of Child Health and Human Development; the National Institute on Aging; the National Eye Institute; the National Heart, Lung, and Blood Institute; the Office of Research on Women's Health; the National Institute on Minority Health and Health Disparities; the Centers for Disease Control and Prevention; and the American Diabetes Association. The opinions expressed are those of the investigators and do not necessarily reflect the views of the funding agencies. Bristol-Myers Squibb and Parke-Davis provided additional funding and material support during the project, Lipha (Merck-Sante) provided medication, and LifeScan Inc. donated materials. McKesson BioServices Corp, Matthews Media Group Inc, and the Henry M. Jackson Foundation provided support services under subcontract with the Coordinating Center. NR 27 TC 10 Z9 10 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD NOV PY 2013 VL 113 IS 11 BP 1455 EP 1464 DI 10.1016/j.jand.2013.07.003 PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 253QH UT WOS:000327103900005 PM 24144073 ER PT J AU Lee, CG Schwartz, AV Yaffe, K Hillier, TA LeBlanc, ES Cawthon, PM AF Lee, Christine G. Schwartz, Ann V. Yaffe, Kristine Hillier, Teresa A. LeBlanc, Erin S. Cawthon, Peggy M. CA Osteoporotic Fractures Res Grp TI Changes in Physical Performance in Older Women According to Presence and Treatment of Diabetes Mellitus SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE elderly; diabetes mellitus; insulin sensitizer; physical performance; walk speed ID IMPAIRED FASTING GLUCOSE; COGNITIVE IMPAIRMENT; INSULIN-RESISTANCE; SKELETAL-MUSCLE; METFORMIN INCREASES; BODY-COMPOSITION; ADULTS; HEALTH; DISABILITY; RISK AB ObjectivesTo determine whether older women with diabetes mellitus have a greater longitudinal decline in physical performance than those without and whether any decline differs according to insulin sensitizer use. DesignProspective cohort study. SettingBaltimore, Maryland; Minneapolis, Minnesota; Portland, Oregon; and the Monongahela, Pennsylvania. ParticipantsCommunity-dwelling women (mean age 78.53.6) enrolled in the Study of Osteoporotic Fractures in 1997-98 and restudied 4.90.6years later (N=2,864). MeasurementsWomen were categorized as having no diabetes mellitus (n=2,680) or having diabetes mellitus (n=184). A prescription medication inventory was used to determine use of insulin sensitizers (metformin and thiazolidinedione). The outcomes were longitudinal changes in physical performance measures, including grip strength, usual walk speed, and rapid walk speed. ResultsEstimates from fully adjusted models showed that women with diabetes mellitus had greater declines in usual walk speed (-0.16m/s, 95% confidence interval (CI)=-0.19 to -0.14) and rapid walk speed (-0.21m/s, 95% CI=-0.24 to -0.17) than those without (usual walk speed -0.11m/s, 95% CI=-0.12 to -0.11, P<.001; rapid walk speed -0.15m/s, 95% CI=-0.16 to -0.14; P=.005). Women with diabetes mellitus taking insulin sensitizers had less decline in usual walk speed than those not taking insulin sensitizers (P<.001). Declines in grip strength did not differ significantly by diabetes mellitus status or insulin sensitizer use. ConclusionOlder women with diabetes mellitus have a greater decline in walk speed, but not grip strength, than older women without diabetes mellitus. Clinical studies in older adults to determine whether diabetes mellitus treatments such as insulin sensitizers can prevent loss in walk speed and mobility are needed. C1 [Lee, Christine G.] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Res Serv, Portland, OR 97201 USA. [Lee, Christine G.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Lee, Christine G.; Hillier, Teresa A.; LeBlanc, Erin S.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Schwartz, Ann V.; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Cawthon, Peggy M.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. RP Lee, CG (reprint author), Portland VA Med Ctr, Res Serv, 3710 SW US Vet Hosp Rd,R&D 45, Portland, OR 97239 USA. EM leechr@ohsu.edu FU National Institute on Aging [R01AG005407, R01AR35582, R01AR35583, R01AR35584, R01AG005394, R01AG027574, R01AG027576]; Office of Research on Women's Health; National Institute of Child Health and Human Development, Building Interdisciplinary Research Careers in Women's Health Grant [HD043488-08]; GlaxoSmithKline; Amgen; Merck; National Institutes of Health FX The Study of Osteoporotic Fractures is supported by National Institutes of Health funding. The National Institute on Aging provides support under Grants R01AG005407, R01AR35582, R01AR35583, R01AR35584, R01AG005394, R01AG027574, and R01AG027576. Christine G. Lee was supported by the Office of Research on Women's Health and the National Institute of Child Health and Human Development, Building Interdisciplinary Research Careers in Women's Health Grant HD043488-08. Ann V. Schwartz has served as a consultant for GlaxoSmithKline and has received research support from GlaxoSmithKline, Amgen, and Merck. Kristine Yaffe has served as a consultant for Novartis and on Data and Safety Monitoring Boards for Pfizer, Medivation, and Takeda Pharmaceuticals. Peggy M. Cawthon has received research support from Amgen and Merck. NR 37 TC 6 Z9 6 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2013 VL 61 IS 11 BP 1872 EP 1878 DI 10.1111/jgs.12502 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 251VZ UT WOS:000326961300003 PM 24219188 ER PT J AU Nazir, A LaMantia, M Chodosh, J Khan, B Campbell, N Hui, S Boustani, M AF Nazir, Arif LaMantia, Michael Chodosh, Joshua Khan, Babar Campbell, Noll Hui, Siu Boustani, Malaz TI Interaction Between Cognitive Impairment and Discharge Destination and Its Effect on Rehospitalization SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE rehospitalization; cognitive impairment; discharge destination ID RANDOMIZED CONTROLLED-TRIAL; OLDER-ADULTS; HOSPITAL DISCHARGE; 30-DAY READMISSION; HEART-FAILURE; CARE; DEMENTIA; INTERVENTIONS; PHYSICIANS; DISEASE AB ObjectivesTo evaluate the effect of cognitive impairment on rehospitalization in older adults. DesignOne-year longitudinal study. SettingMedical service of an urban, 340-bed public hospital in Indianapolis between July 2006 and March 2008. ParticipantsIndividuals aged 65 and older admitted to the medical service (N=976). MeasurementsRehospitalization was defined as any hospital admission after the index admission. Participant demographics, discharge destination, Charlson Comorbidity Index, Acute Physiology Score, and prior hospitalizations were measured as the confounders. Participants were considered to have cognitive impairment if they had two or more errors on the Short Portable Mental Status Questionnaire. ResultsAfter adjusting for confounders, a significant interaction between cognitive impairment and discharge location was found to predict rehospitalization rate (P=.008) and time to 1-year rehospitalization (P=.03). Participants with cognitive impairment discharged to a facility had a longer time to rehospitalization (median 142days) than participants with no cognitive impairment (median 98days) (hazard ratio (HR)=0.77, 95% confidence interval (CI)=0.58-1.02, P=.07), whereas participants with cognitive impairment discharged to home had a slightly shorter time to rehospitalization (median 182days) than those without cognitive impairment (median 224days) (HR=1.15, 95% CI=0.92-1.43, P=.23). These two nonsignificant HRs in opposite directions were significantly different from each other (P=.03). ConclusionDischarge destination modifies the association between cognitive impairment and rehospitalization. Of participants discharged to a facility, those without cognitive impairment had higher rehospitalization rates, whereas the rates were similar between cognitively impaired and intact participants discharged to the community. C1 [Nazir, Arif; LaMantia, Michael; Khan, Babar; Hui, Siu; Boustani, Malaz] Indiana Univ, Sch Med, Indianapolis, IN 46202 USA. [LaMantia, Michael; Khan, Babar; Campbell, Noll; Hui, Siu; Boustani, Malaz] Indiana Univ, Ctr Aging Res, Indianapolis, IN USA. [LaMantia, Michael; Khan, Babar; Campbell, Noll; Hui, Siu; Boustani, Malaz] Regenstrief Inst Inc, Indianapolis, IN USA. [Chodosh, Joshua] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Chodosh, Joshua] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Campbell, Noll] Purdue Univ, Coll Pharm, W Lafayette, IN USA. RP Nazir, A (reprint author), Indiana Univ, Sch Med, Indianapolis, IN 46202 USA. EM anazir@iu.edu OI Chodosh, Joshua/0000-0001-7784-4306 FU Health Resources and Services Administration; National Institute on Aging [R01AG034205, K23-AG043476]; John A. Hartford Foundation Center for Excellence in Geriatric Medicine FX This work was supported by grants from a Geriatric Academic Career Award through the Health Resources and Services Administration; R01AG034205 and K23-AG043476 from the National Institute on Aging, and the John A. Hartford Foundation Center for Excellence in Geriatric Medicine. NR 33 TC 7 Z9 7 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2013 VL 61 IS 11 BP 1958 EP 1963 DI 10.1111/jgs.12501 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 251VZ UT WOS:000326961300016 PM 24219196 ER PT J AU Ahalt, C Trestman, RL Rich, JD Greifinger, RB Williams, BA AF Ahalt, Cyrus Trestman, Robert L. Rich, Josiah D. Greifinger, Robert B. Williams, Brie A. TI Paying the Price: The Pressing Need for Quality, Cost, and Outcomes Data to Improve Correctional Health Care for Older Prisoners SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE correctional health; health disparities; healthcare value; older prisoners; research ID DISPARITIES; INCARCERATION; MEDICINE; RELEASE; AGENDA; SYSTEM; RISK AB Despite a recent decline in the U.S. prison population, the older prisoner population is growing rapidly. U.S. prisons are constitutionally required to provide health care to prisoners. As the population ages, healthcare costs rise, states are forced to cut spending, and many correctional agencies struggle to meet this legal standard of care. Failure to meet the healthcare needs of older prisoners, who now account for nearly 10% of the prison population, can cause avoidable suffering in a medically vulnerable population and violation of the constitutional mandate for timely access to an appropriate level of care while incarcerated. Older prisoners who cannot access adequate health care in prison also affect community healthcare systems because more than 95% of prisoners are eventually released, many to urban communities where healthcare disparities are common and acute healthcare resources are overused. A lack of uniform quality and cost data has significantly hampered innovations in policy and practice to improve value in correctional health care (achieving desired health outcomes at sustainable costs). With their unique knowledge of complex chronic disease management, experts in geriatrics are positioned to help address the aging crisis in correctional health care. This article delineates the basic health, cost, and outcomes data that geriatricians and gerontologists need to respond to this crisis, identifies gaps in the available data, and anticipates barriers to data collection that, if addressed, could enable clinicians and policy-makers to evaluate and improve the value of geriatric prison health care. C1 [Ahalt, Cyrus; Williams, Brie A.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94118 USA. [Trestman, Robert L.] Univ Connecticut, Ctr Hlth, Farmington, CT USA. [Rich, Josiah D.] Brown Med Sch, Providence, RI USA. [Rich, Josiah D.] Brown Univ, Ctr Prisoner Hlth & Human Rights, Providence, RI 02912 USA. [Rich, Josiah D.] Miriam Hosp, Providence, RI 02906 USA. [Greifinger, Robert B.] CUNY John Jay Coll Criminal Justice, New York, NY 10019 USA. [Williams, Brie A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Williams, BA (reprint author), Univ Calif San Francisco, Div Geriatr, 3333California St,Suite 380, San Francisco, CA 94118 USA. EM brie.williams@ucsf.edu FU National Institute of Aging [K23AG033102]; Jacob & Valeria Langeloth Foundation; University of California at San Francisco (UCSF) Program for the Aging Century; UCSF Older Americans Independence Center; National Institute of Drug Abuse [K24DA022112] FX Dr. Williams is supported by the National Institute of Aging (K23AG033102), The Jacob & Valeria Langeloth Foundation, The University of California at San Francisco (UCSF) Program for the Aging Century, and the UCSF Older Americans Independence Center. Dr. Rich is supported by the National Institute of Drug Abuse (K24DA022112). Dr. Williams is an employee of the Department of Veterans Affairs. NR 47 TC 13 Z9 13 U1 0 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2013 VL 61 IS 11 BP 2013 EP 2019 DI 10.1111/jgs.12510 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 251VZ UT WOS:000326961300024 PM 24219203 ER PT J AU O'Brien, S Radich, JP Abboud, CN Akhtari, M Altman, JK Berman, E DeAngelo, DJ Deininger, M Devine, S Fathi, AT Gotlib, J Jagasia, M Kropf, P Moore, JO Pallera, A Pinilla-Ibarz, J Reddy, VV Shah, NP Smith, BD Snyder, DS Wetzler, M Gregory, K Sundar, H AF O'Brien, Susan Radich, Jerald P. Abboud, Camille N. Akhtari, Mojtaba Altman, Jessica K. Berman, Ellin DeAngelo, Daniel J. Deininger, Michael Devine, Steven Fathi, Amir T. Gotlib, Jason Jagasia, Madan Kropf, Patricia Moore, Joseph O. Pallera, Arnel Pinilla-Ibarz, Javier Reddy, Vishnu Vb. Shah, Neil P. Smith, B. Douglas Snyder, David S. Wetzler, Meir Gregory, Kristina Sundar, Hema TI Chronic Myelogenous Leukemia, Version 1.2014 Featured Updates to the NCCN Guidelines SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Review ID CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITORS; HARMONIZING CURRENT METHODOLOGY; BCR-ABL1 TRANSCRIPT LEVELS; ALPHA PLUS CYTARABINE; BCR-ABL TRANSCRIPTS; DASATINIB 100 MG; CHRONIC-PHASE; MOLECULAR RESPONSES; INTOLERANT PATIENTS AB The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with QPCR (IS) for patients with BCR-ABL1 transcript levels greater than 10% at 3 months. Monitoring with QPCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level <= 10% [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months). C1 [O'Brien, Susan] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Radich, Jerald P.] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA USA. [Abboud, Camille N.] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Altman, Jessica K.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [Berman, Ellin] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [DeAngelo, Daniel J.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Deininger, Michael] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. [Devine, Steven] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp & Solove Res Inst, Columbus, OH 43210 USA. [Fathi, Amir T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Gotlib, Jason] Stanford Canc Inst, Stanford, CA USA. [Jagasia, Madan] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Kropf, Patricia] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Pallera, Arnel] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA. [Pinilla-Ibarz, Javier] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Reddy, Vishnu Vb.] Univ Alabama, Birmingham Comprehens Canc Ctr, Tuscaloosa, AL 35487 USA. [Wetzler, Meir] Roswell Pk Canc Inst, Buffalo, NY USA. RP O'Brien, S (reprint author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. OI Reddy, Vishnu/0000-0001-5474-3289 FU Eisai, Inc.; Millennium: The Takeda Oncology Company; Teva Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc.; Celgene Corporation; Endo Pharmaceuticals and HealthTronics; Genentech; ARIAD Pharmaceuticals, Inc. FX Supported by educational grants from Eisai, Inc.; Millennium: The Takeda Oncology Company; Teva Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc.; Celgene Corporation; Endo Pharmaceuticals and HealthTronics; Genentech; and ARIAD Pharmaceuticals, Inc. NR 48 TC 24 Z9 25 U1 1 U2 8 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD NOV PY 2013 VL 11 IS 11 BP 1327 EP 1340 PG 14 WC Oncology SC Oncology GA 253EY UT WOS:000327066800003 PM 24225967 ER PT J AU Aizer, AA Paly, JJ Zietman, AL Nguyen, PL Beard, CJ Rao, SK Kaplan, ID Niemierko, A Hirsch, MS Wu, CL Olumi, AF Michaelson, MD D'Amico, AV Efstathiou, JA AF Aizer, Ayal A. Paly, Jonathan J. Zietman, Anthony L. Nguyen, Paul L. Beard, Clair J. Rao, Sandhya K. Kaplan, Irving D. Niemierko, Andrzej Hirsch, Michelle S. Wu, Chin-Lee Olumi, Aria F. Michaelson, M. Dror D'Amico, Anthony V. Efstathiou, Jason A. TI Models of Care and NCCN Guideline Adherence in Very-Low-Risk Prostate Cancer SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article ID QUALITY-OF-LIFE; ACTIVE SURVEILLANCE; RADICAL PROSTATECTOMY; RADIATION ONCOLOGISTS; VALIDATION; EXPERIENCE; SURVIVORS; NOMOGRAM; OUTCOMES; PROGRAM AB NCCN Guidelines recommend active surveillance as the primary management option for patients with very-low-risk prostate cancer and an expected survival of less than 20 years, reflecting the favorable prognosis of these men and the lack of perceived benefit of immediate, definitive treatment. The authors hypothesized that care at a multidisciplinary clinic, where multiple physicians have an opportunity to simultaneously review and discuss each case, is associated with increased rates of active surveillance in men with very-low-risk prostate cancer, including those with limited life expectancy. Of 630 patients with low-risk prostate cancer managed at 1 of 3 tertiary care centers in Boston, Massachusetts in 2009, 274 (43.5%) had very-low-risk classification. Patients were either seen by 1 or more individual practitioners in sequential settings or at a multidisciplinary clinic, in which concurrent consultation with 2 or more of the following specialties was obtained: urology, radiation oncology, and medical oncology. Patients seen at a multidisciplinary prostate cancer clinic were more likely to select active surveillance than those seen by individual practitioners (64% vs 30%; P<.001), an association that remained significant on multivariable logistic regression (odds ratio [OR], 4.16; P<.001). When the analysis was limited to patients with an expected survival of less than 20 years, this association remained highly significant (72% vs 34%, P<.001; OR, 5.19; P<.001, respectively). Multidisciplinary care is strongly associated with selection of active surveillance, adherence to NCCN Guidelines and minimization of overtreatment in patients with very-low-risk prostate cancer. C1 [Aizer, Ayal A.] Massachusetts Gen Hosp, Harvard Radiat Oncol Program, Boston, MA 02114 USA. [Aizer, Ayal A.; Paly, Jonathan J.; Zietman, Anthony L.; Efstathiou, Jason A.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Nguyen, Paul L.; Beard, Clair J.; D'Amico, Anthony V.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Rao, Sandhya K.] Massachusetts Gen Hosp, Div Gen Internal Med, Dept Med, Boston, MA 02114 USA. [Kaplan, Irving D.] Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA. [Niemierko, Andrzej] Massachusetts Gen Hosp, Dept Radiat Oncol, Div Biostat & Biomath, Boston, MA 02114 USA. [Hirsch, Michelle S.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Wu, Chin-Lee] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Olumi, Aria F.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. [Michaelson, M. Dror] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA. RP Aizer, AA (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,Cox 3, Boston, MA 02114 USA. EM aaaizer@partners.org FU Department of Radiation Oncology at Massachusetts General Hospital; Prostate Cancer Foundation Young Investigator Award FX This study was funded by departmental support from the Department of Radiation Oncology at Massachusetts General Hospital. Dr. Efstathiou was supported by a Prostate Cancer Foundation Young Investigator Award. Funding was used to facilitate data collection. The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. NR 31 TC 5 Z9 5 U1 0 U2 1 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD NOV PY 2013 VL 11 IS 11 BP 1364 EP 1372 PG 9 WC Oncology SC Oncology GA 253EY UT WOS:000327066800006 PM 24225970 ER PT J AU Streiff, MB Bockenstedt, PL Cataland, SR Chesney, C Eby, C Fanikos, J Fogerty, AE Gao, SW Goldhaber, SZ Hassoun, H Hendrie, P Holmstrom, B Kuderer, N Lee, JT Millenson, MM Neff, AT Ortel, TL Siddiqi, T Smith, JL Yee, GC Zakarija, A McMillian, N Naganuma, M AF Streiff, Michael B. Bockenstedt, Paula L. Cataland, Spero R. Chesney, Carolyn Eby, Charles Fanikos, John Fogerty, Annemarie E. Gao, Shuwei Goldhaber, Samuel Z. Hassoun, Hani Hendrie, Paul Holmstrom, Bjorn Kuderer, Nicole Lee, Jason T. Millenson, Michael M. Neff, Anne T. Ortel, Thomas L. Siddiqi, Tanya Smith, Judy L. Yee, Gary C. Zakarija, Anaadriana McMillian, Nicole Naganuma, Maoko TI Venous Thromboembolic Disease Clinical Practice Guidelines in Oncology SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Article ID DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; VENA-CAVA FILTERS; RANDOMIZED CONTROLLED-TRIAL; SURGICAL ADJUVANT BREAST; LENALIDOMIDE PLUS DEXAMETHASONE; GRADUATED COMPRESSION STOCKINGS; CATHETER-RELATED THROMBOSIS; DIAGNOSED MULTIPLE-MYELOMA; SEVERE RENAL-INSUFFICIENCY AB Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer. C1 [Bockenstedt, Paula L.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Cataland, Spero R.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp & Solove Res Inst, Columbus, OH 43210 USA. [Chesney, Carolyn] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA. [Eby, Charles] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Fogerty, Annemarie E.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Gao, Shuwei] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Hassoun, Hani] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Hendrie, Paul] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA. [Lee, Jason T.] Stanford Canc Inst, Stanford, CA USA. [Neff, Anne T.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Smith, Judy L.] Roswell Pk Canc Inst, Buffalo, NY USA. [Yee, Gary C.] Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA. [Zakarija, Anaadriana] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. NR 170 TC 35 Z9 36 U1 0 U2 8 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 EI 1540-1413 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD NOV PY 2013 VL 11 IS 11 BP 1402 EP 1429 PG 28 WC Oncology SC Oncology GA 253EY UT WOS:000327066800009 PM 24225973 ER EF